14510914	Congenital hypothyroidism due to a new deletion in the sodium / iodide symporter protein .|OBJECTIVE : Iodide transport defect ( ITD ) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells , that often results in congenital hypothyroidism .|When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium / iodide symporter ( NIS ) .|PATIENT : We describe a woman with hypothyroidism identified at the 3rd month of life .|The diagnosis of ITD was suspected because of nodular goitre , and little if any iodide uptake by the thyroid and salivary glands .|Treatment with iodide partially corrected the hypothyroidism ; however , long - term substitution therapy with L - thyroxine was started .|MEASUREMENTS : Thyroid radioiodide uptake was only 1 . 4 % and 0 . 3 % at 1 and 24 h after the administration of recombinant human TSH .|The saliva to plasma I - ratio was 1 . 1 indicating that the inability of the thyroid gland to concentrate I - was also present in the salivary glands .|RESULTS : Analysis of the patient 's NIS gene revealed a 15 nucleotide ( nt ) deletion of the coding sequence ( nt 1314 through nt 1328 ) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron .|The patient was homozygous for this insertion / deletion , while both consanguineous parents were heterozygous .|This deletion predicts the production of a protein lacking the five terminal amino acids of exon XI ( 439 - 443 ) which are located in the 6th intracellular loop .|COS - 7 cells transfected with a vector expressing the mutant del - ( 439 - 443 ) NIS failed to concentrate iodide , suggesting that the mutation was the direct cause of the ITD in this patient .|CONCLUSION : In conclusion we describe the first Italian case of congenital hypothyroidism due to a new deletion in the NIS gene .	1:Association:2	L2R	NON-CROSS	0-2	9-13	D003409	Congenital hypothyroidism|congenital hypothyroidism|congenital hypothyroidism	DiseaseOrPhenotypicFeature	0:52:352	2:54:354	0:1:12	6528	sodium / iodide symporter|sodium / iodide symporter|NIS|NIS|NIS|NIS	GeneOrGeneProduct	9:80:85:217:320:361	13:84:86:218:321:362	0:2:2:8:11:12	1:NR:2	L2R	NON-CROSS	37-38	52-54	D003409	Congenital hypothyroidism|congenital hypothyroidism|congenital hypothyroidism	DiseaseOrPhenotypicFeature	0:52:352	2:54:354	0:1:12	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	1:NR:2	L2R	CROSS	52-54	144-147	D003409	Congenital hypothyroidism|congenital hypothyroidism|congenital hypothyroidism	DiseaseOrPhenotypicFeature	0:52:352	2:54:354	0:1:12	D013974	L - thyroxine	ChemicalEntity	144	147	5	1:NR:2	L2R	CROSS	52-54	177-178	D003409	Congenital hypothyroidism|congenital hypothyroidism|congenital hypothyroidism	DiseaseOrPhenotypicFeature	0:52:352	2:54:354	0:1:12	7200	TSH	GeneOrGeneProduct	177	178	6	1:Positive_Correlation:2	R2L	CROSS	352-354	226-238	c|DEL|1314_1328|	deletion of the coding sequence ( nt 1314 through nt 1328 )	SequenceVariant	226	238	8	D003409	Congenital hypothyroidism|congenital hypothyroidism|congenital hypothyroidism	DiseaseOrPhenotypicFeature	0:52:352	2:54:354	0:1:12	1:Positive_Correlation:2	L2R	CROSS	240-248	352-354	D003409	Congenital hypothyroidism|congenital hypothyroidism|congenital hypothyroidism	DiseaseOrPhenotypicFeature	0:52:352	2:54:354	0:1:12	c|DUP||15	insertion of 15 nt duplicating the first 15	SequenceVariant	240	248	8	1:Positive_Correlation:2	R2L	CROSS	352-354	313-320	p|DEL|439_443|	lacking the five terminal amino acids of exon XI ( 439 - 443 )|del - ( 439 - 443 )	SequenceVariant	279:313	293:320	10:11	D003409	Congenital hypothyroidism|congenital hypothyroidism|congenital hypothyroidism	DiseaseOrPhenotypicFeature	0:52:352	2:54:354	0:1:12	1:Negative_Correlation:2	R2L	NON-CROSS	17-20	9-13	C564766	Iodide transport defect|ITD|ITD|ITD	DiseaseOrPhenotypicFeature	17:21:107:336	20:22:108:337	1:1:4:11	6528	sodium / iodide symporter|sodium / iodide symporter|NIS|NIS|NIS|NIS	GeneOrGeneProduct	9:80:85:217:320:361	13:84:86:218:321:362	0:2:2:8:11:12	1:NR:2	L2R	CROSS	9-13	30-34	6528	sodium / iodide symporter|sodium / iodide symporter|NIS|NIS|NIS|NIS	GeneOrGeneProduct	9:80:85:217:320:361	13:84:86:218:321:362	0:2:2:8:11:12	D050033	inability of the thyroid	DiseaseOrPhenotypicFeature	30	34	1	1:Association:2	R2L	NON-CROSS	324-325	320-321	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	6528	sodium / iodide symporter|sodium / iodide symporter|NIS|NIS|NIS|NIS	GeneOrGeneProduct	9:80:85:217:320:361	13:84:86:218:321:362	0:2:2:8:11:12	1:NR:2	L2R	CROSS	85-86	95-96	6528	sodium / iodide symporter|sodium / iodide symporter|NIS|NIS|NIS|NIS	GeneOrGeneProduct	9:80:85:217:320:361	13:84:86:218:321:362	0:2:2:8:11:12	D007037	hypothyroidism|hypothyroidism	DiseaseOrPhenotypicFeature	95:134	96:135	3:5	1:NR:2	L2R	CROSS	85-86	112-114	6528	sodium / iodide symporter|sodium / iodide symporter|NIS|NIS|NIS|NIS	GeneOrGeneProduct	9:80:85:217:320:361	13:84:86:218:321:362	0:2:2:8:11:12	D020518	nodular goitre	DiseaseOrPhenotypicFeature	112	114	4	1:NR:2	L2R	CROSS	85-86	144-147	6528	sodium / iodide symporter|sodium / iodide symporter|NIS|NIS|NIS|NIS	GeneOrGeneProduct	9:80:85:217:320:361	13:84:86:218:321:362	0:2:2:8:11:12	D013974	L - thyroxine	ChemicalEntity	144	147	5	1:NR:2	L2R	CROSS	177-178	217-218	6528	sodium / iodide symporter|sodium / iodide symporter|NIS|NIS|NIS|NIS	GeneOrGeneProduct	9:80:85:217:320:361	13:84:86:218:321:362	0:2:2:8:11:12	7200	TSH	GeneOrGeneProduct	177	178	6	1:Association:2	L2R	NON-CROSS	107-108	119-120	C564766	Iodide transport defect|ITD|ITD|ITD	DiseaseOrPhenotypicFeature	17:21:107:336	20:22:108:337	1:1:4:11	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	1:NR:2	L2R	CROSS	107-108	144-147	C564766	Iodide transport defect|ITD|ITD|ITD	DiseaseOrPhenotypicFeature	17:21:107:336	20:22:108:337	1:1:4:11	D013974	L - thyroxine	ChemicalEntity	144	147	5	1:NR:2	L2R	CROSS	107-108	177-178	C564766	Iodide transport defect|ITD|ITD|ITD	DiseaseOrPhenotypicFeature	17:21:107:336	20:22:108:337	1:1:4:11	7200	TSH	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	226-238	336-337	C564766	Iodide transport defect|ITD|ITD|ITD	DiseaseOrPhenotypicFeature	17:21:107:336	20:22:108:337	1:1:4:11	c|DEL|1314_1328|	deletion of the coding sequence ( nt 1314 through nt 1328 )	SequenceVariant	226	238	8	1:NR:2	L2R	CROSS	240-248	336-337	C564766	Iodide transport defect|ITD|ITD|ITD	DiseaseOrPhenotypicFeature	17:21:107:336	20:22:108:337	1:1:4:11	c|DUP||15	insertion of 15 nt duplicating the first 15	SequenceVariant	240	248	8	1:Positive_Correlation:2	R2L	NON-CROSS	336-337	313-320	p|DEL|439_443|	lacking the five terminal amino acids of exon XI ( 439 - 443 )|del - ( 439 - 443 )	SequenceVariant	279:313	293:320	10:11	C564766	Iodide transport defect|ITD|ITD|ITD	DiseaseOrPhenotypicFeature	17:21:107:336	20:22:108:337	1:1:4:11	1:Association:2	L2R	NON-CROSS	30-34	37-38	D050033	inability of the thyroid	DiseaseOrPhenotypicFeature	30	34	1	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	1:NR:2	L2R	CROSS	30-34	144-147	D050033	inability of the thyroid	DiseaseOrPhenotypicFeature	30	34	1	D013974	L - thyroxine	ChemicalEntity	144	147	5	1:NR:2	L2R	CROSS	30-34	177-178	D050033	inability of the thyroid	DiseaseOrPhenotypicFeature	30	34	1	7200	TSH	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	30-34	226-238	D050033	inability of the thyroid	DiseaseOrPhenotypicFeature	30	34	1	c|DEL|1314_1328|	deletion of the coding sequence ( nt 1314 through nt 1328 )	SequenceVariant	226	238	8	1:NR:2	L2R	CROSS	30-34	240-248	D050033	inability of the thyroid	DiseaseOrPhenotypicFeature	30	34	1	c|DUP||15	insertion of 15 nt duplicating the first 15	SequenceVariant	240	248	8	1:NR:2	L2R	CROSS	30-34	279-293	D050033	inability of the thyroid	DiseaseOrPhenotypicFeature	30	34	1	p|DEL|439_443|	lacking the five terminal amino acids of exon XI ( 439 - 443 )|del - ( 439 - 443 )	SequenceVariant	279:313	293:320	10:11	1:Negative_Correlation:2	R2L	NON-CROSS	134-135	130-131	D007037	hypothyroidism|hypothyroidism	DiseaseOrPhenotypicFeature	95:134	96:135	3:5	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	1:NR:2	L2R	NON-CROSS	112-114	119-120	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	D020518	nodular goitre	DiseaseOrPhenotypicFeature	112	114	4	1:NR:2	L2R	NON-CROSS	144-147	153-154	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	D013974	L - thyroxine	ChemicalEntity	144	147	5	1:NR:2	L2R	NON-CROSS	177-178	183-185	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	7200	TSH	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	200-202	226-238	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	c|DEL|1314_1328|	deletion of the coding sequence ( nt 1314 through nt 1328 )	SequenceVariant	226	238	8	1:NR:2	L2R	CROSS	200-202	240-248	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	c|DUP||15	insertion of 15 nt duplicating the first 15	SequenceVariant	240	248	8	1:Negative_Correlation:2	L2R	NON-CROSS	313-320	324-325	D007454	iodide|iodide|iodide|radioiodide|I -|I -|iodide	ChemicalEntity	37:119:130:153:183:200:324	38:120:131:154:185:202:325	1:4:5:6:7:7:11	p|DEL|439_443|	lacking the five terminal amino acids of exon XI ( 439 - 443 )|del - ( 439 - 443 )	SequenceVariant	279:313	293:320	10:11	1:Negative_Correlation:2	R2L	NON-CROSS	144-147	134-135	D013974	L - thyroxine	ChemicalEntity	144	147	5	D007037	hypothyroidism|hypothyroidism	DiseaseOrPhenotypicFeature	95:134	96:135	3:5	1:NR:2	L2R	CROSS	134-135	177-178	D007037	hypothyroidism|hypothyroidism	DiseaseOrPhenotypicFeature	95:134	96:135	3:5	7200	TSH	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	134-135	226-238	D007037	hypothyroidism|hypothyroidism	DiseaseOrPhenotypicFeature	95:134	96:135	3:5	c|DEL|1314_1328|	deletion of the coding sequence ( nt 1314 through nt 1328 )	SequenceVariant	226	238	8	1:NR:2	L2R	CROSS	134-135	240-248	D007037	hypothyroidism|hypothyroidism	DiseaseOrPhenotypicFeature	95:134	96:135	3:5	c|DUP||15	insertion of 15 nt duplicating the first 15	SequenceVariant	240	248	8	1:NR:2	L2R	CROSS	134-135	279-293	D007037	hypothyroidism|hypothyroidism	DiseaseOrPhenotypicFeature	95:134	96:135	3:5	p|DEL|439_443|	lacking the five terminal amino acids of exon XI ( 439 - 443 )|del - ( 439 - 443 )	SequenceVariant	279:313	293:320	10:11	1:NR:2	L2R	CROSS	112-114	144-147	D020518	nodular goitre	DiseaseOrPhenotypicFeature	112	114	4	D013974	L - thyroxine	ChemicalEntity	144	147	5	1:NR:2	L2R	CROSS	112-114	177-178	D020518	nodular goitre	DiseaseOrPhenotypicFeature	112	114	4	7200	TSH	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	112-114	226-238	D020518	nodular goitre	DiseaseOrPhenotypicFeature	112	114	4	c|DEL|1314_1328|	deletion of the coding sequence ( nt 1314 through nt 1328 )	SequenceVariant	226	238	8	1:NR:2	L2R	CROSS	112-114	240-248	D020518	nodular goitre	DiseaseOrPhenotypicFeature	112	114	4	c|DUP||15	insertion of 15 nt duplicating the first 15	SequenceVariant	240	248	8	1:NR:2	L2R	CROSS	112-114	279-293	D020518	nodular goitre	DiseaseOrPhenotypicFeature	112	114	4	p|DEL|439_443|	lacking the five terminal amino acids of exon XI ( 439 - 443 )|del - ( 439 - 443 )	SequenceVariant	279:313	293:320	10:11	1:NR:2	L2R	CROSS	144-147	177-178	D013974	L - thyroxine	ChemicalEntity	144	147	5	7200	TSH	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	144-147	226-238	D013974	L - thyroxine	ChemicalEntity	144	147	5	c|DEL|1314_1328|	deletion of the coding sequence ( nt 1314 through nt 1328 )	SequenceVariant	226	238	8	1:NR:2	L2R	CROSS	144-147	240-248	D013974	L - thyroxine	ChemicalEntity	144	147	5	c|DUP||15	insertion of 15 nt duplicating the first 15	SequenceVariant	240	248	8	1:NR:2	L2R	CROSS	144-147	279-293	D013974	L - thyroxine	ChemicalEntity	144	147	5	p|DEL|439_443|	lacking the five terminal amino acids of exon XI ( 439 - 443 )|del - ( 439 - 443 )	SequenceVariant	279:313	293:320	10:11
15096016	Pallidal stimulation : an alternative to pallidotomy ?|A resurgence of interest in the surgical treatment of Parkinson 's disease ( PD ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .|Laitinen 's procedure improved most symptoms in drug - resistant PD , which engendered wide interest in the neurosurgical community .|Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .|Pallidal stimulation has not met with the same success .|According to the literature pallidotomy improves the " on " symptoms of PD , such as dyskinesias , as well as the " off " symptoms , such as rigidity , bradykinesia , and on - off fluctuations .|Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving levodopa - induced dyskinesias .|Stimulation often produces an improvement in the hyper - or dyskinetic upper limbs , but increases the " freezing " phenomenon in the lower limbs at the same time .|Considering the small increase in the patient 's independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .	1:NR:2	L2R	CROSS	109-110	156-157	D010300	Parkinson 's disease|PD|PD|PD	DiseaseOrPhenotypicFeature	17:21:45:109	20:22:46:110	1:1:2:5	D007980	levodopa	ChemicalEntity	156	157	6	1:Positive_Correlation:2	R2L	NON-CROSS	159-160	156-157	D007980	levodopa	ChemicalEntity	156	157	6	D004409	dyskinesias|dyskinesias	DiseaseOrPhenotypicFeature	113:159	114:160	5:6	1:NR:2	L2R	NON-CROSS	141-142	156-157	D009127	rigidity|rigidity	DiseaseOrPhenotypicFeature	126:141	127:142	5:6	D007980	levodopa	ChemicalEntity	156	157	6	1:NR:2	L2R	NON-CROSS	139-140	156-157	D018476	bradykinesia|bradykinesia	DiseaseOrPhenotypicFeature	128:139	129:140	5:6	D007980	levodopa	ChemicalEntity	156	157	6	1:NR:2	L2R	CROSS	156-157	168-172	D007980	levodopa	ChemicalEntity	156	157	6	D004409,D006948	hyper - or dyskinetic	DiseaseOrPhenotypicFeature	168	172	7
16152606	Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies .|Nijmegen breakage syndrome ( NBS ) is a human autosomal recessive disease characterized by genomic instability and enhanced cancer predisposition , in particular to lymphoma and leukemia .|Recently , significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation , 657del5 , were found in Russian children with sporadic lymphoid malignancies , and in Polish adults with non - Hodgkin lymphoma ( NHL ) .|In addition , the substitution 643C > T ( R215W ) has also been found in excess among children with acute lymphoblastic leukemia ( ALL ) .|In an attempt to asses the contribution of both mutations to the development of sporadic lymphoid malignancies , we analyzed DNA samples from a large group of Polish pediatric patients .|The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL ; no carrier was found among 63 patients with Hodgkin lymphoma ( HL ) .|No carriers of the variant R215W were detected in any studied group .|The relative frequency of the 657del5 mutation was calculated from a total of 6 , 984 controls matched by place of patient residence , of whom 42 were found to be carriers ( frequency = 0 . 006 ) .|In the analyzed population with malignancies , an increased odds ratio for the occurrence of mutation 657del5 was found in comparison with the control Polish population ( OR range 1 . 48 - 1 . 85 , 95 % confidence interval 1 . 18 - 2 . 65 ) .|This finding indicates that the frequency of the mutation carriers was indeed increased in patients with ALL and NHL ( p < 0 . 05 ) .|Nonetheless , NBS1 gene heterozygosity is not a major risk factor for lymphoid malignancies in childhood and adolescence .	1:Association:2	R2L	NON-CROSS	72-75	64-65	D008223	sporadic lymphoid malignancies|lymphoma|sporadic lymphoid malignancies|sporadic lymphoid malignancies|lymphoid malignancies	DiseaseOrPhenotypicFeature	17:45:72:130:329	20:46:75:133:331	0:1:2:4:10	c|DEL|657|5	657del5|657del5|657del5|657del5|657del5	SequenceVariant	4:64:150:205:256	5:65:151:206:257	0:2:5:7:8	1:NR:2	L2R	CROSS	4-5	21-24	c|DEL|657|5	657del5|657del5|657del5|657del5|657del5	SequenceVariant	4:64:150:205:256	5:65:151:206:257	0:2:5:7:8	D049932	Nijmegen breakage syndrome|NBS	DiseaseOrPhenotypicFeature	21:25	24:26	1:1	1:NR:2	L2R	CROSS	4-5	30-33	c|DEL|657|5	657del5|657del5|657del5|657del5|657del5	SequenceVariant	4:64:150:205:256	5:65:151:206:257	0:2:5:7:8	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	30	33	1	1:Association:2	R2L	NON-CROSS	256-257	245-246	D009369	cancer|malignancies	DiseaseOrPhenotypicFeature	39:245	40:246	1:8	c|DEL|657|5	657del5|657del5|657del5|657del5|657del5	SequenceVariant	4:64:150:205:256	5:65:151:206:257	0:2:5:7:8	1:NR:2	L2R	CROSS	47-48	64-65	c|DEL|657|5	657del5|657del5|657del5|657del5|657del5	SequenceVariant	4:64:150:205:256	5:65:151:206:257	0:2:5:7:8	D007938	leukemia	DiseaseOrPhenotypicFeature	47	48	1	1:Association:2	L2R	NON-CROSS	64-65	81-85	c|DEL|657|5	657del5|657del5|657del5|657del5|657del5	SequenceVariant	4:64:150:205:256	5:65:151:206:257	0:2:5:7:8	D008228	non - Hodgkin lymphoma|NHL|NHL|NHL	DiseaseOrPhenotypicFeature	81:86:171:308	85:87:172:309	2:2:5:9	1:Association:2	R2L	NON-CROSS	162-163	150-151	D054198	acute lymphoblastic leukemia|ALL|ALL|ALL	DiseaseOrPhenotypicFeature	109:113:162:306	112:114:163:307	3:3:5:9	c|DEL|657|5	657del5|657del5|657del5|657del5|657del5	SequenceVariant	4:64:150:205:256	5:65:151:206:257	0:2:5:7:8	1:NR:2	L2R	NON-CROSS	184-185	205-206	c|DEL|657|5	657del5|657del5|657del5|657del5|657del5	SequenceVariant	4:64:150:205:256	5:65:151:206:257	0:2:5:7:8	D006689	Hodgkin lymphoma|HL	DiseaseOrPhenotypicFeature	181:184	183:185	5:5	1:Association:2	L2R	NON-CROSS	7-8	17-20	4683	NBS1|NBS1|NBS1|NBS1	GeneOrGeneProduct	7:61:148:319	8:62:149:320	0:2:5:10	D008223	sporadic lymphoid malignancies|lymphoma|sporadic lymphoid malignancies|sporadic lymphoid malignancies|lymphoid malignancies	DiseaseOrPhenotypicFeature	17:45:72:130:329	20:46:75:133:331	0:1:2:4:10	1:NR:2	L2R	CROSS	7-8	21-24	4683	NBS1|NBS1|NBS1|NBS1	GeneOrGeneProduct	7:61:148:319	8:62:149:320	0:2:5:10	D049932	Nijmegen breakage syndrome|NBS	DiseaseOrPhenotypicFeature	21:25	24:26	1:1	1:NR:2	L2R	CROSS	7-8	30-33	4683	NBS1|NBS1|NBS1|NBS1	GeneOrGeneProduct	7:61:148:319	8:62:149:320	0:2:5:10	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	30	33	1	1:Association:2	L2R	CROSS	39-40	61-62	4683	NBS1|NBS1|NBS1|NBS1	GeneOrGeneProduct	7:61:148:319	8:62:149:320	0:2:5:10	D009369	cancer|malignancies	DiseaseOrPhenotypicFeature	39:245	40:246	1:8	1:NR:2	L2R	CROSS	47-48	61-62	4683	NBS1|NBS1|NBS1|NBS1	GeneOrGeneProduct	7:61:148:319	8:62:149:320	0:2:5:10	D007938	leukemia	DiseaseOrPhenotypicFeature	47	48	1	1:Association:2	L2R	NON-CROSS	308-309	319-320	4683	NBS1|NBS1|NBS1|NBS1	GeneOrGeneProduct	7:61:148:319	8:62:149:320	0:2:5:10	D008228	non - Hodgkin lymphoma|NHL|NHL|NHL	DiseaseOrPhenotypicFeature	81:86:171:308	85:87:172:309	2:2:5:9	1:Association:2	L2R	NON-CROSS	306-307	319-320	4683	NBS1|NBS1|NBS1|NBS1	GeneOrGeneProduct	7:61:148:319	8:62:149:320	0:2:5:10	D054198	acute lymphoblastic leukemia|ALL|ALL|ALL	DiseaseOrPhenotypicFeature	109:113:162:306	112:114:163:307	3:3:5:9	1:NR:2	L2R	NON-CROSS	148-149	181-183	4683	NBS1|NBS1|NBS1|NBS1	GeneOrGeneProduct	7:61:148:319	8:62:149:320	0:2:5:10	D006689	Hodgkin lymphoma|HL	DiseaseOrPhenotypicFeature	181:184	183:185	5:5	1:NR:2	L2R	CROSS	72-75	94-97	D008223	sporadic lymphoid malignancies|lymphoma|sporadic lymphoid malignancies|sporadic lymphoid malignancies|lymphoid malignancies	DiseaseOrPhenotypicFeature	17:45:72:130:329	20:46:75:133:331	0:1:2:4:10	c|SUB|C|643|T	643C > T	SequenceVariant	94	97	3	1:NR:2	L2R	CROSS	72-75	98-99	D008223	sporadic lymphoid malignancies|lymphoma|sporadic lymphoid malignancies|sporadic lymphoid malignancies|lymphoid malignancies	DiseaseOrPhenotypicFeature	17:45:72:130:329	20:46:75:133:331	0:1:2:4:10	p|SUB|R|215|W	R215W|R215W	SequenceVariant	98:192	99:193	3:6	1:NR:2	L2R	CROSS	25-26	94-97	D049932	Nijmegen breakage syndrome|NBS	DiseaseOrPhenotypicFeature	21:25	24:26	1:1	c|SUB|C|643|T	643C > T	SequenceVariant	94	97	3	1:NR:2	L2R	CROSS	25-26	98-99	D049932	Nijmegen breakage syndrome|NBS	DiseaseOrPhenotypicFeature	21:25	24:26	1:1	p|SUB|R|215|W	R215W|R215W	SequenceVariant	98:192	99:193	3:6	1:NR:2	L2R	CROSS	30-33	94-97	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	30	33	1	c|SUB|C|643|T	643C > T	SequenceVariant	94	97	3	1:NR:2	L2R	CROSS	30-33	98-99	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	30	33	1	p|SUB|R|215|W	R215W|R215W	SequenceVariant	98:192	99:193	3:6	1:NR:2	L2R	CROSS	39-40	94-97	D009369	cancer|malignancies	DiseaseOrPhenotypicFeature	39:245	40:246	1:8	c|SUB|C|643|T	643C > T	SequenceVariant	94	97	3	1:NR:2	L2R	CROSS	192-193	245-246	D009369	cancer|malignancies	DiseaseOrPhenotypicFeature	39:245	40:246	1:8	p|SUB|R|215|W	R215W|R215W	SequenceVariant	98:192	99:193	3:6	1:NR:2	L2R	CROSS	47-48	94-97	D007938	leukemia	DiseaseOrPhenotypicFeature	47	48	1	c|SUB|C|643|T	643C > T	SequenceVariant	94	97	3	1:NR:2	L2R	CROSS	47-48	98-99	D007938	leukemia	DiseaseOrPhenotypicFeature	47	48	1	p|SUB|R|215|W	R215W|R215W	SequenceVariant	98:192	99:193	3:6	1:NR:2	L2R	CROSS	86-87	94-97	D008228	non - Hodgkin lymphoma|NHL|NHL|NHL	DiseaseOrPhenotypicFeature	81:86:171:308	85:87:172:309	2:2:5:9	c|SUB|C|643|T	643C > T	SequenceVariant	94	97	3	1:NR:2	L2R	CROSS	86-87	98-99	D008228	non - Hodgkin lymphoma|NHL|NHL|NHL	DiseaseOrPhenotypicFeature	81:86:171:308	85:87:172:309	2:2:5:9	p|SUB|R|215|W	R215W|R215W	SequenceVariant	98:192	99:193	3:6	1:Association:2	R2L	NON-CROSS	109-112	94-97	D054198	acute lymphoblastic leukemia|ALL|ALL|ALL	DiseaseOrPhenotypicFeature	109:113:162:306	112:114:163:307	3:3:5:9	c|SUB|C|643|T	643C > T	SequenceVariant	94	97	3	1:NR:2	L2R	CROSS	94-97	181-183	c|SUB|C|643|T	643C > T	SequenceVariant	94	97	3	D006689	Hodgkin lymphoma|HL	DiseaseOrPhenotypicFeature	181:184	183:185	5:5	1:Association:2	R2L	NON-CROSS	109-112	98-99	D054198	acute lymphoblastic leukemia|ALL|ALL|ALL	DiseaseOrPhenotypicFeature	109:113:162:306	112:114:163:307	3:3:5:9	p|SUB|R|215|W	R215W|R215W	SequenceVariant	98:192	99:193	3:6	1:NR:2	L2R	CROSS	184-185	192-193	p|SUB|R|215|W	R215W|R215W	SequenceVariant	98:192	99:193	3:6	D006689	Hodgkin lymphoma|HL	DiseaseOrPhenotypicFeature	181:184	183:185	5:5
16277682	Segregation of a M404V mutation of the p62 / sequestosome 1 ( p62 / SQSTM1 ) gene with polyostotic Paget 's disease of bone in an Italian family .|Mutations of the p62 / Sequestosome 1 gene ( p62 / SQSTM1 ) account for both sporadic and familial forms of Paget 's disease of bone ( PDB ) .|We originally described a methionine - - > valine substitution at codon 404 ( M404V ) of exon 8 , in the ubiquitin protein - binding domain of p62 / SQSTM1 gene in an Italian PDB patient .|The collection of data from the patient 's pedigree provided evidence for a familial form of PDB .|Extension of the genetic analysis to other relatives in this family demonstrated segregation of the M404V mutation with the polyostotic PDB phenotype and provided the identification of six asymptomatic gene carriers .|DNA for mutational analysis of the exon 8 coding sequence was obtained from 22 subjects , 4 PDB patients and 18 clinically unaffected members .|Of the five clinically ascertained affected members of the family , four possessed the M404V mutation and exhibited the polyostotic form of PDB , except one patient with a single X - ray - assessed skeletal localization and one with a polyostotic disease who had died several years before the DNA analysis .|By both reconstitution and mutational analysis of the pedigree , six unaffected subjects were shown to bear the M404V mutation , representing potential asymptomatic gene carriers whose circulating levels of alkaline phosphatase were recently assessed as still within the normal range .|Taken together , these results support a genotype - phenotype correlation between the M404V mutation in the p62 / SQSTM1 gene and a polyostotic form of PDB in this family .|The high penetrance of the PDB trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype - phenotype correlation and to evaluate the potential use of mutational analysis of the p62 / SQSTM1 gene in the early detection of relatives at risk for PDB .	1:Positive_Correlation:2	R2L	NON-CROSS	135-136	130-131	C538098	Paget 's disease of bone|Paget 's disease of bone|PDB|PDB|PDB|PDB|PDB|PDB|PDB|PDB|PDB	DiseaseOrPhenotypicFeature	19:50:56:94:113:135:164:194:293:303:352	24:55:57:95:114:136:165:195:294:304:353	0:1:1:2:3:4:5:6:8:9:9	rs771966860	M404V|methionine - - > valine substitution at codon 404|M404V|M404V|M404V|M404V|M404V	SequenceVariant	3:63:73:130:186:243:280	4:72:74:131:187:244:281	0:2:2:4:6:7:8	1:Association:2	L2R	NON-CROSS	186-187	213-215	rs771966860	M404V|methionine - - > valine substitution at codon 404|M404V|M404V|M404V|M404V|M404V	SequenceVariant	3:63:73:130:186:243:280	4:72:74:131:187:244:281	0:2:2:4:6:7:8	D005357	polyostotic disease	DiseaseOrPhenotypicFeature	213	215	6	1:NR:2	L2R	NON-CROSS	243-244	255-257	rs771966860	M404V|methionine - - > valine substitution at codon 404|M404V|M404V|M404V|M404V|M404V	SequenceVariant	3:63:73:130:186:243:280	4:72:74:131:187:244:281	0:2:2:4:6:7:8	D000469	alkaline phosphatase	ChemicalEntity	255	257	7	1:Association:2	L2R	NON-CROSS	14-15	19-24	8878	p62|sequestosome 1|p62|SQSTM1|p62|Sequestosome 1|p62|SQSTM1|p62|SQSTM1|p62|SQSTM1|p62|SQSTM1	GeneOrGeneProduct	7:9:12:14:32:34:38:40:87:89:284:286:339:341	8:11:13:15:33:36:39:41:88:90:285:287:340:342	0:0:0:0:1:1:1:1:2:2:8:8:9:9	C538098	Paget 's disease of bone|Paget 's disease of bone|PDB|PDB|PDB|PDB|PDB|PDB|PDB|PDB|PDB	DiseaseOrPhenotypicFeature	19:50:56:94:113:135:164:194:293:303:352	24:55:57:95:114:136:165:195:294:304:353	0:1:1:2:3:4:5:6:8:9:9	1:Association:2	L2R	CROSS	213-215	284-285	8878	p62|sequestosome 1|p62|SQSTM1|p62|Sequestosome 1|p62|SQSTM1|p62|SQSTM1|p62|SQSTM1|p62|SQSTM1	GeneOrGeneProduct	7:9:12:14:32:34:38:40:87:89:284:286:339:341	8:11:13:15:33:36:39:41:88:90:285:287:340:342	0:0:0:0:1:1:1:1:2:2:8:8:9:9	D005357	polyostotic disease	DiseaseOrPhenotypicFeature	213	215	6	1:NR:2	L2R	CROSS	255-257	284-285	8878	p62|sequestosome 1|p62|SQSTM1|p62|Sequestosome 1|p62|SQSTM1|p62|SQSTM1|p62|SQSTM1|p62|SQSTM1	GeneOrGeneProduct	7:9:12:14:32:34:38:40:87:89:284:286:339:341	8:11:13:15:33:36:39:41:88:90:285:287:340:342	0:0:0:0:1:1:1:1:2:2:8:8:9:9	D000469	alkaline phosphatase	ChemicalEntity	255	257	7	1:NR:2	L2R	CROSS	255-257	293-294	C538098	Paget 's disease of bone|Paget 's disease of bone|PDB|PDB|PDB|PDB|PDB|PDB|PDB|PDB|PDB	DiseaseOrPhenotypicFeature	19:50:56:94:113:135:164:194:293:303:352	24:55:57:95:114:136:165:195:294:304:353	0:1:1:2:3:4:5:6:8:9:9	D000469	alkaline phosphatase	ChemicalEntity	255	257	7	1:NR:2	L2R	CROSS	213-215	255-257	D005357	polyostotic disease	DiseaseOrPhenotypicFeature	213	215	6	D000469	alkaline phosphatase	ChemicalEntity	255	257	7
1671881	Two distinct mutations at a single BamHI site in phenylketonuria .|Classical phenylketonuria is an autosomal recessive disease caused by a deficiency of hepatic phenylalanine hydroxylase ( PAH ) .|The abolition of an invariant BamHI site located in the coding sequence of the PAH gene ( exon 7 ) led to the recognition of two new point mutations at codon 272 and 273 ( 272gly - - - - stop and 273ser - - - - phe , respectively ) .|Both mutations were detected in north eastern France or Belgium and occurred on the background of RFLP haplotype 7 alleles .|The present study supports the view that the clinical heterogeneity in PKU is accounted for by the large variety of mutant genotypes associated with PAH deficiencies . .	1:Association:2	R2L	NON-CROSS	27-28	11-13	5053	PAH|PAH	GeneOrGeneProduct	27:44	28:45	1:2	D010661	phenylketonuria|Classical phenylketonuria|PKU	DiseaseOrPhenotypicFeature	9:11:114	10:13:115	0:1:4	1:Positive_Correlation:2	L2R	CROSS	65-71	114-115	D010661	phenylketonuria|Classical phenylketonuria|PKU	DiseaseOrPhenotypicFeature	9:11:114	10:13:115	0:1:4	rs62514952	272gly - - - - stop	SequenceVariant	65	71	2	1:Positive_Correlation:2	L2R	CROSS	72-78	114-115	D010661	phenylketonuria|Classical phenylketonuria|PKU	DiseaseOrPhenotypicFeature	9:11:114	10:13:115	0:1:4	rs62514953	273ser - - - - phe	SequenceVariant	72	78	2	1:NR:2	L2R	NON-CROSS	15-18	27-28	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	15	18	1	5053	PAH|PAH	GeneOrGeneProduct	27:44	28:45	1:2	1:NR:2	L2R	CROSS	15-18	65-71	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	15	18	1	rs62514952	272gly - - - - stop	SequenceVariant	65	71	2	1:NR:2	L2R	CROSS	15-18	72-78	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	15	18	1	rs62514953	273ser - - - - phe	SequenceVariant	72	78	2	1:Negative_Correlation:2	R2L	NON-CROSS	27-28	21-26	5053	PAH|PAH	GeneOrGeneProduct	27:44	28:45	1:2	OMIM:261600	deficiency of hepatic phenylalanine hydroxylase|PAH deficiencies	DiseaseOrPhenotypicFeature	21:127	26:129	1:4	1:Positive_Correlation:2	R2L	CROSS	65-71	21-26	rs62514952	272gly - - - - stop	SequenceVariant	65	71	2	OMIM:261600	deficiency of hepatic phenylalanine hydroxylase|PAH deficiencies	DiseaseOrPhenotypicFeature	21:127	26:129	1:4	1:Positive_Correlation:2	R2L	CROSS	72-78	21-26	rs62514953	273ser - - - - phe	SequenceVariant	72	78	2	OMIM:261600	deficiency of hepatic phenylalanine hydroxylase|PAH deficiencies	DiseaseOrPhenotypicFeature	21:127	26:129	1:4
16867246	Association of DRD2 polymorphisms and chlorpromazine - induced extrapyramidal syndrome in Chinese schizophrenic patients .|AIM : Extrapyramidal syndrome ( EPS ) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor .|Recently , many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression .|In this study , we evaluate the role DRD2 plays in chlorpromazine - induced EPS in schizophrenic patients .|METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , Ser311Cys , rs6275 , rs6277 and TaqIA ) in the DRD2 gene in 146 schizophrenic inpatients ( 59 with EPS and 87 without EPS according to the Simpson - Angus Scale ) treated with chlorpromazine after 8 weeks .|The alleles of all loci were determined by PCR ( polymerase chain reaction ) .|RESULTS : Polymorphisms TaqID , Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study .|No statistical significance was found in the allele distribution of - 141Cins > del , TaqIB , rs6275 and TaqIA or in the estimated haplotypes ( constituted by TaqIB , rs6275 and TaqIA ) in linkage disequilibrium between the two groups .|CONCLUSION : Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine , at least in Chinese patients with schizophrenia .|Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians .	1:NR:2	L2R	NON-CROSS	2-3	5-6	1813	DRD2|D2 receptor|DRD2|DRD2|DRD2|DRD2|DRD2	GeneOrGeneProduct	2:37:57:90:132:256:290	3:39:58:91:133:257:291	0:1:2:3:4:8:9	D002746	chlorpromazine|chlorpromazine|chlorpromazine|chlorpromazine	ChemicalEntity	5:93:156:270	6:94:157:271	0:3:4:8	1:Association:2	R2L	NON-CROSS	292-293	290-291	D001480	extrapyramidal syndrome|Extrapyramidal syndrome|EPS|EPS|EPS|EPS|EPS	DiseaseOrPhenotypicFeature	8:17:20:96:141:145:292	10:19:21:97:142:146:293	0:1:1:3:4:4:9	1813	DRD2|D2 receptor|DRD2|DRD2|DRD2|DRD2|DRD2	GeneOrGeneProduct	2:37:57:90:132:256:290	3:39:58:91:133:257:291	0:1:2:3:4:8:9	1:Association:2	L2R	NON-CROSS	132-133	136-137	1813	DRD2|D2 receptor|DRD2|DRD2|DRD2|DRD2|DRD2	GeneOrGeneProduct	2:37:57:90:132:256:290	3:39:58:91:133:257:291	0:1:2:3:4:8:9	D012559	schizophrenic|schizophrenia|schizophrenic|schizophrenic|schizophrenia	DiseaseOrPhenotypicFeature	12:64:98:136:278	13:65:99:137:279	0:2:3:4:8	1:Association:2	R2L	NON-CROSS	37-39	28-30	D014150	antipsychotic drugs	ChemicalEntity	28	30	1	1813	DRD2|D2 receptor|DRD2|DRD2|DRD2|DRD2|DRD2	GeneOrGeneProduct	2:37:57:90:132:256:290	3:39:58:91:133:257:291	0:1:2:3:4:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	5-6	8-10	D002746	chlorpromazine|chlorpromazine|chlorpromazine|chlorpromazine	ChemicalEntity	5:93:156:270	6:94:157:271	0:3:4:8	D001480	extrapyramidal syndrome|Extrapyramidal syndrome|EPS|EPS|EPS|EPS|EPS	DiseaseOrPhenotypicFeature	8:17:20:96:141:145:292	10:19:21:97:142:146:293	0:1:1:3:4:4:9	1:Negative_Correlation:2	R2L	NON-CROSS	98-99	93-94	D012559	schizophrenic|schizophrenia|schizophrenic|schizophrenic|schizophrenia	DiseaseOrPhenotypicFeature	12:64:98:136:278	13:65:99:137:279	0:2:3:4:8	D002746	chlorpromazine|chlorpromazine|chlorpromazine|chlorpromazine	ChemicalEntity	5:93:156:270	6:94:157:271	0:3:4:8	1:NR:2	L2R	CROSS	5-6	28-30	D002746	chlorpromazine|chlorpromazine|chlorpromazine|chlorpromazine	ChemicalEntity	5:93:156:270	6:94:157:271	0:3:4:8	D014150	antipsychotic drugs	ChemicalEntity	28	30	1	1:NR:2	L2R	NON-CROSS	93-94	113-117	D002746	chlorpromazine|chlorpromazine|chlorpromazine|chlorpromazine	ChemicalEntity	5:93:156:270	6:94:157:271	0:3:4:8	c|INDEL|0141|C	- 141Cins > del|- 141Cins > del	SequenceVariant	113:206	117:210	4:7	1:NR:2	L2R	NON-CROSS	156-157	181-182	D002746	chlorpromazine|chlorpromazine|chlorpromazine|chlorpromazine	ChemicalEntity	5:93:156:270	6:94:157:271	0:3:4:8	c|SUB|S|311|C	Ser311Cys|Ser311Cys	SequenceVariant	122:181	123:182	4:6	1:NR:2	L2R	NON-CROSS	93-94	124-125	D002746	chlorpromazine|chlorpromazine|chlorpromazine|chlorpromazine	ChemicalEntity	5:93:156:270	6:94:157:271	0:3:4:8	rs6275	rs6275|rs6275|rs6275	SequenceVariant	124:213:226	125:214:227	4:7:7	1:NR:2	L2R	NON-CROSS	156-157	183-184	D002746	chlorpromazine|chlorpromazine|chlorpromazine|chlorpromazine	ChemicalEntity	5:93:156:270	6:94:157:271	0:3:4:8	rs6277	rs6277|rs6277	SequenceVariant	126:183	127:184	4:6	1:Positive_Correlation:2	L2R	NON-CROSS	20-21	28-30	D001480	extrapyramidal syndrome|Extrapyramidal syndrome|EPS|EPS|EPS|EPS|EPS	DiseaseOrPhenotypicFeature	8:17:20:96:141:145:292	10:19:21:97:142:146:293	0:1:1:3:4:4:9	D014150	antipsychotic drugs	ChemicalEntity	28	30	1	1:NR:2	L2R	NON-CROSS	96-97	113-117	D001480	extrapyramidal syndrome|Extrapyramidal syndrome|EPS|EPS|EPS|EPS|EPS	DiseaseOrPhenotypicFeature	8:17:20:96:141:145:292	10:19:21:97:142:146:293	0:1:1:3:4:4:9	c|INDEL|0141|C	- 141Cins > del|- 141Cins > del	SequenceVariant	113:206	117:210	4:7	1:NR:2	L2R	NON-CROSS	122-123	141-142	D001480	extrapyramidal syndrome|Extrapyramidal syndrome|EPS|EPS|EPS|EPS|EPS	DiseaseOrPhenotypicFeature	8:17:20:96:141:145:292	10:19:21:97:142:146:293	0:1:1:3:4:4:9	c|SUB|S|311|C	Ser311Cys|Ser311Cys	SequenceVariant	122:181	123:182	4:6	1:NR:2	L2R	NON-CROSS	124-125	141-142	D001480	extrapyramidal syndrome|Extrapyramidal syndrome|EPS|EPS|EPS|EPS|EPS	DiseaseOrPhenotypicFeature	8:17:20:96:141:145:292	10:19:21:97:142:146:293	0:1:1:3:4:4:9	rs6275	rs6275|rs6275|rs6275	SequenceVariant	124:213:226	125:214:227	4:7:7	1:NR:2	L2R	NON-CROSS	126-127	141-142	D001480	extrapyramidal syndrome|Extrapyramidal syndrome|EPS|EPS|EPS|EPS|EPS	DiseaseOrPhenotypicFeature	8:17:20:96:141:145:292	10:19:21:97:142:146:293	0:1:1:3:4:4:9	rs6277	rs6277|rs6277	SequenceVariant	126:183	127:184	4:6	1:NR:2	L2R	CROSS	12-13	28-30	D012559	schizophrenic|schizophrenia|schizophrenic|schizophrenic|schizophrenia	DiseaseOrPhenotypicFeature	12:64:98:136:278	13:65:99:137:279	0:2:3:4:8	D014150	antipsychotic drugs	ChemicalEntity	28	30	1	1:NR:2	L2R	NON-CROSS	98-99	113-117	D012559	schizophrenic|schizophrenia|schizophrenic|schizophrenic|schizophrenia	DiseaseOrPhenotypicFeature	12:64:98:136:278	13:65:99:137:279	0:2:3:4:8	c|INDEL|0141|C	- 141Cins > del|- 141Cins > del	SequenceVariant	113:206	117:210	4:7	1:NR:2	L2R	NON-CROSS	122-123	136-137	D012559	schizophrenic|schizophrenia|schizophrenic|schizophrenic|schizophrenia	DiseaseOrPhenotypicFeature	12:64:98:136:278	13:65:99:137:279	0:2:3:4:8	c|SUB|S|311|C	Ser311Cys|Ser311Cys	SequenceVariant	122:181	123:182	4:6	1:NR:2	L2R	NON-CROSS	124-125	136-137	D012559	schizophrenic|schizophrenia|schizophrenic|schizophrenic|schizophrenia	DiseaseOrPhenotypicFeature	12:64:98:136:278	13:65:99:137:279	0:2:3:4:8	rs6275	rs6275|rs6275|rs6275	SequenceVariant	124:213:226	125:214:227	4:7:7	1:NR:2	L2R	NON-CROSS	126-127	136-137	D012559	schizophrenic|schizophrenia|schizophrenic|schizophrenic|schizophrenia	DiseaseOrPhenotypicFeature	12:64:98:136:278	13:65:99:137:279	0:2:3:4:8	rs6277	rs6277|rs6277	SequenceVariant	126:183	127:184	4:6	1:NR:2	L2R	CROSS	28-30	113-117	D014150	antipsychotic drugs	ChemicalEntity	28	30	1	c|INDEL|0141|C	- 141Cins > del|- 141Cins > del	SequenceVariant	113:206	117:210	4:7	1:NR:2	L2R	CROSS	28-30	122-123	D014150	antipsychotic drugs	ChemicalEntity	28	30	1	c|SUB|S|311|C	Ser311Cys|Ser311Cys	SequenceVariant	122:181	123:182	4:6	1:NR:2	L2R	CROSS	28-30	124-125	D014150	antipsychotic drugs	ChemicalEntity	28	30	1	rs6275	rs6275|rs6275|rs6275	SequenceVariant	124:213:226	125:214:227	4:7:7	1:NR:2	L2R	CROSS	28-30	126-127	D014150	antipsychotic drugs	ChemicalEntity	28	30	1	rs6277	rs6277|rs6277	SequenceVariant	126:183	127:184	4:6
17549393	A novel IRF6 nonsense mutation ( Y67X ) in a German family with Van der Woude syndrome .|Van der Woude syndrome ( VWS ) is the most common type of syndromic orofacial cleft , which accounts for approximately 2 % of all cleft lip and palate cases .|It is characterised by variable association of lower lip pits , cleft lip and cleft palate , and hypodontia .|VWS arises as the result of mutations in the gene encoding interferon regulatory factor 6 ( IRF6 ) .|The disorder is transmitted in an autosomal dominant manner , with high penetrance and variable expressivity .|Very recently , mutations of the IRF6 gene in exons 2 - 9 have been found in VWS patients , suggesting that this gene plays an important role in orofacial development .|We report a novel mutation of the IRF6 gene in a German family .|Five out of the 12 persons affected were able to be investigated .|The mutation produced a stop codon within exon 4 of the IRF6 gene .|All 5 patients were heterozygous for a base substitution c . 201C > A changing the tyrosine codon at amino acid position 67 into a stop codon ( p . Y67X ) in exon 4 .|The premature stop codon was responsible for a truncated protein lacking parts of the DNA - binding domain and the complete Smad - interferon regulatory factor - binding domain probably essential for interactions with the Smad transcription factors .	1:Association:2	L2R	NON-CROSS	2-3	13-17	3664	IRF6|interferon regulatory factor 6|IRF6|IRF6|IRF6|IRF6|interferon regulatory factor	GeneOrGeneProduct	2:80:85:111:144:175:237	3:84:86:112:145:176:240	0:3:3:5:6:8:10	C536528	Van der Woude syndrome|Van der Woude syndrome|VWS|lip pits|VWS|VWS	DiseaseOrPhenotypicFeature	13:18:23:57:69:122	17:22:24:59:70:123	0:1:1:2:3:5	1:NR:2	L2R	CROSS	63-65	80-84	3664	IRF6|interferon regulatory factor 6|IRF6|IRF6|IRF6|IRF6|interferon regulatory factor	GeneOrGeneProduct	2:80:85:111:144:175:237	3:84:86:112:145:176:240	0:3:3:5:6:8:10	D002972	syndromic orofacial cleft|cleft palate	DiseaseOrPhenotypicFeature	31:63	34:65	1:2	1:NR:2	L2R	CROSS	43-47	85-86	3664	IRF6|interferon regulatory factor 6|IRF6|IRF6|IRF6|IRF6|interferon regulatory factor	GeneOrGeneProduct	2:80:85:111:144:175:237	3:84:86:112:145:176:240	0:3:3:5:6:8:10	D002971,D002972	cleft lip and palate	DiseaseOrPhenotypicFeature	43	47	1	1:NR:2	L2R	CROSS	60-62	80-84	3664	IRF6|interferon regulatory factor 6|IRF6|IRF6|IRF6|IRF6|interferon regulatory factor	GeneOrGeneProduct	2:80:85:111:144:175:237	3:84:86:112:145:176:240	0:3:3:5:6:8:10	D002971	cleft lip	DiseaseOrPhenotypicFeature	60	62	2	1:NR:2	L2R	CROSS	67-68	80-84	3664	IRF6|interferon regulatory factor 6|IRF6|IRF6|IRF6|IRF6|interferon regulatory factor	GeneOrGeneProduct	2:80:85:111:144:175:237	3:84:86:112:145:176:240	0:3:3:5:6:8:10	D000848	hypodontia	DiseaseOrPhenotypicFeature	67	68	2	1:Bind:2	L2R	NON-CROSS	235-236	237-240	3664	IRF6|interferon regulatory factor 6|IRF6|IRF6|IRF6|IRF6|interferon regulatory factor	GeneOrGeneProduct	2:80:85:111:144:175:237	3:84:86:112:145:176:240	0:3:3:5:6:8:10	4086	Smad|Smad	GeneOrGeneProduct	235:249	236:250	10:10	1:Positive_Correlation:2	L2R	NON-CROSS	6-7	13-17	p|SUB|Y|67|X	Y67X|tyrosine codon at amino acid position 67 into a stop|p . Y67X	SequenceVariant	6:194:206	7:204:209	0:9:9	C536528	Van der Woude syndrome|Van der Woude syndrome|VWS|lip pits|VWS|VWS	DiseaseOrPhenotypicFeature	13:18:23:57:69:122	17:22:24:59:70:123	0:1:1:2:3:5	1:NR:2	L2R	CROSS	6-7	31-34	p|SUB|Y|67|X	Y67X|tyrosine codon at amino acid position 67 into a stop|p . Y67X	SequenceVariant	6:194:206	7:204:209	0:9:9	D002972	syndromic orofacial cleft|cleft palate	DiseaseOrPhenotypicFeature	31:63	34:65	1:2	1:NR:2	L2R	CROSS	6-7	43-47	p|SUB|Y|67|X	Y67X|tyrosine codon at amino acid position 67 into a stop|p . Y67X	SequenceVariant	6:194:206	7:204:209	0:9:9	D002971,D002972	cleft lip and palate	DiseaseOrPhenotypicFeature	43	47	1	1:NR:2	L2R	CROSS	6-7	60-62	p|SUB|Y|67|X	Y67X|tyrosine codon at amino acid position 67 into a stop|p . Y67X	SequenceVariant	6:194:206	7:204:209	0:9:9	D002971	cleft lip	DiseaseOrPhenotypicFeature	60	62	2	1:NR:2	L2R	CROSS	6-7	67-68	p|SUB|Y|67|X	Y67X|tyrosine codon at amino acid position 67 into a stop|p . Y67X	SequenceVariant	6:194:206	7:204:209	0:9:9	D000848	hypodontia	DiseaseOrPhenotypicFeature	67	68	2	1:Positive_Correlation:2	L2R	CROSS	122-123	187-192	C536528	Van der Woude syndrome|Van der Woude syndrome|VWS|lip pits|VWS|VWS	DiseaseOrPhenotypicFeature	13:18:23:57:69:122	17:22:24:59:70:123	0:1:1:2:3:5	c|SUB|C|201|A	c . 201C > A	SequenceVariant	187	192	9	1:NR:2	L2R	CROSS	122-123	235-236	C536528	Van der Woude syndrome|Van der Woude syndrome|VWS|lip pits|VWS|VWS	DiseaseOrPhenotypicFeature	13:18:23:57:69:122	17:22:24:59:70:123	0:1:1:2:3:5	4086	Smad|Smad	GeneOrGeneProduct	235:249	236:250	10:10	1:NR:2	L2R	CROSS	63-65	187-192	D002972	syndromic orofacial cleft|cleft palate	DiseaseOrPhenotypicFeature	31:63	34:65	1:2	c|SUB|C|201|A	c . 201C > A	SequenceVariant	187	192	9	1:NR:2	L2R	CROSS	63-65	235-236	D002972	syndromic orofacial cleft|cleft palate	DiseaseOrPhenotypicFeature	31:63	34:65	1:2	4086	Smad|Smad	GeneOrGeneProduct	235:249	236:250	10:10	1:NR:2	L2R	CROSS	43-47	187-192	D002971,D002972	cleft lip and palate	DiseaseOrPhenotypicFeature	43	47	1	c|SUB|C|201|A	c . 201C > A	SequenceVariant	187	192	9	1:NR:2	L2R	CROSS	43-47	235-236	D002971,D002972	cleft lip and palate	DiseaseOrPhenotypicFeature	43	47	1	4086	Smad|Smad	GeneOrGeneProduct	235:249	236:250	10:10	1:NR:2	L2R	CROSS	60-62	187-192	D002971	cleft lip	DiseaseOrPhenotypicFeature	60	62	2	c|SUB|C|201|A	c . 201C > A	SequenceVariant	187	192	9	1:NR:2	L2R	CROSS	60-62	235-236	D002971	cleft lip	DiseaseOrPhenotypicFeature	60	62	2	4086	Smad|Smad	GeneOrGeneProduct	235:249	236:250	10:10	1:NR:2	L2R	CROSS	67-68	187-192	D000848	hypodontia	DiseaseOrPhenotypicFeature	67	68	2	c|SUB|C|201|A	c . 201C > A	SequenceVariant	187	192	9	1:NR:2	L2R	CROSS	67-68	235-236	D000848	hypodontia	DiseaseOrPhenotypicFeature	67	68	2	4086	Smad|Smad	GeneOrGeneProduct	235:249	236:250	10:10
17962394	Skewed X inactivation in an X linked nystagmus family resulted from a novel , p . R229G , missense mutation in the FRMD7 gene .|AIMS : This study aimed to identify the underlying genetic defect of a large Turkish X linked nystagmus ( NYS ) family .|METHODS : Both Xp11 and Xq26 loci were tested by linkage analysis .|The 12 exons and intron - exon junctions of the FRMD7 gene were screened by direct sequencing .|X chromosome inactivation analysis was performed by enzymatic predigestion of DNA with a methylation - sensitive enzyme , followed by PCR of the polymorphic CAG repeat of the androgen receptor gene .|RESULTS : The family contained 162 individuals , among whom 28 had NYS .|Linkage analysis confirmed the Xq26 locus .|A novel missense c . 686C > G mutation , which causes the substitution of a conserved arginine at amino acid position 229 by glycine ( p . R229G ) in exon 8 of the FRMD7 gene , was observed .|This change was not documented in 120 control individuals .|The clinical findings in a female who was homozygous for the mutation were not different from those of affected heterozygous females .|Skewed X inactivation was remarkable in the affected females of the family .|CONCLUSIONS : A novel p . R229G mutation in the FRMD7 gene causes the NYS phenotype , and skewed X inactivation influences the manifestation of the disease in X linked NYS females .	1:Positive_Correlation:2	L2R	NON-CROSS	5-8	14-17	C580539	X linked nystagmus|X linked nystagmus|NYS|NYS|NYS|X linked NYS	DiseaseOrPhenotypicFeature	5:40:44:123:232:246	8:43:45:124:233:249	0:1:1:5:11:11	rs137852212	p . R229G|c . 686C > G|arginine at amino acid position 229 by glycine|p . R229G|p . R229G	SequenceVariant	14:135:149:158:222	17:140:157:161:225	0:7:7:7:11	1:Association:2	L2R	NON-CROSS	228-229	232-233	C580539	X linked nystagmus|X linked nystagmus|NYS|NYS|NYS|X linked NYS	DiseaseOrPhenotypicFeature	5:40:44:123:232:246	8:43:45:124:233:249	0:1:1:5:11:11	90167	FRMD7|FRMD7|FRMD7|FRMD7	GeneOrGeneProduct	22:71:167:228	23:72:168:229	0:3:7:11	1:NR:2	L2R	CROSS	103-105	123-124	C580539	X linked nystagmus|X linked nystagmus|NYS|NYS|NYS|X linked NYS	DiseaseOrPhenotypicFeature	5:40:44:123:232:246	8:43:45:124:233:249	0:1:1:5:11:11	c|DUP||CAG|	CAG repeat	SequenceVariant	103	105	4	1:NR:2	L2R	CROSS	107-109	123-124	C580539	X linked nystagmus|X linked nystagmus|NYS|NYS|NYS|X linked NYS	DiseaseOrPhenotypicFeature	5:40:44:123:232:246	8:43:45:124:233:249	0:1:1:5:11:11	367	androgen receptor	GeneOrGeneProduct	107	109	4	1:NR:2	L2R	CROSS	14-17	34-36	rs137852212	p . R229G|c . 686C > G|arginine at amino acid position 229 by glycine|p . R229G|p . R229G	SequenceVariant	14:135:149:158:222	17:140:157:161:225	0:7:7:7:11	D030342	genetic defect	DiseaseOrPhenotypicFeature	34	36	1	1:NR:2	L2R	CROSS	22-23	34-36	90167	FRMD7|FRMD7|FRMD7|FRMD7	GeneOrGeneProduct	22:71:167:228	23:72:168:229	0:3:7:11	D030342	genetic defect	DiseaseOrPhenotypicFeature	34	36	1	1:NR:2	L2R	CROSS	71-72	107-109	90167	FRMD7|FRMD7|FRMD7|FRMD7	GeneOrGeneProduct	22:71:167:228	23:72:168:229	0:3:7:11	367	androgen receptor	GeneOrGeneProduct	107	109	4	1:NR:2	L2R	CROSS	34-36	103-105	D030342	genetic defect	DiseaseOrPhenotypicFeature	34	36	1	c|DUP||CAG|	CAG repeat	SequenceVariant	103	105	4	1:NR:2	L2R	CROSS	34-36	107-109	D030342	genetic defect	DiseaseOrPhenotypicFeature	34	36	1	367	androgen receptor	GeneOrGeneProduct	107	109	4
18046082	Identification of apolipoprotein E Guangzhou ( arginine 150 proline ) , a new variant associated with lipoprotein glomerulopathy .|BACKGROUND / AIMS : Lipoprotein glomerulopathy ( LPG ) is a rare disease characterized by thrombus - like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E ( apoE ) .|Previous studies have shown that genetic disorders of apoE may contribute to the pathogenesis of LPG , but LPG may not be caused by apoE gene mutations in Chinese patients .|This study investigated the association of a new variant of apoE with LPG in a Chinese family .|METHODS : The apoE gene in a family with 4 LPG patients was sequenced .|The polymerase chain reaction product of coding region of apoE exon 4 was cloned into pMD 18 - T vector and then sequenced .|RESULTS : A novel point mutation in exon 4 of the apoE gene was identified in all 4 LPG patients and 1 asymptomatic family member .|Sequence analysis confirmed a nucleotide G to C point mutation in exon 4 ( base 308 ) of the apoE gene in all patients and the asymptomatic family member .|This missense mutation denotes amino acid substitution of the proline residue for arginine residue at position 150 of apoE .|Those patients were all heterozygotes with apoE Guangzhou .|One of 2 grandsons was a heterozygous carrier of apoE Guangzhou , although he did not have proteinuria .|CONCLUSION : The results of this study suggest that apoE ( arginine 150 proline ) is a novel apoE variant that etiologically related to LPG .|This variant ( apoE Guangzhou ) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to lipids .	1:Association:2	L2R	NON-CROSS	95-96	97-98	348	apolipoprotein E|apolipoprotein E|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE	GeneOrGeneProduct	2:48:51:62:78:95:106:127:153:187:216:224:236:255:264:275:287	4:50:52:63:79:96:107:128:154:188:217:225:237:256:265:276:288	0:1:1:2:2:3:4:5:6:7:8:9:10:11:11:12:12	C567089	lipoprotein glomerulopathy|Lipoprotein glomerulopathy|LPG|LPG|LPG|LPG|LPG|LPG|LPG	DiseaseOrPhenotypicFeature	16:23:26:69:72:97:113:160:270	18:25:27:70:73:98:114:161:271	0:1:1:2:2:3:4:6:11	1:NR:2	L2R	NON-CROSS	34-35	48-50	348	apolipoprotein E|apolipoprotein E|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE	GeneOrGeneProduct	2:48:51:62:78:95:106:127:153:187:216:224:236:255:264:275:287	4:50:52:63:79:96:107:128:154:188:217:225:237:256:265:276:288	0:1:1:2:2:3:4:5:6:7:8:9:10:11:11:12:12	D013927	thrombus	DiseaseOrPhenotypicFeature	34	35	1	1:NR:2	L2R	NON-CROSS	40-43	48-50	348	apolipoprotein E|apolipoprotein E|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE	GeneOrGeneProduct	2:48:51:62:78:95:106:127:153:187:216:224:236:255:264:275:287	4:50:52:63:79:96:107:128:154:188:217:225:237:256:265:276:288	0:1:1:2:2:3:4:5:6:7:8:9:10:11:11:12:12	D007674	dilated glomerular capillaries	DiseaseOrPhenotypicFeature	40	43	1	1:NR:2	L2R	NON-CROSS	236-237	244-245	348	apolipoprotein E|apolipoprotein E|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE	GeneOrGeneProduct	2:48:51:62:78:95:106:127:153:187:216:224:236:255:264:275:287	4:50:52:63:79:96:107:128:154:188:217:225:237:256:265:276:288	0:1:1:2:2:3:4:5:6:7:8:9:10:11:11:12:12	D011507	proteinuria	DiseaseOrPhenotypicFeature	244	245	10	1:Bind:2	L2R	NON-CROSS	287-288	295-296	348	apolipoprotein E|apolipoprotein E|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE|apoE	GeneOrGeneProduct	2:48:51:62:78:95:106:127:153:187:216:224:236:255:264:275:287	4:50:52:63:79:96:107:128:154:188:217:225:237:256:265:276:288	0:1:1:2:2:3:4:5:6:7:8:9:10:11:11:12:12	D008055	lipids	ChemicalEntity	295	296	12	1:Association:2	L2R	NON-CROSS	6-9	16-18	p|SUB|R|150|P	arginine 150 proline|proline residue for arginine residue at position 150|arginine 150 proline	SequenceVariant	6:207:257	9:215:260	0:8:11	C567089	lipoprotein glomerulopathy|Lipoprotein glomerulopathy|LPG|LPG|LPG|LPG|LPG|LPG|LPG	DiseaseOrPhenotypicFeature	16:23:26:69:72:97:113:160:270	18:25:27:70:73:98:114:161:271	0:1:1:2:2:3:4:6:11	1:NR:2	L2R	CROSS	6-9	34-35	p|SUB|R|150|P	arginine 150 proline|proline residue for arginine residue at position 150|arginine 150 proline	SequenceVariant	6:207:257	9:215:260	0:8:11	D013927	thrombus	DiseaseOrPhenotypicFeature	34	35	1	1:NR:2	L2R	CROSS	6-9	40-43	p|SUB|R|150|P	arginine 150 proline|proline residue for arginine residue at position 150|arginine 150 proline	SequenceVariant	6:207:257	9:215:260	0:8:11	D007674	dilated glomerular capillaries	DiseaseOrPhenotypicFeature	40	43	1	1:NR:2	L2R	CROSS	244-245	257-260	p|SUB|R|150|P	arginine 150 proline|proline residue for arginine residue at position 150|arginine 150 proline	SequenceVariant	6:207:257	9:215:260	0:8:11	D011507	proteinuria	DiseaseOrPhenotypicFeature	244	245	10	1:Association:2	L2R	CROSS	257-260	295-296	p|SUB|R|150|P	arginine 150 proline|proline residue for arginine residue at position 150|arginine 150 proline	SequenceVariant	6:207:257	9:215:260	0:8:11	D008055	lipids	ChemicalEntity	295	296	12	1:NR:2	L2R	CROSS	160-161	173-185	C567089	lipoprotein glomerulopathy|Lipoprotein glomerulopathy|LPG|LPG|LPG|LPG|LPG|LPG|LPG	DiseaseOrPhenotypicFeature	16:23:26:69:72:97:113:160:270	18:25:27:70:73:98:114:161:271	0:1:1:2:2:3:4:6:11	c|SUB|G|308|C	G to C point mutation in exon 4 ( base 308 )	SequenceVariant	173	185	7	1:NR:2	L2R	CROSS	270-271	295-296	C567089	lipoprotein glomerulopathy|Lipoprotein glomerulopathy|LPG|LPG|LPG|LPG|LPG|LPG|LPG	DiseaseOrPhenotypicFeature	16:23:26:69:72:97:113:160:270	18:25:27:70:73:98:114:161:271	0:1:1:2:2:3:4:6:11	D008055	lipids	ChemicalEntity	295	296	12	1:NR:2	L2R	CROSS	34-35	173-185	D013927	thrombus	DiseaseOrPhenotypicFeature	34	35	1	c|SUB|G|308|C	G to C point mutation in exon 4 ( base 308 )	SequenceVariant	173	185	7	1:NR:2	L2R	CROSS	34-35	295-296	D013927	thrombus	DiseaseOrPhenotypicFeature	34	35	1	D008055	lipids	ChemicalEntity	295	296	12	1:NR:2	L2R	CROSS	40-43	173-185	D007674	dilated glomerular capillaries	DiseaseOrPhenotypicFeature	40	43	1	c|SUB|G|308|C	G to C point mutation in exon 4 ( base 308 )	SequenceVariant	173	185	7	1:NR:2	L2R	CROSS	40-43	295-296	D007674	dilated glomerular capillaries	DiseaseOrPhenotypicFeature	40	43	1	D008055	lipids	ChemicalEntity	295	296	12	1:NR:2	L2R	CROSS	173-185	244-245	c|SUB|G|308|C	G to C point mutation in exon 4 ( base 308 )	SequenceVariant	173	185	7	D011507	proteinuria	DiseaseOrPhenotypicFeature	244	245	10	1:Association:2	L2R	CROSS	173-185	295-296	c|SUB|G|308|C	G to C point mutation in exon 4 ( base 308 )	SequenceVariant	173	185	7	D008055	lipids	ChemicalEntity	295	296	12	1:NR:2	L2R	CROSS	244-245	295-296	D011507	proteinuria	DiseaseOrPhenotypicFeature	244	245	10	D008055	lipids	ChemicalEntity	295	296	12
21054465	Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography .|WHAT IS KNOWN AND OBJECTIVE : CYP2C8 is involved in the cytochrome P450 ( CYP ) epoxygenase pathway .|Arachidonic acid metabolites such as epoxyeicosatrienenoic acids and hydroxyeicosatetrenoic acids , produced may have a role in hypertension .|We aimed to develop a medium through - put method for screening samples of known and new mutations of CYP2C8 using denaturing high performance liquid chromatography ( DHPLC ) .|METHODS : DNA samples from 200 subjects ( hypertensive patients and healthy controls ) were screened for SNPs in CYP2C8 using DHPLC .|Genotypes and allelic frequencies of CYP2C8 between the healthy controls and patients with hypertension were compared .|RESULTS AND DISCUSSIONS : Six variants were detected and two were new ; T deletion at 5063 and substitution of C to T at 33468 in exon 8 .|Differences in variant frequencies were detected between the controls and hypertensive patients .|The controls have significantly higher prevalence of C35322C compared to the patients .|The functional significance of the SNP at 35322 requires further study .|Having homozygous C35322C could be a protective factor for hypertension .|WHAT IS NEW AND CONCLUSION : Denaturing high performance liquid chromatography is useful for population screening to identify new and existing SNPs .|A higher frequency of the C35322T SNP was observed among hypertensive patients than control subjects .|This potentially important observation requires confirmation and the clinical significance assessed .	1:Association:2	L2R	NON-CROSS	3-4	5-6	1558	CYP2C8|CYP2C8|cytochrome P450 ( CYP ) epoxygenase|CYP2C8|CYP2C8|CYP2C8	GeneOrGeneProduct	3:20:25:71:101:110	4:21:31:72:102:111	0:1:1:3:4:5	D006973	hypertensive|hypertension|hypertensive|hypertension|hypertensive|hypertension|hypertensive	DiseaseOrPhenotypicFeature	5:50:90:118:161:198:233	6:51:91:119:162:199:234	0:2:4:5:7:10:12	1:NR:2	L2R	CROSS	25-31	33-35	1558	CYP2C8|CYP2C8|cytochrome P450 ( CYP ) epoxygenase|CYP2C8|CYP2C8|CYP2C8	GeneOrGeneProduct	3:20:25:71:101:110	4:21:31:72:102:111	0:1:1:3:4:5	D016718	Arachidonic acid	ChemicalEntity	33	35	2	1:NR:2	L2R	CROSS	25-31	38-40	1558	CYP2C8|CYP2C8|cytochrome P450 ( CYP ) epoxygenase|CYP2C8|CYP2C8|CYP2C8	GeneOrGeneProduct	3:20:25:71:101:110	4:21:31:72:102:111	0:1:1:3:4:5	-	epoxyeicosatrienenoic acids|hydroxyeicosatetrenoic acids	ChemicalEntity	38:41	40:43	2:2	1:Association:2	R2L	NON-CROSS	50-51	33-35	D016718	Arachidonic acid	ChemicalEntity	33	35	2	D006973	hypertensive|hypertension|hypertensive|hypertension|hypertensive|hypertension|hypertensive	DiseaseOrPhenotypicFeature	5:50:90:118:161:198:233	6:51:91:119:162:199:234	0:2:4:5:7:10:12	1:NR:2	L2R	NON-CROSS	41-43	50-51	D006973	hypertensive|hypertension|hypertensive|hypertension|hypertensive|hypertension|hypertensive	DiseaseOrPhenotypicFeature	5:50:90:118:161:198:233	6:51:91:119:162:199:234	0:2:4:5:7:10:12	-	epoxyeicosatrienenoic acids|hydroxyeicosatetrenoic acids	ChemicalEntity	38:41	40:43	2:2	1:Association:2	R2L	CROSS	135-139	118-119	c|DEL|5063|T	T deletion at 5063	SequenceVariant	135	139	6	D006973	hypertensive|hypertension|hypertensive|hypertension|hypertensive|hypertension|hypertensive	DiseaseOrPhenotypicFeature	5:50:90:118:161:198:233	6:51:91:119:162:199:234	0:2:4:5:7:10:12	1:Association:2	R2L	CROSS	161-162	142-147	c|SUB|C|33468|T	C to T at 33468	SequenceVariant	142	147	6	D006973	hypertensive|hypertension|hypertensive|hypertension|hypertensive|hypertension|hypertensive	DiseaseOrPhenotypicFeature	5:50:90:118:161:198:233	6:51:91:119:162:199:234	0:2:4:5:7:10:12	1:Association:2	L2R	NON-CROSS	191-192	198-199	D006973	hypertensive|hypertension|hypertensive|hypertension|hypertensive|hypertension|hypertensive	DiseaseOrPhenotypicFeature	5:50:90:118:161:198:233	6:51:91:119:162:199:234	0:2:4:5:7:10:12	c|SUB|C|35322|C	C35322C|C35322C	SequenceVariant	171:191	172:192	8:10	1:Positive_Correlation:2	R2L	NON-CROSS	233-234	228-229	c|SUB|C|35322|T	C35322T	SequenceVariant	228	229	12	D006973	hypertensive|hypertension|hypertensive|hypertension|hypertensive|hypertension|hypertensive	DiseaseOrPhenotypicFeature	5:50:90:118:161:198:233	6:51:91:119:162:199:234	0:2:4:5:7:10:12	1:NR:2	L2R	NON-CROSS	33-35	38-40	D016718	Arachidonic acid	ChemicalEntity	33	35	2	-	epoxyeicosatrienenoic acids|hydroxyeicosatetrenoic acids	ChemicalEntity	38:41	40:43	2:2	1:NR:2	L2R	CROSS	33-35	135-139	D016718	Arachidonic acid	ChemicalEntity	33	35	2	c|DEL|5063|T	T deletion at 5063	SequenceVariant	135	139	6	1:NR:2	L2R	CROSS	33-35	142-147	D016718	Arachidonic acid	ChemicalEntity	33	35	2	c|SUB|C|33468|T	C to T at 33468	SequenceVariant	142	147	6	1:NR:2	L2R	CROSS	33-35	171-172	D016718	Arachidonic acid	ChemicalEntity	33	35	2	c|SUB|C|35322|C	C35322C|C35322C	SequenceVariant	171:191	172:192	8:10	1:NR:2	L2R	CROSS	33-35	228-229	D016718	Arachidonic acid	ChemicalEntity	33	35	2	c|SUB|C|35322|T	C35322T	SequenceVariant	228	229	12	1:NR:2	L2R	CROSS	41-43	135-139	-	epoxyeicosatrienenoic acids|hydroxyeicosatetrenoic acids	ChemicalEntity	38:41	40:43	2:2	c|DEL|5063|T	T deletion at 5063	SequenceVariant	135	139	6	1:NR:2	L2R	CROSS	41-43	142-147	-	epoxyeicosatrienenoic acids|hydroxyeicosatetrenoic acids	ChemicalEntity	38:41	40:43	2:2	c|SUB|C|33468|T	C to T at 33468	SequenceVariant	142	147	6	1:NR:2	L2R	CROSS	41-43	171-172	-	epoxyeicosatrienenoic acids|hydroxyeicosatetrenoic acids	ChemicalEntity	38:41	40:43	2:2	c|SUB|C|35322|C	C35322C|C35322C	SequenceVariant	171:191	172:192	8:10	1:NR:2	L2R	CROSS	41-43	228-229	-	epoxyeicosatrienenoic acids|hydroxyeicosatetrenoic acids	ChemicalEntity	38:41	40:43	2:2	c|SUB|C|35322|T	C35322T	SequenceVariant	228	229	12
22711886	TNFR - associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia / small lymphocytic lymphoma in mice .|We have previously shown that transgenic ( tg ) mice expressing in B lymphocytes both BCL - 2 and a TNFR - associated factor 2 ( TRAF2 ) mutant lacking the really interesting new gene and zinc finger domains ( TRAF2DN ) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence ( Zapata et al . 2004 .|Proc .|Nat .|Acad .|Sci .|USA 101 : 16600 - 16605 ) .|Further analysis of the expression of TRAF2 and TRAF2DN in purified B cells demonstrated that expression of both endogenous TRAF2 and tg TRAF2DN was negligible in Traf2DN - tg B cells compared with wild - type mice .|This was the result of proteasome - dependent degradation , and rendered TRAF2DN B cells as bona fide TRAF2 - deficient B cells .|Similar to B cells with targeted Traf2 deletion , Traf2DN - tg mice show expanded marginal zone B cell population and have constitutive p100 NF - kappaB2 processing .|Also , TRAF3 , X - linked inhibitor of apoptosis , and Bcl - X ( L ) expression levels were increased , whereas cellular inhibitors of apoptosis 1 and 2 levels were drastically reduced compared with those found in wild - type B cells .|Moreover , consistent with previous results , we also show that TRAF2 was required for efficient JNK and ERK activation in response to CD40 engagement .|However , TRAF2 was deleterious for BCR - mediated activation of these kinases .|In contrast , TRAF2 deficiency had no effect on CD40 - mediated p38 MAPK activation but significantly reduced BCR - mediated p38 activation .|Finally , we further confirm that TRAF2 was required for CD40 - mediated proliferation , but its absence relieved B cells of the need for B cell activating factor for survival .|Altogether , our results suggest that TRAF2 deficiency cooperates with BCL - 2 in promoting chronic lymphocytic leukemia / small lymphocytic lymphoma in mice , possibly by specifically enforcing marginal zone B cell accumulation , increasing X - linked inhibitor of apoptosis expression , and rendering B cells independent of B cell activating factor for survival .	1:Negative_Correlation:2	L2R	NON-CROSS	0-5	11-14	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	1:Association:2	L2R	NON-CROSS	336-337	340-343	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	1:NR:2	L2R	NON-CROSS	140-141	153-154	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	16912	proteasome	GeneOrGeneProduct	140	141	8	1:NR:2	L2R	NON-CROSS	165-166	182-186	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	1:NR:2	L2R	CROSS	165-166	190-191	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	22031	TRAF3	GeneOrGeneProduct	190	191	10	1:Negative_Correlation:2	L2R	NON-CROSS	165-166	192-198	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	1:NR:2	L2R	CROSS	165-166	200-206	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	1:NR:2	L2R	CROSS	212-219	245-246	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	1:Positive_Correlation:2	L2R	NON-CROSS	245-246	250-251	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	26419	JNK	GeneOrGeneProduct	250	251	11	1:Positive_Correlation:2	L2R	NON-CROSS	245-246	252-253	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	26413	ERK	GeneOrGeneProduct	252	253	11	1:Association:2	L2R	NON-CROSS	304-305	308-309	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:Association:2	L2R	NON-CROSS	262-263	266-267	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:Positive_Correlation:2	L2R	NON-CROSS	277-278	286-288	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:Association:2	L2R	NON-CROSS	323-327	336-337	22030	TNFR - associated factor 2|TNFR - associated factor 2|TRAF2|TRAF2|TRAF2|TRAF2|Traf2|TRAF2|TRAF2|TRAF2|TRAF2|TRAF2	GeneOrGeneProduct	0:41:47:103:116:153:165:245:262:277:304:336	5:46:48:104:117:154:166:246:263:278:305:337	0:1:1:7:7:8:9:11:12:13:14:15	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:Association:2	R2L	NON-CROSS	345-348	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	1:NR:2	L2R	CROSS	68-71	140-141	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	16912	proteasome	GeneOrGeneProduct	140	141	8	1:NR:2	L2R	CROSS	68-71	182-186	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	1:NR:2	L2R	CROSS	68-71	190-191	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	22031	TRAF3	GeneOrGeneProduct	190	191	10	1:NR:2	L2R	NON-CROSS	349-352	366-372	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	1:NR:2	L2R	CROSS	68-71	200-206	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	1:NR:2	L2R	CROSS	212-219	349-352	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	1:NR:2	L2R	CROSS	250-251	345-348	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	26419	JNK	GeneOrGeneProduct	250	251	11	1:NR:2	L2R	CROSS	252-253	345-348	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	26413	ERK	GeneOrGeneProduct	252	253	11	1:NR:2	L2R	CROSS	308-309	345-348	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	292-293	345-348	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	295-296	345-348	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	NON-CROSS	323-327	349-352	D015451	chronic lymphocytic leukemia|small lymphocytic lymphoma|small lymphocytic lymphoma|chronic lymphocytic leukemia|chronic lymphocytic leukemia|small lymphocytic lymphoma	DiseaseOrPhenotypicFeature	11:15:64:68:345:349	14:18:67:71:348:352	0:0:1:1:15:15	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	CROSS	36-39	140-141	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	16912	proteasome	GeneOrGeneProduct	140	141	8	1:NR:2	L2R	CROSS	36-39	182-186	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	1:NR:2	L2R	CROSS	190-191	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	22031	TRAF3	GeneOrGeneProduct	190	191	10	1:Association:2	L2R	NON-CROSS	340-343	366-372	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	1:NR:2	L2R	CROSS	200-206	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	1:NR:2	L2R	CROSS	212-219	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	1:NR:2	L2R	CROSS	250-251	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	26419	JNK	GeneOrGeneProduct	250	251	11	1:NR:2	L2R	CROSS	252-253	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	26413	ERK	GeneOrGeneProduct	252	253	11	1:NR:2	L2R	CROSS	308-309	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	292-293	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	295-296	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	NON-CROSS	323-327	340-343	596	BCL - 2|BCL - 2	GeneOrGeneProduct	36:340	39:343	1:15	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	CROSS	140-141	182-186	16912	proteasome	GeneOrGeneProduct	140	141	8	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	1:NR:2	L2R	CROSS	140-141	190-191	16912	proteasome	GeneOrGeneProduct	140	141	8	22031	TRAF3	GeneOrGeneProduct	190	191	10	1:NR:2	L2R	CROSS	140-141	192-198	16912	proteasome	GeneOrGeneProduct	140	141	8	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	1:NR:2	L2R	CROSS	140-141	200-206	16912	proteasome	GeneOrGeneProduct	140	141	8	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	1:NR:2	L2R	CROSS	140-141	212-219	16912	proteasome	GeneOrGeneProduct	140	141	8	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	1:NR:2	L2R	CROSS	140-141	250-251	16912	proteasome	GeneOrGeneProduct	140	141	8	26419	JNK	GeneOrGeneProduct	250	251	11	1:NR:2	L2R	CROSS	140-141	252-253	16912	proteasome	GeneOrGeneProduct	140	141	8	26413	ERK	GeneOrGeneProduct	252	253	11	1:NR:2	L2R	CROSS	140-141	257-258	16912	proteasome	GeneOrGeneProduct	140	141	8	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	140-141	266-267	16912	proteasome	GeneOrGeneProduct	140	141	8	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	140-141	286-288	16912	proteasome	GeneOrGeneProduct	140	141	8	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	CROSS	140-141	323-327	16912	proteasome	GeneOrGeneProduct	140	141	8	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	CROSS	182-186	190-191	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	22031	TRAF3	GeneOrGeneProduct	190	191	10	1:NR:2	L2R	CROSS	182-186	192-198	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	1:NR:2	L2R	CROSS	182-186	200-206	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	1:NR:2	L2R	CROSS	182-186	212-219	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	1:NR:2	L2R	CROSS	182-186	250-251	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	26419	JNK	GeneOrGeneProduct	250	251	11	1:NR:2	L2R	CROSS	182-186	252-253	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	26413	ERK	GeneOrGeneProduct	252	253	11	1:NR:2	L2R	CROSS	182-186	257-258	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	182-186	266-267	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	182-186	286-288	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	CROSS	182-186	323-327	18034	p100 NF - kappaB2	GeneOrGeneProduct	182	186	9	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	NON-CROSS	190-191	192-198	22031	TRAF3	GeneOrGeneProduct	190	191	10	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	1:NR:2	L2R	NON-CROSS	190-191	200-206	22031	TRAF3	GeneOrGeneProduct	190	191	10	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	1:NR:2	L2R	NON-CROSS	190-191	212-219	22031	TRAF3	GeneOrGeneProduct	190	191	10	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	1:NR:2	L2R	CROSS	190-191	250-251	22031	TRAF3	GeneOrGeneProduct	190	191	10	26419	JNK	GeneOrGeneProduct	250	251	11	1:NR:2	L2R	CROSS	190-191	252-253	22031	TRAF3	GeneOrGeneProduct	190	191	10	26413	ERK	GeneOrGeneProduct	252	253	11	1:NR:2	L2R	CROSS	190-191	257-258	22031	TRAF3	GeneOrGeneProduct	190	191	10	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	190-191	266-267	22031	TRAF3	GeneOrGeneProduct	190	191	10	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	190-191	286-288	22031	TRAF3	GeneOrGeneProduct	190	191	10	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	CROSS	190-191	323-327	22031	TRAF3	GeneOrGeneProduct	190	191	10	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	NON-CROSS	192-198	200-206	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	1:NR:2	L2R	NON-CROSS	192-198	212-219	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	1:NR:2	L2R	CROSS	192-198	250-251	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	26419	JNK	GeneOrGeneProduct	250	251	11	1:NR:2	L2R	CROSS	192-198	252-253	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	26413	ERK	GeneOrGeneProduct	252	253	11	1:NR:2	L2R	CROSS	308-309	366-372	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	192-198	266-267	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	295-296	366-372	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	NON-CROSS	366-372	380-384	11798	X - linked inhibitor of apoptosis|X - linked inhibitor of apoptosis	GeneOrGeneProduct	192:366	198:372	10:15	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	NON-CROSS	200-206	212-219	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	1:NR:2	L2R	CROSS	200-206	250-251	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	26419	JNK	GeneOrGeneProduct	250	251	11	1:NR:2	L2R	CROSS	200-206	252-253	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	26413	ERK	GeneOrGeneProduct	252	253	11	1:NR:2	L2R	CROSS	200-206	257-258	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	200-206	266-267	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	200-206	286-288	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	CROSS	200-206	323-327	12048	Bcl - X ( L )	GeneOrGeneProduct	200	206	10	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	CROSS	212-219	250-251	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	26419	JNK	GeneOrGeneProduct	250	251	11	1:NR:2	L2R	CROSS	212-219	252-253	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	26413	ERK	GeneOrGeneProduct	252	253	11	1:NR:2	L2R	CROSS	212-219	257-258	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	212-219	266-267	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	212-219	286-288	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	CROSS	212-219	323-327	11796,11797	cellular inhibitors of apoptosis 1 and 2	GeneOrGeneProduct	212	219	10	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	NON-CROSS	250-251	252-253	26419	JNK	GeneOrGeneProduct	250	251	11	26413	ERK	GeneOrGeneProduct	252	253	11	1:Association:2	L2R	NON-CROSS	250-251	257-258	26419	JNK	GeneOrGeneProduct	250	251	11	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	250-251	266-267	26419	JNK	GeneOrGeneProduct	250	251	11	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	250-251	286-288	26419	JNK	GeneOrGeneProduct	250	251	11	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	CROSS	250-251	323-327	26419	JNK	GeneOrGeneProduct	250	251	11	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:Association:2	L2R	NON-CROSS	252-253	257-258	26413	ERK	GeneOrGeneProduct	252	253	11	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	1:NR:2	L2R	CROSS	252-253	266-267	26413	ERK	GeneOrGeneProduct	252	253	11	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:NR:2	L2R	CROSS	252-253	286-288	26413	ERK	GeneOrGeneProduct	252	253	11	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	CROSS	252-253	323-327	26413	ERK	GeneOrGeneProduct	252	253	11	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	NON-CROSS	257-258	266-267	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	1:Association:2	L2R	NON-CROSS	283-284	286-288	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	NON-CROSS	308-309	323-327	21939	CD40|CD40|CD40	GeneOrGeneProduct	257:283:308	258:284:309	11:13:14	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:Association:2	L2R	NON-CROSS	292-293	295-296	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	1:NR:2	L2R	CROSS	292-293	323-327	12518	BCR|BCR	GeneOrGeneProduct	266:292	267:293	12:13	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15	1:NR:2	L2R	CROSS	295-296	323-327	26416	p38 MAPK|p38	GeneOrGeneProduct	286:295	288:296	13:13	24099	B cell activating factor|B cell activating factor	GeneOrGeneProduct	323:380	327:384	14:15
24036311	CTR9 / PAF1c regulates molecular lineage identity , histone H3K36 trimethylation and genomic imprinting during preimplantation development .|Genome - wide epigenetic reprogramming is required for successful preimplantation development .|Inappropriate or deficient chromatin regulation can result in defective lineage specification and loss of genomic imprinting , compromising normal development .|Here we report that two members of the RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex ( PAF1 complex ) components , Ctr9 and Rtf1 , are required during mammalian preimplantation development .|We demonstrate that Ctr9 - deficient embryos fail to correctly specify lineages at the blastocyst stage .|Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos , including Eomes , Elf5 and Sox2 , while others are inappropriately expressed ( Oct4 , Nanog , Gata6 , Fgf4 and Sox17 ) .|We also show that several imprinted genes ( Mest , Peg3 , Snrpn and Meg3 ) are aberrantly expressed although allele specific DNA methylation is not altered .|We document a loss of histone H3 lysine 36 trimethylation ( H3K36me3 ) in Ctr9 - deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes .|These findings show that the PAF1 complex is required for mammalian development , likely through regulation of H3K36me3 , and indicate functional conservation of the PAF1 complex from yeast to mammals in vivo .	1:NR:2	L2R	NON-CROSS	0-1	2-3	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	1:Association:2	L2R	NON-CROSS	182-183	185-186	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	1:Bind:2	L2R	NON-CROSS	77-78	79-80	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	1:Positive_Correlation:2	L2R	NON-CROSS	115-116	120-121	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	13813	Eomes	GeneOrGeneProduct	120	121	5	1:Positive_Correlation:2	L2R	NON-CROSS	115-116	122-123	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	13711	Elf5	GeneOrGeneProduct	122	123	5	1:Positive_Correlation:2	L2R	NON-CROSS	115-116	124-125	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	20674	Sox2	GeneOrGeneProduct	124	125	5	1:Negative_Correlation:2	L2R	NON-CROSS	115-116	132-133	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	18999	Oct4	GeneOrGeneProduct	132	133	5	1:Negative_Correlation:2	L2R	NON-CROSS	115-116	134-135	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	71950	Nanog	GeneOrGeneProduct	134	135	5	1:Association:2	L2R	NON-CROSS	115-116	136-137	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	14465	Gata6	GeneOrGeneProduct	136	137	5	1:Negative_Correlation:2	L2R	NON-CROSS	115-116	138-139	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:Negative_Correlation:2	L2R	NON-CROSS	115-116	140-141	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	20671	Sox17	GeneOrGeneProduct	140	141	5	1:Negative_Correlation:2	L2R	CROSS	151-152	185-186	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	17294	Mest	GeneOrGeneProduct	151	152	6	1:Negative_Correlation:2	L2R	CROSS	153-154	185-186	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	18616	Peg3	GeneOrGeneProduct	153	154	6	1:Negative_Correlation:2	L2R	CROSS	155-156	185-186	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:Negative_Correlation:2	L2R	CROSS	157-158	185-186	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	NON-CROSS	185-186	195-196	22083	CTR9|Ctr9|Ctr9|Ctr9|Ctr9	GeneOrGeneProduct	0:77:91:115:185	1:78:92:116:186	0:3:4:5:7	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	2-3	8-10	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	1:NR:2	L2R	NON-CROSS	72-74	79-80	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	1:NR:2	L2R	CROSS	72-74	120-121	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	13813	Eomes	GeneOrGeneProduct	120	121	5	1:NR:2	L2R	CROSS	72-74	122-123	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	13711	Elf5	GeneOrGeneProduct	122	123	5	1:NR:2	L2R	CROSS	72-74	124-125	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	20674	Sox2	GeneOrGeneProduct	124	125	5	1:NR:2	L2R	CROSS	72-74	132-133	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	18999	Oct4	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	72-74	134-135	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	71950	Nanog	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	72-74	136-137	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	14465	Gata6	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	CROSS	72-74	138-139	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	CROSS	72-74	140-141	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	151-152	208-210	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	153-154	208-210	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	155-156	208-210	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	157-158	208-210	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	195-196	208-210	22083,54624,76246	PAF1c|RNA polymerase II associated factor , homolog ( Saccharomyces cerevisiae ) complex|PAF1 complex|PAF1 complex|PAF1 complex	GeneOrGeneProduct	2:59:72:208:228	3:71:74:210:230	0:3:3:8:8	235626	Setd2	GeneOrGeneProduct	195	196	7	1:Association:2	R2L	NON-CROSS	197-198	182-183	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	1:NR:2	L2R	CROSS	120-121	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	13813	Eomes	GeneOrGeneProduct	120	121	5	1:NR:2	L2R	CROSS	122-123	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	13711	Elf5	GeneOrGeneProduct	122	123	5	1:NR:2	L2R	CROSS	124-125	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	20674	Sox2	GeneOrGeneProduct	124	125	5	1:NR:2	L2R	CROSS	132-133	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	18999	Oct4	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	134-135	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	71950	Nanog	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	136-137	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	14465	Gata6	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	CROSS	138-139	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	CROSS	140-141	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	151-152	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	153-154	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	155-156	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	157-158	176-178	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	17263	Meg3	GeneOrGeneProduct	157	158	6	1:Association:2	R2L	NON-CROSS	195-196	182-183	235626	Setd2	GeneOrGeneProduct	195	196	7	260423	histone H3|histone H3|H3|H3	GeneOrGeneProduct	8:176:182:220	10:178:183:221	0:7:7:8	1:NR:2	L2R	CROSS	79-80	120-121	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	13813	Eomes	GeneOrGeneProduct	120	121	5	1:NR:2	L2R	CROSS	79-80	122-123	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	13711	Elf5	GeneOrGeneProduct	122	123	5	1:NR:2	L2R	CROSS	79-80	124-125	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	20674	Sox2	GeneOrGeneProduct	124	125	5	1:NR:2	L2R	CROSS	79-80	132-133	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	18999	Oct4	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	79-80	134-135	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	71950	Nanog	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	79-80	136-137	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	14465	Gata6	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	CROSS	79-80	138-139	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	CROSS	140-141	197-198	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	151-152	197-198	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	153-154	197-198	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	155-156	197-198	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	157-158	197-198	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	NON-CROSS	195-196	197-198	76246	Rtf1|Rtf1	GeneOrGeneProduct	79:197	80:198	3:7	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	120-121	122-123	13813	Eomes	GeneOrGeneProduct	120	121	5	13711	Elf5	GeneOrGeneProduct	122	123	5	1:NR:2	L2R	NON-CROSS	120-121	124-125	13813	Eomes	GeneOrGeneProduct	120	121	5	20674	Sox2	GeneOrGeneProduct	124	125	5	1:NR:2	L2R	NON-CROSS	120-121	132-133	13813	Eomes	GeneOrGeneProduct	120	121	5	18999	Oct4	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	NON-CROSS	120-121	134-135	13813	Eomes	GeneOrGeneProduct	120	121	5	71950	Nanog	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	NON-CROSS	120-121	136-137	13813	Eomes	GeneOrGeneProduct	120	121	5	14465	Gata6	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	120-121	138-139	13813	Eomes	GeneOrGeneProduct	120	121	5	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	120-121	140-141	13813	Eomes	GeneOrGeneProduct	120	121	5	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	120-121	151-152	13813	Eomes	GeneOrGeneProduct	120	121	5	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	120-121	153-154	13813	Eomes	GeneOrGeneProduct	120	121	5	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	120-121	155-156	13813	Eomes	GeneOrGeneProduct	120	121	5	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	120-121	157-158	13813	Eomes	GeneOrGeneProduct	120	121	5	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	120-121	195-196	13813	Eomes	GeneOrGeneProduct	120	121	5	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	122-123	124-125	13711	Elf5	GeneOrGeneProduct	122	123	5	20674	Sox2	GeneOrGeneProduct	124	125	5	1:NR:2	L2R	NON-CROSS	122-123	132-133	13711	Elf5	GeneOrGeneProduct	122	123	5	18999	Oct4	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	NON-CROSS	122-123	134-135	13711	Elf5	GeneOrGeneProduct	122	123	5	71950	Nanog	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	NON-CROSS	122-123	136-137	13711	Elf5	GeneOrGeneProduct	122	123	5	14465	Gata6	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	122-123	138-139	13711	Elf5	GeneOrGeneProduct	122	123	5	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	122-123	140-141	13711	Elf5	GeneOrGeneProduct	122	123	5	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	122-123	151-152	13711	Elf5	GeneOrGeneProduct	122	123	5	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	122-123	153-154	13711	Elf5	GeneOrGeneProduct	122	123	5	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	122-123	155-156	13711	Elf5	GeneOrGeneProduct	122	123	5	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	122-123	157-158	13711	Elf5	GeneOrGeneProduct	122	123	5	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	122-123	195-196	13711	Elf5	GeneOrGeneProduct	122	123	5	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	124-125	132-133	20674	Sox2	GeneOrGeneProduct	124	125	5	18999	Oct4	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	NON-CROSS	124-125	134-135	20674	Sox2	GeneOrGeneProduct	124	125	5	71950	Nanog	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	NON-CROSS	124-125	136-137	20674	Sox2	GeneOrGeneProduct	124	125	5	14465	Gata6	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	124-125	138-139	20674	Sox2	GeneOrGeneProduct	124	125	5	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	124-125	140-141	20674	Sox2	GeneOrGeneProduct	124	125	5	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	124-125	151-152	20674	Sox2	GeneOrGeneProduct	124	125	5	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	124-125	153-154	20674	Sox2	GeneOrGeneProduct	124	125	5	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	124-125	155-156	20674	Sox2	GeneOrGeneProduct	124	125	5	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	124-125	157-158	20674	Sox2	GeneOrGeneProduct	124	125	5	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	124-125	195-196	20674	Sox2	GeneOrGeneProduct	124	125	5	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	132-133	134-135	18999	Oct4	GeneOrGeneProduct	132	133	5	71950	Nanog	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	NON-CROSS	132-133	136-137	18999	Oct4	GeneOrGeneProduct	132	133	5	14465	Gata6	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	132-133	138-139	18999	Oct4	GeneOrGeneProduct	132	133	5	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	132-133	140-141	18999	Oct4	GeneOrGeneProduct	132	133	5	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	132-133	151-152	18999	Oct4	GeneOrGeneProduct	132	133	5	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	132-133	153-154	18999	Oct4	GeneOrGeneProduct	132	133	5	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	132-133	155-156	18999	Oct4	GeneOrGeneProduct	132	133	5	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	132-133	157-158	18999	Oct4	GeneOrGeneProduct	132	133	5	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	132-133	195-196	18999	Oct4	GeneOrGeneProduct	132	133	5	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	134-135	136-137	71950	Nanog	GeneOrGeneProduct	134	135	5	14465	Gata6	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	134-135	138-139	71950	Nanog	GeneOrGeneProduct	134	135	5	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	134-135	140-141	71950	Nanog	GeneOrGeneProduct	134	135	5	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	134-135	151-152	71950	Nanog	GeneOrGeneProduct	134	135	5	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	134-135	153-154	71950	Nanog	GeneOrGeneProduct	134	135	5	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	134-135	155-156	71950	Nanog	GeneOrGeneProduct	134	135	5	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	134-135	157-158	71950	Nanog	GeneOrGeneProduct	134	135	5	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	134-135	195-196	71950	Nanog	GeneOrGeneProduct	134	135	5	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	136-137	138-139	14465	Gata6	GeneOrGeneProduct	136	137	5	14175	Fgf4	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	136-137	140-141	14465	Gata6	GeneOrGeneProduct	136	137	5	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	136-137	151-152	14465	Gata6	GeneOrGeneProduct	136	137	5	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	136-137	153-154	14465	Gata6	GeneOrGeneProduct	136	137	5	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	136-137	155-156	14465	Gata6	GeneOrGeneProduct	136	137	5	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	136-137	157-158	14465	Gata6	GeneOrGeneProduct	136	137	5	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	136-137	195-196	14465	Gata6	GeneOrGeneProduct	136	137	5	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	138-139	140-141	14175	Fgf4	GeneOrGeneProduct	138	139	5	20671	Sox17	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	138-139	151-152	14175	Fgf4	GeneOrGeneProduct	138	139	5	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	138-139	153-154	14175	Fgf4	GeneOrGeneProduct	138	139	5	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	138-139	155-156	14175	Fgf4	GeneOrGeneProduct	138	139	5	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	138-139	157-158	14175	Fgf4	GeneOrGeneProduct	138	139	5	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	138-139	195-196	14175	Fgf4	GeneOrGeneProduct	138	139	5	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	CROSS	140-141	151-152	20671	Sox17	GeneOrGeneProduct	140	141	5	17294	Mest	GeneOrGeneProduct	151	152	6	1:NR:2	L2R	CROSS	140-141	153-154	20671	Sox17	GeneOrGeneProduct	140	141	5	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	CROSS	140-141	155-156	20671	Sox17	GeneOrGeneProduct	140	141	5	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	CROSS	140-141	157-158	20671	Sox17	GeneOrGeneProduct	140	141	5	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	140-141	195-196	20671	Sox17	GeneOrGeneProduct	140	141	5	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	151-152	153-154	17294	Mest	GeneOrGeneProduct	151	152	6	18616	Peg3	GeneOrGeneProduct	153	154	6	1:NR:2	L2R	NON-CROSS	151-152	155-156	17294	Mest	GeneOrGeneProduct	151	152	6	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	NON-CROSS	151-152	157-158	17294	Mest	GeneOrGeneProduct	151	152	6	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	151-152	195-196	17294	Mest	GeneOrGeneProduct	151	152	6	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	153-154	155-156	18616	Peg3	GeneOrGeneProduct	153	154	6	20646	Snrpn	GeneOrGeneProduct	155	156	6	1:NR:2	L2R	NON-CROSS	153-154	157-158	18616	Peg3	GeneOrGeneProduct	153	154	6	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	153-154	195-196	18616	Peg3	GeneOrGeneProduct	153	154	6	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	NON-CROSS	155-156	157-158	20646	Snrpn	GeneOrGeneProduct	155	156	6	17263	Meg3	GeneOrGeneProduct	157	158	6	1:NR:2	L2R	CROSS	155-156	195-196	20646	Snrpn	GeneOrGeneProduct	155	156	6	235626	Setd2	GeneOrGeneProduct	195	196	7	1:NR:2	L2R	CROSS	157-158	195-196	17263	Meg3	GeneOrGeneProduct	157	158	6	235626	Setd2	GeneOrGeneProduct	195	196	7
25080425	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol - induced acute myocardial injury in rats .|The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 ( STAT3 ) and apoptotic pathways as the potential mechanism underlying the drug effect .|Male Sprague Dawley rats were treated with betaine ( 100 , 200 , and 400 mg / kg ) orally for 40 days .|Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol ( 85 mg / kg ) , for two consecutive days .|Serum cardiac marker enzyme , histopathological variables and expression of protein levels were analyzed .|Oral administration of betaine ( 200 and 400 mg / kg ) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling .|Western blot analysis showed that isoproterenol - induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium .|Furthermore , betaine ( 200 and 400 mg / kg ) treatment increased the ventricular expression of Bcl - 2 and reduced the level of Bax , therefore causing a significant increase in the ratio of Bcl - 2 / Bax .|The protective role of betaine on myocardial damage was further confirmed by histopathological examination .|In summary , our results showed that betaine pretreatment attenuated isoproterenol - induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways .	1:Association:2	R2L	NON-CROSS	13-14	2-9	D001622	betaine|betaine|betaine|betaine|betaine|betaine|betaine|betaine	ChemicalEntity	13:35:77:137:180:187:231:249	14:36:78:138:181:188:232:250	0:1:2:5:6:7:8:9	25125	signal transducer and activator of transcription 3|signal transducer and activator of transcription 3|STAT3|STAT3|STAT3	GeneOrGeneProduct	2:48:56:173:262	9:55:57:174:263	0:1:1:6:9	1:Association:2	R2L	NON-CROSS	173-174	168-169	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	15:106:168:252	16:107:169:253	0:3:6:9	25125	signal transducer and activator of transcription 3|signal transducer and activator of transcription 3|STAT3|STAT3|STAT3	GeneOrGeneProduct	2:48:56:173:262	9:55:57:174:263	0:1:1:6:9	1:Association:2	R2L	NON-CROSS	19-21	2-9	D009202	myocardial injury|myocardial damage	DiseaseOrPhenotypicFeature	19:233	21:235	0:8	25125	signal transducer and activator of transcription 3|signal transducer and activator of transcription 3|STAT3|STAT3|STAT3	GeneOrGeneProduct	2:48:56:173:262	9:55:57:174:263	0:1:1:6:9	1:Association:2	R2L	NON-CROSS	262-263	256-258	D017202	myocardial ischemia|myocardial ischemic injury|myocardial ischemia	DiseaseOrPhenotypicFeature	38:95:256	40:98:258	1:3:9	25125	signal transducer and activator of transcription 3|signal transducer and activator of transcription 3|STAT3|STAT3|STAT3	GeneOrGeneProduct	2:48:56:173:262	9:55:57:174:263	0:1:1:6:9	1:NR:2	L2R	CROSS	160-162	173-174	25125	signal transducer and activator of transcription 3|signal transducer and activator of transcription 3|STAT3|STAT3|STAT3	GeneOrGeneProduct	2:48:56:173:262	9:55:57:174:263	0:1:1:6:9	D020257	ventricular remodeling	DiseaseOrPhenotypicFeature	160	162	5	1:NR:2	L2R	CROSS	173-174	202-205	25125	signal transducer and activator of transcription 3|signal transducer and activator of transcription 3|STAT3|STAT3|STAT3	GeneOrGeneProduct	2:48:56:173:262	9:55:57:174:263	0:1:1:6:9	24224	Bcl - 2|Bcl - 2	GeneOrGeneProduct	202:221	205:224	7:7	1:NR:2	L2R	CROSS	173-174	210-211	25125	signal transducer and activator of transcription 3|signal transducer and activator of transcription 3|STAT3|STAT3|STAT3	GeneOrGeneProduct	2:48:56:173:262	9:55:57:174:263	0:1:1:6:9	24887	Bax|Bax	GeneOrGeneProduct	210:225	211:226	7:7	1:Negative_Correlation:2	L2R	NON-CROSS	13-14	15-16	D001622	betaine|betaine|betaine|betaine|betaine|betaine|betaine|betaine	ChemicalEntity	13:35:77:137:180:187:231:249	14:36:78:138:181:188:232:250	0:1:2:5:6:7:8:9	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	15:106:168:252	16:107:169:253	0:3:6:9	1:Negative_Correlation:2	L2R	NON-CROSS	231-232	233-235	D001622	betaine|betaine|betaine|betaine|betaine|betaine|betaine|betaine	ChemicalEntity	13:35:77:137:180:187:231:249	14:36:78:138:181:188:232:250	0:1:2:5:6:7:8:9	D009202	myocardial injury|myocardial damage	DiseaseOrPhenotypicFeature	19:233	21:235	0:8	1:Negative_Correlation:2	L2R	NON-CROSS	35-36	38-40	D001622	betaine|betaine|betaine|betaine|betaine|betaine|betaine|betaine	ChemicalEntity	13:35:77:137:180:187:231:249	14:36:78:138:181:188:232:250	0:1:2:5:6:7:8:9	D017202	myocardial ischemia|myocardial ischemic injury|myocardial ischemia	DiseaseOrPhenotypicFeature	38:95:256	40:98:258	1:3:9	1:Negative_Correlation:2	L2R	NON-CROSS	160-162	180-181	D001622	betaine|betaine|betaine|betaine|betaine|betaine|betaine|betaine	ChemicalEntity	13:35:77:137:180:187:231:249	14:36:78:138:181:188:232:250	0:1:2:5:6:7:8:9	D020257	ventricular remodeling	DiseaseOrPhenotypicFeature	160	162	5	1:Positive_Correlation:2	L2R	NON-CROSS	221-224	231-232	D001622	betaine|betaine|betaine|betaine|betaine|betaine|betaine|betaine	ChemicalEntity	13:35:77:137:180:187:231:249	14:36:78:138:181:188:232:250	0:1:2:5:6:7:8:9	24224	Bcl - 2|Bcl - 2	GeneOrGeneProduct	202:221	205:224	7:7	1:Negative_Correlation:2	L2R	NON-CROSS	225-226	231-232	D001622	betaine|betaine|betaine|betaine|betaine|betaine|betaine|betaine	ChemicalEntity	13:35:77:137:180:187:231:249	14:36:78:138:181:188:232:250	0:1:2:5:6:7:8:9	24887	Bax|Bax	GeneOrGeneProduct	210:225	211:226	7:7	1:Positive_Correlation:2	L2R	NON-CROSS	15-16	19-21	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	15:106:168:252	16:107:169:253	0:3:6:9	D009202	myocardial injury|myocardial damage	DiseaseOrPhenotypicFeature	19:233	21:235	0:8	1:Positive_Correlation:2	R2L	NON-CROSS	256-258	252-253	D017202	myocardial ischemia|myocardial ischemic injury|myocardial ischemia	DiseaseOrPhenotypicFeature	38:95:256	40:98:258	1:3:9	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	15:106:168:252	16:107:169:253	0:3:6:9	1:NR:2	L2R	CROSS	160-162	168-169	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	15:106:168:252	16:107:169:253	0:3:6:9	D020257	ventricular remodeling	DiseaseOrPhenotypicFeature	160	162	5	1:NR:2	L2R	CROSS	221-224	252-253	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	15:106:168:252	16:107:169:253	0:3:6:9	24224	Bcl - 2|Bcl - 2	GeneOrGeneProduct	202:221	205:224	7:7	1:NR:2	L2R	CROSS	225-226	252-253	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	15:106:168:252	16:107:169:253	0:3:6:9	24887	Bax|Bax	GeneOrGeneProduct	210:225	211:226	7:7	1:NR:2	L2R	CROSS	221-224	233-235	D009202	myocardial injury|myocardial damage	DiseaseOrPhenotypicFeature	19:233	21:235	0:8	24224	Bcl - 2|Bcl - 2	GeneOrGeneProduct	202:221	205:224	7:7	1:NR:2	L2R	CROSS	225-226	233-235	D009202	myocardial injury|myocardial damage	DiseaseOrPhenotypicFeature	19:233	21:235	0:8	24887	Bax|Bax	GeneOrGeneProduct	210:225	211:226	7:7	1:NR:2	L2R	CROSS	221-224	256-258	D017202	myocardial ischemia|myocardial ischemic injury|myocardial ischemia	DiseaseOrPhenotypicFeature	38:95:256	40:98:258	1:3:9	24224	Bcl - 2|Bcl - 2	GeneOrGeneProduct	202:221	205:224	7:7	1:NR:2	L2R	CROSS	225-226	256-258	D017202	myocardial ischemia|myocardial ischemic injury|myocardial ischemia	DiseaseOrPhenotypicFeature	38:95:256	40:98:258	1:3:9	24887	Bax|Bax	GeneOrGeneProduct	210:225	211:226	7:7	1:NR:2	L2R	CROSS	160-162	202-205	D020257	ventricular remodeling	DiseaseOrPhenotypicFeature	160	162	5	24224	Bcl - 2|Bcl - 2	GeneOrGeneProduct	202:221	205:224	7:7	1:NR:2	L2R	CROSS	160-162	210-211	D020257	ventricular remodeling	DiseaseOrPhenotypicFeature	160	162	5	24887	Bax|Bax	GeneOrGeneProduct	210:225	211:226	7:7	1:NR:2	L2R	NON-CROSS	221-224	225-226	24224	Bcl - 2|Bcl - 2	GeneOrGeneProduct	202:221	205:224	7:7	24887	Bax|Bax	GeneOrGeneProduct	210:225	211:226	7:7
27509880	Combination of the histone deacetylase inhibitor depsipeptide and 5 - fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase - 3 / 7 in human colon cancer HCT - 116 cells .|Epigenetic anticancer drugs such as histone deacetylase ( HDAC ) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects .|In the present study , we found that a very low concentration of depsipeptide , an HDAC inhibitor , potentiated the antitumor activity of 5 - fluorouracil ( 5 - FU ) in a human colon cancer cell model using HCT - 116 , HT29 , and SW48 cells via the inhibition of colony formation ability or cellular viability .|Exposure to a combination of 5 - FU ( 1 . 75 uM ) and 1 nM depsipeptide for 24 and 48 h resulted in a 3 - to 4 - fold increase in activated caspase - 3 / 7 , while 5 - FU alone failed to activate caspase - 3 / 7 .|Microarray and subsequent gene ontology analyses revealed that compared to 5 - FU or depsipeptide alone , the combination treatment of 5 - FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase - 3 / 7 activation .|These analyses indicated marked upregulation of antigen processing and presentation of peptide or polysaccharide antigen via major histocompatibility complex ( MHC ) class ( GO : 0002504 ) and MHC protein complex ( GO : 0042611 ) .|Compared with vehicle controls , the cells treated with the combination of 5 - FU and depsipeptide showed marked induction ( 3 - to 8 . 5 - fold ) of expression of MHC class II genes , but not of MHC class I genes .|Furthermore , our global analysis of gene expression , which was focused on genes involved in the molecular regulation of MHC class II genes , showed enhancement of pro - apoptotic PCAF and CIITA after the combination of 5 - FU and depsipeptide .|These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of depsipeptide and 5 - FU .|To the best of our knowledge , this is the first study to report that the combination of 5 - FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression .	1:Negative_Correlation:2	L2R	NON-CROSS	3-5	6-7	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	1:NR:2	L2R	NON-CROSS	3-5	8-11	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	1:NR:2	L2R	NON-CROSS	3-5	12-17	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	1:NR:2	L2R	NON-CROSS	3-5	18-19	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	1026	p21	GeneOrGeneProduct	18	19	0	1:NR:2	L2R	NON-CROSS	22-27	44-45	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	1:NR:2	L2R	NON-CROSS	29-31	41-43	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	1:NR:2	L2R	CROSS	76-77	239-240	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	D011134	polysaccharide	ChemicalEntity	239	240	5	1:NR:2	L2R	CROSS	76-77	242-249	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	1:NR:2	L2R	CROSS	76-77	305-309	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:NR:2	L2R	CROSS	76-77	341-342	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	8850	PCAF	GeneOrGeneProduct	341	342	7	1:NR:2	L2R	CROSS	76-77	343-344	3065	histone deacetylase|histone deacetylase|HDAC|HDAC	GeneOrGeneProduct	3:41:44:76	5:43:45:77	0:1:1:2	4261	CIITA	GeneOrGeneProduct	343	344	7	1:Cotreatment:2	L2R	NON-CROSS	6-7	8-11	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	1:Positive_Correlation:2	R2L	NON-CROSS	12-17	6-7	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	6-7	18-19	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	1026	p21	GeneOrGeneProduct	18	19	0	1:NR:2	L2R	NON-CROSS	6-7	22-27	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	1:Negative_Correlation:2	L2R	NON-CROSS	404-405	407-409	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	1:NR:2	L2R	CROSS	200-201	239-240	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	D011134	polysaccharide	ChemicalEntity	239	240	5	1:NR:2	L2R	CROSS	255-258	280-281	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	1:NR:2	L2R	NON-CROSS	280-281	305-309	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:Association:2	L2R	NON-CROSS	341-342	352-353	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	8850	PCAF	GeneOrGeneProduct	341	342	7	1:Association:2	L2R	NON-CROSS	343-344	352-353	D047630	depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide|depsipeptide	ChemicalEntity	6:73:137:189:200:280:352:376:404	7:74:138:190:201:281:353:377:405	0:2:3:4:4:6:7:8:9	4261	CIITA	GeneOrGeneProduct	343	344	7	1:Positive_Correlation:2	R2L	NON-CROSS	12-17	8-11	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	8-11	18-19	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	1026	p21	GeneOrGeneProduct	18	19	0	1:NR:2	L2R	NON-CROSS	162-165	169-174	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	1:Negative_Correlation:2	L2R	NON-CROSS	88-91	95-97	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	1:NR:2	L2R	CROSS	239-240	276-279	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	D011134	polysaccharide	ChemicalEntity	239	240	5	1:NR:2	L2R	CROSS	255-258	276-279	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	1:NR:2	L2R	NON-CROSS	276-279	305-309	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:Association:2	L2R	NON-CROSS	341-342	348-351	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	8850	PCAF	GeneOrGeneProduct	341	342	7	1:Association:2	L2R	NON-CROSS	343-344	348-351	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	8:84:88:125:162:185:196:276:348:378:400	11:87:91:128:165:188:199:279:351:381:403	0:2:2:3:3:4:4:6:7:8:9	4261	CIITA	GeneOrGeneProduct	343	344	7	1:NR:2	L2R	NON-CROSS	12-17	18-19	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	1026	p21	GeneOrGeneProduct	18	19	0	1:NR:2	L2R	NON-CROSS	12-17	22-27	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	1:NR:2	L2R	NON-CROSS	407-409	419-422	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	1:NR:2	L2R	CROSS	239-240	297-301	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	D011134	polysaccharide	ChemicalEntity	239	240	5	1:NR:2	L2R	CROSS	255-258	297-301	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	1:NR:2	L2R	NON-CROSS	297-301	305-309	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:NR:2	L2R	NON-CROSS	330-334	341-342	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	8850	PCAF	GeneOrGeneProduct	341	342	7	1:NR:2	L2R	NON-CROSS	330-334	343-344	3119	major histocompatibility complex class II|MHC class II genes|MHC class II genes|MHC class II|MHC class II	GeneOrGeneProduct	12:297:330:364:419	17:301:334:367:422	0:6:7:8:9	4261	CIITA	GeneOrGeneProduct	343	344	7	1:NR:2	L2R	NON-CROSS	18-19	22-27	1026	p21	GeneOrGeneProduct	18	19	0	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	1:NR:2	L2R	NON-CROSS	18-19	29-31	1026	p21	GeneOrGeneProduct	18	19	0	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	1:NR:2	L2R	CROSS	18-19	239-240	1026	p21	GeneOrGeneProduct	18	19	0	D011134	polysaccharide	ChemicalEntity	239	240	5	1:NR:2	L2R	CROSS	18-19	242-249	1026	p21	GeneOrGeneProduct	18	19	0	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	1:NR:2	L2R	CROSS	18-19	305-309	1026	p21	GeneOrGeneProduct	18	19	0	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:NR:2	L2R	CROSS	18-19	341-342	1026	p21	GeneOrGeneProduct	18	19	0	8850	PCAF	GeneOrGeneProduct	341	342	7	1:NR:2	L2R	CROSS	18-19	343-344	1026	p21	GeneOrGeneProduct	18	19	0	4261	CIITA	GeneOrGeneProduct	343	344	7	1:NR:2	L2R	NON-CROSS	22-27	29-31	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	1:NR:2	L2R	CROSS	219-224	239-240	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	D011134	polysaccharide	ChemicalEntity	239	240	5	1:NR:2	L2R	CROSS	219-224	242-249	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	1:NR:2	L2R	CROSS	219-224	305-309	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:NR:2	L2R	CROSS	219-224	341-342	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	8850	PCAF	GeneOrGeneProduct	341	342	7	1:NR:2	L2R	CROSS	219-224	343-344	836,840	caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7|caspase - 3 / 7	GeneOrGeneProduct	22:155:169:219	27:160:174:224	0:3:3:4	4261	CIITA	GeneOrGeneProduct	343	344	7	1:NR:2	L2R	CROSS	95-97	239-240	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	D011134	polysaccharide	ChemicalEntity	239	240	5	1:NR:2	L2R	CROSS	95-97	242-249	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	1:NR:2	L2R	CROSS	305-309	407-409	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:NR:2	L2R	CROSS	341-342	407-409	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	8850	PCAF	GeneOrGeneProduct	341	342	7	1:NR:2	L2R	CROSS	343-344	407-409	D003110	colon cancer|colon cancer|colon cancer	DiseaseOrPhenotypicFeature	29:95:407	31:97:409	0:2:9	4261	CIITA	GeneOrGeneProduct	343	344	7	1:Association:2	L2R	NON-CROSS	239-240	242-249	D011134	polysaccharide	ChemicalEntity	239	240	5	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	1:NR:2	L2R	CROSS	239-240	305-309	D011134	polysaccharide	ChemicalEntity	239	240	5	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:NR:2	L2R	CROSS	239-240	341-342	D011134	polysaccharide	ChemicalEntity	239	240	5	8850	PCAF	GeneOrGeneProduct	341	342	7	1:NR:2	L2R	CROSS	239-240	343-344	D011134	polysaccharide	ChemicalEntity	239	240	5	4261	CIITA	GeneOrGeneProduct	343	344	7	1:NR:2	L2R	CROSS	255-258	305-309	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	1:NR:2	L2R	CROSS	255-258	341-342	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	8850	PCAF	GeneOrGeneProduct	341	342	7	1:NR:2	L2R	CROSS	255-258	343-344	3123	major histocompatibility complex ( MHC ) class|MHC protein complex	GeneOrGeneProduct	242:255	249:258	5:5	4261	CIITA	GeneOrGeneProduct	343	344	7	1:NR:2	L2R	CROSS	305-309	341-342	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	8850	PCAF	GeneOrGeneProduct	341	342	7	1:NR:2	L2R	CROSS	305-309	343-344	3106	MHC class I genes	GeneOrGeneProduct	305	309	6	4261	CIITA	GeneOrGeneProduct	343	344	7	1:NR:2	L2R	NON-CROSS	341-342	343-344	8850	PCAF	GeneOrGeneProduct	341	342	7	4261	CIITA	GeneOrGeneProduct	343	344	7
27840894	Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets .|Inactivating mutations in phosphate - regulating gene with homologies to endopeptidase on the X chromosome ( PHEX ) have been identified as a cause of X - linked hypophosphatemic rickets ( XLH ; OMIM 307800 ) .|In the present study , we enrolled 43 patients from 18 unrelated families clinically diagnosed with hypophosphatemic rickets and 250 healthy controls .|For each available individual , all 22 exons with their exon - intron boundaries of the PHEX gene were directly sequenced .|The levels of serum fibroblast growth factor 23 ( FGF23 ) were measured as well .|Sequencing analysis detected 17 different PHEX gene mutations , and 7 of these were identified as novel : 3 missense mutations , including c . 304G > A ( p . Gly102Arg ) in exon 3 , c . 229T > C ( p . Cys77Arg ) in exon 3 and c . 824T > C ( p . Leu275Pro ) in exon 7 ; 2 deletion mutations , including c . 528delT ( p . Glu177LysfsX44 ) in exon 5 and c . 1234delA ( p . Ser412ValfsX12 ) in exon 11 ; and 2 alternative splicing mutations , including c . 436_436 + 1delAG in intron 4 at splicing donor sites and c . 1483 - 1G > C in intron 13 at splicing acceptor sites .|Moreover , 6 mutations were proven to be de novo in 6 sporadic cases and the probands were all females .|No mutations were found in the 250 healthy controls .|The serum levels of FGF23 varied widely among the patients with XLH , and no significant difference was found when compared with those of the healthy controls .|On the whole , the findings of this study provide new insight into the spectrum of PHEX mutations and provide potential evidence of a critical domain in PHEX protein .|In addition , the finding of an overlap of the serum FGF23 levels between the patients with XLH and the healthy controls indicates its limited diagnostic value in XLH .	1:Association:2	L2R	NON-CROSS	12-14	18-30	5251	PHEX|phosphate - regulating gene with homologies to endopeptidase on the X chromosome|PHEX|PHEX|PHEX|PHEX|PHEX	GeneOrGeneProduct	6:18:31:91:118:317:328	7:30:32:92:119:318:329	0:1:1:3:5:9:9	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	1:Negative_Correlation:2	L2R	NON-CROSS	31-32	40-45	5251	PHEX|phosphate - regulating gene with homologies to endopeptidase on the X chromosome|PHEX|PHEX|PHEX|PHEX|PHEX	GeneOrGeneProduct	6:18:31:91:118:317:328	7:30:32:92:119:318:329	0:1:1:3:5:9:9	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	1:NR:2	L2R	CROSS	91-92	101-105	5251	PHEX|phosphate - regulating gene with homologies to endopeptidase on the X chromosome|PHEX|PHEX|PHEX|PHEX|PHEX	GeneOrGeneProduct	6:18:31:91:118:317:328	7:30:32:92:119:318:329	0:1:1:3:5:9:9	8074	fibroblast growth factor 23|FGF23|FGF23|FGF23	GeneOrGeneProduct	101:106:277:342	105:107:278:343	4:4:8:10	1:NR:2	L2R	CROSS	68-70	101-105	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	8074	fibroblast growth factor 23|FGF23|FGF23|FGF23	GeneOrGeneProduct	101:106:277:342	105:107:278:343	4:4:8:10	1:Positive_Correlation:2	L2R	CROSS	68-70	136-141	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	c|SUB|G|304|A	c . 304G > A	SequenceVariant	136	141	5	1:Positive_Correlation:2	L2R	CROSS	68-70	142-145	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	p|SUB|G|102|R	p . Gly102Arg	SequenceVariant	142	145	5	1:Positive_Correlation:2	L2R	CROSS	68-70	150-155	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	c|SUB|T|229|C	c . 229T > C	SequenceVariant	150	155	5	1:Positive_Correlation:2	L2R	CROSS	68-70	156-159	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	p|SUB|C|77|R	p . Cys77Arg	SequenceVariant	156	159	5	1:Positive_Correlation:2	L2R	CROSS	68-70	164-169	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	c|SUB|T|284|C	c . 824T > C	SequenceVariant	164	169	5	1:Positive_Correlation:2	L2R	CROSS	68-70	170-173	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	p|SUB|L|275|P	p . Leu275Pro	SequenceVariant	170	173	5	1:Positive_Correlation:2	L2R	CROSS	68-70	183-186	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	c|DEL|528|T	c . 528delT	SequenceVariant	183	186	5	1:Positive_Correlation:2	L2R	CROSS	68-70	187-190	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	p|SUB|E|177|K|44	p . Glu177LysfsX44	SequenceVariant	187	190	5	1:Positive_Correlation:2	L2R	CROSS	68-70	195-198	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	c|DEL|1234|A	c . 1234delA	SequenceVariant	195	198	5	1:Positive_Correlation:2	L2R	CROSS	68-70	199-202	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	p|SUB|S|412|V|12	p . Ser412ValfsX12	SequenceVariant	199	202	5	1:Positive_Correlation:2	L2R	CROSS	68-70	214-219	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	c|DEL|436_436+1|AG	c . 436_436 + 1delAG	SequenceVariant	214	219	5	1:Positive_Correlation:2	L2R	CROSS	68-70	227-234	D063730	hypophosphatemic rickets|hypophosphatemic rickets	DiseaseOrPhenotypicFeature	12:68	14:70	0:2	c|SUB|G|1483-1|C	c . 1483 - 1G > C	SequenceVariant	227	234	5	1:NR:2	L2R	NON-CROSS	342-343	348-349	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	8074	fibroblast growth factor 23|FGF23|FGF23|FGF23	GeneOrGeneProduct	101:106:277:342	105:107:278:343	4:4:8:10	1:Positive_Correlation:2	L2R	CROSS	48-50	136-141	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	c|SUB|G|304|A	c . 304G > A	SequenceVariant	136	141	5	1:Positive_Correlation:2	L2R	CROSS	48-50	142-145	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	p|SUB|G|102|R	p . Gly102Arg	SequenceVariant	142	145	5	1:Positive_Correlation:2	L2R	CROSS	48-50	150-155	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	c|SUB|T|229|C	c . 229T > C	SequenceVariant	150	155	5	1:Positive_Correlation:2	L2R	CROSS	48-50	156-159	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	p|SUB|C|77|R	p . Cys77Arg	SequenceVariant	156	159	5	1:Positive_Correlation:2	L2R	CROSS	48-50	164-169	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	c|SUB|T|284|C	c . 824T > C	SequenceVariant	164	169	5	1:Positive_Correlation:2	L2R	CROSS	170-173	284-285	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	p|SUB|L|275|P	p . Leu275Pro	SequenceVariant	170	173	5	1:Positive_Correlation:2	L2R	CROSS	183-186	284-285	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	c|DEL|528|T	c . 528delT	SequenceVariant	183	186	5	1:Positive_Correlation:2	L2R	CROSS	187-190	284-285	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	p|SUB|E|177|K|44	p . Glu177LysfsX44	SequenceVariant	187	190	5	1:Positive_Correlation:2	L2R	CROSS	195-198	284-285	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	c|DEL|1234|A	c . 1234delA	SequenceVariant	195	198	5	1:Positive_Correlation:2	L2R	CROSS	199-202	284-285	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	p|SUB|S|412|V|12	p . Ser412ValfsX12	SequenceVariant	199	202	5	1:Positive_Correlation:2	L2R	CROSS	214-219	284-285	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	c|DEL|436_436+1|AG	c . 436_436 + 1delAG	SequenceVariant	214	219	5	1:Positive_Correlation:2	L2R	CROSS	227-234	284-285	D053098	X - linked hypophosphatemic rickets|XLH|OMIM 307800|XLH|XLH|XLH	DiseaseOrPhenotypicFeature	40:46:48:284:348:359	45:47:50:285:349:360	1:1:1:8:10:10	c|SUB|G|1483-1|C	c . 1483 - 1G > C	SequenceVariant	227	234	5
6086495	Localisation of the Becker muscular dystrophy gene on the short arm of the X chromosome by linkage to cloned DNA sequences .|A linkage study in 30 Becker muscular dystrophy ( BMD ) kindreds using three cloned DNA sequences from the X chromosome which demonstrate restriction fragment length polymorphisms ( RFLPs ) , suggests that the BMD gene is located on the short arm of the X chromosome , in the p21 region .|The genes for Becker and Duchenne dystrophies must therefore be closely linked , if not allelic , and any future DNA probes found to be of practical use in one disorder should be equally applicable to the other .|The linkage analysis also provides data on the frequency of recombination along the short arm of the X chromosome , and across the centromeric region . .	1:Association:2	L2R	NON-CROSS	3-7	27-30	1756	Becker muscular dystrophy gene|BMD	GeneOrGeneProduct	3:56	7:57	0:1	D020388	Becker muscular dystrophy|BMD|Becker and Duchenne dystrophies	DiseaseOrPhenotypicFeature	27:31:77	30:32:81	1:1:2
7811247	X - linked adrenoleukodystrophy ( ALD ) : a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes .|Fragments of the adrenoleukodystrophy ( ALD ) cDNA from a patient with adolescent ALD were amplified by polymerase chain reaction and subcloned .|Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five , resulting in substitution of proline 484 by arginine .|Five of nine siblings of the patient , comprising two cerebral ALD , one adrenomyeloneuropathy , one Addison only as well as the symptomatic mother ( all accumulating very long chain fatty acids ) carried this mutation , which was not found in the unaffected persons , in five unrelated ALD patients , and in twenty controls .|We propose that this missense mutation generated the disease per se as well as the metabolic defect ; the different phenotypes , however , must have originated by means of additional pathogenetic factors . .	1:Association:2	L2R	NON-CROSS	5-6	13-14	D000326	X - linked adrenoleukodystrophy|ALD|adrenoleukodystrophy|ALD|ALD|ALD|adrenomyeloneuropathy|ALD	DiseaseOrPhenotypicFeature	0:5:30:32:40:91:94:130	4:6:31:33:41:92:95:131	0:0:1:1:1:3:3:3	215	ALD|ALD	GeneOrGeneProduct	13:56	14:57	0:2	1:Positive_Correlation:2	R2L	CROSS	91-92	75-79	rs128624214	cytosine to guanine transversion at nucleotide 1451|proline 484 by arginine	SequenceVariant	60:75	67:79	2:2	D000326	X - linked adrenoleukodystrophy|ALD|adrenoleukodystrophy|ALD|ALD|ALD|adrenomyeloneuropathy|ALD	DiseaseOrPhenotypicFeature	0:5:30:32:40:91:94:130	4:6:31:33:41:92:95:131	0:0:1:1:1:3:3:3	1:NR:2	L2R	NON-CROSS	94-95	109-113	D000326	X - linked adrenoleukodystrophy|ALD|adrenoleukodystrophy|ALD|ALD|ALD|adrenomyeloneuropathy|ALD	DiseaseOrPhenotypicFeature	0:5:30:32:40:91:94:130	4:6:31:33:41:92:95:131	0:0:1:1:1:3:3:3	D005227	long chain fatty acids	ChemicalEntity	109	113	3	1:Association:2	L2R	CROSS	56-57	97-98	215	ALD|ALD	GeneOrGeneProduct	13:56	14:57	0:2	D000224	Addison	DiseaseOrPhenotypicFeature	97	98	3	1:NR:2	L2R	CROSS	56-57	109-113	215	ALD|ALD	GeneOrGeneProduct	13:56	14:57	0:2	D005227	long chain fatty acids	ChemicalEntity	109	113	3	1:Positive_Correlation:2	L2R	CROSS	75-79	97-98	rs128624214	cytosine to guanine transversion at nucleotide 1451|proline 484 by arginine	SequenceVariant	60:75	67:79	2:2	D000224	Addison	DiseaseOrPhenotypicFeature	97	98	3	1:NR:2	L2R	CROSS	75-79	109-113	rs128624214	cytosine to guanine transversion at nucleotide 1451|proline 484 by arginine	SequenceVariant	60:75	67:79	2:2	D005227	long chain fatty acids	ChemicalEntity	109	113	3	1:NR:2	L2R	NON-CROSS	97-98	109-113	D000224	Addison	DiseaseOrPhenotypicFeature	97	98	3	D005227	long chain fatty acids	ChemicalEntity	109	113	3
16838170	Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus : the STOP - NIDDM trial .|Hepatocyte nuclear factor 4alpha ( HNF4alpha ) is a transcription factor , which is necessary for normal function of human liver and pancreatic islets .|We investigated whether single nucleotide polymorphisms ( SNPs ) of HNF4A , encoding HNF4alpha , influenced the conversion from impaired glucose tolerance ( IGT ) to type 2 diabetes mellitus in subjects of the STOP - NIDDM trial .|This trial aimed at evaluating the effect of acarbose compared to placebo in the prevention of type 2 diabetes mellitus .|Eight SNPs covering the intragenic and alternate P2 promoter regions of HNF4A were genotyped in study samples using the TaqMan Allelic Discrimination Assays .|Three SNPs in the P2 promoter region ( rs4810424 , rs1884614 , and rs2144908 ) were in almost complete association ( D ' > 0 . 97 , r ( 2 ) > 0 . 95 ) and , therefore , only rs4810424 was included in further analyses .|Female carriers of the less frequent C allele of rs4810424 had a 1 . 7 - fold elevated risk [ 95 % confidence interval ( CI ) 1 . 09 - 2 . 66 ; P = 0 . 020 ] for the conversion to diabetes compared to women with the common genotype after the adjustment for age , treatment group ( placebo or acarbose ) , smoking , weight at baseline , and weight change .|No association was found in men .|Haplotype analysis based on three SNPs ( rs4810424 , rs2071197 , and rs3818247 ) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women .|Our results suggest that SNPs of HNF4A and their haplotypes predispose to type 2 diabetes mellitus in female subjects of the STOP - NIDDM study population .	1:Association:2	L2R	NON-CROSS	318-319	324-328	3172	HNF4alpha|Hepatocyte nuclear factor 4alpha|HNF4alpha|HNF4A|HNF4alpha|HNF4A|HNF4A	GeneOrGeneProduct	5:24:29:59:62:120:318	6:28:30:60:63:121:319	0:1:1:2:2:4:9	D003924	type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus	DiseaseOrPhenotypicFeature	13:75:104:294:324	17:79:108:298:328	0:2:3:8:9	1:NR:2	L2R	NON-CROSS	62-63	68-71	3172	HNF4alpha|Hepatocyte nuclear factor 4alpha|HNF4alpha|HNF4A|HNF4alpha|HNF4A|HNF4A	GeneOrGeneProduct	5:24:29:59:62:120:318	6:28:30:60:63:121:319	0:1:1:2:2:4:9	D018149	impaired glucose tolerance|IGT	DiseaseOrPhenotypicFeature	68:72	71:73	2:2	1:NR:2	L2R	CROSS	96-97	120-121	3172	HNF4alpha|Hepatocyte nuclear factor 4alpha|HNF4alpha|HNF4A|HNF4alpha|HNF4A|HNF4A	GeneOrGeneProduct	5:24:29:59:62:120:318	6:28:30:60:63:121:319	0:1:1:2:2:4:9	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	1:NR:2	L2R	CROSS	227-228	318-319	3172	HNF4alpha|Hepatocyte nuclear factor 4alpha|HNF4alpha|HNF4A|HNF4alpha|HNF4A|HNF4A	GeneOrGeneProduct	5:24:29:59:62:120:318	6:28:30:60:63:121:319	0:1:1:2:2:4:9	D003920	diabetes	DiseaseOrPhenotypicFeature	227	228	6	1:Negative_Correlation:2	R2L	NON-CROSS	104-108	96-97	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	D003924	type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus	DiseaseOrPhenotypicFeature	13:75:104:294:324	17:79:108:298:328	0:2:3:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	273-274	294-298	D003924	type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus	DiseaseOrPhenotypicFeature	13:75:104:294:324	17:79:108:298:328	0:2:3:8:9	rs4810424	rs4810424|rs4810424|rs4810424|rs4810424	SequenceVariant	141:175:191:273	142:176:192:274	5:5:6:8	1:Association:2	R2L	CROSS	143-144	104-108	rs1884614	rs1884614	SequenceVariant	143	144	5	D003924	type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus	DiseaseOrPhenotypicFeature	13:75:104:294:324	17:79:108:298:328	0:2:3:8:9	1:Association:2	R2L	CROSS	146-147	104-108	rs2144908	rs2144908	SequenceVariant	146	147	5	D003924	type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus	DiseaseOrPhenotypicFeature	13:75:104:294:324	17:79:108:298:328	0:2:3:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	275-276	294-298	D003924	type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus	DiseaseOrPhenotypicFeature	13:75:104:294:324	17:79:108:298:328	0:2:3:8:9	rs2071197	rs2071197	SequenceVariant	275	276	8	1:Positive_Correlation:2	L2R	NON-CROSS	278-279	294-298	D003924	type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus|type 2 diabetes mellitus	DiseaseOrPhenotypicFeature	13:75:104:294:324	17:79:108:298:328	0:2:3:8:9	rs3818247	rs3818247	SequenceVariant	278	279	8	1:Negative_Correlation:2	R2L	CROSS	96-97	72-73	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	D018149	impaired glucose tolerance|IGT	DiseaseOrPhenotypicFeature	68:72	71:73	2:2	1:NR:2	L2R	CROSS	72-73	141-142	D018149	impaired glucose tolerance|IGT	DiseaseOrPhenotypicFeature	68:72	71:73	2:2	rs4810424	rs4810424|rs4810424|rs4810424|rs4810424	SequenceVariant	141:175:191:273	142:176:192:274	5:5:6:8	1:NR:2	L2R	CROSS	72-73	143-144	D018149	impaired glucose tolerance|IGT	DiseaseOrPhenotypicFeature	68:72	71:73	2:2	rs1884614	rs1884614	SequenceVariant	143	144	5	1:NR:2	L2R	CROSS	72-73	146-147	D018149	impaired glucose tolerance|IGT	DiseaseOrPhenotypicFeature	68:72	71:73	2:2	rs2144908	rs2144908	SequenceVariant	146	147	5	1:NR:2	L2R	CROSS	72-73	275-276	D018149	impaired glucose tolerance|IGT	DiseaseOrPhenotypicFeature	68:72	71:73	2:2	rs2071197	rs2071197	SequenceVariant	275	276	8	1:NR:2	L2R	CROSS	72-73	278-279	D018149	impaired glucose tolerance|IGT	DiseaseOrPhenotypicFeature	68:72	71:73	2:2	rs3818247	rs3818247	SequenceVariant	278	279	8	1:NR:2	L2R	NON-CROSS	246-247	273-274	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	rs4810424	rs4810424|rs4810424|rs4810424|rs4810424	SequenceVariant	141:175:191:273	142:176:192:274	5:5:6:8	1:NR:2	L2R	CROSS	96-97	143-144	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	rs1884614	rs1884614	SequenceVariant	143	144	5	1:NR:2	L2R	CROSS	96-97	146-147	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	rs2144908	rs2144908	SequenceVariant	146	147	5	1:NR:2	L2R	NON-CROSS	227-228	246-247	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	D003920	diabetes	DiseaseOrPhenotypicFeature	227	228	6	1:NR:2	L2R	CROSS	246-247	275-276	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	rs2071197	rs2071197	SequenceVariant	275	276	8	1:NR:2	L2R	CROSS	246-247	278-279	D020909	acarbose|acarbose	ChemicalEntity	96:246	97:247	3:6	rs3818247	rs3818247	SequenceVariant	278	279	8	1:Positive_Correlation:2	L2R	NON-CROSS	191-192	227-228	rs4810424	rs4810424|rs4810424|rs4810424|rs4810424	SequenceVariant	141:175:191:273	142:176:192:274	5:5:6:8	D003920	diabetes	DiseaseOrPhenotypicFeature	227	228	6	1:Association:2	L2R	NON-CROSS	273-274	275-276	rs4810424	rs4810424|rs4810424|rs4810424|rs4810424	SequenceVariant	141:175:191:273	142:176:192:274	5:5:6:8	rs2071197	rs2071197	SequenceVariant	275	276	8	1:Association:2	L2R	NON-CROSS	273-274	278-279	rs4810424	rs4810424|rs4810424|rs4810424|rs4810424	SequenceVariant	141:175:191:273	142:176:192:274	5:5:6:8	rs3818247	rs3818247	SequenceVariant	278	279	8	1:Association:2	R2L	CROSS	227-228	143-144	D003920	diabetes	DiseaseOrPhenotypicFeature	227	228	6	rs1884614	rs1884614	SequenceVariant	143	144	5	1:Association:2	R2L	CROSS	227-228	146-147	D003920	diabetes	DiseaseOrPhenotypicFeature	227	228	6	rs2144908	rs2144908	SequenceVariant	146	147	5	1:NR:2	L2R	CROSS	227-228	275-276	D003920	diabetes	DiseaseOrPhenotypicFeature	227	228	6	rs2071197	rs2071197	SequenceVariant	275	276	8	1:NR:2	L2R	CROSS	227-228	278-279	D003920	diabetes	DiseaseOrPhenotypicFeature	227	228	6	rs3818247	rs3818247	SequenceVariant	278	279	8	1:Association:2	L2R	NON-CROSS	275-276	278-279	rs2071197	rs2071197	SequenceVariant	275	276	8	rs3818247	rs3818247	SequenceVariant	278	279	8
20801540	Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation .|BACKGROUND _ # 38 ; AIMS : Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders , retinal degeneration , and diabetes mellitus .|Ceruloplasmin is a multi - copper ferroxidase that is secreted into plasma and facilitates cellular iron export and iron binding to transferrin .|RESULTS : A novel homozygous ceruloplasmin gene mutation , c . 2554 + 1G > T , was identified as the cause of aceruloplasminemia in three affected siblings .|Two siblings presented with movement disorders and diabetes .|Complementary DNA sequencing showed that this mutation causes skipping of exon 14 and deletion of amino acids 809 - 852 while preserving the open reading frame .|Western blotting of liver extracts and sera of affected patients showed retention of the abnormal protein in the liver .|Aceruloplasminemia was associated with severe brain and liver iron overload , where hepatic mRNA expression of the iron hormone hepcidin was increased , corresponding to the degree of iron overload .|Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with deferasirox , which was also associated with reduced insulin demands .|During short term treatment there was no clinical or imaging evidence for significant effects on brain iron overload .|CONCLUSIONS : Aceruloplasminemia can show an incomplete clinical penetrance but is invariably associated with iron accumulation in the liver and in the brain .|Iron accumulation in aceruloplasminemia is a result of defective cellular iron export , where hepcidin regulation is appropriate for the degree of iron overload .|Iron chelation with deferasirox was effective in mobilizing hepatic iron but has no effect on brain iron .	1:Bind:2	L2R	NON-CROSS	286-287	289-290	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	1:Positive_Correlation:2	R2L	NON-CROSS	264-265	261-262	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	1:NR:2	L2R	NON-CROSS	30-34	39-40	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	1:Positive_Correlation:2	L2R	NON-CROSS	39-40	45-47	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	1:Positive_Correlation:2	L2R	NON-CROSS	39-40	48-50	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	1:Positive_Correlation:2	L2R	NON-CROSS	39-40	52-54	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	1:Association:2	R2L	NON-CROSS	83-84	73-74	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	1:NR:2	L2R	NON-CROSS	61-62	70-71	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	-	ferroxidase	ChemicalEntity	61	62	2	1:Bind:2	L2R	NON-CROSS	73-74	76-77	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	7018	transferrin	GeneOrGeneProduct	76	77	2	1:NR:2	L2R	CROSS	73-74	87-94	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	1:NR:2	L2R	CROSS	129-136	180-181	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	1:Positive_Correlation:2	R2L	NON-CROSS	286-287	283-285	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	1:NR:2	L2R	NON-CROSS	180-181	182-183	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	NON-CROSS	203-204	215-216	D007501	iron|iron|iron|iron|iron|iron|iron|iron|Iron|iron|Iron|iron|iron	ChemicalEntity	4:39:70:73:180:195:203:251:261:271:286:295:302	5:40:71:74:181:196:204:252:262:272:287:296:303	0:1:2:2:7:8:8:10:11:11:12:12:12	3630	insulin	GeneOrGeneProduct	215	216	8	1:Negative_Correlation:2	L2R	NON-CROSS	9-10	11-12	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	1:NR:2	L2R	CROSS	9-10	30-34	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	1:NR:2	L2R	CROSS	9-10	45-47	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	1:NR:2	L2R	CROSS	9-10	48-50	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	1:NR:2	L2R	CROSS	9-10	52-54	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	1:NR:2	L2R	CROSS	9-10	55-56	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	1:NR:2	L2R	CROSS	9-10	61-62	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	-	ferroxidase	ChemicalEntity	61	62	2	1:NR:2	L2R	CROSS	9-10	76-77	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	7018	transferrin	GeneOrGeneProduct	76	77	2	1:NR:2	L2R	CROSS	9-10	87-94	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	1:NR:2	L2R	CROSS	129-136	207-208	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	1:Negative_Correlation:2	R2L	CROSS	289-290	283-285	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	1:NR:2	L2R	CROSS	275-276	289-290	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:Negative_Correlation:2	L2R	NON-CROSS	207-208	215-216	D000077588	deferasirox|deferasirox|deferasirox	ChemicalEntity	9:207:289	10:208:290	0:8:12	3630	insulin	GeneOrGeneProduct	215	216	8	1:Association:2	R2L	NON-CROSS	101-102	83-84	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	1:NR:2	L2R	CROSS	26-27	61-62	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	-	ferroxidase	ChemicalEntity	61	62	2	1:NR:2	L2R	CROSS	76-77	101-102	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	7018	transferrin	GeneOrGeneProduct	76	77	2	1:Positive_Correlation:2	R2L	NON-CROSS	101-102	87-94	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	1:NR:2	L2R	CROSS	101-102	129-136	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	1:Association:2	L2R	NON-CROSS	264-265	275-276	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	CROSS	215-216	239-240	C536004	aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia|Aceruloplasminemia|Aceruloplasminemia|aceruloplasminemia	DiseaseOrPhenotypicFeature	11:26:101:163:239:264	12:27:102:164:240:265	0:1:3:7:10:11	3630	insulin	GeneOrGeneProduct	215	216	8	1:NR:2	L2R	CROSS	30-34	55-56	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	1:NR:2	L2R	CROSS	30-34	61-62	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	-	ferroxidase	ChemicalEntity	61	62	2	1:NR:2	L2R	CROSS	30-34	76-77	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	7018	transferrin	GeneOrGeneProduct	76	77	2	1:NR:2	L2R	CROSS	30-34	87-94	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	1:NR:2	L2R	CROSS	30-34	129-136	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	1:NR:2	L2R	CROSS	30-34	182-183	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	CROSS	30-34	215-216	D020271	autosomal recessive neurodegenerative disease	DiseaseOrPhenotypicFeature	30	34	1	3630	insulin	GeneOrGeneProduct	215	216	8	1:Association:2	R2L	CROSS	55-56	45-47	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	1:NR:2	L2R	CROSS	45-47	61-62	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	-	ferroxidase	ChemicalEntity	61	62	2	1:NR:2	L2R	CROSS	45-47	76-77	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	7018	transferrin	GeneOrGeneProduct	76	77	2	1:Association:2	R2L	CROSS	111-113	87-94	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	1:NR:2	L2R	CROSS	111-113	129-136	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	1:NR:2	L2R	CROSS	111-113	182-183	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	CROSS	111-113	215-216	D009069	movement disorders|movement disorders	DiseaseOrPhenotypicFeature	45:111	47:113	1:4	3630	insulin	GeneOrGeneProduct	215	216	8	1:NR:2	L2R	CROSS	48-50	55-56	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	1:NR:2	L2R	CROSS	48-50	61-62	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	-	ferroxidase	ChemicalEntity	61	62	2	1:NR:2	L2R	CROSS	48-50	76-77	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	7018	transferrin	GeneOrGeneProduct	76	77	2	1:NR:2	L2R	CROSS	48-50	87-94	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	1:NR:2	L2R	CROSS	48-50	129-136	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	1:NR:2	L2R	CROSS	48-50	182-183	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	CROSS	48-50	215-216	D012162	retinal degeneration	DiseaseOrPhenotypicFeature	48	50	1	3630	insulin	GeneOrGeneProduct	215	216	8	1:Association:2	R2L	CROSS	55-56	52-54	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	1:NR:2	L2R	CROSS	52-54	61-62	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	-	ferroxidase	ChemicalEntity	61	62	2	1:NR:2	L2R	CROSS	52-54	76-77	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	7018	transferrin	GeneOrGeneProduct	76	77	2	1:Association:2	R2L	CROSS	114-115	87-94	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	1:NR:2	L2R	CROSS	114-115	129-136	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	1:NR:2	L2R	CROSS	114-115	182-183	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	CROSS	114-115	215-216	D003920	diabetes mellitus|diabetes	DiseaseOrPhenotypicFeature	52:114	54:115	1:4	3630	insulin	GeneOrGeneProduct	215	216	8	1:NR:2	L2R	NON-CROSS	55-56	61-62	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	-	ferroxidase	ChemicalEntity	61	62	2	1:NR:2	L2R	NON-CROSS	76-77	83-84	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	7018	transferrin	GeneOrGeneProduct	76	77	2	1:NR:2	L2R	CROSS	83-84	171-173	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	1:NR:2	L2R	CROSS	83-84	182-183	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	CROSS	83-84	215-216	1356	Ceruloplasmin|ceruloplasmin	GeneOrGeneProduct	55:83	56:84	2:3	3630	insulin	GeneOrGeneProduct	215	216	8	1:NR:2	L2R	NON-CROSS	61-62	76-77	-	ferroxidase	ChemicalEntity	61	62	2	7018	transferrin	GeneOrGeneProduct	76	77	2	1:NR:2	L2R	CROSS	61-62	87-94	-	ferroxidase	ChemicalEntity	61	62	2	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	1:NR:2	L2R	CROSS	61-62	129-136	-	ferroxidase	ChemicalEntity	61	62	2	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	1:NR:2	L2R	CROSS	61-62	171-173	-	ferroxidase	ChemicalEntity	61	62	2	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	1:NR:2	L2R	CROSS	61-62	182-183	-	ferroxidase	ChemicalEntity	61	62	2	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	CROSS	61-62	215-216	-	ferroxidase	ChemicalEntity	61	62	2	3630	insulin	GeneOrGeneProduct	215	216	8	1:NR:2	L2R	CROSS	76-77	171-173	7018	transferrin	GeneOrGeneProduct	76	77	2	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	1:NR:2	L2R	CROSS	76-77	182-183	7018	transferrin	GeneOrGeneProduct	76	77	2	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	1:NR:2	L2R	CROSS	76-77	215-216	7018	transferrin	GeneOrGeneProduct	76	77	2	3630	insulin	GeneOrGeneProduct	215	216	8	1:NR:2	L2R	CROSS	87-94	171-173	c|SUB|G|2554+1|T	c . 2554 + 1G > T	SequenceVariant	87	94	3	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	1:NR:2	L2R	CROSS	129-136	171-173	c|DEL|809_852|	deletion of amino acids 809 - 852	SequenceVariant	129	136	5	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	1:Negative_Correlation:2	R2L	NON-CROSS	283-285	275-276	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	1:NR:2	L2R	CROSS	215-216	234-236	D019190	iron overload|iron overload|iron overload|iron overload	DiseaseOrPhenotypicFeature	171:191:234:283	173:193:236:285	7:7:9:11	3630	insulin	GeneOrGeneProduct	215	216	8	1:NR:2	L2R	CROSS	182-183	215-216	57817	hepcidin|hepcidin	GeneOrGeneProduct	182:275	183:276	7:11	3630	insulin	GeneOrGeneProduct	215	216	8
25550469	The androgen receptor confers protection against diet - induced atherosclerosis , obesity , and dyslipidemia in female mice .|Androgens have important cardiometabolic actions in males , but their metabolic role in females is unclear .|To determine the physiologic androgen receptor ( AR ) - dependent actions of androgens on atherogenesis in female mice , we generated female AR - knockout ( ARKO ) mice on an atherosclerosis - prone apolipoprotein E ( apoE ) - deficient background .|After 8 weeks on a high - fat diet , but not on a normal chow diet , atherosclerosis in aorta was increased in ARKO females ( + 59 % vs . control apoE - deficient mice with intact AR gene ) .|They also displayed increased body weight ( + 18 % ) , body fat percentage ( + 62 % ) , and hepatic triglyceride levels , reduced insulin sensitivity , and a marked atherogenic dyslipidemia ( serum cholesterol , + 52 % ) .|Differences in atherosclerosis , body weight , and lipid levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty , consistent with a protective action of ovarian androgens mediated via the AR .|Furthermore , the AR agonist dihydrotestosterone reduced atherosclerosis ( - 41 % ; thoracic aorta ) , subcutaneous fat mass ( - 44 % ) , and cholesterol levels ( - 35 % ) in ovariectomized mice , reduced hepatocyte lipid accumulation in hepatoma cells in vitro , and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis .|In conclusion , we demonstrate that the AR protects against diet - induced atherosclerosis in female mice and propose that this is mediated by modulation of body composition and lipid metabolism .	1:Negative_Correlation:2	L2R	NON-CROSS	208-209	212-213	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	D050197	atherosclerosis|atherogenesis|atherosclerosis|atherosclerosis|atherogenic|atherosclerosis|atherosclerosis|atherosclerosis	DiseaseOrPhenotypicFeature	9:51:68:98:156:169:212:278	10:52:69:99:157:170:213:279	0:2:2:3:4:5:6:7	1:Negative_Correlation:2	L2R	NON-CROSS	1-3	11-12	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	D009765	obesity	DiseaseOrPhenotypicFeature	11	12	0	1:Negative_Correlation:2	R2L	NON-CROSS	14-15	1-3	D050171	dyslipidemia|dyslipidemia	DiseaseOrPhenotypicFeature	14:157	15:158	0:4	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	1:Bind:2	L2R	NON-CROSS	199-200	203-204	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	1:NR:2	L2R	NON-CROSS	113-114	119-120	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	1:Negative_Correlation:2	R2L	CROSS	146-147	119-120	100035834	triglyceride	GeneOrGeneProduct	146	147	4	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	1:Positive_Correlation:2	L2R	CROSS	150-151	178-179	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	16334	insulin	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	160-161	178-179	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:NR:2	L2R	NON-CROSS	175-176	178-179	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	208-209	210-211	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	1:NR:2	L2R	NON-CROSS	248-249	272-273	11835	androgen receptor|androgen receptor|AR|AR|AR|AR|AR|AR|AR|AR|AR	GeneOrGeneProduct	1:40:43:59:63:104:119:178:203:208:272	3:42:44:60:64:105:120:179:204:209:273	0:2:2:2:2:3:3:5:5:6:7	D006528	hepatoma	DiseaseOrPhenotypicFeature	248	249	6	1:NR:2	L2R	NON-CROSS	49-50	51-52	D050197	atherosclerosis|atherogenesis|atherosclerosis|atherosclerosis|atherogenic|atherosclerosis|atherosclerosis|atherosclerosis	DiseaseOrPhenotypicFeature	9:51:68:98:156:169:212:278	10:52:69:99:157:170:213:279	0:2:2:3:4:5:6:7	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	1:NR:2	L2R	NON-CROSS	68-69	71-73	D050197	atherosclerosis|atherogenesis|atherosclerosis|atherosclerosis|atherogenic|atherosclerosis|atherosclerosis|atherosclerosis	DiseaseOrPhenotypicFeature	9:51:68:98:156:169:212:278	10:52:69:99:157:170:213:279	0:2:2:3:4:5:6:7	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	1:NR:2	L2R	NON-CROSS	146-147	156-157	D050197	atherosclerosis|atherogenesis|atherosclerosis|atherosclerosis|atherogenic|atherosclerosis|atherosclerosis|atherosclerosis	DiseaseOrPhenotypicFeature	9:51:68:98:156:169:212:278	10:52:69:99:157:170:213:279	0:2:2:3:4:5:6:7	100035834	triglyceride	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	150-151	156-157	D050197	atherosclerosis|atherogenesis|atherosclerosis|atherosclerosis|atherogenic|atherosclerosis|atherosclerosis|atherosclerosis	DiseaseOrPhenotypicFeature	9:51:68:98:156:169:212:278	10:52:69:99:157:170:213:279	0:2:2:3:4:5:6:7	16334	insulin	GeneOrGeneProduct	150	151	4	1:Positive_Correlation:2	L2R	NON-CROSS	156-157	160-161	D050197	atherosclerosis|atherogenesis|atherosclerosis|atherosclerosis|atherogenic|atherosclerosis|atherosclerosis|atherosclerosis	DiseaseOrPhenotypicFeature	9:51:68:98:156:169:212:278	10:52:69:99:157:170:213:279	0:2:2:3:4:5:6:7	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:Association:2	L2R	NON-CROSS	169-170	175-176	D050197	atherosclerosis|atherogenesis|atherosclerosis|atherosclerosis|atherogenic|atherosclerosis|atherosclerosis|atherosclerosis	DiseaseOrPhenotypicFeature	9:51:68:98:156:169:212:278	10:52:69:99:157:170:213:279	0:2:2:3:4:5:6:7	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:Negative_Correlation:2	R2L	NON-CROSS	212-213	210-211	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	D050197	atherosclerosis|atherogenesis|atherosclerosis|atherosclerosis|atherogenic|atherosclerosis|atherosclerosis|atherosclerosis	DiseaseOrPhenotypicFeature	9:51:68:98:156:169:212:278	10:52:69:99:157:170:213:279	0:2:2:3:4:5:6:7	1:NR:2	L2R	CROSS	11-12	19-20	D009765	obesity	DiseaseOrPhenotypicFeature	11	12	0	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	1:NR:2	L2R	CROSS	11-12	71-73	D009765	obesity	DiseaseOrPhenotypicFeature	11	12	0	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	1:NR:2	L2R	CROSS	11-12	146-147	D009765	obesity	DiseaseOrPhenotypicFeature	11	12	0	100035834	triglyceride	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	CROSS	11-12	150-151	D009765	obesity	DiseaseOrPhenotypicFeature	11	12	0	16334	insulin	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	CROSS	11-12	160-161	D009765	obesity	DiseaseOrPhenotypicFeature	11	12	0	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:NR:2	L2R	CROSS	11-12	175-176	D009765	obesity	DiseaseOrPhenotypicFeature	11	12	0	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:NR:2	L2R	CROSS	11-12	210-211	D009765	obesity	DiseaseOrPhenotypicFeature	11	12	0	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	1:NR:2	L2R	CROSS	14-15	19-20	D050171	dyslipidemia|dyslipidemia	DiseaseOrPhenotypicFeature	14:157	15:158	0:4	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	1:NR:2	L2R	CROSS	113-114	157-158	D050171	dyslipidemia|dyslipidemia	DiseaseOrPhenotypicFeature	14:157	15:158	0:4	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	1:NR:2	L2R	NON-CROSS	146-147	157-158	D050171	dyslipidemia|dyslipidemia	DiseaseOrPhenotypicFeature	14:157	15:158	0:4	100035834	triglyceride	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	150-151	157-158	D050171	dyslipidemia|dyslipidemia	DiseaseOrPhenotypicFeature	14:157	15:158	0:4	16334	insulin	GeneOrGeneProduct	150	151	4	1:Positive_Correlation:2	L2R	NON-CROSS	157-158	160-161	D050171	dyslipidemia|dyslipidemia	DiseaseOrPhenotypicFeature	14:157	15:158	0:4	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:NR:2	L2R	CROSS	157-158	175-176	D050171	dyslipidemia|dyslipidemia	DiseaseOrPhenotypicFeature	14:157	15:158	0:4	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:NR:2	L2R	CROSS	157-158	210-211	D050171	dyslipidemia|dyslipidemia	DiseaseOrPhenotypicFeature	14:157	15:158	0:4	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	1:NR:2	L2R	NON-CROSS	49-50	71-73	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	1:NR:2	L2R	CROSS	146-147	199-200	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	100035834	triglyceride	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	CROSS	150-151	199-200	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	16334	insulin	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	CROSS	199-200	232-233	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:NR:2	L2R	NON-CROSS	175-176	199-200	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:NR:2	L2R	CROSS	199-200	210-211	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	1:NR:2	L2R	CROSS	199-200	248-249	D000728	Androgens|androgens|androgens	ChemicalEntity	19:49:199	20:50:200	1:2:5	D006528	hepatoma	DiseaseOrPhenotypicFeature	248	249	6	1:NR:2	L2R	CROSS	113-114	146-147	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	100035834	triglyceride	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	CROSS	113-114	150-151	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	16334	insulin	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	CROSS	113-114	160-161	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:NR:2	L2R	CROSS	113-114	175-176	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:NR:2	L2R	CROSS	113-114	210-211	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	1:NR:2	L2R	CROSS	113-114	248-249	11816	apolipoprotein E|apoE|apoE	GeneOrGeneProduct	71:74:113	73:75:114	2:2:3	D006528	hepatoma	DiseaseOrPhenotypicFeature	248	249	6	1:NR:2	L2R	NON-CROSS	146-147	150-151	100035834	triglyceride	GeneOrGeneProduct	146	147	4	16334	insulin	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	146-147	160-161	100035834	triglyceride	GeneOrGeneProduct	146	147	4	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:NR:2	L2R	CROSS	146-147	175-176	100035834	triglyceride	GeneOrGeneProduct	146	147	4	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:NR:2	L2R	CROSS	146-147	210-211	100035834	triglyceride	GeneOrGeneProduct	146	147	4	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	1:NR:2	L2R	CROSS	146-147	248-249	100035834	triglyceride	GeneOrGeneProduct	146	147	4	D006528	hepatoma	DiseaseOrPhenotypicFeature	248	249	6	1:NR:2	L2R	NON-CROSS	150-151	160-161	16334	insulin	GeneOrGeneProduct	150	151	4	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:NR:2	L2R	CROSS	150-151	175-176	16334	insulin	GeneOrGeneProduct	150	151	4	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:NR:2	L2R	CROSS	150-151	210-211	16334	insulin	GeneOrGeneProduct	150	151	4	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	1:NR:2	L2R	CROSS	150-151	248-249	16334	insulin	GeneOrGeneProduct	150	151	4	D006528	hepatoma	DiseaseOrPhenotypicFeature	248	249	6	1:NR:2	L2R	NON-CROSS	232-233	245-246	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:Negative_Correlation:2	R2L	NON-CROSS	232-233	210-211	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	1:NR:2	L2R	NON-CROSS	232-233	248-249	D002784	cholesterol|cholesterol	ChemicalEntity	160:232	161:233	4:6	D006528	hepatoma	DiseaseOrPhenotypicFeature	248	249	6	1:Negative_Correlation:2	R2L	NON-CROSS	210-211	175-176	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	1:NR:2	L2R	NON-CROSS	245-246	248-249	D008055	lipid|lipid|lipid|lipid	ChemicalEntity	175:245:262:294	176:246:263:295	5:6:6:7	D006528	hepatoma	DiseaseOrPhenotypicFeature	248	249	6	1:NR:2	L2R	NON-CROSS	210-211	248-249	D013196	dihydrotestosterone	ChemicalEntity	210	211	6	D006528	hepatoma	DiseaseOrPhenotypicFeature	248	249	6
27090298	Circulating Fatty Acid Synthase in pregnant women : Relationship to blood pressure , maternal metabolism and newborn parameters .|The enzyme FASN ( fatty acid synthase ) is potentially related with hypertension and metabolic dysfunction .|FASN is highly expressed in the human placenta .|We aimed to investigate the relationship circulating FASN has with blood pressure , maternal metabolism and newborn parameters in healthy pregnant women .|Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C - peptide , fasting glucose and insulin , post - load glucose lipids , HMW - adiponectin and blood pressure ( the latter was assessed in each trimester of gestation ) .|At birth , newborns and placentas were weighed .|FASN expression was also able to be assessed in 80 placentas .|Higher circulating FASN was associated with lower systolic blood pressure ( SBP ) , with a more favourable metabolic phenotype ( lower fasting glucose and insulin , post load glucose , HbAc1 , HOMA - IR and C - peptide ) , and with lower placental and birth weight ( all p < 0 . 05 to p < 0 . 001 ) .|Placental FASN expression related positively to circulating FASN ( p < 0 . 005 ) and negatively to placental weight ( p < 0 . 05 ) .|Our observations suggest a physiological role of placental FASN in human pregnancy .|Future studies will clarify whether circulating FASN of placental origin does actually regulate placental and fetal growth , and ( thereby ) has a favourable influence on the pregnant mother 's insulin sensitivity and blood pressure .	1:Association:2	L2R	NON-CROSS	31-32	36-37	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	D006973	hypertension	DiseaseOrPhenotypicFeature	31	32	1	1:Association:2	L2R	NON-CROSS	33-35	36-37	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	D008659	metabolic dysfunction	DiseaseOrPhenotypicFeature	33	35	1	1:Negative_Correlation:2	L2R	NON-CROSS	69-70	85-88	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	1:Negative_Correlation:2	L2R	NON-CROSS	69-70	90-91	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	1:Negative_Correlation:2	L2R	NON-CROSS	69-70	92-93	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	1:NR:2	L2R	NON-CROSS	69-70	98-99	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	D008055	lipids	ChemicalEntity	98	99	4	1:NR:2	L2R	NON-CROSS	100-101	127-128	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	57587	HMW	GeneOrGeneProduct	100	101	4	1:NR:2	L2R	NON-CROSS	102-103	127-128	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	9370	adiponectin	GeneOrGeneProduct	102	103	4	1:Negative_Correlation:2	L2R	NON-CROSS	141-142	170-171	2194	Fatty Acid Synthase|FASN|fatty acid synthase|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN|FASN	GeneOrGeneProduct	1:21:23:36:52:69:127:141:204:210:239:250	4:22:26:37:53:70:128:142:205:211:240:251	0:1:1:2:3:4:6:7:8:8:9:10	3043	HbAc1	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	31-32	85-88	D006973	hypertension	DiseaseOrPhenotypicFeature	31	32	1	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	1:NR:2	L2R	CROSS	31-32	90-91	D006973	hypertension	DiseaseOrPhenotypicFeature	31	32	1	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	1:NR:2	L2R	CROSS	31-32	92-93	D006973	hypertension	DiseaseOrPhenotypicFeature	31	32	1	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	1:NR:2	L2R	CROSS	31-32	98-99	D006973	hypertension	DiseaseOrPhenotypicFeature	31	32	1	D008055	lipids	ChemicalEntity	98	99	4	1:NR:2	L2R	CROSS	31-32	100-101	D006973	hypertension	DiseaseOrPhenotypicFeature	31	32	1	57587	HMW	GeneOrGeneProduct	100	101	4	1:NR:2	L2R	CROSS	31-32	102-103	D006973	hypertension	DiseaseOrPhenotypicFeature	31	32	1	9370	adiponectin	GeneOrGeneProduct	102	103	4	1:NR:2	L2R	CROSS	31-32	170-171	D006973	hypertension	DiseaseOrPhenotypicFeature	31	32	1	3043	HbAc1	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	33-35	85-88	D008659	metabolic dysfunction	DiseaseOrPhenotypicFeature	33	35	1	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	1:NR:2	L2R	CROSS	33-35	90-91	D008659	metabolic dysfunction	DiseaseOrPhenotypicFeature	33	35	1	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	1:NR:2	L2R	CROSS	33-35	92-93	D008659	metabolic dysfunction	DiseaseOrPhenotypicFeature	33	35	1	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	1:NR:2	L2R	CROSS	33-35	98-99	D008659	metabolic dysfunction	DiseaseOrPhenotypicFeature	33	35	1	D008055	lipids	ChemicalEntity	98	99	4	1:NR:2	L2R	CROSS	33-35	100-101	D008659	metabolic dysfunction	DiseaseOrPhenotypicFeature	33	35	1	57587	HMW	GeneOrGeneProduct	100	101	4	1:NR:2	L2R	CROSS	33-35	102-103	D008659	metabolic dysfunction	DiseaseOrPhenotypicFeature	33	35	1	9370	adiponectin	GeneOrGeneProduct	102	103	4	1:NR:2	L2R	CROSS	33-35	170-171	D008659	metabolic dysfunction	DiseaseOrPhenotypicFeature	33	35	1	3043	HbAc1	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	NON-CROSS	85-88	90-91	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	1:NR:2	L2R	NON-CROSS	85-88	92-93	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	1:NR:2	L2R	NON-CROSS	85-88	98-99	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	D008055	lipids	ChemicalEntity	98	99	4	1:NR:2	L2R	NON-CROSS	85-88	100-101	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	57587	HMW	GeneOrGeneProduct	100	101	4	1:NR:2	L2R	NON-CROSS	85-88	102-103	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	9370	adiponectin	GeneOrGeneProduct	102	103	4	1:NR:2	L2R	NON-CROSS	170-171	176-179	D002096	C - peptide|C - peptide	ChemicalEntity	85:176	88:179	4:7	3043	HbAc1	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	NON-CROSS	90-91	92-93	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	1:NR:2	L2R	NON-CROSS	97-98	98-99	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	D008055	lipids	ChemicalEntity	98	99	4	1:NR:2	L2R	NON-CROSS	97-98	100-101	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	57587	HMW	GeneOrGeneProduct	100	101	4	1:NR:2	L2R	NON-CROSS	97-98	102-103	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	9370	adiponectin	GeneOrGeneProduct	102	103	4	1:NR:2	L2R	NON-CROSS	168-169	170-171	D005947	glucose|glucose|glucose|glucose	ChemicalEntity	90:97:162:168	91:98:163:169	4:4:7:7	3043	HbAc1	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	NON-CROSS	92-93	98-99	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	D008055	lipids	ChemicalEntity	98	99	4	1:NR:2	L2R	NON-CROSS	92-93	100-101	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	57587	HMW	GeneOrGeneProduct	100	101	4	1:NR:2	L2R	NON-CROSS	92-93	102-103	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	9370	adiponectin	GeneOrGeneProduct	102	103	4	1:NR:2	L2R	NON-CROSS	164-165	170-171	3630	insulin|insulin|insulin	GeneOrGeneProduct	92:164:275	93:165:276	4:7:10	3043	HbAc1	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	NON-CROSS	98-99	100-101	D008055	lipids	ChemicalEntity	98	99	4	57587	HMW	GeneOrGeneProduct	100	101	4	1:NR:2	L2R	NON-CROSS	98-99	102-103	D008055	lipids	ChemicalEntity	98	99	4	9370	adiponectin	GeneOrGeneProduct	102	103	4	1:NR:2	L2R	CROSS	98-99	170-171	D008055	lipids	ChemicalEntity	98	99	4	3043	HbAc1	GeneOrGeneProduct	170	171	7	1:Association:2	L2R	NON-CROSS	100-101	102-103	57587	HMW	GeneOrGeneProduct	100	101	4	9370	adiponectin	GeneOrGeneProduct	102	103	4	1:NR:2	L2R	CROSS	100-101	170-171	57587	HMW	GeneOrGeneProduct	100	101	4	3043	HbAc1	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	102-103	170-171	9370	adiponectin	GeneOrGeneProduct	102	103	4	3043	HbAc1	GeneOrGeneProduct	170	171	7
27860185	Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells .|The recruitment of bone marrow ( BM ) - derived progenitor cells to the lung is related to pulmonary remodelling and the pathogenesis of pulmonary hypertension ( PH ) .|Although sildenafil is a known target in PH treatment , the underlying molecular mechanism is still elusive .|To test the hypothesis that the therapeutic effect of sildenafil is linked to the reduced recruitment of BM - derived progenitor cells , we induced pulmonary remodelling in rats by two - week exposure to chronic hypoxia ( CH , 10 % oxygen ) , a trigger of BM - derived progenitor cells .|Rats were treated with either placebo ( saline ) or sildenafil ( 1 . 4 mg / kg / day ip ) during CH .|Control rats were kept in room air ( 21 % oxygen ) with no treatment .|As expected , sildenafil attenuated the CH - induced increase in right ventricular systolic pressure and right ventricular hypertrophy .|However , sildenafil suppressed the CH - induced increase in c - kit ( + ) cells in the adventitia of pulmonary arteries .|Moreover , sildenafil reduced the number of c - kit ( + ) cells that colocalize with tyrosine kinase receptor 2 ( VEGF - R2 ) and CD68 ( a marker for macrophages ) , indicating a positive effect on moderating hypoxia - induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia - inducible factor ( HIF ) - 1a .|Furthermore , sildenafil depressed the number of CXCR4 ( + ) cells .|Collectively , these findings indicate that the improvement in pulmonary haemodynamic by sildenafil is linked to decreased recruitment of BM - derived c - kit ( + ) cells in the pulmonary tissue .|The attenuation of the recruitment of BM - derived c - kit ( + ) cells by sildenafil may provide novel therapeutic insights into the control of pulmonary remodelling .	1:Negative_Correlation:2	L2R	NON-CROSS	0-1	2-5	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	D066253	hypoxic pulmonary remodelling|pulmonary remodelling|pulmonary remodelling|pulmonary remodelling	DiseaseOrPhenotypicFeature	2:30:85:339	5:32:87:341	0:1:3:11	1:Negative_Correlation:2	L2R	NON-CROSS	39-40	43-44	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	D006976	pulmonary hypertension|PH|PH	DiseaseOrPhenotypicFeature	36:39:49	38:40:50	1:1:2	1:Negative_Correlation:2	L2R	NON-CROSS	158-159	161-162	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	D000860	hypoxia|CH|CH|CH|CH|hypoxia	DiseaseOrPhenotypicFeature	96:98:137:161:180:240	97:99:138:162:181:241	3:3:4:6:7:8	1:NR:2	L2R	NON-CROSS	149-150	158-159	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	1:Negative_Correlation:2	L2R	NON-CROSS	171-174	177-178	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	D017380	right ventricular hypertrophy	DiseaseOrPhenotypicFeature	171	174	6	1:NR:2	L2R	NON-CROSS	201-202	206-209	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	1:Association:2	L2R	NON-CROSS	201-202	216-220	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	1:Association:2	L2R	NON-CROSS	201-202	226-227	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	287435	CD68	GeneOrGeneProduct	226	227	8	1:Negative_Correlation:2	L2R	NON-CROSS	248-249	267-268	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	D007249	inflammation	DiseaseOrPhenotypicFeature	248	249	8	1:NR:2	L2R	NON-CROSS	255-264	267-268	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:Negative_Correlation:2	L2R	NON-CROSS	267-268	272-273	D000068677	Sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil|sildenafil	ChemicalEntity	0:43:69:124:158:177:201:267:290:329	1:44:70:125:159:178:202:268:291:330	0:2:3:4:6:7:8:9:10:11	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	NON-CROSS	85-87	102-103	D066253	hypoxic pulmonary remodelling|pulmonary remodelling|pulmonary remodelling|pulmonary remodelling	DiseaseOrPhenotypicFeature	2:30:85:339	5:32:87:341	0:1:3:11	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	1:NR:2	L2R	NON-CROSS	321-324	339-341	D066253	hypoxic pulmonary remodelling|pulmonary remodelling|pulmonary remodelling|pulmonary remodelling	DiseaseOrPhenotypicFeature	2:30:85:339	5:32:87:341	0:1:3:11	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	1:NR:2	L2R	CROSS	221-224	339-341	D066253	hypoxic pulmonary remodelling|pulmonary remodelling|pulmonary remodelling|pulmonary remodelling	DiseaseOrPhenotypicFeature	2:30:85:339	5:32:87:341	0:1:3:11	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	1:NR:2	L2R	CROSS	226-227	339-341	D066253	hypoxic pulmonary remodelling|pulmonary remodelling|pulmonary remodelling|pulmonary remodelling	DiseaseOrPhenotypicFeature	2:30:85:339	5:32:87:341	0:1:3:11	287435	CD68	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	255-264	339-341	D066253	hypoxic pulmonary remodelling|pulmonary remodelling|pulmonary remodelling|pulmonary remodelling	DiseaseOrPhenotypicFeature	2:30:85:339	5:32:87:341	0:1:3:11	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	272-273	339-341	D066253	hypoxic pulmonary remodelling|pulmonary remodelling|pulmonary remodelling|pulmonary remodelling	DiseaseOrPhenotypicFeature	2:30:85:339	5:32:87:341	0:1:3:11	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	CROSS	49-50	102-103	D006976	pulmonary hypertension|PH|PH	DiseaseOrPhenotypicFeature	36:39:49	38:40:50	1:1:2	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	1:NR:2	L2R	CROSS	49-50	185-188	D006976	pulmonary hypertension|PH|PH	DiseaseOrPhenotypicFeature	36:39:49	38:40:50	1:1:2	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	1:NR:2	L2R	CROSS	49-50	216-220	D006976	pulmonary hypertension|PH|PH	DiseaseOrPhenotypicFeature	36:39:49	38:40:50	1:1:2	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	1:NR:2	L2R	CROSS	49-50	226-227	D006976	pulmonary hypertension|PH|PH	DiseaseOrPhenotypicFeature	36:39:49	38:40:50	1:1:2	287435	CD68	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	49-50	255-264	D006976	pulmonary hypertension|PH|PH	DiseaseOrPhenotypicFeature	36:39:49	38:40:50	1:1:2	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	49-50	272-273	D006976	pulmonary hypertension|PH|PH	DiseaseOrPhenotypicFeature	36:39:49	38:40:50	1:1:2	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	NON-CROSS	98-99	102-103	D000860	hypoxia|CH|CH|CH|CH|hypoxia	DiseaseOrPhenotypicFeature	96:98:137:161:180:240	97:99:138:162:181:241	3:3:4:6:7:8	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	1:NR:2	L2R	NON-CROSS	180-181	185-188	D000860	hypoxia|CH|CH|CH|CH|hypoxia	DiseaseOrPhenotypicFeature	96:98:137:161:180:240	97:99:138:162:181:241	3:3:4:6:7:8	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	1:NR:2	L2R	NON-CROSS	221-224	240-241	D000860	hypoxia|CH|CH|CH|CH|hypoxia	DiseaseOrPhenotypicFeature	96:98:137:161:180:240	97:99:138:162:181:241	3:3:4:6:7:8	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	1:NR:2	L2R	NON-CROSS	226-227	240-241	D000860	hypoxia|CH|CH|CH|CH|hypoxia	DiseaseOrPhenotypicFeature	96:98:137:161:180:240	97:99:138:162:181:241	3:3:4:6:7:8	287435	CD68	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	NON-CROSS	240-241	255-264	D000860	hypoxia|CH|CH|CH|CH|hypoxia	DiseaseOrPhenotypicFeature	96:98:137:161:180:240	97:99:138:162:181:241	3:3:4:6:7:8	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	240-241	272-273	D000860	hypoxia|CH|CH|CH|CH|hypoxia	DiseaseOrPhenotypicFeature	96:98:137:161:180:240	97:99:138:162:181:241	3:3:4:6:7:8	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	CROSS	149-150	171-174	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	D017380	right ventricular hypertrophy	DiseaseOrPhenotypicFeature	171	174	6	1:NR:2	L2R	CROSS	149-150	185-188	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	1:NR:2	L2R	CROSS	149-150	216-220	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	1:NR:2	L2R	CROSS	149-150	226-227	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	287435	CD68	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	149-150	248-249	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	D007249	inflammation	DiseaseOrPhenotypicFeature	248	249	8	1:NR:2	L2R	CROSS	149-150	255-264	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	149-150	272-273	D010100	oxygen|oxygen	ChemicalEntity	102:149	103:150	3:5	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	CROSS	171-174	185-188	D017380	right ventricular hypertrophy	DiseaseOrPhenotypicFeature	171	174	6	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	1:NR:2	L2R	CROSS	171-174	216-220	D017380	right ventricular hypertrophy	DiseaseOrPhenotypicFeature	171	174	6	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	1:NR:2	L2R	CROSS	171-174	226-227	D017380	right ventricular hypertrophy	DiseaseOrPhenotypicFeature	171	174	6	287435	CD68	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	171-174	255-264	D017380	right ventricular hypertrophy	DiseaseOrPhenotypicFeature	171	174	6	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	171-174	272-273	D017380	right ventricular hypertrophy	DiseaseOrPhenotypicFeature	171	174	6	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	NON-CROSS	206-209	216-220	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	1:NR:2	L2R	NON-CROSS	206-209	226-227	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	287435	CD68	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	NON-CROSS	206-209	248-249	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	D007249	inflammation	DiseaseOrPhenotypicFeature	248	249	8	1:NR:2	L2R	NON-CROSS	255-264	300-303	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	272-273	300-303	64030	c - kit|c - kit|c - kit|c - kit	GeneOrGeneProduct	185:206:300:321	188:209:303:324	7:8:10:11	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	NON-CROSS	221-224	226-227	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	287435	CD68	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	NON-CROSS	221-224	248-249	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	D007249	inflammation	DiseaseOrPhenotypicFeature	248	249	8	1:NR:2	L2R	NON-CROSS	221-224	255-264	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	221-224	272-273	25589	tyrosine kinase receptor 2|VEGF - R2	GeneOrGeneProduct	216:221	220:224	8:8	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	NON-CROSS	226-227	248-249	287435	CD68	GeneOrGeneProduct	226	227	8	D007249	inflammation	DiseaseOrPhenotypicFeature	248	249	8	1:NR:2	L2R	NON-CROSS	226-227	255-264	287435	CD68	GeneOrGeneProduct	226	227	8	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	226-227	272-273	287435	CD68	GeneOrGeneProduct	226	227	8	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	NON-CROSS	248-249	255-264	D007249	inflammation	DiseaseOrPhenotypicFeature	248	249	8	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	1:NR:2	L2R	CROSS	248-249	272-273	D007249	inflammation	DiseaseOrPhenotypicFeature	248	249	8	60628	CXCR4	GeneOrGeneProduct	272	273	9	1:NR:2	L2R	CROSS	255-264	272-273	29560	hypoxia - inducible factor ( HIF ) - 1a	GeneOrGeneProduct	255	264	8	60628	CXCR4	GeneOrGeneProduct	272	273	9
15867855	Genetic variants of the T - cell immunoglobulin mucin 1 but not the T - cell immunoglobulin mucin 3 gene are associated with asthma in an African American population .|BACKGROUND : The T - cell immunoglobulin mucin ( TIM ) proteins and their genetic variants have been suggested to play a role in regulating allergic diseases .|OBJECTIVE : Genetic association of the sequence variants for TIM - 1 and TIM - 3 genes with asthma in an African American population was investigated .|METHODS : Both case - control and family - based association analyses were performed for a total of 7 polymorphisms , including 3 single nucleotide polymorphism ( SNPs ) and 1 insertion / deletion polymorphism in the TIM - 1 and 3 SNPs in the TIM - 3 genes .|The exposure to hepatitis A virus as judged by seropositivity was also examined .|RESULTS : In the case - control design , the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant ( 157delMTTTVP ) in the fourth exon of the TIM - 1 gene were higher among patients with patients with asthma compared with the controls ( odds ratio [ OR ] , 2 . 779 , P = . 016 ; and OR , 3 . 09 , P = . 022 , respectively ) .|This association was substantiated by haplotype analysis of these and 2 additional SNPs ( OR , 2 . 48 ; P = . 004 ) , and also by family - based tests for the allele and haplotype carrying 157delMTTTVP ( P = . 009 and P = . 048 , respectively ) .|Furthermore , this association seems to exist even in the hepatitis A virus - seronegative subjects in our data .|None of the 3 variants in TIM - 3 genes yielded significant association with either asthma or asthma - related phenotypes .|CONCLUSION : Our findings suggest that the genetic variants of the TIM - 1 but not the TIM - 3 gene contribute to asthma susceptibility in this African - American population .	1:NR:2	L2R	NON-CROSS	67-70	71-74	26762	T - cell immunoglobulin mucin 1|TIM - 1|TIM - 1|TIM - 1	GeneOrGeneProduct	4:67:181:335	10:70:184:338	0:2:5:9	84868	T - cell immunoglobulin mucin 3|TIM - 3|TIM - 3|TIM - 3|TIM - 3	GeneOrGeneProduct	13:71:130:308:341	19:74:133:311:344	0:2:3:8:9	1:Association:2	L2R	NON-CROSS	67-70	76-77	26762	T - cell immunoglobulin mucin 1|TIM - 1|TIM - 1|TIM - 1	GeneOrGeneProduct	4:67:181:335	10:70:184:338	0:2:5:9	D001249	asthma|asthma|asthma|asthma|asthma|asthma	DiseaseOrPhenotypicFeature	23:76:192:317:319:347	24:77:193:318:320:348	0:2:5:8:8:9	1:NR:2	L2R	CROSS	4-10	33-38	26762	T - cell immunoglobulin mucin 1|TIM - 1|TIM - 1|TIM - 1	GeneOrGeneProduct	4:67:181:335	10:70:184:338	0:2:5:9	26762,84868	T - cell immunoglobulin mucin|TIM|TIM - 1 and 3	GeneOrGeneProduct	33:39:122	38:40:127	1:1:3	1:Association:2	L2R	CROSS	55-57	67-70	26762	T - cell immunoglobulin mucin 1|TIM - 1|TIM - 1|TIM - 1	GeneOrGeneProduct	4:67:181:335	10:70:184:338	0:2:5:9	D004342	allergic diseases	DiseaseOrPhenotypicFeature	55	57	1	1:NR:2	L2R	NON-CROSS	71-74	76-77	84868	T - cell immunoglobulin mucin 3|TIM - 3|TIM - 3|TIM - 3|TIM - 3	GeneOrGeneProduct	13:71:130:308:341	19:74:133:311:344	0:2:3:8:9	D001249	asthma|asthma|asthma|asthma|asthma|asthma	DiseaseOrPhenotypicFeature	23:76:192:317:319:347	24:77:193:318:320:348	0:2:5:8:8:9	1:NR:2	L2R	NON-CROSS	122-127	130-133	84868	T - cell immunoglobulin mucin 3|TIM - 3|TIM - 3|TIM - 3|TIM - 3	GeneOrGeneProduct	13:71:130:308:341	19:74:133:311:344	0:2:3:8:9	26762,84868	T - cell immunoglobulin mucin|TIM|TIM - 1 and 3	GeneOrGeneProduct	33:39:122	38:40:127	1:1:3	1:Association:2	L2R	CROSS	55-57	71-74	84868	T - cell immunoglobulin mucin 3|TIM - 3|TIM - 3|TIM - 3|TIM - 3	GeneOrGeneProduct	13:71:130:308:341	19:74:133:311:344	0:2:3:8:9	D004342	allergic diseases	DiseaseOrPhenotypicFeature	55	57	1	1:NR:2	L2R	CROSS	23-24	33-38	D001249	asthma|asthma|asthma|asthma|asthma|asthma	DiseaseOrPhenotypicFeature	23:76:192:317:319:347	24:77:193:318:320:348	0:2:5:8:8:9	26762,84868	T - cell immunoglobulin mucin|TIM|TIM - 1 and 3	GeneOrGeneProduct	33:39:122	38:40:127	1:1:3	1:Positive_Correlation:2	R2L	NON-CROSS	192-193	166-167	rs2277025	rs2277025	SequenceVariant	166	167	5	D001249	asthma|asthma|asthma|asthma|asthma|asthma	DiseaseOrPhenotypicFeature	23:76:192:317:319:347	24:77:193:318:320:348	0:2:5:8:8:9	1:Positive_Correlation:2	R2L	NON-CROSS	192-193	173-174	p|DEL|157|MTTTVP	157delMTTTVP|157delMTTTVP	SequenceVariant	173:267	174:268	5:6	D001249	asthma|asthma|asthma|asthma|asthma|asthma	DiseaseOrPhenotypicFeature	23:76:192:317:319:347	24:77:193:318:320:348	0:2:5:8:8:9	1:NR:2	L2R	NON-CROSS	39-40	55-57	26762,84868	T - cell immunoglobulin mucin|TIM|TIM - 1 and 3	GeneOrGeneProduct	33:39:122	38:40:127	1:1:3	D004342	allergic diseases	DiseaseOrPhenotypicFeature	55	57	1	1:NR:2	L2R	CROSS	55-57	166-167	D004342	allergic diseases	DiseaseOrPhenotypicFeature	55	57	1	rs2277025	rs2277025	SequenceVariant	166	167	5	1:NR:2	L2R	CROSS	55-57	173-174	D004342	allergic diseases	DiseaseOrPhenotypicFeature	55	57	1	p|DEL|157|MTTTVP	157delMTTTVP|157delMTTTVP	SequenceVariant	173:267	174:268	5:6
26684240	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors .|Genomic profiles of gastroenteropancreatic neuroendocrine tumors ( GEP - NETs ) are still insufficiently understood , and the genetic alterations associated with drug responses have not been studied .|Here , we performed whole exome sequencing of 12 GEP - NETs from patients enrolled in a nonrandomized , open - labeled , single - center phase II study for pazopanib , and integrated our results with previously published results on pancreas ( n = 12 ) and small intestine NETs ( n = 50 ) .|The mean numbers of somatic mutations in each case varied widely from 20 to 4682 .|Among 12 GEP - NETs , eight showed mutations of more than one cancer - related gene , including TP53 , CNBD1 , RB1 , APC , BCOR , BRAF , CTNNB1 , EGFR , EP300 , ERBB3 , KDM6A , KRAS , MGA , MLL3 , PTEN , RASA1 , SMARCB1 , SPEN , TBC1D12 , and VHL .|TP53 was recurrently mutated in three cases , whereas CNBD1 and RB1 mutations were identified in two cases .|Three GEP - NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade ( G ) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment .|We found BRAF V600E ( G1 NET from rectum and two G3 NETs from colon ) and BRAF G593S ( G2 NET from pancreas ) missense mutations ( 9 . 1 % ) in an independent cohort of 44 GEP - NETs from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .|All tumor specimens were obtained before chemotherapy .|In conclusion , BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP - NETs patients .	1:Association:2	L2R	NON-CROSS	3-4	7-10	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	1:Negative_Correlation:2	L2R	NON-CROSS	222-223	227-228	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	1:Association:2	R2L	NON-CROSS	216-217	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	1:Association:2	L2R	NON-CROSS	316-317	326-327	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:NR:2	L2R	NON-CROSS	132-133	142-143	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	1:NR:2	L2R	NON-CROSS	134-135	142-143	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	1:NR:2	L2R	NON-CROSS	136-137	142-143	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	1:NR:2	L2R	NON-CROSS	138-139	142-143	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	324	APC	GeneOrGeneProduct	138	139	4	1:NR:2	L2R	NON-CROSS	140-141	142-143	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	54880	BCOR	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	NON-CROSS	142-143	144-145	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:NR:2	L2R	NON-CROSS	142-143	146-147	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	142-143	148-149	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	NON-CROSS	142-143	150-151	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	142-143	152-153	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	142-143	154-155	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	142-143	156-157	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	142-143	158-159	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	142-143	160-161	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	142-143	162-163	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	142-143	164-165	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	142-143	166-167	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	142-143	168-169	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	142-143	171-172	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	7428	VHL	GeneOrGeneProduct	171	172	4	1:Association:2	L2R	NON-CROSS	227-228	231-232	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:142:216:227:242:326	4:143:217:228:243:327	0:4:6:7:7:9	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:Association:2	L2R	NON-CROSS	4-5	7-10	rs113488022	V600E|V600E|V600E|V600E	SequenceVariant	4:217:228:327	5:218:229:328	0:6:7:9	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	1:Negative_Correlation:2	L2R	NON-CROSS	217-218	222-223	rs113488022	V600E|V600E|V600E|V600E	SequenceVariant	4:217:228:327	5:218:229:328	0:6:7:9	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	1:Association:2	R2L	NON-CROSS	217-218	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	rs113488022	V600E|V600E|V600E|V600E	SequenceVariant	4:217:228:327	5:218:229:328	0:6:7:9	1:NR:2	L2R	CROSS	316-317	327-328	rs113488022	V600E|V600E|V600E|V600E	SequenceVariant	4:217:228:327	5:218:229:328	0:6:7:9	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	L2R	NON-CROSS	228-229	231-232	rs113488022	V600E|V600E|V600E|V600E	SequenceVariant	4:217:228:327	5:218:229:328	0:6:7:9	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:Negative_Correlation:2	L2R	NON-CROSS	336-337	346-349	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	1:Association:2	L2R	NON-CROSS	193-196	198-199	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	1:Association:2	L2R	NON-CROSS	182-183	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	1:Association:2	L2R	NON-CROSS	184-185	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	1:Association:2	L2R	NON-CROSS	115-118	138-139	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	324	APC	GeneOrGeneProduct	138	139	4	1:Association:2	L2R	NON-CROSS	115-118	140-141	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	54880	BCOR	GeneOrGeneProduct	140	141	4	1:Association:2	L2R	NON-CROSS	115-118	144-145	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:Association:2	L2R	NON-CROSS	115-118	146-147	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	1956	EGFR	GeneOrGeneProduct	146	147	4	1:Association:2	L2R	NON-CROSS	115-118	148-149	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	2033	EP300	GeneOrGeneProduct	148	149	4	1:Association:2	L2R	NON-CROSS	115-118	150-151	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:Association:2	L2R	NON-CROSS	115-118	152-153	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:Association:2	L2R	NON-CROSS	115-118	154-155	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	3845	KRAS	GeneOrGeneProduct	154	155	4	1:Association:2	L2R	NON-CROSS	156-157	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	23269	MGA	GeneOrGeneProduct	156	157	4	1:Association:2	L2R	NON-CROSS	158-159	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	58508	MLL3	GeneOrGeneProduct	158	159	4	1:Association:2	L2R	NON-CROSS	160-161	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	5728	PTEN	GeneOrGeneProduct	160	161	4	1:Association:2	L2R	NON-CROSS	162-163	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	5921	RASA1	GeneOrGeneProduct	162	163	4	1:Association:2	L2R	NON-CROSS	164-165	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:Association:2	L2R	NON-CROSS	166-167	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	23013	SPEN	GeneOrGeneProduct	166	167	4	1:Association:2	L2R	NON-CROSS	168-169	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:Association:2	L2R	NON-CROSS	171-172	193-196	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	7428	VHL	GeneOrGeneProduct	171	172	4	1:Association:2	L2R	NON-CROSS	243-244	264-267	C535650	gastroenteropancreatic neuroendocrine tumors|gastroenteropancreatic neuroendocrine tumors|GEP - NETs|GEP - NETs|GEP - NETs|GEP - NET|GEP - NETs|GEP - NETs	DiseaseOrPhenotypicFeature	7:14:18:49:115:193:264:346	10:17:21:52:118:196:267:349	0:1:1:2:4:6:7:9	p.G593S	G593S	SequenceVariant	243	244	7	1:Negative_Correlation:2	R2L	NON-CROSS	222-223	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	1:NR:2	L2R	CROSS	316-317	336-337	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:NR:2	L2R	NON-CROSS	198-199	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	1:NR:2	L2R	CROSS	182-183	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	1:NR:2	L2R	CROSS	184-185	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	1:NR:2	L2R	CROSS	70-71	138-139	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	324	APC	GeneOrGeneProduct	138	139	4	1:NR:2	L2R	CROSS	70-71	140-141	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	54880	BCOR	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	CROSS	70-71	144-145	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:NR:2	L2R	CROSS	70-71	146-147	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	CROSS	148-149	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	CROSS	150-151	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	CROSS	152-153	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	CROSS	154-155	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	CROSS	156-157	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	CROSS	158-159	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	CROSS	160-161	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	CROSS	162-163	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	CROSS	164-165	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	CROSS	166-167	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	CROSS	168-169	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	CROSS	171-172	222-223	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	222-223	231-232	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	CROSS	222-223	243-244	C516667	pazopanib|pazopanib|pazopanib	ChemicalEntity	70:222:336	71:223:337	2:6:9	p.G593S	G593S	SequenceVariant	243	244	7	1:NR:2	L2R	NON-CROSS	198-199	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	1:NR:2	L2R	CROSS	182-183	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	1:NR:2	L2R	CROSS	184-185	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	1:NR:2	L2R	CROSS	89-91	138-139	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	324	APC	GeneOrGeneProduct	138	139	4	1:NR:2	L2R	CROSS	89-91	140-141	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	54880	BCOR	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	CROSS	89-91	144-145	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:NR:2	L2R	CROSS	89-91	146-147	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	CROSS	89-91	148-149	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	CROSS	150-151	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	CROSS	152-153	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	CROSS	154-155	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	CROSS	156-157	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	CROSS	158-159	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	CROSS	160-161	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	CROSS	162-163	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	CROSS	164-165	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	CROSS	166-167	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	CROSS	168-169	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	CROSS	171-172	207-214	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	207-214	243-244	D007414	intestine NETs|intestinal grade ( G ) 1 NET	DiseaseOrPhenotypicFeature	89:207	91:214	2:6	p.G593S	G593S	SequenceVariant	243	244	7	1:Association:2	R2L	NON-CROSS	132-133	126-127	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	134-135	126-127	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	136-137	126-127	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	138-139	126-127	324	APC	GeneOrGeneProduct	138	139	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	140-141	126-127	54880	BCOR	GeneOrGeneProduct	140	141	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	144-145	126-127	1499	CTNNB1	GeneOrGeneProduct	144	145	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	146-147	126-127	1956	EGFR	GeneOrGeneProduct	146	147	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	148-149	126-127	2033	EP300	GeneOrGeneProduct	148	149	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	L2R	NON-CROSS	126-127	150-151	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:Association:2	R2L	NON-CROSS	152-153	126-127	7403	KDM6A	GeneOrGeneProduct	152	153	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	154-155	126-127	3845	KRAS	GeneOrGeneProduct	154	155	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	156-157	126-127	23269	MGA	GeneOrGeneProduct	156	157	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	158-159	126-127	58508	MLL3	GeneOrGeneProduct	158	159	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	160-161	126-127	5728	PTEN	GeneOrGeneProduct	160	161	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	162-163	126-127	5921	RASA1	GeneOrGeneProduct	162	163	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	164-165	126-127	6598	SMARCB1	GeneOrGeneProduct	164	165	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	166-167	126-127	23013	SPEN	GeneOrGeneProduct	166	167	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	168-169	126-127	23232	TBC1D12	GeneOrGeneProduct	168	169	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:Association:2	R2L	NON-CROSS	171-172	126-127	7428	VHL	GeneOrGeneProduct	171	172	4	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	1:NR:2	L2R	CROSS	243-244	316-317	D009369	cancer|tumor	DiseaseOrPhenotypicFeature	126:316	127:317	4:8	p.G593S	G593S	SequenceVariant	243	244	7	1:NR:2	L2R	NON-CROSS	132-133	134-135	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	1:NR:2	L2R	NON-CROSS	132-133	136-137	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	1:NR:2	L2R	NON-CROSS	132-133	138-139	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	324	APC	GeneOrGeneProduct	138	139	4	1:NR:2	L2R	NON-CROSS	132-133	140-141	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	54880	BCOR	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	NON-CROSS	132-133	144-145	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:NR:2	L2R	NON-CROSS	132-133	146-147	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	132-133	148-149	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	NON-CROSS	132-133	150-151	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	132-133	152-153	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	154-155	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	156-157	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	158-159	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	160-161	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	162-163	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	164-165	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	166-167	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	168-169	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	171-172	173-174	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	198-199	231-232	7157	TP53|TP53|TP53	GeneOrGeneProduct	132:173:198	133:174:199	4:5:6	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	134-135	136-137	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	1:NR:2	L2R	NON-CROSS	134-135	138-139	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	324	APC	GeneOrGeneProduct	138	139	4	1:NR:2	L2R	NON-CROSS	134-135	140-141	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	54880	BCOR	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	NON-CROSS	134-135	144-145	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:NR:2	L2R	NON-CROSS	134-135	146-147	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	134-135	148-149	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	NON-CROSS	134-135	150-151	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	134-135	152-153	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	134-135	154-155	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	134-135	156-157	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	134-135	158-159	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	160-161	182-183	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	162-163	182-183	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	164-165	182-183	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	166-167	182-183	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	168-169	182-183	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	171-172	182-183	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	182-183	231-232	168975	CNBD1|CNBD1	GeneOrGeneProduct	134:182	135:183	4:5	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	136-137	138-139	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	324	APC	GeneOrGeneProduct	138	139	4	1:NR:2	L2R	NON-CROSS	136-137	140-141	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	54880	BCOR	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	NON-CROSS	136-137	144-145	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:NR:2	L2R	NON-CROSS	136-137	146-147	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	136-137	148-149	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	NON-CROSS	136-137	150-151	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	136-137	152-153	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	136-137	154-155	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	136-137	156-157	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	136-137	158-159	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	136-137	160-161	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	162-163	184-185	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	164-165	184-185	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	166-167	184-185	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	168-169	184-185	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	171-172	184-185	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	184-185	231-232	5925	RB1|RB1	GeneOrGeneProduct	136:184	137:185	4:5	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	138-139	140-141	324	APC	GeneOrGeneProduct	138	139	4	54880	BCOR	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	NON-CROSS	138-139	144-145	324	APC	GeneOrGeneProduct	138	139	4	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:NR:2	L2R	NON-CROSS	138-139	146-147	324	APC	GeneOrGeneProduct	138	139	4	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	138-139	148-149	324	APC	GeneOrGeneProduct	138	139	4	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	NON-CROSS	138-139	150-151	324	APC	GeneOrGeneProduct	138	139	4	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	138-139	152-153	324	APC	GeneOrGeneProduct	138	139	4	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	138-139	154-155	324	APC	GeneOrGeneProduct	138	139	4	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	138-139	156-157	324	APC	GeneOrGeneProduct	138	139	4	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	138-139	158-159	324	APC	GeneOrGeneProduct	138	139	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	138-139	160-161	324	APC	GeneOrGeneProduct	138	139	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	138-139	162-163	324	APC	GeneOrGeneProduct	138	139	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	138-139	164-165	324	APC	GeneOrGeneProduct	138	139	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	138-139	166-167	324	APC	GeneOrGeneProduct	138	139	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	138-139	168-169	324	APC	GeneOrGeneProduct	138	139	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	138-139	171-172	324	APC	GeneOrGeneProduct	138	139	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	138-139	231-232	324	APC	GeneOrGeneProduct	138	139	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	140-141	144-145	54880	BCOR	GeneOrGeneProduct	140	141	4	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1:NR:2	L2R	NON-CROSS	140-141	146-147	54880	BCOR	GeneOrGeneProduct	140	141	4	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	140-141	148-149	54880	BCOR	GeneOrGeneProduct	140	141	4	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	NON-CROSS	140-141	150-151	54880	BCOR	GeneOrGeneProduct	140	141	4	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	140-141	152-153	54880	BCOR	GeneOrGeneProduct	140	141	4	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	140-141	154-155	54880	BCOR	GeneOrGeneProduct	140	141	4	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	140-141	156-157	54880	BCOR	GeneOrGeneProduct	140	141	4	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	140-141	158-159	54880	BCOR	GeneOrGeneProduct	140	141	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	140-141	160-161	54880	BCOR	GeneOrGeneProduct	140	141	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	140-141	162-163	54880	BCOR	GeneOrGeneProduct	140	141	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	140-141	164-165	54880	BCOR	GeneOrGeneProduct	140	141	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	140-141	166-167	54880	BCOR	GeneOrGeneProduct	140	141	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	140-141	168-169	54880	BCOR	GeneOrGeneProduct	140	141	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	140-141	171-172	54880	BCOR	GeneOrGeneProduct	140	141	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	140-141	231-232	54880	BCOR	GeneOrGeneProduct	140	141	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	144-145	146-147	1499	CTNNB1	GeneOrGeneProduct	144	145	4	1956	EGFR	GeneOrGeneProduct	146	147	4	1:NR:2	L2R	NON-CROSS	144-145	148-149	1499	CTNNB1	GeneOrGeneProduct	144	145	4	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	NON-CROSS	144-145	150-151	1499	CTNNB1	GeneOrGeneProduct	144	145	4	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	144-145	152-153	1499	CTNNB1	GeneOrGeneProduct	144	145	4	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	144-145	154-155	1499	CTNNB1	GeneOrGeneProduct	144	145	4	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	144-145	156-157	1499	CTNNB1	GeneOrGeneProduct	144	145	4	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	144-145	158-159	1499	CTNNB1	GeneOrGeneProduct	144	145	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	144-145	160-161	1499	CTNNB1	GeneOrGeneProduct	144	145	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	144-145	162-163	1499	CTNNB1	GeneOrGeneProduct	144	145	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	144-145	164-165	1499	CTNNB1	GeneOrGeneProduct	144	145	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	144-145	166-167	1499	CTNNB1	GeneOrGeneProduct	144	145	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	144-145	168-169	1499	CTNNB1	GeneOrGeneProduct	144	145	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	144-145	171-172	1499	CTNNB1	GeneOrGeneProduct	144	145	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	144-145	231-232	1499	CTNNB1	GeneOrGeneProduct	144	145	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	146-147	148-149	1956	EGFR	GeneOrGeneProduct	146	147	4	2033	EP300	GeneOrGeneProduct	148	149	4	1:NR:2	L2R	NON-CROSS	146-147	150-151	1956	EGFR	GeneOrGeneProduct	146	147	4	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	146-147	152-153	1956	EGFR	GeneOrGeneProduct	146	147	4	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	146-147	154-155	1956	EGFR	GeneOrGeneProduct	146	147	4	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	146-147	156-157	1956	EGFR	GeneOrGeneProduct	146	147	4	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	146-147	158-159	1956	EGFR	GeneOrGeneProduct	146	147	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	146-147	160-161	1956	EGFR	GeneOrGeneProduct	146	147	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	146-147	162-163	1956	EGFR	GeneOrGeneProduct	146	147	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	146-147	164-165	1956	EGFR	GeneOrGeneProduct	146	147	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	146-147	166-167	1956	EGFR	GeneOrGeneProduct	146	147	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	146-147	168-169	1956	EGFR	GeneOrGeneProduct	146	147	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	146-147	171-172	1956	EGFR	GeneOrGeneProduct	146	147	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	146-147	231-232	1956	EGFR	GeneOrGeneProduct	146	147	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	148-149	150-151	2033	EP300	GeneOrGeneProduct	148	149	4	2065	ERBB3	GeneOrGeneProduct	150	151	4	1:NR:2	L2R	NON-CROSS	148-149	152-153	2033	EP300	GeneOrGeneProduct	148	149	4	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	148-149	154-155	2033	EP300	GeneOrGeneProduct	148	149	4	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	148-149	156-157	2033	EP300	GeneOrGeneProduct	148	149	4	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	148-149	158-159	2033	EP300	GeneOrGeneProduct	148	149	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	148-149	160-161	2033	EP300	GeneOrGeneProduct	148	149	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	148-149	162-163	2033	EP300	GeneOrGeneProduct	148	149	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	148-149	164-165	2033	EP300	GeneOrGeneProduct	148	149	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	148-149	166-167	2033	EP300	GeneOrGeneProduct	148	149	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	148-149	168-169	2033	EP300	GeneOrGeneProduct	148	149	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	148-149	171-172	2033	EP300	GeneOrGeneProduct	148	149	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	148-149	231-232	2033	EP300	GeneOrGeneProduct	148	149	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	150-151	152-153	2065	ERBB3	GeneOrGeneProduct	150	151	4	7403	KDM6A	GeneOrGeneProduct	152	153	4	1:NR:2	L2R	NON-CROSS	150-151	154-155	2065	ERBB3	GeneOrGeneProduct	150	151	4	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	150-151	156-157	2065	ERBB3	GeneOrGeneProduct	150	151	4	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	150-151	158-159	2065	ERBB3	GeneOrGeneProduct	150	151	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	150-151	160-161	2065	ERBB3	GeneOrGeneProduct	150	151	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	150-151	162-163	2065	ERBB3	GeneOrGeneProduct	150	151	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	150-151	164-165	2065	ERBB3	GeneOrGeneProduct	150	151	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	150-151	166-167	2065	ERBB3	GeneOrGeneProduct	150	151	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	150-151	168-169	2065	ERBB3	GeneOrGeneProduct	150	151	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	150-151	171-172	2065	ERBB3	GeneOrGeneProduct	150	151	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	150-151	231-232	2065	ERBB3	GeneOrGeneProduct	150	151	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	152-153	154-155	7403	KDM6A	GeneOrGeneProduct	152	153	4	3845	KRAS	GeneOrGeneProduct	154	155	4	1:NR:2	L2R	NON-CROSS	152-153	156-157	7403	KDM6A	GeneOrGeneProduct	152	153	4	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	152-153	158-159	7403	KDM6A	GeneOrGeneProduct	152	153	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	152-153	160-161	7403	KDM6A	GeneOrGeneProduct	152	153	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	152-153	162-163	7403	KDM6A	GeneOrGeneProduct	152	153	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	152-153	164-165	7403	KDM6A	GeneOrGeneProduct	152	153	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	152-153	166-167	7403	KDM6A	GeneOrGeneProduct	152	153	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	152-153	168-169	7403	KDM6A	GeneOrGeneProduct	152	153	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	152-153	171-172	7403	KDM6A	GeneOrGeneProduct	152	153	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	152-153	231-232	7403	KDM6A	GeneOrGeneProduct	152	153	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	154-155	156-157	3845	KRAS	GeneOrGeneProduct	154	155	4	23269	MGA	GeneOrGeneProduct	156	157	4	1:NR:2	L2R	NON-CROSS	154-155	158-159	3845	KRAS	GeneOrGeneProduct	154	155	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	154-155	160-161	3845	KRAS	GeneOrGeneProduct	154	155	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	154-155	162-163	3845	KRAS	GeneOrGeneProduct	154	155	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	154-155	164-165	3845	KRAS	GeneOrGeneProduct	154	155	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	154-155	166-167	3845	KRAS	GeneOrGeneProduct	154	155	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	154-155	168-169	3845	KRAS	GeneOrGeneProduct	154	155	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	154-155	171-172	3845	KRAS	GeneOrGeneProduct	154	155	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	154-155	231-232	3845	KRAS	GeneOrGeneProduct	154	155	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	156-157	158-159	23269	MGA	GeneOrGeneProduct	156	157	4	58508	MLL3	GeneOrGeneProduct	158	159	4	1:NR:2	L2R	NON-CROSS	156-157	160-161	23269	MGA	GeneOrGeneProduct	156	157	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	156-157	162-163	23269	MGA	GeneOrGeneProduct	156	157	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	156-157	164-165	23269	MGA	GeneOrGeneProduct	156	157	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	156-157	166-167	23269	MGA	GeneOrGeneProduct	156	157	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	156-157	168-169	23269	MGA	GeneOrGeneProduct	156	157	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	156-157	171-172	23269	MGA	GeneOrGeneProduct	156	157	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	156-157	231-232	23269	MGA	GeneOrGeneProduct	156	157	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	158-159	160-161	58508	MLL3	GeneOrGeneProduct	158	159	4	5728	PTEN	GeneOrGeneProduct	160	161	4	1:NR:2	L2R	NON-CROSS	158-159	162-163	58508	MLL3	GeneOrGeneProduct	158	159	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	158-159	164-165	58508	MLL3	GeneOrGeneProduct	158	159	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	158-159	166-167	58508	MLL3	GeneOrGeneProduct	158	159	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	158-159	168-169	58508	MLL3	GeneOrGeneProduct	158	159	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	158-159	171-172	58508	MLL3	GeneOrGeneProduct	158	159	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	158-159	231-232	58508	MLL3	GeneOrGeneProduct	158	159	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	160-161	162-163	5728	PTEN	GeneOrGeneProduct	160	161	4	5921	RASA1	GeneOrGeneProduct	162	163	4	1:NR:2	L2R	NON-CROSS	160-161	164-165	5728	PTEN	GeneOrGeneProduct	160	161	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	160-161	166-167	5728	PTEN	GeneOrGeneProduct	160	161	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	160-161	168-169	5728	PTEN	GeneOrGeneProduct	160	161	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	160-161	171-172	5728	PTEN	GeneOrGeneProduct	160	161	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	160-161	231-232	5728	PTEN	GeneOrGeneProduct	160	161	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	162-163	164-165	5921	RASA1	GeneOrGeneProduct	162	163	4	6598	SMARCB1	GeneOrGeneProduct	164	165	4	1:NR:2	L2R	NON-CROSS	162-163	166-167	5921	RASA1	GeneOrGeneProduct	162	163	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	162-163	168-169	5921	RASA1	GeneOrGeneProduct	162	163	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	162-163	171-172	5921	RASA1	GeneOrGeneProduct	162	163	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	162-163	231-232	5921	RASA1	GeneOrGeneProduct	162	163	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	164-165	166-167	6598	SMARCB1	GeneOrGeneProduct	164	165	4	23013	SPEN	GeneOrGeneProduct	166	167	4	1:NR:2	L2R	NON-CROSS	164-165	168-169	6598	SMARCB1	GeneOrGeneProduct	164	165	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	164-165	171-172	6598	SMARCB1	GeneOrGeneProduct	164	165	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	164-165	231-232	6598	SMARCB1	GeneOrGeneProduct	164	165	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	166-167	168-169	23013	SPEN	GeneOrGeneProduct	166	167	4	23232	TBC1D12	GeneOrGeneProduct	168	169	4	1:NR:2	L2R	NON-CROSS	166-167	171-172	23013	SPEN	GeneOrGeneProduct	166	167	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	166-167	231-232	23013	SPEN	GeneOrGeneProduct	166	167	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	NON-CROSS	168-169	171-172	23232	TBC1D12	GeneOrGeneProduct	168	169	4	7428	VHL	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	168-169	231-232	23232	TBC1D12	GeneOrGeneProduct	168	169	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:NR:2	L2R	CROSS	171-172	231-232	7428	VHL	GeneOrGeneProduct	171	172	4	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7	1:Association:2	R2L	NON-CROSS	246-247	243-244	p.G593S	G593S	SequenceVariant	243	244	7	D018358	NET|NETs|NET	DiseaseOrPhenotypicFeature	231:237:246	232:238:247	7:7:7
27707793	MicroRNA deep sequencing in two adult stem cell populations identifies miR - 501 as a novel regulator of myosin heavy chain during muscle regeneration .|MicroRNAs ( miRNAs ) are important regulators of skeletal muscle regeneration , but the underlying mechanisms are still incompletely understood .|Here , comparative miRNA sequencing analysis of myogenic progenitor cells ( MPs ) and non - myogenic fibroblast - adipocyte progenitors ( FAPs ) during cardiotoxin ( CTX ) - induced muscle injury uncovered miR - 501 as a novel muscle - specific miRNA . miR - 501 is an intronic miRNA and its expression levels in MPs correlated with its host gene , chloride channel , voltage - sensitive 5 ( Clcn5 ) .|Pharmacological inhibition of miR - 501 dramatically blunted the induction of embryonic myosin heavy chain ( MYH3 ) and , to a lesser extent , adult myosin isoforms during muscle regeneration , and promoted small - diameter neofibers .|An unbiased target identification approach in primary myoblasts validated gigaxonin as a target of miR - 501 that mimicked the effect of miR - 501 inhibition on MYH3 expression .|In the mdx mouse model , which models a pathological disease state , not only was miR - 501 induced in regenerating skeletal muscle , but also its serum levels were increased , which correlated with the disease state of the animals .|Our results suggest that miR - 501 plays a key role in adult muscle regeneration and might serve as a novel serum biomarker for the activation of adult muscle stem cells .	1:Negative_Correlation:2	L2R	NON-CROSS	182-185	187-188	751560	miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501	GeneOrGeneProduct	10:80:91:124:174:182:206:237	13:83:94:127:177:185:209:240	0:2:2:3:4:4:5:6	17883	myosin heavy chain|myosin heavy chain|MYH3|MYH3	GeneOrGeneProduct	18:133:137:187	21:136:138:188	0:3:3:4	1:NR:2	L2R	NON-CROSS	73-74	80-83	751560	miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501	GeneOrGeneProduct	10:80:91:124:174:182:206:237	13:83:94:127:177:185:209:240	0:2:2:3:4:4:5:6	D054715	cardiotoxin|CTX	ChemicalEntity	71:73	72:74	2:2	1:Association:2	L2R	NON-CROSS	77-79	80-83	751560	miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501	GeneOrGeneProduct	10:80:91:124:174:182:206:237	13:83:94:127:177:185:209:240	0:2:2:3:4:4:5:6	D009135	muscle injury	DiseaseOrPhenotypicFeature	77	79	2	1:Association:2	L2R	NON-CROSS	118-119	124-127	751560	miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501	GeneOrGeneProduct	10:80:91:124:174:182:206:237	13:83:94:127:177:185:209:240	0:2:2:3:4:4:5:6	12728	chloride channel , voltage - sensitive 5|Clcn5	GeneOrGeneProduct	110:118	117:119	2:2	1:NR:2	L2R	NON-CROSS	124-127	146-149	751560	miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501	GeneOrGeneProduct	10:80:91:124:174:182:206:237	13:83:94:127:177:185:209:240	0:2:2:3:4:4:5:6	17879	adult myosin isoforms	GeneOrGeneProduct	146	149	3	1:Negative_Correlation:2	R2L	NON-CROSS	174-177	169-170	209239	gigaxonin	GeneOrGeneProduct	169	170	4	751560	miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501|miR - 501	GeneOrGeneProduct	10:80:91:124:174:182:206:237	13:83:94:127:177:185:209:240	0:2:2:3:4:4:5:6	1:NR:2	L2R	CROSS	18-21	71-72	17883	myosin heavy chain|myosin heavy chain|MYH3|MYH3	GeneOrGeneProduct	18:133:137:187	21:136:138:188	0:3:3:4	D054715	cardiotoxin|CTX	ChemicalEntity	71:73	72:74	2:2	1:NR:2	L2R	CROSS	77-79	133-136	17883	myosin heavy chain|myosin heavy chain|MYH3|MYH3	GeneOrGeneProduct	18:133:137:187	21:136:138:188	0:3:3:4	D009135	muscle injury	DiseaseOrPhenotypicFeature	77	79	2	1:NR:2	L2R	CROSS	118-119	133-136	17883	myosin heavy chain|myosin heavy chain|MYH3|MYH3	GeneOrGeneProduct	18:133:137:187	21:136:138:188	0:3:3:4	12728	chloride channel , voltage - sensitive 5|Clcn5	GeneOrGeneProduct	110:118	117:119	2:2	1:NR:2	L2R	NON-CROSS	137-138	146-149	17883	myosin heavy chain|myosin heavy chain|MYH3|MYH3	GeneOrGeneProduct	18:133:137:187	21:136:138:188	0:3:3:4	17879	adult myosin isoforms	GeneOrGeneProduct	146	149	3	1:NR:2	L2R	NON-CROSS	169-170	187-188	17883	myosin heavy chain|myosin heavy chain|MYH3|MYH3	GeneOrGeneProduct	18:133:137:187	21:136:138:188	0:3:3:4	209239	gigaxonin	GeneOrGeneProduct	169	170	4	1:Positive_Correlation:2	L2R	NON-CROSS	73-74	77-79	D054715	cardiotoxin|CTX	ChemicalEntity	71:73	72:74	2:2	D009135	muscle injury	DiseaseOrPhenotypicFeature	77	79	2	1:NR:2	L2R	NON-CROSS	73-74	110-117	D054715	cardiotoxin|CTX	ChemicalEntity	71:73	72:74	2:2	12728	chloride channel , voltage - sensitive 5|Clcn5	GeneOrGeneProduct	110:118	117:119	2:2	1:NR:2	L2R	CROSS	73-74	146-149	D054715	cardiotoxin|CTX	ChemicalEntity	71:73	72:74	2:2	17879	adult myosin isoforms	GeneOrGeneProduct	146	149	3	1:NR:2	L2R	CROSS	73-74	169-170	D054715	cardiotoxin|CTX	ChemicalEntity	71:73	72:74	2:2	209239	gigaxonin	GeneOrGeneProduct	169	170	4	1:NR:2	L2R	NON-CROSS	77-79	110-117	D009135	muscle injury	DiseaseOrPhenotypicFeature	77	79	2	12728	chloride channel , voltage - sensitive 5|Clcn5	GeneOrGeneProduct	110:118	117:119	2:2	1:NR:2	L2R	CROSS	77-79	146-149	D009135	muscle injury	DiseaseOrPhenotypicFeature	77	79	2	17879	adult myosin isoforms	GeneOrGeneProduct	146	149	3	1:NR:2	L2R	CROSS	77-79	169-170	D009135	muscle injury	DiseaseOrPhenotypicFeature	77	79	2	209239	gigaxonin	GeneOrGeneProduct	169	170	4	1:NR:2	L2R	CROSS	118-119	146-149	12728	chloride channel , voltage - sensitive 5|Clcn5	GeneOrGeneProduct	110:118	117:119	2:2	17879	adult myosin isoforms	GeneOrGeneProduct	146	149	3	1:NR:2	L2R	CROSS	118-119	169-170	12728	chloride channel , voltage - sensitive 5|Clcn5	GeneOrGeneProduct	110:118	117:119	2:2	209239	gigaxonin	GeneOrGeneProduct	169	170	4	1:NR:2	L2R	CROSS	146-149	169-170	17879	adult myosin isoforms	GeneOrGeneProduct	146	149	3	209239	gigaxonin	GeneOrGeneProduct	169	170	4
21799811	Strong association of 677 C > T substitution in the MTHFR gene with male infertility - - a study on an indian population and a meta - analysis .|BACKGROUND : Methylenetetrahydrofolate reductase ( MTHFR ) is an important enzyme of folate and methionine metabolism , making it crucial for DNA synthesis and methylation .|The objective of this study was to analyze MTHFR gene 677C > T polymorphism in infertile male individuals from North India , followed by a meta - analysis on our data and published studies .|METHODOLOGY / PRINCIPAL FINDINGS : We undertook genotyping on a total of 837 individuals including well characterized infertile ( N = 522 ) and confirmed fertile ( N = 315 ) individuals .|The SNP was typed by direct DNA sequencing .|Chi square test was done for statistical analysis .|Published studies were searched using appropriate keywords .|Source of data collection for meta - analysis included ' Pubmed ' , ' Ovid ' and ' Google Scholar ' .|Those studies analyzing 677C > T polymorphism in male infertility and presenting all relevant data were included in meta - analysis .|The genotype data for infertile subjects and fertile controls was extracted from each study .|Chi square test was done to obtain odds ratio ( OR ) and p - value .|Meta - analysis was performed using Comprehensive Meta - analysis software ( Version 2 ) .|The frequency of mutant ( T ) allele ( p = 0 . 0025 ) and genotypes ( CT + TT ) ( p = 0 . 0187 ) was significantly higher in infertile individuals in comparison to fertile controls in our case - control study .|The overall summary estimate ( OR ) for allele and genotype meta - analysis were 1 . 304 ( p = 0 . 000 ) , 1 . 310 ( p = 0 . 000 ) , respectively , establishing significant association of 677C > T polymorphism with male infertility .|CONCLUSIONS / SIGNIFICANCE : 677C > T substitution associated strongly with male infertility in Indian population .|Allele and genotype meta - analysis also supported its strong correlation with male infertility , thus establishing it as a risk factor .	1:Positive_Correlation:2	L2R	NON-CROSS	174-177	179-181	rs1801133	677 C > T|677C > T|677C > T|677C > T|677C > T	SequenceVariant	3:65:174:331:343	7:68:177:334:346	0:2:8:13:14	D007248	male infertility|male infertility|male infertility|male infertility|male infertility	DiseaseOrPhenotypicFeature	13:179:336:350:368	15:181:338:352:370	0:8:13:14:15	1:NR:2	L2R	CROSS	41-42	65-68	rs1801133	677 C > T|677C > T|677C > T|677C > T|677C > T	SequenceVariant	3:65:174:331:343	7:68:177:334:346	0:2:8:13:14	D005492	folate	ChemicalEntity	41	42	1	1:NR:2	L2R	CROSS	43-44	65-68	rs1801133	677 C > T|677C > T|677C > T|677C > T|677C > T	SequenceVariant	3:65:174:331:343	7:68:177:334:346	0:2:8:13:14	D008715	methionine	ChemicalEntity	43	44	1	1:Association:2	L2R	NON-CROSS	10-11	13-15	4524	MTHFR|Methylenetetrahydrofolate reductase|MTHFR|MTHFR	GeneOrGeneProduct	10:31:34:63	11:33:35:64	0:1:1:2	D007248	male infertility|male infertility|male infertility|male infertility|male infertility	DiseaseOrPhenotypicFeature	13:179:336:350:368	15:181:338:352:370	0:8:13:14:15	1:Association:2	L2R	NON-CROSS	34-35	41-42	4524	MTHFR|Methylenetetrahydrofolate reductase|MTHFR|MTHFR	GeneOrGeneProduct	10:31:34:63	11:33:35:64	0:1:1:2	D005492	folate	ChemicalEntity	41	42	1	1:Association:2	L2R	NON-CROSS	34-35	43-44	4524	MTHFR|Methylenetetrahydrofolate reductase|MTHFR|MTHFR	GeneOrGeneProduct	10:31:34:63	11:33:35:64	0:1:1:2	D008715	methionine	ChemicalEntity	43	44	1	1:NR:2	L2R	CROSS	13-15	41-42	D007248	male infertility|male infertility|male infertility|male infertility|male infertility	DiseaseOrPhenotypicFeature	13:179:336:350:368	15:181:338:352:370	0:8:13:14:15	D005492	folate	ChemicalEntity	41	42	1	1:NR:2	L2R	CROSS	13-15	43-44	D007248	male infertility|male infertility|male infertility|male infertility|male infertility	DiseaseOrPhenotypicFeature	13:179:336:350:368	15:181:338:352:370	0:8:13:14:15	D008715	methionine	ChemicalEntity	43	44	1	1:NR:2	L2R	NON-CROSS	41-42	43-44	D005492	folate	ChemicalEntity	41	42	1	D008715	methionine	ChemicalEntity	43	44	1
15951966	Screening for exonic copy number mutations at MSH2 and MLH1 by MAPH .|BACKGROUND : Exonic deletions in MSH2 and MLH1 are significant contributors to the mutation spectrum in HNPCC , and heterozygous changes in exon copy number are not detected by conventional mutation screening methods .|AIMS : We aimed to develop methods for screening copy number changes in all the exons of the MLH1 and MSH2 genes using a single multiplex amplifiable probe hybridisation ( MAPH ) assay .|METHODS : We developed a probe set consisting of probes from the 19 exons of MLH1 and 16 exons of MSH2 , and 3 control probes , and applied it to screening for deletions and duplications using fluorescent detection of amplified fragments .|RESULTS : We tested 73 DNA samples from controls and 50 from HNPCC patients in whom no point mutations had been found , and detected 10 copy number changes among the patient samples .|A deletion of about 1 . 4 kb including exon 3 of MSH2 was confirmed by amplification of a junction fragment , and was shown to be the result of an unequal recombination between intronic Alu elements .|CONCLUSIONS : MAPH can detect exonic copy number changes in MLH1 and MSH2 in DNA from HNPCC patients .|Since finding an exonic deletion or duplication makes full sequence analysis unnecessary , it may be most cost - effective to pre - screen samples by MAPH or MLPA before screening for point mutations .	1:NR:2	L2R	NON-CROSS	7-8	9-10	4436	MSH2|MSH2|MSH2|MSH2|MSH2|MSH2	GeneOrGeneProduct	7:18:67:101:170:208	8:19:68:102:171:209	0:1:2:3:5:6	4292	MLH1|MLH1|MLH1|MLH1|MLH1	GeneOrGeneProduct	9:20:65:96:206	10:21:66:97:207	0:1:2:3:6	1:Association:2	L2R	NON-CROSS	208-209	212-213	4436	MSH2|MSH2|MSH2|MSH2|MSH2|MSH2	GeneOrGeneProduct	7:18:67:101:170:208	8:19:68:102:171:209	0:1:2:3:5:6	D003123	HNPCC|HNPCC|HNPCC	DiseaseOrPhenotypicFeature	29:136:212	30:137:213	1:4:6	1:Association:2	L2R	NON-CROSS	206-207	212-213	4292	MLH1|MLH1|MLH1|MLH1|MLH1	GeneOrGeneProduct	9:20:65:96:206	10:21:66:97:207	0:1:2:3:6	D003123	HNPCC|HNPCC|HNPCC	DiseaseOrPhenotypicFeature	29:136:212	30:137:213	1:4:6
17968299	Analysis of - 1082 IL - 10 gene polymorphism in Iranian patients with generalized aggressive periodontitis .|BACKGROUND : Periodontitis is a multifactorial disease and its severe forms , such as aggressive periodontitis , are suggested to have a genetic basis .|Among the genetic factors , polymorphisms in cytokine genes have recently been described in susceptibility to periodontitis .|IL - 10 is a multi - functional cytokine thought to play a role in the pathogenesis of periodontitis .|A substitution G / A polymorphism in the promoter region of the IL - 10 gene at position - 1082 has been associated with different amounts of IL - 10 production .|The aim of the present study was to investigate the possible links between - 1082 ( G / A ) polymorphism of the IL - 10 gene and the generalized form of aggressive periodontitis .|MATERIAL / METHODS : This study included 52 Iranian Khorasanian ( north - east province of Iran ) subjects suffering from generalized aggressive periodontitis referred to the Periodontology Department of Mashhad Dental School .|They were compared to 61 age and sex - matched healthy controls of the same race .|DNA was isolated from peripheral blood cells and genotyping was performed by means of the amplification refractory mutation system polymerase chain reaction ( ARMS - PCR ) method .|Data were analyzed using the chi - squared test .|RESULTS : There was no marked difference in genotype frequencies between the controls and generalized aggressive periodontitis patients ( p = 0 . 585 ) .|Moreover , no association between patients and normal subjects was found in their allele frequency ( p = 0 . 329 ) .|CONCLUSIONS : We conclude that the polymorphic nucleotide A at position - 1082 of the IL - 10 gene is not associated with generalized aggressive periodontitis in the Iranian population .	1:NR:2	L2R	NON-CROSS	135-138	144-146	3586	IL - 10|IL - 10|IL - 10|IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	4:60:92:107:135:301	7:63:95:110:138:304	0:3:4:4:5:12	D010520	aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis	DiseaseOrPhenotypicFeature	14:31:144:169:252:310	16:33:146:171:254:312	0:1:5:6:10:12	1:Association:2	L2R	NON-CROSS	58-59	60-63	3586	IL - 10|IL - 10|IL - 10|IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	4:60:92:107:135:301	7:63:95:110:138:304	0:3:4:4:5:12	D010518	Periodontitis|periodontitis|periodontitis	DiseaseOrPhenotypicFeature	19:58:78	20:59:79	1:2:3	1:NR:2	L2R	CROSS	31-33	82-85	D010520	aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis	DiseaseOrPhenotypicFeature	14:31:144:169:252:310	16:33:146:171:254:312	0:1:5:6:10:12	c|SUB|G||A	G / A	SequenceVariant	82	85	4	1:NR:2	L2R	NON-CROSS	125-132	144-146	D010520	aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis	DiseaseOrPhenotypicFeature	14:31:144:169:252:310	16:33:146:171:254:312	0:1:5:6:10:12	c|SUB|G|-1082|A	- 1082 ( G / A )	SequenceVariant	125	132	5	1:NR:2	L2R	NON-CROSS	294-299	310-312	D010520	aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis|aggressive periodontitis	DiseaseOrPhenotypicFeature	14:31:144:169:252:310	16:33:146:171:254:312	0:1:5:6:10:12	c|Allele|A|-1082	A at position - 1082	SequenceVariant	294	299	12	1:NR:2	L2R	CROSS	78-79	82-85	D010518	Periodontitis|periodontitis|periodontitis	DiseaseOrPhenotypicFeature	19:58:78	20:59:79	1:2:3	c|SUB|G||A	G / A	SequenceVariant	82	85	4	1:NR:2	L2R	CROSS	78-79	125-132	D010518	Periodontitis|periodontitis|periodontitis	DiseaseOrPhenotypicFeature	19:58:78	20:59:79	1:2:3	c|SUB|G|-1082|A	- 1082 ( G / A )	SequenceVariant	125	132	5	1:NR:2	L2R	CROSS	78-79	294-299	D010518	Periodontitis|periodontitis|periodontitis	DiseaseOrPhenotypicFeature	19:58:78	20:59:79	1:2:3	c|Allele|A|-1082	A at position - 1082	SequenceVariant	294	299	12
20126413	U87MG decoded : the genomic sequence of a cytogenetically aberrant human cancer cell line .|U87MG is a commonly studied grade IV glioma cell line that has been analyzed in at least 1 , 700 publications over four decades .|In order to comprehensively characterize the genome of this cell line and to serve as a model of broad cancer genome sequencing , we have generated greater than 30x genomic sequence coverage using a novel 50 - base mate paired strategy with a 1 . 4kb mean insert library .|A total of 1 , 014 , 984 , 286 mate - end and 120 , 691 , 623 single - end two - base encoded reads were generated from five slides .|All data were aligned using a custom designed tool called BFAST , allowing optimal color space read alignment and accurate identification of DNA variants .|The aligned sequence reads and mate - pair information identified 35 interchromosomal translocation events , 1 , 315 structural variations ( > 100 bp ) , 191 , 743 small ( < 21 bp ) insertions and deletions ( indels ) , and 2 , 384 , 470 single nucleotide variations ( SNVs ) .|Among these observations , the known homozygous mutation in PTEN was robustly identified , and genes involved in cell adhesion were overrepresented in the mutated gene list .|Data were compared to 219 , 187 heterozygous single nucleotide polymorphisms assayed by Illumina 1M Duo genotyping array to assess accuracy : 93 . 83 % of all SNPs were reliably detected at filtering thresholds that yield greater than 99 . 99 % sequence accuracy .|Protein coding sequences were disrupted predominantly in this cancer cell line due to small indels , large deletions , and translocations .|In total , 512 genes were homozygously mutated , including 154 by SNVs , 178 by small indels , 145 by large microdeletions , and 35 by interchromosomal translocations to reveal a highly mutated cell line genome .|Of the small homozygously mutated variants , 8 SNVs and 99 indels were novel events not present in dbSNP .|These data demonstrate that routine generation of broad cancer genome sequence is possible outside of genome centers .|The sequence analysis of U87MG provides an unparalleled level of mutational resolution compared to any cell line to date .	1:Association:2	R2L	CROSS	285-286	212-213	5728	PTEN	GeneOrGeneProduct	212	213	6	D009369	cancer|cancer|cancer|cancer	DiseaseOrPhenotypicFeature	11:59:285:365	12:60:286:366	0:2:8:11	1:NR:2	L2R	CROSS	20-23	212-213	D005909	grade IV glioma	DiseaseOrPhenotypicFeature	20	23	1	5728	PTEN	GeneOrGeneProduct	212	213	6
27866394	Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress .|Otilonium bromide ( OB ) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome ( IBS ) .|Its efficacy has been attributed to the block of L - and T - type Ca ( 2 + ) channels and muscarinic and tachykinin receptors in the smooth muscle .|Furthermore , in healthy rats , repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action .|On this basis , we investigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress ( WRS ) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms .|In control , WRS and OB / WRS rats functional parameters were measured in vivo and morphological investigations were done ex vivo in the colon .|The results showed that OB counteracts most of the neurotransmitters changes caused by WRS .|In particular , the drug prevents the decrease in SP - , NK1r - , nNOS - , VIP - , and S100b - immunoreactivity ( IR ) and the increase in CGRP - , and CRF1r - IR .|On the contrary , OB does not affect the increase in CRF2r - IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS .|Finally , OB per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric ChAT - IR neurons .|Functional findings show a significantly reduction in the number of spontaneous abdominal contraction in OB treated rats .|The ability of OB to block L - type Ca ( 2 + ) channels , also expressed by enteric neurons , might represent a possible mechanism through which OB exerts its actions .	1:Association:2	L2R	NON-CROSS	1-3	5-6	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	1:Negative_Correlation:2	L2R	NON-CROSS	129-130	139-140	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	1:NR:2	L2R	CROSS	48-60	77-78	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	1:NR:2	L2R	CROSS	61-65	77-78	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	1:Positive_Correlation:2	R2L	CROSS	184-185	164-165	24806	SP	GeneOrGeneProduct	184	185	7	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1:Positive_Correlation:2	R2L	CROSS	187-188	164-165	24807	NK1r	GeneOrGeneProduct	187	188	7	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1:Positive_Correlation:2	R2L	CROSS	190-191	164-165	24598	nNOS	GeneOrGeneProduct	190	191	7	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1:Positive_Correlation:2	R2L	CROSS	219-220	193-194	117064	VIP	GeneOrGeneProduct	193	194	7	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1:Positive_Correlation:2	R2L	CROSS	219-220	197-198	25742	S100b	GeneOrGeneProduct	197	198	7	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1:Negative_Correlation:2	R2L	CROSS	219-220	207-208	24241	CGRP	GeneOrGeneProduct	207	208	7	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1:Negative_Correlation:2	R2L	CROSS	219-220	211-212	58959	CRF1r	GeneOrGeneProduct	211	212	7	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1:NR:2	L2R	NON-CROSS	219-220	226-227	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	NON-CROSS	241-243	249-250	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:Positive_Correlation:2	L2R	NON-CROSS	249-250	254-255	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	81645	Mr2	GeneOrGeneProduct	254	255	9	1:Negative_Correlation:2	L2R	NON-CROSS	249-250	267-268	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	290567	ChAT	GeneOrGeneProduct	267	268	9	1:Negative_Correlation:2	R2L	NON-CROSS	296-305	293-294	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	C013934	otilonium bromide|Otilonium bromide|OB|OB|OB|OB|OB|OB|OB|OB|OB|OB	ChemicalEntity	1:17:20:77:98:139:164:219:249:286:293:319	3:19:21:78:99:140:165:220:250:287:294:320	0:1:1:3:4:5:6:8:9:10:11:11	1:NR:2	L2R	CROSS	5-6	32-35	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	1:NR:2	L2R	CROSS	48-60	80-81	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	1:NR:2	L2R	CROSS	61-65	80-81	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	1:NR:2	L2R	CROSS	169-170	184-185	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	24806	SP	GeneOrGeneProduct	184	185	7	1:NR:2	L2R	CROSS	169-170	187-188	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	24807	NK1r	GeneOrGeneProduct	187	188	7	1:NR:2	L2R	CROSS	169-170	190-191	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	24598	nNOS	GeneOrGeneProduct	190	191	7	1:NR:2	L2R	CROSS	169-170	193-194	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	117064	VIP	GeneOrGeneProduct	193	194	7	1:NR:2	L2R	CROSS	169-170	197-198	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	25742	S100b	GeneOrGeneProduct	197	198	7	1:NR:2	L2R	CROSS	169-170	207-208	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	CROSS	169-170	211-212	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	169-170	226-227	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	169-170	241-243	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	169-170	254-255	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	169-170	267-268	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	169-170	296-305	D018377	neurotransmitter|neurotransmitter|neurotransmitters	ChemicalEntity	5:80:169	6:81:170	0:3:6	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	CROSS	36-37	48-60	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	1:NR:2	L2R	CROSS	36-37	61-65	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	1:NR:2	L2R	CROSS	129-130	184-185	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	24806	SP	GeneOrGeneProduct	184	185	7	1:NR:2	L2R	CROSS	129-130	187-188	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	24807	NK1r	GeneOrGeneProduct	187	188	7	1:NR:2	L2R	CROSS	129-130	190-191	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	24598	nNOS	GeneOrGeneProduct	190	191	7	1:NR:2	L2R	CROSS	129-130	193-194	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	117064	VIP	GeneOrGeneProduct	193	194	7	1:NR:2	L2R	CROSS	129-130	197-198	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	25742	S100b	GeneOrGeneProduct	197	198	7	1:NR:2	L2R	CROSS	129-130	207-208	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	CROSS	129-130	211-212	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	129-130	226-227	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	129-130	254-255	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	129-130	267-268	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	290567	ChAT	GeneOrGeneProduct	267	268	9	1:Association:2	R2L	CROSS	296-305	129-130	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	D043183	irritable bowel syndrome|IBS|IBS	DiseaseOrPhenotypicFeature	32:36:129	35:37:130	1:1:4	1:NR:2	L2R	NON-CROSS	48-60	61-65	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	1:NR:2	L2R	CROSS	48-60	184-185	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	24806	SP	GeneOrGeneProduct	184	185	7	1:NR:2	L2R	CROSS	48-60	187-188	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	24807	NK1r	GeneOrGeneProduct	187	188	7	1:NR:2	L2R	CROSS	48-60	190-191	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	24598	nNOS	GeneOrGeneProduct	190	191	7	1:NR:2	L2R	CROSS	48-60	193-194	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	117064	VIP	GeneOrGeneProduct	193	194	7	1:NR:2	L2R	CROSS	48-60	197-198	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	25742	S100b	GeneOrGeneProduct	197	198	7	1:NR:2	L2R	CROSS	48-60	207-208	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	CROSS	48-60	211-212	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	48-60	226-227	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	48-60	241-243	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	48-60	254-255	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	48-60	267-268	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	48-60	296-305	24239,83810	L - and T - type Ca ( 2 + ) channels	GeneOrGeneProduct	48	60	2	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	CROSS	61-65	184-185	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	24806	SP	GeneOrGeneProduct	184	185	7	1:NR:2	L2R	CROSS	61-65	187-188	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	24807	NK1r	GeneOrGeneProduct	187	188	7	1:NR:2	L2R	CROSS	61-65	190-191	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	24598	nNOS	GeneOrGeneProduct	190	191	7	1:NR:2	L2R	CROSS	61-65	193-194	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	117064	VIP	GeneOrGeneProduct	193	194	7	1:NR:2	L2R	CROSS	61-65	197-198	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	25742	S100b	GeneOrGeneProduct	197	198	7	1:NR:2	L2R	CROSS	61-65	207-208	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	CROSS	61-65	211-212	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	61-65	226-227	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	61-65	241-243	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	61-65	254-255	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	61-65	267-268	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	61-65	296-305	1128,6869	muscarinic and tachykinin receptors	GeneOrGeneProduct	61	65	2	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	NON-CROSS	184-185	187-188	24806	SP	GeneOrGeneProduct	184	185	7	24807	NK1r	GeneOrGeneProduct	187	188	7	1:NR:2	L2R	NON-CROSS	184-185	190-191	24806	SP	GeneOrGeneProduct	184	185	7	24598	nNOS	GeneOrGeneProduct	190	191	7	1:NR:2	L2R	NON-CROSS	184-185	193-194	24806	SP	GeneOrGeneProduct	184	185	7	117064	VIP	GeneOrGeneProduct	193	194	7	1:NR:2	L2R	NON-CROSS	184-185	197-198	24806	SP	GeneOrGeneProduct	184	185	7	25742	S100b	GeneOrGeneProduct	197	198	7	1:NR:2	L2R	NON-CROSS	184-185	207-208	24806	SP	GeneOrGeneProduct	184	185	7	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	NON-CROSS	184-185	211-212	24806	SP	GeneOrGeneProduct	184	185	7	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	184-185	226-227	24806	SP	GeneOrGeneProduct	184	185	7	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	184-185	241-243	24806	SP	GeneOrGeneProduct	184	185	7	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	184-185	254-255	24806	SP	GeneOrGeneProduct	184	185	7	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	184-185	267-268	24806	SP	GeneOrGeneProduct	184	185	7	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	184-185	296-305	24806	SP	GeneOrGeneProduct	184	185	7	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	NON-CROSS	187-188	190-191	24807	NK1r	GeneOrGeneProduct	187	188	7	24598	nNOS	GeneOrGeneProduct	190	191	7	1:NR:2	L2R	NON-CROSS	187-188	193-194	24807	NK1r	GeneOrGeneProduct	187	188	7	117064	VIP	GeneOrGeneProduct	193	194	7	1:NR:2	L2R	NON-CROSS	187-188	197-198	24807	NK1r	GeneOrGeneProduct	187	188	7	25742	S100b	GeneOrGeneProduct	197	198	7	1:NR:2	L2R	NON-CROSS	187-188	207-208	24807	NK1r	GeneOrGeneProduct	187	188	7	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	NON-CROSS	187-188	211-212	24807	NK1r	GeneOrGeneProduct	187	188	7	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	187-188	226-227	24807	NK1r	GeneOrGeneProduct	187	188	7	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	187-188	241-243	24807	NK1r	GeneOrGeneProduct	187	188	7	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	187-188	254-255	24807	NK1r	GeneOrGeneProduct	187	188	7	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	187-188	267-268	24807	NK1r	GeneOrGeneProduct	187	188	7	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	187-188	296-305	24807	NK1r	GeneOrGeneProduct	187	188	7	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	NON-CROSS	190-191	193-194	24598	nNOS	GeneOrGeneProduct	190	191	7	117064	VIP	GeneOrGeneProduct	193	194	7	1:NR:2	L2R	NON-CROSS	190-191	197-198	24598	nNOS	GeneOrGeneProduct	190	191	7	25742	S100b	GeneOrGeneProduct	197	198	7	1:NR:2	L2R	NON-CROSS	190-191	207-208	24598	nNOS	GeneOrGeneProduct	190	191	7	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	NON-CROSS	190-191	211-212	24598	nNOS	GeneOrGeneProduct	190	191	7	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	190-191	226-227	24598	nNOS	GeneOrGeneProduct	190	191	7	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	190-191	241-243	24598	nNOS	GeneOrGeneProduct	190	191	7	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	190-191	254-255	24598	nNOS	GeneOrGeneProduct	190	191	7	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	190-191	267-268	24598	nNOS	GeneOrGeneProduct	190	191	7	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	190-191	296-305	24598	nNOS	GeneOrGeneProduct	190	191	7	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	NON-CROSS	193-194	197-198	117064	VIP	GeneOrGeneProduct	193	194	7	25742	S100b	GeneOrGeneProduct	197	198	7	1:NR:2	L2R	NON-CROSS	193-194	207-208	117064	VIP	GeneOrGeneProduct	193	194	7	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	NON-CROSS	193-194	211-212	117064	VIP	GeneOrGeneProduct	193	194	7	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	193-194	226-227	117064	VIP	GeneOrGeneProduct	193	194	7	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	193-194	241-243	117064	VIP	GeneOrGeneProduct	193	194	7	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	193-194	254-255	117064	VIP	GeneOrGeneProduct	193	194	7	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	193-194	267-268	117064	VIP	GeneOrGeneProduct	193	194	7	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	193-194	296-305	117064	VIP	GeneOrGeneProduct	193	194	7	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	NON-CROSS	197-198	207-208	25742	S100b	GeneOrGeneProduct	197	198	7	24241	CGRP	GeneOrGeneProduct	207	208	7	1:NR:2	L2R	NON-CROSS	197-198	211-212	25742	S100b	GeneOrGeneProduct	197	198	7	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	197-198	226-227	25742	S100b	GeneOrGeneProduct	197	198	7	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	197-198	241-243	25742	S100b	GeneOrGeneProduct	197	198	7	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	197-198	254-255	25742	S100b	GeneOrGeneProduct	197	198	7	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	197-198	267-268	25742	S100b	GeneOrGeneProduct	197	198	7	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	197-198	296-305	25742	S100b	GeneOrGeneProduct	197	198	7	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	NON-CROSS	207-208	211-212	24241	CGRP	GeneOrGeneProduct	207	208	7	58959	CRF1r	GeneOrGeneProduct	211	212	7	1:NR:2	L2R	CROSS	207-208	226-227	24241	CGRP	GeneOrGeneProduct	207	208	7	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	207-208	241-243	24241	CGRP	GeneOrGeneProduct	207	208	7	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	207-208	254-255	24241	CGRP	GeneOrGeneProduct	207	208	7	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	207-208	267-268	24241	CGRP	GeneOrGeneProduct	207	208	7	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	207-208	296-305	24241	CGRP	GeneOrGeneProduct	207	208	7	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	CROSS	211-212	226-227	58959	CRF1r	GeneOrGeneProduct	211	212	7	64680	CRF2r	GeneOrGeneProduct	226	227	8	1:NR:2	L2R	CROSS	211-212	241-243	58959	CRF1r	GeneOrGeneProduct	211	212	7	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	211-212	254-255	58959	CRF1r	GeneOrGeneProduct	211	212	7	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	211-212	267-268	58959	CRF1r	GeneOrGeneProduct	211	212	7	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	211-212	296-305	58959	CRF1r	GeneOrGeneProduct	211	212	7	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	NON-CROSS	226-227	241-243	64680	CRF2r	GeneOrGeneProduct	226	227	8	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	1:NR:2	L2R	CROSS	226-227	254-255	64680	CRF2r	GeneOrGeneProduct	226	227	8	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	226-227	267-268	64680	CRF2r	GeneOrGeneProduct	226	227	8	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	226-227	296-305	64680	CRF2r	GeneOrGeneProduct	226	227	8	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	CROSS	241-243	254-255	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	81645	Mr2	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	241-243	267-268	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	241-243	296-305	D052016	mucosal inflammation	DiseaseOrPhenotypicFeature	241	243	8	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	NON-CROSS	254-255	267-268	81645	Mr2	GeneOrGeneProduct	254	255	9	290567	ChAT	GeneOrGeneProduct	267	268	9	1:NR:2	L2R	CROSS	254-255	296-305	81645	Mr2	GeneOrGeneProduct	254	255	9	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11	1:NR:2	L2R	CROSS	267-268	296-305	290567	ChAT	GeneOrGeneProduct	267	268	9	24239	L - type Ca ( 2 + ) channels	GeneOrGeneProduct	296	305	11
29049388	An inducible mouse model of podocin - mutation - related nephrotic syndrome .|Mutations in the NPHS2 gene , encoding podocin , cause hereditary nephrotic syndrome .|The most common podocin mutation , R138Q , is associated with early disease onset and rapid progression to end - stage renal disease .|Knock - in mice carrying a R140Q mutation , the mouse analogue of human R138Q , show developmental arrest of podocytes and lethal renal failure at neonatal age .|Here we created a conditional podocin knock - in model named NPHS2 R140Q / - , using a tamoxifen - inducible Cre recombinase , which permits to study the effects of the mutation in postnatal life .|Within the first week of R140Q hemizygosity induction the animals developed proteinuria , which peaked after 4 - 5 weeks .|Subsequently the animals developed progressive renal failure , with a median survival time of 12 ( 95 % CI : 11 - 13 ) weeks .|Foot process fusion was observed within one week , progressing to severe and global effacement in the course of the disease .|The number of podocytes per glomerulus gradually diminished to 18 % compared to healthy controls 12 - 16 weeks after induction .|The fraction of segmentally sclerosed glomeruli was 25 % , 85 % and 97 % at 2 , 4 and 8 weeks , respectively .|Severe tubulointerstitial fibrosis was present at later disease stage and was correlated quantitatively with the level of proteinuria at early disease stages .|While R140Q podocin mRNA expression was elevated , protein abundance was reduced by more than 50 % within one week following induction .|Whereas miRNA21 expression persistently increased during the first 4 weeks , miRNA - 193a expression peaked 2 weeks after induction .|In conclusion , the inducible R140Q - podocin mouse model is an auspicious model of the most common genetic cause of human nephrotic syndrome , with a spontaneous disease course strongly reminiscent of the human disorder .|This model constitutes a valuable tool to test the efficacy of novel pharmacological interventions aimed to improve podocyte function and viability and attenuate proteinuria , glomerulosclerosis and progressive renal failure .	1:Association:2	L2R	NON-CROSS	5-6	10-12	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	DiseaseOrPhenotypicFeature	10:24:322	12:26:324	0:1:13	1:NR:2	L2R	CROSS	5-6	16-17	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	1:NR:2	L2R	CROSS	234-236	258-259	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	D007674	renal disease|tubulointerstitial fibrosis	DiseaseOrPhenotypicFeature	48:234	50:236	2:10	1:Association:2	L2R	CROSS	74-76	85-86	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	D051437	renal failure|renal failure|renal failure	DiseaseOrPhenotypicFeature	74:143:365	76:145:367	3:6:14	1:NR:2	L2R	NON-CROSS	91-92	98-99	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	D013629	tamoxifen	ChemicalEntity	98	99	4	1:Association:2	L2R	CROSS	250-251	258-259	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	D011507	proteinuria|proteinuria|proteinuria	DiseaseOrPhenotypicFeature	128:250:360	129:251:361	5:10:14	1:NR:2	L2R	CROSS	258-259	280-281	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	406991	miRNA21	GeneOrGeneProduct	280	281	12	1:NR:2	L2R	CROSS	290-293	307-308	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	1:NR:2	L2R	CROSS	307-308	362-363	170484	podocin|podocin|NPHS2|podocin|podocin	GeneOrGeneProduct	5:85:91:258:307	6:86:92:259:308	0:4:4:11:13	D005921	glomerulosclerosis	DiseaseOrPhenotypicFeature	362	363	14	1:Association:2	R2L	NON-CROSS	24-26	20-21	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	DiseaseOrPhenotypicFeature	10:24:322	12:26:324	0:1:13	1:NR:2	L2R	CROSS	24-26	33-34	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	DiseaseOrPhenotypicFeature	10:24:322	12:26:324	0:1:13	rs74315342	R138Q|R138Q	SequenceVariant	33:65	34:66	2:3	1:Positive_Correlation:2	R2L	NON-CROSS	322-324	305-306	p|SUB|R|140|Q	R140Q|R140Q|R140Q|R140Q|R140Q	SequenceVariant	57:92:122:257:305	58:93:123:258:306	3:4:5:11:13	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	DiseaseOrPhenotypicFeature	10:24:322	12:26:324	0:1:13	1:NR:2	L2R	CROSS	24-26	98-99	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	DiseaseOrPhenotypicFeature	10:24:322	12:26:324	0:1:13	D013629	tamoxifen	ChemicalEntity	98	99	4	1:NR:2	L2R	CROSS	280-281	322-324	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	DiseaseOrPhenotypicFeature	10:24:322	12:26:324	0:1:13	406991	miRNA21	GeneOrGeneProduct	280	281	12	1:NR:2	L2R	CROSS	290-293	322-324	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	DiseaseOrPhenotypicFeature	10:24:322	12:26:324	0:1:13	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	1:Association:2	L2R	NON-CROSS	30-31	48-50	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	D007674	renal disease|tubulointerstitial fibrosis	DiseaseOrPhenotypicFeature	48:234	50:236	2:10	1:Association:2	L2R	CROSS	30-31	74-76	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	D051437	renal failure|renal failure|renal failure	DiseaseOrPhenotypicFeature	74:143:365	76:145:367	3:6:14	1:NR:2	L2R	CROSS	30-31	98-99	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	D013629	tamoxifen	ChemicalEntity	98	99	4	1:Association:2	L2R	CROSS	30-31	128-129	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	D011507	proteinuria|proteinuria|proteinuria	DiseaseOrPhenotypicFeature	128:250:360	129:251:361	5:10:14	1:NR:2	L2R	CROSS	30-31	280-281	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	406991	miRNA21	GeneOrGeneProduct	280	281	12	1:NR:2	L2R	CROSS	30-31	290-293	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	1:NR:2	L2R	CROSS	30-31	362-363	7827	NPHS2|podocin|podocin	GeneOrGeneProduct	16:20:30	17:21:31	1:1:2	D005921	glomerulosclerosis	DiseaseOrPhenotypicFeature	362	363	14	1:Positive_Correlation:2	L2R	NON-CROSS	33-34	48-50	rs74315342	R138Q|R138Q	SequenceVariant	33:65	34:66	2:3	D007674	renal disease|tubulointerstitial fibrosis	DiseaseOrPhenotypicFeature	48:234	50:236	2:10	1:Positive_Correlation:2	L2R	NON-CROSS	65-66	74-76	rs74315342	R138Q|R138Q	SequenceVariant	33:65	34:66	2:3	D051437	renal failure|renal failure|renal failure	DiseaseOrPhenotypicFeature	74:143:365	76:145:367	3:6:14	1:NR:2	L2R	CROSS	65-66	98-99	rs74315342	R138Q|R138Q	SequenceVariant	33:65	34:66	2:3	D013629	tamoxifen	ChemicalEntity	98	99	4	1:NR:2	L2R	CROSS	65-66	128-129	rs74315342	R138Q|R138Q	SequenceVariant	33:65	34:66	2:3	D011507	proteinuria|proteinuria|proteinuria	DiseaseOrPhenotypicFeature	128:250:360	129:251:361	5:10:14	1:NR:2	L2R	CROSS	65-66	362-363	rs74315342	R138Q|R138Q	SequenceVariant	33:65	34:66	2:3	D005921	glomerulosclerosis	DiseaseOrPhenotypicFeature	362	363	14	1:NR:2	L2R	CROSS	48-50	57-58	D007674	renal disease|tubulointerstitial fibrosis	DiseaseOrPhenotypicFeature	48:234	50:236	2:10	p|SUB|R|140|Q	R140Q|R140Q|R140Q|R140Q|R140Q	SequenceVariant	57:92:122:257:305	58:93:123:258:306	3:4:5:11:13	1:NR:2	L2R	CROSS	48-50	98-99	D007674	renal disease|tubulointerstitial fibrosis	DiseaseOrPhenotypicFeature	48:234	50:236	2:10	D013629	tamoxifen	ChemicalEntity	98	99	4	1:NR:2	L2R	CROSS	234-236	280-281	D007674	renal disease|tubulointerstitial fibrosis	DiseaseOrPhenotypicFeature	48:234	50:236	2:10	406991	miRNA21	GeneOrGeneProduct	280	281	12	1:NR:2	L2R	CROSS	234-236	290-293	D007674	renal disease|tubulointerstitial fibrosis	DiseaseOrPhenotypicFeature	48:234	50:236	2:10	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	1:Positive_Correlation:2	L2R	NON-CROSS	57-58	74-76	p|SUB|R|140|Q	R140Q|R140Q|R140Q|R140Q|R140Q	SequenceVariant	57:92:122:257:305	58:93:123:258:306	3:4:5:11:13	D051437	renal failure|renal failure|renal failure	DiseaseOrPhenotypicFeature	74:143:365	76:145:367	3:6:14	1:NR:2	L2R	NON-CROSS	92-93	98-99	p|SUB|R|140|Q	R140Q|R140Q|R140Q|R140Q|R140Q	SequenceVariant	57:92:122:257:305	58:93:123:258:306	3:4:5:11:13	D013629	tamoxifen	ChemicalEntity	98	99	4	1:Positive_Correlation:2	L2R	NON-CROSS	122-123	128-129	p|SUB|R|140|Q	R140Q|R140Q|R140Q|R140Q|R140Q	SequenceVariant	57:92:122:257:305	58:93:123:258:306	3:4:5:11:13	D011507	proteinuria|proteinuria|proteinuria	DiseaseOrPhenotypicFeature	128:250:360	129:251:361	5:10:14	1:NR:2	L2R	CROSS	305-306	362-363	p|SUB|R|140|Q	R140Q|R140Q|R140Q|R140Q|R140Q	SequenceVariant	57:92:122:257:305	58:93:123:258:306	3:4:5:11:13	D005921	glomerulosclerosis	DiseaseOrPhenotypicFeature	362	363	14	1:NR:2	L2R	CROSS	74-76	98-99	D051437	renal failure|renal failure|renal failure	DiseaseOrPhenotypicFeature	74:143:365	76:145:367	3:6:14	D013629	tamoxifen	ChemicalEntity	98	99	4	1:NR:2	L2R	CROSS	280-281	365-367	D051437	renal failure|renal failure|renal failure	DiseaseOrPhenotypicFeature	74:143:365	76:145:367	3:6:14	406991	miRNA21	GeneOrGeneProduct	280	281	12	1:NR:2	L2R	CROSS	290-293	365-367	D051437	renal failure|renal failure|renal failure	DiseaseOrPhenotypicFeature	74:143:365	76:145:367	3:6:14	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	1:NR:2	L2R	CROSS	98-99	128-129	D013629	tamoxifen	ChemicalEntity	98	99	4	D011507	proteinuria|proteinuria|proteinuria	DiseaseOrPhenotypicFeature	128:250:360	129:251:361	5:10:14	1:NR:2	L2R	CROSS	98-99	280-281	D013629	tamoxifen	ChemicalEntity	98	99	4	406991	miRNA21	GeneOrGeneProduct	280	281	12	1:NR:2	L2R	CROSS	98-99	290-293	D013629	tamoxifen	ChemicalEntity	98	99	4	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	1:NR:2	L2R	CROSS	98-99	362-363	D013629	tamoxifen	ChemicalEntity	98	99	4	D005921	glomerulosclerosis	DiseaseOrPhenotypicFeature	362	363	14	1:NR:2	L2R	CROSS	250-251	280-281	D011507	proteinuria|proteinuria|proteinuria	DiseaseOrPhenotypicFeature	128:250:360	129:251:361	5:10:14	406991	miRNA21	GeneOrGeneProduct	280	281	12	1:NR:2	L2R	CROSS	250-251	290-293	D011507	proteinuria|proteinuria|proteinuria	DiseaseOrPhenotypicFeature	128:250:360	129:251:361	5:10:14	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	1:NR:2	L2R	NON-CROSS	280-281	290-293	406991	miRNA21	GeneOrGeneProduct	280	281	12	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	1:NR:2	L2R	CROSS	280-281	362-363	406991	miRNA21	GeneOrGeneProduct	280	281	12	D005921	glomerulosclerosis	DiseaseOrPhenotypicFeature	362	363	14	1:NR:2	L2R	CROSS	290-293	362-363	406968	miRNA - 193a	GeneOrGeneProduct	290	293	12	D005921	glomerulosclerosis	DiseaseOrPhenotypicFeature	362	363	14
17345627	Over - expression of BMP4 and BMP5 in a child with axial skeletal malformations and heterotopic ossification : a new syndrome .|Bone morphogenetic proteins ( BMPs ) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo .|Dysregulated expression of bone morphogenetic protein 4 ( BMP4 ) is found in the cells of patients who have fibrodysplasia ossificans progressiva ( FOP ) , a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification .|Loss of function mutations in the bone morphogenetic protein 5 ( bmp5 ) gene leading to under - expression of BMP5 cause the murine short ear syndrome , characterized by small malformed ears and a broad range of axial skeletal malformations .|We found features reminiscent of both the short ear mouse and FOP in a child with malformed external ears , multiple malformations of the axial skeleton , and progressive heterotopic ossification in the neck and back .|We examined BMP mRNA expression in transformed lymphocytes by semi - quantitative RT - PCR and protein expression by ELISA assays and immunohistochemistry .|Elevated levels of BMP4 and BMP5 mRNA and protein were detected in the patient 's cells while levels of BMP2 mRNA were unchanged .|Our data suggest that dysregulated expression of BMP4 and BMP5 genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and FOP .	1:NR:2	L2R	NON-CROSS	4-5	6-7	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	1:Association:2	R2L	NON-CROSS	11-14	4-5	D001848	axial skeletal malformations|axial and appendicular skeletal malformation|axial skeletal malformations|multiple malformations of the axial skeleton|axial skeletal abnormalities	DiseaseOrPhenotypicFeature	11:76:124:148:231	14:81:127:154:234	0:2:3:4:7	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	1:Association:2	R2L	NON-CROSS	15-17	4-5	D009999	heterotopic ossification|heterotopic ossification|heterotopic ossification	DiseaseOrPhenotypicFeature	15:83:157	17:85:159	0:2:4	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	1:NR:2	L2R	CROSS	4-5	22-25	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	1:NR:2	L2R	CROSS	38-43	54-55	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	D001847,D002357	ectopic cartilage and bone formation	DiseaseOrPhenotypicFeature	38	43	1	1:Association:2	L2R	NON-CROSS	54-55	65-68	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	D009221	fibrodysplasia ossificans progressiva|FOP|FOP|FOP	DiseaseOrPhenotypicFeature	65:69:139:241	68:70:140:242	2:2:4:7	1:Association:2	L2R	CROSS	54-55	110-113	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	D004427	short ear syndrome	DiseaseOrPhenotypicFeature	110	113	3	1:NR:2	L2R	CROSS	144-147	192-193	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	D004426	malformed external ears	DiseaseOrPhenotypicFeature	144	147	4	1:NR:2	L2R	NON-CROSS	208-209	220-221	652	BMP4|bone morphogenetic protein 4|BMP4|BMP4|BMP4	GeneOrGeneProduct	4:49:54:192:220	5:53:55:193:221	0:2:2:6:7	650	BMP2	GeneOrGeneProduct	208	209	6	1:Association:2	R2L	NON-CROSS	11-14	6-7	D001848	axial skeletal malformations|axial and appendicular skeletal malformation|axial skeletal malformations|multiple malformations of the axial skeleton|axial skeletal abnormalities	DiseaseOrPhenotypicFeature	11:76:124:148:231	14:81:127:154:234	0:2:3:4:7	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	1:Association:2	R2L	NON-CROSS	92-96	83-85	D009999	heterotopic ossification|heterotopic ossification|heterotopic ossification	DiseaseOrPhenotypicFeature	15:83:157	17:85:159	0:2:4	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	1:NR:2	L2R	CROSS	6-7	22-25	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	1:NR:2	L2R	CROSS	6-7	38-43	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	D001847,D002357	ectopic cartilage and bone formation	DiseaseOrPhenotypicFeature	38	43	1	1:Association:2	L2R	NON-CROSS	222-223	241-242	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	D009221	fibrodysplasia ossificans progressiva|FOP|FOP|FOP	DiseaseOrPhenotypicFeature	65:69:139:241	68:70:140:242	2:2:4:7	1:Association:2	L2R	NON-CROSS	106-107	110-113	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	D004427	short ear syndrome	DiseaseOrPhenotypicFeature	110	113	3	1:NR:2	L2R	CROSS	106-107	144-147	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	D004426	malformed external ears	DiseaseOrPhenotypicFeature	144	147	4	1:NR:2	L2R	NON-CROSS	194-195	208-209	653	BMP5|bone morphogenetic protein 5|bmp5|BMP5|BMP5|BMP5	GeneOrGeneProduct	6:92:97:106:194:222	7:96:98:107:195:223	0:3:3:3:6:7	650	BMP2	GeneOrGeneProduct	208	209	6	1:NR:2	L2R	CROSS	11-14	22-25	D001848	axial skeletal malformations|axial and appendicular skeletal malformation|axial skeletal malformations|multiple malformations of the axial skeleton|axial skeletal abnormalities	DiseaseOrPhenotypicFeature	11:76:124:148:231	14:81:127:154:234	0:2:3:4:7	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	1:NR:2	L2R	CROSS	208-209	231-234	D001848	axial skeletal malformations|axial and appendicular skeletal malformation|axial skeletal malformations|multiple malformations of the axial skeleton|axial skeletal abnormalities	DiseaseOrPhenotypicFeature	11:76:124:148:231	14:81:127:154:234	0:2:3:4:7	650	BMP2	GeneOrGeneProduct	208	209	6	1:NR:2	L2R	CROSS	15-17	22-25	D009999	heterotopic ossification|heterotopic ossification|heterotopic ossification	DiseaseOrPhenotypicFeature	15:83:157	17:85:159	0:2:4	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	1:NR:2	L2R	CROSS	157-159	208-209	D009999	heterotopic ossification|heterotopic ossification|heterotopic ossification	DiseaseOrPhenotypicFeature	15:83:157	17:85:159	0:2:4	650	BMP2	GeneOrGeneProduct	208	209	6	1:NR:2	L2R	NON-CROSS	26-27	38-43	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	D001847,D002357	ectopic cartilage and bone formation	DiseaseOrPhenotypicFeature	38	43	1	1:NR:2	L2R	CROSS	139-140	167-168	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	D009221	fibrodysplasia ossificans progressiva|FOP|FOP|FOP	DiseaseOrPhenotypicFeature	65:69:139:241	68:70:140:242	2:2:4:7	1:NR:2	L2R	CROSS	110-113	167-168	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	D004427	short ear syndrome	DiseaseOrPhenotypicFeature	110	113	3	1:NR:2	L2R	CROSS	144-147	167-168	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	D004426	malformed external ears	DiseaseOrPhenotypicFeature	144	147	4	1:NR:2	L2R	CROSS	167-168	208-209	649,650,652,653	Bone morphogenetic proteins|BMPs|BMP	GeneOrGeneProduct	22:26:167	25:27:168	1:1:5	650	BMP2	GeneOrGeneProduct	208	209	6	1:NR:2	L2R	CROSS	38-43	208-209	D001847,D002357	ectopic cartilage and bone formation	DiseaseOrPhenotypicFeature	38	43	1	650	BMP2	GeneOrGeneProduct	208	209	6	1:NR:2	L2R	CROSS	208-209	241-242	D009221	fibrodysplasia ossificans progressiva|FOP|FOP|FOP	DiseaseOrPhenotypicFeature	65:69:139:241	68:70:140:242	2:2:4:7	650	BMP2	GeneOrGeneProduct	208	209	6	1:NR:2	L2R	CROSS	110-113	208-209	D004427	short ear syndrome	DiseaseOrPhenotypicFeature	110	113	3	650	BMP2	GeneOrGeneProduct	208	209	6	1:NR:2	L2R	CROSS	144-147	208-209	D004426	malformed external ears	DiseaseOrPhenotypicFeature	144	147	4	650	BMP2	GeneOrGeneProduct	208	209	6
20540798	Sex - differential genetic effect of phosphodiesterase 4D ( PDE4D ) on carotid atherosclerosis .|BACKGROUND : The phosphodiesterase 4D ( PDE4D ) gene was reported as a susceptibility gene to stroke .|The genetic effect might be attributed to its role in modulating the atherogenic process in the carotid arteries .|Using carotid intima - media thickness ( IMT ) and plaque index as phenotypes , the present study sought to determine the influence of this gene on subclinical atherosclerosis .|METHODS : Carotid ultrasonography was performed on 1013 stroke - free subjects who participated in the health screening programs ( age 52 . 6 + / - 12 . 2 ; 47 . 6 % men ) .|Genotype distribution was compared among the high - risk ( plaque index > or = 4 ) , low - risk ( index = 1 - 3 ) , and reference ( index = 0 ) groups .|We analyzed continuous IMT data and further dichotomized IMT data using mean plus one standard deviation as the cutoff level .|Because the plaque prevalence and IMT values displayed a notable difference between men and women , we carried out sex - specific analyses in addition to analyzing the overall data .|Rs702553 at the PDE4D gene was selected because it conferred a risk for young stroke in our previous report .|Previous young stroke data ( 190 cases and 211 controls ) with an additional 532 control subjects without ultrasonic data were shown as a cross - validation for the genetic effect .|RESULTS : In the overall analyses , the rare homozygote of rs702553 led to an OR of 3 . 1 ( p = 0 . 034 ) for a plaque index > or = 4 .|When subjects were stratified by sex , the genetic effect was only evident in men but not in women .|Comparing male subjects with plaque index > or = 4 and those with plaque index = 0 , the TT genotype was over - represented ( 27 . 6 % vs . 13 . 4 % , p = 0 . 008 ) .|For dichotomized IMT data in men , the TT genotype had an OR of 2 . 1 ( p = 0 . 032 ) for a thicker IMT at the common carotid artery compared with the ( AA + AT ) genotypes .|In women , neither IMT nor plaque index was associated with rs702553 .|Similarly , SNP rs702553 was only significant in young stroke men ( OR = 1 . 8 , p = 0 . 025 ) but not in women ( p = 0 . 27 ) .|CONCLUSIONS : The present study demonstrates a sex - differential effect of PDE4D on IMT , plaque index and stroke , which highlights its influence on various aspects of atherogenesis .	1:Association:2	L2R	NON-CROSS	9-10	12-14	5144	phosphodiesterase 4D|PDE4D|phosphodiesterase 4D|PDE4D|PDE4D|PDE4D	GeneOrGeneProduct	6:9:18:21:213:466	8:10:20:22:214:467	0:0:1:1:8:16	D002340	carotid atherosclerosis	DiseaseOrPhenotypicFeature	12	14	0	1:Association:2	L2R	NON-CROSS	466-467	473-474	5144	phosphodiesterase 4D|PDE4D|phosphodiesterase 4D|PDE4D|PDE4D|PDE4D	GeneOrGeneProduct	6:9:18:21:213:466	8:10:20:22:214:467	0:0:1:1:8:16	D020521	stroke|stroke|stroke|stroke|stroke|stroke	DiseaseOrPhenotypicFeature	31:90:224:232:427:473	32:91:225:233:428:474	1:4:8:9:15:16	1:Association:2	L2R	NON-CROSS	466-467	483-484	5144	phosphodiesterase 4D|PDE4D|phosphodiesterase 4D|PDE4D|PDE4D|PDE4D	GeneOrGeneProduct	6:9:18:21:213:466	8:10:20:22:214:467	0:0:1:1:8:16	D050197	atherogenic|atherosclerosis|atherogenesis	DiseaseOrPhenotypicFeature	45:80:483	46:81:484	2:3:16	1:NR:2	L2R	CROSS	12-14	210-211	D002340	carotid atherosclerosis	DiseaseOrPhenotypicFeature	12	14	0	rs702553	Rs702553|rs702553|rs702553|rs702553	SequenceVariant	210:273:416:421	211:274:417:422	8:10:14:15	1:Positive_Correlation:2	R2L	NON-CROSS	427-428	421-422	rs702553	Rs702553|rs702553|rs702553|rs702553	SequenceVariant	210:273:416:421	211:274:417:422	8:10:14:15	D020521	stroke|stroke|stroke|stroke|stroke|stroke	DiseaseOrPhenotypicFeature	31:90:224:232:427:473	32:91:225:233:428:474	1:4:8:9:15:16	1:Association:2	L2R	CROSS	421-422	483-484	D050197	atherogenic|atherosclerosis|atherogenesis	DiseaseOrPhenotypicFeature	45:80:483	46:81:484	2:3:16	rs702553	Rs702553|rs702553|rs702553|rs702553	SequenceVariant	210:273:416:421	211:274:417:422	8:10:14:15
21130517	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors .|AIMS : EGFR mutations now guide the clinical use of EGFR - targeted therapy in lung cancer .|However , standard EGFR mutation analysis requires a minimum amount of tumor tissue , which may not be available in certain situations .|In this study , we combined a mass spectrometry genotyping assay ( Sequenom ) with a mutant - enriched PCR ( ME - PCR ) to detect EGFR mutations in free plasma DNA from patients with lung cancer .|METHOD : DNAs were extracted from 31 plasma samples from 31 patients and analyzed by both methods for EGFR Exon 19 deletion and EGFR L858R mutation .|Results in plasma DNA samples were compared with EGFR mutation status obtained in tumor DNA ( 18 / 31 EGFR mutant ) .|The relationship of EGFR mutation status in tumor and / or plasma samples to overall survival was assessed .|RESULTS : The EGFR mutation status in plasma DNA was identical to the primary tumor in 61 % of patients ( 19 / 31 ) .|By mass spectrometry genotyping , the plasma samples contained mutant DNA corresponding to 5 / 14 EGFR Exon 19 deletions and 3 / 4 EGFR L858R mutations previously diagnosed in the matched tumors .|Two samples were positive in plasma DNA but negative in primary tumor tissue .|Results were similar for samples studied by ME - PCR .|For patients treated with erlotinib , overall survival was correlated with the presence of EGFR mutation in plasma and / or tumor tissue ( p = 0 . 002 ) , with the two patients positive only in plasma DNA showing responses and favorable outcomes .|CONCLUSION : The detection of EGFR mutations in plasma DNA samples by mass spectrometry genotyping and ME - PCR is feasible .|A positive EGFR result in plasma DNA has a high predictive value for tumor EGFR status and for favorable clinical course on EGFR - targeted therapy and could therefore be useful in guiding clinical decisions in patients with insufficient or unavailable tumor specimens .	1:Association:2	L2R	NON-CROSS	37-38	42-44	1956	EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR	GeneOrGeneProduct	2:19:24:29:37:48:95:125:130:142:153:160:179:218:226:275:312:331:343:351	3:20:25:30:38:49:96:126:131:143:154:161:180:219:227:276:313:332:344:352	0:0:0:1:1:2:3:4:4:5:5:6:7:8:8:11:12:13:13:13	D008175	lung cancer|lung cancer|lung cancer	DiseaseOrPhenotypicFeature	8:42:104	10:44:106	0:1:3	1:Association:2	L2R	NON-CROSS	18-19	19-20	1956	EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR	GeneOrGeneProduct	2:19:24:29:37:48:95:125:130:142:153:160:179:218:226:275:312:331:343:351	3:20:25:30:38:49:96:126:131:143:154:161:180:219:227:276:313:332:344:352	0:0:0:1:1:2:3:4:4:5:5:6:7:8:8:11:12:13:13:13	D009369	tumor|tumor|tumor|tumor|tumor|tumors|tumor|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	18:56:147:164:190:234:247:282:342:370	19:57:148:165:191:235:248:283:343:371	0:2:5:6:7:8:9:11:13:13	1:Association:2	R2L	NON-CROSS	275-276	265-266	D000069347	erlotinib	ChemicalEntity	265	266	11	1956	EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR|EGFR	GeneOrGeneProduct	2:19:24:29:37:48:95:125:130:142:153:160:179:218:226:275:312:331:343:351	3:20:25:30:38:49:96:126:131:143:154:161:180:219:227:276:313:332:344:352	0:0:0:1:1:2:3:4:4:5:5:6:7:8:8:11:12:13:13:13	1:NR:2	L2R	CROSS	104-106	131-132	D008175	lung cancer|lung cancer|lung cancer	DiseaseOrPhenotypicFeature	8:42:104	10:44:106	0:1:3	rs121434568	L858R|L858R	SequenceVariant	131:227	132:228	4:8	1:NR:2	L2R	CROSS	104-106	265-266	D008175	lung cancer|lung cancer|lung cancer	DiseaseOrPhenotypicFeature	8:42:104	10:44:106	0:1:3	D000069347	erlotinib	ChemicalEntity	265	266	11	1:Association:2	R2L	NON-CROSS	234-235	227-228	rs121434568	L858R|L858R	SequenceVariant	131:227	132:228	4:8	D009369	tumor|tumor|tumor|tumor|tumor|tumors|tumor|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	18:56:147:164:190:234:247:282:342:370	19:57:148:165:191:235:248:283:343:371	0:2:5:6:7:8:9:11:13:13	1:Negative_Correlation:2	R2L	NON-CROSS	282-283	265-266	D000069347	erlotinib	ChemicalEntity	265	266	11	D009369	tumor|tumor|tumor|tumor|tumor|tumors|tumor|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	18:56:147:164:190:234:247:282:342:370	19:57:148:165:191:235:248:283:343:371	0:2:5:6:7:8:9:11:13:13	1:Association:2	R2L	CROSS	265-266	227-228	D000069347	erlotinib	ChemicalEntity	265	266	11	rs121434568	L858R|L858R	SequenceVariant	131:227	132:228	4:8
28393239	Psoriasin promotes invasion , aggregation and survival of pancreatic cancer cells ; association with disease progression .|Psoriasin ( S100A7 ) is an 11 - kDa small calcium binding protein initially isolated from psoriatic skin lesions .|It belongs to the S100 family of proteins which play an important role in a range of cell functions including proliferation , differentiation , migration and apoptosis .|Aberrant Psoriasin expression has been implicated in a range of cancers and is often associated with poor prognosis .|This study examined the role of Psoriasin on pancreatic cancer cell functions and the implication in progression of the disease .|Expression of Psoriasin was determined in a cohort of pancreatic tissues comprised of 126 pancreatic tumours and 114 adjacent non - tumour pancreatic tissues .|Knockdown and overexpression of Psoriasin in pancreatic cancer cells was performed using specifically constructed plasmids , which either had anti - Psoriasin ribozyme transgene or the full length human Psoriasin coding sequence .|Psoriasin knockdown and overexpression was verified using conventional RT - PCR and qPCR .|The effect of manipulating Psoriasin expression on pancreatic cancer cell functions was assessed using several in vitro cell function assays .|Local invasive pancreatic cancers extended beyond the pancreas expressed higher levels of Psoriasin transcripts compared with the cancers confined to the pancreas .|Primary tumours with distant metastases exhibited a reduced expression of Psoriasin .|Psoriasin overexpression cell lines exhibited significantly increased growth and migration compared to control cells .|In addition , Psoriasin overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase - 2 ( MMP - 2 ) and MMP - 9 .|Overexpression of Psoriasin also promoted aggregation and survival of pancreatic cancer cells when they lost anchorage .|Taken together , higher expression of Psoriasin was associated with local invasion in pancreatic cancers .|Psoriasin expression is associated with pancreatic cancer cell growth , migration , cell - matrix adhesion , and invasion via regulation of MMPs .|As such , the proposed implications of Psoriasin in invasion , disease progression and as a potential therapeutic target warrant further investigation .	1:Positive_Correlation:2	L2R	NON-CROSS	90-91	92-94	6278	Psoriasin|Psoriasin|S100A7|calcium binding protein|S100|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin	GeneOrGeneProduct	0:17:19:27:41:66:90:107:134:151:159:163:181:210:231:233:251:282:303:313:344	1:18:20:30:42:67:91:108:135:152:160:164:182:211:232:234:252:283:304:314:345	0:1:1:1:2:3:4:5:6:6:6:7:8:9:10:11:12:13:14:15:16	D010190	pancreatic cancer|pancreatic cancer|pancreatic tumours|pancreatic cancer|pancreatic cancer|pancreatic cancers|pancreatic cancer|pancreatic cancer|pancreatic cancers|pancreatic cancer	DiseaseOrPhenotypicFeature	8:92:119:136:184:200:256:289:310:318	10:94:121:138:186:202:258:291:312:320	0:4:5:6:8:9:12:13:14:15	1:Association:2	L2R	NON-CROSS	27-30	33-36	6278	Psoriasin|Psoriasin|S100A7|calcium binding protein|S100|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin	GeneOrGeneProduct	0:17:19:27:41:66:90:107:134:151:159:163:181:210:231:233:251:282:303:313:344	1:18:20:30:42:67:91:108:135:152:160:164:182:211:232:234:252:283:304:314:345	0:1:1:1:2:3:4:5:6:6:6:7:8:9:10:11:12:13:14:15:16	D011565	psoriatic skin lesions	DiseaseOrPhenotypicFeature	33	36	1	1:Association:2	L2R	NON-CROSS	210-211	215-216	6278	Psoriasin|Psoriasin|S100A7|calcium binding protein|S100|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin	GeneOrGeneProduct	0:17:19:27:41:66:90:107:134:151:159:163:181:210:231:233:251:282:303:313:344	1:18:20:30:42:67:91:108:135:152:160:164:182:211:232:234:252:283:304:314:345	0:1:1:1:2:3:4:5:6:6:6:7:8:9:10:11:12:13:14:15:16	D009369	cancers|cancers|Primary tumours	DiseaseOrPhenotypicFeature	75:215:221	76:216:223	3:9:10	1:NR:2	L2R	NON-CROSS	225-226	231-232	6278	Psoriasin|Psoriasin|S100A7|calcium binding protein|S100|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin	GeneOrGeneProduct	0:17:19:27:41:66:90:107:134:151:159:163:181:210:231:233:251:282:303:313:344	1:18:20:30:42:67:91:108:135:152:160:164:182:211:232:234:252:283:304:314:345	0:1:1:1:2:3:4:5:6:6:6:7:8:9:10:11:12:13:14:15:16	D009362	metastases	DiseaseOrPhenotypicFeature	225	226	10	1:Positive_Correlation:2	L2R	NON-CROSS	271-274	282-283	6278	Psoriasin|Psoriasin|S100A7|calcium binding protein|S100|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin	GeneOrGeneProduct	0:17:19:27:41:66:90:107:134:151:159:163:181:210:231:233:251:282:303:313:344	1:18:20:30:42:67:91:108:135:152:160:164:182:211:232:234:252:283:304:314:345	0:1:1:1:2:3:4:5:6:6:6:7:8:9:10:11:12:13:14:15:16	4313	matrix metalloproteinase - 2|MMP - 2	GeneOrGeneProduct	266:271	270:274	12:12	1:Positive_Correlation:2	L2R	NON-CROSS	276-279	282-283	6278	Psoriasin|Psoriasin|S100A7|calcium binding protein|S100|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin	GeneOrGeneProduct	0:17:19:27:41:66:90:107:134:151:159:163:181:210:231:233:251:282:303:313:344	1:18:20:30:42:67:91:108:135:152:160:164:182:211:232:234:252:283:304:314:345	0:1:1:1:2:3:4:5:6:6:6:7:8:9:10:11:12:13:14:15:16	4318	MMP - 9	GeneOrGeneProduct	276	279	12	1:NR:2	L2R	NON-CROSS	335-336	344-345	6278	Psoriasin|Psoriasin|S100A7|calcium binding protein|S100|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin|Psoriasin	GeneOrGeneProduct	0:17:19:27:41:66:90:107:134:151:159:163:181:210:231:233:251:282:303:313:344	1:18:20:30:42:67:91:108:135:152:160:164:182:211:232:234:252:283:304:314:345	0:1:1:1:2:3:4:5:6:6:6:7:8:9:10:11:12:13:14:15:16	4313,4318	MMPs	GeneOrGeneProduct	335	336	15	1:Positive_Correlation:2	L2R	NON-CROSS	256-258	266-270	D010190	pancreatic cancer|pancreatic cancer|pancreatic tumours|pancreatic cancer|pancreatic cancer|pancreatic cancers|pancreatic cancer|pancreatic cancer|pancreatic cancers|pancreatic cancer	DiseaseOrPhenotypicFeature	8:92:119:136:184:200:256:289:310:318	10:94:121:138:186:202:258:291:312:320	0:4:5:6:8:9:12:13:14:15	4313	matrix metalloproteinase - 2|MMP - 2	GeneOrGeneProduct	266:271	270:274	12:12	1:Positive_Correlation:2	L2R	NON-CROSS	276-279	289-291	D010190	pancreatic cancer|pancreatic cancer|pancreatic tumours|pancreatic cancer|pancreatic cancer|pancreatic cancers|pancreatic cancer|pancreatic cancer|pancreatic cancers|pancreatic cancer	DiseaseOrPhenotypicFeature	8:92:119:136:184:200:256:289:310:318	10:94:121:138:186:202:258:291:312:320	0:4:5:6:8:9:12:13:14:15	4318	MMP - 9	GeneOrGeneProduct	276	279	12	1:NR:2	L2R	NON-CROSS	318-320	335-336	D010190	pancreatic cancer|pancreatic cancer|pancreatic tumours|pancreatic cancer|pancreatic cancer|pancreatic cancers|pancreatic cancer|pancreatic cancer|pancreatic cancers|pancreatic cancer	DiseaseOrPhenotypicFeature	8:92:119:136:184:200:256:289:310:318	10:94:121:138:186:202:258:291:312:320	0:4:5:6:8:9:12:13:14:15	4313,4318	MMPs	GeneOrGeneProduct	335	336	15	1:NR:2	L2R	CROSS	33-36	266-270	D011565	psoriatic skin lesions	DiseaseOrPhenotypicFeature	33	36	1	4313	matrix metalloproteinase - 2|MMP - 2	GeneOrGeneProduct	266:271	270:274	12:12	1:NR:2	L2R	CROSS	33-36	276-279	D011565	psoriatic skin lesions	DiseaseOrPhenotypicFeature	33	36	1	4318	MMP - 9	GeneOrGeneProduct	276	279	12	1:NR:2	L2R	CROSS	33-36	335-336	D011565	psoriatic skin lesions	DiseaseOrPhenotypicFeature	33	36	1	4313,4318	MMPs	GeneOrGeneProduct	335	336	15	1:NR:2	L2R	CROSS	221-223	266-270	D009369	cancers|cancers|Primary tumours	DiseaseOrPhenotypicFeature	75:215:221	76:216:223	3:9:10	4313	matrix metalloproteinase - 2|MMP - 2	GeneOrGeneProduct	266:271	270:274	12:12	1:NR:2	L2R	CROSS	221-223	276-279	D009369	cancers|cancers|Primary tumours	DiseaseOrPhenotypicFeature	75:215:221	76:216:223	3:9:10	4318	MMP - 9	GeneOrGeneProduct	276	279	12	1:NR:2	L2R	CROSS	221-223	335-336	D009369	cancers|cancers|Primary tumours	DiseaseOrPhenotypicFeature	75:215:221	76:216:223	3:9:10	4313,4318	MMPs	GeneOrGeneProduct	335	336	15	1:NR:2	L2R	CROSS	225-226	266-270	D009362	metastases	DiseaseOrPhenotypicFeature	225	226	10	4313	matrix metalloproteinase - 2|MMP - 2	GeneOrGeneProduct	266:271	270:274	12:12	1:NR:2	L2R	CROSS	225-226	276-279	D009362	metastases	DiseaseOrPhenotypicFeature	225	226	10	4318	MMP - 9	GeneOrGeneProduct	276	279	12	1:NR:2	L2R	CROSS	225-226	335-336	D009362	metastases	DiseaseOrPhenotypicFeature	225	226	10	4313,4318	MMPs	GeneOrGeneProduct	335	336	15	1:NR:2	L2R	NON-CROSS	271-274	276-279	4313	matrix metalloproteinase - 2|MMP - 2	GeneOrGeneProduct	266:271	270:274	12:12	4318	MMP - 9	GeneOrGeneProduct	276	279	12	1:NR:2	L2R	CROSS	271-274	335-336	4313	matrix metalloproteinase - 2|MMP - 2	GeneOrGeneProduct	266:271	270:274	12:12	4313,4318	MMPs	GeneOrGeneProduct	335	336	15	1:NR:2	L2R	CROSS	276-279	335-336	4318	MMP - 9	GeneOrGeneProduct	276	279	12	4313,4318	MMPs	GeneOrGeneProduct	335	336	15
16018252	Two novel mutations in SRY gene form Chinese sex reversal XY females .|The SRY gene ( sex determining region on Y chromosome ) acts as TDF and is required for regulating male sex determination .|SRY represents a transcription factor belonging to the superfamily of genes sharing the HMG - box motif ( high - mobility group - box ) , which acts as DNA binding region .|Deletion and inactivating mutations of SRY are among the known causes of XY sex reversal .|Here , we described the screening of 10 patients who presented with 46 , XY sex reversal for mutations in open reading frame ( ORF ) of SRY gene .|DNA was isolated from blood samples using standard techniques .|A 609 bp fragment from the central portion of the SRY gene was amplified , using primers XES - 2 and XES - 7 .|The amplified PCR fragments were cloned into the pUCm - T vectors , and direct sequencing were carried out on an ABI 377 - 3 automated DNA sequencer to detect the mutation .|PCR - restriction enzyme digestion was applied to detect the results of DNA sequencing .|In two patients , de novo mutations led to an amino acid substitution .|An A was replaced by a G in codon 38 upstream of the 5 ' border outside the HMG box of the SRY gene , resulting in the replacement of the amino acid glutamate by glycine .|Another heterozygous T to A transition at the nucleotide position + 387 which encodes for a Tyrosine ( Tyr ) instead of a Term , whereas her father was proven to have the wild - type sequence .|These point mutations have been confirmed with PCR - restrict enzyme method .|As demonstrated by the Human Gene Mutation Database analysis , homology search , and review of the literature , these two mutations were not described previously and brought the total number of SRY gene nucleotide substitutions ( missense / nonsense ) to 45 .|These findings indicated that these amino acid substitutions may be responsible for the sex reversal , not only inside the HMG - box but also outside the HMG - box .|The two novel mutations in SRY gene provided valuable information for understanding the molecular mechanism of the patient with 46 , XY female sex reversal .	1:Association:2	R2L	NON-CROSS	8-11	4-5	OMIM:400044	sex reversal XY|XY sex reversal|46 , XY sex reversal|sex reversal|46 , XY female sex reversal	DiseaseOrPhenotypicFeature	8:81:97:357:394	11:84:102:359:400	0:3:4:14:15	6736	SRY|SRY|SRY|SRY|SRY|SRY|SRY|SRY|SRY	GeneOrGeneProduct	4:14:36:74:112:135:234:332:380	5:15:37:75:113:136:235:333:381	0:1:2:3:4:6:10:13:15	1:Positive_Correlation:2	L2R	CROSS	97-102	213-222	OMIM:400044	sex reversal XY|XY sex reversal|46 , XY sex reversal|sex reversal|46 , XY female sex reversal	DiseaseOrPhenotypicFeature	8:81:97:357:394	11:84:102:359:400	0:3:4:14:15	c|SUB|A|CODON38|G	A was replaced by a G in codon 38	SequenceVariant	213	222	10	1:Positive_Correlation:2	L2R	CROSS	245-248	357-359	OMIM:400044	sex reversal XY|XY sex reversal|46 , XY sex reversal|sex reversal|46 , XY female sex reversal	DiseaseOrPhenotypicFeature	8:81:97:357:394	11:84:102:359:400	0:3:4:14:15	p|SUB|E||G	glutamate by glycine	SequenceVariant	245	248	10	1:Positive_Correlation:2	L2R	CROSS	251-261	357-359	OMIM:400044	sex reversal XY|XY sex reversal|46 , XY sex reversal|sex reversal|46 , XY female sex reversal	DiseaseOrPhenotypicFeature	8:81:97:357:394	11:84:102:359:400	0:3:4:14:15	c|SUB|T|387|A	T to A transition at the nucleotide position + 387	SequenceVariant	251	261	11	1:Positive_Correlation:2	L2R	CROSS	265-273	357-359	OMIM:400044	sex reversal XY|XY sex reversal|46 , XY sex reversal|sex reversal|46 , XY female sex reversal	DiseaseOrPhenotypicFeature	8:81:97:357:394	11:84:102:359:400	0:3:4:14:15	c|SUB|Y||X	Tyrosine ( Tyr ) instead of a Term	SequenceVariant	265	273	11
16419642	A novel missense mutation , F826Y , in the mineralocorticoid receptor gene in Japanese hypertensives : its implications for clinical phenotypes .|A gain - of - function mutation resulting in the S810L amino acid substitution in the hormone - binding domain of the mineralocorticoid receptor ( MR , locus symbol NR3C2 ) is responsible for early - onset hypertension that is exacerbated in pregnancy .|The objective of this study was to test whether other types of missense mutations in the hormone - binding domain could be implicated in hypertension in Japanese .|Here , we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR .|We did not identify the S810L mutation in our hypertensive population , indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese .|However , we identified a novel missense mutation , F826Y , in three patients in a heterozygous state , in addition to four single nucleotide polymorphisms , including one synonymous mutation ( L809L ) .|The F826Y mutation is present in the MR hormone - binding domain and might affect the ligand affinity .|The F826Y mutation was also identified in 13 individuals ( 5 hypertensives and 8 normotensives ) in a Japanese general population ( n = 3 , 655 ) .|The allele frequency was 0 . 00178 .|The frequencies of the F826Y mutation in the hypertensive population ( 3 / 942 ) and in the hypertensive group ( 5 / 1 , 480 ) and the normotensive group ( 8 / 2 , 175 ) in the general population were not significantly different , suggesting that this mutation does not greatly affect hypertension .|Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity , this missense mutation may contribute , to some extent , to clinical phenotypes through its effects on MR .	1:Association:2	L2R	NON-CROSS	239-240	243-244	rs13306592	F826Y|F826Y|F826Y|F826Y|F826Y|F826Y	SequenceVariant	5:153:180:199:239:302	6:154:181:200:240:303	0:5:6:7:9:10	D006973	hypertensives|hypertension|hypertension|hypertension|hypertensive|hypertensives|hypertensive|hypertensive|hypertension	DiseaseOrPhenotypicFeature	14:59:90:102:123:209:243:253:290	15:60:91:103:124:210:244:254:291	0:1:2:3:4:7:9:9:9	1:NR:2	L2R	CROSS	139-141	153-154	rs13306592	F826Y|F826Y|F826Y|F826Y|F826Y|F826Y	SequenceVariant	5:153:180:199:239:302	6:154:181:200:240:303	0:5:6:7:9:10	D000075222	essential hypertension	DiseaseOrPhenotypicFeature	139	141	4	1:Association:2	L2R	NON-CROSS	9-11	14-15	4306	mineralocorticoid receptor|mineralocorticoid receptor|MR|NR3C2|MR|MR|mineralocorticoid receptor|MR	GeneOrGeneProduct	9:44:47:51:112:186:310:331	11:46:48:52:113:187:312:332	0:1:1:1:3:6:10:10	D006973	hypertensives|hypertension|hypertension|hypertension|hypertensive|hypertensives|hypertensive|hypertensive|hypertension	DiseaseOrPhenotypicFeature	14:59:90:102:123:209:243:253:290	15:60:91:103:124:210:244:254:291	0:1:2:3:4:7:9:9:9	1:NR:2	L2R	CROSS	112-113	139-141	4306	mineralocorticoid receptor|mineralocorticoid receptor|MR|NR3C2|MR|MR|mineralocorticoid receptor|MR	GeneOrGeneProduct	9:44:47:51:112:186:310:331	11:46:48:52:113:187:312:332	0:1:1:1:3:6:10:10	D000075222	essential hypertension	DiseaseOrPhenotypicFeature	139	141	4	1:Positive_Correlation:2	R2L	NON-CROSS	105-106	102-103	rs41511344	S810L|S810L|S810L|S810L	SequenceVariant	32:105:119:128	33:106:120:129	1:3:4:4	D006973	hypertensives|hypertension|hypertension|hypertension|hypertensive|hypertensives|hypertensive|hypertensive|hypertension	DiseaseOrPhenotypicFeature	14:59:90:102:123:209:243:253:290	15:60:91:103:124:210:244:254:291	0:1:2:3:4:7:9:9:9	1:NR:2	L2R	CROSS	176-177	209-210	D006973	hypertensives|hypertension|hypertension|hypertension|hypertensive|hypertensives|hypertensive|hypertensive|hypertension	DiseaseOrPhenotypicFeature	14:59:90:102:123:209:243:253:290	15:60:91:103:124:210:244:254:291	0:1:2:3:4:7:9:9:9	rs145670736	L809L	SequenceVariant	176	177	5	1:NR:2	L2R	NON-CROSS	128-129	139-141	rs41511344	S810L|S810L|S810L|S810L	SequenceVariant	32:105:119:128	33:106:120:129	1:3:4:4	D000075222	essential hypertension	DiseaseOrPhenotypicFeature	139	141	4	1:Association:2	L2R	CROSS	139-141	176-177	D000075222	essential hypertension	DiseaseOrPhenotypicFeature	139	141	4	rs145670736	L809L	SequenceVariant	176	177	5
17943461	Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .|BACKGROUND : Dilated cardiomyopathy ( DCM ) and myocarditis occur in many HIV - infected individuals , resulting in symptomatic heart failure in up to 5 % of patients .|Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( AIDS ) , but has resulted in an increase in cardiac and skeletal myopathies .|METHODS AND RESULTS : In order to investigate whether the HAART component zidovudine ( 3 ' - azido - 2 ' , 3 ' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of DCM , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .|After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .|NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function .|In contrast , AZT - treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .|These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .|These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .|CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced cardiomyopathy due to activation of apoptotic pathways , resulting in cardiac dilation and dysfunction .	1:Positive_Correlation:2	L2R	NON-CROSS	1-3	7-8	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	1:Association:2	L2R	NON-CROSS	1-3	10-11	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	10:335	11:336	0:9	1:Association:2	L2R	NON-CROSS	122-123	132-134	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation	DiseaseOrPhenotypicFeature	14:17:122:225	16:18:123:227	1:1:3:6	1:NR:2	L2R	CROSS	1-3	20-21	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D009205	myocarditis	DiseaseOrPhenotypicFeature	20	21	1	1:NR:2	L2R	CROSS	1-3	24-27	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D015658	HIV - infected	DiseaseOrPhenotypicFeature	24	27	1	1:NR:2	L2R	CROSS	1-3	32-34	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D006333	heart failure	DiseaseOrPhenotypicFeature	32	34	1	1:NR:2	L2R	CROSS	1-3	56-59	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D000163	acquired immunodeficiency syndrome|AIDS	DiseaseOrPhenotypicFeature	56:60	59:61	2:2	1:NR:2	L2R	CROSS	70-74	132-134	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	C538496	cardiac and skeletal myopathies	DiseaseOrPhenotypicFeature	70	74	2	1:NR:2	L2R	NON-CROSS	106-107	132-134	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:NR:2	L2R	NON-CROSS	132-134	138-139	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:NR:2	L2R	CROSS	228-231	313-315	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D000275	depressed cardiac function	DiseaseOrPhenotypicFeature	228	231	6	1:NR:2	L2R	CROSS	240-241	313-315	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D007249	inflammatory	DiseaseOrPhenotypicFeature	240	241	6	1:NR:2	L2R	CROSS	266-268	313-315	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	CROSS	271-273	313-315	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	293-294	313-315	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	295-298	313-315	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	NON-CROSS	313-315	345-349	356	Fas ligand|Fas ligand|Fas ligand	GeneOrGeneProduct	1:132:313	3:134:315	0:3:9	D002311,D006331	cardiac dilation and dysfunction	DiseaseOrPhenotypicFeature	345	349	9	1:Positive_Correlation:2	L2R	NON-CROSS	7-8	10-11	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	10:335	11:336	0:9	1:Positive_Correlation:2	L2R	NON-CROSS	7-8	14-16	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation	DiseaseOrPhenotypicFeature	14:17:122:225	16:18:123:227	1:1:3:6	1:NR:2	L2R	CROSS	7-8	20-21	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D009205	myocarditis	DiseaseOrPhenotypicFeature	20	21	1	1:NR:2	L2R	CROSS	7-8	24-27	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D015658	HIV - infected	DiseaseOrPhenotypicFeature	24	27	1	1:NR:2	L2R	CROSS	7-8	32-34	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D006333	heart failure	DiseaseOrPhenotypicFeature	32	34	1	1:NR:2	L2R	CROSS	60-61	87-88	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D000163	acquired immunodeficiency syndrome|AIDS	DiseaseOrPhenotypicFeature	56:60	59:61	2:2	1:NR:2	L2R	CROSS	70-74	102-103	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	C538496	cardiac and skeletal myopathies	DiseaseOrPhenotypicFeature	70	74	2	1:Positive_Correlation:2	L2R	NON-CROSS	102-103	106-107	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:Association:2	L2R	NON-CROSS	218-219	221-222	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	218-219	228-231	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D000275	depressed cardiac function	DiseaseOrPhenotypicFeature	228	231	6	1:NR:2	L2R	NON-CROSS	218-219	240-241	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D007249	inflammatory	DiseaseOrPhenotypicFeature	240	241	6	1:Positive_Correlation:2	R2L	CROSS	266-268	218-219	12367	caspase 3	GeneOrGeneProduct	266	268	7	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	1:Association:2	L2R	CROSS	218-219	271-273	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	218-219	293-294	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	218-219	295-298	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	218-219	345-349	D015215	AZT|zidovudine|3 ' - azido - 2 ' , 3 ' - deoxythymidine|AZT|AZT|AZT	ChemicalEntity	7:87:89:102:157:218	8:88:101:103:158:219	0:3:3:3:3:6	D002311,D006331	cardiac dilation and dysfunction	DiseaseOrPhenotypicFeature	345	349	9	1:NR:2	L2R	CROSS	256-257	335-336	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	10:335	11:336	0:9	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:NR:2	L2R	CROSS	258-259	335-336	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	10:335	11:336	0:9	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:NR:2	L2R	CROSS	266-268	335-336	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	10:335	11:336	0:9	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	CROSS	271-273	335-336	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	10:335	11:336	0:9	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	293-294	335-336	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	10:335	11:336	0:9	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	295-298	335-336	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	10:335	11:336	0:9	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:Association:2	L2R	NON-CROSS	106-107	122-123	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation	DiseaseOrPhenotypicFeature	14:17:122:225	16:18:123:227	1:1:3:6	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:Association:2	R2L	NON-CROSS	225-227	221-222	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation	DiseaseOrPhenotypicFeature	14:17:122:225	16:18:123:227	1:1:3:6	1:Association:2	L2R	CROSS	225-227	266-268	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation	DiseaseOrPhenotypicFeature	14:17:122:225	16:18:123:227	1:1:3:6	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:Association:2	L2R	CROSS	225-227	271-273	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation	DiseaseOrPhenotypicFeature	14:17:122:225	16:18:123:227	1:1:3:6	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	225-227	293-294	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation	DiseaseOrPhenotypicFeature	14:17:122:225	16:18:123:227	1:1:3:6	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	225-227	295-298	D002311	Dilated cardiomyopathy|DCM|DCM|cardiac dilation	DiseaseOrPhenotypicFeature	14:17:122:225	16:18:123:227	1:1:3:6	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	20-21	106-107	D009205	myocarditis	DiseaseOrPhenotypicFeature	20	21	1	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:NR:2	L2R	CROSS	20-21	138-139	D009205	myocarditis	DiseaseOrPhenotypicFeature	20	21	1	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:NR:2	L2R	CROSS	20-21	266-268	D009205	myocarditis	DiseaseOrPhenotypicFeature	20	21	1	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	CROSS	20-21	271-273	D009205	myocarditis	DiseaseOrPhenotypicFeature	20	21	1	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	20-21	293-294	D009205	myocarditis	DiseaseOrPhenotypicFeature	20	21	1	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	20-21	295-298	D009205	myocarditis	DiseaseOrPhenotypicFeature	20	21	1	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	24-27	106-107	D015658	HIV - infected	DiseaseOrPhenotypicFeature	24	27	1	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:NR:2	L2R	CROSS	24-27	138-139	D015658	HIV - infected	DiseaseOrPhenotypicFeature	24	27	1	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:NR:2	L2R	CROSS	24-27	266-268	D015658	HIV - infected	DiseaseOrPhenotypicFeature	24	27	1	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	CROSS	24-27	271-273	D015658	HIV - infected	DiseaseOrPhenotypicFeature	24	27	1	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	24-27	293-294	D015658	HIV - infected	DiseaseOrPhenotypicFeature	24	27	1	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	24-27	295-298	D015658	HIV - infected	DiseaseOrPhenotypicFeature	24	27	1	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	32-34	106-107	D006333	heart failure	DiseaseOrPhenotypicFeature	32	34	1	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:NR:2	L2R	CROSS	32-34	138-139	D006333	heart failure	DiseaseOrPhenotypicFeature	32	34	1	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:NR:2	L2R	CROSS	32-34	266-268	D006333	heart failure	DiseaseOrPhenotypicFeature	32	34	1	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	CROSS	32-34	271-273	D006333	heart failure	DiseaseOrPhenotypicFeature	32	34	1	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	32-34	293-294	D006333	heart failure	DiseaseOrPhenotypicFeature	32	34	1	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	32-34	295-298	D006333	heart failure	DiseaseOrPhenotypicFeature	32	34	1	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	60-61	106-107	D000163	acquired immunodeficiency syndrome|AIDS	DiseaseOrPhenotypicFeature	56:60	59:61	2:2	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:NR:2	L2R	CROSS	60-61	138-139	D000163	acquired immunodeficiency syndrome|AIDS	DiseaseOrPhenotypicFeature	56:60	59:61	2:2	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:NR:2	L2R	CROSS	60-61	266-268	D000163	acquired immunodeficiency syndrome|AIDS	DiseaseOrPhenotypicFeature	56:60	59:61	2:2	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	CROSS	60-61	271-273	D000163	acquired immunodeficiency syndrome|AIDS	DiseaseOrPhenotypicFeature	56:60	59:61	2:2	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	60-61	293-294	D000163	acquired immunodeficiency syndrome|AIDS	DiseaseOrPhenotypicFeature	56:60	59:61	2:2	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	60-61	295-298	D000163	acquired immunodeficiency syndrome|AIDS	DiseaseOrPhenotypicFeature	56:60	59:61	2:2	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	70-74	106-107	C538496	cardiac and skeletal myopathies	DiseaseOrPhenotypicFeature	70	74	2	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:NR:2	L2R	CROSS	70-74	138-139	C538496	cardiac and skeletal myopathies	DiseaseOrPhenotypicFeature	70	74	2	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:NR:2	L2R	CROSS	70-74	266-268	C538496	cardiac and skeletal myopathies	DiseaseOrPhenotypicFeature	70	74	2	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	CROSS	70-74	271-273	C538496	cardiac and skeletal myopathies	DiseaseOrPhenotypicFeature	70	74	2	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	70-74	293-294	C538496	cardiac and skeletal myopathies	DiseaseOrPhenotypicFeature	70	74	2	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	70-74	295-298	C538496	cardiac and skeletal myopathies	DiseaseOrPhenotypicFeature	70	74	2	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	NON-CROSS	256-257	258-259	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	1:Association:2	R2L	CROSS	256-257	228-231	D000275	depressed cardiac function	DiseaseOrPhenotypicFeature	228	231	6	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	1:NR:2	L2R	CROSS	240-241	256-257	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	D007249	inflammatory	DiseaseOrPhenotypicFeature	240	241	6	1:NR:2	L2R	NON-CROSS	256-257	266-268	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	NON-CROSS	256-257	271-273	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	256-257	293-294	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	256-257	295-298	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	256-257	345-349	355	Fas|Fas	GeneOrGeneProduct	106:256	107:257	3:7	D002311,D006331	cardiac dilation and dysfunction	DiseaseOrPhenotypicFeature	345	349	9	1:Association:2	L2R	NON-CROSS	221-222	228-231	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	D000275	depressed cardiac function	DiseaseOrPhenotypicFeature	228	231	6	1:NR:2	L2R	NON-CROSS	240-241	258-259	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	D007249	inflammatory	DiseaseOrPhenotypicFeature	240	241	6	1:NR:2	L2R	NON-CROSS	258-259	266-268	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	NON-CROSS	258-259	271-273	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	258-259	293-294	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	258-259	295-298	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	258-259	345-349	14103	FasL|FasL|FasL|FasL	GeneOrGeneProduct	138:201:221:258	139:202:222:259	3:5:6:7	D002311,D006331	cardiac dilation and dysfunction	DiseaseOrPhenotypicFeature	345	349	9	1:Association:2	L2R	CROSS	228-231	266-268	D000275	depressed cardiac function	DiseaseOrPhenotypicFeature	228	231	6	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:Association:2	L2R	CROSS	228-231	271-273	D000275	depressed cardiac function	DiseaseOrPhenotypicFeature	228	231	6	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	228-231	293-294	D000275	depressed cardiac function	DiseaseOrPhenotypicFeature	228	231	6	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	228-231	295-298	D000275	depressed cardiac function	DiseaseOrPhenotypicFeature	228	231	6	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	240-241	266-268	D007249	inflammatory	DiseaseOrPhenotypicFeature	240	241	6	12367	caspase 3	GeneOrGeneProduct	266	268	7	1:NR:2	L2R	CROSS	240-241	271-273	D007249	inflammatory	DiseaseOrPhenotypicFeature	240	241	6	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	240-241	293-294	D007249	inflammatory	DiseaseOrPhenotypicFeature	240	241	6	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	240-241	295-298	D007249	inflammatory	DiseaseOrPhenotypicFeature	240	241	6	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	NON-CROSS	266-268	271-273	12367	caspase 3	GeneOrGeneProduct	266	268	7	12333	calpain 1	GeneOrGeneProduct	271	273	7	1:NR:2	L2R	CROSS	266-268	293-294	12367	caspase 3	GeneOrGeneProduct	266	268	7	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	266-268	295-298	12367	caspase 3	GeneOrGeneProduct	266	268	7	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	266-268	345-349	12367	caspase 3	GeneOrGeneProduct	266	268	7	D002311,D006331	cardiac dilation and dysfunction	DiseaseOrPhenotypicFeature	345	349	9	1:NR:2	L2R	CROSS	271-273	293-294	12333	calpain 1	GeneOrGeneProduct	271	273	7	13405	dystrophin	GeneOrGeneProduct	293	294	8	1:NR:2	L2R	CROSS	271-273	295-298	12333	calpain 1	GeneOrGeneProduct	271	273	7	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	271-273	345-349	12333	calpain 1	GeneOrGeneProduct	271	273	7	D002311,D006331	cardiac dilation and dysfunction	DiseaseOrPhenotypicFeature	345	349	9	1:NR:2	L2R	NON-CROSS	293-294	295-298	13405	dystrophin	GeneOrGeneProduct	293	294	8	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	1:NR:2	L2R	CROSS	293-294	345-349	13405	dystrophin	GeneOrGeneProduct	293	294	8	D002311,D006331	cardiac dilation and dysfunction	DiseaseOrPhenotypicFeature	345	349	9	1:NR:2	L2R	CROSS	295-298	345-349	21954	cardiac troponin I	GeneOrGeneProduct	295	298	8	D002311,D006331	cardiac dilation and dysfunction	DiseaseOrPhenotypicFeature	345	349	9
21042587	Familial glucocorticoid receptor haploinsufficiency by non - sense mediated mRNA decay , adrenal hyperplasia and apparent mineralocorticoid excess .|Primary glucocorticoid resistance ( OMIM 138040 ) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action , due to genetic alterations of the glucocorticoid receptor ( GR ) .|Investigation of adrenal incidentalomas led to the discovery of a family ( eight affected individuals spanning three generations ) , prone to cortisol resistance , bilateral adrenal hyperplasia , arterial hypertension and hypokalemia .|This phenotype exacerbated over time , cosegregates with the first heterozygous nonsense mutation p . R469 [ R , X ] reported to date for the GR , replacing an arginine ( CGA ) by a stop ( TGA ) at amino - acid 469 in the second zinc finger of the DNA - binding domain of the receptor .|In vitro , this mutation leads to a truncated 50 - kDa GR lacking hormone and DNA binding capacity , devoid of hormone - dependent nuclear translocation and transactivation properties .|In the proband 's fibroblasts , we provided evidence for the lack of expression of the defective allele in vivo .|The absence of detectable mutated GR mRNA was accompanied by a 50 % reduction in wild type GR transcript and protein .|This reduced GR expression leads to a significantly below - normal induction of glucocorticoid - induced target genes , FKBP5 in fibroblasts .|We demonstrated that the molecular mechanisms of glucocorticoid signaling dysfunction involved GR haploinsufficiency due to the selective degradation of the mutated GR transcript through a nonsense - mediated mRNA Decay that was experimentally validated on emetine - treated propositus ' fibroblasts .|GR haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance .|Indeed , apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone - tetrahydrocortisol ratio in affected patients , revealing reduced glucocorticoid degradation by renal activity of the 11b - hydroxysteroid dehydrogenase type 2 , a GR regulated gene .|We propose thus that GR haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism , incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid - independent hypertension .	1:Association:2	L2R	NON-CROSS	1-3	12-14	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	1:Association:2	L2R	NON-CROSS	1-3	15-18	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	1:Association:2	L2R	NON-CROSS	1-3	20-22	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	1:NR:2	L2R	NON-CROSS	1-3	23-25	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	1:NR:2	L2R	NON-CROSS	29-31	47-49	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	1:Bind:2	L2R	NON-CROSS	359-360	362-363	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	1:Association:2	L2R	CROSS	50-51	55-57	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	1:Association:2	L2R	CROSS	50-51	75-77	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	1:Association:2	L2R	NON-CROSS	286-287	290-291	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	1:Association:2	L2R	CROSS	85-86	113-114	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	1:Positive_Correlation:2	L2R	NON-CROSS	240-241	255-256	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	NON-CROSS	279-280	286-287	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D004640	emetine	ChemicalEntity	279	280	8	1:Association:2	L2R	NON-CROSS	286-287	297-299	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	NON-CROSS	286-287	301-302	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	NON-CROSS	286-287	306-307	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	NON-CROSS	326-327	351-352	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	NON-CROSS	328-329	351-352	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:Association:2	R2L	NON-CROSS	351-352	343-349	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	1:Association:2	L2R	NON-CROSS	359-360	373-374	2908	glucocorticoid receptor|glucocorticoid receptor|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR|GR	GeneOrGeneProduct	1:47:50:113:159:204:216:223:255:265:286:351:359	3:49:51:114:160:205:217:224:256:266:287:352:360	0:1:1:3:4:6:6:7:8:8:9:10:11	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:Association:2	L2R	NON-CROSS	362-363	377-380	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	1:Association:2	R2L	CROSS	100-108	78-81	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	1:NR:2	L2R	CROSS	240-241	377-380	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	279-280	377-380	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	297-299	377-380	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	301-302	377-380	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	NON-CROSS	377-380	381-382	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	326-327	377-380	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	328-329	377-380	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	343-349	377-380	D000312	adrenal hyperplasia|bilateral adrenal hyperplasia|bilateral adrenal hyperplasia	DiseaseOrPhenotypicFeature	12:78:377	14:81:380	0:2:11	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	NON-CROSS	316-319	336-337	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	1:NR:2	L2R	CROSS	15-18	100-108	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	1:NR:2	L2R	CROSS	240-241	316-319	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	279-280	316-319	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	297-299	316-319	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	301-302	316-319	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	306-307	316-319	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:Association:2	L2R	NON-CROSS	316-319	326-327	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:Association:2	L2R	NON-CROSS	316-319	328-329	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	NON-CROSS	316-319	343-349	C537422	apparent mineralocorticoid excess|apparent mineralocorticoid excess	DiseaseOrPhenotypicFeature	15:316	18:319	0:10	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:Association:2	L2R	NON-CROSS	20-22	38-39	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	1:NR:2	L2R	CROSS	20-22	100-108	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	1:NR:2	L2R	CROSS	240-241	311-313	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	279-280	311-313	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	NON-CROSS	297-299	311-313	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	NON-CROSS	301-302	311-313	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	NON-CROSS	306-307	311-313	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	311-313	326-327	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	311-313	328-329	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	311-313	343-349	C564221	glucocorticoid resistance|glucocorticoid resistance	DiseaseOrPhenotypicFeature	20:311	22:313	1:9	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	NON-CROSS	23-25	38-39	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	1:NR:2	L2R	CROSS	23-25	100-108	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	1:NR:2	L2R	CROSS	23-25	240-241	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	23-25	279-280	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	23-25	297-299	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	23-25	301-302	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	23-25	306-307	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	23-25	326-327	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	23-25	328-329	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	23-25	343-349	OMIM:138040	OMIM 138040	DiseaseOrPhenotypicFeature	23	25	1	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	NON-CROSS	29-31	38-39	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	1:NR:2	L2R	CROSS	29-31	100-108	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	1:NR:2	L2R	CROSS	29-31	240-241	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	29-31	279-280	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	29-31	297-299	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	29-31	301-302	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	29-31	306-307	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	29-31	326-327	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	29-31	328-329	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	29-31	343-349	D030342	hereditary disease	DiseaseOrPhenotypicFeature	29	31	1	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	CROSS	38-39	55-57	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	1:NR:2	L2R	CROSS	38-39	75-77	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	1:NR:2	L2R	NON-CROSS	362-363	384-385	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	1:NR:2	L2R	CROSS	38-39	85-86	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	1:NR:2	L2R	CROSS	38-39	100-108	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	1:Positive_Correlation:2	L2R	NON-CROSS	234-235	240-241	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	NON-CROSS	251-252	279-280	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	297-299	336-337	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	301-302	336-337	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	NON-CROSS	362-363	381-382	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	NON-CROSS	326-327	336-337	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	NON-CROSS	328-329	336-337	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:Positive_Correlation:2	L2R	NON-CROSS	336-337	343-349	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:Association:2	L2R	NON-CROSS	362-363	373-374	D005938	glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid|glucocorticoid	ChemicalEntity	38:234:251:336:362	39:235:252:337:363	1:7:8:10:11	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:Association:2	R2L	CROSS	100-108	55-57	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	1:NR:2	L2R	CROSS	55-57	240-241	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	55-57	279-280	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	55-57	297-299	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	55-57	301-302	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	55-57	306-307	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	55-57	326-327	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	55-57	328-329	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	55-57	343-349	C538238	adrenal incidentalomas	DiseaseOrPhenotypicFeature	55	57	2	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:Association:2	R2L	CROSS	100-108	75-77	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	1:NR:2	L2R	CROSS	75-77	240-241	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	75-77	279-280	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	75-77	297-299	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	75-77	301-302	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	75-77	306-307	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	75-77	326-327	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	75-77	328-329	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	75-77	343-349	C535280	cortisol resistance	DiseaseOrPhenotypicFeature	75	77	2	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:Association:2	R2L	CROSS	100-108	83-84	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	1:NR:2	L2R	CROSS	240-241	290-291	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	279-280	290-291	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	D004640	emetine	ChemicalEntity	279	280	8	1:Association:2	L2R	NON-CROSS	290-291	297-299	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:Association:2	L2R	NON-CROSS	290-291	301-302	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	NON-CROSS	381-382	384-385	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	290-291	326-327	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	290-291	328-329	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	343-349	384-385	D006973	hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	83:290:384	84:291:385	2:9:11	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:Association:2	R2L	CROSS	100-108	85-86	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	1:NR:2	L2R	CROSS	85-86	240-241	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	2289	FKBP5	GeneOrGeneProduct	240	241	7	1:NR:2	L2R	CROSS	85-86	279-280	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	85-86	297-299	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	85-86	301-302	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	85-86	306-307	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	85-86	326-327	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	85-86	328-329	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	85-86	343-349	D007008	hypokalemia	DiseaseOrPhenotypicFeature	85	86	2	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	CROSS	117-132	279-280	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	117-132	301-302	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	117-132	306-307	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	117-132	326-327	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	117-132	328-329	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	117-132	373-374	p|SUB|R|469|X	p . R469 [ R , X ]|arginine ( CGA ) by a stop ( TGA ) at amino - acid 469	SequenceVariant	100:117	108:132	3:3	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:NR:2	L2R	CROSS	240-241	279-280	2289	FKBP5	GeneOrGeneProduct	240	241	7	D004640	emetine	ChemicalEntity	279	280	8	1:NR:2	L2R	CROSS	240-241	297-299	2289	FKBP5	GeneOrGeneProduct	240	241	7	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	240-241	301-302	2289	FKBP5	GeneOrGeneProduct	240	241	7	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	240-241	306-307	2289	FKBP5	GeneOrGeneProduct	240	241	7	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	240-241	326-327	2289	FKBP5	GeneOrGeneProduct	240	241	7	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	240-241	328-329	2289	FKBP5	GeneOrGeneProduct	240	241	7	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	240-241	343-349	2289	FKBP5	GeneOrGeneProduct	240	241	7	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	CROSS	240-241	373-374	2289	FKBP5	GeneOrGeneProduct	240	241	7	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:NR:2	L2R	CROSS	279-280	297-299	D004640	emetine	ChemicalEntity	279	280	8	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	1:NR:2	L2R	CROSS	279-280	301-302	D004640	emetine	ChemicalEntity	279	280	8	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	CROSS	279-280	306-307	D004640	emetine	ChemicalEntity	279	280	8	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	279-280	326-327	D004640	emetine	ChemicalEntity	279	280	8	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	279-280	328-329	D004640	emetine	ChemicalEntity	279	280	8	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	279-280	343-349	D004640	emetine	ChemicalEntity	279	280	8	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	CROSS	279-280	373-374	D004640	emetine	ChemicalEntity	279	280	8	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:Association:2	L2R	NON-CROSS	297-299	301-302	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	D006854	cortisol	ChemicalEntity	301	302	9	1:NR:2	L2R	NON-CROSS	297-299	306-307	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	297-299	326-327	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	297-299	328-329	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	297-299	343-349	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	CROSS	297-299	373-374	4306	mineralocorticoid receptor	GeneOrGeneProduct	297	299	9	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:NR:2	L2R	NON-CROSS	301-302	306-307	D006854	cortisol	ChemicalEntity	301	302	9	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	1:NR:2	L2R	CROSS	301-302	326-327	D006854	cortisol	ChemicalEntity	301	302	9	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	301-302	328-329	D006854	cortisol	ChemicalEntity	301	302	9	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	301-302	343-349	D006854	cortisol	ChemicalEntity	301	302	9	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	CROSS	301-302	373-374	D006854	cortisol	ChemicalEntity	301	302	9	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:NR:2	L2R	CROSS	306-307	326-327	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	1:NR:2	L2R	CROSS	306-307	328-329	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	CROSS	343-349	381-382	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	NON-CROSS	373-374	381-382	D008901	mineralocorticoid|mineralocorticoid	ChemicalEntity	306:381	307:382	9:11	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:NR:2	L2R	NON-CROSS	326-327	328-329	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	1:NR:2	L2R	NON-CROSS	326-327	343-349	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	CROSS	326-327	373-374	D013761	tetrahydrocortisone	ChemicalEntity	326	327	10	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:NR:2	L2R	NON-CROSS	328-329	343-349	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	1:NR:2	L2R	CROSS	328-329	373-374	D013760	tetrahydrocortisol	ChemicalEntity	328	329	10	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11	1:NR:2	L2R	CROSS	343-349	373-374	3291	11b - hydroxysteroid dehydrogenase type 2	GeneOrGeneProduct	343	349	10	D003480	hypercortisolism	DiseaseOrPhenotypicFeature	373	374	11
16051693	Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease ( NAFLD ) .|Phosphatidylethanolamine N - methyltransferase ( PEMT ) catalyzes phosphatidylcholine synthesis .|PEMT knockout mice have fatty livers , and it is possible that , in humans , nonalcoholic fatty liver disease ( NAFLD ) might be associated with PEMT gene polymorphisms .|DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT , which leads to a V175M substitution .|V175M is a loss of function mutation , as determined by transiently transfecting McArdle - RH7777 cells with constructs of wild - type PEMT open reading frame or the V175M mutant .|Met / Met at residue 175 ( loss of function SNP ) occurred in 67 . 9 % of the NAFLD subjects and in only 40 . 7 % of control subjects ( P < 0 . 03 ) .|For the first time we report that a polymorphism of the human PEMT gene ( V175M ) is associated with diminished activity and may confer susceptibility to NAFLD .	1:Association:2	L2R	NON-CROSS	13-14	16-20	10400	PEMT|Phosphatidylethanolamine N - methyltransferase|PEMT|PEMT|PEMT|PEMT	GeneOrGeneProduct	3:16:21:54:83:176	4:20:22:55:84:177	0:1:1:2:3:6	D065626	nonalcoholic fatty liver disease|NAFLD|nonalcoholic fatty liver disease|NAFLD|NAFLD|NAFLD|NAFLD	DiseaseOrPhenotypicFeature	8:13:43:48:71:144:191	12:14:47:49:72:145:192	0:0:2:2:3:5:6	1:Positive_Correlation:2	L2R	NON-CROSS	21-22	24-25	10400	PEMT|Phosphatidylethanolamine N - methyltransferase|PEMT|PEMT|PEMT|PEMT	GeneOrGeneProduct	3:16:21:54:83:176	4:20:22:55:84:177	0:1:1:2:3:6	D010713	phosphatidylcholine	ChemicalEntity	24	25	1	1:NR:2	L2R	NON-CROSS	21-22	27-28	10400	PEMT|Phosphatidylethanolamine N - methyltransferase|PEMT|PEMT|PEMT|PEMT	GeneOrGeneProduct	3:16:21:54:83:176	4:20:22:55:84:177	0:1:1:2:3:6	18618	PEMT	GeneOrGeneProduct	27	28	2	1:NR:2	L2R	NON-CROSS	21-22	31-33	10400	PEMT|Phosphatidylethanolamine N - methyltransferase|PEMT|PEMT|PEMT|PEMT	GeneOrGeneProduct	3:16:21:54:83:176	4:20:22:55:84:177	0:1:1:2:3:6	D005234	fatty livers|fatty liver	DiseaseOrPhenotypicFeature	31:64	33:66	2:3	1:NR:2	L2R	CROSS	83-84	115-116	10400	PEMT|Phosphatidylethanolamine N - methyltransferase|PEMT|PEMT|PEMT|PEMT	GeneOrGeneProduct	3:16:21:54:83:176	4:20:22:55:84:177	0:1:1:2:3:6	25511	PEMT	GeneOrGeneProduct	115	116	4	1:NR:2	L2R	CROSS	13-14	24-25	D065626	nonalcoholic fatty liver disease|NAFLD|nonalcoholic fatty liver disease|NAFLD|NAFLD|NAFLD|NAFLD	DiseaseOrPhenotypicFeature	8:13:43:48:71:144:191	12:14:47:49:72:145:192	0:0:2:2:3:5:6	D010713	phosphatidylcholine	ChemicalEntity	24	25	1	1:NR:2	L2R	NON-CROSS	13-14	27-28	D065626	nonalcoholic fatty liver disease|NAFLD|nonalcoholic fatty liver disease|NAFLD|NAFLD|NAFLD|NAFLD	DiseaseOrPhenotypicFeature	8:13:43:48:71:144:191	12:14:47:49:72:145:192	0:0:2:2:3:5:6	18618	PEMT	GeneOrGeneProduct	27	28	2	1:Positive_Correlation:2	L2R	NON-CROSS	179-180	191-192	D065626	nonalcoholic fatty liver disease|NAFLD|nonalcoholic fatty liver disease|NAFLD|NAFLD|NAFLD|NAFLD	DiseaseOrPhenotypicFeature	8:13:43:48:71:144:191	12:14:47:49:72:145:192	0:0:2:2:3:5:6	rs7946	V175M|V175M|V175M|Met / Met at residue 175|V175M	SequenceVariant	89:92:121:124:179	90:93:122:130:180	3:4:4:5:6	1:Association:2	R2L	CROSS	144-145	115-116	25511	PEMT	GeneOrGeneProduct	115	116	4	D065626	nonalcoholic fatty liver disease|NAFLD|nonalcoholic fatty liver disease|NAFLD|NAFLD|NAFLD|NAFLD	DiseaseOrPhenotypicFeature	8:13:43:48:71:144:191	12:14:47:49:72:145:192	0:0:2:2:3:5:6	1:NR:2	L2R	CROSS	24-25	27-28	D010713	phosphatidylcholine	ChemicalEntity	24	25	1	18618	PEMT	GeneOrGeneProduct	27	28	2	1:NR:2	L2R	CROSS	24-25	31-33	D010713	phosphatidylcholine	ChemicalEntity	24	25	1	D005234	fatty livers|fatty liver	DiseaseOrPhenotypicFeature	31:64	33:66	2:3	1:NR:2	L2R	CROSS	24-25	89-90	D010713	phosphatidylcholine	ChemicalEntity	24	25	1	rs7946	V175M|V175M|V175M|Met / Met at residue 175|V175M	SequenceVariant	89:92:121:124:179	90:93:122:130:180	3:4:4:5:6	1:NR:2	L2R	CROSS	24-25	115-116	D010713	phosphatidylcholine	ChemicalEntity	24	25	1	25511	PEMT	GeneOrGeneProduct	115	116	4	1:Negative_Correlation:2	L2R	NON-CROSS	27-28	31-33	18618	PEMT	GeneOrGeneProduct	27	28	2	D005234	fatty livers|fatty liver	DiseaseOrPhenotypicFeature	31:64	33:66	2:3	1:NR:2	L2R	CROSS	27-28	115-116	18618	PEMT	GeneOrGeneProduct	27	28	2	25511	PEMT	GeneOrGeneProduct	115	116	4	1:NR:2	L2R	NON-CROSS	64-66	89-90	D005234	fatty livers|fatty liver	DiseaseOrPhenotypicFeature	31:64	33:66	2:3	rs7946	V175M|V175M|V175M|Met / Met at residue 175|V175M	SequenceVariant	89:92:121:124:179	90:93:122:130:180	3:4:4:5:6	1:NR:2	L2R	CROSS	64-66	115-116	D005234	fatty livers|fatty liver	DiseaseOrPhenotypicFeature	31:64	33:66	2:3	25511	PEMT	GeneOrGeneProduct	115	116	4
19880293	Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients .|BACKGROUND : Psoriasis is a common dermatological disorder , in which autoimmunity plays an important role .|CD4 ( + ) CD25 ( + ) regulatory T cells ( T - regs ) have been suggested to be involved in the pathogenesis of some autoimmune diseases .|T - regs express the fork head / winged helix transcription factor , FOXP3 , which appears to be of key importance in the development and function of T - regs .|Studies have found that single - nucleotide polymorphisms ( SNPs ) in the FOXP3 gene contribute to susceptibility to some autoimmune disorders .|However , information about FOXP3 gene in psoriasis is limited .|OBJECTIVE : This study evaluated the association between FOXP3 gene SNPs and susceptibility to psoriasis in a Han Chinese population .|METHODS : In a hospital - based case - control study , 524 patients with psoriasis and 549 psoriasis - free controls were recruited according to age and gender .|We investigated four SNPs in the FOXP3 gene ( - 6054 , deletion / ATT ; - 3279 , A / C ; - 924 , A / G ; IVS9 + 459 , A / G ) in psoriatic patients , and assessed allele and genotype frequencies in psoriatic patients ( 237 females , 287 males ) and normal controls ( 272 females , 277 males ) .|The polymorphisms were genotyped using the PCR sequence - specific primer ( PCR - SSP ) technique and PCR - restriction fragment length polymorphism ( RFLP ) analysis .|RESULTS : We found that increased risk of psoriasis was associated with the FOXP3 - 3279 AC genotype ( adjusted OR , 1 . 32 ; 95 % CI , 1 . 01 - 1 . 74 ) and the combined AC + AA genotype ( adjusted OR , 1 . 38 ; 95 % CI , 1 . 07 - 1 . 78 ) , compared with the - 3279 CC genotype .|We also found that an increased risk of psoriasis was associated with the FOXP3 IVS9 + 459 GG genotype ( adjusted OR , 2 . 24 ; 95 % CI , 1 . 41 - 3 . 58 ) .|However , the combined GA + GG genotype showed no such tendency ( adjusted OR = 1 . 28 ; 95 % CI , 1 . 00 - 1 . 64 ) , compared with the IVS9 + 459 AA genotype .|There was no evidence of an increased risk associated with the FOXP3 - 6054 deletion / ATT or FOXP3 - 924 A / G genotype .|In combined genotype analyses , the FOXP3 - 3279 AC + AA genotype was more obviously associated in males ( adjusted OR = 1 . 60 , 95 % CI = 1 . 11 - 2 . 31 ) and severe psoriasis patients ( PASI score > 20 ; adjusted OR = 1 . 97 , 95 % CI = 1 . 41 - 2 . 75 ) .|Meanwhile , the FOXP3 IVS9 + 459 GA + GG genotype was also associated with severe psoriasis patients ( adjusted OR = 1 . 69 , 95 % CI = 1 . 21 - 2 . 36 ) .|CONCLUSIONS : FOXP3 polymorphisms appear to contribute to the risk of psoriasis in a Han Chinese population .|Larger studies are needed to confirm these findings .	1:Association:2	L2R	NON-CROSS	117-118	120-121	50943	FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3	GeneOrGeneProduct	3:71:103:117:132:181:286:360:440:447:461:527:565	4:72:104:118:133:182:287:361:441:448:462:528:566	0:3:4:5:6:8:10:11:13:13:14:15:16	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	1:NR:2	L2R	CROSS	3-4	17-19	50943	FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3	GeneOrGeneProduct	3:71:103:117:132:181:286:360:440:447:461:527:565	4:72:104:118:133:182:287:361:441:448:462:528:566	0:3:4:5:6:8:10:11:13:13:14:15:16	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	1:NR:2	L2R	CROSS	3-4	28-29	50943	FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3	GeneOrGeneProduct	3:71:103:117:132:181:286:360:440:447:461:527:565	4:72:104:118:133:182:287:361:441:448:462:528:566	0:3:4:5:6:8:10:11:13:13:14:15:16	920	CD4	GeneOrGeneProduct	28	29	2	1:NR:2	L2R	CROSS	3-4	32-33	50943	FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3	GeneOrGeneProduct	3:71:103:117:132:181:286:360:440:447:461:527:565	4:72:104:118:133:182:287:361:441:448:462:528:566	0:3:4:5:6:8:10:11:13:13:14:15:16	3559	CD25	GeneOrGeneProduct	32	33	2	1:Association:2	L2R	NON-CROSS	110-112	117-118	50943	FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3|FOXP3	GeneOrGeneProduct	3:71:103:117:132:181:286:360:440:447:461:527:565	4:72:104:118:133:182:287:361:441:448:462:528:566	0:3:4:5:6:8:10:11:13:13:14:15:16	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	1:NR:2	L2R	CROSS	13-14	28-29	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	920	CD4	GeneOrGeneProduct	28	29	2	1:NR:2	L2R	CROSS	13-14	32-33	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	3559	CD25	GeneOrGeneProduct	32	33	2	1:NR:2	L2R	NON-CROSS	163-164	184-190	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	c|DEL|-6054|ATT	- 6054 , deletion / ATT|- 6054 deletion / ATT	SequenceVariant	184:441	190:446	8:13	1:NR:2	L2R	NON-CROSS	191-197	214-215	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	c|SUB|A|-3279|C	- 3279 , A / C	SequenceVariant	191	197	8	1:NR:2	L2R	NON-CROSS	198-204	214-215	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	c|SUB|A|-924|G	- 924 , A / G|- 924 A / G	SequenceVariant	198:448	204:453	8:13	1:NR:2	L2R	NON-CROSS	205-212	214-215	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	c|SUB|A|IVS9+459|G	IVS9 + 459 , A / G	SequenceVariant	205	212	8	1:Positive_Correlation:2	L2R	NON-CROSS	281-282	287-290	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	c|Allele|AC|-3297	- 3279 AC	SequenceVariant	287	290	10	1:NR:2	L2R	NON-CROSS	342-345	355-356	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	c|Allele|CC|-3279	- 3279 CC	SequenceVariant	342	345	10	1:Positive_Correlation:2	L2R	NON-CROSS	355-356	361-365	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	c|Allele|GG|IVS9+459	IVS9 + 459 GG	SequenceVariant	361	365	11	1:NR:2	L2R	CROSS	355-356	423-427	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	c|Allele|AA|IVS9+459	IVS9 + 459 AA	SequenceVariant	423	427	12	1:Association:2	R2L	NON-CROSS	496-497	462-467	c|Allele|AC|-3279	- 3279 AC + AA	SequenceVariant	462	467	14	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	1:Positive_Correlation:2	R2L	NON-CROSS	540-541	528-534	c|Allele|GA|IVS9+459	IVS9 + 459 GA + GG	SequenceVariant	528	534	15	D011565	psoriasis|Psoriasis|psoriasis|psoriasis|psoriasis|psoriasis|psoriatic|psoriatic|psoriasis|psoriasis|psoriasis|psoriasis|psoriasis	DiseaseOrPhenotypicFeature	8:13:120:138:160:163:214:224:281:355:496:540:574	9:14:121:139:161:164:215:225:282:356:497:541:575	0:1:5:6:7:7:8:8:10:11:14:15:16	1:NR:2	L2R	CROSS	17-19	28-29	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	920	CD4	GeneOrGeneProduct	28	29	2	1:NR:2	L2R	CROSS	17-19	32-33	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	3559	CD25	GeneOrGeneProduct	32	33	2	1:NR:2	L2R	CROSS	17-19	184-190	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|DEL|-6054|ATT	- 6054 , deletion / ATT|- 6054 deletion / ATT	SequenceVariant	184:441	190:446	8:13	1:NR:2	L2R	CROSS	17-19	191-197	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|SUB|A|-3279|C	- 3279 , A / C	SequenceVariant	191	197	8	1:NR:2	L2R	CROSS	17-19	198-204	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|SUB|A|-924|G	- 924 , A / G|- 924 A / G	SequenceVariant	198:448	204:453	8:13	1:NR:2	L2R	CROSS	17-19	205-212	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|SUB|A|IVS9+459|G	IVS9 + 459 , A / G	SequenceVariant	205	212	8	1:NR:2	L2R	CROSS	17-19	287-290	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|Allele|AC|-3297	- 3279 AC	SequenceVariant	287	290	10	1:NR:2	L2R	CROSS	17-19	342-345	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|Allele|CC|-3279	- 3279 CC	SequenceVariant	342	345	10	1:NR:2	L2R	CROSS	17-19	361-365	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|Allele|GG|IVS9+459	IVS9 + 459 GG	SequenceVariant	361	365	11	1:NR:2	L2R	CROSS	17-19	423-427	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|Allele|AA|IVS9+459	IVS9 + 459 AA	SequenceVariant	423	427	12	1:NR:2	L2R	CROSS	17-19	462-467	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|Allele|AC|-3279	- 3279 AC + AA	SequenceVariant	462	467	14	1:NR:2	L2R	CROSS	17-19	528-534	D012871	dermatological disorder	DiseaseOrPhenotypicFeature	17	19	1	c|Allele|GA|IVS9+459	IVS9 + 459 GA + GG	SequenceVariant	528	534	15	1:NR:2	L2R	NON-CROSS	28-29	32-33	920	CD4	GeneOrGeneProduct	28	29	2	3559	CD25	GeneOrGeneProduct	32	33	2	1:NR:2	L2R	NON-CROSS	28-29	55-57	920	CD4	GeneOrGeneProduct	28	29	2	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	1:NR:2	L2R	NON-CROSS	32-33	55-57	3559	CD25	GeneOrGeneProduct	32	33	2	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	1:NR:2	L2R	CROSS	110-112	184-190	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|DEL|-6054|ATT	- 6054 , deletion / ATT|- 6054 deletion / ATT	SequenceVariant	184:441	190:446	8:13	1:NR:2	L2R	CROSS	110-112	191-197	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|SUB|A|-3279|C	- 3279 , A / C	SequenceVariant	191	197	8	1:NR:2	L2R	CROSS	110-112	198-204	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|SUB|A|-924|G	- 924 , A / G|- 924 A / G	SequenceVariant	198:448	204:453	8:13	1:NR:2	L2R	CROSS	110-112	205-212	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|SUB|A|IVS9+459|G	IVS9 + 459 , A / G	SequenceVariant	205	212	8	1:NR:2	L2R	CROSS	110-112	287-290	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|Allele|AC|-3297	- 3279 AC	SequenceVariant	287	290	10	1:NR:2	L2R	CROSS	110-112	342-345	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|Allele|CC|-3279	- 3279 CC	SequenceVariant	342	345	10	1:NR:2	L2R	CROSS	110-112	361-365	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|Allele|GG|IVS9+459	IVS9 + 459 GG	SequenceVariant	361	365	11	1:NR:2	L2R	CROSS	110-112	423-427	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|Allele|AA|IVS9+459	IVS9 + 459 AA	SequenceVariant	423	427	12	1:NR:2	L2R	CROSS	110-112	462-467	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|Allele|AC|-3279	- 3279 AC + AA	SequenceVariant	462	467	14	1:NR:2	L2R	CROSS	110-112	528-534	D001327	autoimmune diseases|autoimmune disorders	DiseaseOrPhenotypicFeature	55:110	57:112	2:4	c|Allele|GA|IVS9+459	IVS9 + 459 GA + GG	SequenceVariant	528	534	15
21903317	Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia , hyperuricemia , and CKD .|Homozygous or compound heterozygous mutations in renin ( REN ) cause renal tubular dysgenesis , which is characterized by death in utero due to kidney failure and pulmonary hypoplasia .|The phenotype resembles the fetopathy caused by angiotensin - converting enzyme inhibitor or angiotensin receptor blocker intake during pregnancy .|Recently , heterozygous REN mutations were shown to result in early - onset hyperuricemia , anemia , and chronic kidney disease ( CKD ) .|To date , only 3 different heterozygous REN mutations have been published .|We report mutation analysis of the REN gene in 39 kindreds with hyperuricemia and CKD who previously tested negative for mutations in the UMOD ( uromodulin ) and HNF1B ( hepatocyte nuclear factor 1b ) genes .|We identified one kindred with a novel thymidine to cytosine mutation at position 28 in the REN complementary DNA , corresponding to a tryptophan to arginine substitution at amino acid 10 , which is found within the signal sequence ( c . 28T > C ; p . W10R ) .|On this basis , we conclude that REN mutations are rare events in patients with CKD .|Within the kindred , we found affected individuals over 4 generations who carried the novel REN mutation and were characterized by significant anemia , hyperuricemia , and CKD .|Anemia was severe and disproportional to the degree of decreased kidney function .|Because all heterozygous REN mutations that have been described are localized in the signal sequence , screening of the REN gene for patients with CKD with hyperuricemia and anemia may best be focused on sequencing of exon 1 , which encodes the signal peptide .	1:Association:2	L2R	NON-CROSS	8-9	13-14	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	D000740	anemia|anemia|anemia|Anemia|anemia	DiseaseOrPhenotypicFeature	13:85:235:242:283	14:86:236:243:284	0:3:8:9:10	1:Association:2	L2R	NON-CROSS	114-115	120-121	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	D033461	hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia	DiseaseOrPhenotypicFeature	15:83:120:237:281	16:84:121:238:282	0:3:5:8:10	1:Association:2	L2R	NON-CROSS	274-275	279-280	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	D051436	CKD|chronic kidney disease|CKD|CKD|CKD|CKD|CKD	DiseaseOrPhenotypicFeature	18:88:92:122:211:240:279	19:91:93:123:212:241:280	0:3:3:5:7:8:10	1:Association:2	L2R	NON-CROSS	28-29	31-34	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	C537048	renal tubular dysgenesis	DiseaseOrPhenotypicFeature	31	34	1	1:NR:2	L2R	NON-CROSS	28-29	39-40	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	D003643	death	DiseaseOrPhenotypicFeature	39	40	1	1:NR:2	L2R	NON-CROSS	28-29	44-46	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	D051437	kidney failure	DiseaseOrPhenotypicFeature	44	46	1	1:NR:2	L2R	NON-CROSS	28-29	47-49	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	D008171	pulmonary hypoplasia	DiseaseOrPhenotypicFeature	47	49	1	1:NR:2	L2R	CROSS	54-55	73-74	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	C576203	fetopathy	DiseaseOrPhenotypicFeature	54	55	2	1:NR:2	L2R	CROSS	57-62	73-74	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:NR:2	L2R	CROSS	63-66	73-74	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	NON-CROSS	114-115	131-132	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	NON-CROSS	138-142	161-162	5972	renin|renin|REN|REN|REN|REN|REN|REN|REN|REN|REN	GeneOrGeneProduct	8:26:28:73:102:114:161:203:228:258:274	9:27:29:74:103:115:162:204:229:259:275	0:1:1:3:4:5:6:7:8:10:10	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:NR:2	L2R	CROSS	57-62	85-86	D000740	anemia|anemia|anemia|Anemia|anemia	DiseaseOrPhenotypicFeature	13:85:235:242:283	14:86:236:243:284	0:3:8:9:10	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:NR:2	L2R	CROSS	63-66	85-86	D000740	anemia|anemia|anemia|Anemia|anemia	DiseaseOrPhenotypicFeature	13:85:235:242:283	14:86:236:243:284	0:3:8:9:10	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	CROSS	85-86	131-132	D000740	anemia|anemia|anemia|Anemia|anemia	DiseaseOrPhenotypicFeature	13:85:235:242:283	14:86:236:243:284	0:3:8:9:10	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	CROSS	85-86	136-137	D000740	anemia|anemia|anemia|Anemia|anemia	DiseaseOrPhenotypicFeature	13:85:235:242:283	14:86:236:243:284	0:3:8:9:10	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:Positive_Correlation:2	R2L	CROSS	235-236	185-190	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	D000740	anemia|anemia|anemia|Anemia|anemia	DiseaseOrPhenotypicFeature	13:85:235:242:283	14:86:236:243:284	0:3:8:9:10	1:Positive_Correlation:2	R2L	CROSS	235-236	191-194	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	D000740	anemia|anemia|anemia|Anemia|anemia	DiseaseOrPhenotypicFeature	13:85:235:242:283	14:86:236:243:284	0:3:8:9:10	1:NR:2	L2R	CROSS	57-62	83-84	D033461	hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia	DiseaseOrPhenotypicFeature	15:83:120:237:281	16:84:121:238:282	0:3:5:8:10	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:NR:2	L2R	CROSS	63-66	83-84	D033461	hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia	DiseaseOrPhenotypicFeature	15:83:120:237:281	16:84:121:238:282	0:3:5:8:10	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	NON-CROSS	120-121	131-132	D033461	hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia	DiseaseOrPhenotypicFeature	15:83:120:237:281	16:84:121:238:282	0:3:5:8:10	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	NON-CROSS	120-121	136-137	D033461	hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia	DiseaseOrPhenotypicFeature	15:83:120:237:281	16:84:121:238:282	0:3:5:8:10	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:Positive_Correlation:2	R2L	CROSS	152-159	120-121	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	D033461	hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia	DiseaseOrPhenotypicFeature	15:83:120:237:281	16:84:121:238:282	0:3:5:8:10	1:Positive_Correlation:2	R2L	CROSS	237-238	191-194	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	D033461	hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia|hyperuricemia	DiseaseOrPhenotypicFeature	15:83:120:237:281	16:84:121:238:282	0:3:5:8:10	1:NR:2	L2R	CROSS	57-62	92-93	D051436	CKD|chronic kidney disease|CKD|CKD|CKD|CKD|CKD	DiseaseOrPhenotypicFeature	18:88:92:122:211:240:279	19:91:93:123:212:241:280	0:3:3:5:7:8:10	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:NR:2	L2R	CROSS	63-66	88-91	D051436	CKD|chronic kidney disease|CKD|CKD|CKD|CKD|CKD	DiseaseOrPhenotypicFeature	18:88:92:122:211:240:279	19:91:93:123:212:241:280	0:3:3:5:7:8:10	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	NON-CROSS	122-123	131-132	D051436	CKD|chronic kidney disease|CKD|CKD|CKD|CKD|CKD	DiseaseOrPhenotypicFeature	18:88:92:122:211:240:279	19:91:93:123:212:241:280	0:3:3:5:7:8:10	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	NON-CROSS	122-123	136-137	D051436	CKD|chronic kidney disease|CKD|CKD|CKD|CKD|CKD	DiseaseOrPhenotypicFeature	18:88:92:122:211:240:279	19:91:93:123:212:241:280	0:3:3:5:7:8:10	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:Positive_Correlation:2	R2L	CROSS	211-212	185-190	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	D051436	CKD|chronic kidney disease|CKD|CKD|CKD|CKD|CKD	DiseaseOrPhenotypicFeature	18:88:92:122:211:240:279	19:91:93:123:212:241:280	0:3:3:5:7:8:10	1:Positive_Correlation:2	R2L	CROSS	211-212	191-194	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	D051436	CKD|chronic kidney disease|CKD|CKD|CKD|CKD|CKD	DiseaseOrPhenotypicFeature	18:88:92:122:211:240:279	19:91:93:123:212:241:280	0:3:3:5:7:8:10	1:NR:2	L2R	CROSS	31-34	57-62	C537048	renal tubular dysgenesis	DiseaseOrPhenotypicFeature	31	34	1	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:NR:2	L2R	CROSS	31-34	63-66	C537048	renal tubular dysgenesis	DiseaseOrPhenotypicFeature	31	34	1	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	CROSS	31-34	131-132	C537048	renal tubular dysgenesis	DiseaseOrPhenotypicFeature	31	34	1	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	CROSS	31-34	136-137	C537048	renal tubular dysgenesis	DiseaseOrPhenotypicFeature	31	34	1	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:NR:2	L2R	CROSS	31-34	152-159	C537048	renal tubular dysgenesis	DiseaseOrPhenotypicFeature	31	34	1	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	1:NR:2	L2R	CROSS	31-34	168-176	C537048	renal tubular dysgenesis	DiseaseOrPhenotypicFeature	31	34	1	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	1:NR:2	L2R	CROSS	39-40	57-62	D003643	death	DiseaseOrPhenotypicFeature	39	40	1	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:NR:2	L2R	CROSS	39-40	63-66	D003643	death	DiseaseOrPhenotypicFeature	39	40	1	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	CROSS	39-40	131-132	D003643	death	DiseaseOrPhenotypicFeature	39	40	1	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	CROSS	39-40	136-137	D003643	death	DiseaseOrPhenotypicFeature	39	40	1	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:NR:2	L2R	CROSS	39-40	152-159	D003643	death	DiseaseOrPhenotypicFeature	39	40	1	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	1:NR:2	L2R	CROSS	39-40	168-176	D003643	death	DiseaseOrPhenotypicFeature	39	40	1	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	1:NR:2	L2R	CROSS	44-46	57-62	D051437	kidney failure	DiseaseOrPhenotypicFeature	44	46	1	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:NR:2	L2R	CROSS	44-46	63-66	D051437	kidney failure	DiseaseOrPhenotypicFeature	44	46	1	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	CROSS	44-46	131-132	D051437	kidney failure	DiseaseOrPhenotypicFeature	44	46	1	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	CROSS	44-46	136-137	D051437	kidney failure	DiseaseOrPhenotypicFeature	44	46	1	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:NR:2	L2R	CROSS	44-46	152-159	D051437	kidney failure	DiseaseOrPhenotypicFeature	44	46	1	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	1:NR:2	L2R	CROSS	44-46	168-176	D051437	kidney failure	DiseaseOrPhenotypicFeature	44	46	1	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	1:NR:2	L2R	CROSS	47-49	57-62	D008171	pulmonary hypoplasia	DiseaseOrPhenotypicFeature	47	49	1	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:NR:2	L2R	CROSS	47-49	63-66	D008171	pulmonary hypoplasia	DiseaseOrPhenotypicFeature	47	49	1	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	CROSS	47-49	131-132	D008171	pulmonary hypoplasia	DiseaseOrPhenotypicFeature	47	49	1	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	CROSS	47-49	136-137	D008171	pulmonary hypoplasia	DiseaseOrPhenotypicFeature	47	49	1	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:NR:2	L2R	CROSS	47-49	152-159	D008171	pulmonary hypoplasia	DiseaseOrPhenotypicFeature	47	49	1	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	1:NR:2	L2R	CROSS	47-49	168-176	D008171	pulmonary hypoplasia	DiseaseOrPhenotypicFeature	47	49	1	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	1:Positive_Correlation:2	L2R	NON-CROSS	54-55	57-62	C576203	fetopathy	DiseaseOrPhenotypicFeature	54	55	2	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	1:Positive_Correlation:2	L2R	NON-CROSS	54-55	63-66	C576203	fetopathy	DiseaseOrPhenotypicFeature	54	55	2	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	CROSS	54-55	131-132	C576203	fetopathy	DiseaseOrPhenotypicFeature	54	55	2	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	CROSS	54-55	136-137	C576203	fetopathy	DiseaseOrPhenotypicFeature	54	55	2	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:NR:2	L2R	CROSS	54-55	152-159	C576203	fetopathy	DiseaseOrPhenotypicFeature	54	55	2	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	1:NR:2	L2R	CROSS	54-55	168-176	C576203	fetopathy	DiseaseOrPhenotypicFeature	54	55	2	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	1:NR:2	L2R	NON-CROSS	57-62	63-66	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	1:NR:2	L2R	CROSS	57-62	131-132	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	CROSS	57-62	136-137	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:NR:2	L2R	CROSS	57-62	152-159	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	1:NR:2	L2R	CROSS	57-62	168-176	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	57	62	2	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	1:NR:2	L2R	CROSS	63-66	131-132	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	1:NR:2	L2R	CROSS	63-66	136-137	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5	1:NR:2	L2R	CROSS	63-66	152-159	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	c|SUB|T|28|C	thymidine to cytosine mutation at position 28|c . 28T > C	SequenceVariant	152:185	159:190	6:6	1:NR:2	L2R	CROSS	63-66	168-176	D057911	angiotensin receptor blocker	ChemicalEntity	63	66	2	p|SUB|W|10|R	tryptophan to arginine substitution at amino acid 10|p . W10R	SequenceVariant	168:191	176:194	6:6	1:NR:2	L2R	NON-CROSS	133-134	136-137	7369	UMOD|uromodulin	GeneOrGeneProduct	131:133	132:134	5:5	6928	HNF1B|hepatocyte nuclear factor 1b	GeneOrGeneProduct	136:138	137:142	5:5
27103577	On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury .|The role of peroxisome proliferator - activated receptor a ( PPARa ) - mediated metabolic remodeling in cardiac adaptation to hypoxia has yet to be defined .|Here , mice were housed in hypoxia for 3 wk before in vivo contractile function was measured using cine MRI .|In isolated , perfused hearts , energetics were measured using ( 31 ) P magnetic resonance spectroscopy ( MRS ) , and glycolysis and fatty acid oxidation were measured using [ ( 3 ) H ] labeling .|Compared with a normoxic , chow - fed control mouse heart , hypoxia decreased PPARa expression , fatty acid oxidation , and mitochondrial uncoupling protein 3 ( UCP3 ) levels , while increasing glycolysis , all of which served to maintain normal ATP concentrations ( [ ATP ] ) and thereby , ejection fractions .|A high - fat diet increased cardiac PPARa expression , fatty acid oxidation , and UCP3 levels with decreased glycolysis .|Hypoxia was unable to alter the high PPARa expression or reverse the metabolic changes caused by the high - fat diet , with the result that [ ATP ] and contractile function decreased significantly .|The adaptive metabolic changes caused by hypoxia in control mouse hearts were found to have occurred already in PPARa - deficient ( PPARa ( - / - ) ) mouse hearts and sustained function in hypoxia despite an inability for further metabolic remodeling .|We conclude that decreased cardiac PPARa expression is essential for adaptive metabolic remodeling in hypoxia , but is prevented by dietary fat . - Cole , M . A . , Abd Jamil , A .|H . , Heather , L .|C . , Murray , A . J . , Sutton , E . R . , Slingo , M . , Sebag - Montefiore , L . , Tan , S . C . , Aksentijevic , D . , Gildea , O .|S . , Stuckey , D .|J . , Yeoh , K .|K . , Carr , C .|A . , Evans , R .|D . , Aasum , E . , Schofield , C .|J . , Ratcliffe , P . J . , Neubauer , S . , Robbins , P . A . , Clarke , K .|On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury .	1:Negative_Correlation:2	R2L	NON-CROSS	123-124	121-122	D000860	hypoxia|hypoxic|hypoxia|hypoxia|hypoxia|Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic	DiseaseOrPhenotypicFeature	12:20:43:56:121:185:226:255:278:430:438	13:21:44:57:122:186:227:256:279:431:439	0:0:1:2:4:6:7:7:8:17:17	19013	PPARa|peroxisome proliferator - activated receptor a|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	5:26:33:123:171:192:238:242:269:423	6:32:34:124:172:193:239:243:270:424	0:1:1:4:5:6:7:7:8:17	1:NR:2	L2R	NON-CROSS	123-124	126-128	19013	PPARa|peroxisome proliferator - activated receptor a|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	5:26:33:123:171:192:238:242:269:423	6:32:34:124:172:193:239:243:270:424	0:1:1:4:5:6:7:7:8:17	D005227	fatty acid|fatty acid|fatty acid	ChemicalEntity	95:126:174	97:128:176	3:4:5	1:NR:2	L2R	CROSS	102-106	123-124	19013	PPARa|peroxisome proliferator - activated receptor a|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	5:26:33:123:171:192:238:242:269:423	6:32:34:124:172:193:239:243:270:424	0:1:1:4:5:6:7:7:8:17	D014316	( 3 ) H	ChemicalEntity	102	106	3	1:NR:2	L2R	NON-CROSS	123-124	131-135	19013	PPARa|peroxisome proliferator - activated receptor a|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	5:26:33:123:171:192:238:242:269:423	6:32:34:124:172:193:239:243:270:424	0:1:1:4:5:6:7:7:8:17	22229	mitochondrial uncoupling protein 3|UCP3|UCP3	GeneOrGeneProduct	131:136:179	135:137:180	4:4:5	1:Association:2	L2R	NON-CROSS	155-156	171-172	19013	PPARa|peroxisome proliferator - activated receptor a|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	5:26:33:123:171:192:238:242:269:423	6:32:34:124:172:193:239:243:270:424	0:1:1:4:5:6:7:7:8:17	D000255	ATP|ATP|ATP	ChemicalEntity	151:155:212	152:156:213	4:4:6	1:Negative_Correlation:2	L2R	NON-CROSS	121-122	126-128	D000860	hypoxia|hypoxic|hypoxia|hypoxia|hypoxia|Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic	DiseaseOrPhenotypicFeature	12:20:43:56:121:185:226:255:278:430:438	13:21:44:57:122:186:227:256:279:431:439	0:0:1:2:4:6:7:7:8:17:17	D005227	fatty acid|fatty acid|fatty acid	ChemicalEntity	95:126:174	97:128:176	3:4:5	1:NR:2	L2R	CROSS	102-106	121-122	D000860	hypoxia|hypoxic|hypoxia|hypoxia|hypoxia|Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic	DiseaseOrPhenotypicFeature	12:20:43:56:121:185:226:255:278:430:438	13:21:44:57:122:186:227:256:279:431:439	0:0:1:2:4:6:7:7:8:17:17	D014316	( 3 ) H	ChemicalEntity	102	106	3	1:Negative_Correlation:2	L2R	NON-CROSS	179-180	185-186	D000860	hypoxia|hypoxic|hypoxia|hypoxia|hypoxia|Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic	DiseaseOrPhenotypicFeature	12:20:43:56:121:185:226:255:278:430:438	13:21:44:57:122:186:227:256:279:431:439	0:0:1:2:4:6:7:7:8:17:17	22229	mitochondrial uncoupling protein 3|UCP3|UCP3	GeneOrGeneProduct	131:136:179	135:137:180	4:4:5	1:Negative_Correlation:2	L2R	NON-CROSS	212-213	226-227	D000860	hypoxia|hypoxic|hypoxia|hypoxia|hypoxia|Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic	DiseaseOrPhenotypicFeature	12:20:43:56:121:185:226:255:278:430:438	13:21:44:57:122:186:227:256:279:431:439	0:0:1:2:4:6:7:7:8:17:17	D000255	ATP|ATP|ATP	ChemicalEntity	151:155:212	152:156:213	4:4:6	1:NR:2	L2R	NON-CROSS	95-97	102-106	D005227	fatty acid|fatty acid|fatty acid	ChemicalEntity	95:126:174	97:128:176	3:4:5	D014316	( 3 ) H	ChemicalEntity	102	106	3	1:NR:2	L2R	NON-CROSS	126-128	131-135	D005227	fatty acid|fatty acid|fatty acid	ChemicalEntity	95:126:174	97:128:176	3:4:5	22229	mitochondrial uncoupling protein 3|UCP3|UCP3	GeneOrGeneProduct	131:136:179	135:137:180	4:4:5	1:Association:2	L2R	NON-CROSS	155-156	174-176	D005227	fatty acid|fatty acid|fatty acid	ChemicalEntity	95:126:174	97:128:176	3:4:5	D000255	ATP|ATP|ATP	ChemicalEntity	151:155:212	152:156:213	4:4:6	1:NR:2	L2R	CROSS	102-106	131-135	D014316	( 3 ) H	ChemicalEntity	102	106	3	22229	mitochondrial uncoupling protein 3|UCP3|UCP3	GeneOrGeneProduct	131:136:179	135:137:180	4:4:5	1:NR:2	L2R	CROSS	102-106	151-152	D014316	( 3 ) H	ChemicalEntity	102	106	3	D000255	ATP|ATP|ATP	ChemicalEntity	151:155:212	152:156:213	4:4:6	1:Association:2	L2R	NON-CROSS	136-137	151-152	22229	mitochondrial uncoupling protein 3|UCP3|UCP3	GeneOrGeneProduct	131:136:179	135:137:180	4:4:5	D000255	ATP|ATP|ATP	ChemicalEntity	151:155:212	152:156:213	4:4:6
27491646	Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K / Akt / mTOR and MAPK signalling pathway in human glioma cells .|In central nervous system , glioma is the most common primary brain tumour .|The diffuse migration and rapid proliferation are main obstacles for successful treatment .|Gartanin , a natural xanthone of mangosteen , suppressed proliferation , migration and colony formation in a time - and concentration - dependent manner in T98G glioma cells but not in mouse normal neuronal HT22 cells .|Gartanin , at low micromole , led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1 , while increased expression level of cyclin - dependent kinase inhibitor p27Kip1 .|In addition , the secretion and activity of matrix metalloproteinases 2 / 9 ( MMP - 2 / - 9 ) were significantly suppressed in T98G cells treated with gartanin , and it might result from modulating mitogen - activated protein kinases ( MAPK ) signalling pathway in T98G glioma cells .|Moreover , gartanin significantly induced autophagy in T98G cells and increased GFP - LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3 - II , while suppressed expression level of p62 .|Gartanin treatment resulted in obvious inhibition of PI3K / Akt / mTOR signalling pathway , which is important in modulating autophagy .|Notably , gartanin - mediated anti - viability was significantly abrogated by autophagy inhibitors including 3 - methyladenine ( 3 - MA ) and chloroquine ( CQ ) .|These results indicate that anti - proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy , which is regulated by PI3K / Akt / mTOR signalling pathway , while anti - migration effect is most likely via suppression of MMP - 2 / - 9 activity which is involved in MAPK signalling pathway .	1:NR:2	L2R	NON-CROSS	218-219	225-226	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	1:NR:2	L2R	NON-CROSS	218-219	227-228	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	1:NR:2	L2R	NON-CROSS	218-219	229-230	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	1:NR:2	L2R	NON-CROSS	158-159	166-171	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	1:Negative_Correlation:2	L2R	NON-CROSS	178-179	183-184	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	1:NR:2	L2R	CROSS	35-38	52-53	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	1:NR:2	L2R	NON-CROSS	52-53	56-57	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	C009689	xanthone	ChemicalEntity	56	57	3	1:Negative_Correlation:2	L2R	NON-CROSS	89-90	114-116	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	595	cyclin D1	GeneOrGeneProduct	114	116	4	1:NR:2	L2R	NON-CROSS	89-90	122-126	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:Positive_Correlation:2	L2R	NON-CROSS	127-128	158-159	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	NON-CROSS	143-149	158-159	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:Positive_Correlation:2	L2R	NON-CROSS	183-184	194-195	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:Positive_Correlation:2	L2R	NON-CROSS	204-206	218-219	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	218-219	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	8878	p62	GeneOrGeneProduct	216	217	6	1:Negative_Correlation:2	L2R	NON-CROSS	242-243	255-258	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:Negative_Correlation:2	L2R	NON-CROSS	266-267	278-279	C000605798	Gartanin|Gartanin|Gartanin|gartanin|gartanin|Gartanin|gartanin|gartanin	ChemicalEntity	0:52:89:158:183:218:242:278	1:53:90:159:184:219:243:279	0:3:4:5:6:7:8:9	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:Association:2	L2R	NON-CROSS	11-12	13-14	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	1:Association:2	L2R	NON-CROSS	11-12	15-16	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	1:NR:2	L2R	NON-CROSS	11-12	17-18	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	1:NR:2	L2R	NON-CROSS	11-12	22-23	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	1:NR:2	L2R	CROSS	11-12	35-38	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	1:NR:2	L2R	CROSS	11-12	56-57	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	C009689	xanthone	ChemicalEntity	56	57	3	1:NR:2	L2R	CROSS	11-12	114-116	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	595	cyclin D1	GeneOrGeneProduct	114	116	4	1:NR:2	L2R	CROSS	122-126	225-226	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:NR:2	L2R	CROSS	127-128	225-226	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	NON-CROSS	297-298	316-322	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	207-208	225-226	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	204-206	225-226	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	216-217	225-226	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	225-226	255-258	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	266-267	297-298	5291	PI3K|PI3K|PI3K	GeneOrGeneProduct	11:225:297	12:226:298	0:7:9	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:Association:2	L2R	NON-CROSS	13-14	15-16	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	1:NR:2	L2R	NON-CROSS	13-14	17-18	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	1:NR:2	L2R	NON-CROSS	13-14	22-23	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	1:NR:2	L2R	CROSS	13-14	35-38	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	1:NR:2	L2R	CROSS	13-14	56-57	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	C009689	xanthone	ChemicalEntity	56	57	3	1:NR:2	L2R	CROSS	13-14	114-116	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	595	cyclin D1	GeneOrGeneProduct	114	116	4	1:NR:2	L2R	CROSS	122-126	227-228	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:NR:2	L2R	CROSS	127-128	227-228	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	NON-CROSS	299-300	316-322	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	207-208	227-228	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	204-206	227-228	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	216-217	227-228	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	227-228	255-258	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	266-267	299-300	207	Akt|Akt|Akt	GeneOrGeneProduct	13:227:299	14:228:300	0:7:9	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	NON-CROSS	15-16	17-18	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	1:NR:2	L2R	NON-CROSS	15-16	22-23	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	1:NR:2	L2R	CROSS	15-16	35-38	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	1:NR:2	L2R	CROSS	15-16	56-57	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	C009689	xanthone	ChemicalEntity	56	57	3	1:NR:2	L2R	CROSS	15-16	114-116	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	595	cyclin D1	GeneOrGeneProduct	114	116	4	1:NR:2	L2R	CROSS	122-126	229-230	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:NR:2	L2R	CROSS	127-128	229-230	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	NON-CROSS	301-302	316-322	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	207-208	229-230	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	204-206	229-230	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	216-217	229-230	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	229-230	255-258	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	229-230	264-265	2475	mTOR|mTOR|mTOR	GeneOrGeneProduct	15:229:301	16:230:302	0:7:9	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	NON-CROSS	17-18	22-23	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	1:NR:2	L2R	CROSS	17-18	35-38	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	1:NR:2	L2R	CROSS	17-18	56-57	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	C009689	xanthone	ChemicalEntity	56	57	3	1:NR:2	L2R	CROSS	114-116	166-171	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	595	cyclin D1	GeneOrGeneProduct	114	116	4	1:NR:2	L2R	CROSS	122-126	172-173	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:NR:2	L2R	CROSS	127-128	166-171	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	NON-CROSS	316-322	327-328	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	172-173	194-195	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	172-173	204-206	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	172-173	216-217	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	259-262	327-328	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	266-267	327-328	5594	MAPK|mitogen - activated protein kinases|MAPK|MAPK	GeneOrGeneProduct	17:166:172:327	18:171:173:328	0:5:5:9	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:Association:2	R2L	NON-CROSS	78-79	56-57	C009689	xanthone	ChemicalEntity	56	57	3	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	1:NR:2	L2R	CROSS	78-79	114-116	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	595	cyclin D1	GeneOrGeneProduct	114	116	4	1:NR:2	L2R	CROSS	78-79	122-126	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:NR:2	L2R	CROSS	78-79	127-128	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	NON-CROSS	143-149	178-179	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	178-179	194-195	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	178-179	204-206	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	178-179	216-217	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	178-179	255-258	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	178-179	264-265	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	22:30:78:178	23:31:79:179	0:1:3:5	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	CROSS	35-38	56-57	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	C009689	xanthone	ChemicalEntity	56	57	3	1:NR:2	L2R	CROSS	35-38	114-116	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	595	cyclin D1	GeneOrGeneProduct	114	116	4	1:NR:2	L2R	CROSS	35-38	122-126	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:NR:2	L2R	CROSS	35-38	127-128	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	CROSS	35-38	137-142	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	35-38	194-195	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	35-38	204-206	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	35-38	216-217	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	35-38	255-258	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	35-38	264-265	D001932	primary brain tumour	DiseaseOrPhenotypicFeature	35	38	1	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	CROSS	56-57	114-116	C009689	xanthone	ChemicalEntity	56	57	3	595	cyclin D1	GeneOrGeneProduct	114	116	4	1:NR:2	L2R	CROSS	56-57	122-126	C009689	xanthone	ChemicalEntity	56	57	3	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:NR:2	L2R	CROSS	56-57	127-128	C009689	xanthone	ChemicalEntity	56	57	3	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	CROSS	56-57	137-142	C009689	xanthone	ChemicalEntity	56	57	3	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	56-57	194-195	C009689	xanthone	ChemicalEntity	56	57	3	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	56-57	204-206	C009689	xanthone	ChemicalEntity	56	57	3	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	56-57	216-217	C009689	xanthone	ChemicalEntity	56	57	3	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	56-57	255-258	C009689	xanthone	ChemicalEntity	56	57	3	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	56-57	264-265	C009689	xanthone	ChemicalEntity	56	57	3	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	NON-CROSS	114-116	122-126	595	cyclin D1	GeneOrGeneProduct	114	116	4	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1:NR:2	L2R	NON-CROSS	114-116	127-128	595	cyclin D1	GeneOrGeneProduct	114	116	4	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	CROSS	114-116	137-142	595	cyclin D1	GeneOrGeneProduct	114	116	4	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	114-116	194-195	595	cyclin D1	GeneOrGeneProduct	114	116	4	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	114-116	204-206	595	cyclin D1	GeneOrGeneProduct	114	116	4	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	114-116	216-217	595	cyclin D1	GeneOrGeneProduct	114	116	4	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	114-116	255-258	595	cyclin D1	GeneOrGeneProduct	114	116	4	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	114-116	264-265	595	cyclin D1	GeneOrGeneProduct	114	116	4	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:Negative_Correlation:2	L2R	NON-CROSS	122-126	127-128	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	1027	p27Kip1	GeneOrGeneProduct	127	128	4	1:NR:2	L2R	CROSS	122-126	137-142	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	122-126	194-195	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	122-126	204-206	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	122-126	216-217	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	122-126	255-258	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	122-126	264-265	983	cyclin - dependent kinase	GeneOrGeneProduct	122	126	4	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	CROSS	127-128	137-142	1027	p27Kip1	GeneOrGeneProduct	127	128	4	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	1:NR:2	L2R	CROSS	127-128	194-195	1027	p27Kip1	GeneOrGeneProduct	127	128	4	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	127-128	204-206	1027	p27Kip1	GeneOrGeneProduct	127	128	4	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	127-128	216-217	1027	p27Kip1	GeneOrGeneProduct	127	128	4	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	127-128	255-258	1027	p27Kip1	GeneOrGeneProduct	127	128	4	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	127-128	264-265	1027	p27Kip1	GeneOrGeneProduct	127	128	4	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	CROSS	143-149	194-195	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	1:NR:2	L2R	CROSS	143-149	204-206	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	CROSS	143-149	216-217	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	259-262	316-322	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	266-267	316-322	4313,4318	matrix metalloproteinases 2 / 9|MMP - 2 / - 9|MMP - 2 / - 9	GeneOrGeneProduct	137:143:316	142:149:322	5:5:9	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	NON-CROSS	204-206	207-208	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	8678	Beclin 1	GeneOrGeneProduct	204	206	6	1:NR:2	L2R	NON-CROSS	207-208	216-217	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	207-208	255-258	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	207-208	264-265	84557	LC3|LC3	GeneOrGeneProduct	194:207	195:208	6:6	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	NON-CROSS	204-206	216-217	8678	Beclin 1	GeneOrGeneProduct	204	206	6	8878	p62	GeneOrGeneProduct	216	217	6	1:NR:2	L2R	CROSS	204-206	255-258	8678	Beclin 1	GeneOrGeneProduct	204	206	6	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	204-206	264-265	8678	Beclin 1	GeneOrGeneProduct	204	206	6	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	CROSS	216-217	255-258	8878	p62	GeneOrGeneProduct	216	217	6	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	1:NR:2	L2R	CROSS	216-217	264-265	8878	p62	GeneOrGeneProduct	216	217	6	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8	1:NR:2	L2R	NON-CROSS	259-262	264-265	C025946	3 - methyladenine|3 - MA	ChemicalEntity	255:259	258:262	8:8	D002738	chloroquine|CQ	ChemicalEntity	264:266	265:267	8:8
16611040	Gene therapy for cystic fibrosis airway disease - is clinical success imminent ?|Cystic fibrosis ( CF ) was one of the first inherited disorders for which gene therapy was seriously considered as a realistic option for treatment , and as such , it has long provided a paradigm for gene therapy of inherited diseases .|However , despite the cloning of the cystic fibrosis transmembrane conductance regulator gene in 1989 , over 15 years later a practical gene therapy for CF has not eventuated .|There are a number of reasons for this , and analysis of the specific issues that have delayed the successful development of gene therapy for CF also provides general insights into the practical complexities involved in the development of gene therapy for inherited disorders .|The issues which have prevented the application of gene therapy for CF to date include the lack of suitable gene delivery technologies , the complexities of the interactions between the host and vector , the biology of the lung airways , and the nature of the pathology found in individuals with CF .|We will discuss the history of CF gene therapy with specific reference to these and other issues that pre - occupy the field at present : namely , the question of what vectors appear to be suitable for airway gene delivery in CF , what cells must be targeted , how airway epithelium defences can be overcome or eluded to allow efficient gene delivery , how to ensure safe and long - term transgene expression and the need to identify relevant surrogate success measures that can be used to assess the outcome of gene therapy in CF patients .	1:Association:2	R2L	NON-CROSS	81-82	63-68	1080	cystic fibrosis transmembrane conductance regulator	GeneOrGeneProduct	63	68	2	D003550	cystic fibrosis|Cystic fibrosis|CF|CF|CF|CF|CF|CF|CF|CF	DiseaseOrPhenotypicFeature	3:13:16:81:111:142:182:190:226:280	5:15:17:82:112:143:183:191:227:281	0:1:1:2:3:4:4:5:5:5	1:NR:2	L2R	CROSS	53-55	63-68	D030342	inherited disorders|inherited diseases|inherited disorders	DiseaseOrPhenotypicFeature	23:53:128	25:55:130	1:1:3	1080	cystic fibrosis transmembrane conductance regulator	GeneOrGeneProduct	63	68	2
17033974	Mutation in the auxiliary calcium - channel subunit CACNA2D4 causes autosomal recessive cone dystrophy .|Retinal signal transmission depends on the activity of high voltage - gated l - type calcium channels in photoreceptor ribbon synapses .|We recently identified a truncating frameshift mutation in the Cacna2d4 gene in a spontaneous mouse mutant with profound loss of retinal signaling and an abnormal morphology of ribbon synapses in rods and cones .|The Cacna2d4 gene encodes an l - type calcium - channel auxiliary subunit of the alpha ( 2 ) delta type .|Mutations in its human orthologue , CACNA2D4 , were not yet known to be associated with a disease .|We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness , and , in two affected siblings , we detected a homozygous nucleotide substitution ( c . 2406C - - > A ) in CACNA2D4 .|The mutation introduces a premature stop codon that truncates one - third of the corresponding open reading frame .|Both patients share symptoms of slowly progressing cone dystrophy .|These findings represent the first report of a mutation in the human CACNA2D4 gene and define a novel gene defect that causes autosomal recessive cone dystrophy .	1:Association:2	L2R	NON-CROSS	4-5	8-9	D002118	calcium|calcium	ChemicalEntity	4:30	5:31	0:1	93589	CACNA2D4|CACNA2D4|CACNA2D4|CACNA2D4	GeneOrGeneProduct	8:99:151:194	9:100:152:195	0:4:5:8	1:NR:2	L2R	NON-CROSS	4-5	12-14	D002118	calcium|calcium	ChemicalEntity	4:30	5:31	0:1	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	12:179:206	14:181:208	0:7:8	1:NR:2	L2R	CROSS	30-31	46-47	D002118	calcium|calcium	ChemicalEntity	4:30	5:31	0:1	319734	Cacna2d4|Cacna2d4	GeneOrGeneProduct	46:72	47:73	2:3	1:NR:2	L2R	CROSS	30-31	76-92	D002118	calcium|calcium	ChemicalEntity	4:30	5:31	0:1	781	l - type calcium - channel auxiliary subunit of the alpha ( 2 ) delta type	GeneOrGeneProduct	76	92	3	1:NR:2	L2R	CROSS	30-31	125-127	D002118	calcium|calcium	ChemicalEntity	4:30	5:31	0:1	D009755	night blindness	DiseaseOrPhenotypicFeature	125	127	5	1:NR:2	L2R	CROSS	30-31	142-149	D002118	calcium|calcium	ChemicalEntity	4:30	5:31	0:1	rs71454844	c . 2406C - - > A	SequenceVariant	142	149	5	1:Association:2	L2R	NON-CROSS	8-9	12-14	93589	CACNA2D4|CACNA2D4|CACNA2D4|CACNA2D4	GeneOrGeneProduct	8:99:151:194	9:100:152:195	0:4:5:8	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	12:179:206	14:181:208	0:7:8	1:NR:2	L2R	CROSS	72-73	99-100	93589	CACNA2D4|CACNA2D4|CACNA2D4|CACNA2D4	GeneOrGeneProduct	8:99:151:194	9:100:152:195	0:4:5:8	319734	Cacna2d4|Cacna2d4	GeneOrGeneProduct	46:72	47:73	2:3	1:NR:2	L2R	CROSS	76-92	99-100	93589	CACNA2D4|CACNA2D4|CACNA2D4|CACNA2D4	GeneOrGeneProduct	8:99:151:194	9:100:152:195	0:4:5:8	781	l - type calcium - channel auxiliary subunit of the alpha ( 2 ) delta type	GeneOrGeneProduct	76	92	3	1:Association:2	L2R	NON-CROSS	125-127	151-152	93589	CACNA2D4|CACNA2D4|CACNA2D4|CACNA2D4	GeneOrGeneProduct	8:99:151:194	9:100:152:195	0:4:5:8	D009755	night blindness	DiseaseOrPhenotypicFeature	125	127	5	1:NR:2	L2R	CROSS	12-14	46-47	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	12:179:206	14:181:208	0:7:8	319734	Cacna2d4|Cacna2d4	GeneOrGeneProduct	46:72	47:73	2:3	1:NR:2	L2R	CROSS	12-14	76-92	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	12:179:206	14:181:208	0:7:8	781	l - type calcium - channel auxiliary subunit of the alpha ( 2 ) delta type	GeneOrGeneProduct	76	92	3	1:Positive_Correlation:2	R2L	CROSS	179-181	142-149	rs71454844	c . 2406C - - > A	SequenceVariant	142	149	5	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	12:179:206	14:181:208	0:7:8	1:Association:2	L2R	NON-CROSS	72-73	76-92	319734	Cacna2d4|Cacna2d4	GeneOrGeneProduct	46:72	47:73	2:3	781	l - type calcium - channel auxiliary subunit of the alpha ( 2 ) delta type	GeneOrGeneProduct	76	92	3	1:NR:2	L2R	CROSS	72-73	125-127	319734	Cacna2d4|Cacna2d4	GeneOrGeneProduct	46:72	47:73	2:3	D009755	night blindness	DiseaseOrPhenotypicFeature	125	127	5	1:NR:2	L2R	CROSS	76-92	125-127	781	l - type calcium - channel auxiliary subunit of the alpha ( 2 ) delta type	GeneOrGeneProduct	76	92	3	D009755	night blindness	DiseaseOrPhenotypicFeature	125	127	5	1:Association:2	R2L	NON-CROSS	142-149	125-127	rs71454844	c . 2406C - - > A	SequenceVariant	142	149	5	D009755	night blindness	DiseaseOrPhenotypicFeature	125	127	5
24014394	A homozygous mutation in LYRM7 / MZM1L associated with early onset encephalopathy , lactic acidosis , and severe reduction of mitochondrial complex III activity .|Mutations in nuclear genes associated with defective complex III ( cIII ) of the mitochondrial respiratory chain are rare , having been found in only two cIII assembly factors and , as private changes in single families , three cIII structural subunits .|Recently , human LYRM7 / MZM1L , the ortholog of yeast MZM1 , has been identified as a new assembly factor for cIII .|In a baby patient with early onset , severe encephalopathy , lactic acidosis and profound , isolated cIII deficiency in skeletal muscle , we identified a disease - segregating homozygous mutation ( c . 73G > A ) in LYRM7 / MZM1L , predicting a drastic change in a highly conserved amino - acid residue ( p . Asp25Asn ) .|In a mzm1D yeast strain , the expression of a mzm1 ( D25N ) mutant allele caused temperature - sensitive respiratory growth defect , decreased oxygen consumption , impaired maturation / stabilization of the Rieske Fe - S protein , and reduced complex III activity and amount .|LYRM7 / MZM1L is a novel disease gene , causing cIII - defective , early onset , severe mitochondrial encephalopathy .	1:Association:2	L2R	NON-CROSS	6-7	11-12	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	D001927	encephalopathy|encephalopathy	DiseaseOrPhenotypicFeature	11:101	12:102	0:3	1:Association:2	L2R	NON-CROSS	6-7	13-15	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	D000140	lactic acidosis|lactic acidosis	DiseaseOrPhenotypicFeature	13:103	15:105	0:3	1:Association:2	L2R	NON-CROSS	203-204	211-214	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	C565128	reduction of mitochondrial complex III|defective complex III ( cIII ) of the mitochondrial|cIII deficiency|cIII - defective	DiseaseOrPhenotypicFeature	18:31:109:211	23:40:111:214	0:1:3:5	1:Association:2	L2R	NON-CROSS	195-197	201-202	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	1:NR:2	L2R	NON-CROSS	73-74	79-80	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	1:Association:2	R2L	CROSS	201-202	173-176	D012131	respiratory growth defect	DiseaseOrPhenotypicFeature	173	176	4	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	1:NR:2	L2R	CROSS	178-179	201-202	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	D010100	oxygen	ChemicalEntity	178	179	4	1:NR:2	L2R	CROSS	187-192	203-204	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	1:Association:2	L2R	NON-CROSS	203-204	219-221	90624	LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L|LYRM7|MZM1L	GeneOrGeneProduct	4:6:71:73:131:133:201:203	5:7:72:74:132:134:202:204	0:0:2:2:3:3:5:5	C538525	mitochondrial encephalopathy	DiseaseOrPhenotypicFeature	219	221	5	1:NR:2	L2R	CROSS	90-91	101-102	D001927	encephalopathy|encephalopathy	DiseaseOrPhenotypicFeature	11:101	12:102	0:3	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	1:NR:2	L2R	CROSS	79-80	101-102	D001927	encephalopathy|encephalopathy	DiseaseOrPhenotypicFeature	11:101	12:102	0:3	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	1:Positive_Correlation:2	R2L	NON-CROSS	124-129	101-102	rs587777433	c . 73G > A|p . Asp25Asn|D25N	SequenceVariant	124:148:165	129:151:166	3:3:4	D001927	encephalopathy|encephalopathy	DiseaseOrPhenotypicFeature	11:101	12:102	0:3	1:NR:2	L2R	CROSS	101-102	178-179	D001927	encephalopathy|encephalopathy	DiseaseOrPhenotypicFeature	11:101	12:102	0:3	D010100	oxygen	ChemicalEntity	178	179	4	1:NR:2	L2R	CROSS	101-102	187-192	D001927	encephalopathy|encephalopathy	DiseaseOrPhenotypicFeature	11:101	12:102	0:3	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	1:NR:2	L2R	CROSS	90-91	103-105	D000140	lactic acidosis|lactic acidosis	DiseaseOrPhenotypicFeature	13:103	15:105	0:3	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	1:NR:2	L2R	CROSS	79-80	103-105	D000140	lactic acidosis|lactic acidosis	DiseaseOrPhenotypicFeature	13:103	15:105	0:3	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	1:Positive_Correlation:2	L2R	NON-CROSS	103-105	124-129	D000140	lactic acidosis|lactic acidosis	DiseaseOrPhenotypicFeature	13:103	15:105	0:3	rs587777433	c . 73G > A|p . Asp25Asn|D25N	SequenceVariant	124:148:165	129:151:166	3:3:4	1:NR:2	L2R	CROSS	103-105	178-179	D000140	lactic acidosis|lactic acidosis	DiseaseOrPhenotypicFeature	13:103	15:105	0:3	D010100	oxygen	ChemicalEntity	178	179	4	1:NR:2	L2R	CROSS	103-105	187-192	D000140	lactic acidosis|lactic acidosis	DiseaseOrPhenotypicFeature	13:103	15:105	0:3	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	1:Negative_Correlation:2	L2R	NON-CROSS	31-40	51-52	C565128	reduction of mitochondrial complex III|defective complex III ( cIII ) of the mitochondrial|cIII deficiency|cIII - defective	DiseaseOrPhenotypicFeature	18:31:109:211	23:40:111:214	0:1:3:5	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	1:NR:2	L2R	CROSS	79-80	109-111	C565128	reduction of mitochondrial complex III|defective complex III ( cIII ) of the mitochondrial|cIII deficiency|cIII - defective	DiseaseOrPhenotypicFeature	18:31:109:211	23:40:111:214	0:1:3:5	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	1:Positive_Correlation:2	L2R	NON-CROSS	109-111	124-129	C565128	reduction of mitochondrial complex III|defective complex III ( cIII ) of the mitochondrial|cIII deficiency|cIII - defective	DiseaseOrPhenotypicFeature	18:31:109:211	23:40:111:214	0:1:3:5	rs587777433	c . 73G > A|p . Asp25Asn|D25N	SequenceVariant	124:148:165	129:151:166	3:3:4	1:NR:2	L2R	CROSS	178-179	211-214	C565128	reduction of mitochondrial complex III|defective complex III ( cIII ) of the mitochondrial|cIII deficiency|cIII - defective	DiseaseOrPhenotypicFeature	18:31:109:211	23:40:111:214	0:1:3:5	D010100	oxygen	ChemicalEntity	178	179	4	1:NR:2	L2R	CROSS	187-192	211-214	C565128	reduction of mitochondrial complex III|defective complex III ( cIII ) of the mitochondrial|cIII deficiency|cIII - defective	DiseaseOrPhenotypicFeature	18:31:109:211	23:40:111:214	0:1:3:5	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	1:Negative_Correlation:2	R2L	NON-CROSS	90-91	79-80	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	1:NR:2	L2R	NON-CROSS	173-176	195-197	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	D012131	respiratory growth defect	DiseaseOrPhenotypicFeature	173	176	4	1:NR:2	L2R	NON-CROSS	178-179	195-197	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	D010100	oxygen	ChemicalEntity	178	179	4	1:NR:2	L2R	NON-CROSS	187-192	195-197	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	1:NR:2	L2R	CROSS	195-197	219-221	617	cIII|cIII|cIII|complex III	GeneOrGeneProduct	51:64:90:195	52:65:91:197	1:1:2:4	C538525	mitochondrial encephalopathy	DiseaseOrPhenotypicFeature	219	221	5	1:Association:2	L2R	NON-CROSS	163-164	173-176	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	D012131	respiratory growth defect	DiseaseOrPhenotypicFeature	173	176	4	1:Association:2	L2R	NON-CROSS	163-164	178-179	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	D010100	oxygen	ChemicalEntity	178	179	4	1:Association:2	L2R	NON-CROSS	163-164	187-192	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	1:NR:2	L2R	CROSS	163-164	219-221	852104	MZM1|mzm1D|mzm1	GeneOrGeneProduct	79:155:163	80:156:164	2:4:4	C538525	mitochondrial encephalopathy	DiseaseOrPhenotypicFeature	219	221	5	1:Positive_Correlation:2	L2R	NON-CROSS	165-166	173-176	rs587777433	c . 73G > A|p . Asp25Asn|D25N	SequenceVariant	124:148:165	129:151:166	3:3:4	D012131	respiratory growth defect	DiseaseOrPhenotypicFeature	173	176	4	1:Association:2	L2R	NON-CROSS	165-166	178-179	rs587777433	c . 73G > A|p . Asp25Asn|D25N	SequenceVariant	124:148:165	129:151:166	3:3:4	D010100	oxygen	ChemicalEntity	178	179	4	1:NR:2	L2R	CROSS	165-166	219-221	rs587777433	c . 73G > A|p . Asp25Asn|D25N	SequenceVariant	124:148:165	129:151:166	3:3:4	C538525	mitochondrial encephalopathy	DiseaseOrPhenotypicFeature	219	221	5	1:NR:2	L2R	NON-CROSS	173-176	178-179	D012131	respiratory growth defect	DiseaseOrPhenotypicFeature	173	176	4	D010100	oxygen	ChemicalEntity	178	179	4	1:NR:2	L2R	NON-CROSS	173-176	187-192	D012131	respiratory growth defect	DiseaseOrPhenotypicFeature	173	176	4	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	1:NR:2	L2R	NON-CROSS	178-179	187-192	D010100	oxygen	ChemicalEntity	178	179	4	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	1:NR:2	L2R	CROSS	178-179	219-221	D010100	oxygen	ChemicalEntity	178	179	4	C538525	mitochondrial encephalopathy	DiseaseOrPhenotypicFeature	219	221	5	1:NR:2	L2R	CROSS	187-192	219-221	856689	Rieske Fe - S protein	GeneOrGeneProduct	187	192	4	C538525	mitochondrial encephalopathy	DiseaseOrPhenotypicFeature	219	221	5
15018851	Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy .|BACKGROUND : Long - term anti - cytomegalovirus ( CMV ) treatments in immunocompromised patients are hampered by resistance to antiviral drugs .|Longitudinal changes in the resistance genotype may depend on changes in selective pressure and the complexity of CMV isolates .|OBJECTIVE : To evaluate longitudinal changes in the CMV resistance genotype and phenotype along with strain - specific variability in a patient with non - Hodgkin 's lymphoma in whom successive anti - CMV treatments failed .|STUDY DESIGN : The resistance phenotype and genotype of seven CMV isolates collected from one patient during a 2 - year follow - up period were retrospectively analysed .|In parallel , we used glycoprotein B ( gB ) genotyping , and a - and UL10 - 13 - sequence analysis to study CMV interstrain variability .|RESULTS : The patient was infected by at least three CMV strains plus variants of the parental strains .|Resistance to ganciclovir , cidofovir and foscarnet was successively detected during the follow - up period .|UL97 protein kinase changes responsible for resistance to ganciclovir were initially detected at residues 591 and 592 , and then at position 594 .|Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase , whereas cross - resistance to ganciclovir and cidofovir was due to the L501I substitution .|CONCLUSIONS : The CMV isolates obtained from our patient were complex mixtures of strains .|Changes in resistance genotypes depended on resistance selective pressure and were not linked to interstrain variation .	1:NR:2	L2R	CROSS	9-10	129-131	D008223	lymphoma	DiseaseOrPhenotypicFeature	9	10	0	2813	glycoprotein B|gB	GeneOrGeneProduct	129:132	131:133	5:5	1:NR:2	L2R	CROSS	9-10	173-174	D008223	lymphoma	DiseaseOrPhenotypicFeature	9	10	0	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	1:NR:2	L2R	CROSS	9-10	175-176	D008223	lymphoma	DiseaseOrPhenotypicFeature	9	10	0	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	1:NR:2	L2R	CROSS	9-10	177-178	D008223	lymphoma	DiseaseOrPhenotypicFeature	9	10	0	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	1:NR:2	L2R	CROSS	9-10	188-191	D008223	lymphoma	DiseaseOrPhenotypicFeature	9	10	0	3077517	UL97 protein kinase	GeneOrGeneProduct	188	191	8	1:NR:2	L2R	CROSS	9-10	224-225	D008223	lymphoma	DiseaseOrPhenotypicFeature	9	10	0	p|SUB|N|495|K	N495K	SequenceVariant	224	225	9	1:NR:2	L2R	CROSS	9-10	241-242	D008223	lymphoma	DiseaseOrPhenotypicFeature	9	10	0	p|SUB|L|501|I	L501I	SequenceVariant	241	242	9	1:Association:2	R2L	NON-CROSS	148-149	132-133	2813	glycoprotein B|gB	GeneOrGeneProduct	129:132	131:133	5:5	D003586	Long - term anti - cytomegalovirus|CMV|CMV|CMV|CMV|CMV|CMV|CMV|CMV	DiseaseOrPhenotypicFeature	17:24:55:66:91:105:148:162:247	23:25:56:67:92:106:149:163:248	1:1:2:3:3:4:5:6:10	1:Negative_Correlation:2	L2R	CROSS	162-163	173-174	D003586	Long - term anti - cytomegalovirus|CMV|CMV|CMV|CMV|CMV|CMV|CMV|CMV	DiseaseOrPhenotypicFeature	17:24:55:66:91:105:148:162:247	23:25:56:67:92:106:149:163:248	1:1:2:3:3:4:5:6:10	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	1:Negative_Correlation:2	L2R	CROSS	236-237	247-248	D003586	Long - term anti - cytomegalovirus|CMV|CMV|CMV|CMV|CMV|CMV|CMV|CMV	DiseaseOrPhenotypicFeature	17:24:55:66:91:105:148:162:247	23:25:56:67:92:106:149:163:248	1:1:2:3:3:4:5:6:10	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	1:Negative_Correlation:2	L2R	CROSS	162-163	177-178	D003586	Long - term anti - cytomegalovirus|CMV|CMV|CMV|CMV|CMV|CMV|CMV|CMV	DiseaseOrPhenotypicFeature	17:24:55:66:91:105:148:162:247	23:25:56:67:92:106:149:163:248	1:1:2:3:3:4:5:6:10	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	1:NR:2	L2R	CROSS	162-163	188-191	D003586	Long - term anti - cytomegalovirus|CMV|CMV|CMV|CMV|CMV|CMV|CMV|CMV	DiseaseOrPhenotypicFeature	17:24:55:66:91:105:148:162:247	23:25:56:67:92:106:149:163:248	1:1:2:3:3:4:5:6:10	3077517	UL97 protein kinase	GeneOrGeneProduct	188	191	8	1:NR:2	L2R	CROSS	224-225	247-248	D003586	Long - term anti - cytomegalovirus|CMV|CMV|CMV|CMV|CMV|CMV|CMV|CMV	DiseaseOrPhenotypicFeature	17:24:55:66:91:105:148:162:247	23:25:56:67:92:106:149:163:248	1:1:2:3:3:4:5:6:10	p|SUB|N|495|K	N495K	SequenceVariant	224	225	9	1:NR:2	L2R	CROSS	241-242	247-248	D003586	Long - term anti - cytomegalovirus|CMV|CMV|CMV|CMV|CMV|CMV|CMV|CMV	DiseaseOrPhenotypicFeature	17:24:55:66:91:105:148:162:247	23:25:56:67:92:106:149:163:248	1:1:2:3:3:4:5:6:10	p|SUB|L|501|I	L501I	SequenceVariant	241	242	9	1:NR:2	L2R	CROSS	81-86	129-131	D008228	non - Hodgkin 's lymphoma	DiseaseOrPhenotypicFeature	81	86	3	2813	glycoprotein B|gB	GeneOrGeneProduct	129:132	131:133	5:5	1:NR:2	L2R	CROSS	81-86	173-174	D008228	non - Hodgkin 's lymphoma	DiseaseOrPhenotypicFeature	81	86	3	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	1:NR:2	L2R	CROSS	81-86	175-176	D008228	non - Hodgkin 's lymphoma	DiseaseOrPhenotypicFeature	81	86	3	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	1:NR:2	L2R	CROSS	81-86	177-178	D008228	non - Hodgkin 's lymphoma	DiseaseOrPhenotypicFeature	81	86	3	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	1:NR:2	L2R	CROSS	81-86	188-191	D008228	non - Hodgkin 's lymphoma	DiseaseOrPhenotypicFeature	81	86	3	3077517	UL97 protein kinase	GeneOrGeneProduct	188	191	8	1:NR:2	L2R	CROSS	81-86	224-225	D008228	non - Hodgkin 's lymphoma	DiseaseOrPhenotypicFeature	81	86	3	p|SUB|N|495|K	N495K	SequenceVariant	224	225	9	1:NR:2	L2R	CROSS	81-86	241-242	D008228	non - Hodgkin 's lymphoma	DiseaseOrPhenotypicFeature	81	86	3	p|SUB|L|501|I	L501I	SequenceVariant	241	242	9	1:NR:2	L2R	CROSS	132-133	173-174	2813	glycoprotein B|gB	GeneOrGeneProduct	129:132	131:133	5:5	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	1:NR:2	L2R	CROSS	132-133	175-176	2813	glycoprotein B|gB	GeneOrGeneProduct	129:132	131:133	5:5	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	1:NR:2	L2R	CROSS	132-133	177-178	2813	glycoprotein B|gB	GeneOrGeneProduct	129:132	131:133	5:5	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	1:NR:2	L2R	CROSS	132-133	188-191	2813	glycoprotein B|gB	GeneOrGeneProduct	129:132	131:133	5:5	3077517	UL97 protein kinase	GeneOrGeneProduct	188	191	8	1:NR:2	L2R	NON-CROSS	173-174	175-176	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	1:NR:2	L2R	NON-CROSS	173-174	177-178	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	1:Association:2	R2L	NON-CROSS	196-197	188-191	3077517	UL97 protein kinase	GeneOrGeneProduct	188	191	8	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	1:NR:2	L2R	NON-CROSS	224-225	234-235	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	p|SUB|N|495|K	N495K	SequenceVariant	224	225	9	1:Negative_Correlation:2	L2R	NON-CROSS	234-235	241-242	D015774	ganciclovir|ganciclovir|ganciclovir	ChemicalEntity	173:196:234	174:197:235	7:8:9	p|SUB|L|501|I	L501I	SequenceVariant	241	242	9	1:NR:2	L2R	NON-CROSS	175-176	177-178	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	1:Association:2	R2L	CROSS	188-191	175-176	3077517	UL97 protein kinase	GeneOrGeneProduct	188	191	8	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	1:NR:2	L2R	NON-CROSS	224-225	236-237	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	p|SUB|N|495|K	N495K	SequenceVariant	224	225	9	1:Negative_Correlation:2	L2R	NON-CROSS	236-237	241-242	D000077404	cidofovir|cidofovir	ChemicalEntity	175:236	176:237	7:9	p|SUB|L|501|I	L501I	SequenceVariant	241	242	9	1:Association:2	R2L	CROSS	188-191	177-178	3077517	UL97 protein kinase	GeneOrGeneProduct	188	191	8	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	1:Negative_Correlation:2	L2R	NON-CROSS	215-216	224-225	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	p|SUB|N|495|K	N495K	SequenceVariant	224	225	9	1:NR:2	L2R	NON-CROSS	215-216	241-242	D017245	foscarnet|foscarnet	ChemicalEntity	177:215	178:216	7:9	p|SUB|L|501|I	L501I	SequenceVariant	241	242	9
17671735	Coincidence of mutations in different connexin genes in Hungarian patients .|Mutations in the GJB2 gene are the most common cause of hereditary prelingual sensorineural hearing impairment in Europe .|Several studies indicate that different members of the connexin protein family interact to form gap junctions in the inner ear .|Mutations in different connexin genes may accumulate and , consequently lead to hearing impairment .|Therefore , we screened 47 Hungarian GJB2 - heterozygous ( one mutation in coding exon of the GJB2 gene ) patients with hearing impairment for DNA changes in two further connexin genes ( GJB6 and GJB3 ) and in the 5 ' non - coding region of GJB2 including the splice sites .|Eleven out of 47 GJB2 - heterozygous patients analyzed carried the splice site mutation - 3170G > A in the 5 ' UTR region of GJB2 .|One out of these 11 patients showed homozygous - 3170G > A genotype in combination with p . R127H .|Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [ Delta ( GJB6 - D13S1830 ) ] and 3 ( 2 new and 1 described ) base substitutions in GJB3 [ c . 357C > T , c . 798C > T and c . 94C > T ( p . R32W ) ] which are unlikely disease - causing .|Our results suggest the importance of routine screening for the rather frequent - 3170G > A mutation ( in addition to c . 35delG ) in patients with hearing impairment .	1:Association:2	L2R	NON-CROSS	83-84	88-90	2706	GJB2|GJB2|GJB2|GJB2|GJB2|GJB2|GJB2	GeneOrGeneProduct	14:72:83:113:123:144:169	15:73:84:114:124:145:170	1:4:4:4:5:5:7	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	1:NR:2	L2R	NON-CROSS	169-170	178-179	2706	GJB2|GJB2|GJB2|GJB2|GJB2|GJB2|GJB2	GeneOrGeneProduct	14:72:83:113:123:144:169	15:73:84:114:124:145:170	1:4:4:4:5:5:7	10804	GJB6|GJB6|GJB6	GeneOrGeneProduct	99:178:182	100:179:183	4:7:7	1:NR:2	L2R	NON-CROSS	101-102	113-114	2706	GJB2|GJB2|GJB2|GJB2|GJB2|GJB2|GJB2	GeneOrGeneProduct	14:72:83:113:123:144:169	15:73:84:114:124:145:170	1:4:4:4:5:5:7	2707	GJB3|GJB3	GeneOrGeneProduct	101:199	102:200	4:7	1:NR:2	L2R	NON-CROSS	88-90	99-100	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	10804	GJB6|GJB6|GJB6	GeneOrGeneProduct	99:178:182	100:179:183	4:7:7	1:NR:2	L2R	NON-CROSS	88-90	101-102	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	2707	GJB3|GJB3	GeneOrGeneProduct	101:199	102:200	4:7	1:Positive_Correlation:2	R2L	NON-CROSS	259-261	243-247	c|SUB|G|-3170|A	- 3170G > A|- 3170G > A|- 3170G > A	SequenceVariant	133:154:243	137:158:247	5:6:8	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	1:NR:2	L2R	CROSS	88-90	162-165	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	rs111033196	p . R127H	SequenceVariant	162	165	6	1:NR:2	L2R	CROSS	201-206	259-261	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	rs41310442	c . 357C > T	SequenceVariant	201	206	7	1:NR:2	L2R	CROSS	207-212	259-261	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	rs35983826	c . 798C > T	SequenceVariant	207	212	7	1:NR:2	L2R	CROSS	219-222	259-261	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	rs1805063	c . 94C > T|p . R32W	SequenceVariant	213:219	218:222	7:7	1:Positive_Correlation:2	R2L	NON-CROSS	259-261	252-255	rs80338939	c . 35delG	SequenceVariant	252	255	8	D034381	sensorineural hearing impairment|hearing impairment|hearing impairment|hearing impairment	DiseaseOrPhenotypicFeature	24:63:88:259	27:65:90:261	1:3:4:8	1:NR:2	L2R	NON-CROSS	99-100	101-102	10804	GJB6|GJB6|GJB6	GeneOrGeneProduct	99:178:182	100:179:183	4:7:7	2707	GJB3|GJB3	GeneOrGeneProduct	101:199	102:200	4:7
28518143	Calcium sensing receptor protects high glucose - induced energy metabolism disorder via blocking gp78 - ubiquitin proteasome pathway .|Diabetic cardiomyopathy ( DCM ) is a major complication and fatal cause of the patients with diabetes .|The calcium sensing receptor ( CaSR ) is a G protein - coupled receptor , which is involved in maintaining calcium homeostasis , regulating cell proliferation and apoptosis , and so on .|In our previous study , we found that CaSR expression , intracellular calcium levels and cardiac function were all significantly decreased in DCM rats ; however , the exact mechanism are not clear yet .|The present study revealed the protective role of CaSR in myocardial energy metabolism disorder induced by high glucose ( HG ) as well as the underlying mechanism .|Here , we demonstrated that HG decreased the expression of CaSR , mitochondrial fusion proteins ( Mfn1 , Mfn2 ) , cell gap junction related proteins ( Cx43 , beta - catenin , N - cadherin ) , and intracellular ATP concentration .|In contrast , HG increased extracellular ATP concentration , the expression of gp78 , mitochondrial fission proteins ( Fis1 , Drp1 ) , and the ubiquitination levels of Mfn1 , Mfn2 and Cx43 .|Moreover , CaSR agonist and gp78 - siRNA significantly reduced the above changes .|Taken together , these results suggest that HG induces myocardial energy metabolism disorder via decrease of CaSR expression , and activation of gp78 - ubiquitin proteasome system .|In turn , these effects disrupt the structure and function of the mitochondria and the cell gap junction , result in the reduced ATP synthesis and the increased ATP leakage .|Stimulation of CaSR significantly attenuates HG - induced abnormal myocardial energy metabolism , suggesting CaSR would be a promising potential therapeutic target for DCM .	1:Negative_Correlation:2	L2R	NON-CROSS	0-3	5-6	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	1:Association:2	L2R	NON-CROSS	0-3	9-11	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	1:NR:2	L2R	NON-CROSS	212-213	215-216	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	1:NR:2	L2R	CROSS	0-3	19-21	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	1:Negative_Correlation:2	L2R	NON-CROSS	297-298	306-307	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	1:NR:2	L2R	CROSS	35-36	38-41	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	1:Association:2	L2R	NON-CROSS	78-79	82-83	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	1:Association:2	L2R	NON-CROSS	113-114	115-119	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	1:Association:2	L2R	NON-CROSS	143-144	149-150	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:Association:2	L2R	NON-CROSS	206-207	212-213	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:Association:2	L2R	NON-CROSS	208-209	212-213	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	NON-CROSS	143-144	162-165	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	NON-CROSS	143-144	166-169	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:Association:2	L2R	NON-CROSS	280-281	285-286	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:Association:2	L2R	CROSS	194-195	212-213	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	288584	Fis1	GeneOrGeneProduct	194	195	6	1:Association:2	L2R	CROSS	196-197	212-213	24247	Calcium sensing receptor|calcium sensing receptor|CaSR|G protein - coupled receptor|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR|CaSR	GeneOrGeneProduct	0:38:42:46:78:113:143:212:240:285:297	3:41:43:51:79:114:144:213:241:286:298	0:2:2:2:3:4:5:7:8:10:10	114114	Drp1	GeneOrGeneProduct	196	197	6	1:Positive_Correlation:2	L2R	NON-CROSS	5-6	9-11	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	1:Positive_Correlation:2	L2R	NON-CROSS	5-6	13-14	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	1:NR:2	L2R	CROSS	5-6	19-21	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	1:NR:2	L2R	CROSS	5-6	22-23	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	1:NR:2	L2R	CROSS	5-6	35-36	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	1:NR:2	L2R	CROSS	82-83	122-123	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	1:Positive_Correlation:2	L2R	NON-CROSS	115-119	122-123	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	1:Negative_Correlation:2	L2R	CROSS	122-123	149-150	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:Negative_Correlation:2	L2R	CROSS	122-123	151-152	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:Negative_Correlation:2	L2R	CROSS	122-123	160-161	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:Negative_Correlation:2	L2R	CROSS	122-123	162-165	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:Negative_Correlation:2	L2R	CROSS	122-123	166-169	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:Association:2	L2R	CROSS	122-123	173-174	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:Positive_Correlation:2	L2R	CROSS	122-123	194-195	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	288584	Fis1	GeneOrGeneProduct	194	195	6	1:Positive_Correlation:2	L2R	CROSS	122-123	196-197	D005947	glucose|glucose	ChemicalEntity	5:122	6:123	0:4	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	9-11	13-14	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	1:NR:2	L2R	CROSS	9-11	57-58	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	1:NR:2	L2R	CROSS	9-11	149-150	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:NR:2	L2R	CROSS	9-11	151-152	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:NR:2	L2R	CROSS	9-11	160-161	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	CROSS	9-11	162-165	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	CROSS	9-11	166-169	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	CROSS	9-11	173-174	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	CROSS	9-11	194-195	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	CROSS	9-11	196-197	D008659	metabolism disorder	DiseaseOrPhenotypicFeature	9	11	0	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	13-14	19-21	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	1:NR:2	L2R	CROSS	13-14	22-23	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	1:NR:2	L2R	CROSS	13-14	35-36	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	1:NR:2	L2R	CROSS	13-14	57-58	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	1:Association:2	L2R	NON-CROSS	233-237	246-247	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	1:Association:2	L2R	NON-CROSS	204-205	215-216	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:Association:2	L2R	NON-CROSS	206-207	215-216	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:Association:2	L2R	NON-CROSS	208-209	215-216	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	CROSS	162-165	188-189	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	CROSS	166-169	188-189	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:Association:2	L2R	NON-CROSS	182-183	188-189	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:Association:2	L2R	NON-CROSS	188-189	194-195	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	288584	Fis1	GeneOrGeneProduct	194	195	6	1:Association:2	L2R	NON-CROSS	188-189	196-197	361367	gp78|gp78|gp78|gp78	GeneOrGeneProduct	13:188:215:246	14:189:216:247	0:6:7:8	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	19-21	57-58	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	1:NR:2	L2R	CROSS	19-21	149-150	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:NR:2	L2R	CROSS	19-21	151-152	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:NR:2	L2R	CROSS	19-21	160-161	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	CROSS	19-21	162-165	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	CROSS	19-21	166-169	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	CROSS	19-21	173-174	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	CROSS	19-21	194-195	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	CROSS	19-21	196-197	D058065	Diabetic cardiomyopathy	DiseaseOrPhenotypicFeature	19	21	1	114114	Drp1	GeneOrGeneProduct	196	197	6	1:Negative_Correlation:2	R2L	NON-CROSS	92-93	82-83	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	1:NR:2	L2R	CROSS	92-93	149-150	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:NR:2	L2R	CROSS	92-93	151-152	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:NR:2	L2R	CROSS	92-93	160-161	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	CROSS	92-93	162-165	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	CROSS	92-93	166-169	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	CROSS	280-281	306-307	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	CROSS	92-93	194-195	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	CROSS	92-93	196-197	D002311	DCM|DCM|DCM	DiseaseOrPhenotypicFeature	22:92:306	23:93:307	1:3:10	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	35-36	57-58	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	1:NR:2	L2R	CROSS	35-36	149-150	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:NR:2	L2R	CROSS	35-36	151-152	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:NR:2	L2R	CROSS	35-36	160-161	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	CROSS	35-36	162-165	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	CROSS	35-36	166-169	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	CROSS	35-36	173-174	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	CROSS	35-36	194-195	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	CROSS	35-36	196-197	D003920	diabetes	DiseaseOrPhenotypicFeature	35	36	1	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	82-83	115-119	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	1:NR:2	L2R	CROSS	82-83	149-150	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:NR:2	L2R	CROSS	82-83	151-152	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:NR:2	L2R	CROSS	82-83	160-161	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	CROSS	82-83	162-165	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	CROSS	82-83	166-169	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	CROSS	82-83	173-174	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	CROSS	82-83	194-195	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	CROSS	82-83	196-197	D002118	calcium|calcium	ChemicalEntity	57:82	58:83	2:3	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	204-205	233-237	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	1:NR:2	L2R	CROSS	206-207	233-237	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:NR:2	L2R	CROSS	208-209	233-237	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	CROSS	115-119	162-165	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	CROSS	115-119	166-169	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:Association:2	R2L	CROSS	291-295	280-281	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	1:NR:2	L2R	CROSS	194-195	233-237	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	CROSS	196-197	233-237	D009202	myocardial energy metabolism disorder|myocardial energy metabolism disorder|abnormal myocardial energy metabolism	DiseaseOrPhenotypicFeature	115:233:291	119:237:295	4:8:10	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	149-150	151-152	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	1:NR:2	L2R	NON-CROSS	204-205	208-209	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	NON-CROSS	149-150	162-165	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	NON-CROSS	149-150	166-169	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	NON-CROSS	182-183	204-205	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	NON-CROSS	194-195	204-205	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	NON-CROSS	196-197	204-205	192647	Mfn1|Mfn1	GeneOrGeneProduct	149:204	150:205	5:6	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	206-207	208-209	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	1:NR:2	L2R	NON-CROSS	151-152	162-165	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	NON-CROSS	151-152	166-169	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	NON-CROSS	151-152	173-174	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	NON-CROSS	194-195	206-207	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	NON-CROSS	196-197	206-207	64476	Mfn2|Mfn2	GeneOrGeneProduct	151:206	152:207	5:6	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	160-161	162-165	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	84353	beta - catenin	GeneOrGeneProduct	162	165	5	1:NR:2	L2R	NON-CROSS	160-161	166-169	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	NON-CROSS	160-161	173-174	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	NON-CROSS	194-195	208-209	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	NON-CROSS	196-197	208-209	24392	Cx43|Cx43	GeneOrGeneProduct	160:208	161:209	5:6	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	162-165	166-169	84353	beta - catenin	GeneOrGeneProduct	162	165	5	83501	N - cadherin	GeneOrGeneProduct	166	169	5	1:NR:2	L2R	NON-CROSS	162-165	173-174	84353	beta - catenin	GeneOrGeneProduct	162	165	5	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	CROSS	162-165	194-195	84353	beta - catenin	GeneOrGeneProduct	162	165	5	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	CROSS	162-165	196-197	84353	beta - catenin	GeneOrGeneProduct	162	165	5	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	166-169	173-174	83501	N - cadherin	GeneOrGeneProduct	166	169	5	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	1:NR:2	L2R	CROSS	166-169	194-195	83501	N - cadherin	GeneOrGeneProduct	166	169	5	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	CROSS	166-169	196-197	83501	N - cadherin	GeneOrGeneProduct	166	169	5	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	182-183	194-195	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	288584	Fis1	GeneOrGeneProduct	194	195	6	1:NR:2	L2R	NON-CROSS	182-183	196-197	D000255	ATP|ATP|ATP|ATP	ChemicalEntity	173:182:275:280	174:183:276:281	5:6:9:9	114114	Drp1	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	194-195	196-197	288584	Fis1	GeneOrGeneProduct	194	195	6	114114	Drp1	GeneOrGeneProduct	196	197	6
17600377	A novel compound , maltolyl p - coumarate , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models .|To develop a novel and effective drug that could enhance cognitive function and neuroprotection , we newly synthesized maltolyl p - coumarate by the esterification of maltol and p - coumaric acid .|In the present study , we investigated whether maltolyl p - coumarate could improve cognitive decline in scopolamine - injected rats and in amyloid beta peptide ( 1 - 42 ) - infused rats .|Maltolyl p - coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide ( 1 - 42 ) - infused rats .|We also examined the neuroprotective effects of maltolyl p - coumarate in vitro using SH - SY5Y cells .|Cells were pretreated with maltolyl p - coumarate , before exposed to amyloid beta peptide ( 1 - 42 ) , glutamate or H2O2 .|We found that maltolyl p - coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species , cytochrome c release , and caspase 3 activation .|Taking these in vitro and in vivo results together , our study suggests that maltolyl p - coumarate is a potentially effective candidate against Alzheimer 's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function .	1:Negative_Correlation:2	L2R	NON-CROSS	4-8	10-12	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	1:Association:2	L2R	NON-CROSS	4-8	21-22	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	1:Association:2	L2R	NON-CROSS	42-46	50-51	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	C008316	maltol	ChemicalEntity	50	51	1	1:Association:2	L2R	NON-CROSS	42-46	52-56	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	C495469	p - coumaric acid	ChemicalEntity	52	56	1	1:NR:2	L2R	NON-CROSS	65-69	74-75	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D012601	scopolamine	ChemicalEntity	74	75	2	1:Association:2	L2R	NON-CROSS	157-161	165-173	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	1:NR:2	L2R	NON-CROSS	174-175	181-185	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D018698	glutamate	ChemicalEntity	174	175	5	1:NR:2	L2R	NON-CROSS	176-177	181-185	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D006861	H2O2	ChemicalEntity	176	177	5	1:Negative_Correlation:2	L2R	NON-CROSS	181-185	192-195	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:Negative_Correlation:2	L2R	NON-CROSS	181-185	196-198	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D045304	cytochrome c	ChemicalEntity	196	198	6	1:Negative_Correlation:2	L2R	NON-CROSS	181-185	201-203	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:Negative_Correlation:2	L2R	NON-CROSS	219-223	229-232	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:Negative_Correlation:2	L2R	NON-CROSS	219-223	238-240	C524754	maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|Maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate|maltolyl p - coumarate	ChemicalEntity	4:42:65:92:141:157:181:219	8:46:69:96:145:161:185:223	0:1:2:3:4:5:6:7	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	CROSS	50-51	71-73	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	C008316	maltol	ChemicalEntity	50	51	1	1:NR:2	L2R	CROSS	52-56	71-73	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	C495469	p - coumaric acid	ChemicalEntity	52	56	1	1:Positive_Correlation:2	L2R	NON-CROSS	71-73	74-75	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	D012601	scopolamine	ChemicalEntity	74	75	2	1:Positive_Correlation:2	L2R	NON-CROSS	71-73	80-88	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	1:NR:2	L2R	CROSS	174-175	242-246	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	D018698	glutamate	ChemicalEntity	174	175	5	1:NR:2	L2R	CROSS	176-177	242-246	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	D006861	H2O2	ChemicalEntity	176	177	5	1:NR:2	L2R	CROSS	192-195	242-246	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:NR:2	L2R	CROSS	196-198	242-246	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	CROSS	201-203	242-246	D003072	cognitive deficits|cognitive decline|cognitive deficits|decline of cognitive function	DiseaseOrPhenotypicFeature	10:71:100:242	12:73:102:246	0:2:3:7	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	21-22	50-51	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	C008316	maltol	ChemicalEntity	50	51	1	1:NR:2	L2R	CROSS	21-22	52-56	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	C495469	p - coumaric acid	ChemicalEntity	52	56	1	1:NR:2	L2R	CROSS	21-22	74-75	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	D012601	scopolamine	ChemicalEntity	74	75	2	1:NR:2	L2R	CROSS	21-22	80-88	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	1:NR:2	L2R	CROSS	21-22	174-175	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	D018698	glutamate	ChemicalEntity	174	175	5	1:NR:2	L2R	CROSS	21-22	176-177	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	D006861	H2O2	ChemicalEntity	176	177	5	1:NR:2	L2R	CROSS	21-22	192-195	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:NR:2	L2R	CROSS	21-22	196-198	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	CROSS	21-22	201-203	D003704	dementia	DiseaseOrPhenotypicFeature	21	22	0	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:Association:2	L2R	NON-CROSS	50-51	52-56	C008316	maltol	ChemicalEntity	50	51	1	C495469	p - coumaric acid	ChemicalEntity	52	56	1	1:NR:2	L2R	CROSS	50-51	74-75	C008316	maltol	ChemicalEntity	50	51	1	D012601	scopolamine	ChemicalEntity	74	75	2	1:NR:2	L2R	CROSS	50-51	80-88	C008316	maltol	ChemicalEntity	50	51	1	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	1:NR:2	L2R	CROSS	50-51	174-175	C008316	maltol	ChemicalEntity	50	51	1	D018698	glutamate	ChemicalEntity	174	175	5	1:NR:2	L2R	CROSS	50-51	176-177	C008316	maltol	ChemicalEntity	50	51	1	D006861	H2O2	ChemicalEntity	176	177	5	1:NR:2	L2R	CROSS	50-51	192-195	C008316	maltol	ChemicalEntity	50	51	1	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:NR:2	L2R	CROSS	50-51	196-198	C008316	maltol	ChemicalEntity	50	51	1	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	CROSS	50-51	201-203	C008316	maltol	ChemicalEntity	50	51	1	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	50-51	229-232	C008316	maltol	ChemicalEntity	50	51	1	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	50-51	238-240	C008316	maltol	ChemicalEntity	50	51	1	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	CROSS	52-56	74-75	C495469	p - coumaric acid	ChemicalEntity	52	56	1	D012601	scopolamine	ChemicalEntity	74	75	2	1:NR:2	L2R	CROSS	52-56	80-88	C495469	p - coumaric acid	ChemicalEntity	52	56	1	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	1:NR:2	L2R	CROSS	52-56	174-175	C495469	p - coumaric acid	ChemicalEntity	52	56	1	D018698	glutamate	ChemicalEntity	174	175	5	1:NR:2	L2R	CROSS	52-56	176-177	C495469	p - coumaric acid	ChemicalEntity	52	56	1	D006861	H2O2	ChemicalEntity	176	177	5	1:NR:2	L2R	CROSS	52-56	192-195	C495469	p - coumaric acid	ChemicalEntity	52	56	1	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:NR:2	L2R	CROSS	52-56	196-198	C495469	p - coumaric acid	ChemicalEntity	52	56	1	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	CROSS	52-56	201-203	C495469	p - coumaric acid	ChemicalEntity	52	56	1	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	52-56	229-232	C495469	p - coumaric acid	ChemicalEntity	52	56	1	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	52-56	238-240	C495469	p - coumaric acid	ChemicalEntity	52	56	1	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	NON-CROSS	74-75	80-88	D012601	scopolamine	ChemicalEntity	74	75	2	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	1:NR:2	L2R	CROSS	74-75	174-175	D012601	scopolamine	ChemicalEntity	74	75	2	D018698	glutamate	ChemicalEntity	174	175	5	1:NR:2	L2R	CROSS	74-75	176-177	D012601	scopolamine	ChemicalEntity	74	75	2	D006861	H2O2	ChemicalEntity	176	177	5	1:NR:2	L2R	CROSS	74-75	192-195	D012601	scopolamine	ChemicalEntity	74	75	2	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:NR:2	L2R	CROSS	74-75	196-198	D012601	scopolamine	ChemicalEntity	74	75	2	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	CROSS	74-75	201-203	D012601	scopolamine	ChemicalEntity	74	75	2	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	74-75	229-232	D012601	scopolamine	ChemicalEntity	74	75	2	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	74-75	238-240	D012601	scopolamine	ChemicalEntity	74	75	2	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	NON-CROSS	165-173	174-175	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	D018698	glutamate	ChemicalEntity	174	175	5	1:NR:2	L2R	NON-CROSS	165-173	176-177	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	D006861	H2O2	ChemicalEntity	176	177	5	1:NR:2	L2R	CROSS	165-173	192-195	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:NR:2	L2R	CROSS	165-173	196-198	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	CROSS	165-173	201-203	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	165-173	229-232	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	165-173	238-240	C544092	amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )|amyloid beta peptide ( 1 - 42 )	ChemicalEntity	80:122:165	88:130:173	2:3:5	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	NON-CROSS	174-175	176-177	D018698	glutamate	ChemicalEntity	174	175	5	D006861	H2O2	ChemicalEntity	176	177	5	1:NR:2	L2R	CROSS	174-175	192-195	D018698	glutamate	ChemicalEntity	174	175	5	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:NR:2	L2R	CROSS	174-175	196-198	D018698	glutamate	ChemicalEntity	174	175	5	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	CROSS	174-175	201-203	D018698	glutamate	ChemicalEntity	174	175	5	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	174-175	229-232	D018698	glutamate	ChemicalEntity	174	175	5	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	174-175	238-240	D018698	glutamate	ChemicalEntity	174	175	5	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	CROSS	176-177	192-195	D006861	H2O2	ChemicalEntity	176	177	5	D017382	reactive oxygen species	ChemicalEntity	192	195	6	1:NR:2	L2R	CROSS	176-177	196-198	D006861	H2O2	ChemicalEntity	176	177	5	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	CROSS	176-177	201-203	D006861	H2O2	ChemicalEntity	176	177	5	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	176-177	229-232	D006861	H2O2	ChemicalEntity	176	177	5	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	176-177	238-240	D006861	H2O2	ChemicalEntity	176	177	5	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	NON-CROSS	192-195	196-198	D017382	reactive oxygen species	ChemicalEntity	192	195	6	D045304	cytochrome c	ChemicalEntity	196	198	6	1:NR:2	L2R	NON-CROSS	192-195	201-203	D017382	reactive oxygen species	ChemicalEntity	192	195	6	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	192-195	229-232	D017382	reactive oxygen species	ChemicalEntity	192	195	6	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	192-195	238-240	D017382	reactive oxygen species	ChemicalEntity	192	195	6	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	NON-CROSS	196-198	201-203	D045304	cytochrome c	ChemicalEntity	196	198	6	25402	caspase 3	GeneOrGeneProduct	201	203	6	1:NR:2	L2R	CROSS	196-198	229-232	D045304	cytochrome c	ChemicalEntity	196	198	6	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	196-198	238-240	D045304	cytochrome c	ChemicalEntity	196	198	6	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7	1:NR:2	L2R	CROSS	201-203	229-232	25402	caspase 3	GeneOrGeneProduct	201	203	6	D000544	Alzheimer 's disease	DiseaseOrPhenotypicFeature	229	232	7	1:NR:2	L2R	CROSS	201-203	238-240	25402	caspase 3	GeneOrGeneProduct	201	203	6	D009410	neuronal death	DiseaseOrPhenotypicFeature	238	240	7
16181814	Mono - allelic POLG expression resulting from nonsense - mediated decay and alternative splicing in a patient with Alpers syndrome .|Alpers syndrome is an autosomal recessive mitochondrial DNA depletion disorder that affects children and young adults .|It is characterized by a progressive , fatal brain and liver disease .|This syndrome has been associated with mutations in POLG , the gene encoding the mitochondrial DNA polymerase ( pol gamma ) .|Most patients with Alpers syndrome have been found to be compound heterozygotes , carrying two pathogenic mutations in trans at the POLG locus .|POLG is a nuclear - encoded gene whose protein product is imported into mitochondria , where it is essential for mtDNA replication and repair .|We studied the skin fibroblasts of a patient with Alpers syndrome having the genotype E873stop / A467T .|The E873stop mutation produces a premature termination codon ( TAG ) in exon 17 .|The A467T mutation produces a threonine to alanine substitution at a highly conserved site in exon 7 .|The allele bearing the stop codon ( E873 - TAG ) is predicted to produce a truncated , catalytically inactive polymerase .|However , only full - length pol gamma protein was detected by Western blot analysis .|Here , we show that transcripts containing this stop codon undergo nonsense - associated alternative splicing and nonsense - mediated decay .|More than 95 % of the functional POLG mRNA was derived from the allele bearing the A467T mutation and less than 5 % contained the E873stop mutation .|These events ensured that virtually all POLG protein in the cell was expressed from the A467T allele .|Therefore , the Alpers phenotype in this patient was a consequence of a single - copy gene dose of the A467T allele , and selective elimination of transcripts bearing the E873stop mutation .	1:Association:2	R2L	NON-CROSS	76-78	69-71	D002549	Alpers syndrome|Alpers syndrome|Alpers syndrome|Alpers syndrome	DiseaseOrPhenotypicFeature	18:21:76:131	20:23:78:133	0:1:4:6	5428	POLG|POLG|pol gamma|POLG|POLG|pol gamma|POLG|POLG	GeneOrGeneProduct	3:59:69:94:97:201:240:267	4:60:71:95:98:203:241:268	0:3:3:4:5:10:12:13	1:NR:2	L2R	CROSS	3-4	27-30	5428	POLG|POLG|pol gamma|POLG|POLG|pol gamma|POLG|POLG	GeneOrGeneProduct	3:59:69:94:97:201:240:267	4:60:71:95:98:203:241:268	0:3:3:4:5:10:12:13	D028361	mitochondrial DNA depletion	DiseaseOrPhenotypicFeature	27	30	1	1:NR:2	L2R	CROSS	48-50	59-60	5428	POLG|POLG|pol gamma|POLG|POLG|pol gamma|POLG|POLG	GeneOrGeneProduct	3:59:69:94:97:201:240:267	4:60:71:95:98:203:241:268	0:3:3:4:5:10:12:13	D008107	liver disease	DiseaseOrPhenotypicFeature	48	50	2	1:Association:2	L2R	NON-CROSS	131-133	136-137	D002549	Alpers syndrome|Alpers syndrome|Alpers syndrome|Alpers syndrome	DiseaseOrPhenotypicFeature	18:21:76:131	20:23:78:133	0:1:4:6	rs121918047	E873stop|E873stop|E873 - TAG|E873stop|E873stop	SequenceVariant	136:141:180:258:309	137:142:183:259:310	6:7:9:12:14	1:Association:2	L2R	NON-CROSS	131-133	138-139	D002549	Alpers syndrome|Alpers syndrome|Alpers syndrome|Alpers syndrome	DiseaseOrPhenotypicFeature	18:21:76:131	20:23:78:133	0:1:4:6	rs113994095	A467T|A467T|threonine to alanine|A467T|A467T|A467T	SequenceVariant	138:156:160:249:276:299	139:157:163:250:277:300	6:8:8:12:13:14	1:NR:2	L2R	CROSS	27-30	136-137	D028361	mitochondrial DNA depletion	DiseaseOrPhenotypicFeature	27	30	1	rs121918047	E873stop|E873stop|E873 - TAG|E873stop|E873stop	SequenceVariant	136:141:180:258:309	137:142:183:259:310	6:7:9:12:14	1:NR:2	L2R	CROSS	27-30	138-139	D028361	mitochondrial DNA depletion	DiseaseOrPhenotypicFeature	27	30	1	rs113994095	A467T|A467T|threonine to alanine|A467T|A467T|A467T	SequenceVariant	138:156:160:249:276:299	139:157:163:250:277:300	6:8:8:12:13:14	1:NR:2	L2R	CROSS	48-50	136-137	D008107	liver disease	DiseaseOrPhenotypicFeature	48	50	2	rs121918047	E873stop|E873stop|E873 - TAG|E873stop|E873stop	SequenceVariant	136:141:180:258:309	137:142:183:259:310	6:7:9:12:14	1:NR:2	L2R	CROSS	48-50	138-139	D008107	liver disease	DiseaseOrPhenotypicFeature	48	50	2	rs113994095	A467T|A467T|threonine to alanine|A467T|A467T|A467T	SequenceVariant	138:156:160:249:276:299	139:157:163:250:277:300	6:8:8:12:13:14
20143913	Large deletion involving exon 5 of the arylsulfatase B gene caused apparent homozygosity in a mucopolysaccharidosis type VI patient .|Apparent homozygosity for the mutation p . R315X present on exon 5 of the arylsulfatase B ( ARSB ) gene in a mucopolysaccharidosis type VI patient was solved in this study by further testing for a second mutation .|Patient cDNA analysis revealed that the entire exon 5 of the ARSB gene was lacking ; this new mutation was identified as c . 899 - 1142del .|As the genomic DNA sequencing excluded the presence of splicing mutations , polymerase chain reaction analysis was performed for polymorphisms listed in the NCBI SNP database for the ARSB gene .|This allowed the mutation at the genomic DNA level to be identified as g . 99367 - 102002del ; this gross deletion , involving the entire exon 5 of the gene and parts of introns 4 and 5 led to a frameshift starting at amino acid 300 and resulting in a protein with 39 % amino acids different from the normal enzyme .|We stress that extensive DNA analysis needs to be performed in case of apparent homozygosity to avoid potential errors in genetic counseling .	1:Association:2	R2L	NON-CROSS	42-45	37-38	D009087	mucopolysaccharidosis type VI|mucopolysaccharidosis type VI	DiseaseOrPhenotypicFeature	15:42	18:45	0:1	411	arylsulfatase B|arylsulfatase B|ARSB|ARSB|ARSB	GeneOrGeneProduct	7:34:37:70:115	9:36:38:71:116	0:1:1:2:3	1:Association:2	L2R	NON-CROSS	15-18	25-28	D009087	mucopolysaccharidosis type VI|mucopolysaccharidosis type VI	DiseaseOrPhenotypicFeature	15:42	18:45	0:1	p|SUB|R|315|X	p . R315X	SequenceVariant	25	28	1	1:Association:2	L2R	CROSS	42-45	81-86	D009087	mucopolysaccharidosis type VI|mucopolysaccharidosis type VI	DiseaseOrPhenotypicFeature	15:42	18:45	0:1	c|DEL|899_1142|	c . 899 - 1142del	SequenceVariant	81	86	2	1:Association:2	R2L	CROSS	131-136	42-45	g|DEL|99367_102002|	g . 99367 - 102002del	SequenceVariant	131	136	4	D009087	mucopolysaccharidosis type VI|mucopolysaccharidosis type VI	DiseaseOrPhenotypicFeature	15:42	18:45	0:1
15579441	Hypoxia in renal disease with proteinuria and / or glomerular hypertension .|Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .|In this study , we developed a new hypoxia - responsive reporter vector using a hypoxia - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel hypoxia - sensing transgenic rat .|We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney .|With this model , we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .|Expression of the hypoxia - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .|The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models .|Finally , we identified the localization of proliferating cell nuclear antigen - positive , ED - 1 - positive , and terminal dUTP nick - end labeled - positive cells in the hypoxic cortical area in the remnant kidney model .|We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases .	1:Association:2	L2R	NON-CROSS	57-61	67-68	D000860	Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic|hypoxia	DiseaseOrPhenotypicFeature	0:42:49:67:84:101:114:124:186:231:250	1:43:50:68:85:102:115:125:187:232:251	0:2:2:2:3:4:4:5:6:7:8	83785	vascular endothelial growth factor|vascular endothelial growth factor	GeneOrGeneProduct	57:166	61:170	2:5	1:Association:2	L2R	NON-CROSS	101-102	104-106	D000860	Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic|hypoxia	DiseaseOrPhenotypicFeature	0:42:49:67:84:101:114:124:186:231:250	1:43:50:68:85:102:115:125:187:232:251	0:2:2:2:3:4:4:5:6:7:8	D011692	puromycin aminonucleoside|puromycin aminonucleoside	ChemicalEntity	104:145	106:147	4:5	1:Association:2	R2L	NON-CROSS	231-232	213-216	302424	ED - 1	GeneOrGeneProduct	213	216	7	D000860	Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic|hypoxia	DiseaseOrPhenotypicFeature	0:42:49:67:84:101:114:124:186:231:250	1:43:50:68:85:102:115:125:187:232:251	0:2:2:2:3:4:4:5:6:7:8	1:Association:2	R2L	NON-CROSS	231-232	221-222	C027078	dUTP	ChemicalEntity	221	222	7	D000860	Hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxia|hypoxic|hypoxia	DiseaseOrPhenotypicFeature	0:42:49:67:84:101:114:124:186:231:250	1:43:50:68:85:102:115:125:187:232:251	0:2:2:2:3:4:4:5:6:7:8	1:NR:2	L2R	CROSS	166-170	193-195	D007674	renal disease|diseased kidney|tubulointerstitial injury|glomerular diseases	DiseaseOrPhenotypicFeature	2:87:193:253	4:89:195:255	0:3:6:8	83785	vascular endothelial growth factor|vascular endothelial growth factor	GeneOrGeneProduct	57:166	61:170	2:5	1:NR:2	L2R	CROSS	87-89	104-106	D007674	renal disease|diseased kidney|tubulointerstitial injury|glomerular diseases	DiseaseOrPhenotypicFeature	2:87:193:253	4:89:195:255	0:3:6:8	D011692	puromycin aminonucleoside|puromycin aminonucleoside	ChemicalEntity	104:145	106:147	4:5	1:NR:2	L2R	CROSS	193-195	213-216	D007674	renal disease|diseased kidney|tubulointerstitial injury|glomerular diseases	DiseaseOrPhenotypicFeature	2:87:193:253	4:89:195:255	0:3:6:8	302424	ED - 1	GeneOrGeneProduct	213	216	7	1:NR:2	L2R	CROSS	193-195	221-222	D007674	renal disease|diseased kidney|tubulointerstitial injury|glomerular diseases	DiseaseOrPhenotypicFeature	2:87:193:253	4:89:195:255	0:3:6:8	C027078	dUTP	ChemicalEntity	221	222	7	1:NR:2	L2R	CROSS	5-6	57-61	D011507	proteinuria	DiseaseOrPhenotypicFeature	5	6	0	83785	vascular endothelial growth factor|vascular endothelial growth factor	GeneOrGeneProduct	57:166	61:170	2:5	1:NR:2	L2R	CROSS	5-6	104-106	D011507	proteinuria	DiseaseOrPhenotypicFeature	5	6	0	D011692	puromycin aminonucleoside|puromycin aminonucleoside	ChemicalEntity	104:145	106:147	4:5	1:NR:2	L2R	CROSS	5-6	213-216	D011507	proteinuria	DiseaseOrPhenotypicFeature	5	6	0	302424	ED - 1	GeneOrGeneProduct	213	216	7	1:NR:2	L2R	CROSS	5-6	221-222	D011507	proteinuria	DiseaseOrPhenotypicFeature	5	6	0	C027078	dUTP	ChemicalEntity	221	222	7	1:NR:2	L2R	CROSS	10-11	57-61	D006973	hypertension	DiseaseOrPhenotypicFeature	10	11	0	83785	vascular endothelial growth factor|vascular endothelial growth factor	GeneOrGeneProduct	57:166	61:170	2:5	1:NR:2	L2R	CROSS	10-11	104-106	D006973	hypertension	DiseaseOrPhenotypicFeature	10	11	0	D011692	puromycin aminonucleoside|puromycin aminonucleoside	ChemicalEntity	104:145	106:147	4:5	1:NR:2	L2R	CROSS	10-11	213-216	D006973	hypertension	DiseaseOrPhenotypicFeature	10	11	0	302424	ED - 1	GeneOrGeneProduct	213	216	7	1:NR:2	L2R	CROSS	10-11	221-222	D006973	hypertension	DiseaseOrPhenotypicFeature	10	11	0	C027078	dUTP	ChemicalEntity	221	222	7	1:NR:2	L2R	NON-CROSS	145-147	166-170	83785	vascular endothelial growth factor|vascular endothelial growth factor	GeneOrGeneProduct	57:166	61:170	2:5	D011692	puromycin aminonucleoside|puromycin aminonucleoside	ChemicalEntity	104:145	106:147	4:5	1:NR:2	L2R	CROSS	57-61	108-110	83785	vascular endothelial growth factor|vascular endothelial growth factor	GeneOrGeneProduct	57:166	61:170	2:5	D009404	nephrotic syndrome	DiseaseOrPhenotypicFeature	108	110	4	1:NR:2	L2R	CROSS	166-170	213-216	83785	vascular endothelial growth factor|vascular endothelial growth factor	GeneOrGeneProduct	57:166	61:170	2:5	302424	ED - 1	GeneOrGeneProduct	213	216	7	1:NR:2	L2R	CROSS	166-170	221-222	83785	vascular endothelial growth factor|vascular endothelial growth factor	GeneOrGeneProduct	57:166	61:170	2:5	C027078	dUTP	ChemicalEntity	221	222	7	1:Positive_Correlation:2	L2R	NON-CROSS	104-106	108-110	D011692	puromycin aminonucleoside|puromycin aminonucleoside	ChemicalEntity	104:145	106:147	4:5	D009404	nephrotic syndrome	DiseaseOrPhenotypicFeature	108	110	4	1:NR:2	L2R	CROSS	145-147	213-216	D011692	puromycin aminonucleoside|puromycin aminonucleoside	ChemicalEntity	104:145	106:147	4:5	302424	ED - 1	GeneOrGeneProduct	213	216	7	1:NR:2	L2R	CROSS	145-147	221-222	D011692	puromycin aminonucleoside|puromycin aminonucleoside	ChemicalEntity	104:145	106:147	4:5	C027078	dUTP	ChemicalEntity	221	222	7	1:NR:2	L2R	CROSS	108-110	213-216	D009404	nephrotic syndrome	DiseaseOrPhenotypicFeature	108	110	4	302424	ED - 1	GeneOrGeneProduct	213	216	7	1:NR:2	L2R	CROSS	108-110	221-222	D009404	nephrotic syndrome	DiseaseOrPhenotypicFeature	108	110	4	C027078	dUTP	ChemicalEntity	221	222	7	1:NR:2	L2R	NON-CROSS	213-216	221-222	302424	ED - 1	GeneOrGeneProduct	213	216	7	C027078	dUTP	ChemicalEntity	221	222	7
15754732	Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics .|Primary hyperparathyroidism ( pHPT ) is a common endocrine disease that in more than 95 % of cases is sporadic and only in some cases is caused by inherited disorders , isolated or as part of multiple endocrine neoplasia ( MEN1 and 2 ) .|Somatic mutations of MEN1 gene have also been described in sporadic parathyroid tumors .|In our study , we examined the presence of alterations in MEN1 gene in a series of 39 patients who had undergone surgery for sporadic pHPT ( 35 with parathyroid adenoma or hyperplasia , 4 with a carcinoma ) .|A genotype - phenotype correlation was also analysed .|After DNA extraction from paraffin - embedded tissues , we amplified by PCR and sequenced the exons 2 - 10 of the MEN1 gene .|Somatic MEN1 mutations were detected in 6 of the 35 patients with a benign parathyroid lesion examined ( 17 . 1 % ) , whereas no alterations were found in the carcinomas .|Four novel MEN1 gene mutations were identified as follows : one frameshift mutation ( 222insT , exon 2 ) , one frameshift deletion ( 912delTA , exon 5 ) , one in - frame deletion ( 835del18 , exon 4 ) and one missense mutation ( P291A , exon 6 ) .|In addition , one missense mutation ( L89R , exon 2 ) and one nonsense mutation ( Q536X , exon 10 ) were previously reported .|Moreover , two polymorphisms were also found : one allele carried a R171Q polymorphism ( 1 / 39 tumors ) , while a D418D polymorphism ( GAC / GAT ) was found in 15 and 8 tumors in hetero ( CT ) and homozygosity ( TT ) , respectively .|In no case ( mutations and / or polymorphisms ) did we find a genotype - phenotype correlation .|In conclusion , our data demonstrate the presence of somatic alterations of the MEN1 tumor suppressor gene in about one fifth of benign sporadic parathyroid tumors .|The absence of a genotype - phenotype correlation , however , suggests the involvement of other genetic / epigenetic factors for the full expression of the disease .	1:Association:2	L2R	NON-CROSS	2-3	7-9	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	1:NR:2	L2R	CROSS	2-3	23-25	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	1:NR:2	L2R	CROSS	43-45	63-64	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	1:NR:2	L2R	CROSS	51-54	63-64	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	1:NR:2	L2R	CROSS	55-58	63-64	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	1:Association:2	L2R	NON-CROSS	63-64	71-73	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	1:Association:2	R2L	NON-CROSS	183-184	179-180	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	1:NR:2	L2R	NON-CROSS	127-128	145-146	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D010232	paraffin	ChemicalEntity	127	128	5	1:Association:2	L2R	NON-CROSS	149-150	161-164	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	1:Association:2	L2R	NON-CROSS	341-342	342-343	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	2:63:85:145:149:183:341	3:64:86:146:150:184:342	0:2:3:5:6:7:11	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:NR:2	L2R	CROSS	99-100	127-128	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	D010232	paraffin	ChemicalEntity	127	128	5	1:Association:2	L2R	CROSS	99-100	195-196	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	c|INS|222|T	222insT	SequenceVariant	195	196	7	1:Association:2	L2R	CROSS	99-100	205-206	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	1:Association:2	L2R	CROSS	99-100	217-218	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	c|DEL|835|18	835del18	SequenceVariant	217	218	7	1:Association:2	L2R	CROSS	99-100	227-228	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	1:Association:2	L2R	CROSS	99-100	240-241	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	1:Association:2	L2R	CROSS	99-100	250-251	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	1:Association:2	L2R	CROSS	99-100	271-272	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	rs607969	R171Q	SequenceVariant	271	272	9	1:Association:2	L2R	CROSS	99-100	282-283	D049950	primary hyperparathyroidism|Primary hyperparathyroidism|pHPT|pHPT	DiseaseOrPhenotypicFeature	7:15:18:99	9:17:19:100	0:1:1:3	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:NR:2	L2R	CROSS	23-25	127-128	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	D010232	paraffin	ChemicalEntity	127	128	5	1:NR:2	L2R	CROSS	23-25	195-196	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	c|INS|222|T	222insT	SequenceVariant	195	196	7	1:NR:2	L2R	CROSS	23-25	205-206	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	1:NR:2	L2R	CROSS	23-25	217-218	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	c|DEL|835|18	835del18	SequenceVariant	217	218	7	1:NR:2	L2R	CROSS	23-25	227-228	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	1:NR:2	L2R	CROSS	23-25	240-241	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	1:NR:2	L2R	CROSS	23-25	250-251	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	1:NR:2	L2R	CROSS	23-25	271-272	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	rs607969	R171Q	SequenceVariant	271	272	9	1:NR:2	L2R	CROSS	23-25	282-283	D004700	endocrine disease	DiseaseOrPhenotypicFeature	23	25	1	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:NR:2	L2R	CROSS	43-45	127-128	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	D010232	paraffin	ChemicalEntity	127	128	5	1:NR:2	L2R	CROSS	43-45	195-196	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	c|INS|222|T	222insT	SequenceVariant	195	196	7	1:NR:2	L2R	CROSS	43-45	205-206	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	1:NR:2	L2R	CROSS	43-45	217-218	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	c|DEL|835|18	835del18	SequenceVariant	217	218	7	1:NR:2	L2R	CROSS	43-45	227-228	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	1:NR:2	L2R	CROSS	43-45	240-241	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	1:NR:2	L2R	CROSS	43-45	250-251	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	1:NR:2	L2R	CROSS	43-45	271-272	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	rs607969	R171Q	SequenceVariant	271	272	9	1:NR:2	L2R	CROSS	43-45	282-283	D030342	inherited disorders	DiseaseOrPhenotypicFeature	43	45	1	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:NR:2	L2R	CROSS	51-54	127-128	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	D010232	paraffin	ChemicalEntity	127	128	5	1:NR:2	L2R	CROSS	51-54	195-196	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	c|INS|222|T	222insT	SequenceVariant	195	196	7	1:NR:2	L2R	CROSS	51-54	205-206	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	1:NR:2	L2R	CROSS	51-54	217-218	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	c|DEL|835|18	835del18	SequenceVariant	217	218	7	1:NR:2	L2R	CROSS	51-54	227-228	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	1:NR:2	L2R	CROSS	51-54	240-241	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	1:NR:2	L2R	CROSS	51-54	250-251	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	1:NR:2	L2R	CROSS	51-54	271-272	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	rs607969	R171Q	SequenceVariant	271	272	9	1:NR:2	L2R	CROSS	51-54	282-283	D009377	multiple endocrine neoplasia	DiseaseOrPhenotypicFeature	51	54	1	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:NR:2	L2R	CROSS	55-58	127-128	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	D010232	paraffin	ChemicalEntity	127	128	5	1:NR:2	L2R	CROSS	55-58	195-196	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	c|INS|222|T	222insT	SequenceVariant	195	196	7	1:NR:2	L2R	CROSS	55-58	205-206	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	1:NR:2	L2R	CROSS	55-58	217-218	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	c|DEL|835|18	835del18	SequenceVariant	217	218	7	1:NR:2	L2R	CROSS	55-58	227-228	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	1:NR:2	L2R	CROSS	55-58	240-241	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	1:NR:2	L2R	CROSS	55-58	250-251	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	1:NR:2	L2R	CROSS	55-58	271-272	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	rs607969	R171Q	SequenceVariant	271	272	9	1:NR:2	L2R	CROSS	55-58	282-283	D018761,D018813	MEN1 and 2	DiseaseOrPhenotypicFeature	55	58	1	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:NR:2	L2R	CROSS	103-107	127-128	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	D010232	paraffin	ChemicalEntity	127	128	5	1:Association:2	R2L	CROSS	195-196	103-107	c|INS|222|T	222insT	SequenceVariant	195	196	7	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	1:Association:2	R2L	CROSS	205-206	103-107	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	1:Association:2	R2L	CROSS	217-218	103-107	c|DEL|835|18	835del18	SequenceVariant	217	218	7	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	1:Association:2	R2L	CROSS	227-228	103-107	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	1:Association:2	R2L	CROSS	352-354	240-241	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	1:Association:2	R2L	CROSS	352-354	250-251	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	1:NR:2	L2R	CROSS	271-272	352-354	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	rs607969	R171Q	SequenceVariant	271	272	9	1:NR:2	L2R	CROSS	285-288	352-354	D010282	parathyroid tumors|parathyroid adenoma or hyperplasia|parathyroid tumors	DiseaseOrPhenotypicFeature	71:103:352	73:107:354	2:3:11	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:NR:2	L2R	CROSS	111-112	127-128	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	D010232	paraffin	ChemicalEntity	127	128	5	1:NR:2	L2R	CROSS	179-180	195-196	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	c|INS|222|T	222insT	SequenceVariant	195	196	7	1:NR:2	L2R	CROSS	179-180	205-206	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	1:NR:2	L2R	CROSS	179-180	217-218	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	c|DEL|835|18	835del18	SequenceVariant	217	218	7	1:NR:2	L2R	CROSS	179-180	227-228	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	1:NR:2	L2R	CROSS	179-180	240-241	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	1:NR:2	L2R	CROSS	179-180	250-251	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	1:NR:2	L2R	CROSS	179-180	271-272	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	rs607969	R171Q	SequenceVariant	271	272	9	1:NR:2	L2R	CROSS	179-180	282-283	D002277	carcinoma|carcinomas	DiseaseOrPhenotypicFeature	111:179	112:180	3:6	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:NR:2	L2R	CROSS	127-128	161-164	D010232	paraffin	ChemicalEntity	127	128	5	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	1:NR:2	L2R	CROSS	127-128	195-196	D010232	paraffin	ChemicalEntity	127	128	5	c|INS|222|T	222insT	SequenceVariant	195	196	7	1:NR:2	L2R	CROSS	127-128	205-206	D010232	paraffin	ChemicalEntity	127	128	5	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	1:NR:2	L2R	CROSS	127-128	217-218	D010232	paraffin	ChemicalEntity	127	128	5	c|DEL|835|18	835del18	SequenceVariant	217	218	7	1:NR:2	L2R	CROSS	127-128	227-228	D010232	paraffin	ChemicalEntity	127	128	5	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	1:NR:2	L2R	CROSS	127-128	240-241	D010232	paraffin	ChemicalEntity	127	128	5	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	1:NR:2	L2R	CROSS	127-128	250-251	D010232	paraffin	ChemicalEntity	127	128	5	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	1:NR:2	L2R	CROSS	127-128	271-272	D010232	paraffin	ChemicalEntity	127	128	5	rs607969	R171Q	SequenceVariant	271	272	9	1:NR:2	L2R	CROSS	127-128	277-278	D010232	paraffin	ChemicalEntity	127	128	5	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:NR:2	L2R	CROSS	127-128	282-283	D010232	paraffin	ChemicalEntity	127	128	5	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:Association:2	R2L	CROSS	195-196	161-164	c|INS|222|T	222insT	SequenceVariant	195	196	7	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	1:Association:2	R2L	CROSS	205-206	161-164	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	1:Association:2	R2L	CROSS	217-218	161-164	c|DEL|835|18	835del18	SequenceVariant	217	218	7	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	1:Association:2	R2L	CROSS	227-228	161-164	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	1:Association:2	R2L	CROSS	240-241	161-164	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	1:Association:2	R2L	CROSS	250-251	161-164	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	1:NR:2	L2R	CROSS	161-164	271-272	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	rs607969	R171Q	SequenceVariant	271	272	9	1:NR:2	L2R	CROSS	161-164	282-283	D010279	benign parathyroid lesion	DiseaseOrPhenotypicFeature	161	164	6	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	1:NR:2	L2R	CROSS	195-196	277-278	c|INS|222|T	222insT	SequenceVariant	195	196	7	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:NR:2	L2R	CROSS	205-206	277-278	c|DEL|912|TA	912delTA	SequenceVariant	205	206	7	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:NR:2	L2R	CROSS	217-218	277-278	c|DEL|835|18	835del18	SequenceVariant	217	218	7	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:NR:2	L2R	CROSS	227-228	277-278	p|SUB|P|291|A	P291A	SequenceVariant	227	228	7	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:NR:2	L2R	CROSS	240-241	277-278	p|SUB|L|89|R	L89R	SequenceVariant	240	241	8	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:NR:2	L2R	CROSS	250-251	277-278	p|SUB|Q|536|X	Q536X	SequenceVariant	250	251	8	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:Association:2	L2R	NON-CROSS	271-272	277-278	rs607969	R171Q	SequenceVariant	271	272	9	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11	1:Association:2	R2L	NON-CROSS	282-283	277-278	rs2071313	D418D|GAC / GAT	SequenceVariant	282:285	283:288	9:9	D009369	tumors|tumors|tumor	DiseaseOrPhenotypicFeature	277:295:342	278:296:343	9:9:11
18385794	Identification of novel mutations and sequence variants in the SOX2 and CHX10 genes in patients with anophthalmia / microphthalmia .|PURPOSE : Mutations in the SOX2 and CHX10 genes have been reported in patients with anophthalmia and / or microphthalmia .|In this study , we evaluated 34 anophthalmic / microphthalmic patient DNA samples ( two sets of siblings included ) for mutations and sequence variants in SOX2 and CHX10 .|METHODS : Conformational sensitive gel electrophoresis ( CSGE ) was used for the initial SOX2 and CHX10 screening of 34 affected individuals ( two sets of siblings ) , five unaffected family members , and 80 healthy controls .|Patient samples containing heteroduplexes were selected for sequence analysis .|Base pair changes in SOX2 and CHX10 were confirmed by sequencing bidirectionally in patient samples .|RESULTS : Two novel heterozygous mutations and two sequence variants ( one known ) in SOX2 were identified in this cohort .|Mutation c . 310 G > T ( p . Glu104X ) , found in one patient , was in the region encoding the high mobility group ( HMG ) DNA - binding domain and resulted in a change from glutamic acid to a stop codon .|The second mutation , noted in two affected siblings , was a single nucleotide deletion c . 549delC ( p . Pro184ArgfsX19 ) in the region encoding the activation domain , resulting in a frameshift and premature termination of the coding sequence .|The shortened protein products may result in the loss of function .|In addition , a novel nucleotide substitution c . * 557G > A was identified in the 3 ' - untranslated region in one patient .|The relationship between the nucleotide change and the protein function is indeterminate .|A known single nucleotide polymorphism ( c . * 469 C > A , SNP rs11915160 ) was also detected in 2 of the 34 patients .|Screening of CHX10 identified two synonymous sequence variants , c . 471 C > T ( p . Ser157Ser , rs35435463 ) and c . 579 G > A ( p . Gln193Gln , novel SNP ) , and one non - synonymous sequence variant , c . 871 G > A ( p . Asp291Asn , novel SNP ) .|The non - synonymous polymorphism was also present in healthy controls , suggesting non - causality .|CONCLUSIONS : These results support the role of SOX2 in ocular development .|Loss of SOX2 function results in severe eye malformation .|CHX10 was not implicated with microphthalmia / anophthalmia in our patient cohort .	1:NR:2	L2R	NON-CROSS	9-10	11-12	6657	SOX2|SOX2|SOX2|SOX2|SOX2|SOX2|SOX2|SOX2	GeneOrGeneProduct	9:25:67:85:124:151:412:419	10:26:68:86:125:152:413:420	0:1:2:3:5:6:15:16	338917	CHX10|CHX10|CHX10|CHX10|CHX10|CHX10|CHX10	GeneOrGeneProduct	11:27:69:87:126:328:427	12:28:70:88:127:329:428	0:1:2:3:5:13:17	1:Association:2	L2R	NON-CROSS	9-10	16-17	6657	SOX2|SOX2|SOX2|SOX2|SOX2|SOX2|SOX2|SOX2	GeneOrGeneProduct	9:25:67:85:124:151:412:419	10:26:68:86:125:152:413:420	0:1:2:3:5:6:15:16	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	1:Association:2	L2R	NON-CROSS	18-19	25-26	6657	SOX2|SOX2|SOX2|SOX2|SOX2|SOX2|SOX2|SOX2	GeneOrGeneProduct	9:25:67:85:124:151:412:419	10:26:68:86:125:152:413:420	0:1:2:3:5:6:15:16	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	1:Negative_Correlation:2	L2R	NON-CROSS	419-420	424-426	6657	SOX2|SOX2|SOX2|SOX2|SOX2|SOX2|SOX2|SOX2	GeneOrGeneProduct	9:25:67:85:124:151:412:419	10:26:68:86:125:152:413:420	0:1:2:3:5:6:15:16	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:Association:2	L2R	NON-CROSS	11-12	16-17	338917	CHX10|CHX10|CHX10|CHX10|CHX10|CHX10|CHX10	GeneOrGeneProduct	11:27:69:87:126:328:427	12:28:70:88:127:329:428	0:1:2:3:5:13:17	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	1:Association:2	L2R	NON-CROSS	427-428	432-433	338917	CHX10|CHX10|CHX10|CHX10|CHX10|CHX10|CHX10	GeneOrGeneProduct	11:27:69:87:126:328:427	12:28:70:88:127:329:428	0:1:2:3:5:13:17	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	1:NR:2	L2R	CROSS	424-426	427-428	338917	CHX10|CHX10|CHX10|CHX10|CHX10|CHX10|CHX10	GeneOrGeneProduct	11:27:69:87:126:328:427	12:28:70:88:127:329:428	0:1:2:3:5:13:17	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:Association:2	R2L	CROSS	159-165	48-49	c|SUB|G|310|T	c . 310 G > T	SequenceVariant	159	165	7	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	1:Association:2	R2L	CROSS	166-169	48-49	p|SUB|E|104|X	p . Glu104X	SequenceVariant	166	169	7	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	1:Association:2	R2L	CROSS	198-204	48-49	p|SUB|E||X	glutamic acid to a stop codon	SequenceVariant	198	204	7	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	1:Association:2	R2L	CROSS	220-223	48-49	rs587776776	c . 549delC|p . Pro184ArgfsX19	SequenceVariant	220:224	223:227	8:8	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	1:Association:2	R2L	CROSS	434-435	267-273	rs77677339	c . * 557G > A	SequenceVariant	267	273	10	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	1:Association:2	R2L	CROSS	434-435	314-315	rs11915160	c . * 469 C > A|rs11915160	SequenceVariant	305:314	312:315	12:12	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	1:NR:2	L2R	CROSS	346-347	434-435	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	rs35435463	c . 471 C > T|p . Ser157Ser|rs35435463	SequenceVariant	335:342:346	341:345:347	13:13:13	1:NR:2	L2R	CROSS	356-359	434-435	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	rs182972044	c . 579 G > A|p . Gln193Gln	SequenceVariant	349:356	355:359	13:13	1:NR:2	L2R	CROSS	379-382	434-435	D000853	anophthalmia|anophthalmia|anophthalmic|anophthalmia	DiseaseOrPhenotypicFeature	16:35:48:434	17:36:49:435	0:1:2:17	rs75395981	c . 871 G > A|p . Asp291Asn	SequenceVariant	372:379	378:382	13:13	1:Association:2	R2L	CROSS	159-165	50-51	c|SUB|G|310|T	c . 310 G > T	SequenceVariant	159	165	7	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	1:Association:2	R2L	CROSS	166-169	50-51	p|SUB|E|104|X	p . Glu104X	SequenceVariant	166	169	7	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	1:Association:2	R2L	CROSS	198-204	50-51	p|SUB|E||X	glutamic acid to a stop codon	SequenceVariant	198	204	7	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	1:Association:2	R2L	CROSS	220-223	50-51	rs587776776	c . 549delC|p . Pro184ArgfsX19	SequenceVariant	220:224	223:227	8:8	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	1:Association:2	L2R	CROSS	267-273	432-433	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	rs77677339	c . * 557G > A	SequenceVariant	267	273	10	1:Association:2	R2L	CROSS	432-433	314-315	rs11915160	c . * 469 C > A|rs11915160	SequenceVariant	305:314	312:315	12:12	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	1:NR:2	L2R	CROSS	346-347	432-433	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	rs35435463	c . 471 C > T|p . Ser157Ser|rs35435463	SequenceVariant	335:342:346	341:345:347	13:13:13	1:NR:2	L2R	CROSS	356-359	432-433	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	rs182972044	c . 579 G > A|p . Gln193Gln	SequenceVariant	349:356	355:359	13:13	1:NR:2	L2R	CROSS	379-382	432-433	D008850	microphthalmia|microphthalmia|microphthalmic|microphthalmia	DiseaseOrPhenotypicFeature	18:39:50:432	19:40:51:433	0:1:2:17	rs75395981	c . 871 G > A|p . Asp291Asn	SequenceVariant	372:379	378:382	13:13	1:Positive_Correlation:2	L2R	CROSS	159-165	424-426	c|SUB|G|310|T	c . 310 G > T	SequenceVariant	159	165	7	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:Positive_Correlation:2	L2R	CROSS	166-169	424-426	p|SUB|E|104|X	p . Glu104X	SequenceVariant	166	169	7	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:Positive_Correlation:2	L2R	CROSS	198-204	424-426	p|SUB|E||X	glutamic acid to a stop codon	SequenceVariant	198	204	7	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:Positive_Correlation:2	L2R	CROSS	224-227	424-426	rs587776776	c . 549delC|p . Pro184ArgfsX19	SequenceVariant	220:224	223:227	8:8	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:Association:2	L2R	CROSS	267-273	424-426	rs77677339	c . * 557G > A	SequenceVariant	267	273	10	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:Association:2	L2R	CROSS	314-315	424-426	rs11915160	c . * 469 C > A|rs11915160	SequenceVariant	305:314	312:315	12:12	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:NR:2	L2R	CROSS	346-347	424-426	rs35435463	c . 471 C > T|p . Ser157Ser|rs35435463	SequenceVariant	335:342:346	341:345:347	13:13:13	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:NR:2	L2R	CROSS	356-359	424-426	rs182972044	c . 579 G > A|p . Gln193Gln	SequenceVariant	349:356	355:359	13:13	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16	1:NR:2	L2R	CROSS	379-382	424-426	rs75395981	c . 871 G > A|p . Asp291Asn	SequenceVariant	372:379	378:382	13:13	D005124	eye malformation	DiseaseOrPhenotypicFeature	424	426	16
25589620	Pharmacogenetic Analysis of INT 0144 Trial : Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5 - FU and Radiation .|PURPOSE : We tested whether 18 polymorphisms in 16 genes ( GSTP1 , COX2 , IL10 , EGFR , EGF , FGFR4 , CCDN1 , VEGFR2 , VEGF , CXCR2 , IL8 , MMP3 , ICAM1 , ERCC1 , RAD51 , and XRCC3 ) would predict disease - free survival ( DFS ) , overall survival ( OS ) , and toxicity in the INT0144 trial , which was designed to investigate different postoperative regimens of 5 - fluorouracil ( 5 - FU ) - based chemoradiation ( CRT ) in locally advanced rectal cancers : Arm 1 consisted of bolus 5 - FU followed by 5 - FU protracted venous infusion ( PVI ) with radiotherapy ; arm 2 was induction and concomitant PVI 5 - FU with radiotherapy and arm 3 was induction and concomitant bolus 5 - FU with radiotherapy .|EXPERIMENTAL DESIGN : DNA from 746 stage II / III rectal patients enrolled in the Southwest Oncology Group ( SWOG ) S9304 phase III trial was analyzed .|Genomic DNA was extracted from formalin - fixed , paraffin - embedded ( FFPE ) tumor tissue .|The polymorphisms were analyzed using direct DNA - sequencing or polymerase chain reaction - restriction fragment length polymorphism ( PCR - RFLP ) .|RESULTS : GSTP1 - Ile105Val ( rs1695 ) was significantly associated with DFS and OS and its effect did not vary by treatment arm .|The five - year DFS and OS were 53 % and 58 % , respectively , for G / G , 66 % and 72 % for G / A , and 57 % and 66 % for A / A patients .|In arm 2 , IL8 - 251A / A genotype ( rs4073 ) was associated with a lower risk of toxicities ( P = 0 . 04 ) .|The VEGFR2 H472Q Q / Q genotype ( rs1870377 ) was associated with a higher risk of grade 3 - 5 proximal upper gastrointestinal tract ( PUGIT ) mucositis ( P = 0 . 04 ) in arm 2 .|However , in arm 1 , this genotype was associated with a lower risk of PUGIT mucositis ( P = 0 . 004 ) .|CONCLUSION : rs1695 may be prognostic in patients with rectal cancer treated with adjuvant CRT . rs4073 and rs1870377 may exhibit different associations with toxicity , according to the 5 - FU schedule .	1:NR:2	L2R	NON-CROSS	426-427	431-434	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	1:NR:2	L2R	NON-CROSS	13-14	37-38	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	1:NR:2	L2R	NON-CROSS	13-14	39-40	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	4513	COX2	GeneOrGeneProduct	39	40	1	1:NR:2	L2R	NON-CROSS	13-14	41-42	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	3586	IL10	GeneOrGeneProduct	41	42	1	1:NR:2	L2R	NON-CROSS	13-14	43-44	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	1956	EGFR	GeneOrGeneProduct	43	44	1	1:NR:2	L2R	NON-CROSS	13-14	45-46	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	1950	EGF	GeneOrGeneProduct	45	46	1	1:NR:2	L2R	NON-CROSS	13-14	47-48	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	2264	FGFR4	GeneOrGeneProduct	47	48	1	1:NR:2	L2R	NON-CROSS	13-14	49-50	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	595	CCDN1	GeneOrGeneProduct	49	50	1	1:NR:2	L2R	NON-CROSS	328-329	338-339	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	53-54	87-88	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	55-56	87-88	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	312-313	328-329	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	59-60	87-88	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	61-62	87-88	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	63-64	87-88	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	65-66	87-88	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	68-69	87-88	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	87-88	203-204	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	87-88	207-208	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	NON-CROSS	404-405	426-427	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	rs1695	Ile105Val|rs1695|rs1695	SequenceVariant	244:246:404	245:247:405	5:5:10	1:NR:2	L2R	NON-CROSS	418-419	426-427	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	rs4073	- 251A / A|rs4073|rs4073	SequenceVariant	313:319:418	317:320:419	7:7:10	1:NR:2	L2R	NON-CROSS	420-421	426-427	D064420	Toxicity|toxicity|toxicities|toxicity	DiseaseOrPhenotypicFeature	13:87:328:426	14:88:329:427	0:1:7:10	rs1870377	H472Q|rs1870377|rs1870377	SequenceVariant	339:345:420	340:346:421	8:8:10	1:Negative_Correlation:2	R2L	NON-CROSS	20-23	15-17	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	1:Association:2	L2R	NON-CROSS	15-17	37-38	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	1:NR:2	L2R	NON-CROSS	15-17	39-40	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	4513	COX2	GeneOrGeneProduct	39	40	1	1:NR:2	L2R	NON-CROSS	15-17	41-42	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	3586	IL10	GeneOrGeneProduct	41	42	1	1:NR:2	L2R	NON-CROSS	15-17	43-44	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	1956	EGFR	GeneOrGeneProduct	43	44	1	1:NR:2	L2R	NON-CROSS	15-17	45-46	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	1950	EGF	GeneOrGeneProduct	45	46	1	1:NR:2	L2R	NON-CROSS	15-17	47-48	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	2264	FGFR4	GeneOrGeneProduct	47	48	1	1:NR:2	L2R	NON-CROSS	15-17	49-50	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	595	CCDN1	GeneOrGeneProduct	49	50	1	1:NR:2	L2R	NON-CROSS	15-17	51-52	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	15-17	53-54	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	15-17	55-56	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	15-17	57-58	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	15-17	59-60	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	15-17	61-62	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	15-17	63-64	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	15-17	65-66	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	68-69	119-121	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	119-121	203-204	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	119-121	207-208	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	D010232	paraffin	ChemicalEntity	207	208	3	1:Association:2	R2L	NON-CROSS	411-413	404-405	rs1695	Ile105Val|rs1695|rs1695	SequenceVariant	244:246:404	245:247:405	5:5:10	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	1:NR:2	L2R	NON-CROSS	411-413	418-419	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	rs4073	- 251A / A|rs4073|rs4073	SequenceVariant	313:319:418	317:320:419	7:7:10	1:NR:2	L2R	NON-CROSS	411-413	420-421	D012004	Rectal Cancer|rectal cancers|rectal cancer	DiseaseOrPhenotypicFeature	15:119:411	17:121:413	0:1:10	rs1870377	H472Q|rs1870377|rs1870377	SequenceVariant	339:345:420	340:346:421	8:8:10	1:NR:2	L2R	NON-CROSS	20-23	37-38	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	1:NR:2	L2R	NON-CROSS	20-23	39-40	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	4513	COX2	GeneOrGeneProduct	39	40	1	1:NR:2	L2R	NON-CROSS	20-23	41-42	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	3586	IL10	GeneOrGeneProduct	41	42	1	1:NR:2	L2R	NON-CROSS	20-23	43-44	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	1956	EGFR	GeneOrGeneProduct	43	44	1	1:NR:2	L2R	NON-CROSS	20-23	45-46	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	1950	EGF	GeneOrGeneProduct	45	46	1	1:NR:2	L2R	NON-CROSS	20-23	47-48	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	2264	FGFR4	GeneOrGeneProduct	47	48	1	1:NR:2	L2R	NON-CROSS	20-23	49-50	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	595	CCDN1	GeneOrGeneProduct	49	50	1	1:Association:2	R2L	NON-CROSS	51-52	20-23	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	1:NR:2	L2R	NON-CROSS	20-23	53-54	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	20-23	55-56	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:Association:2	R2L	NON-CROSS	57-58	20-23	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	1:NR:2	L2R	NON-CROSS	20-23	59-60	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	20-23	61-62	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	63-64	102-105	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	65-66	102-105	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	68-69	102-105	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	164-167	203-204	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	164-167	207-208	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	164-167	213-214	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	NON-CROSS	404-405	431-434	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	rs1695	Ile105Val|rs1695|rs1695	SequenceVariant	244:246:404	245:247:405	5:5:10	1:Association:2	R2L	NON-CROSS	431-434	418-419	rs4073	- 251A / A|rs4073|rs4073	SequenceVariant	313:319:418	317:320:419	7:7:10	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	1:Association:2	R2L	NON-CROSS	431-434	420-421	rs1870377	H472Q|rs1870377|rs1870377	SequenceVariant	339:345:420	340:346:421	8:8:10	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	1:NR:2	L2R	CROSS	393-394	431-434	D005472	5 - FU|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	20:102:106:127:132:151:164:431	23:105:109:130:135:154:167:434	0:1:1:1:1:1:1:10	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	37-38	39-40	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	4513	COX2	GeneOrGeneProduct	39	40	1	1:NR:2	L2R	NON-CROSS	37-38	41-42	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	3586	IL10	GeneOrGeneProduct	41	42	1	1:NR:2	L2R	NON-CROSS	37-38	43-44	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	1956	EGFR	GeneOrGeneProduct	43	44	1	1:NR:2	L2R	NON-CROSS	37-38	45-46	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	1950	EGF	GeneOrGeneProduct	45	46	1	1:NR:2	L2R	NON-CROSS	37-38	47-48	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	2264	FGFR4	GeneOrGeneProduct	47	48	1	1:NR:2	L2R	NON-CROSS	37-38	49-50	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	595	CCDN1	GeneOrGeneProduct	49	50	1	1:NR:2	L2R	NON-CROSS	37-38	51-52	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	37-38	53-54	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	37-38	55-56	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	37-38	57-58	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	37-38	59-60	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	37-38	61-62	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	37-38	63-64	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	37-38	65-66	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	37-38	68-69	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	203-204	242-243	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	207-208	242-243	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	213-214	242-243	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	242-243	365-366	2950	GSTP1|GSTP1	GeneOrGeneProduct	37:242	38:243	1:5	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	39-40	41-42	4513	COX2	GeneOrGeneProduct	39	40	1	3586	IL10	GeneOrGeneProduct	41	42	1	1:NR:2	L2R	NON-CROSS	39-40	43-44	4513	COX2	GeneOrGeneProduct	39	40	1	1956	EGFR	GeneOrGeneProduct	43	44	1	1:NR:2	L2R	NON-CROSS	39-40	45-46	4513	COX2	GeneOrGeneProduct	39	40	1	1950	EGF	GeneOrGeneProduct	45	46	1	1:NR:2	L2R	NON-CROSS	39-40	47-48	4513	COX2	GeneOrGeneProduct	39	40	1	2264	FGFR4	GeneOrGeneProduct	47	48	1	1:NR:2	L2R	NON-CROSS	39-40	49-50	4513	COX2	GeneOrGeneProduct	39	40	1	595	CCDN1	GeneOrGeneProduct	49	50	1	1:NR:2	L2R	NON-CROSS	39-40	51-52	4513	COX2	GeneOrGeneProduct	39	40	1	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	39-40	53-54	4513	COX2	GeneOrGeneProduct	39	40	1	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	39-40	55-56	4513	COX2	GeneOrGeneProduct	39	40	1	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	39-40	57-58	4513	COX2	GeneOrGeneProduct	39	40	1	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	39-40	59-60	4513	COX2	GeneOrGeneProduct	39	40	1	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	39-40	61-62	4513	COX2	GeneOrGeneProduct	39	40	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	39-40	63-64	4513	COX2	GeneOrGeneProduct	39	40	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	39-40	65-66	4513	COX2	GeneOrGeneProduct	39	40	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	39-40	68-69	4513	COX2	GeneOrGeneProduct	39	40	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	39-40	203-204	4513	COX2	GeneOrGeneProduct	39	40	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	39-40	207-208	4513	COX2	GeneOrGeneProduct	39	40	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	39-40	213-214	4513	COX2	GeneOrGeneProduct	39	40	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	39-40	365-366	4513	COX2	GeneOrGeneProduct	39	40	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	41-42	43-44	3586	IL10	GeneOrGeneProduct	41	42	1	1956	EGFR	GeneOrGeneProduct	43	44	1	1:NR:2	L2R	NON-CROSS	41-42	45-46	3586	IL10	GeneOrGeneProduct	41	42	1	1950	EGF	GeneOrGeneProduct	45	46	1	1:NR:2	L2R	NON-CROSS	41-42	47-48	3586	IL10	GeneOrGeneProduct	41	42	1	2264	FGFR4	GeneOrGeneProduct	47	48	1	1:NR:2	L2R	NON-CROSS	41-42	49-50	3586	IL10	GeneOrGeneProduct	41	42	1	595	CCDN1	GeneOrGeneProduct	49	50	1	1:NR:2	L2R	NON-CROSS	41-42	51-52	3586	IL10	GeneOrGeneProduct	41	42	1	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	41-42	53-54	3586	IL10	GeneOrGeneProduct	41	42	1	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	41-42	55-56	3586	IL10	GeneOrGeneProduct	41	42	1	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	41-42	57-58	3586	IL10	GeneOrGeneProduct	41	42	1	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	41-42	59-60	3586	IL10	GeneOrGeneProduct	41	42	1	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	41-42	61-62	3586	IL10	GeneOrGeneProduct	41	42	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	41-42	63-64	3586	IL10	GeneOrGeneProduct	41	42	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	41-42	65-66	3586	IL10	GeneOrGeneProduct	41	42	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	41-42	68-69	3586	IL10	GeneOrGeneProduct	41	42	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	41-42	203-204	3586	IL10	GeneOrGeneProduct	41	42	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	41-42	207-208	3586	IL10	GeneOrGeneProduct	41	42	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	41-42	213-214	3586	IL10	GeneOrGeneProduct	41	42	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	41-42	365-366	3586	IL10	GeneOrGeneProduct	41	42	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	43-44	45-46	1956	EGFR	GeneOrGeneProduct	43	44	1	1950	EGF	GeneOrGeneProduct	45	46	1	1:NR:2	L2R	NON-CROSS	43-44	47-48	1956	EGFR	GeneOrGeneProduct	43	44	1	2264	FGFR4	GeneOrGeneProduct	47	48	1	1:NR:2	L2R	NON-CROSS	43-44	49-50	1956	EGFR	GeneOrGeneProduct	43	44	1	595	CCDN1	GeneOrGeneProduct	49	50	1	1:NR:2	L2R	NON-CROSS	43-44	51-52	1956	EGFR	GeneOrGeneProduct	43	44	1	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	43-44	53-54	1956	EGFR	GeneOrGeneProduct	43	44	1	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	43-44	55-56	1956	EGFR	GeneOrGeneProduct	43	44	1	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	43-44	57-58	1956	EGFR	GeneOrGeneProduct	43	44	1	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	43-44	59-60	1956	EGFR	GeneOrGeneProduct	43	44	1	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	43-44	61-62	1956	EGFR	GeneOrGeneProduct	43	44	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	43-44	63-64	1956	EGFR	GeneOrGeneProduct	43	44	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	43-44	65-66	1956	EGFR	GeneOrGeneProduct	43	44	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	43-44	68-69	1956	EGFR	GeneOrGeneProduct	43	44	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	43-44	203-204	1956	EGFR	GeneOrGeneProduct	43	44	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	43-44	207-208	1956	EGFR	GeneOrGeneProduct	43	44	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	43-44	213-214	1956	EGFR	GeneOrGeneProduct	43	44	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	43-44	365-366	1956	EGFR	GeneOrGeneProduct	43	44	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	45-46	47-48	1950	EGF	GeneOrGeneProduct	45	46	1	2264	FGFR4	GeneOrGeneProduct	47	48	1	1:NR:2	L2R	NON-CROSS	45-46	49-50	1950	EGF	GeneOrGeneProduct	45	46	1	595	CCDN1	GeneOrGeneProduct	49	50	1	1:NR:2	L2R	NON-CROSS	45-46	51-52	1950	EGF	GeneOrGeneProduct	45	46	1	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	45-46	53-54	1950	EGF	GeneOrGeneProduct	45	46	1	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	45-46	55-56	1950	EGF	GeneOrGeneProduct	45	46	1	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	45-46	57-58	1950	EGF	GeneOrGeneProduct	45	46	1	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	45-46	59-60	1950	EGF	GeneOrGeneProduct	45	46	1	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	45-46	61-62	1950	EGF	GeneOrGeneProduct	45	46	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	45-46	63-64	1950	EGF	GeneOrGeneProduct	45	46	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	45-46	65-66	1950	EGF	GeneOrGeneProduct	45	46	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	45-46	68-69	1950	EGF	GeneOrGeneProduct	45	46	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	45-46	203-204	1950	EGF	GeneOrGeneProduct	45	46	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	45-46	207-208	1950	EGF	GeneOrGeneProduct	45	46	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	45-46	213-214	1950	EGF	GeneOrGeneProduct	45	46	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	45-46	365-366	1950	EGF	GeneOrGeneProduct	45	46	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	47-48	49-50	2264	FGFR4	GeneOrGeneProduct	47	48	1	595	CCDN1	GeneOrGeneProduct	49	50	1	1:NR:2	L2R	NON-CROSS	47-48	51-52	2264	FGFR4	GeneOrGeneProduct	47	48	1	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	47-48	53-54	2264	FGFR4	GeneOrGeneProduct	47	48	1	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	47-48	55-56	2264	FGFR4	GeneOrGeneProduct	47	48	1	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	47-48	57-58	2264	FGFR4	GeneOrGeneProduct	47	48	1	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	47-48	59-60	2264	FGFR4	GeneOrGeneProduct	47	48	1	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	47-48	61-62	2264	FGFR4	GeneOrGeneProduct	47	48	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	47-48	63-64	2264	FGFR4	GeneOrGeneProduct	47	48	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	47-48	65-66	2264	FGFR4	GeneOrGeneProduct	47	48	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	47-48	68-69	2264	FGFR4	GeneOrGeneProduct	47	48	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	47-48	203-204	2264	FGFR4	GeneOrGeneProduct	47	48	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	47-48	207-208	2264	FGFR4	GeneOrGeneProduct	47	48	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	47-48	213-214	2264	FGFR4	GeneOrGeneProduct	47	48	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	47-48	365-366	2264	FGFR4	GeneOrGeneProduct	47	48	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	49-50	51-52	595	CCDN1	GeneOrGeneProduct	49	50	1	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	1:NR:2	L2R	NON-CROSS	49-50	53-54	595	CCDN1	GeneOrGeneProduct	49	50	1	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	49-50	55-56	595	CCDN1	GeneOrGeneProduct	49	50	1	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	49-50	57-58	595	CCDN1	GeneOrGeneProduct	49	50	1	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	49-50	59-60	595	CCDN1	GeneOrGeneProduct	49	50	1	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	49-50	61-62	595	CCDN1	GeneOrGeneProduct	49	50	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	49-50	63-64	595	CCDN1	GeneOrGeneProduct	49	50	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	49-50	65-66	595	CCDN1	GeneOrGeneProduct	49	50	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	49-50	68-69	595	CCDN1	GeneOrGeneProduct	49	50	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	49-50	203-204	595	CCDN1	GeneOrGeneProduct	49	50	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	49-50	207-208	595	CCDN1	GeneOrGeneProduct	49	50	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	49-50	213-214	595	CCDN1	GeneOrGeneProduct	49	50	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	49-50	365-366	595	CCDN1	GeneOrGeneProduct	49	50	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	51-52	53-54	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	7422	VEGF	GeneOrGeneProduct	53	54	1	1:NR:2	L2R	NON-CROSS	51-52	55-56	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	51-52	57-58	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	51-52	59-60	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	51-52	61-62	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	51-52	63-64	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	51-52	65-66	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	51-52	68-69	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	203-204	338-339	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	207-208	338-339	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	213-214	338-339	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:Association:2	L2R	NON-CROSS	338-339	365-366	3791	VEGFR2|VEGFR2	GeneOrGeneProduct	51:338	52:339	1:8	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	53-54	55-56	7422	VEGF	GeneOrGeneProduct	53	54	1	3579	CXCR2	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	53-54	57-58	7422	VEGF	GeneOrGeneProduct	53	54	1	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	53-54	59-60	7422	VEGF	GeneOrGeneProduct	53	54	1	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	53-54	61-62	7422	VEGF	GeneOrGeneProduct	53	54	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	53-54	63-64	7422	VEGF	GeneOrGeneProduct	53	54	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	53-54	65-66	7422	VEGF	GeneOrGeneProduct	53	54	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	53-54	68-69	7422	VEGF	GeneOrGeneProduct	53	54	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	53-54	203-204	7422	VEGF	GeneOrGeneProduct	53	54	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	53-54	207-208	7422	VEGF	GeneOrGeneProduct	53	54	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	53-54	213-214	7422	VEGF	GeneOrGeneProduct	53	54	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	53-54	365-366	7422	VEGF	GeneOrGeneProduct	53	54	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	55-56	57-58	3579	CXCR2	GeneOrGeneProduct	55	56	1	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	1:NR:2	L2R	NON-CROSS	55-56	59-60	3579	CXCR2	GeneOrGeneProduct	55	56	1	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	55-56	61-62	3579	CXCR2	GeneOrGeneProduct	55	56	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	55-56	63-64	3579	CXCR2	GeneOrGeneProduct	55	56	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	55-56	65-66	3579	CXCR2	GeneOrGeneProduct	55	56	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	55-56	68-69	3579	CXCR2	GeneOrGeneProduct	55	56	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	55-56	203-204	3579	CXCR2	GeneOrGeneProduct	55	56	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	55-56	207-208	3579	CXCR2	GeneOrGeneProduct	55	56	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	55-56	213-214	3579	CXCR2	GeneOrGeneProduct	55	56	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	55-56	365-366	3579	CXCR2	GeneOrGeneProduct	55	56	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	57-58	59-60	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	4314	MMP3	GeneOrGeneProduct	59	60	1	1:NR:2	L2R	NON-CROSS	57-58	61-62	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	57-58	63-64	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	57-58	65-66	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	57-58	68-69	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	203-204	312-313	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	207-208	312-313	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	213-214	312-313	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	312-313	365-366	3576	IL8|IL8	GeneOrGeneProduct	57:312	58:313	1:7	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	59-60	61-62	4314	MMP3	GeneOrGeneProduct	59	60	1	3383	ICAM1	GeneOrGeneProduct	61	62	1	1:NR:2	L2R	NON-CROSS	59-60	63-64	4314	MMP3	GeneOrGeneProduct	59	60	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	59-60	65-66	4314	MMP3	GeneOrGeneProduct	59	60	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	59-60	68-69	4314	MMP3	GeneOrGeneProduct	59	60	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	59-60	203-204	4314	MMP3	GeneOrGeneProduct	59	60	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	59-60	207-208	4314	MMP3	GeneOrGeneProduct	59	60	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	59-60	213-214	4314	MMP3	GeneOrGeneProduct	59	60	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	59-60	365-366	4314	MMP3	GeneOrGeneProduct	59	60	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	61-62	63-64	3383	ICAM1	GeneOrGeneProduct	61	62	1	2067	ERCC1	GeneOrGeneProduct	63	64	1	1:NR:2	L2R	NON-CROSS	61-62	65-66	3383	ICAM1	GeneOrGeneProduct	61	62	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	61-62	68-69	3383	ICAM1	GeneOrGeneProduct	61	62	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	61-62	203-204	3383	ICAM1	GeneOrGeneProduct	61	62	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	61-62	207-208	3383	ICAM1	GeneOrGeneProduct	61	62	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	61-62	213-214	3383	ICAM1	GeneOrGeneProduct	61	62	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	61-62	365-366	3383	ICAM1	GeneOrGeneProduct	61	62	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	63-64	65-66	2067	ERCC1	GeneOrGeneProduct	63	64	1	5888	RAD51	GeneOrGeneProduct	65	66	1	1:NR:2	L2R	NON-CROSS	63-64	68-69	2067	ERCC1	GeneOrGeneProduct	63	64	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	63-64	203-204	2067	ERCC1	GeneOrGeneProduct	63	64	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	63-64	207-208	2067	ERCC1	GeneOrGeneProduct	63	64	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	63-64	213-214	2067	ERCC1	GeneOrGeneProduct	63	64	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	63-64	365-366	2067	ERCC1	GeneOrGeneProduct	63	64	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	65-66	68-69	5888	RAD51	GeneOrGeneProduct	65	66	1	7517	XRCC3	GeneOrGeneProduct	68	69	1	1:NR:2	L2R	CROSS	65-66	203-204	5888	RAD51	GeneOrGeneProduct	65	66	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	65-66	207-208	5888	RAD51	GeneOrGeneProduct	65	66	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	65-66	213-214	5888	RAD51	GeneOrGeneProduct	65	66	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	65-66	365-366	5888	RAD51	GeneOrGeneProduct	65	66	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	CROSS	68-69	203-204	7517	XRCC3	GeneOrGeneProduct	68	69	1	D005557	formalin	ChemicalEntity	203	204	3	1:NR:2	L2R	CROSS	68-69	207-208	7517	XRCC3	GeneOrGeneProduct	68	69	1	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	CROSS	68-69	213-214	7517	XRCC3	GeneOrGeneProduct	68	69	1	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	68-69	365-366	7517	XRCC3	GeneOrGeneProduct	68	69	1	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	203-204	207-208	D005557	formalin	ChemicalEntity	203	204	3	D010232	paraffin	ChemicalEntity	207	208	3	1:NR:2	L2R	NON-CROSS	203-204	213-214	D005557	formalin	ChemicalEntity	203	204	3	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	203-204	244-245	D005557	formalin	ChemicalEntity	203	204	3	rs1695	Ile105Val|rs1695|rs1695	SequenceVariant	244:246:404	245:247:405	5:5:10	1:NR:2	L2R	CROSS	203-204	313-317	D005557	formalin	ChemicalEntity	203	204	3	rs4073	- 251A / A|rs4073|rs4073	SequenceVariant	313:319:418	317:320:419	7:7:10	1:NR:2	L2R	CROSS	203-204	339-340	D005557	formalin	ChemicalEntity	203	204	3	rs1870377	H472Q|rs1870377|rs1870377	SequenceVariant	339:345:420	340:346:421	8:8:10	1:NR:2	L2R	CROSS	203-204	365-366	D005557	formalin	ChemicalEntity	203	204	3	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	NON-CROSS	207-208	213-214	D010232	paraffin	ChemicalEntity	207	208	3	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	1:NR:2	L2R	CROSS	207-208	244-245	D010232	paraffin	ChemicalEntity	207	208	3	rs1695	Ile105Val|rs1695|rs1695	SequenceVariant	244:246:404	245:247:405	5:5:10	1:NR:2	L2R	CROSS	207-208	313-317	D010232	paraffin	ChemicalEntity	207	208	3	rs4073	- 251A / A|rs4073|rs4073	SequenceVariant	313:319:418	317:320:419	7:7:10	1:NR:2	L2R	CROSS	207-208	339-340	D010232	paraffin	ChemicalEntity	207	208	3	rs1870377	H472Q|rs1870377|rs1870377	SequenceVariant	339:345:420	340:346:421	8:8:10	1:NR:2	L2R	CROSS	207-208	365-366	D010232	paraffin	ChemicalEntity	207	208	3	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	CROSS	213-214	244-245	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	rs1695	Ile105Val|rs1695|rs1695	SequenceVariant	244:246:404	245:247:405	5:5:10	1:NR:2	L2R	CROSS	213-214	313-317	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	rs4073	- 251A / A|rs4073|rs4073	SequenceVariant	313:319:418	317:320:419	7:7:10	1:NR:2	L2R	CROSS	213-214	339-340	D009369	tumor	DiseaseOrPhenotypicFeature	213	214	3	rs1870377	H472Q|rs1870377|rs1870377	SequenceVariant	339:345:420	340:346:421	8:8:10	1:NR:2	L2R	CROSS	393-394	404-405	rs1695	Ile105Val|rs1695|rs1695	SequenceVariant	244:246:404	245:247:405	5:5:10	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:NR:2	L2R	CROSS	393-394	418-419	rs4073	- 251A / A|rs4073|rs4073	SequenceVariant	313:319:418	317:320:419	7:7:10	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9	1:Positive_Correlation:2	L2R	NON-CROSS	345-346	365-366	rs1870377	H472Q|rs1870377|rs1870377	SequenceVariant	339:345:420	340:346:421	8:8:10	D052016	mucositis|mucositis	DiseaseOrPhenotypicFeature	365:393	366:394	8:9
15086325	Identification of three F5 gene mutations associated with inherited coagulation factor V deficiency in two Chinese pedigrees .|To investigate the molecular defects in two Chinese pedigrees with inherited factor V ( FV ) deficiency .|A 37 - year - old male ( proband 1 ) and an 18 - month - old boy ( proband 2 ) were diagnosed as inherited coagulation FV deficiency by severely reduced plasma levels of FV activity and antigen .|All 25 exons and their flanking sequence of F5 gene were amplified by polymerase chain reaction ( PCR ) for both probands and the PCR products were directly sequenced .|Total RNA was extracted from the peripheral lymphocytes of proband 1 for detecting the changes at mRNA level .|The homozygous deletion IVS8 - 2A > G was identified in the F5 gene of proband 1 and complementary DNA ( cDNA ) analysis revealed the abolishment of the canonical splicing site by the mutation and the activation of the cryptic acceptor site 24 bp upstream instead .|The insertion introduced eight additional amino acids ( AA ) into the FV protein .|Two heterozygous mutations of F5 gene were discovered in proband 2 .|The 2238 - 9del AG in exon 13 introduced a premature termination code at 689 AA and the substitution of G6410 by T in exon 23 lead to the missense mutation Gly2079Val .|Three F5 gene mutations , IVS8 - 2A > G , 2238 - 9del AG and G6410T , have been identified in two Chinese pedigree with congenital FV deficiency , respectively .	1:Association:2	L2R	NON-CROSS	3-4	8-13	2153	F5|FV|F5|F5|FV|F5|F5	GeneOrGeneProduct	3:72:85:138:186:193:235	4:73:86:139:187:194:236	0:2:3:5:6:7:9	D005166	inherited coagulation factor V deficiency|inherited factor V ( FV ) deficiency|inherited coagulation FV deficiency|congenital FV deficiency	DiseaseOrPhenotypicFeature	8:28:62:260	13:35:66:263	0:1:2:9	1:Association:2	R2L	NON-CROSS	260-263	239-244	c|SUB|A|IVS8-2|G	IVS8 - 2A > G|IVS8 - 2A > G	SequenceVariant	129:239	134:244	5:9	D005166	inherited coagulation factor V deficiency|inherited factor V ( FV ) deficiency|inherited coagulation FV deficiency|congenital FV deficiency	DiseaseOrPhenotypicFeature	8:28:62:260	13:35:66:263	0:1:2:9	1:Association:2	L2R	CROSS	175-181	260-263	D005166	inherited coagulation factor V deficiency|inherited factor V ( FV ) deficiency|inherited coagulation FV deficiency|congenital FV deficiency	DiseaseOrPhenotypicFeature	8:28:62:260	13:35:66:263	0:1:2:9	p|INS||8	insertion introduced eight additional amino acids	SequenceVariant	175	181	6	1:Association:2	R2L	NON-CROSS	260-263	245-249	c|DEL|2238_2239|AG	2238 - 9del AG|2238 - 9del AG	SequenceVariant	202:245	206:249	8:9	D005166	inherited coagulation factor V deficiency|inherited factor V ( FV ) deficiency|inherited coagulation FV deficiency|congenital FV deficiency	DiseaseOrPhenotypicFeature	8:28:62:260	13:35:66:263	0:1:2:9	1:Association:2	L2R	CROSS	215-217	260-263	D005166	inherited coagulation factor V deficiency|inherited factor V ( FV ) deficiency|inherited coagulation FV deficiency|congenital FV deficiency	DiseaseOrPhenotypicFeature	8:28:62:260	13:35:66:263	0:1:2:9	c|Allele|A|689	689 AA	SequenceVariant	215	217	8	1:Association:2	R2L	NON-CROSS	260-263	250-251	g|SUB|G|6410|T	G6410 by T|G6410T	SequenceVariant	221:250	224:251	8:9	D005166	inherited coagulation factor V deficiency|inherited factor V ( FV ) deficiency|inherited coagulation FV deficiency|congenital FV deficiency	DiseaseOrPhenotypicFeature	8:28:62:260	13:35:66:263	0:1:2:9	1:Association:2	L2R	CROSS	232-233	260-263	D005166	inherited coagulation factor V deficiency|inherited factor V ( FV ) deficiency|inherited coagulation FV deficiency|congenital FV deficiency	DiseaseOrPhenotypicFeature	8:28:62:260	13:35:66:263	0:1:2:9	p|SUB|G|2079|V	Gly2079Val	SequenceVariant	232	233	8
19300402	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model .|PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy was investigated .|METHODS : The changes in pain thresholds were determined using mechanical stimuli - - the modification of the classic paw withdrawal test described by Randall - Selitto .|RESULTS : The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia .|Pretreatment with L - NOArg and L - NIL but not 7 - NI , significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140 .|It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine .|Moreover , L - NOArg and 7 - NI but not L - NIL intensify antihyperalgesic activity of HOE 140 or des - Arg10HOE 140 in toxic neuropathy .|CONCLUSIONS : Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy .|In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .|Therefore , concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain , even in hospital care .	1:NR:2	L2R	NON-CROSS	0-3	4-8	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	1:NR:2	L2R	NON-CROSS	0-3	9-10	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	1:NR:2	L2R	NON-CROSS	0-3	11-12	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	1:NR:2	L2R	NON-CROSS	0-3	13-14	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	1:NR:2	L2R	NON-CROSS	0-3	17-19	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	1:NR:2	L2R	CROSS	0-3	31-34	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	1:NR:2	L2R	CROSS	0-3	35-38	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	1:NR:2	L2R	CROSS	336-339	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	1:NR:2	L2R	CROSS	0-3	57-60	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:NR:2	L2R	CROSS	356-359	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	CROSS	0-3	79-82	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	CROSS	312-316	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	CROSS	293-295	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	CROSS	296-300	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	CROSS	325-329	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	0-3	169-170	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	352-353	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	301-303	369-372	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:Negative_Correlation:2	L2R	NON-CROSS	369-372	382-384	D065168	Bradykinin receptors antagonists|bradykinin receptor antagonists	ChemicalEntity	0:369	3:372	0:9	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	NON-CROSS	4-8	9-10	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	1:NR:2	L2R	NON-CROSS	4-8	11-12	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	1:NR:2	L2R	NON-CROSS	4-8	13-14	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	1:NR:2	L2R	NON-CROSS	4-8	17-19	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	1:NR:2	L2R	CROSS	4-8	31-34	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	1:NR:2	L2R	CROSS	4-8	35-38	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	1:NR:2	L2R	CROSS	336-339	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	1:NR:2	L2R	CROSS	4-8	57-60	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:NR:2	L2R	CROSS	356-359	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	CROSS	4-8	79-82	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	CROSS	312-316	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	CROSS	293-295	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	CROSS	296-300	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	CROSS	325-329	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	4-8	169-170	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	352-353	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	301-303	373-376	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	NON-CROSS	373-376	382-384	C080122,C090663,D019335	nitric oxide synthase inhibitors|NO synthase inhibitors	ChemicalEntity	4:373	8:376	0:9	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	NON-CROSS	9-10	11-12	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	1:Positive_Correlation:2	L2R	NON-CROSS	270-271	273-274	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	1:NR:2	L2R	NON-CROSS	9-10	17-19	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	1:NR:2	L2R	CROSS	9-10	31-34	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	1:NR:2	L2R	CROSS	273-274	277-280	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	1:NR:2	L2R	NON-CROSS	336-339	348-349	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	1:NR:2	L2R	CROSS	273-274	286-289	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:NR:2	L2R	NON-CROSS	348-349	356-359	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	CROSS	273-274	281-284	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	CROSS	312-316	348-349	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	CROSS	273-274	293-295	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	CROSS	273-274	296-300	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	CROSS	325-329	348-349	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	169-170	273-274	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	273-274	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	NON-CROSS	344-345	348-349	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	273-274	301-303	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	348-349	382-384	D014750	vincristine|vincristine|vincristine	ChemicalEntity	9:273:348	10:274:349	0:5:8	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:Positive_Correlation:2	L2R	NON-CROSS	11-12	13-14	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	1:NR:2	L2R	NON-CROSS	11-12	17-19	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	1:NR:2	L2R	CROSS	11-12	31-34	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	1:NR:2	L2R	CROSS	11-12	35-38	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	1:NR:2	L2R	NON-CROSS	331-332	336-339	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	1:NR:2	L2R	CROSS	286-289	331-332	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:NR:2	L2R	NON-CROSS	331-332	356-359	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	CROSS	281-284	331-332	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	CROSS	312-316	331-332	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	CROSS	293-295	331-332	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	CROSS	296-300	331-332	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	CROSS	325-329	331-332	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	11-12	169-170	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	331-332	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	NON-CROSS	331-332	344-345	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	301-303	331-332	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	331-332	382-384	D013311	streptozotocin|streptozotocin	ChemicalEntity	11:331	12:332	0:8	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	CROSS	13-14	31-34	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	1:NR:2	L2R	CROSS	270-271	277-280	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	1:Association:2	R2L	NON-CROSS	336-339	334-335	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	1:NR:2	L2R	CROSS	270-271	286-289	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:Association:2	R2L	NON-CROSS	356-359	351-352	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	1:NR:2	L2R	CROSS	270-271	281-284	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	CROSS	312-316	334-335	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	CROSS	270-271	293-295	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	CROSS	270-271	296-300	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:Association:2	R2L	NON-CROSS	352-353	351-352	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	D006930	hyperalgesia|hyperalgesia|hyperalgesia|hyperalgesia	DiseaseOrPhenotypicFeature	13:270:334:351	14:271:335:352	0:5:8:8	1:NR:2	L2R	CROSS	17-19	31-34	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	1:NR:2	L2R	CROSS	17-19	35-38	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	1:NR:2	L2R	CROSS	17-19	53-56	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	1:NR:2	L2R	CROSS	17-19	57-60	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:NR:2	L2R	CROSS	17-19	75-78	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	CROSS	17-19	79-82	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	CROSS	17-19	99-103	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	CROSS	17-19	104-120	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	CROSS	17-19	131-135	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	CROSS	17-19	266-267	D003929	diabetic neuropathy	DiseaseOrPhenotypicFeature	17	19	0	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:Negative_Correlation:2	L2R	NON-CROSS	31-34	35-38	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	1:NR:2	L2R	NON-CROSS	31-34	53-56	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	1:NR:2	L2R	NON-CROSS	31-34	57-60	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:NR:2	L2R	NON-CROSS	31-34	75-78	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	NON-CROSS	31-34	79-82	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	NON-CROSS	31-34	99-103	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	NON-CROSS	31-34	104-120	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	NON-CROSS	31-34	131-135	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	NON-CROSS	31-34	147-161	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	31-34	169-170	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	31-34	216-218	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	31-34	266-267	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	31-34	301-303	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	31-34	382-384	24600	constitutive NO synthase	GeneOrGeneProduct	31	34	1	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	NON-CROSS	206-209	221-224	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	1:NR:2	L2R	NON-CROSS	221-224	225-228	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:NR:2	L2R	NON-CROSS	211-214	221-224	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	NON-CROSS	277-280	281-284	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	NON-CROSS	203-205	221-224	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:Positive_Correlation:2	L2R	NON-CROSS	277-280	293-295	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:Positive_Correlation:2	L2R	NON-CROSS	277-280	296-300	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	NON-CROSS	277-280	325-329	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	169-170	221-224	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	221-224	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	266-267	277-280	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:Association:2	L2R	NON-CROSS	277-280	301-303	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:Negative_Correlation:2	L2R	CROSS	277-280	382-384	D019335	L - NOArg|L - NOArg|L - NOArg	ChemicalEntity	35:221:277	38:224:280	1:4:6	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:Negative_Correlation:2	L2R	NON-CROSS	53-56	57-60	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	1:NR:2	L2R	NON-CROSS	255-258	259-262	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	NON-CROSS	206-209	230-233	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	NON-CROSS	203-205	206-209	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	NON-CROSS	239-241	255-258	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	NON-CROSS	242-246	255-258	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	NON-CROSS	325-329	336-339	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	169-170	206-209	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	NON-CROSS	206-209	216-218	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:Association:2	L2R	NON-CROSS	336-339	344-345	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	301-303	336-339	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	336-339	382-384	24599	inducible NO synthase|inducible NO synthase|inducible NO synthase|inducible NO synthase	GeneOrGeneProduct	53:206:255:336	56:209:258:339	1:3:5:8	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	NON-CROSS	211-214	225-228	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	1:NR:2	L2R	NON-CROSS	225-228	230-233	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	NON-CROSS	203-205	225-228	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:Positive_Correlation:2	L2R	NON-CROSS	286-289	293-295	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:Positive_Correlation:2	L2R	NON-CROSS	286-289	296-300	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	NON-CROSS	286-289	325-329	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	169-170	225-228	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	225-228	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	266-267	286-289	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	NON-CROSS	286-289	301-303	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:Negative_Correlation:2	L2R	CROSS	286-289	382-384	C090663	L - NIL|L - NIL|L - NIL	ChemicalEntity	57:225:286	60:228:289	1:4:6	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:Negative_Correlation:2	L2R	NON-CROSS	75-78	79-82	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	1:NR:2	L2R	NON-CROSS	203-205	211-214	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:NR:2	L2R	NON-CROSS	239-241	259-262	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	NON-CROSS	242-246	259-262	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	NON-CROSS	325-329	356-359	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	169-170	211-214	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	NON-CROSS	211-214	216-218	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	NON-CROSS	352-353	356-359	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	259-262	301-303	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	356-359	382-384	24598	neuronal NO synthase|neuronal NO synthase|neuronal NO synthase|neuronal NO synthase	GeneOrGeneProduct	75:211:259:356	78:214:262:359	1:3:5:8	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	NON-CROSS	79-82	99-103	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	1:Association:2	L2R	NON-CROSS	230-233	239-241	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:Association:2	L2R	NON-CROSS	230-233	242-246	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	NON-CROSS	281-284	325-329	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	169-170	230-233	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	230-233	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	266-267	281-284	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:Association:2	L2R	NON-CROSS	281-284	301-303	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:Negative_Correlation:2	L2R	CROSS	281-284	382-384	C080122	7 - NI|7 - NI|7 - NI	ChemicalEntity	79:230:281	82:233:284	1:4:6	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	NON-CROSS	99-103	104-120	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	1:NR:2	L2R	NON-CROSS	296-300	312-316	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	NON-CROSS	312-316	325-329	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	169-170	203-205	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	NON-CROSS	203-205	216-218	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	312-316	344-345	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	301-303	312-316	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	312-316	382-384	25245,81509	B2 and B1 receptors|bradykinin receptors|B1 and B2 receptors	GeneOrGeneProduct	99:203:312	103:205:316	1:3:7	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	NON-CROSS	239-241	242-246	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	1:NR:2	L2R	NON-CROSS	121-123	147-161	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	121-123	169-170	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	239-241	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	239-241	266-267	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:Association:2	L2R	NON-CROSS	293-295	301-303	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	293-295	382-384	C065679	D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin|HOE 140|HOE 140|HOE 140	ChemicalEntity	104:121:239:293	120:123:241:295	1:1:4:6	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	NON-CROSS	131-135	147-161	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	1:NR:2	L2R	CROSS	131-135	169-170	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	1:NR:2	L2R	CROSS	216-218	242-246	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	1:NR:2	L2R	CROSS	242-246	266-267	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:Association:2	L2R	NON-CROSS	296-300	301-303	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	296-300	382-384	C078665	des Arg10 HOE 140|des Arg10 HOE 140|des - Arg10HOE 140	ChemicalEntity	131:242:296	135:246:300	1:4:6	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9	1:NR:2	L2R	CROSS	325-329	344-345	D003929,D010523	diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy|diabetic and toxic neuropathy	DiseaseOrPhenotypicFeature	147:325	161:329	1:7	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	169-170	266-267	D010146	pain	DiseaseOrPhenotypicFeature	169	170	2	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	216-218	266-267	D003920,D006930	diabetic hyperalgesia	DiseaseOrPhenotypicFeature	216	218	3	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	1:NR:2	L2R	CROSS	266-267	301-303	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	D010523	toxic neuropathy	DiseaseOrPhenotypicFeature	301	303	6	1:NR:2	L2R	CROSS	352-353	382-384	3827	bradykinin|bradykinin|bradykinin	GeneOrGeneProduct	266:344:352	267:345:353	5:8:8	D009437	neuropathic pain	DiseaseOrPhenotypicFeature	382	384	9
24288432	Association of a FGFR - 4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distress .|BACKGROUND : Bronchopulmonary dysplasia ( BPD ) is the most common chronic lung disease of premature birth , characterized by impaired alveolar development and inflammation .|Pathomechanisms contributing to BPD are poorly understood .|However , it is assumed that genetic factors predispose to BPD and other pulmonary diseases of preterm neonates , such as neonatal respiratory distress syndrome ( RDS ) .|For association studies , genes upregulated during alveolarization are major candidates for genetic analysis , for example , matrix metalloproteinases ( MMPs ) and fibroblast growth factors ( FGFs ) and their receptors ( FGFR ) .|OBJECTIVE : Determining genetic risk variants in a Caucasian population of premature neonates with BPD and RDS .|Methods .|We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism ( RFLP ) : MMP - 1 , - 2 , - 9 , and - 12 , - 16 , FGF receptors 2 and 4 , FGF - 2 , - 3 , - 4 , - 7 , and - 18 , Signal - Regulatory Protein a ( SIRPA ) and Thyroid Transcription Factor - 1 ( TTF - 1 ) .|RESULTS : Five single nucleotide polymorphisms ( SNPs ) in MMP - 9 , MMP - 12 , FGFR - 4 , FGF - 3 , and FGF - 7 are associated ( P < 0 . 05 ) with RDS , defined as surfactant application within the first 24 hours after birth .|One of them , in FGFR - 4 ( rs1966265 ) , is associated with both RDS ( P = 0 . 003 ) and BPD ( P = 0 . 023 ) .|CONCLUSION : rs1966265 in FGF receptor 4 is a possible genetic key variant in alveolar diseases of preterm newborns .	1:Association:2	L2R	NON-CROSS	3-6	9-11	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	1:Association:2	L2R	NON-CROSS	3-6	12-15	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	1:NR:2	L2R	CROSS	3-6	28-30	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	1:NR:2	L2R	CROSS	3-6	31-33	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	1:NR:2	L2R	CROSS	3-6	40-41	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	1:NR:2	L2R	CROSS	153-169	231-234	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	1:NR:2	L2R	CROSS	176-192	231-234	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	1:NR:2	L2R	CROSS	170-175	231-234	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	1:NR:2	L2R	CROSS	199-200	231-234	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	CROSS	208-211	231-234	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	NON-CROSS	223-226	231-234	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	NON-CROSS	227-230	231-234	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:Bind:2	R2L	NON-CROSS	235-238	231-234	2248	FGF - 3	GeneOrGeneProduct	235	238	8	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	1:Bind:2	R2L	NON-CROSS	240-243	231-234	2252	FGF - 7	GeneOrGeneProduct	240	243	8	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	1:Association:2	L2R	NON-CROSS	305-308	315-317	2264	FGFR - 4|FGFR - 4|FGFR - 4|FGF receptor 4	GeneOrGeneProduct	3:231:272:305	6:234:275:308	0:8:9:10	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	CROSS	130-131	153-169	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	1:NR:2	L2R	CROSS	107-108	130-131	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	1:NR:2	L2R	CROSS	113-114	130-131	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	1:NR:2	L2R	CROSS	130-131	193-198	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	CROSS	130-131	202-207	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	CROSS	223-226	292-293	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	227-230	292-293	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	235-238	292-293	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	240-243	292-293	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:Positive_Correlation:2	R2L	NON-CROSS	303-304	292-293	rs1966265	rs1966265|rs1966265	SequenceVariant	276:303	277:304	9:10	D001997	bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|BPD|BPD|BPD|BPD	DiseaseOrPhenotypicFeature	9:18:21:45:60:130:292	11:20:22:46:61:131:293	0:1:1:2:3:5:9	1:NR:2	L2R	CROSS	76-77	97-99	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	1:NR:2	L2R	CROSS	107-108	132-133	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	1:NR:2	L2R	CROSS	113-114	132-133	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	1:NR:2	L2R	CROSS	199-200	253-254	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	CROSS	208-211	253-254	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:Association:2	R2L	NON-CROSS	253-254	223-226	4318	MMP - 9	GeneOrGeneProduct	223	226	8	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	1:Association:2	R2L	NON-CROSS	253-254	227-230	4321	MMP - 12	GeneOrGeneProduct	227	230	8	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	1:Association:2	R2L	NON-CROSS	253-254	235-238	2248	FGF - 3	GeneOrGeneProduct	235	238	8	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	1:Association:2	R2L	NON-CROSS	253-254	240-243	2252	FGF - 7	GeneOrGeneProduct	240	243	8	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	1:Positive_Correlation:2	R2L	NON-CROSS	283-284	276-277	rs1966265	rs1966265|rs1966265	SequenceVariant	276:303	277:304	9:10	D012127	neonatal respiratory distress|neonatal respiratory distress syndrome|RDS|RDS|RDS|RDS	DiseaseOrPhenotypicFeature	12:71:76:132:253:283	15:75:77:133:254:284	0:3:3:5:8:9	1:NR:2	L2R	CROSS	63-65	97-99	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	1:NR:2	L2R	CROSS	63-65	103-106	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	1:NR:2	L2R	CROSS	63-65	113-114	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	1:NR:2	L2R	CROSS	63-65	193-198	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	CROSS	63-65	202-207	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	CROSS	63-65	223-226	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	63-65	227-230	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	63-65	235-238	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	63-65	240-243	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	63-65	276-277	D008171	lung disease|impaired alveolar development|pulmonary diseases	DiseaseOrPhenotypicFeature	28:36:63	30:39:65	1:1:3	rs1966265	rs1966265|rs1966265	SequenceVariant	276:303	277:304	9:10	1:NR:2	L2R	CROSS	31-33	97-99	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	1:NR:2	L2R	CROSS	31-33	103-106	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	1:NR:2	L2R	CROSS	31-33	113-114	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	1:NR:2	L2R	CROSS	31-33	193-198	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	CROSS	31-33	202-207	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	CROSS	31-33	223-226	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	31-33	227-230	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	31-33	235-238	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	31-33	240-243	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	31-33	276-277	D047928	premature birth	DiseaseOrPhenotypicFeature	31	33	1	rs1966265	rs1966265|rs1966265	SequenceVariant	276:303	277:304	9:10	1:NR:2	L2R	CROSS	40-41	97-99	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	1:NR:2	L2R	CROSS	40-41	103-106	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	1:NR:2	L2R	CROSS	40-41	113-114	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	1:NR:2	L2R	CROSS	40-41	193-198	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	CROSS	40-41	202-207	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	CROSS	40-41	223-226	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	40-41	227-230	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	40-41	235-238	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	40-41	240-243	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	40-41	276-277	D007249	inflammation	DiseaseOrPhenotypicFeature	40	41	1	rs1966265	rs1966265|rs1966265	SequenceVariant	276:303	277:304	9:10	1:NR:2	L2R	NON-CROSS	100-101	103-106	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	1:NR:2	L2R	NON-CROSS	153-169	170-175	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	1:NR:2	L2R	NON-CROSS	153-169	193-198	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	NON-CROSS	153-169	202-207	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	CROSS	153-169	223-226	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	153-169	227-230	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	153-169	235-238	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	153-169	240-243	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	153-169	315-317	4312,4313,4318,4321,4325	matrix metalloproteinases|MMPs|MMP - 1 , - 2 , - 9 , and - 12 , - 16	GeneOrGeneProduct	97:100:153	99:101:169	4:4:7	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	NON-CROSS	170-175	176-192	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	1:NR:2	L2R	NON-CROSS	176-192	193-198	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	NON-CROSS	176-192	202-207	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	CROSS	176-192	223-226	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	176-192	227-230	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	176-192	235-238	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	176-192	240-243	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	176-192	315-317	2247,2248,2249,2252,8817	fibroblast growth factors|FGFs|FGF - 2 , - 3 , - 4 , - 7 , and - 18	GeneOrGeneProduct	103:107:176	106:108:192	4:4:7	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	NON-CROSS	170-175	193-198	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	1:NR:2	L2R	NON-CROSS	170-175	202-207	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	CROSS	170-175	223-226	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	170-175	227-230	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	170-175	235-238	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	170-175	240-243	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	170-175	315-317	2263,2264	FGFR|FGF receptors 2 and 4	GeneOrGeneProduct	113:170	114:175	4:7	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	NON-CROSS	199-200	202-207	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	1:NR:2	L2R	CROSS	199-200	223-226	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	199-200	227-230	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	199-200	235-238	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	199-200	240-243	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	199-200	315-317	140885	Signal - Regulatory Protein a|SIRPA	GeneOrGeneProduct	193:199	198:200	7:7	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	CROSS	208-211	223-226	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	4318	MMP - 9	GeneOrGeneProduct	223	226	8	1:NR:2	L2R	CROSS	208-211	227-230	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	CROSS	208-211	235-238	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	CROSS	208-211	240-243	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	208-211	315-317	7080	Thyroid Transcription Factor - 1|TTF - 1	GeneOrGeneProduct	202:208	207:211	7:7	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	NON-CROSS	223-226	227-230	4318	MMP - 9	GeneOrGeneProduct	223	226	8	4321	MMP - 12	GeneOrGeneProduct	227	230	8	1:NR:2	L2R	NON-CROSS	223-226	235-238	4318	MMP - 9	GeneOrGeneProduct	223	226	8	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	NON-CROSS	223-226	240-243	4318	MMP - 9	GeneOrGeneProduct	223	226	8	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	223-226	315-317	4318	MMP - 9	GeneOrGeneProduct	223	226	8	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	NON-CROSS	227-230	235-238	4321	MMP - 12	GeneOrGeneProduct	227	230	8	2248	FGF - 3	GeneOrGeneProduct	235	238	8	1:NR:2	L2R	NON-CROSS	227-230	240-243	4321	MMP - 12	GeneOrGeneProduct	227	230	8	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	227-230	315-317	4321	MMP - 12	GeneOrGeneProduct	227	230	8	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	NON-CROSS	235-238	240-243	2248	FGF - 3	GeneOrGeneProduct	235	238	8	2252	FGF - 7	GeneOrGeneProduct	240	243	8	1:NR:2	L2R	CROSS	235-238	315-317	2248	FGF - 3	GeneOrGeneProduct	235	238	8	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:NR:2	L2R	CROSS	240-243	315-317	2252	FGF - 7	GeneOrGeneProduct	240	243	8	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10	1:Positive_Correlation:2	L2R	NON-CROSS	303-304	315-317	rs1966265	rs1966265|rs1966265	SequenceVariant	276:303	277:304	9:10	D002282	alveolar diseases	DiseaseOrPhenotypicFeature	315	317	10
28259923	Pleomorphic adenoma gene like - 2 induces epithelial - mesenchymal transition via Wnt / b - catenin signaling pathway in human colorectal adenocarcinoma .|Epithelial - mesenchymal transition ( EMT ) is a critical step in the acquisition of metastatic and invasive power for tumor cells .|Colorectal adenocarcinoma ( CRC ) is a common cancer where metastasis is directly linked to patient survival .|Recent studies show that pleomorphic adenoma gene like - 2 ( PLAGL2 ) could induce tumor EMT and is an independent predictive factor associated with poor prognosis in cancer .|In the present study , we confirmed the role of PLAGL2 in the prognosis of CRC patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480 .|We found that PLAGL2 expression was upregulated in the paraffin - embedded CRC tissues compared to borderline or benign tissues .|Experimental EMT induced by PLAGL2 plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound - healing and transwell ability and significantly upregulated mesenchymal marker proteins , N - cadherin and vimentin and concurrently downregulated epithelial marker of E - cadherin .|Subsequently , through western blot assay , we found that PLAGL2 could activate the wnt - signaling component b - catenin in the nuclei .|More CRC cell metastasis to the lungs was observed when the PLAGL2 overexpressing SW480 cells were injected into the tail vein of rats , compared with the cell control and PLAGL2 silence group .|Our findings indicated that PLAGL2 might be a very upstream key molecule regulating EMT involved in Wnt / b - catenin signaling pathway .	1:Association:2	L2R	NON-CROSS	201-202	205-206	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	1:Positive_Correlation:2	L2R	NON-CROSS	201-202	209-212	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	1:Association:2	L2R	NON-CROSS	117-118	121-122	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	D015179	colorectal adenocarcinoma|Colorectal adenocarcinoma|CRC|CRC|CRC|CRC|CRC	DiseaseOrPhenotypicFeature	21:47:50:110:121:138:217	23:49:51:111:122:139:218	0:2:2:4:4:5:8	1:Association:2	L2R	NON-CROSS	76-77	80-81	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	D009369	tumor|cancer|tumor|cancer	DiseaseOrPhenotypicFeature	44:55:80:93	45:56:81:94	1:2:3:3	1:NR:2	L2R	NON-CROSS	219-220	227-228	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	D009362	metastasis|metastasis	DiseaseOrPhenotypicFeature	57:219	58:220	2:8	1:Association:2	L2R	NON-CROSS	129-130	135-136	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	D010232	paraffin	ChemicalEntity	135	136	5	1:Positive_Correlation:2	L2R	NON-CROSS	155-156	176-179	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	1000	N - cadherin	GeneOrGeneProduct	176	179	6	1:Positive_Correlation:2	L2R	NON-CROSS	180-181	201-202	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	7431	vimentin	GeneOrGeneProduct	180	181	6	1:Negative_Correlation:2	L2R	NON-CROSS	187-190	201-202	5326	Pleomorphic adenoma gene like - 2|pleomorphic adenoma gene like - 2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2|PLAGL2	GeneOrGeneProduct	0:69:76:105:117:129:151:155:201:227:246:254	6:75:77:106:118:130:152:156:202:228:247:255	0:3:3:4:4:5:6:6:7:8:8:9	999	E - cadherin	GeneOrGeneProduct	187	190	6	1:Association:2	L2R	NON-CROSS	12-13	14-17	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	1:Association:2	L2R	NON-CROSS	12-13	21-23	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	D015179	colorectal adenocarcinoma|Colorectal adenocarcinoma|CRC|CRC|CRC|CRC|CRC	DiseaseOrPhenotypicFeature	21:47:50:110:121:138:217	23:49:51:111:122:139:218	0:2:2:4:4:5:8	1:NR:2	L2R	CROSS	12-13	44-45	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	D009369	tumor|cancer|tumor|cancer	DiseaseOrPhenotypicFeature	44:55:80:93	45:56:81:94	1:2:3:3	1:NR:2	L2R	CROSS	205-206	219-220	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	D009362	metastasis|metastasis	DiseaseOrPhenotypicFeature	57:219	58:220	2:8	1:NR:2	L2R	CROSS	135-136	205-206	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	D010232	paraffin	ChemicalEntity	135	136	5	1:NR:2	L2R	CROSS	176-179	205-206	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	1000	N - cadherin	GeneOrGeneProduct	176	179	6	1:NR:2	L2R	CROSS	180-181	205-206	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	7431	vimentin	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	187-190	205-206	7474	Wnt|wnt|Wnt	GeneOrGeneProduct	12:205:266	13:206:267	0:7:9	999	E - cadherin	GeneOrGeneProduct	187	190	6	1:Association:2	L2R	NON-CROSS	14-17	21-23	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	D015179	colorectal adenocarcinoma|Colorectal adenocarcinoma|CRC|CRC|CRC|CRC|CRC	DiseaseOrPhenotypicFeature	21:47:50:110:121:138:217	23:49:51:111:122:139:218	0:2:2:4:4:5:8	1:NR:2	L2R	CROSS	14-17	44-45	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	D009369	tumor|cancer|tumor|cancer	DiseaseOrPhenotypicFeature	44:55:80:93	45:56:81:94	1:2:3:3	1:NR:2	L2R	CROSS	209-212	219-220	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	D009362	metastasis|metastasis	DiseaseOrPhenotypicFeature	57:219	58:220	2:8	1:NR:2	L2R	CROSS	135-136	209-212	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	D010232	paraffin	ChemicalEntity	135	136	5	1:NR:2	L2R	CROSS	176-179	209-212	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	1000	N - cadherin	GeneOrGeneProduct	176	179	6	1:NR:2	L2R	CROSS	180-181	209-212	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	7431	vimentin	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	187-190	209-212	1499	b - catenin|b - catenin|b - catenin	GeneOrGeneProduct	14:209:268	17:212:271	0:7:9	999	E - cadherin	GeneOrGeneProduct	187	190	6	1:Association:2	R2L	NON-CROSS	138-139	135-136	D010232	paraffin	ChemicalEntity	135	136	5	D015179	colorectal adenocarcinoma|Colorectal adenocarcinoma|CRC|CRC|CRC|CRC|CRC	DiseaseOrPhenotypicFeature	21:47:50:110:121:138:217	23:49:51:111:122:139:218	0:2:2:4:4:5:8	1:NR:2	L2R	CROSS	138-139	176-179	D015179	colorectal adenocarcinoma|Colorectal adenocarcinoma|CRC|CRC|CRC|CRC|CRC	DiseaseOrPhenotypicFeature	21:47:50:110:121:138:217	23:49:51:111:122:139:218	0:2:2:4:4:5:8	1000	N - cadherin	GeneOrGeneProduct	176	179	6	1:NR:2	L2R	CROSS	180-181	217-218	D015179	colorectal adenocarcinoma|Colorectal adenocarcinoma|CRC|CRC|CRC|CRC|CRC	DiseaseOrPhenotypicFeature	21:47:50:110:121:138:217	23:49:51:111:122:139:218	0:2:2:4:4:5:8	7431	vimentin	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	187-190	217-218	D015179	colorectal adenocarcinoma|Colorectal adenocarcinoma|CRC|CRC|CRC|CRC|CRC	DiseaseOrPhenotypicFeature	21:47:50:110:121:138:217	23:49:51:111:122:139:218	0:2:2:4:4:5:8	999	E - cadherin	GeneOrGeneProduct	187	190	6	1:NR:2	L2R	CROSS	93-94	135-136	D009369	tumor|cancer|tumor|cancer	DiseaseOrPhenotypicFeature	44:55:80:93	45:56:81:94	1:2:3:3	D010232	paraffin	ChemicalEntity	135	136	5	1:NR:2	L2R	CROSS	93-94	176-179	D009369	tumor|cancer|tumor|cancer	DiseaseOrPhenotypicFeature	44:55:80:93	45:56:81:94	1:2:3:3	1000	N - cadherin	GeneOrGeneProduct	176	179	6	1:NR:2	L2R	CROSS	93-94	180-181	D009369	tumor|cancer|tumor|cancer	DiseaseOrPhenotypicFeature	44:55:80:93	45:56:81:94	1:2:3:3	7431	vimentin	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	93-94	187-190	D009369	tumor|cancer|tumor|cancer	DiseaseOrPhenotypicFeature	44:55:80:93	45:56:81:94	1:2:3:3	999	E - cadherin	GeneOrGeneProduct	187	190	6	1:NR:2	L2R	CROSS	57-58	135-136	D009362	metastasis|metastasis	DiseaseOrPhenotypicFeature	57:219	58:220	2:8	D010232	paraffin	ChemicalEntity	135	136	5	1:NR:2	L2R	CROSS	176-179	219-220	D009362	metastasis|metastasis	DiseaseOrPhenotypicFeature	57:219	58:220	2:8	1000	N - cadherin	GeneOrGeneProduct	176	179	6	1:NR:2	L2R	CROSS	180-181	219-220	D009362	metastasis|metastasis	DiseaseOrPhenotypicFeature	57:219	58:220	2:8	7431	vimentin	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	187-190	219-220	D009362	metastasis|metastasis	DiseaseOrPhenotypicFeature	57:219	58:220	2:8	999	E - cadherin	GeneOrGeneProduct	187	190	6	1:NR:2	L2R	CROSS	135-136	176-179	D010232	paraffin	ChemicalEntity	135	136	5	1000	N - cadherin	GeneOrGeneProduct	176	179	6	1:NR:2	L2R	CROSS	135-136	180-181	D010232	paraffin	ChemicalEntity	135	136	5	7431	vimentin	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	135-136	187-190	D010232	paraffin	ChemicalEntity	135	136	5	999	E - cadherin	GeneOrGeneProduct	187	190	6	1:NR:2	L2R	NON-CROSS	176-179	180-181	1000	N - cadherin	GeneOrGeneProduct	176	179	6	7431	vimentin	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	NON-CROSS	176-179	187-190	1000	N - cadherin	GeneOrGeneProduct	176	179	6	999	E - cadherin	GeneOrGeneProduct	187	190	6	1:NR:2	L2R	NON-CROSS	180-181	187-190	7431	vimentin	GeneOrGeneProduct	180	181	6	999	E - cadherin	GeneOrGeneProduct	187	190	6
16000134	Successful therapy with argatroban for superior mesenteric vein thrombosis in a patient with congenital antithrombin deficiency .|A 38 - year - old woman was admitted with superior mesenteric vein ( SMV ) thrombosis , which was refractory to anticoagulation therapy .|The plasma antithrombin activity was decreased and hardly compensated by concentrated antithrombin preparation due to high consumption rate .|However , successful anticoagulation was achieved by administration of direct thrombin inhibitor , argatroban .|Family studies of antithrombin activity revealed that she had type I congenital antithrombin deficiency .|A novel heterozygous mutation in the gene for antithrombin ( single nucleotide T insertion at 7916 and 7917 , Glu 272 to stop in exon 4 ) was identified .|Argatroban administration would be effective in the treatment of congenital antithrombin deficiency with SMV thrombosis .	1:Negative_Correlation:2	L2R	NON-CROSS	3-4	7-9	C031942	argatroban|argatroban|Argatroban	ChemicalEntity	3:74:121	4:75:122	0:3:6	D020246	vein thrombosis|superior mesenteric vein ( SMV ) thrombosis|SMV thrombosis	DiseaseOrPhenotypicFeature	7:27:134	9:34:136	0:1:6	1:Negative_Correlation:2	L2R	NON-CROSS	121-122	130-133	C031942	argatroban|argatroban|Argatroban	ChemicalEntity	3:74:121	4:75:122	0:3:6	D020152	congenital antithrombin deficiency|congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	13:130	16:133	0:6	1:NR:2	L2R	CROSS	74-75	79-80	C031942	argatroban|argatroban|Argatroban	ChemicalEntity	3:74:121	4:75:122	0:3:6	462	antithrombin|antithrombin|antithrombin|antithrombin	GeneOrGeneProduct	44:53:79:99	45:54:80:100	2:2:4:5	1:Negative_Correlation:2	R2L	NON-CROSS	74-75	71-72	2147	thrombin	GeneOrGeneProduct	71	72	3	C031942	argatroban|argatroban|Argatroban	ChemicalEntity	3:74:121	4:75:122	0:3:6	1:NR:2	L2R	CROSS	74-75	85-90	C031942	argatroban|argatroban|Argatroban	ChemicalEntity	3:74:121	4:75:122	0:3:6	D025861	type I congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	85	90	4	1:NR:2	L2R	CROSS	102-109	121-122	C031942	argatroban|argatroban|Argatroban	ChemicalEntity	3:74:121	4:75:122	0:3:6	c|INS|7916_7917|T	nucleotide T insertion at 7916 and 7917	SequenceVariant	102	109	5	1:NR:2	L2R	CROSS	110-114	121-122	C031942	argatroban|argatroban|Argatroban	ChemicalEntity	3:74:121	4:75:122	0:3:6	p|SUB|E|272|X	Glu 272 to stop	SequenceVariant	110	114	5	1:Association:2	L2R	CROSS	27-34	44-45	D020246	vein thrombosis|superior mesenteric vein ( SMV ) thrombosis|SMV thrombosis	DiseaseOrPhenotypicFeature	7:27:134	9:34:136	0:1:6	462	antithrombin|antithrombin|antithrombin|antithrombin	GeneOrGeneProduct	44:53:79:99	45:54:80:100	2:2:4:5	1:NR:2	L2R	CROSS	27-34	71-72	D020246	vein thrombosis|superior mesenteric vein ( SMV ) thrombosis|SMV thrombosis	DiseaseOrPhenotypicFeature	7:27:134	9:34:136	0:1:6	2147	thrombin	GeneOrGeneProduct	71	72	3	1:NR:2	L2R	CROSS	102-109	134-136	D020246	vein thrombosis|superior mesenteric vein ( SMV ) thrombosis|SMV thrombosis	DiseaseOrPhenotypicFeature	7:27:134	9:34:136	0:1:6	c|INS|7916_7917|T	nucleotide T insertion at 7916 and 7917	SequenceVariant	102	109	5	1:NR:2	L2R	CROSS	110-114	134-136	D020246	vein thrombosis|superior mesenteric vein ( SMV ) thrombosis|SMV thrombosis	DiseaseOrPhenotypicFeature	7:27:134	9:34:136	0:1:6	p|SUB|E|272|X	Glu 272 to stop	SequenceVariant	110	114	5	1:NR:2	L2R	CROSS	13-16	44-45	D020152	congenital antithrombin deficiency|congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	13:130	16:133	0:6	462	antithrombin|antithrombin|antithrombin|antithrombin	GeneOrGeneProduct	44:53:79:99	45:54:80:100	2:2:4:5	1:NR:2	L2R	CROSS	13-16	71-72	D020152	congenital antithrombin deficiency|congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	13:130	16:133	0:6	2147	thrombin	GeneOrGeneProduct	71	72	3	1:NR:2	L2R	CROSS	102-109	130-133	D020152	congenital antithrombin deficiency|congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	13:130	16:133	0:6	c|INS|7916_7917|T	nucleotide T insertion at 7916 and 7917	SequenceVariant	102	109	5	1:NR:2	L2R	CROSS	110-114	130-133	D020152	congenital antithrombin deficiency|congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	13:130	16:133	0:6	p|SUB|E|272|X	Glu 272 to stop	SequenceVariant	110	114	5	1:NR:2	L2R	CROSS	71-72	79-80	462	antithrombin|antithrombin|antithrombin|antithrombin	GeneOrGeneProduct	44:53:79:99	45:54:80:100	2:2:4:5	2147	thrombin	GeneOrGeneProduct	71	72	3	1:Association:2	L2R	NON-CROSS	79-80	85-90	462	antithrombin|antithrombin|antithrombin|antithrombin	GeneOrGeneProduct	44:53:79:99	45:54:80:100	2:2:4:5	D025861	type I congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	85	90	4	1:NR:2	L2R	CROSS	71-72	85-90	2147	thrombin	GeneOrGeneProduct	71	72	3	D025861	type I congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	85	90	4	1:Association:2	L2R	CROSS	85-90	102-109	D025861	type I congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	85	90	4	c|INS|7916_7917|T	nucleotide T insertion at 7916 and 7917	SequenceVariant	102	109	5	1:Association:2	L2R	CROSS	85-90	110-114	D025861	type I congenital antithrombin deficiency	DiseaseOrPhenotypicFeature	85	90	4	p|SUB|E|272|X	Glu 272 to stop	SequenceVariant	110	114	5
16225977	Amisulpride related tic - like symptoms in an adolescent schizophrenic .|Tic disorders can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .|However , there are two case reports that show tic - like symptoms , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .|We present a 15 - year - old girl schizophrenic who developed frequent involuntary eye - blinking movements after 5 months of amisulpride treatment ( 1000 mg per day ) .|The tic - like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day .|However , her psychosis recurred after the dose reduction .|We then placed her on an additional 100 mg per day of quetiapine .|She has been in complete remission under the combined medications for more than one year and maintains a fair role function .|No more tic - like symptoms or other side effects have been reported .|Together with previously reported cases , our patient suggests that tic - like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .	1:NR:2	L2R	NON-CROSS	0-1	2-6	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	-	tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	DiseaseOrPhenotypicFeature	2:37:88:156:178	6:41:92:160:182	0:2:4:8:9	1:Negative_Correlation:2	L2R	NON-CROSS	0-1	9-10	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	D012559	schizophrenic|schizophrenic	DiseaseOrPhenotypicFeature	9:65	10:66	0:3	1:NR:2	L2R	CROSS	0-1	11-13	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	D013981	Tic disorders	DiseaseOrPhenotypicFeature	11	13	1	1:NR:2	L2R	NON-CROSS	192-193	200-201	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	1:NR:2	L2R	CROSS	0-1	22-23	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	D018967	risperidone	ChemicalEntity	22	23	1	1:NR:2	L2R	CROSS	0-1	24-25	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	D000077152	olanzapine	ChemicalEntity	24	25	1	1:NR:2	L2R	CROSS	0-1	26-27	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	C092292	ziprasidone	ChemicalEntity	26	27	1	1:Cotreatment:2	L2R	NON-CROSS	195-196	200-201	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	NON-CROSS	197-198	200-201	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:Positive_Correlation:2	R2L	NON-CROSS	78-79	69-74	D020820	involuntary eye - blinking movements	DiseaseOrPhenotypicFeature	69	74	3	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	1:Negative_Correlation:2	L2R	CROSS	100-101	111-112	D000077582	Amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	0:78:100:200	1:79:101:201	0:3:4:9	D011605	psychosis	DiseaseOrPhenotypicFeature	111	112	5	1:NR:2	L2R	NON-CROSS	178-182	192-193	-	tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	DiseaseOrPhenotypicFeature	2:37:88:156:178	6:41:92:160:182	0:2:4:8:9	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	1:NR:2	L2R	CROSS	22-23	37-41	-	tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	DiseaseOrPhenotypicFeature	2:37:88:156:178	6:41:92:160:182	0:2:4:8:9	D018967	risperidone	ChemicalEntity	22	23	1	1:NR:2	L2R	CROSS	24-25	37-41	-	tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	DiseaseOrPhenotypicFeature	2:37:88:156:178	6:41:92:160:182	0:2:4:8:9	D000077152	olanzapine	ChemicalEntity	24	25	1	1:NR:2	L2R	CROSS	26-27	37-41	-	tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	DiseaseOrPhenotypicFeature	2:37:88:156:178	6:41:92:160:182	0:2:4:8:9	C092292	ziprasidone	ChemicalEntity	26	27	1	1:NR:2	L2R	NON-CROSS	37-41	52-53	-	tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	DiseaseOrPhenotypicFeature	2:37:88:156:178	6:41:92:160:182	0:2:4:8:9	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	NON-CROSS	37-41	54-55	-	tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms|tic - like symptoms	DiseaseOrPhenotypicFeature	2:37:88:156:178	6:41:92:160:182	0:2:4:8:9	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:NR:2	L2R	CROSS	9-10	19-20	D012559	schizophrenic|schizophrenic	DiseaseOrPhenotypicFeature	9:65	10:66	0:3	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	1:NR:2	L2R	CROSS	9-10	22-23	D012559	schizophrenic|schizophrenic	DiseaseOrPhenotypicFeature	9:65	10:66	0:3	D018967	risperidone	ChemicalEntity	22	23	1	1:NR:2	L2R	CROSS	9-10	24-25	D012559	schizophrenic|schizophrenic	DiseaseOrPhenotypicFeature	9:65	10:66	0:3	D000077152	olanzapine	ChemicalEntity	24	25	1	1:NR:2	L2R	CROSS	9-10	26-27	D012559	schizophrenic|schizophrenic	DiseaseOrPhenotypicFeature	9:65	10:66	0:3	C092292	ziprasidone	ChemicalEntity	26	27	1	1:NR:2	L2R	CROSS	52-53	65-66	D012559	schizophrenic|schizophrenic	DiseaseOrPhenotypicFeature	9:65	10:66	0:3	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	CROSS	54-55	65-66	D012559	schizophrenic|schizophrenic	DiseaseOrPhenotypicFeature	9:65	10:66	0:3	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:Negative_Correlation:2	L2R	NON-CROSS	11-13	19-20	D013981	Tic disorders	DiseaseOrPhenotypicFeature	11	13	1	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	1:Negative_Correlation:2	L2R	NON-CROSS	11-13	22-23	D013981	Tic disorders	DiseaseOrPhenotypicFeature	11	13	1	D018967	risperidone	ChemicalEntity	22	23	1	1:Negative_Correlation:2	L2R	NON-CROSS	11-13	24-25	D013981	Tic disorders	DiseaseOrPhenotypicFeature	11	13	1	D000077152	olanzapine	ChemicalEntity	24	25	1	1:Negative_Correlation:2	L2R	NON-CROSS	11-13	26-27	D013981	Tic disorders	DiseaseOrPhenotypicFeature	11	13	1	C092292	ziprasidone	ChemicalEntity	26	27	1	1:NR:2	L2R	CROSS	11-13	52-53	D013981	Tic disorders	DiseaseOrPhenotypicFeature	11	13	1	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	CROSS	11-13	54-55	D013981	Tic disorders	DiseaseOrPhenotypicFeature	11	13	1	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:NR:2	L2R	NON-CROSS	19-20	22-23	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	D018967	risperidone	ChemicalEntity	22	23	1	1:NR:2	L2R	NON-CROSS	19-20	24-25	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	D000077152	olanzapine	ChemicalEntity	24	25	1	1:NR:2	L2R	NON-CROSS	19-20	26-27	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	C092292	ziprasidone	ChemicalEntity	26	27	1	1:NR:2	L2R	NON-CROSS	192-193	195-196	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	NON-CROSS	192-193	197-198	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:NR:2	L2R	CROSS	19-20	69-74	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	D020820	involuntary eye - blinking movements	DiseaseOrPhenotypicFeature	69	74	3	1:NR:2	L2R	CROSS	111-112	192-193	D014150	antipsychotics|antipsychotics	ChemicalEntity	19:192	20:193	1:9	D011605	psychosis	DiseaseOrPhenotypicFeature	111	112	5	1:NR:2	L2R	NON-CROSS	22-23	24-25	D018967	risperidone	ChemicalEntity	22	23	1	D000077152	olanzapine	ChemicalEntity	24	25	1	1:NR:2	L2R	NON-CROSS	22-23	26-27	D018967	risperidone	ChemicalEntity	22	23	1	C092292	ziprasidone	ChemicalEntity	26	27	1	1:NR:2	L2R	CROSS	22-23	52-53	D018967	risperidone	ChemicalEntity	22	23	1	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	CROSS	22-23	54-55	D018967	risperidone	ChemicalEntity	22	23	1	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:NR:2	L2R	CROSS	22-23	69-74	D018967	risperidone	ChemicalEntity	22	23	1	D020820	involuntary eye - blinking movements	DiseaseOrPhenotypicFeature	69	74	3	1:NR:2	L2R	CROSS	22-23	111-112	D018967	risperidone	ChemicalEntity	22	23	1	D011605	psychosis	DiseaseOrPhenotypicFeature	111	112	5	1:NR:2	L2R	NON-CROSS	24-25	26-27	D000077152	olanzapine	ChemicalEntity	24	25	1	C092292	ziprasidone	ChemicalEntity	26	27	1	1:NR:2	L2R	CROSS	24-25	52-53	D000077152	olanzapine	ChemicalEntity	24	25	1	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	CROSS	24-25	54-55	D000077152	olanzapine	ChemicalEntity	24	25	1	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:NR:2	L2R	CROSS	24-25	69-74	D000077152	olanzapine	ChemicalEntity	24	25	1	D020820	involuntary eye - blinking movements	DiseaseOrPhenotypicFeature	69	74	3	1:NR:2	L2R	CROSS	24-25	111-112	D000077152	olanzapine	ChemicalEntity	24	25	1	D011605	psychosis	DiseaseOrPhenotypicFeature	111	112	5	1:NR:2	L2R	CROSS	26-27	52-53	C092292	ziprasidone	ChemicalEntity	26	27	1	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	CROSS	26-27	54-55	C092292	ziprasidone	ChemicalEntity	26	27	1	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:NR:2	L2R	CROSS	26-27	69-74	C092292	ziprasidone	ChemicalEntity	26	27	1	D020820	involuntary eye - blinking movements	DiseaseOrPhenotypicFeature	69	74	3	1:NR:2	L2R	CROSS	26-27	111-112	C092292	ziprasidone	ChemicalEntity	26	27	1	D011605	psychosis	DiseaseOrPhenotypicFeature	111	112	5	1:NR:2	L2R	NON-CROSS	52-53	54-55	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	1:NR:2	L2R	CROSS	52-53	69-74	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	D020820	involuntary eye - blinking movements	DiseaseOrPhenotypicFeature	69	74	3	1:Negative_Correlation:2	R2L	CROSS	130-131	111-112	D011605	psychosis	DiseaseOrPhenotypicFeature	111	112	5	D000069348	quetiapine|quetiapine|quetiapine	ChemicalEntity	52:130:195	53:131:196	2:6:9	1:NR:2	L2R	CROSS	54-55	69-74	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	D020820	involuntary eye - blinking movements	DiseaseOrPhenotypicFeature	69	74	3	1:NR:2	L2R	CROSS	54-55	111-112	D003024	clozapine|clozapine	ChemicalEntity	54:197	55:198	2:9	D011605	psychosis	DiseaseOrPhenotypicFeature	111	112	5
20859899	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin - converting enzyme inhibitor and spironolactone .|A 76 year - old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia .|The concentration of serum potassium was high , and normal sinus rhythm was restored after correction of the serum potassium level .|The cause of hyperkalemia was considered to be several doses of spiranolactone , an aldosterone antagonist , in addition to the long - term intake of ramipril , an ACE inhibitor .|This case is a good example of electrolyte imbalance causing acute life - threatening cardiac events .|Clinicians should be alert to the possibility of hyperkalemia , especially in elderly patients using ACE / ARB in combination with potassium sparing agents and who have mild renal disturbance .	1:Positive_Correlation:2	L2R	NON-CROSS	0-1	12-17	D013575	Syncope	DiseaseOrPhenotypicFeature	0	1	0	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	1:Positive_Correlation:2	L2R	NON-CROSS	0-1	18-19	D013575	Syncope	DiseaseOrPhenotypicFeature	0	1	0	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	1:NR:2	L2R	CROSS	0-1	60-61	D013575	Syncope	DiseaseOrPhenotypicFeature	0	1	0	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	1:NR:2	L2R	CROSS	0-1	92-93	D013575	Syncope	DiseaseOrPhenotypicFeature	0	1	0	D000450	aldosterone	ChemicalEntity	92	93	3	1:NR:2	L2R	CROSS	0-1	104-105	D013575	Syncope	DiseaseOrPhenotypicFeature	0	1	0	D017257	ramipril	ChemicalEntity	104	105	3	1:NR:2	L2R	CROSS	0-1	107-108	D013575	Syncope	DiseaseOrPhenotypicFeature	0	1	0	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	1:NR:2	L2R	CROSS	0-1	144-145	D013575	Syncope	DiseaseOrPhenotypicFeature	0	1	0	D057911	ARB	ChemicalEntity	144	145	5	1:Negative_Correlation:2	L2R	NON-CROSS	3-4	12-17	D006947	hyperkalemia|hyperkalemia|hyperkalemia|hyperkalemia	DiseaseOrPhenotypicFeature	3:54:81:135	4:55:82:136	0:1:3:5	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	1:Negative_Correlation:2	L2R	NON-CROSS	81-82	89-90	D006947	hyperkalemia|hyperkalemia|hyperkalemia|hyperkalemia	DiseaseOrPhenotypicFeature	3:54:81:135	4:55:82:136	0:1:3:5	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	1:Positive_Correlation:2	R2L	NON-CROSS	60-61	54-55	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	D006947	hyperkalemia|hyperkalemia|hyperkalemia|hyperkalemia	DiseaseOrPhenotypicFeature	3:54:81:135	4:55:82:136	0:1:3:5	1:NR:2	L2R	NON-CROSS	81-82	92-93	D006947	hyperkalemia|hyperkalemia|hyperkalemia|hyperkalemia	DiseaseOrPhenotypicFeature	3:54:81:135	4:55:82:136	0:1:3:5	D000450	aldosterone	ChemicalEntity	92	93	3	1:Positive_Correlation:2	L2R	NON-CROSS	81-82	104-105	D006947	hyperkalemia|hyperkalemia|hyperkalemia|hyperkalemia	DiseaseOrPhenotypicFeature	3:54:81:135	4:55:82:136	0:1:3:5	D017257	ramipril	ChemicalEntity	104	105	3	1:Association:2	R2L	NON-CROSS	142-143	135-136	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	D006947	hyperkalemia|hyperkalemia|hyperkalemia|hyperkalemia	DiseaseOrPhenotypicFeature	3:54:81:135	4:55:82:136	0:1:3:5	1:Association:2	R2L	NON-CROSS	144-145	135-136	D057911	ARB	ChemicalEntity	144	145	5	D006947	hyperkalemia|hyperkalemia|hyperkalemia|hyperkalemia	DiseaseOrPhenotypicFeature	3:54:81:135	4:55:82:136	0:1:3:5	1:Cotreatment:2	L2R	NON-CROSS	12-17	18-19	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	1:NR:2	L2R	CROSS	12-17	36-38	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	36	38	1	1:NR:2	L2R	CROSS	12-17	45-48	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D014474	loss of consciousness	DiseaseOrPhenotypicFeature	45	48	1	1:NR:2	L2R	CROSS	12-17	51-52	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D001919	bradycardia	DiseaseOrPhenotypicFeature	51	52	1	1:NR:2	L2R	CROSS	12-17	60-61	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	1:NR:2	L2R	CROSS	12-17	92-93	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D000450	aldosterone	ChemicalEntity	92	93	3	1:NR:2	L2R	CROSS	12-17	104-105	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D017257	ramipril	ChemicalEntity	104	105	3	1:NR:2	L2R	CROSS	12-17	107-108	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	1:NR:2	L2R	CROSS	12-17	144-145	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D057911	ARB	ChemicalEntity	144	145	5	1:NR:2	L2R	CROSS	12-17	155-157	D000806	angiotensin - converting enzyme inhibitor	ChemicalEntity	12	17	0	D007674	renal disturbance	DiseaseOrPhenotypicFeature	155	157	5	1:NR:2	L2R	CROSS	18-19	36-38	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	36	38	1	1:NR:2	L2R	CROSS	18-19	45-48	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	D014474	loss of consciousness	DiseaseOrPhenotypicFeature	45	48	1	1:NR:2	L2R	CROSS	18-19	51-52	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	D001919	bradycardia	DiseaseOrPhenotypicFeature	51	52	1	1:NR:2	L2R	CROSS	75-76	89-90	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	1:Negative_Correlation:2	R2L	NON-CROSS	92-93	89-90	D000450	aldosterone	ChemicalEntity	92	93	3	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	1:NR:2	L2R	NON-CROSS	89-90	104-105	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	D017257	ramipril	ChemicalEntity	104	105	3	1:NR:2	L2R	NON-CROSS	89-90	107-108	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	1:NR:2	L2R	CROSS	89-90	144-145	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	D057911	ARB	ChemicalEntity	144	145	5	1:NR:2	L2R	CROSS	89-90	155-157	D013148	spironolactone|spiranolactone	ChemicalEntity	18:89	19:90	0:3	D007674	renal disturbance	DiseaseOrPhenotypicFeature	155	157	5	1:NR:2	L2R	CROSS	36-38	60-61	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	36	38	1	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	1:NR:2	L2R	CROSS	36-38	92-93	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	36	38	1	D000450	aldosterone	ChemicalEntity	92	93	3	1:NR:2	L2R	CROSS	36-38	104-105	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	36	38	1	D017257	ramipril	ChemicalEntity	104	105	3	1:NR:2	L2R	CROSS	36-38	107-108	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	36	38	1	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	1:NR:2	L2R	CROSS	36-38	144-145	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	36	38	1	D057911	ARB	ChemicalEntity	144	145	5	1:NR:2	L2R	CROSS	45-48	60-61	D014474	loss of consciousness	DiseaseOrPhenotypicFeature	45	48	1	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	1:NR:2	L2R	CROSS	45-48	92-93	D014474	loss of consciousness	DiseaseOrPhenotypicFeature	45	48	1	D000450	aldosterone	ChemicalEntity	92	93	3	1:NR:2	L2R	CROSS	45-48	104-105	D014474	loss of consciousness	DiseaseOrPhenotypicFeature	45	48	1	D017257	ramipril	ChemicalEntity	104	105	3	1:NR:2	L2R	CROSS	45-48	107-108	D014474	loss of consciousness	DiseaseOrPhenotypicFeature	45	48	1	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	1:NR:2	L2R	CROSS	45-48	144-145	D014474	loss of consciousness	DiseaseOrPhenotypicFeature	45	48	1	D057911	ARB	ChemicalEntity	144	145	5	1:NR:2	L2R	CROSS	51-52	60-61	D001919	bradycardia	DiseaseOrPhenotypicFeature	51	52	1	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	1:NR:2	L2R	CROSS	51-52	92-93	D001919	bradycardia	DiseaseOrPhenotypicFeature	51	52	1	D000450	aldosterone	ChemicalEntity	92	93	3	1:NR:2	L2R	CROSS	51-52	104-105	D001919	bradycardia	DiseaseOrPhenotypicFeature	51	52	1	D017257	ramipril	ChemicalEntity	104	105	3	1:NR:2	L2R	CROSS	51-52	107-108	D001919	bradycardia	DiseaseOrPhenotypicFeature	51	52	1	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	1:NR:2	L2R	CROSS	51-52	144-145	D001919	bradycardia	DiseaseOrPhenotypicFeature	51	52	1	D057911	ARB	ChemicalEntity	144	145	5	1:NR:2	L2R	CROSS	75-76	92-93	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	D000450	aldosterone	ChemicalEntity	92	93	3	1:NR:2	L2R	CROSS	75-76	104-105	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	D017257	ramipril	ChemicalEntity	104	105	3	1:Cotreatment:2	R2L	NON-CROSS	148-149	142-143	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	1:Cotreatment:2	R2L	NON-CROSS	148-149	144-145	D057911	ARB	ChemicalEntity	144	145	5	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	1:Association:2	L2R	NON-CROSS	148-149	155-157	D011188	potassium|potassium|potassium	ChemicalEntity	60:75:148	61:76:149	2:2:5	D007674	renal disturbance	DiseaseOrPhenotypicFeature	155	157	5	1:NR:2	L2R	NON-CROSS	92-93	104-105	D000450	aldosterone	ChemicalEntity	92	93	3	D017257	ramipril	ChemicalEntity	104	105	3	1:NR:2	L2R	NON-CROSS	92-93	107-108	D000450	aldosterone	ChemicalEntity	92	93	3	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	1:NR:2	L2R	CROSS	92-93	144-145	D000450	aldosterone	ChemicalEntity	92	93	3	D057911	ARB	ChemicalEntity	144	145	5	1:NR:2	L2R	CROSS	92-93	155-157	D000450	aldosterone	ChemicalEntity	92	93	3	D007674	renal disturbance	DiseaseOrPhenotypicFeature	155	157	5	1:Negative_Correlation:2	L2R	NON-CROSS	104-105	107-108	D017257	ramipril	ChemicalEntity	104	105	3	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	1:NR:2	L2R	CROSS	104-105	144-145	D017257	ramipril	ChemicalEntity	104	105	3	D057911	ARB	ChemicalEntity	144	145	5	1:NR:2	L2R	CROSS	104-105	155-157	D017257	ramipril	ChemicalEntity	104	105	3	D007674	renal disturbance	DiseaseOrPhenotypicFeature	155	157	5	1:Cotreatment:2	L2R	NON-CROSS	142-143	144-145	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	D057911	ARB	ChemicalEntity	144	145	5	1:Association:2	L2R	NON-CROSS	142-143	155-157	1636	ACE|ACE	GeneOrGeneProduct	107:142	108:143	3:5	D007674	renal disturbance	DiseaseOrPhenotypicFeature	155	157	5	1:Association:2	L2R	NON-CROSS	144-145	155-157	D057911	ARB	ChemicalEntity	144	145	5	D007674	renal disturbance	DiseaseOrPhenotypicFeature	155	157	5
15041272	A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation .|Clinical , laboratory and genetic defect of a Taiwanese family with type 2B von Willebrand disease ( VWD ) were studied .|The proband was a 55 - year - old woman who gave birth to two daughters and one son aged 30 , 29 and 27 , respectively .|All had abnormal mucocutaneous bleedings since their childhood .|In proband , PT , PTT and platelet count were normal ; template bleeding time was 14 min ; VIII : C was 51 % , von Willebrand factor antigen ( VWF : Ag ) , 42 % and von Willerand factor ristocetin - cofactor ( VWF : RCo , 15 % ) ; ristocetin - induced platelet aggregation ( RIPA ) at 0 . 3 and 0 . 6 mg / ml of ristocetin was 16 % and 68 % , respectively .|The enhanced response to ristocetin was identified to be in plasma , not in platelet itself , by mixing studies .|Analysis of von Willebrand factor ( VWF ) multimer of plasma but not of platelets showed absence of high - molecular weight ( HMW ) multimer .|All three children had similar laboratory findings .|Exon 28 of VWF gene was amplified using polymerase chain reaction ( PCR ) and sequenced .|The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp ( R1306W ) substitution .|This mutation in the glycoprotein Ib ( GPIb ) - binding site has been found to increase the affinity of plasma VWF for platelets , and thus cause loss of HMW multimers and often thrombocytopenia .|In conclusion , a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described .	1:Association:2	L2R	NON-CROSS	6-11	12-13	D056728	type 2B von Willebrand disease|type 2B von Willebrand disease|type 2B VWD	DiseaseOrPhenotypicFeature	6:26:303	11:31:306	0:1:11	rs61749384	R1306W|C to T transition at nucleotide 3916|Arg 1306 Trp|R1306W|R1306W	SequenceVariant	12:243:252:256:313	13:250:255:257:314	0:9:9:9:11	1:NR:2	L2R	CROSS	26-31	93-94	D056728	type 2B von Willebrand disease|type 2B von Willebrand disease|type 2B VWD	DiseaseOrPhenotypicFeature	6:26:303	11:31:306	0:1:11	2157	VIII	GeneOrGeneProduct	93	94	4	1:Association:2	L2R	NON-CROSS	303-306	316-317	D056728	type 2B von Willebrand disease|type 2B von Willebrand disease|type 2B VWD	DiseaseOrPhenotypicFeature	6:26:303	11:31:306	0:1:11	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	1:NR:2	L2R	CROSS	26-31	116-117	D056728	type 2B von Willebrand disease|type 2B von Willebrand disease|type 2B VWD	DiseaseOrPhenotypicFeature	6:26:303	11:31:306	0:1:11	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	1:NR:2	L2R	CROSS	267-268	303-306	D056728	type 2B von Willebrand disease|type 2B von Willebrand disease|type 2B VWD	DiseaseOrPhenotypicFeature	6:26:303	11:31:306	0:1:11	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	1:NR:2	L2R	CROSS	12-13	19-21	rs61749384	R1306W|C to T transition at nucleotide 3916|Arg 1306 Trp|R1306W|R1306W	SequenceVariant	12:243:252:256:313	13:250:255:257:314	0:9:9:9:11	D030342	genetic defect	DiseaseOrPhenotypicFeature	19	21	1	1:NR:2	L2R	CROSS	12-13	32-33	rs61749384	R1306W|C to T transition at nucleotide 3916|Arg 1306 Trp|R1306W|R1306W	SequenceVariant	12:243:252:256:313	13:250:255:257:314	0:9:9:9:11	D014842	VWD	DiseaseOrPhenotypicFeature	32	33	1	1:NR:2	L2R	CROSS	12-13	69-70	rs61749384	R1306W|C to T transition at nucleotide 3916|Arg 1306 Trp|R1306W|R1306W	SequenceVariant	12:243:252:256:313	13:250:255:257:314	0:9:9:9:11	D006470	bleedings|bleeding	DiseaseOrPhenotypicFeature	69:87	70:88	3:4	1:NR:2	L2R	CROSS	162-163	243-250	rs61749384	R1306W|C to T transition at nucleotide 3916|Arg 1306 Trp|R1306W|R1306W	SequenceVariant	12:243:252:256:313	13:250:255:257:314	0:9:9:9:11	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	1:NR:2	L2R	CROSS	134-135	243-250	rs61749384	R1306W|C to T transition at nucleotide 3916|Arg 1306 Trp|R1306W|R1306W	SequenceVariant	12:243:252:256:313	13:250:255:257:314	0:9:9:9:11	D001791	ristocetin - induced platelet aggregation|RIPA	DiseaseOrPhenotypicFeature	128:134	133:135	4:4	1:Positive_Correlation:2	L2R	CROSS	294-295	313-314	rs61749384	R1306W|C to T transition at nucleotide 3916|Arg 1306 Trp|R1306W|R1306W	SequenceVariant	12:243:252:256:313	13:250:255:257:314	0:9:9:9:11	D013921	thrombocytopenia	DiseaseOrPhenotypicFeature	294	295	10	1:NR:2	L2R	CROSS	19-21	93-94	D030342	genetic defect	DiseaseOrPhenotypicFeature	19	21	1	2157	VIII	GeneOrGeneProduct	93	94	4	1:NR:2	L2R	CROSS	19-21	100-103	D030342	genetic defect	DiseaseOrPhenotypicFeature	19	21	1	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	1:NR:2	L2R	CROSS	19-21	116-117	D030342	genetic defect	DiseaseOrPhenotypicFeature	19	21	1	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	1:NR:2	L2R	CROSS	19-21	264-266	D030342	genetic defect	DiseaseOrPhenotypicFeature	19	21	1	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	1:NR:2	L2R	CROSS	32-33	93-94	D014842	VWD	DiseaseOrPhenotypicFeature	32	33	1	2157	VIII	GeneOrGeneProduct	93	94	4	1:NR:2	L2R	CROSS	32-33	100-103	D014842	VWD	DiseaseOrPhenotypicFeature	32	33	1	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	1:NR:2	L2R	CROSS	32-33	116-117	D014842	VWD	DiseaseOrPhenotypicFeature	32	33	1	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	1:NR:2	L2R	CROSS	32-33	264-266	D014842	VWD	DiseaseOrPhenotypicFeature	32	33	1	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	1:NR:2	L2R	NON-CROSS	87-88	93-94	D006470	bleedings|bleeding	DiseaseOrPhenotypicFeature	69:87	70:88	3:4	2157	VIII	GeneOrGeneProduct	93	94	4	1:NR:2	L2R	NON-CROSS	87-88	100-103	D006470	bleedings|bleeding	DiseaseOrPhenotypicFeature	69:87	70:88	3:4	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	1:NR:2	L2R	NON-CROSS	87-88	116-117	D006470	bleedings|bleeding	DiseaseOrPhenotypicFeature	69:87	70:88	3:4	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	1:NR:2	L2R	CROSS	87-88	264-266	D006470	bleedings|bleeding	DiseaseOrPhenotypicFeature	69:87	70:88	3:4	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	1:NR:2	L2R	NON-CROSS	93-94	100-103	2157	VIII	GeneOrGeneProduct	93	94	4	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	1:NR:2	L2R	NON-CROSS	93-94	116-117	2157	VIII	GeneOrGeneProduct	93	94	4	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	1:NR:2	L2R	NON-CROSS	93-94	128-133	2157	VIII	GeneOrGeneProduct	93	94	4	D001791	ristocetin - induced platelet aggregation|RIPA	DiseaseOrPhenotypicFeature	128:134	133:135	4:4	1:NR:2	L2R	CROSS	93-94	264-266	2157	VIII	GeneOrGeneProduct	93	94	4	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	1:NR:2	L2R	CROSS	93-94	294-295	2157	VIII	GeneOrGeneProduct	93	94	4	D013921	thrombocytopenia	DiseaseOrPhenotypicFeature	294	295	10	1:Association:2	L2R	NON-CROSS	113-116	116-117	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	1:NR:2	L2R	NON-CROSS	120-121	128-133	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	D001791	ristocetin - induced platelet aggregation|RIPA	DiseaseOrPhenotypicFeature	128:134	133:135	4:4	1:Association:2	R2L	NON-CROSS	281-282	267-268	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	1:Association:2	L2R	NON-CROSS	281-282	294-295	7450	von Willebrand factor|VWF|von Willerand factor|VWF|von Willebrand factor|VWF|VWF|VWF|VWF	GeneOrGeneProduct	100:105:113:120:181:185:217:281:316	103:106:116:121:184:186:218:282:317	4:4:4:4:6:6:8:10:11	D013921	thrombocytopenia	DiseaseOrPhenotypicFeature	294	295	10	1:Positive_Correlation:2	R2L	NON-CROSS	128-133	116-117	D001791	ristocetin - induced platelet aggregation|RIPA	DiseaseOrPhenotypicFeature	128:134	133:135	4:4	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	1:NR:2	L2R	CROSS	162-163	264-266	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	1:NR:2	L2R	CROSS	162-163	294-295	D012310	ristocetin|ristocetin|ristocetin	ChemicalEntity	116:148:162	117:149:163	4:4:5	D013921	thrombocytopenia	DiseaseOrPhenotypicFeature	294	295	10	1:NR:2	L2R	CROSS	134-135	264-266	D001791	ristocetin - induced platelet aggregation|RIPA	DiseaseOrPhenotypicFeature	128:134	133:135	4:4	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	1:Association:2	L2R	NON-CROSS	267-268	294-295	2811	glycoprotein Ib|GPIb	GeneOrGeneProduct	264:267	266:268	10:10	D013921	thrombocytopenia	DiseaseOrPhenotypicFeature	294	295	10
17395743	Identification of PVT1 as a candidate gene for end - stage renal disease in type 2 diabetes using a pooling - based genome - wide single nucleotide polymorphism association study .|To identify genetic variants contributing to end - stage renal disease ( ESRD ) in type 2 diabetes , we performed a genome - wide analysis of 115 , 352 single nucleotide polymorphisms ( SNPs ) in pools of 105 unrelated case subjects with ESRD and 102 unrelated control subjects who have had type 2 diabetes for > or = 10 years without macroalbuminuria .|Using a sliding window statistic of ranked SNPs , we identified a 200 - kb region on 8q24 harboring three SNPs showing substantial differences in allelic frequency between case and control pools .|These SNPs were genotyped in individuals comprising each pool , and strong evidence for association was found with rs2720709 ( P = 0 . 000021 ; odds ratio 2 . 57 [ 95 % CI 1 . 66 - 3 . 96 ] ) , which is located in the plasmacytoma variant translocation gene PVT1 .|We sequenced all exons , exon - intron boundaries , and the promoter of PVT1 and identified 47 variants , 11 of which represented nonredundant markers with minor allele frequency > or = 0 . 05 .|We subsequently genotyped these 11 variants and an additional 87 SNPs identified through public databases in 319 - kb flanking rs2720709 ( approximately 1 SNP / 3 . 5 kb ) ; 23 markers were associated with ESRD at P < 0 . 01 .|The strongest evidence for association was found for rs2648875 ( P = 0 . 0000018 ; 2 . 97 [ 1 . 90 - 4 . 65 ] ) , which maps to intron 8 of PVT1 .|Together , these results suggest that PVT1 may contribute to ESRD susceptibility in diabetes .	1:Association:2	L2R	NON-CROSS	311-312	315-316	5820	PVT1|PVT1|PVT1|PVT1|PVT1	GeneOrGeneProduct	2:183:199:303:311	3:184:200:304:312	0:3:4:6:7	D007676	end - stage renal disease|end - stage renal disease|ESRD|ESRD|ESRD|ESRD	DiseaseOrPhenotypicFeature	8:37:43:75:259:315	13:42:44:76:260:316	0:1:1:1:5:7	1:Association:2	L2R	NON-CROSS	2-3	14-17	5820	PVT1|PVT1|PVT1|PVT1|PVT1	GeneOrGeneProduct	2:183:199:303:311	3:184:200:304:312	0:3:4:6:7	D003924	type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	14:46:84	17:49:87	0:1:1	1:Association:2	L2R	NON-CROSS	311-312	318-319	5820	PVT1|PVT1|PVT1|PVT1|PVT1	GeneOrGeneProduct	2:183:199:303:311	3:184:200:304:312	0:3:4:6:7	D003920	diabetes	DiseaseOrPhenotypicFeature	318	319	7	1:Positive_Correlation:2	R2L	NON-CROSS	259-260	242-243	rs2720709	rs2720709|rs2720709	SequenceVariant	147:242	148:243	3:5	D007676	end - stage renal disease|end - stage renal disease|ESRD|ESRD|ESRD|ESRD	DiseaseOrPhenotypicFeature	8:37:43:75:259:315	13:42:44:76:260:316	0:1:1:1:5:7	1:Positive_Correlation:2	R2L	CROSS	275-276	259-260	rs2648875	rs2648875	SequenceVariant	275	276	6	D007676	end - stage renal disease|end - stage renal disease|ESRD|ESRD|ESRD|ESRD	DiseaseOrPhenotypicFeature	8:37:43:75:259:315	13:42:44:76:260:316	0:1:1:1:5:7	1:Association:2	L2R	CROSS	84-87	147-148	D003924	type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	14:46:84	17:49:87	0:1:1	rs2720709	rs2720709|rs2720709	SequenceVariant	147:242	148:243	3:5	1:Association:2	L2R	CROSS	84-87	275-276	D003924	type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	14:46:84	17:49:87	0:1:1	rs2648875	rs2648875	SequenceVariant	275	276	6	1:NR:2	L2R	CROSS	242-243	318-319	rs2720709	rs2720709|rs2720709	SequenceVariant	147:242	148:243	3:5	D003920	diabetes	DiseaseOrPhenotypicFeature	318	319	7	1:NR:2	L2R	CROSS	275-276	318-319	rs2648875	rs2648875	SequenceVariant	275	276	6	D003920	diabetes	DiseaseOrPhenotypicFeature	318	319	7
27729412	Reduced adiponectin expression after high - fat diet is associated with selective up - regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue .|Adiponectin is an adipocyte - derived adipokine with potent antidiabetic , anti - inflammatory , and antiatherogenic activity .|Long - term , high - fat diet results in gain of body weight , adiposity , further inflammatory - based cardiovascular diseases , and reduced adiponectin secretion .|Vitamin A derivatives / retinoids are involved in several of these processes , which mainly take place in white adipose tissue ( WAT ) .|In this study , we examined adiponectin expression as a function of dietary high - fat and high - vitamin A conditions in mice .|A decrease of adiponectin expression in addition to an up - regulation of aldehyde dehydrogenase A1 ( ALDH1A1 ) , retinoid signaling , and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal - vitamin A , high - fat diet .|Reduced adiponectin expression in WAT was also observed in mice fed a high - vitamin A diet .|Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor ( RAR ) a - and RARg - selective agonists , as well as a synthetic retinoid X receptor agonist , efficiently reduced adiponectin expression , whereas ALDH1A1 expression only increased with RAR agonists .|We conclude that reduced adiponectin expression under high - fat dietary conditions is dependent on 1 ) increased ALDH1A1 expression in adipocytes , which does not increase all - trans - retinoic acid levels ; 2 ) further RAR ligand - induced , WAT - selective , increased retinoic acid response element - mediated signaling ; and 3 ) RAR ligand - dependent reduction of adiponectin expression . - Landrier , J . - F . , Kasiri , E . , Karkeni , E . , Mihaly , J . , Beke , G . , Weiss , K . , Lucas , R . , Aydemir , G . , Salles , J . , Walrand , S . , de Lera , A .|R . , Ruhl , R .|Reduced adiponectin expression after high - fat diet is associated with selective up - regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue .	1:Negative_Correlation:2	L2R	NON-CROSS	225-226	229-230	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	1:NR:2	L2R	NON-CROSS	296-297	302-303	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	1:Negative_Correlation:2	L2R	NON-CROSS	33-34	40-41	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	1:NR:2	L2R	NON-CROSS	61-62	72-73	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	1:NR:2	L2R	NON-CROSS	67-69	72-73	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	1:Negative_Correlation:2	L2R	NON-CROSS	72-73	75-77	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	1:NR:2	L2R	CROSS	72-73	79-80	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	D012176	retinoids	ChemicalEntity	79	80	3	1:Negative_Correlation:2	L2R	NON-CROSS	285-287	302-303	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:Negative_Correlation:2	R2L	NON-CROSS	225-226	199-206	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	1:Negative_Correlation:2	R2L	NON-CROSS	225-226	208-209	19411	RARg	GeneOrGeneProduct	208	209	7	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	1:Negative_Correlation:2	R2L	NON-CROSS	225-226	218-221	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	11450	adiponectin|Adiponectin|adipokine|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin|adiponectin	GeneOrGeneProduct	1:27:33:72:106:128:174:225:241:302:372	2:28:34:73:107:129:175:226:242:303:373	0:1:1:2:4:5:6:7:8:8:10	1:NR:2	L2R	NON-CROSS	16-17	19-22	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	1:NR:2	L2R	CROSS	16-17	40-41	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	1:NR:2	L2R	CROSS	16-17	61-62	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	1:NR:2	L2R	CROSS	16-17	67-69	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	1:Positive_Correlation:2	L2R	NON-CROSS	119-121	138-141	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	1:NR:2	L2R	CROSS	79-80	138-141	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	D012176	retinoids	ChemicalEntity	79	80	3	1:NR:2	L2R	NON-CROSS	142-143	149-151	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:Positive_Correlation:2	L2R	NON-CROSS	199-206	229-230	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	1:Positive_Correlation:2	L2R	NON-CROSS	208-209	229-230	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	19411	RARg	GeneOrGeneProduct	208	209	7	1:Positive_Correlation:2	L2R	NON-CROSS	218-221	229-230	11668	ALDH1A1|aldehyde dehydrogenase A1|ALDH1A1|ALDH1A1|ALDH1A1|ALDH1A1	GeneOrGeneProduct	16:138:142:229:255:387	17:141:143:230:256:388	0:5:5:7:8:10	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	1:NR:2	L2R	CROSS	19-22	40-41	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	1:NR:2	L2R	CROSS	19-22	61-62	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	1:NR:2	L2R	CROSS	19-22	67-69	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	1:NR:2	L2R	CROSS	187-189	234-235	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	1:NR:2	L2R	CROSS	19-22	79-80	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	D012176	retinoids	ChemicalEntity	79	80	3	1:NR:2	L2R	NON-CROSS	268-270	275-276	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:NR:2	L2R	NON-CROSS	199-206	234-235	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	1:NR:2	L2R	NON-CROSS	208-209	234-235	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	19411	RARg	GeneOrGeneProduct	208	209	7	1:NR:2	L2R	NON-CROSS	218-221	234-235	19401,19411,20181	retinoic acid receptor|RAR|RAR|RAR|retinoic acid receptor	GeneOrGeneProduct	19:234:275:296:390	22:235:276:297:393	0:7:8:8:10	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	1:NR:2	L2R	CROSS	64-65	75-77	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	1:NR:2	L2R	CROSS	64-65	79-80	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	D012176	retinoids	ChemicalEntity	79	80	3	1:NR:2	L2R	CROSS	64-65	149-151	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:NR:2	L2R	CROSS	64-65	199-206	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	1:NR:2	L2R	CROSS	64-65	208-209	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	19411	RARg	GeneOrGeneProduct	208	209	7	1:NR:2	L2R	CROSS	64-65	218-221	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	40:64	41:65	1:2	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	1:NR:2	L2R	CROSS	61-62	75-77	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	1:NR:2	L2R	CROSS	61-62	79-80	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	D012176	retinoids	ChemicalEntity	79	80	3	1:NR:2	L2R	CROSS	61-62	149-151	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:NR:2	L2R	CROSS	61-62	199-206	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	1:NR:2	L2R	CROSS	61-62	208-209	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	19411	RARg	GeneOrGeneProduct	208	209	7	1:NR:2	L2R	CROSS	61-62	218-221	D009765	adiposity	DiseaseOrPhenotypicFeature	61	62	2	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	1:NR:2	L2R	CROSS	67-69	75-77	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	1:NR:2	L2R	CROSS	67-69	79-80	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	D012176	retinoids	ChemicalEntity	79	80	3	1:NR:2	L2R	CROSS	67-69	149-151	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:NR:2	L2R	CROSS	67-69	199-206	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	1:NR:2	L2R	CROSS	67-69	208-209	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	19411	RARg	GeneOrGeneProduct	208	209	7	1:NR:2	L2R	CROSS	67-69	218-221	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	67	69	2	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	1:NR:2	L2R	NON-CROSS	75-77	79-80	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	D012176	retinoids	ChemicalEntity	79	80	3	1:Association:2	R2L	NON-CROSS	165-167	149-151	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	1:NR:2	L2R	CROSS	187-189	199-206	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	1:NR:2	L2R	CROSS	187-189	208-209	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	19411	RARg	GeneOrGeneProduct	208	209	7	1:NR:2	L2R	CROSS	187-189	218-221	D014801	Vitamin A|vitamin A|vitamin A|vitamin A	ChemicalEntity	75:119:165:187	77:121:167:189	3:4:5:6	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	1:NR:2	L2R	CROSS	79-80	149-151	D012176	retinoids	ChemicalEntity	79	80	3	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:NR:2	L2R	CROSS	79-80	199-206	D012176	retinoids	ChemicalEntity	79	80	3	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	1:NR:2	L2R	CROSS	79-80	208-209	D012176	retinoids	ChemicalEntity	79	80	3	19411	RARg	GeneOrGeneProduct	208	209	7	1:NR:2	L2R	CROSS	79-80	218-221	D012176	retinoids	ChemicalEntity	79	80	3	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	1:Positive_Correlation:2	R2L	CROSS	199-206	149-151	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:Positive_Correlation:2	R2L	CROSS	208-209	149-151	19411	RARg	GeneOrGeneProduct	208	209	7	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:Positive_Correlation:2	R2L	CROSS	268-270	218-221	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	D014212	retinoic acid|retinoic acid|retinoic acid	ChemicalEntity	149:268:285	151:270:287	5:8:8	1:NR:2	L2R	NON-CROSS	199-206	208-209	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	19411	RARg	GeneOrGeneProduct	208	209	7	1:NR:2	L2R	NON-CROSS	199-206	218-221	19401	retinoic acid receptor ( RAR ) a	GeneOrGeneProduct	199	206	7	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7	1:NR:2	L2R	NON-CROSS	208-209	218-221	19411	RARg	GeneOrGeneProduct	208	209	7	20181	retinoid X receptor	GeneOrGeneProduct	218	221	7
29183288	Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma , but not lung mechanics , in female mice .|BACKGROUND : ( Over - ) expression of arginase may limit local availability of arginine for nitric oxide synthesis .|We investigated the significance of arginase1 ( ARG1 ) for the development of airway hyperresponsiveness ( AHR ) and lung inflammation in female mice with ovalbumin ( OVA ) - induced allergic asthma .|METHODS : Arg1 was ablated in the lung by crossing Arg1 fl / fl and Tie2Cre tg / - mice .|OVA sensitization and challenge were conducted , and AHR to methacholine was determined using the Flexivent system .|Changes in gene expression , chemokine and cytokine secretion , plasma IgE , and lung histology were quantified using RT - qPCR , ELISA , and immunohistochemistry , respectively .|RESULTS : Arg1 ablation had no influence on the development of OVA - induced AHR , but attenuated OVA - induced increases in expression of Arg2 and Nos2 , Slc7a1 , Slc7a2 , and Slc7a7 ( arginine transporters ) , Il4 , Il5 and Il13 ( TH2 - type cytokines ) , Ccl2 and Ccl11 ( chemokines ) , Ifng ( TH1 - type cytokine ) , Clca3 and Muc5ac ( goblet cell markers ) , and OVA - specific IgE .|Pulmonary IL - 10 protein content increased , but IL - 4 , IL - 5 , IL - 13 , TNFalpha and IFNgamma content , and lung histopathology , were not affected .|Arg1 elimination also decreased number and tightness of correlations between adaptive changes in lung function and inflammatory parameters in OVA / OVA - treated female mice .|OVA / OVA - treated female mice mounted a higher OVA - IgE response than males , but the correlation between lung function and inflammation was lower .|Arg1 - deficient OVA / OVA - treated females differed from males in a more pronounced decline of arginine - metabolizing and - transporting genes , higher plasma arginine levels , a smaller OVA - specific IgE response , and no improvement of peripheral lung function .|CONCLUSION : Complete ablation of Arg1 in the lung affects mRNA abundance of arginine - transporting and - metabolizing genes , and pro - inflammatory genes , but not methacholine responsiveness or accumulation of inflammatory cells .	1:Association:2	L2R	NON-CROSS	313-314	317-318	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	1:Association:2	L2R	NON-CROSS	75-76	79-80	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	1:Association:2	L2R	NON-CROSS	31-32	39-41	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	D009569	nitric oxide	ChemicalEntity	39	41	1	1:NR:2	L2R	NON-CROSS	50-51	62-64	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	1:Positive_Correlation:2	L2R	NON-CROSS	317-318	320-321	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	1:NR:2	L2R	NON-CROSS	87-88	108-109	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	1:Positive_Correlation:2	L2R	NON-CROSS	301-302	317-318	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	1:Positive_Correlation:2	L2R	NON-CROSS	148-149	171-172	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	11847	Arg2	GeneOrGeneProduct	171	172	6	1:Positive_Correlation:2	L2R	NON-CROSS	148-149	173-174	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	18126	Nos2	GeneOrGeneProduct	173	174	6	1:Positive_Correlation:2	L2R	NON-CROSS	148-149	175-176	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:Positive_Correlation:2	L2R	NON-CROSS	148-149	177-178	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:Positive_Correlation:2	L2R	NON-CROSS	148-149	180-181	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	NON-CROSS	148-149	182-184	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:Positive_Correlation:2	L2R	NON-CROSS	237-240	262-263	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:Positive_Correlation:2	L2R	NON-CROSS	241-244	262-263	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:Positive_Correlation:2	L2R	NON-CROSS	245-248	262-263	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	148-149	192-196	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:Positive_Correlation:2	L2R	NON-CROSS	148-149	198-199	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:Positive_Correlation:2	L2R	NON-CROSS	148-149	200-201	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	148-149	202-203	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:Positive_Correlation:2	L2R	NON-CROSS	251-252	262-263	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	213-214	262-263	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	23844	Clca3	GeneOrGeneProduct	213	214	6	1:Positive_Correlation:2	L2R	NON-CROSS	215-216	262-263	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:Negative_Correlation:2	L2R	CROSS	229-232	262-263	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	249-250	262-263	11846	Arginase 1|arginase|arginase1|ARG1|Arg1|Arg1|Arg1|Arg1|Arg1|Arg1	GeneOrGeneProduct	0:31:48:50:79:87:148:262:317:369	2:32:49:51:80:88:149:263:318:370	0:1:2:2:3:3:6:8:10:11	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	8-9	39-41	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	D009569	nitric oxide	ChemicalEntity	39	41	1	1:NR:2	L2R	NON-CROSS	278-279	281-282	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	1:NR:2	L2R	NON-CROSS	388-389	393-394	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	1:NR:2	L2R	NON-CROSS	301-302	313-314	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	1:NR:2	L2R	CROSS	171-172	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	11847	Arg2	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	173-174	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	18126	Nos2	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	175-176	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	177-178	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	180-181	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	182-184	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	CROSS	237-240	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	CROSS	241-244	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	CROSS	245-248	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	CROSS	192-196	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	CROSS	198-199	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	CROSS	200-201	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	CROSS	202-203	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	CROSS	251-252	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	CROSS	213-214	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	CROSS	215-216	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	229-232	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	249-250	278-279	D007249	inflammatory|inflammatory|inflammation|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	8:278:313:388:398	9:279:314:389:399	0:8:9:11:11	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	12-13	39-41	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	D009569	nitric oxide	ChemicalEntity	39	41	1	1:NR:2	L2R	NON-CROSS	70-71	75-76	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	1:NR:2	L2R	CROSS	75-76	108-109	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	1:NR:2	L2R	CROSS	75-76	127-128	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	1:NR:2	L2R	CROSS	75-76	171-172	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	11847	Arg2	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	75-76	173-174	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	18126	Nos2	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	75-76	175-176	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	75-76	177-178	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	75-76	180-181	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	75-76	182-184	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	CROSS	75-76	186-187	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	CROSS	75-76	188-189	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	CROSS	75-76	190-191	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	CROSS	75-76	192-196	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	CROSS	75-76	198-199	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	CROSS	75-76	200-201	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	CROSS	75-76	202-203	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	CROSS	75-76	205-206	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	CROSS	75-76	213-214	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	CROSS	75-76	215-216	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	75-76	229-232	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	75-76	249-250	D001249	asthma|asthma	DiseaseOrPhenotypicFeature	12:75	13:76	0:2	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	39-41	62-64	D009569	nitric oxide	ChemicalEntity	39	41	1	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	1:NR:2	L2R	CROSS	39-41	68-69	D009569	nitric oxide	ChemicalEntity	39	41	1	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	1:NR:2	L2R	CROSS	39-41	108-109	D009569	nitric oxide	ChemicalEntity	39	41	1	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	1:NR:2	L2R	CROSS	39-41	127-128	D009569	nitric oxide	ChemicalEntity	39	41	1	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	1:NR:2	L2R	CROSS	39-41	171-172	D009569	nitric oxide	ChemicalEntity	39	41	1	11847	Arg2	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	39-41	173-174	D009569	nitric oxide	ChemicalEntity	39	41	1	18126	Nos2	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	39-41	175-176	D009569	nitric oxide	ChemicalEntity	39	41	1	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	39-41	177-178	D009569	nitric oxide	ChemicalEntity	39	41	1	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	39-41	180-181	D009569	nitric oxide	ChemicalEntity	39	41	1	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	39-41	182-184	D009569	nitric oxide	ChemicalEntity	39	41	1	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	CROSS	39-41	186-187	D009569	nitric oxide	ChemicalEntity	39	41	1	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	CROSS	39-41	188-189	D009569	nitric oxide	ChemicalEntity	39	41	1	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	CROSS	39-41	190-191	D009569	nitric oxide	ChemicalEntity	39	41	1	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	CROSS	39-41	192-196	D009569	nitric oxide	ChemicalEntity	39	41	1	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	CROSS	39-41	198-199	D009569	nitric oxide	ChemicalEntity	39	41	1	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	CROSS	39-41	200-201	D009569	nitric oxide	ChemicalEntity	39	41	1	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	CROSS	39-41	202-203	D009569	nitric oxide	ChemicalEntity	39	41	1	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	CROSS	39-41	205-206	D009569	nitric oxide	ChemicalEntity	39	41	1	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	CROSS	39-41	213-214	D009569	nitric oxide	ChemicalEntity	39	41	1	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	CROSS	39-41	215-216	D009569	nitric oxide	ChemicalEntity	39	41	1	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	39-41	229-232	D009569	nitric oxide	ChemicalEntity	39	41	1	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	39-41	249-250	D009569	nitric oxide	ChemicalEntity	39	41	1	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	62-64	68-69	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	1:NR:2	L2R	CROSS	62-64	108-109	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	1:NR:2	L2R	CROSS	62-64	127-128	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	1:NR:2	L2R	CROSS	62-64	171-172	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	11847	Arg2	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	62-64	173-174	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	18126	Nos2	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	62-64	175-176	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	62-64	177-178	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	62-64	180-181	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	62-64	182-184	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	CROSS	62-64	186-187	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	CROSS	62-64	188-189	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	CROSS	62-64	190-191	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	CROSS	62-64	192-196	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	CROSS	62-64	198-199	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	CROSS	62-64	200-201	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	CROSS	62-64	202-203	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	CROSS	62-64	205-206	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	CROSS	62-64	213-214	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	CROSS	62-64	215-216	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	62-64	229-232	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	62-64	249-250	D011014	lung inflammation	DiseaseOrPhenotypicFeature	62	64	2	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	98-99	108-109	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	1:Positive_Correlation:2	R2L	NON-CROSS	301-302	299-300	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	1:Positive_Correlation:2	L2R	NON-CROSS	164-165	171-172	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	11847	Arg2	GeneOrGeneProduct	171	172	6	1:Positive_Correlation:2	L2R	NON-CROSS	164-165	173-174	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	18126	Nos2	GeneOrGeneProduct	173	174	6	1:Positive_Correlation:2	L2R	NON-CROSS	164-165	175-176	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:Positive_Correlation:2	L2R	NON-CROSS	164-165	177-178	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:Positive_Correlation:2	L2R	NON-CROSS	164-165	180-181	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	NON-CROSS	164-165	182-184	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:Positive_Correlation:2	L2R	NON-CROSS	223-224	237-240	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:Positive_Correlation:2	L2R	NON-CROSS	223-224	241-244	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:Positive_Correlation:2	L2R	NON-CROSS	223-224	245-248	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	164-165	192-196	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:Positive_Correlation:2	L2R	NON-CROSS	198-199	223-224	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:Positive_Correlation:2	L2R	NON-CROSS	200-201	223-224	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	202-203	223-224	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:Positive_Correlation:2	L2R	NON-CROSS	207-211	223-224	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	213-214	223-224	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	23844	Clca3	GeneOrGeneProduct	213	214	6	1:Positive_Correlation:2	L2R	NON-CROSS	215-216	223-224	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	223-224	229-232	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	223-224	249-250	66222	ovalbumin|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA|OVA	GeneOrGeneProduct	68:70:98:157:164:223:281:283:289:291:299:320:322:350	69:71:99:158:165:224:282:284:290:292:300:321:323:351	2:2:4:6:6:6:8:8:9:9:9:10:10:10	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	108-109	127-128	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	1:NR:2	L2R	CROSS	108-109	171-172	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	11847	Arg2	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	108-109	173-174	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	18126	Nos2	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	108-109	175-176	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	108-109	177-178	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	108-109	180-181	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	CROSS	108-109	182-184	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	CROSS	108-109	186-187	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	CROSS	108-109	188-189	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	CROSS	108-109	190-191	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	CROSS	108-109	192-196	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	CROSS	108-109	198-199	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	CROSS	108-109	200-201	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	CROSS	108-109	202-203	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	CROSS	108-109	205-206	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	CROSS	108-109	213-214	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	CROSS	108-109	215-216	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	108-109	229-232	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	108-109	249-250	D016210	methacholine|methacholine	ChemicalEntity	108:393	109:394	4:11	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	127-128	171-172	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	11847	Arg2	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	NON-CROSS	127-128	173-174	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	18126	Nos2	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	NON-CROSS	127-128	175-176	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	177-178	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	180-181	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	NON-CROSS	182-184	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	NON-CROSS	226-227	237-240	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	NON-CROSS	226-227	241-244	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	NON-CROSS	226-227	245-248	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	192-196	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	198-199	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	200-201	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	202-203	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	207-211	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	213-214	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	215-216	226-227	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	226-227	229-232	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	226-227	249-250	629822	IgE|IgE|IgE|IgE	GeneOrGeneProduct	127:226:301:353	128:227:302:354	5:6:9:10	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	171-172	173-174	11847	Arg2	GeneOrGeneProduct	171	172	6	18126	Nos2	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	NON-CROSS	171-172	175-176	11847	Arg2	GeneOrGeneProduct	171	172	6	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	171-172	177-178	11847	Arg2	GeneOrGeneProduct	171	172	6	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	171-172	180-181	11847	Arg2	GeneOrGeneProduct	171	172	6	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	NON-CROSS	171-172	182-184	11847	Arg2	GeneOrGeneProduct	171	172	6	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	NON-CROSS	171-172	186-187	11847	Arg2	GeneOrGeneProduct	171	172	6	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	NON-CROSS	171-172	188-189	11847	Arg2	GeneOrGeneProduct	171	172	6	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	NON-CROSS	171-172	190-191	11847	Arg2	GeneOrGeneProduct	171	172	6	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	171-172	192-196	11847	Arg2	GeneOrGeneProduct	171	172	6	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	171-172	198-199	11847	Arg2	GeneOrGeneProduct	171	172	6	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	171-172	200-201	11847	Arg2	GeneOrGeneProduct	171	172	6	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	171-172	202-203	11847	Arg2	GeneOrGeneProduct	171	172	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	171-172	205-206	11847	Arg2	GeneOrGeneProduct	171	172	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	171-172	213-214	11847	Arg2	GeneOrGeneProduct	171	172	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	171-172	215-216	11847	Arg2	GeneOrGeneProduct	171	172	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	171-172	229-232	11847	Arg2	GeneOrGeneProduct	171	172	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	171-172	249-250	11847	Arg2	GeneOrGeneProduct	171	172	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	173-174	175-176	18126	Nos2	GeneOrGeneProduct	173	174	6	11987	Slc7a1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	173-174	177-178	18126	Nos2	GeneOrGeneProduct	173	174	6	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	173-174	180-181	18126	Nos2	GeneOrGeneProduct	173	174	6	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	NON-CROSS	173-174	182-184	18126	Nos2	GeneOrGeneProduct	173	174	6	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	NON-CROSS	173-174	186-187	18126	Nos2	GeneOrGeneProduct	173	174	6	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	NON-CROSS	173-174	188-189	18126	Nos2	GeneOrGeneProduct	173	174	6	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	NON-CROSS	173-174	190-191	18126	Nos2	GeneOrGeneProduct	173	174	6	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	173-174	192-196	18126	Nos2	GeneOrGeneProduct	173	174	6	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	173-174	198-199	18126	Nos2	GeneOrGeneProduct	173	174	6	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	173-174	200-201	18126	Nos2	GeneOrGeneProduct	173	174	6	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	173-174	202-203	18126	Nos2	GeneOrGeneProduct	173	174	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	173-174	205-206	18126	Nos2	GeneOrGeneProduct	173	174	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	173-174	213-214	18126	Nos2	GeneOrGeneProduct	173	174	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	173-174	215-216	18126	Nos2	GeneOrGeneProduct	173	174	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	173-174	229-232	18126	Nos2	GeneOrGeneProduct	173	174	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	173-174	249-250	18126	Nos2	GeneOrGeneProduct	173	174	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	175-176	177-178	11987	Slc7a1	GeneOrGeneProduct	175	176	6	11988	Slc7a2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	175-176	180-181	11987	Slc7a1	GeneOrGeneProduct	175	176	6	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	NON-CROSS	175-176	182-184	11987	Slc7a1	GeneOrGeneProduct	175	176	6	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	NON-CROSS	175-176	186-187	11987	Slc7a1	GeneOrGeneProduct	175	176	6	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	NON-CROSS	175-176	188-189	11987	Slc7a1	GeneOrGeneProduct	175	176	6	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	NON-CROSS	175-176	190-191	11987	Slc7a1	GeneOrGeneProduct	175	176	6	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	175-176	192-196	11987	Slc7a1	GeneOrGeneProduct	175	176	6	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	175-176	198-199	11987	Slc7a1	GeneOrGeneProduct	175	176	6	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	175-176	200-201	11987	Slc7a1	GeneOrGeneProduct	175	176	6	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	175-176	202-203	11987	Slc7a1	GeneOrGeneProduct	175	176	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	175-176	205-206	11987	Slc7a1	GeneOrGeneProduct	175	176	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	175-176	213-214	11987	Slc7a1	GeneOrGeneProduct	175	176	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	175-176	215-216	11987	Slc7a1	GeneOrGeneProduct	175	176	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	175-176	229-232	11987	Slc7a1	GeneOrGeneProduct	175	176	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	175-176	249-250	11987	Slc7a1	GeneOrGeneProduct	175	176	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	177-178	180-181	11988	Slc7a2	GeneOrGeneProduct	177	178	6	20540	Slc7a7	GeneOrGeneProduct	180	181	6	1:NR:2	L2R	NON-CROSS	177-178	182-184	11988	Slc7a2	GeneOrGeneProduct	177	178	6	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	NON-CROSS	177-178	186-187	11988	Slc7a2	GeneOrGeneProduct	177	178	6	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	NON-CROSS	177-178	188-189	11988	Slc7a2	GeneOrGeneProduct	177	178	6	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	NON-CROSS	177-178	190-191	11988	Slc7a2	GeneOrGeneProduct	177	178	6	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	177-178	192-196	11988	Slc7a2	GeneOrGeneProduct	177	178	6	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	177-178	198-199	11988	Slc7a2	GeneOrGeneProduct	177	178	6	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	177-178	200-201	11988	Slc7a2	GeneOrGeneProduct	177	178	6	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	177-178	202-203	11988	Slc7a2	GeneOrGeneProduct	177	178	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	177-178	205-206	11988	Slc7a2	GeneOrGeneProduct	177	178	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	177-178	213-214	11988	Slc7a2	GeneOrGeneProduct	177	178	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	177-178	215-216	11988	Slc7a2	GeneOrGeneProduct	177	178	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	177-178	229-232	11988	Slc7a2	GeneOrGeneProduct	177	178	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	177-178	249-250	11988	Slc7a2	GeneOrGeneProduct	177	178	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	180-181	182-184	20540	Slc7a7	GeneOrGeneProduct	180	181	6	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	1:NR:2	L2R	NON-CROSS	180-181	186-187	20540	Slc7a7	GeneOrGeneProduct	180	181	6	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	NON-CROSS	180-181	188-189	20540	Slc7a7	GeneOrGeneProduct	180	181	6	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	NON-CROSS	180-181	190-191	20540	Slc7a7	GeneOrGeneProduct	180	181	6	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	180-181	192-196	20540	Slc7a7	GeneOrGeneProduct	180	181	6	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	180-181	198-199	20540	Slc7a7	GeneOrGeneProduct	180	181	6	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	180-181	200-201	20540	Slc7a7	GeneOrGeneProduct	180	181	6	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	180-181	202-203	20540	Slc7a7	GeneOrGeneProduct	180	181	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	180-181	205-206	20540	Slc7a7	GeneOrGeneProduct	180	181	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	180-181	213-214	20540	Slc7a7	GeneOrGeneProduct	180	181	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	180-181	215-216	20540	Slc7a7	GeneOrGeneProduct	180	181	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	180-181	229-232	20540	Slc7a7	GeneOrGeneProduct	180	181	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	180-181	249-250	20540	Slc7a7	GeneOrGeneProduct	180	181	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	182-184	186-187	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	1:NR:2	L2R	NON-CROSS	182-184	188-189	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	NON-CROSS	182-184	190-191	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	182-184	192-196	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	182-184	198-199	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	182-184	200-201	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	182-184	202-203	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	182-184	205-206	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	182-184	213-214	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	182-184	215-216	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	182-184	229-232	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	182-184	249-250	11987,11988,20540	arginine transporters	GeneOrGeneProduct	182	184	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	186-187	188-189	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	1:NR:2	L2R	NON-CROSS	186-187	190-191	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	186-187	192-196	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	186-187	198-199	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	186-187	200-201	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	186-187	202-203	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	237-240	251-252	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	213-214	237-240	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	215-216	237-240	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	NON-CROSS	229-232	237-240	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	NON-CROSS	237-240	249-250	16189	Il4|IL - 4	GeneOrGeneProduct	186:237	187:240	6:7	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	188-189	190-191	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	1:NR:2	L2R	NON-CROSS	188-189	192-196	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	188-189	198-199	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	188-189	200-201	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	188-189	202-203	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	241-244	251-252	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	188-189	213-214	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	215-216	241-244	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	NON-CROSS	229-232	241-244	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	NON-CROSS	241-244	249-250	16191	Il5|IL - 5	GeneOrGeneProduct	188:241	189:244	6:7	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	190-191	192-196	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	1:NR:2	L2R	NON-CROSS	190-191	198-199	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	190-191	200-201	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	190-191	202-203	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	245-248	251-252	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	190-191	213-214	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	190-191	215-216	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	NON-CROSS	229-232	245-248	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	NON-CROSS	245-248	249-250	16163	Il13|IL - 13	GeneOrGeneProduct	190:245	191:248	6:7	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	192-196	198-199	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	20296	Ccl2	GeneOrGeneProduct	198	199	6	1:NR:2	L2R	NON-CROSS	192-196	200-201	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	192-196	202-203	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	192-196	205-206	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	192-196	213-214	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	192-196	215-216	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	192-196	229-232	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	192-196	249-250	16163,16189,16191	TH2 - type cytokines	GeneOrGeneProduct	192	196	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	198-199	200-201	20296	Ccl2	GeneOrGeneProduct	198	199	6	20292	Ccl11	GeneOrGeneProduct	200	201	6	1:NR:2	L2R	NON-CROSS	198-199	202-203	20296	Ccl2	GeneOrGeneProduct	198	199	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	198-199	205-206	20296	Ccl2	GeneOrGeneProduct	198	199	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	198-199	213-214	20296	Ccl2	GeneOrGeneProduct	198	199	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	198-199	215-216	20296	Ccl2	GeneOrGeneProduct	198	199	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	198-199	229-232	20296	Ccl2	GeneOrGeneProduct	198	199	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	198-199	249-250	20296	Ccl2	GeneOrGeneProduct	198	199	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	200-201	202-203	20292	Ccl11	GeneOrGeneProduct	200	201	6	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	1:NR:2	L2R	NON-CROSS	200-201	205-206	20292	Ccl11	GeneOrGeneProduct	200	201	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	200-201	213-214	20292	Ccl11	GeneOrGeneProduct	200	201	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	200-201	215-216	20292	Ccl11	GeneOrGeneProduct	200	201	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	200-201	229-232	20292	Ccl11	GeneOrGeneProduct	200	201	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	200-201	249-250	20292	Ccl11	GeneOrGeneProduct	200	201	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	202-203	205-206	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	1:NR:2	L2R	NON-CROSS	202-203	213-214	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	202-203	215-216	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	202-203	229-232	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	202-203	249-250	20292,20296	chemokines	GeneOrGeneProduct	202	203	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	207-211	213-214	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	23844	Clca3	GeneOrGeneProduct	213	214	6	1:NR:2	L2R	NON-CROSS	207-211	215-216	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	NON-CROSS	207-211	229-232	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	NON-CROSS	249-250	251-252	15978	Ifng|TH1 - type cytokine|IFNgamma	GeneOrGeneProduct	205:207:251	206:211:252	6:6:7	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	213-214	215-216	23844	Clca3	GeneOrGeneProduct	213	214	6	17833	Muc5ac	GeneOrGeneProduct	215	216	6	1:NR:2	L2R	CROSS	213-214	229-232	23844	Clca3	GeneOrGeneProduct	213	214	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	213-214	249-250	23844	Clca3	GeneOrGeneProduct	213	214	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	215-216	229-232	17833	Muc5ac	GeneOrGeneProduct	215	216	6	16153	IL - 10	GeneOrGeneProduct	229	232	7	1:NR:2	L2R	CROSS	215-216	249-250	17833	Muc5ac	GeneOrGeneProduct	215	216	6	21926	TNFalpha	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	229-232	249-250	16153	IL - 10	GeneOrGeneProduct	229	232	7	21926	TNFalpha	GeneOrGeneProduct	249	250	7
20959502	Cerebrospinal fluid penetration of high - dose daptomycin in suspected Staphylococcus aureus meningitis .|OBJECTIVE : To report a case of methicillin - sensitive Staphylococcus aureus ( MSSA ) bacteremia with suspected MSSA meningitis treated with high - dose daptomycin assessed with concurrent serum and cerebrospinal fluid ( CSF ) concentrations .|CASE SUMMARY : A 54 - year - old male presented to the emergency department with generalized weakness and presumed health - care - associated pneumonia shown on chest radiograph .|Treatment was empirically initiated with vancomycin , levofloxacin , and piperacillin / tazobactam .|Blood cultures revealed S . aureus susceptible to oxacillin .|Empiric antibiotic treatment was narrowed to nafcillin on day 4 .|On day 8 , the patient developed acute renal failure ( serum creatinine 1 . 9 mg / dL , increased from 1 . 2 mg / dL the previous day and 0 . 8 mg / dL on admission ) .|The patient 's Glasgow Coma Score was 3 , with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10 .|The patient experienced relapsing MSSA bacteremia on day 9 , increasing the suspicion for a central nervous system ( CNS ) infection .|Nafcillin was discontinued and daptomycin 9 mg / kg daily was initiated for suspected meningitis and was continued until the patient 's death on day 16 .|Daptomycin serum and CSF trough concentrations were 11 . 21 ug / mL and 0 . 52 ug / mL , respectively , prior to the third dose .|Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA .|Creatine kinase levels were normal prior to daptomycin therapy and were not reassessed .|DISCUSSION : Daptomycin was initiated in our patient secondary to possible nafcillin - induced acute interstitial nephritis and relapsing bacteremia .|At a dose of 9 mg / kg , resultant penetration of 5 % was higher than in previous reports , more consistent with inflamed meninges .|CONCLUSIONS : High - dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or can not tolerate standard therapy .|Further clinical evaluation in patients with confirmed meningitis is warranted .	1:Negative_Correlation:2	L2R	NON-CROSS	7-8	12-13	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	1:NR:2	L2R	NON-CROSS	7-8	21-22	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D008712	methicillin	ChemicalEntity	21	22	1	1:Negative_Correlation:2	L2R	NON-CROSS	353-354	361-362	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	1:NR:2	L2R	CROSS	39-40	69-70	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	1:NR:2	L2R	CROSS	39-40	77-78	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	1:NR:2	L2R	CROSS	39-40	88-89	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D014640	vancomycin	ChemicalEntity	88	89	3	1:NR:2	L2R	CROSS	39-40	90-91	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D064704	levofloxacin	ChemicalEntity	90	91	3	1:NR:2	L2R	CROSS	39-40	93-96	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1:NR:2	L2R	CROSS	39-40	105-106	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D010068	oxacillin	ChemicalEntity	105	106	4	1:NR:2	L2R	CROSS	39-40	108-109	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D000900	antibiotic	ChemicalEntity	108	109	5	1:NR:2	L2R	NON-CROSS	215-216	219-220	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	39-40	125-128	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1:NR:2	L2R	CROSS	130-131	219-220	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	164-165	219-220	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	186-188	219-220	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	207-214	219-220	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	NON-CROSS	237-238	242-243	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	NON-CROSS	286-288	293-294	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:Negative_Correlation:2	L2R	NON-CROSS	302-303	315-317	D017576	daptomycin|daptomycin|daptomycin|Daptomycin|daptomycin|Daptomycin|daptomycin	ChemicalEntity	7:39:219:242:293:302:353	8:40:220:243:294:303:354	0:1:9:10:12:13:15	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:NR:2	L2R	NON-CROSS	12-13	21-22	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	D008712	methicillin	ChemicalEntity	21	22	1	1:NR:2	L2R	CROSS	33-34	88-89	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	D014640	vancomycin	ChemicalEntity	88	89	3	1:NR:2	L2R	CROSS	33-34	90-91	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	D064704	levofloxacin	ChemicalEntity	90	91	3	1:NR:2	L2R	CROSS	33-34	93-96	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1:NR:2	L2R	CROSS	33-34	105-106	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	D010068	oxacillin	ChemicalEntity	105	106	4	1:NR:2	L2R	CROSS	33-34	108-109	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	D000900	antibiotic	ChemicalEntity	108	109	5	1:NR:2	L2R	NON-CROSS	215-216	229-230	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	33-34	130-131	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	229-230	286-288	D008581	meningitis|meningitis|meningitis|meningitis	DiseaseOrPhenotypicFeature	12:33:229:387	13:34:230:388	0:1:9:16	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:Association:2	L2R	NON-CROSS	21-22	29-30	D008712	methicillin	ChemicalEntity	21	22	1	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	1:NR:2	L2R	CROSS	21-22	69-70	D008712	methicillin	ChemicalEntity	21	22	1	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	1:NR:2	L2R	CROSS	21-22	77-78	D008712	methicillin	ChemicalEntity	21	22	1	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	1:NR:2	L2R	CROSS	21-22	88-89	D008712	methicillin	ChemicalEntity	21	22	1	D014640	vancomycin	ChemicalEntity	88	89	3	1:NR:2	L2R	CROSS	21-22	90-91	D008712	methicillin	ChemicalEntity	21	22	1	D064704	levofloxacin	ChemicalEntity	90	91	3	1:NR:2	L2R	CROSS	21-22	93-96	D008712	methicillin	ChemicalEntity	21	22	1	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1:NR:2	L2R	CROSS	21-22	105-106	D008712	methicillin	ChemicalEntity	21	22	1	D010068	oxacillin	ChemicalEntity	105	106	4	1:NR:2	L2R	CROSS	21-22	108-109	D008712	methicillin	ChemicalEntity	21	22	1	D000900	antibiotic	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	21-22	113-114	D008712	methicillin	ChemicalEntity	21	22	1	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	21-22	125-128	D008712	methicillin	ChemicalEntity	21	22	1	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1:NR:2	L2R	CROSS	21-22	130-131	D008712	methicillin	ChemicalEntity	21	22	1	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	21-22	164-165	D008712	methicillin	ChemicalEntity	21	22	1	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	21-22	186-188	D008712	methicillin	ChemicalEntity	21	22	1	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	21-22	207-214	D008712	methicillin	ChemicalEntity	21	22	1	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	CROSS	21-22	237-238	D008712	methicillin	ChemicalEntity	21	22	1	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	21-22	286-288	D008712	methicillin	ChemicalEntity	21	22	1	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	21-22	315-317	D008712	methicillin	ChemicalEntity	21	22	1	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:NR:2	L2R	CROSS	29-30	88-89	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	D014640	vancomycin	ChemicalEntity	88	89	3	1:NR:2	L2R	CROSS	29-30	90-91	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	D064704	levofloxacin	ChemicalEntity	90	91	3	1:NR:2	L2R	CROSS	29-30	93-96	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1:NR:2	L2R	CROSS	29-30	105-106	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	D010068	oxacillin	ChemicalEntity	105	106	4	1:NR:2	L2R	CROSS	29-30	108-109	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	D000900	antibiotic	ChemicalEntity	108	109	5	1:Positive_Correlation:2	R2L	NON-CROSS	319-320	311-312	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	1:NR:2	L2R	CROSS	130-131	197-198	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	286-288	319-320	D016470	bacteremia|bacteremia|bacteremia|bacteremia	DiseaseOrPhenotypicFeature	29:197:319:361	30:198:320:362	1:8:13:15	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:Negative_Correlation:2	L2R	CROSS	69-70	88-89	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	D014640	vancomycin	ChemicalEntity	88	89	3	1:Negative_Correlation:2	L2R	CROSS	69-70	90-91	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	D064704	levofloxacin	ChemicalEntity	90	91	3	1:Negative_Correlation:2	L2R	CROSS	69-70	93-96	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1:NR:2	L2R	CROSS	69-70	105-106	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	D010068	oxacillin	ChemicalEntity	105	106	4	1:NR:2	L2R	CROSS	69-70	108-109	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	D000900	antibiotic	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	69-70	113-114	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	69-70	130-131	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	69-70	286-288	D018908	weakness	DiseaseOrPhenotypicFeature	69	70	2	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:Negative_Correlation:2	L2R	CROSS	77-78	88-89	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	D014640	vancomycin	ChemicalEntity	88	89	3	1:Negative_Correlation:2	L2R	CROSS	77-78	90-91	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	D064704	levofloxacin	ChemicalEntity	90	91	3	1:Negative_Correlation:2	L2R	CROSS	77-78	93-96	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1:NR:2	L2R	CROSS	77-78	105-106	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	D010068	oxacillin	ChemicalEntity	105	106	4	1:Negative_Correlation:2	R2L	CROSS	108-109	77-78	D000900	antibiotic	ChemicalEntity	108	109	5	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	1:NR:2	L2R	CROSS	77-78	113-114	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	77-78	130-131	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	77-78	286-288	D011014	pneumonia	DiseaseOrPhenotypicFeature	77	78	2	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:Cotreatment:2	L2R	NON-CROSS	88-89	90-91	D014640	vancomycin	ChemicalEntity	88	89	3	D064704	levofloxacin	ChemicalEntity	90	91	3	1:Cotreatment:2	L2R	NON-CROSS	88-89	93-96	D014640	vancomycin	ChemicalEntity	88	89	3	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1:NR:2	L2R	CROSS	88-89	105-106	D014640	vancomycin	ChemicalEntity	88	89	3	D010068	oxacillin	ChemicalEntity	105	106	4	1:NR:2	L2R	CROSS	88-89	108-109	D014640	vancomycin	ChemicalEntity	88	89	3	D000900	antibiotic	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	88-89	113-114	D014640	vancomycin	ChemicalEntity	88	89	3	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	88-89	125-128	D014640	vancomycin	ChemicalEntity	88	89	3	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1:NR:2	L2R	CROSS	88-89	130-131	D014640	vancomycin	ChemicalEntity	88	89	3	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	88-89	164-165	D014640	vancomycin	ChemicalEntity	88	89	3	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	88-89	186-188	D014640	vancomycin	ChemicalEntity	88	89	3	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	88-89	207-214	D014640	vancomycin	ChemicalEntity	88	89	3	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	CROSS	88-89	237-238	D014640	vancomycin	ChemicalEntity	88	89	3	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	88-89	286-288	D014640	vancomycin	ChemicalEntity	88	89	3	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	88-89	315-317	D014640	vancomycin	ChemicalEntity	88	89	3	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:Cotreatment:2	L2R	NON-CROSS	90-91	93-96	D064704	levofloxacin	ChemicalEntity	90	91	3	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1:NR:2	L2R	CROSS	90-91	105-106	D064704	levofloxacin	ChemicalEntity	90	91	3	D010068	oxacillin	ChemicalEntity	105	106	4	1:NR:2	L2R	CROSS	90-91	108-109	D064704	levofloxacin	ChemicalEntity	90	91	3	D000900	antibiotic	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	90-91	113-114	D064704	levofloxacin	ChemicalEntity	90	91	3	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	90-91	125-128	D064704	levofloxacin	ChemicalEntity	90	91	3	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1:NR:2	L2R	CROSS	90-91	130-131	D064704	levofloxacin	ChemicalEntity	90	91	3	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	90-91	164-165	D064704	levofloxacin	ChemicalEntity	90	91	3	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	90-91	186-188	D064704	levofloxacin	ChemicalEntity	90	91	3	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	90-91	207-214	D064704	levofloxacin	ChemicalEntity	90	91	3	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	CROSS	90-91	237-238	D064704	levofloxacin	ChemicalEntity	90	91	3	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	90-91	286-288	D064704	levofloxacin	ChemicalEntity	90	91	3	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	90-91	315-317	D064704	levofloxacin	ChemicalEntity	90	91	3	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:NR:2	L2R	CROSS	93-96	105-106	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D010068	oxacillin	ChemicalEntity	105	106	4	1:NR:2	L2R	CROSS	93-96	108-109	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D000900	antibiotic	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	93-96	113-114	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	93-96	125-128	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1:NR:2	L2R	CROSS	93-96	130-131	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	93-96	164-165	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	93-96	186-188	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	93-96	207-214	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	CROSS	93-96	237-238	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	93-96	286-288	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	93-96	315-317	D000077725	piperacillin / tazobactam	ChemicalEntity	93	96	3	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:NR:2	L2R	CROSS	105-106	108-109	D010068	oxacillin	ChemicalEntity	105	106	4	D000900	antibiotic	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	105-106	113-114	D010068	oxacillin	ChemicalEntity	105	106	4	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	105-106	125-128	D010068	oxacillin	ChemicalEntity	105	106	4	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1:NR:2	L2R	CROSS	105-106	130-131	D010068	oxacillin	ChemicalEntity	105	106	4	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	105-106	164-165	D010068	oxacillin	ChemicalEntity	105	106	4	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	105-106	186-188	D010068	oxacillin	ChemicalEntity	105	106	4	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	105-106	207-214	D010068	oxacillin	ChemicalEntity	105	106	4	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	CROSS	105-106	237-238	D010068	oxacillin	ChemicalEntity	105	106	4	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	105-106	286-288	D010068	oxacillin	ChemicalEntity	105	106	4	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	105-106	315-317	D010068	oxacillin	ChemicalEntity	105	106	4	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:NR:2	L2R	NON-CROSS	108-109	113-114	D000900	antibiotic	ChemicalEntity	108	109	5	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1:NR:2	L2R	CROSS	108-109	125-128	D000900	antibiotic	ChemicalEntity	108	109	5	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1:NR:2	L2R	CROSS	108-109	130-131	D000900	antibiotic	ChemicalEntity	108	109	5	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	108-109	164-165	D000900	antibiotic	ChemicalEntity	108	109	5	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	108-109	186-188	D000900	antibiotic	ChemicalEntity	108	109	5	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	108-109	207-214	D000900	antibiotic	ChemicalEntity	108	109	5	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	CROSS	108-109	237-238	D000900	antibiotic	ChemicalEntity	108	109	5	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	108-109	286-288	D000900	antibiotic	ChemicalEntity	108	109	5	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	108-109	315-317	D000900	antibiotic	ChemicalEntity	108	109	5	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:NR:2	L2R	CROSS	113-114	125-128	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1:NR:2	L2R	CROSS	113-114	130-131	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	113-114	164-165	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	186-188	215-216	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	207-214	215-216	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	NON-CROSS	215-216	237-238	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	286-288	311-312	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:Positive_Correlation:2	L2R	NON-CROSS	311-312	315-317	D009254	nafcillin|Nafcillin|nafcillin	ChemicalEntity	113:215:311	114:216:312	5:9:13	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:Positive_Correlation:2	L2R	NON-CROSS	125-128	130-131	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	D003404	creatinine	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	125-128	286-288	D058186	acute renal failure	DiseaseOrPhenotypicFeature	125	128	6	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	130-131	164-165	D003404	creatinine	ChemicalEntity	130	131	6	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1:NR:2	L2R	CROSS	130-131	186-188	D003404	creatinine	ChemicalEntity	130	131	6	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1:NR:2	L2R	CROSS	130-131	207-214	D003404	creatinine	ChemicalEntity	130	131	6	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1:NR:2	L2R	CROSS	130-131	237-238	D003404	creatinine	ChemicalEntity	130	131	6	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	130-131	286-288	D003404	creatinine	ChemicalEntity	130	131	6	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	130-131	315-317	D003404	creatinine	ChemicalEntity	130	131	6	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13	1:NR:2	L2R	CROSS	164-165	286-288	D003128	Coma	DiseaseOrPhenotypicFeature	164	165	7	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	186-188	286-288	D006323	cardiac arrest	DiseaseOrPhenotypicFeature	186	188	7	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	207-214	286-288	D002494	central nervous system ( CNS ) infection	DiseaseOrPhenotypicFeature	207	214	8	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	237-238	286-288	D003643	death	DiseaseOrPhenotypicFeature	237	238	9	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	1:NR:2	L2R	CROSS	286-288	315-317	1152	Creatine kinase	GeneOrGeneProduct	286	288	12	D009395	interstitial nephritis	DiseaseOrPhenotypicFeature	315	317	13
20682662	Lack of association of C - C chemokine receptor 5 DD32 deletion status with rheumatoid arthritis , systemic lupus erythematosus , lupus nephritis , and disease severity .|OBJECTIVE : C - C chemokine receptor 5 ( CCR5 ) plays an important role in inflammation .|A 32 base - pair ( DD32 ) deletion in the CCR5 gene leads to a nonfunctional receptor .|This deletion has been reported to have a protective effect on the development and progression of several autoimmune diseases .|We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis ( RA ) , systemic lupus erythematosus ( SLE ) , and lupus nephritis ( LN ) ; and whether it is associated with disease severity .|METHODS : DNA samples from 405 RA patients , 97 SLE patients , 113 LN patients , and 431 healthy controls were genotyped for the CCR5 DD32 deletion .|Differences in genotype frequencies were tested between patients and controls .|Association of genotypes with disease severity was analyzed .|RESULTS : Genotype frequencies of each group were in Hardy - Weinberg equilibrium .|The genotype frequencies of patients did not differ significantly from controls ( CCR5 / DD32 , DD32 / DD32 : RA 18 . 3 % and 1 . 2 % , respectively ; SLE 17 . 5 % and 2 . 1 % ; LN 13 . 3 % and 1 . 8 % ; controls 20 . 0 % and 2 . 8 % ) .|However , there was a trend for lower DD32 deletion allele frequency in LN patients compared to controls ( p = 0 . 08 ) .|There was no significant association between the CCR5 status and disease severity in RA , SLE , or LN .|CONCLUSION : Although an association with LN can not be excluded , the CCR5 DD32 deletion does not seem to be a disease susceptibility genotype for RA , SLE , or LN .|No significant effect of the DD32 deletion on disease severity was demonstrated .	1:NR:2	L2R	NON-CROSS	4-10	14-16	1234	C - C chemokine receptor 5|C - C chemokine receptor 5|CCR5|CCR5|CCR5|CCR5|CCR5|CCR5	GeneOrGeneProduct	4:30:37:57:156:206:294:320	10:36:38:58:157:207:295:321	0:1:1:2:5:9:11:12	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA|RA|RA|RA	DiseaseOrPhenotypicFeature	14:102:105:137:214:300:333	16:104:106:138:215:301:334	0:4:4:5:9:11:12	1:NR:2	L2R	NON-CROSS	4-10	17-20	1234	C - C chemokine receptor 5|C - C chemokine receptor 5|CCR5|CCR5|CCR5|CCR5|CCR5|CCR5	GeneOrGeneProduct	4:30:37:57:156:206:294:320	10:36:38:58:157:207:295:321	0:1:1:2:5:9:11:12	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE|SLE|SLE	DiseaseOrPhenotypicFeature	17:108:112:141:227:302:335	20:111:113:142:228:303:336	0:4:4:5:9:11:12	1:NR:2	L2R	NON-CROSS	313-314	320-321	1234	C - C chemokine receptor 5|C - C chemokine receptor 5|CCR5|CCR5|CCR5|CCR5|CCR5|CCR5	GeneOrGeneProduct	4:30:37:57:156:206:294:320	10:36:38:58:157:207:295:321	0:1:1:2:5:9:11:12	D008181	lupus nephritis|lupus nephritis|LN|LN|LN|LN|LN|LN|LN	DiseaseOrPhenotypicFeature	21:116:119:145:238:274:305:313:338	23:118:120:146:239:275:306:314:339	0:4:4:5:9:10:11:12:12	1:Association:2	L2R	NON-CROSS	37-38	44-45	1234	C - C chemokine receptor 5|C - C chemokine receptor 5|CCR5|CCR5|CCR5|CCR5|CCR5|CCR5	GeneOrGeneProduct	4:30:37:57:156:206:294:320	10:36:38:58:157:207:295:321	0:1:1:2:5:9:11:12	D007249	inflammation	DiseaseOrPhenotypicFeature	44	45	1	1:Positive_Correlation:2	L2R	CROSS	57-58	82-84	1234	C - C chemokine receptor 5|C - C chemokine receptor 5|CCR5|CCR5|CCR5|CCR5|CCR5|CCR5	GeneOrGeneProduct	4:30:37:57:156:206:294:320	10:36:38:58:157:207:295:321	0:1:1:2:5:9:11:12	D001327	autoimmune diseases	DiseaseOrPhenotypicFeature	82	84	3	1:NR:2	L2R	NON-CROSS	212-213	214-215	c|DEL||32	DD32 deletion|32 base - pair ( DD32 ) deletion|DD32 deletion|DD32 deletion|DD32|DD32|DD32|DD32 deletion|DD32 deletion|DD32 deletion	SequenceVariant	10:47:89:157:208:210:212:269:321:345	12:55:91:159:209:211:213:271:323:347	0:2:4:5:9:9:9:10:12:13	D001172	rheumatoid arthritis|rheumatoid arthritis|RA|RA|RA|RA|RA	DiseaseOrPhenotypicFeature	14:102:105:137:214:300:333	16:104:106:138:215:301:334	0:4:4:5:9:11:12	1:NR:2	L2R	NON-CROSS	10-12	17-20	c|DEL||32	DD32 deletion|32 base - pair ( DD32 ) deletion|DD32 deletion|DD32 deletion|DD32|DD32|DD32|DD32 deletion|DD32 deletion|DD32 deletion	SequenceVariant	10:47:89:157:208:210:212:269:321:345	12:55:91:159:209:211:213:271:323:347	0:2:4:5:9:9:9:10:12:13	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE|SLE|SLE	DiseaseOrPhenotypicFeature	17:108:112:141:227:302:335	20:111:113:142:228:303:336	0:4:4:5:9:11:12	1:NR:2	L2R	NON-CROSS	269-271	274-275	c|DEL||32	DD32 deletion|32 base - pair ( DD32 ) deletion|DD32 deletion|DD32 deletion|DD32|DD32|DD32|DD32 deletion|DD32 deletion|DD32 deletion	SequenceVariant	10:47:89:157:208:210:212:269:321:345	12:55:91:159:209:211:213:271:323:347	0:2:4:5:9:9:9:10:12:13	D008181	lupus nephritis|lupus nephritis|LN|LN|LN|LN|LN|LN|LN	DiseaseOrPhenotypicFeature	21:116:119:145:238:274:305:313:338	23:118:120:146:239:275:306:314:339	0:4:4:5:9:10:11:12:12	1:NR:2	L2R	CROSS	44-45	47-55	c|DEL||32	DD32 deletion|32 base - pair ( DD32 ) deletion|DD32 deletion|DD32 deletion|DD32|DD32|DD32|DD32 deletion|DD32 deletion|DD32 deletion	SequenceVariant	10:47:89:157:208:210:212:269:321:345	12:55:91:159:209:211:213:271:323:347	0:2:4:5:9:9:9:10:12:13	D007249	inflammation	DiseaseOrPhenotypicFeature	44	45	1	1:Negative_Correlation:2	L2R	CROSS	82-84	89-91	c|DEL||32	DD32 deletion|32 base - pair ( DD32 ) deletion|DD32 deletion|DD32 deletion|DD32|DD32|DD32|DD32 deletion|DD32 deletion|DD32 deletion	SequenceVariant	10:47:89:157:208:210:212:269:321:345	12:55:91:159:209:211:213:271:323:347	0:2:4:5:9:9:9:10:12:13	D001327	autoimmune diseases	DiseaseOrPhenotypicFeature	82	84	3
23285048	Context - and cell - dependent effects of Delta - like 4 targeting in the bone marrow microenvironment .|Delta - like 4 ( Dll4 ) is a ligand of the Notch pathway family which has been widely studied in the context of tumor angiogenesis , its blockade shown to result in non - productive angiogenesis and halted tumor growth .|As Dll4 inhibitors enter the clinic , there is an emerging need to understand their side effects , namely the systemic consequences of Dll4 : Notch blockade in tissues other than tumors .|The present study focused on the effects of systemic anti - Dll4 targeting in the bone marrow ( BM ) microenvironment .|Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub - lethally irradiated mice , resulting in increased CD31 ( + ) , VE - Cadherin ( + ) and c - kit ( + ) vessel density , and also increased megakaryocytes , whereas CD105 ( + ) , VEGFR3 ( + ) , SMA ( + ) and lectin ( + ) vessel density remained unaltered .|We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo , and demonstrate that IGFbp2 , IGFbp3 , Angpt2 , Dll4 , DHH and VEGF - A are upregulated , while FGF1 and CSF2 are reduced .|In vitro treatment of endothelial cells with anti - Dll4 reduced Akt phosphorylation while maintaining similar levels of Erk 1 / 2 phosphorylation .|Besides its effects in the BM vascular niche , anti - Dll4 treatment perturbed hematopoiesis , as evidenced by increased myeloid ( CD11b ( + ) ) , decreased B ( B220 ( + ) ) and T ( CD3 ( + ) ) lymphoid BM content of treated mice , with a corresponding increase in myeloid circulating cells .|Moreover , anti - Dll4 treatment also increased the number of CFU - M and - G colonies in methylcellulose assays , independently of Notch1 .|Finally , anti - Dll4 treatment of donor BM improved the hematopoietic recovery of lethally irradiated recipients in a transplant setting .|Together , our data reveals the hematopoietic ( BM ) effects of systemic anti - Dll4 treatment result from qualitative vascular changes and also direct hematopoietic cell modulation , which may be favorable in a transplant setting .	1:Association:2	L2R	NON-CROSS	84-85	86-87	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	1:Association:2	L2R	NON-CROSS	58-59	62-63	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	1:Association:2	L2R	NON-CROSS	120-121	140-141	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	18613	CD31	GeneOrGeneProduct	140	141	4	1:Association:2	L2R	NON-CROSS	120-121	145-148	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	1:Association:2	L2R	NON-CROSS	120-121	152-155	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	16590	c - kit	GeneOrGeneProduct	152	155	4	1:NR:2	L2R	NON-CROSS	167-168	200-201	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	13805	CD105	GeneOrGeneProduct	167	168	4	1:NR:2	L2R	NON-CROSS	172-173	200-201	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	14257	VEGFR3	GeneOrGeneProduct	172	173	4	1:NR:2	L2R	NON-CROSS	177-178	200-201	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	11475	SMA	GeneOrGeneProduct	177	178	4	1:NR:2	L2R	NON-CROSS	182-183	200-201	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	-	lectin	GeneOrGeneProduct	182	183	4	1:Positive_Correlation:2	L2R	NON-CROSS	208-209	214-215	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:Positive_Correlation:2	L2R	NON-CROSS	210-211	214-215	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:Positive_Correlation:2	L2R	NON-CROSS	212-213	214-215	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:Positive_Correlation:2	L2R	NON-CROSS	214-215	216-217	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	13363	DHH	GeneOrGeneProduct	216	217	5	1:Positive_Correlation:2	L2R	NON-CROSS	214-215	218-221	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:Positive_Correlation:2	L2R	NON-CROSS	214-215	225-226	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	14164	FGF1	GeneOrGeneProduct	225	226	5	1:Positive_Correlation:2	L2R	NON-CROSS	214-215	227-228	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	12981	CSF2	GeneOrGeneProduct	227	228	5	1:Association:2	L2R	NON-CROSS	240-241	242-243	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	NON-CROSS	240-241	249-253	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:Negative_Correlation:2	L2R	NON-CROSS	266-267	277-278	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	16409	CD11b	GeneOrGeneProduct	277	278	7	1:Positive_Correlation:2	L2R	NON-CROSS	266-267	286-287	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	19264	B220	GeneOrGeneProduct	286	287	7	1:Positive_Correlation:2	L2R	NON-CROSS	294-295	319-320	54485	Delta - like 4|Delta - like 4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4|Dll4	GeneOrGeneProduct	8:19:24:62:84:105:120:200:214:240:266:319:345:378	12:23:25:63:85:106:121:201:215:241:267:320:346:379	0:1:1:2:2:3:4:5:5:6:7:8:9:10	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	86-87	92-93	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	1:NR:2	L2R	CROSS	86-87	140-141	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	18613	CD31	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	CROSS	86-87	145-148	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	1:NR:2	L2R	CROSS	86-87	152-155	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	16590	c - kit	GeneOrGeneProduct	152	155	4	1:NR:2	L2R	CROSS	86-87	167-168	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	13805	CD105	GeneOrGeneProduct	167	168	4	1:NR:2	L2R	CROSS	86-87	172-173	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	14257	VEGFR3	GeneOrGeneProduct	172	173	4	1:NR:2	L2R	CROSS	86-87	177-178	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	11475	SMA	GeneOrGeneProduct	177	178	4	1:NR:2	L2R	CROSS	86-87	182-183	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	-	lectin	GeneOrGeneProduct	182	183	4	1:NR:2	L2R	CROSS	86-87	208-209	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	86-87	210-211	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	86-87	212-213	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	216-217	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	218-221	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	225-226	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	227-228	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	242-243	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	249-253	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	277-278	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	286-287	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	294-295	339-340	18128	Notch|Notch|Notch1	GeneOrGeneProduct	31:86:339	32:87:340	1:2:8	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	CROSS	92-93	140-141	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	18613	CD31	GeneOrGeneProduct	140	141	4	1:NR:2	L2R	CROSS	92-93	145-148	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	1:NR:2	L2R	CROSS	92-93	152-155	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	16590	c - kit	GeneOrGeneProduct	152	155	4	1:NR:2	L2R	CROSS	92-93	167-168	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	13805	CD105	GeneOrGeneProduct	167	168	4	1:NR:2	L2R	CROSS	92-93	172-173	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	14257	VEGFR3	GeneOrGeneProduct	172	173	4	1:NR:2	L2R	CROSS	92-93	177-178	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	11475	SMA	GeneOrGeneProduct	177	178	4	1:NR:2	L2R	CROSS	92-93	182-183	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	-	lectin	GeneOrGeneProduct	182	183	4	1:NR:2	L2R	CROSS	92-93	208-209	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	92-93	210-211	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	92-93	212-213	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	92-93	216-217	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	92-93	218-221	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	92-93	225-226	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	92-93	227-228	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	92-93	242-243	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	92-93	249-253	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	92-93	277-278	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	92-93	286-287	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	92-93	294-295	D009369	tumor|tumor|tumors	DiseaseOrPhenotypicFeature	43:58:92	44:59:93	1:1:2	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	140-141	145-148	18613	CD31	GeneOrGeneProduct	140	141	4	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	1:NR:2	L2R	NON-CROSS	140-141	152-155	18613	CD31	GeneOrGeneProduct	140	141	4	16590	c - kit	GeneOrGeneProduct	152	155	4	1:NR:2	L2R	NON-CROSS	140-141	167-168	18613	CD31	GeneOrGeneProduct	140	141	4	13805	CD105	GeneOrGeneProduct	167	168	4	1:NR:2	L2R	NON-CROSS	140-141	172-173	18613	CD31	GeneOrGeneProduct	140	141	4	14257	VEGFR3	GeneOrGeneProduct	172	173	4	1:NR:2	L2R	NON-CROSS	140-141	177-178	18613	CD31	GeneOrGeneProduct	140	141	4	11475	SMA	GeneOrGeneProduct	177	178	4	1:NR:2	L2R	NON-CROSS	140-141	182-183	18613	CD31	GeneOrGeneProduct	140	141	4	-	lectin	GeneOrGeneProduct	182	183	4	1:NR:2	L2R	CROSS	140-141	208-209	18613	CD31	GeneOrGeneProduct	140	141	4	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	140-141	210-211	18613	CD31	GeneOrGeneProduct	140	141	4	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	140-141	212-213	18613	CD31	GeneOrGeneProduct	140	141	4	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	140-141	216-217	18613	CD31	GeneOrGeneProduct	140	141	4	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	140-141	218-221	18613	CD31	GeneOrGeneProduct	140	141	4	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	140-141	225-226	18613	CD31	GeneOrGeneProduct	140	141	4	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	140-141	227-228	18613	CD31	GeneOrGeneProduct	140	141	4	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	140-141	242-243	18613	CD31	GeneOrGeneProduct	140	141	4	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	140-141	249-253	18613	CD31	GeneOrGeneProduct	140	141	4	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	140-141	277-278	18613	CD31	GeneOrGeneProduct	140	141	4	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	140-141	286-287	18613	CD31	GeneOrGeneProduct	140	141	4	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	140-141	294-295	18613	CD31	GeneOrGeneProduct	140	141	4	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	145-148	152-155	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	16590	c - kit	GeneOrGeneProduct	152	155	4	1:NR:2	L2R	NON-CROSS	145-148	167-168	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	13805	CD105	GeneOrGeneProduct	167	168	4	1:NR:2	L2R	NON-CROSS	145-148	172-173	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	14257	VEGFR3	GeneOrGeneProduct	172	173	4	1:NR:2	L2R	NON-CROSS	145-148	177-178	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	11475	SMA	GeneOrGeneProduct	177	178	4	1:NR:2	L2R	NON-CROSS	145-148	182-183	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	-	lectin	GeneOrGeneProduct	182	183	4	1:NR:2	L2R	CROSS	145-148	208-209	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	145-148	210-211	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	145-148	212-213	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	145-148	216-217	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	145-148	218-221	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	145-148	225-226	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	145-148	227-228	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	145-148	242-243	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	145-148	249-253	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	145-148	277-278	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	145-148	286-287	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	145-148	294-295	12562	VE - Cadherin	GeneOrGeneProduct	145	148	4	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	152-155	167-168	16590	c - kit	GeneOrGeneProduct	152	155	4	13805	CD105	GeneOrGeneProduct	167	168	4	1:NR:2	L2R	NON-CROSS	152-155	172-173	16590	c - kit	GeneOrGeneProduct	152	155	4	14257	VEGFR3	GeneOrGeneProduct	172	173	4	1:NR:2	L2R	NON-CROSS	152-155	177-178	16590	c - kit	GeneOrGeneProduct	152	155	4	11475	SMA	GeneOrGeneProduct	177	178	4	1:NR:2	L2R	NON-CROSS	152-155	182-183	16590	c - kit	GeneOrGeneProduct	152	155	4	-	lectin	GeneOrGeneProduct	182	183	4	1:NR:2	L2R	CROSS	152-155	208-209	16590	c - kit	GeneOrGeneProduct	152	155	4	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	152-155	210-211	16590	c - kit	GeneOrGeneProduct	152	155	4	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	152-155	212-213	16590	c - kit	GeneOrGeneProduct	152	155	4	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	152-155	216-217	16590	c - kit	GeneOrGeneProduct	152	155	4	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	152-155	218-221	16590	c - kit	GeneOrGeneProduct	152	155	4	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	152-155	225-226	16590	c - kit	GeneOrGeneProduct	152	155	4	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	152-155	227-228	16590	c - kit	GeneOrGeneProduct	152	155	4	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	152-155	242-243	16590	c - kit	GeneOrGeneProduct	152	155	4	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	152-155	249-253	16590	c - kit	GeneOrGeneProduct	152	155	4	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	152-155	277-278	16590	c - kit	GeneOrGeneProduct	152	155	4	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	152-155	286-287	16590	c - kit	GeneOrGeneProduct	152	155	4	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	152-155	294-295	16590	c - kit	GeneOrGeneProduct	152	155	4	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	167-168	172-173	13805	CD105	GeneOrGeneProduct	167	168	4	14257	VEGFR3	GeneOrGeneProduct	172	173	4	1:NR:2	L2R	NON-CROSS	167-168	177-178	13805	CD105	GeneOrGeneProduct	167	168	4	11475	SMA	GeneOrGeneProduct	177	178	4	1:NR:2	L2R	NON-CROSS	167-168	182-183	13805	CD105	GeneOrGeneProduct	167	168	4	-	lectin	GeneOrGeneProduct	182	183	4	1:NR:2	L2R	CROSS	167-168	208-209	13805	CD105	GeneOrGeneProduct	167	168	4	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	167-168	210-211	13805	CD105	GeneOrGeneProduct	167	168	4	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	167-168	212-213	13805	CD105	GeneOrGeneProduct	167	168	4	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	167-168	216-217	13805	CD105	GeneOrGeneProduct	167	168	4	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	167-168	218-221	13805	CD105	GeneOrGeneProduct	167	168	4	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	167-168	225-226	13805	CD105	GeneOrGeneProduct	167	168	4	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	167-168	227-228	13805	CD105	GeneOrGeneProduct	167	168	4	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	167-168	242-243	13805	CD105	GeneOrGeneProduct	167	168	4	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	167-168	249-253	13805	CD105	GeneOrGeneProduct	167	168	4	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	167-168	277-278	13805	CD105	GeneOrGeneProduct	167	168	4	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	167-168	286-287	13805	CD105	GeneOrGeneProduct	167	168	4	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	167-168	294-295	13805	CD105	GeneOrGeneProduct	167	168	4	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	172-173	177-178	14257	VEGFR3	GeneOrGeneProduct	172	173	4	11475	SMA	GeneOrGeneProduct	177	178	4	1:NR:2	L2R	NON-CROSS	172-173	182-183	14257	VEGFR3	GeneOrGeneProduct	172	173	4	-	lectin	GeneOrGeneProduct	182	183	4	1:NR:2	L2R	CROSS	172-173	208-209	14257	VEGFR3	GeneOrGeneProduct	172	173	4	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	172-173	210-211	14257	VEGFR3	GeneOrGeneProduct	172	173	4	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	172-173	212-213	14257	VEGFR3	GeneOrGeneProduct	172	173	4	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	172-173	216-217	14257	VEGFR3	GeneOrGeneProduct	172	173	4	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	172-173	218-221	14257	VEGFR3	GeneOrGeneProduct	172	173	4	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	172-173	225-226	14257	VEGFR3	GeneOrGeneProduct	172	173	4	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	172-173	227-228	14257	VEGFR3	GeneOrGeneProduct	172	173	4	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	172-173	242-243	14257	VEGFR3	GeneOrGeneProduct	172	173	4	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	172-173	249-253	14257	VEGFR3	GeneOrGeneProduct	172	173	4	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	172-173	277-278	14257	VEGFR3	GeneOrGeneProduct	172	173	4	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	172-173	286-287	14257	VEGFR3	GeneOrGeneProduct	172	173	4	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	172-173	294-295	14257	VEGFR3	GeneOrGeneProduct	172	173	4	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	177-178	182-183	11475	SMA	GeneOrGeneProduct	177	178	4	-	lectin	GeneOrGeneProduct	182	183	4	1:NR:2	L2R	CROSS	177-178	208-209	11475	SMA	GeneOrGeneProduct	177	178	4	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	177-178	210-211	11475	SMA	GeneOrGeneProduct	177	178	4	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	177-178	212-213	11475	SMA	GeneOrGeneProduct	177	178	4	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	177-178	216-217	11475	SMA	GeneOrGeneProduct	177	178	4	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	177-178	218-221	11475	SMA	GeneOrGeneProduct	177	178	4	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	177-178	225-226	11475	SMA	GeneOrGeneProduct	177	178	4	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	177-178	227-228	11475	SMA	GeneOrGeneProduct	177	178	4	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	177-178	242-243	11475	SMA	GeneOrGeneProduct	177	178	4	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	177-178	249-253	11475	SMA	GeneOrGeneProduct	177	178	4	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	177-178	277-278	11475	SMA	GeneOrGeneProduct	177	178	4	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	177-178	286-287	11475	SMA	GeneOrGeneProduct	177	178	4	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	177-178	294-295	11475	SMA	GeneOrGeneProduct	177	178	4	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	CROSS	182-183	208-209	-	lectin	GeneOrGeneProduct	182	183	4	16008	IGFbp2	GeneOrGeneProduct	208	209	5	1:NR:2	L2R	CROSS	182-183	210-211	-	lectin	GeneOrGeneProduct	182	183	4	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	CROSS	182-183	212-213	-	lectin	GeneOrGeneProduct	182	183	4	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	CROSS	182-183	216-217	-	lectin	GeneOrGeneProduct	182	183	4	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	CROSS	182-183	218-221	-	lectin	GeneOrGeneProduct	182	183	4	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	CROSS	182-183	225-226	-	lectin	GeneOrGeneProduct	182	183	4	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	CROSS	182-183	227-228	-	lectin	GeneOrGeneProduct	182	183	4	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	182-183	242-243	-	lectin	GeneOrGeneProduct	182	183	4	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	182-183	249-253	-	lectin	GeneOrGeneProduct	182	183	4	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	182-183	277-278	-	lectin	GeneOrGeneProduct	182	183	4	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	182-183	286-287	-	lectin	GeneOrGeneProduct	182	183	4	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	182-183	294-295	-	lectin	GeneOrGeneProduct	182	183	4	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	208-209	210-211	16008	IGFbp2	GeneOrGeneProduct	208	209	5	16009	IGFbp3	GeneOrGeneProduct	210	211	5	1:NR:2	L2R	NON-CROSS	208-209	212-213	16008	IGFbp2	GeneOrGeneProduct	208	209	5	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	NON-CROSS	208-209	216-217	16008	IGFbp2	GeneOrGeneProduct	208	209	5	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	NON-CROSS	208-209	218-221	16008	IGFbp2	GeneOrGeneProduct	208	209	5	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	NON-CROSS	208-209	225-226	16008	IGFbp2	GeneOrGeneProduct	208	209	5	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	NON-CROSS	208-209	227-228	16008	IGFbp2	GeneOrGeneProduct	208	209	5	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	208-209	242-243	16008	IGFbp2	GeneOrGeneProduct	208	209	5	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	208-209	249-253	16008	IGFbp2	GeneOrGeneProduct	208	209	5	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	208-209	277-278	16008	IGFbp2	GeneOrGeneProduct	208	209	5	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	208-209	286-287	16008	IGFbp2	GeneOrGeneProduct	208	209	5	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	208-209	294-295	16008	IGFbp2	GeneOrGeneProduct	208	209	5	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	210-211	212-213	16009	IGFbp3	GeneOrGeneProduct	210	211	5	11601	Angpt2	GeneOrGeneProduct	212	213	5	1:NR:2	L2R	NON-CROSS	210-211	216-217	16009	IGFbp3	GeneOrGeneProduct	210	211	5	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	NON-CROSS	210-211	218-221	16009	IGFbp3	GeneOrGeneProduct	210	211	5	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	NON-CROSS	210-211	225-226	16009	IGFbp3	GeneOrGeneProduct	210	211	5	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	NON-CROSS	210-211	227-228	16009	IGFbp3	GeneOrGeneProduct	210	211	5	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	210-211	242-243	16009	IGFbp3	GeneOrGeneProduct	210	211	5	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	210-211	249-253	16009	IGFbp3	GeneOrGeneProduct	210	211	5	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	210-211	277-278	16009	IGFbp3	GeneOrGeneProduct	210	211	5	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	210-211	286-287	16009	IGFbp3	GeneOrGeneProduct	210	211	5	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	210-211	294-295	16009	IGFbp3	GeneOrGeneProduct	210	211	5	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	212-213	216-217	11601	Angpt2	GeneOrGeneProduct	212	213	5	13363	DHH	GeneOrGeneProduct	216	217	5	1:NR:2	L2R	NON-CROSS	212-213	218-221	11601	Angpt2	GeneOrGeneProduct	212	213	5	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	NON-CROSS	212-213	225-226	11601	Angpt2	GeneOrGeneProduct	212	213	5	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	NON-CROSS	212-213	227-228	11601	Angpt2	GeneOrGeneProduct	212	213	5	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	212-213	242-243	11601	Angpt2	GeneOrGeneProduct	212	213	5	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	212-213	249-253	11601	Angpt2	GeneOrGeneProduct	212	213	5	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	212-213	277-278	11601	Angpt2	GeneOrGeneProduct	212	213	5	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	212-213	286-287	11601	Angpt2	GeneOrGeneProduct	212	213	5	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	212-213	294-295	11601	Angpt2	GeneOrGeneProduct	212	213	5	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	216-217	218-221	13363	DHH	GeneOrGeneProduct	216	217	5	22339	VEGF - A	GeneOrGeneProduct	218	221	5	1:NR:2	L2R	NON-CROSS	216-217	225-226	13363	DHH	GeneOrGeneProduct	216	217	5	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	NON-CROSS	216-217	227-228	13363	DHH	GeneOrGeneProduct	216	217	5	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	216-217	242-243	13363	DHH	GeneOrGeneProduct	216	217	5	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	216-217	249-253	13363	DHH	GeneOrGeneProduct	216	217	5	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	216-217	277-278	13363	DHH	GeneOrGeneProduct	216	217	5	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	216-217	286-287	13363	DHH	GeneOrGeneProduct	216	217	5	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	216-217	294-295	13363	DHH	GeneOrGeneProduct	216	217	5	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	218-221	225-226	22339	VEGF - A	GeneOrGeneProduct	218	221	5	14164	FGF1	GeneOrGeneProduct	225	226	5	1:NR:2	L2R	NON-CROSS	218-221	227-228	22339	VEGF - A	GeneOrGeneProduct	218	221	5	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	218-221	242-243	22339	VEGF - A	GeneOrGeneProduct	218	221	5	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	218-221	249-253	22339	VEGF - A	GeneOrGeneProduct	218	221	5	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	218-221	277-278	22339	VEGF - A	GeneOrGeneProduct	218	221	5	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	218-221	286-287	22339	VEGF - A	GeneOrGeneProduct	218	221	5	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	218-221	294-295	22339	VEGF - A	GeneOrGeneProduct	218	221	5	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	225-226	227-228	14164	FGF1	GeneOrGeneProduct	225	226	5	12981	CSF2	GeneOrGeneProduct	227	228	5	1:NR:2	L2R	CROSS	225-226	242-243	14164	FGF1	GeneOrGeneProduct	225	226	5	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	225-226	249-253	14164	FGF1	GeneOrGeneProduct	225	226	5	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	225-226	277-278	14164	FGF1	GeneOrGeneProduct	225	226	5	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	225-226	286-287	14164	FGF1	GeneOrGeneProduct	225	226	5	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	225-226	294-295	14164	FGF1	GeneOrGeneProduct	225	226	5	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	CROSS	227-228	242-243	12981	CSF2	GeneOrGeneProduct	227	228	5	11651	Akt	GeneOrGeneProduct	242	243	6	1:NR:2	L2R	CROSS	227-228	249-253	12981	CSF2	GeneOrGeneProduct	227	228	5	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	227-228	277-278	12981	CSF2	GeneOrGeneProduct	227	228	5	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	227-228	286-287	12981	CSF2	GeneOrGeneProduct	227	228	5	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	227-228	294-295	12981	CSF2	GeneOrGeneProduct	227	228	5	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	242-243	249-253	11651	Akt	GeneOrGeneProduct	242	243	6	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	1:NR:2	L2R	CROSS	242-243	277-278	11651	Akt	GeneOrGeneProduct	242	243	6	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	242-243	286-287	11651	Akt	GeneOrGeneProduct	242	243	6	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	242-243	294-295	11651	Akt	GeneOrGeneProduct	242	243	6	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	CROSS	249-253	277-278	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	16409	CD11b	GeneOrGeneProduct	277	278	7	1:NR:2	L2R	CROSS	249-253	286-287	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	CROSS	249-253	294-295	26413,26417	Erk 1 / 2	GeneOrGeneProduct	249	253	6	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	277-278	286-287	16409	CD11b	GeneOrGeneProduct	277	278	7	19264	B220	GeneOrGeneProduct	286	287	7	1:NR:2	L2R	NON-CROSS	277-278	294-295	16409	CD11b	GeneOrGeneProduct	277	278	7	12501	CD3	GeneOrGeneProduct	294	295	7	1:NR:2	L2R	NON-CROSS	286-287	294-295	19264	B220	GeneOrGeneProduct	286	287	7	12501	CD3	GeneOrGeneProduct	294	295	7
27663860	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate - salt hypertension .|The aim of this study was to investigate the in vivo role of angiotensin II type 1a ( AT1a ) receptor in renal damage as a result of hypertension by using transgenic mice with AT1a receptor gene disruption .|Transgenic mice that express human liver - type fatty acid binding protein ( L - FABP ) with or without disruption of the AT1a receptor gene ( L - FABP ( + / - ) AT1a ( - / - ) , and L - FABP ( + / - ) AT1a ( + / + ) , respectively ) were used with urinary L - FABP as an indicator of tubulointerstitial damage .|Those female mice were administered subcutaneously deoxycorticosterone acetate ( DOCA ) - salt tablets plus drinking water that contained 1 % saline for 28 d after uninephrectomy .|In L - FABP ( + / - ) AT1a ( + / + ) mice that received DOCA - salt treatment , hypertension was induced and slight expansion of glomerular area , glomerular sclerosis , and tubulointerstitial damage were observed .|In L - FABP ( + / - ) AT1a ( - / - ) mice that received DOCA - salt treatment , hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L - FABP ( + / - ) AT1a ( + / + ) - DOCA mice .|Urinary L - FABP levels were significantly higher in L - FABP ( + / - ) AT1a ( - / - ) - DOCA mice compared with those in L - FABP ( + / - ) AT1a ( + / + ) - DOCA mice .|Hydralazine treatment significantly attenuated renal damage that was found in L - FABP ( + / - ) AT1a ( - / - ) - DOCA mice along with a reduction in blood pressure .|In summary , activation of the AT1a receptor may contribute to maintenance of the glomerular structure against hypertensive renal damage . - Hisamichi , M . , Kamijo - Ikemori , A . , Sugaya , T . , Ichikawa , D . , Natsuki , T . , Hoshino , S . , Kimura , K . , Shibagaki , Y .|Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate - salt hypertension .	1:Association:2	L2R	NON-CROSS	2-7	8-10	11607	angiotensin II type 1a receptor|angiotensin II type 1a ( AT1a ) receptor|AT1a receptor|AT1a receptor|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a receptor|angiotensin II type 1a receptor	GeneOrGeneProduct	2:31:52:80:92:108:168:210:248:275:296:324:347:406	7:39:54:82:93:109:169:211:249:276:297:325:349:411	0:1:1:2:2:2:4:5:5:6:6:7:8:9	D007674	renal injury|renal damage|tubulointerstitial damage|glomerular sclerosis|tubulointerstitial damage|glomerular damage|renal damage|renal injury	DiseaseOrPhenotypicFeature	8:40:128:192:196:232:310:412	10:42:130:194:198:234:312:414	0:1:2:4:4:5:7:9	1:Association:2	R2L	NON-CROSS	12-14	2-7	D064791	deoxycorticosterone acetate|deoxycorticosterone acetate|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|deoxycorticosterone acetate	ChemicalEntity	12:137:140:177:219:255:282:303:331:416	14:139:141:178:220:256:283:304:332:418	0:3:3:4:5:5:6:6:7:9	11607	angiotensin II type 1a receptor|angiotensin II type 1a ( AT1a ) receptor|AT1a receptor|AT1a receptor|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a receptor|angiotensin II type 1a receptor	GeneOrGeneProduct	2:31:52:80:92:108:168:210:248:275:296:324:347:406	7:39:54:82:93:109:169:211:249:276:297:325:349:411	0:1:1:2:2:2:4:5:5:6:6:7:8:9	1:NR:2	L2R	NON-CROSS	46-47	52-54	11607	angiotensin II type 1a receptor|angiotensin II type 1a ( AT1a ) receptor|AT1a receptor|AT1a receptor|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a receptor|angiotensin II type 1a receptor	GeneOrGeneProduct	2:31:52:80:92:108:168:210:248:275:296:324:347:406	7:39:54:82:93:109:169:211:249:276:297:325:349:411	0:1:1:2:2:2:4:5:5:6:6:7:8:9	D006973	hypertension|hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	16:46:182:224:420	17:47:183:225:421	0:1:4:5:9	1:Negative_Correlation:2	R2L	NON-CROSS	84-87	80-82	2168	liver - type fatty acid binding protein|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP	GeneOrGeneProduct	62:70:84:100:121:160:202:240:259:267:288:316	69:73:87:103:124:163:205:243:262:270:291:319	2:2:2:2:2:4:5:5:6:6:6:7	11607	angiotensin II type 1a receptor|angiotensin II type 1a ( AT1a ) receptor|AT1a receptor|AT1a receptor|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a receptor|angiotensin II type 1a receptor	GeneOrGeneProduct	2:31:52:80:92:108:168:210:248:275:296:324:347:406	7:39:54:82:93:109:169:211:249:276:297:325:349:411	0:1:1:2:2:2:4:5:5:6:6:7:8:9	1:NR:2	L2R	NON-CROSS	296-297	306-307	11607	angiotensin II type 1a receptor|angiotensin II type 1a ( AT1a ) receptor|AT1a receptor|AT1a receptor|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a receptor|angiotensin II type 1a receptor	GeneOrGeneProduct	2:31:52:80:92:108:168:210:248:275:296:324:347:406	7:39:54:82:93:109:169:211:249:276:297:325:349:411	0:1:1:2:2:2:4:5:5:6:6:7:8:9	D006830	Hydralazine	ChemicalEntity	306	307	7	1:NR:2	L2R	NON-CROSS	347-349	358-361	11607	angiotensin II type 1a receptor|angiotensin II type 1a ( AT1a ) receptor|AT1a receptor|AT1a receptor|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a|AT1a receptor|angiotensin II type 1a receptor	GeneOrGeneProduct	2:31:52:80:92:108:168:210:248:275:296:324:347:406	7:39:54:82:93:109:169:211:249:276:297:325:349:411	0:1:1:2:2:2:4:5:5:6:6:7:8:9	D006973,D007674	hypertensive renal damage	DiseaseOrPhenotypicFeature	358	361	8	1:Positive_Correlation:2	L2R	NON-CROSS	8-10	12-14	D007674	renal injury|renal damage|tubulointerstitial damage|glomerular sclerosis|tubulointerstitial damage|glomerular damage|renal damage|renal injury	DiseaseOrPhenotypicFeature	8:40:128:192:196:232:310:412	10:42:130:194:198:234:312:414	0:1:2:4:4:5:7:9	D064791	deoxycorticosterone acetate|deoxycorticosterone acetate|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|deoxycorticosterone acetate	ChemicalEntity	12:137:140:177:219:255:282:303:331:416	14:139:141:178:220:256:283:304:332:418	0:3:3:4:5:5:6:6:7:9	1:Association:2	R2L	NON-CROSS	202-205	196-198	2168	liver - type fatty acid binding protein|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP	GeneOrGeneProduct	62:70:84:100:121:160:202:240:259:267:288:316	69:73:87:103:124:163:205:243:262:270:291:319	2:2:2:2:2:4:5:5:6:6:6:7	D007674	renal injury|renal damage|tubulointerstitial damage|glomerular sclerosis|tubulointerstitial damage|glomerular damage|renal damage|renal injury	DiseaseOrPhenotypicFeature	8:40:128:192:196:232:310:412	10:42:130:194:198:234:312:414	0:1:2:4:4:5:7:9	1:Negative_Correlation:2	R2L	NON-CROSS	310-312	306-307	D006830	Hydralazine	ChemicalEntity	306	307	7	D007674	renal injury|renal damage|tubulointerstitial damage|glomerular sclerosis|tubulointerstitial damage|glomerular damage|renal damage|renal injury	DiseaseOrPhenotypicFeature	8:40:128:192:196:232:310:412	10:42:130:194:198:234:312:414	0:1:2:4:4:5:7:9	1:Positive_Correlation:2	L2R	NON-CROSS	12-14	16-17	D064791	deoxycorticosterone acetate|deoxycorticosterone acetate|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|deoxycorticosterone acetate	ChemicalEntity	12:137:140:177:219:255:282:303:331:416	14:139:141:178:220:256:283:304:332:418	0:3:3:4:5:5:6:6:7:9	D006973	hypertension|hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	16:46:182:224:420	17:47:183:225:421	0:1:4:5:9	1:Association:2	L2R	NON-CROSS	255-256	259-262	D064791	deoxycorticosterone acetate|deoxycorticosterone acetate|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|deoxycorticosterone acetate	ChemicalEntity	12:137:140:177:219:255:282:303:331:416	14:139:141:178:220:256:283:304:332:418	0:3:3:4:5:5:6:6:7:9	2168	liver - type fatty acid binding protein|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP	GeneOrGeneProduct	62:70:84:100:121:160:202:240:259:267:288:316	69:73:87:103:124:163:205:243:262:270:291:319	2:2:2:2:2:4:5:5:6:6:6:7	1:NR:2	L2R	NON-CROSS	303-304	306-307	D064791	deoxycorticosterone acetate|deoxycorticosterone acetate|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|deoxycorticosterone acetate	ChemicalEntity	12:137:140:177:219:255:282:303:331:416	14:139:141:178:220:256:283:304:332:418	0:3:3:4:5:5:6:6:7:9	D006830	Hydralazine	ChemicalEntity	306	307	7	1:NR:2	L2R	CROSS	331-332	358-361	D064791	deoxycorticosterone acetate|deoxycorticosterone acetate|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|DOCA|deoxycorticosterone acetate	ChemicalEntity	12:137:140:177:219:255:282:303:331:416	14:139:141:178:220:256:283:304:332:418	0:3:3:4:5:5:6:6:7:9	D006973,D007674	hypertensive renal damage	DiseaseOrPhenotypicFeature	358	361	8	1:NR:2	L2R	NON-CROSS	46-47	62-69	D006973	hypertension|hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	16:46:182:224:420	17:47:183:225:421	0:1:4:5:9	2168	liver - type fatty acid binding protein|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP	GeneOrGeneProduct	62:70:84:100:121:160:202:240:259:267:288:316	69:73:87:103:124:163:205:243:262:270:291:319	2:2:2:2:2:4:5:5:6:6:6:7	1:NR:2	L2R	CROSS	224-225	306-307	D006973	hypertension|hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	16:46:182:224:420	17:47:183:225:421	0:1:4:5:9	D006830	Hydralazine	ChemicalEntity	306	307	7	1:NR:2	L2R	NON-CROSS	306-307	316-319	2168	liver - type fatty acid binding protein|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP	GeneOrGeneProduct	62:70:84:100:121:160:202:240:259:267:288:316	69:73:87:103:124:163:205:243:262:270:291:319	2:2:2:2:2:4:5:5:6:6:6:7	D006830	Hydralazine	ChemicalEntity	306	307	7	1:NR:2	L2R	CROSS	316-319	358-361	2168	liver - type fatty acid binding protein|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP|L - FABP	GeneOrGeneProduct	62:70:84:100:121:160:202:240:259:267:288:316	69:73:87:103:124:163:205:243:262:270:291:319	2:2:2:2:2:4:5:5:6:6:6:7	D006973,D007674	hypertensive renal damage	DiseaseOrPhenotypicFeature	358	361	8	1:NR:2	L2R	CROSS	306-307	358-361	D006830	Hydralazine	ChemicalEntity	306	307	7	D006973,D007674	hypertensive renal damage	DiseaseOrPhenotypicFeature	358	361	8
27807193	PTPN22 Is a Critical Regulator of Fcg Receptor - Mediated Neutrophil Activation .|Neutrophils act as a first line of defense against bacterial and fungal infections , but they are also important effectors of acute and chronic inflammation .|Genome - wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 ( PTPN22 ) makes an important contribution to susceptibility to autoimmune disease , notably rheumatoid arthritis .|Although PTPN22 is most highly expressed in neutrophils , its function in these cells remains poorly characterized .|We show in this article that neutrophil effector functions , including adhesion , production of reactive oxygen species , and degranulation induced by immobilized immune complexes , were reduced in Ptpn22 ( - / - ) neutrophils .|Tyrosine phosphorylation of Lyn and Syk was altered in Ptpn22 ( - / - ) neutrophils .|On stimulation with immobilized immune complexes , Ptpn22 ( - / - ) neutrophils manifested reduced activation of key signaling intermediates .|Ptpn22 ( - / - ) mice were protected from immune complex - mediated arthritis , induced by the transfer of arthritogenic serum .|In contrast , in vivo neutrophil recruitment following thioglycollate - induced peritonitis and in vitro chemotaxis were not affected by lack of PTPN22 .|Our data suggest an important role for PTPN22 - dependent dephosphorylation events , which are required to enable full FcgR - induced activation , pointing to an important role for this molecule in neutrophil function .	1:Association:2	L2R	NON-CROSS	0-1	6-8	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	1:NR:2	L2R	CROSS	0-1	24-26	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	D009181	fungal infections	DiseaseOrPhenotypicFeature	24	26	1	1:NR:2	L2R	CROSS	34-38	57-58	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	D007249	acute and chronic inflammation	DiseaseOrPhenotypicFeature	34	38	1	1:Association:2	L2R	NON-CROSS	66-68	74-75	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	D001327	autoimmune disease	DiseaseOrPhenotypicFeature	66	68	2	1:Association:2	L2R	NON-CROSS	70-72	74-75	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	D001172	rheumatoid arthritis	DiseaseOrPhenotypicFeature	70	72	2	1:Negative_Correlation:2	L2R	NON-CROSS	106-109	121-122	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	D017382	reactive oxygen species	ChemicalEntity	106	109	4	1:Association:2	R2L	NON-CROSS	138-139	132-133	17096	Lyn	GeneOrGeneProduct	132	133	5	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	1:Association:2	R2L	NON-CROSS	138-139	134-135	20963	Syk	GeneOrGeneProduct	134	135	5	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	1:Association:2	L2R	NON-CROSS	168-169	182-183	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	D001168	arthritis	DiseaseOrPhenotypicFeature	182	183	7	1:NR:2	L2R	NON-CROSS	200-201	214-215	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	NON-CROSS	203-204	214-215	19260	PTPN22|protein tyrosine phosphatase nonreceptor 22|PTPN22|PTPN22|Ptpn22|Ptpn22|Ptpn22|Ptpn22|PTPN22|PTPN22	GeneOrGeneProduct	0:51:57:74:121:138:153:168:214:223	1:56:58:75:122:139:154:169:215:224	0:2:2:3:4:5:6:7:8:9	D010538	peritonitis	DiseaseOrPhenotypicFeature	203	204	8	1:NR:2	L2R	CROSS	6-8	24-26	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	D009181	fungal infections	DiseaseOrPhenotypicFeature	24	26	1	1:NR:2	L2R	CROSS	6-8	34-38	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	D007249	acute and chronic inflammation	DiseaseOrPhenotypicFeature	34	38	1	1:NR:2	L2R	CROSS	6-8	66-68	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	D001327	autoimmune disease	DiseaseOrPhenotypicFeature	66	68	2	1:NR:2	L2R	CROSS	6-8	70-72	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	D001172	rheumatoid arthritis	DiseaseOrPhenotypicFeature	70	72	2	1:NR:2	L2R	CROSS	6-8	106-109	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	D017382	reactive oxygen species	ChemicalEntity	106	109	4	1:NR:2	L2R	CROSS	132-133	235-236	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	17096	Lyn	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	134-135	235-236	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	20963	Syk	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	182-183	235-236	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	D001168	arthritis	DiseaseOrPhenotypicFeature	182	183	7	1:NR:2	L2R	CROSS	200-201	235-236	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	CROSS	203-204	235-236	14130	Fcg Receptor|FcgR	GeneOrGeneProduct	6:235	8:236	0:9	D010538	peritonitis	DiseaseOrPhenotypicFeature	203	204	8	1:NR:2	L2R	CROSS	24-26	106-109	D009181	fungal infections	DiseaseOrPhenotypicFeature	24	26	1	D017382	reactive oxygen species	ChemicalEntity	106	109	4	1:NR:2	L2R	CROSS	24-26	132-133	D009181	fungal infections	DiseaseOrPhenotypicFeature	24	26	1	17096	Lyn	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	24-26	134-135	D009181	fungal infections	DiseaseOrPhenotypicFeature	24	26	1	20963	Syk	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	24-26	200-201	D009181	fungal infections	DiseaseOrPhenotypicFeature	24	26	1	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	CROSS	34-38	106-109	D007249	acute and chronic inflammation	DiseaseOrPhenotypicFeature	34	38	1	D017382	reactive oxygen species	ChemicalEntity	106	109	4	1:NR:2	L2R	CROSS	34-38	132-133	D007249	acute and chronic inflammation	DiseaseOrPhenotypicFeature	34	38	1	17096	Lyn	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	34-38	134-135	D007249	acute and chronic inflammation	DiseaseOrPhenotypicFeature	34	38	1	20963	Syk	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	34-38	200-201	D007249	acute and chronic inflammation	DiseaseOrPhenotypicFeature	34	38	1	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	CROSS	66-68	106-109	D001327	autoimmune disease	DiseaseOrPhenotypicFeature	66	68	2	D017382	reactive oxygen species	ChemicalEntity	106	109	4	1:NR:2	L2R	CROSS	66-68	132-133	D001327	autoimmune disease	DiseaseOrPhenotypicFeature	66	68	2	17096	Lyn	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	66-68	134-135	D001327	autoimmune disease	DiseaseOrPhenotypicFeature	66	68	2	20963	Syk	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	66-68	200-201	D001327	autoimmune disease	DiseaseOrPhenotypicFeature	66	68	2	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	CROSS	70-72	106-109	D001172	rheumatoid arthritis	DiseaseOrPhenotypicFeature	70	72	2	D017382	reactive oxygen species	ChemicalEntity	106	109	4	1:NR:2	L2R	CROSS	70-72	132-133	D001172	rheumatoid arthritis	DiseaseOrPhenotypicFeature	70	72	2	17096	Lyn	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	70-72	134-135	D001172	rheumatoid arthritis	DiseaseOrPhenotypicFeature	70	72	2	20963	Syk	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	70-72	200-201	D001172	rheumatoid arthritis	DiseaseOrPhenotypicFeature	70	72	2	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	CROSS	106-109	132-133	D017382	reactive oxygen species	ChemicalEntity	106	109	4	17096	Lyn	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	106-109	134-135	D017382	reactive oxygen species	ChemicalEntity	106	109	4	20963	Syk	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	106-109	182-183	D017382	reactive oxygen species	ChemicalEntity	106	109	4	D001168	arthritis	DiseaseOrPhenotypicFeature	182	183	7	1:NR:2	L2R	CROSS	106-109	200-201	D017382	reactive oxygen species	ChemicalEntity	106	109	4	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	CROSS	106-109	203-204	D017382	reactive oxygen species	ChemicalEntity	106	109	4	D010538	peritonitis	DiseaseOrPhenotypicFeature	203	204	8	1:NR:2	L2R	NON-CROSS	132-133	134-135	17096	Lyn	GeneOrGeneProduct	132	133	5	20963	Syk	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	132-133	182-183	17096	Lyn	GeneOrGeneProduct	132	133	5	D001168	arthritis	DiseaseOrPhenotypicFeature	182	183	7	1:NR:2	L2R	CROSS	132-133	200-201	17096	Lyn	GeneOrGeneProduct	132	133	5	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	CROSS	132-133	203-204	17096	Lyn	GeneOrGeneProduct	132	133	5	D010538	peritonitis	DiseaseOrPhenotypicFeature	203	204	8	1:NR:2	L2R	CROSS	134-135	182-183	20963	Syk	GeneOrGeneProduct	134	135	5	D001168	arthritis	DiseaseOrPhenotypicFeature	182	183	7	1:NR:2	L2R	CROSS	134-135	200-201	20963	Syk	GeneOrGeneProduct	134	135	5	D013864	thioglycollate	ChemicalEntity	200	201	8	1:NR:2	L2R	CROSS	134-135	203-204	20963	Syk	GeneOrGeneProduct	134	135	5	D010538	peritonitis	DiseaseOrPhenotypicFeature	203	204	8	1:NR:2	L2R	CROSS	182-183	200-201	D001168	arthritis	DiseaseOrPhenotypicFeature	182	183	7	D013864	thioglycollate	ChemicalEntity	200	201	8	1:Positive_Correlation:2	L2R	NON-CROSS	200-201	203-204	D013864	thioglycollate	ChemicalEntity	200	201	8	D010538	peritonitis	DiseaseOrPhenotypicFeature	203	204	8
15069170	Four novel mutations in the thiazide - sensitive Na - Cl co - transporter gene in Japanese patients with Gitelman 's syndrome .|BACKGROUND : Gitelman 's syndrome ( GS ) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide - sensitive Na - Cl co - transporter ( NCCT ) gene .|To date , almost 90 mutations have been identified .|It is possible that there is a population - specific distribution of mutations .|In this study , we analysed mutations in the NCCT gene of seven Japanese patients with GS .|METHODS : Peripheral blood mononuclear cells were isolated from patients with GS , their family members and healthy control subjects .|A mutation analysis of the NCCT gene was performed completely by direct automated sequencing of polymerase chain reaction - amplified DNA products .|In patients with a deletion or splice site mutation , we undertook cDNA sequence analysis .|RESULTS : We identified nine mutations .|Five of them [ c . 185C > T ( Thr60Met ) , c . 1712C > T ( Ala569Val ) , c . 1930C > T ( Arg642Cys ) , c . 2552T > A ( Leu849His ) and c . 1932delC ] have been reported in Japanese patients , but not in GS patients from other ethnic groups .|The remaining four mutations [ c . 7A > T ( Met1Leu ) , c . 1181_1186 + 20del26 , c . 1811_1812delAT and IVS16 + 1G > A ] were novel .|In cDNA derived from a patient with c . 1181_1186 + 20del26 , a deletion of exon 9 and a frameshift at the start of exon 10 were observed .|In cDNA derived from patients with IVS16 + 1G > A , an additional 96 bp insertion between exons 16 and 17 was observed .|Six out of seven patients were compound heterozygotes , and the remaining one carried a single heterozygous mutation .|CONCLUSIONS : We found four novel mutations in the NCCT gene in seven Japanese patients with GS .|Moreover , our study suggests that the distribution of mutations in the NCCT gene in Japanese GS patients potentially differs from that in other populations .	1:Positive_Correlation:2	L2R	NON-CROSS	5-6	8-14	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	6559	Na - Cl co - transporter|Na - Cl co - transporter|NCCT|NCCT|NCCT|NCCT|NCCT	GeneOrGeneProduct	8:45:52:89:124:342:363	14:51:53:90:125:343:364	0:1:1:4:6:14:15	1:NR:2	L2R	NON-CROSS	29-30	42-43	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	1:NR:2	L2R	NON-CROSS	33-36	42-43	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	1:NR:2	L2R	CROSS	42-43	169-174	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	rs371443644	c . 185C > T|Thr60Met	SequenceVariant	169:175	174:176	9:9	1:NR:2	L2R	CROSS	42-43	178-183	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	rs79351185	c . 1712C > T|Ala569Val	SequenceVariant	178:184	183:185	9:9	1:NR:2	L2R	CROSS	42-43	187-192	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	rs200697179	c . 1930C > T|Arg642Cys	SequenceVariant	187:193	192:194	9:9	1:NR:2	L2R	CROSS	42-43	196-201	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	rs185927948	c . 2552T > A|Leu849His	SequenceVariant	196:202	201:203	9:9	1:NR:2	L2R	CROSS	42-43	205-208	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	c|DEL|1932|C	c . 1932delC	SequenceVariant	205	208	9	1:NR:2	L2R	CROSS	42-43	231-236	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	c|SUB|A|7|T	c . 7A > T	SequenceVariant	231	236	10	1:NR:2	L2R	CROSS	42-43	237-238	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	p|SUB|M|1|L	Met1Leu	SequenceVariant	237	238	10	1:NR:2	L2R	CROSS	42-43	240-245	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	c|DEL|1181_1186+20|26	c . 1181_1186 + 20del26|c . 1181_1186 + 20del26	SequenceVariant	240:266	245:271	10:11	1:NR:2	L2R	CROSS	42-43	246-249	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	c|DEL|1811_1812|AT	c . 1811_1812delAT	SequenceVariant	246	249	10	1:NR:2	L2R	CROSS	42-43	250-255	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	c|SUB|G|IVS16+1|A	IVS16 + 1G > A|IVS16 + 1G > A	SequenceVariant	250:295	255:300	10:12	1:NR:2	L2R	CROSS	42-43	303-306	D049971	thiazide|thiazide	ChemicalEntity	5:42	6:43	0:1	c|INS||96	96 bp insertion	SequenceVariant	303	306	12	1:Association:2	L2R	NON-CROSS	363-364	367-368	6559	Na - Cl co - transporter|Na - Cl co - transporter|NCCT|NCCT|NCCT|NCCT|NCCT	GeneOrGeneProduct	8:45:52:89:124:342:363	14:51:53:90:125:343:364	0:1:1:4:6:14:15	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	1:NR:2	L2R	NON-CROSS	33-36	45-51	6559	Na - Cl co - transporter|Na - Cl co - transporter|NCCT|NCCT|NCCT|NCCT|NCCT	GeneOrGeneProduct	8:45:52:89:124:342:363	14:51:53:90:125:343:364	0:1:1:4:6:14:15	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	1:Positive_Correlation:2	R2L	NON-CROSS	219-220	175-176	rs371443644	c . 185C > T|Thr60Met	SequenceVariant	169:175	174:176	9:9	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	1:Positive_Correlation:2	R2L	NON-CROSS	219-220	184-185	rs79351185	c . 1712C > T|Ala569Val	SequenceVariant	178:184	183:185	9:9	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	1:Positive_Correlation:2	R2L	NON-CROSS	219-220	193-194	rs200697179	c . 1930C > T|Arg642Cys	SequenceVariant	187:193	192:194	9:9	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	1:Positive_Correlation:2	R2L	NON-CROSS	219-220	202-203	rs185927948	c . 2552T > A|Leu849His	SequenceVariant	196:202	201:203	9:9	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	1:Positive_Correlation:2	R2L	NON-CROSS	219-220	205-208	c|DEL|1932|C	c . 1932delC	SequenceVariant	205	208	9	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	1:Positive_Correlation:2	L2R	CROSS	219-220	231-236	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	c|SUB|A|7|T	c . 7A > T	SequenceVariant	231	236	10	1:Positive_Correlation:2	L2R	CROSS	219-220	237-238	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	p|SUB|M|1|L	Met1Leu	SequenceVariant	237	238	10	1:Positive_Correlation:2	L2R	CROSS	219-220	240-245	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	c|DEL|1181_1186+20|26	c . 1181_1186 + 20del26|c . 1181_1186 + 20del26	SequenceVariant	240:266	245:271	10:11	1:Positive_Correlation:2	L2R	CROSS	219-220	246-249	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	c|DEL|1811_1812|AT	c . 1811_1812delAT	SequenceVariant	246	249	10	1:Positive_Correlation:2	L2R	CROSS	219-220	250-255	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	c|SUB|G|IVS16+1|A	IVS16 + 1G > A|IVS16 + 1G > A	SequenceVariant	250:295	255:300	10:12	1:Positive_Correlation:2	L2R	CROSS	303-306	349-350	D053579	Gitelman 's syndrome|Gitelman 's syndrome|GS|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	19:25:29:96:109:219:349:367	22:28:30:97:110:220:350:368	0:1:1:4:5:9:14:15	c|INS||96	96 bp insertion	SequenceVariant	303	306	12	1:NR:2	L2R	CROSS	33-36	169-174	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	rs371443644	c . 185C > T|Thr60Met	SequenceVariant	169:175	174:176	9:9	1:NR:2	L2R	CROSS	33-36	178-183	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	rs79351185	c . 1712C > T|Ala569Val	SequenceVariant	178:184	183:185	9:9	1:NR:2	L2R	CROSS	33-36	187-192	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	rs200697179	c . 1930C > T|Arg642Cys	SequenceVariant	187:193	192:194	9:9	1:NR:2	L2R	CROSS	33-36	196-201	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	rs185927948	c . 2552T > A|Leu849His	SequenceVariant	196:202	201:203	9:9	1:NR:2	L2R	CROSS	33-36	205-208	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	c|DEL|1932|C	c . 1932delC	SequenceVariant	205	208	9	1:NR:2	L2R	CROSS	33-36	231-236	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	c|SUB|A|7|T	c . 7A > T	SequenceVariant	231	236	10	1:NR:2	L2R	CROSS	33-36	237-238	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	p|SUB|M|1|L	Met1Leu	SequenceVariant	237	238	10	1:NR:2	L2R	CROSS	33-36	240-245	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	c|DEL|1181_1186+20|26	c . 1181_1186 + 20del26|c . 1181_1186 + 20del26	SequenceVariant	240:266	245:271	10:11	1:NR:2	L2R	CROSS	33-36	246-249	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	c|DEL|1811_1812|AT	c . 1811_1812delAT	SequenceVariant	246	249	10	1:NR:2	L2R	CROSS	33-36	250-255	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	c|SUB|G|IVS16+1|A	IVS16 + 1G > A|IVS16 + 1G > A	SequenceVariant	250:295	255:300	10:12	1:NR:2	L2R	CROSS	33-36	303-306	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	33	36	1	c|INS||96	96 bp insertion	SequenceVariant	303	306	12
17397547	Regulatory network of inflammation downstream of proteinase - activated receptors .|BACKGROUND : Protease - activated receptors ( PAR ) are present in the urinary bladder , and their expression is altered in response to inflammation .|PARs are a unique class of G protein - coupled that carry their own ligands , which remain cryptic until unmasked by proteolytic cleavage .|Although the canonical signal transduction pathway downstream of PAR activation and coupling with various G proteins is known and leads to the rapid transcription of genes involved in inflammation , the effect of PAR activation on the downstream transcriptome is unknown .|We have shown that intravesical administration of PAR - activating peptides leads to an inflammatory reaction characterized by edema and granulocyte infiltration .|Moreover , the inflammatory response to intravesical instillation of known pro - inflammatory stimuli such as E . coli lipopolysaccharide ( LPS ) , substance P ( SP ) , and antigen was strongly attenuated by PAR1 - and to a lesser extent by PAR2 - deficiency .|RESULTS : Here , cDNA array experiments determined inflammatory genes whose expression is dependent on PAR1 activation .|For this purpose , we compared the alteration in gene expression in wild type and PAR1 - / - mice induced by classical pro - inflammatory stimuli ( LPS , SP , and antigen ) .|75 transcripts were considered to be dependent on PAR - 1 activation and further annotated in silico by Ingenuity Pathways Analysis ( IPA ) and gene ontology ( GO ) .|Selected transcripts were target validated by quantitative PCR ( Q - PCR ) .|Among PAR1 - dependent transcripts , the following have been implicated in the inflammatory process : b2m , ccl7 , cd200 , cd63 , cdbpd , cfl1 , dusp1 , fkbp1a , fth1 , hspb1 , marcksl1 , mmp2 , myo5a , nfkbia , pax1 , plaur , ppia , ptpn1 , ptprcap , s100a10 , sim2 , and tnfaip2 .|However , a balanced response to signals of injury requires a transient cellular activation of a panel of genes together with inhibitory systems that temper the overwhelming inflammation .|In this context , the activation of genes such as dusp1 and nfkbia seems to counter - balance the inflammatory response to PAR activation by limiting prolonged activation of p38 MAPK and increased cytokine production .|In contrast , transcripts such as arf6 and dcnt1 that are involved in the mechanism of PAR re - sensitization would tend to perpetuate the inflammatory reaction in response to common pro - inflammatory stimuli .|CONCLUSION : The combination of cDNA array results and genomic networks reveals an overriding participation of PAR1 in bladder inflammation , provides a working model for the involvement of downstream signaling , and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation .|It remains to be determined whether or not mechanisms targeting PAR1 gene silencing or PAR1 blockade will ameliorate the clinical manifestation of cystitis .	1:NR:2	L2R	NON-CROSS	35-36	37-38	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	1:Positive_Correlation:2	L2R	NON-CROSS	218-219	221-222	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	1:Positive_Correlation:2	L2R	NON-CROSS	218-219	223-224	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	1:Association:2	L2R	NON-CROSS	183-184	190-191	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	1:Association:2	L2R	NON-CROSS	171-172	183-184	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	14063	PAR2	GeneOrGeneProduct	171	172	5	1:Association:2	L2R	NON-CROSS	287-288	290-291	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	12010	b2m	GeneOrGeneProduct	290	291	10	1:Association:2	L2R	NON-CROSS	287-288	292-293	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	20306	ccl7	GeneOrGeneProduct	292	293	10	1:Association:2	L2R	NON-CROSS	287-288	294-295	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	17470	cd200	GeneOrGeneProduct	294	295	10	1:Association:2	L2R	NON-CROSS	287-288	296-297	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	NON-CROSS	287-288	298-299	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	-	cdbpd	GeneOrGeneProduct	298	299	10	1:Association:2	L2R	NON-CROSS	287-288	300-301	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	12631	cfl1	GeneOrGeneProduct	300	301	10	1:Association:2	L2R	NON-CROSS	374-375	383-384	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:Association:2	L2R	NON-CROSS	287-288	304-305	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:Association:2	L2R	NON-CROSS	287-288	306-307	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	14319	fth1	GeneOrGeneProduct	306	307	10	1:Association:2	L2R	NON-CROSS	287-288	308-309	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	15507	hspb1	GeneOrGeneProduct	308	309	10	1:Association:2	L2R	NON-CROSS	287-288	310-311	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:Association:2	L2R	NON-CROSS	287-288	312-313	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	17390	mmp2	GeneOrGeneProduct	312	313	10	1:Association:2	L2R	NON-CROSS	287-288	314-315	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	17918	myo5a	GeneOrGeneProduct	314	315	10	1:Association:2	L2R	NON-CROSS	376-377	383-384	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:Association:2	L2R	NON-CROSS	287-288	318-319	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	18503	pax1	GeneOrGeneProduct	318	319	10	1:Association:2	L2R	NON-CROSS	287-288	320-321	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	18793	plaur	GeneOrGeneProduct	320	321	10	1:Association:2	L2R	NON-CROSS	287-288	322-323	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	268373	ppia	GeneOrGeneProduct	322	323	10	1:Association:2	L2R	NON-CROSS	287-288	324-325	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:Association:2	L2R	NON-CROSS	326-327	362-363	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:Association:2	L2R	NON-CROSS	328-329	362-363	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	20194	s100a10	GeneOrGeneProduct	328	329	10	1:Association:2	L2R	NON-CROSS	330-331	362-363	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	20465	sim2	GeneOrGeneProduct	330	331	10	1:Association:2	L2R	NON-CROSS	333-334	362-363	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:Association:2	L2R	NON-CROSS	383-384	393-395	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:Association:2	L2R	NON-CROSS	406-407	425-426	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	11845	arf6	GeneOrGeneProduct	406	407	13	1:Association:2	L2R	NON-CROSS	408-409	425-426	D007249	inflammation|inflammation|inflammation|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammatory|inflammation|inflammatory|inflammatory|inflammatory	DiseaseOrPhenotypicFeature	3:35:90:118:130:139:183:218:287:362:383:425:433	4:36:91:119:131:140:184:219:288:363:384:426:434	0:1:3:4:5:5:6:7:10:11:12:13:13	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	NON-CROSS	111-112	122-123	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	1:NR:2	L2R	CROSS	111-112	146-147	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	1:NR:2	L2R	CROSS	111-112	151-153	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	1:NR:2	L2R	CROSS	416-417	452-453	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	1:NR:2	L2R	CROSS	111-112	171-172	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	14063	PAR2	GeneOrGeneProduct	171	172	5	1:NR:2	L2R	CROSS	290-291	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	12010	b2m	GeneOrGeneProduct	290	291	10	1:NR:2	L2R	CROSS	292-293	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	20306	ccl7	GeneOrGeneProduct	292	293	10	1:NR:2	L2R	CROSS	294-295	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	17470	cd200	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	296-297	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	CROSS	298-299	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	CROSS	300-301	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	NON-CROSS	374-375	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	CROSS	304-305	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	CROSS	306-307	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	CROSS	308-309	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	CROSS	310-311	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	CROSS	312-313	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	CROSS	314-315	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	376-377	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	CROSS	318-319	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	CROSS	320-321	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	CROSS	322-323	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	CROSS	324-325	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	CROSS	326-327	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	CROSS	328-329	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	CROSS	330-331	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	CROSS	333-334	386-387	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	NON-CROSS	386-387	393-395	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	NON-CROSS	406-407	416-417	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	NON-CROSS	408-409	416-417	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	416-417	454-456	14062,14063	proteinase - activated receptors|Protease - activated receptors|PAR|PARs|PAR|PAR|PAR|PAR|PAR	GeneOrGeneProduct	6:13:18:37:70:95:111:386:416	10:17:19:38:71:96:112:387:417	0:1:1:2:3:3:4:12:13	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	CROSS	122-123	146-147	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	1:NR:2	L2R	CROSS	122-123	151-153	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	1:Association:2	R2L	CROSS	163-164	122-123	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	1:Association:2	R2L	CROSS	171-172	122-123	14063	PAR2	GeneOrGeneProduct	171	172	5	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	1:NR:2	L2R	CROSS	122-123	290-291	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	12010	b2m	GeneOrGeneProduct	290	291	10	1:NR:2	L2R	CROSS	122-123	292-293	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	20306	ccl7	GeneOrGeneProduct	292	293	10	1:NR:2	L2R	CROSS	122-123	294-295	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	17470	cd200	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	122-123	296-297	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	CROSS	122-123	298-299	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	CROSS	122-123	300-301	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	CROSS	122-123	302-303	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	CROSS	122-123	304-305	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	CROSS	122-123	306-307	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	CROSS	122-123	308-309	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	CROSS	122-123	310-311	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	CROSS	122-123	312-313	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	CROSS	122-123	314-315	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	CROSS	122-123	316-317	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	CROSS	122-123	318-319	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	CROSS	122-123	320-321	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	CROSS	122-123	322-323	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	CROSS	122-123	324-325	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	CROSS	122-123	326-327	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	CROSS	122-123	328-329	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	CROSS	122-123	330-331	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	CROSS	122-123	333-334	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	122-123	393-395	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	122-123	406-407	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	122-123	408-409	D004487	edema	DiseaseOrPhenotypicFeature	122	123	4	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	NON-CROSS	221-222	223-224	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	1:Positive_Correlation:2	R2L	NON-CROSS	221-222	208-209	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	1:Positive_Correlation:2	R2L	NON-CROSS	171-172	148-149	14063	PAR2	GeneOrGeneProduct	171	172	5	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	1:NR:2	L2R	CROSS	221-222	290-291	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	12010	b2m	GeneOrGeneProduct	290	291	10	1:NR:2	L2R	CROSS	221-222	292-293	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	20306	ccl7	GeneOrGeneProduct	292	293	10	1:NR:2	L2R	CROSS	221-222	294-295	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	17470	cd200	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	221-222	296-297	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	CROSS	221-222	298-299	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	CROSS	221-222	300-301	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	CROSS	221-222	302-303	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	CROSS	221-222	304-305	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	CROSS	221-222	306-307	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	CROSS	221-222	308-309	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	CROSS	221-222	310-311	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	CROSS	221-222	312-313	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	CROSS	221-222	314-315	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	CROSS	221-222	316-317	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	CROSS	221-222	318-319	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	CROSS	221-222	320-321	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	CROSS	221-222	322-323	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	CROSS	221-222	324-325	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	CROSS	221-222	326-327	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	CROSS	221-222	328-329	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	CROSS	221-222	330-331	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	CROSS	221-222	333-334	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	221-222	393-395	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	221-222	406-407	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	221-222	408-409	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	221-222	454-456	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	146:148:221	147:149:222	5:5:7	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:Positive_Correlation:2	R2L	NON-CROSS	163-164	154-155	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	1:Positive_Correlation:2	R2L	NON-CROSS	171-172	154-155	14063	PAR2	GeneOrGeneProduct	171	172	5	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	1:NR:2	L2R	CROSS	223-224	290-291	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	12010	b2m	GeneOrGeneProduct	290	291	10	1:NR:2	L2R	CROSS	223-224	292-293	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	20306	ccl7	GeneOrGeneProduct	292	293	10	1:NR:2	L2R	CROSS	223-224	294-295	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	17470	cd200	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	223-224	296-297	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	CROSS	223-224	298-299	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	CROSS	223-224	300-301	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	CROSS	223-224	302-303	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	CROSS	223-224	304-305	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	CROSS	223-224	306-307	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	CROSS	223-224	308-309	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	CROSS	223-224	310-311	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	CROSS	223-224	312-313	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	CROSS	223-224	314-315	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	CROSS	223-224	316-317	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	CROSS	223-224	318-319	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	CROSS	223-224	320-321	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	CROSS	223-224	322-323	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	CROSS	223-224	324-325	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	CROSS	223-224	326-327	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	CROSS	223-224	328-329	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	CROSS	223-224	330-331	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	CROSS	223-224	333-334	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	223-224	393-395	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	223-224	406-407	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	223-224	408-409	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	223-224	454-456	D013373	substance P|SP|SP	ChemicalEntity	151:154:223	153:155:224	5:5:7	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	163-164	171-172	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	14063	PAR2	GeneOrGeneProduct	171	172	5	1:Association:2	L2R	NON-CROSS	275-276	290-291	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	12010	b2m	GeneOrGeneProduct	290	291	10	1:Association:2	L2R	NON-CROSS	275-276	292-293	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	20306	ccl7	GeneOrGeneProduct	292	293	10	1:Association:2	L2R	NON-CROSS	275-276	294-295	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	17470	cd200	GeneOrGeneProduct	294	295	10	1:Association:2	L2R	NON-CROSS	275-276	296-297	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	NON-CROSS	275-276	298-299	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	-	cdbpd	GeneOrGeneProduct	298	299	10	1:Association:2	L2R	NON-CROSS	275-276	300-301	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	12631	cfl1	GeneOrGeneProduct	300	301	10	1:Association:2	L2R	NON-CROSS	275-276	302-303	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:Association:2	L2R	NON-CROSS	275-276	304-305	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:Association:2	L2R	NON-CROSS	275-276	306-307	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	14319	fth1	GeneOrGeneProduct	306	307	10	1:Association:2	L2R	NON-CROSS	275-276	308-309	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	15507	hspb1	GeneOrGeneProduct	308	309	10	1:Association:2	L2R	NON-CROSS	275-276	310-311	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:Association:2	L2R	NON-CROSS	275-276	312-313	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	17390	mmp2	GeneOrGeneProduct	312	313	10	1:Association:2	L2R	NON-CROSS	275-276	314-315	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	17918	myo5a	GeneOrGeneProduct	314	315	10	1:Association:2	L2R	NON-CROSS	275-276	316-317	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:Association:2	L2R	NON-CROSS	275-276	318-319	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	18503	pax1	GeneOrGeneProduct	318	319	10	1:Association:2	L2R	NON-CROSS	275-276	320-321	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	18793	plaur	GeneOrGeneProduct	320	321	10	1:Association:2	L2R	NON-CROSS	275-276	322-323	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	268373	ppia	GeneOrGeneProduct	322	323	10	1:Association:2	L2R	NON-CROSS	275-276	324-325	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:Association:2	L2R	NON-CROSS	275-276	326-327	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:Association:2	L2R	NON-CROSS	275-276	328-329	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	20194	s100a10	GeneOrGeneProduct	328	329	10	1:Association:2	L2R	NON-CROSS	275-276	330-331	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	20465	sim2	GeneOrGeneProduct	330	331	10	1:Association:2	L2R	NON-CROSS	275-276	333-334	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:Association:2	L2R	CROSS	393-395	452-453	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:Association:2	R2L	CROSS	452-453	406-407	11845	arf6	GeneOrGeneProduct	406	407	13	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	1:Association:2	R2L	CROSS	452-453	408-409	13426	dcnt1	GeneOrGeneProduct	408	409	13	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	1:Association:2	L2R	NON-CROSS	452-453	454-456	14062	PAR1|PAR1|PAR1|PAR - 1|PAR1|PAR1|PAR1|PAR1|PAR1	GeneOrGeneProduct	163:190:208:237:275:452:477:490:494	164:191:209:240:276:453:478:491:495	5:6:7:8:10:14:14:15:15	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	CROSS	171-172	290-291	14063	PAR2	GeneOrGeneProduct	171	172	5	12010	b2m	GeneOrGeneProduct	290	291	10	1:NR:2	L2R	CROSS	171-172	292-293	14063	PAR2	GeneOrGeneProduct	171	172	5	20306	ccl7	GeneOrGeneProduct	292	293	10	1:NR:2	L2R	CROSS	171-172	294-295	14063	PAR2	GeneOrGeneProduct	171	172	5	17470	cd200	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	171-172	296-297	14063	PAR2	GeneOrGeneProduct	171	172	5	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	CROSS	171-172	298-299	14063	PAR2	GeneOrGeneProduct	171	172	5	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	CROSS	171-172	300-301	14063	PAR2	GeneOrGeneProduct	171	172	5	12631	cfl1	GeneOrGeneProduct	300	301	10	1:Association:2	R2L	CROSS	302-303	171-172	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	14063	PAR2	GeneOrGeneProduct	171	172	5	1:NR:2	L2R	CROSS	171-172	304-305	14063	PAR2	GeneOrGeneProduct	171	172	5	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	CROSS	171-172	306-307	14063	PAR2	GeneOrGeneProduct	171	172	5	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	CROSS	171-172	308-309	14063	PAR2	GeneOrGeneProduct	171	172	5	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	CROSS	171-172	310-311	14063	PAR2	GeneOrGeneProduct	171	172	5	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	CROSS	171-172	312-313	14063	PAR2	GeneOrGeneProduct	171	172	5	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	CROSS	171-172	314-315	14063	PAR2	GeneOrGeneProduct	171	172	5	17918	myo5a	GeneOrGeneProduct	314	315	10	1:Association:2	R2L	CROSS	316-317	171-172	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	14063	PAR2	GeneOrGeneProduct	171	172	5	1:NR:2	L2R	CROSS	171-172	318-319	14063	PAR2	GeneOrGeneProduct	171	172	5	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	CROSS	171-172	320-321	14063	PAR2	GeneOrGeneProduct	171	172	5	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	CROSS	171-172	322-323	14063	PAR2	GeneOrGeneProduct	171	172	5	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	CROSS	171-172	324-325	14063	PAR2	GeneOrGeneProduct	171	172	5	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	CROSS	171-172	326-327	14063	PAR2	GeneOrGeneProduct	171	172	5	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	CROSS	171-172	328-329	14063	PAR2	GeneOrGeneProduct	171	172	5	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	CROSS	171-172	330-331	14063	PAR2	GeneOrGeneProduct	171	172	5	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	CROSS	171-172	333-334	14063	PAR2	GeneOrGeneProduct	171	172	5	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:Association:2	L2R	CROSS	171-172	393-395	14063	PAR2	GeneOrGeneProduct	171	172	5	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:Association:2	R2L	CROSS	406-407	171-172	11845	arf6	GeneOrGeneProduct	406	407	13	14063	PAR2	GeneOrGeneProduct	171	172	5	1:Association:2	R2L	CROSS	408-409	171-172	13426	dcnt1	GeneOrGeneProduct	408	409	13	14063	PAR2	GeneOrGeneProduct	171	172	5	1:NR:2	L2R	CROSS	171-172	454-456	14063	PAR2	GeneOrGeneProduct	171	172	5	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	290-291	292-293	12010	b2m	GeneOrGeneProduct	290	291	10	20306	ccl7	GeneOrGeneProduct	292	293	10	1:NR:2	L2R	NON-CROSS	290-291	294-295	12010	b2m	GeneOrGeneProduct	290	291	10	17470	cd200	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	NON-CROSS	290-291	296-297	12010	b2m	GeneOrGeneProduct	290	291	10	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	NON-CROSS	290-291	298-299	12010	b2m	GeneOrGeneProduct	290	291	10	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	NON-CROSS	290-291	300-301	12010	b2m	GeneOrGeneProduct	290	291	10	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	NON-CROSS	290-291	302-303	12010	b2m	GeneOrGeneProduct	290	291	10	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	NON-CROSS	290-291	304-305	12010	b2m	GeneOrGeneProduct	290	291	10	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	NON-CROSS	290-291	306-307	12010	b2m	GeneOrGeneProduct	290	291	10	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	NON-CROSS	290-291	308-309	12010	b2m	GeneOrGeneProduct	290	291	10	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	290-291	310-311	12010	b2m	GeneOrGeneProduct	290	291	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	290-291	312-313	12010	b2m	GeneOrGeneProduct	290	291	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	290-291	314-315	12010	b2m	GeneOrGeneProduct	290	291	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	290-291	316-317	12010	b2m	GeneOrGeneProduct	290	291	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	290-291	318-319	12010	b2m	GeneOrGeneProduct	290	291	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	290-291	320-321	12010	b2m	GeneOrGeneProduct	290	291	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	290-291	322-323	12010	b2m	GeneOrGeneProduct	290	291	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	290-291	324-325	12010	b2m	GeneOrGeneProduct	290	291	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	290-291	326-327	12010	b2m	GeneOrGeneProduct	290	291	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	290-291	328-329	12010	b2m	GeneOrGeneProduct	290	291	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	290-291	330-331	12010	b2m	GeneOrGeneProduct	290	291	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	290-291	333-334	12010	b2m	GeneOrGeneProduct	290	291	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	290-291	393-395	12010	b2m	GeneOrGeneProduct	290	291	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	290-291	406-407	12010	b2m	GeneOrGeneProduct	290	291	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	290-291	408-409	12010	b2m	GeneOrGeneProduct	290	291	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	290-291	454-456	12010	b2m	GeneOrGeneProduct	290	291	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	292-293	294-295	20306	ccl7	GeneOrGeneProduct	292	293	10	17470	cd200	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	NON-CROSS	292-293	296-297	20306	ccl7	GeneOrGeneProduct	292	293	10	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	NON-CROSS	292-293	298-299	20306	ccl7	GeneOrGeneProduct	292	293	10	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	NON-CROSS	292-293	300-301	20306	ccl7	GeneOrGeneProduct	292	293	10	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	NON-CROSS	292-293	302-303	20306	ccl7	GeneOrGeneProduct	292	293	10	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	NON-CROSS	292-293	304-305	20306	ccl7	GeneOrGeneProduct	292	293	10	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	NON-CROSS	292-293	306-307	20306	ccl7	GeneOrGeneProduct	292	293	10	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	NON-CROSS	292-293	308-309	20306	ccl7	GeneOrGeneProduct	292	293	10	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	292-293	310-311	20306	ccl7	GeneOrGeneProduct	292	293	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	292-293	312-313	20306	ccl7	GeneOrGeneProduct	292	293	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	292-293	314-315	20306	ccl7	GeneOrGeneProduct	292	293	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	292-293	316-317	20306	ccl7	GeneOrGeneProduct	292	293	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	292-293	318-319	20306	ccl7	GeneOrGeneProduct	292	293	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	292-293	320-321	20306	ccl7	GeneOrGeneProduct	292	293	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	292-293	322-323	20306	ccl7	GeneOrGeneProduct	292	293	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	292-293	324-325	20306	ccl7	GeneOrGeneProduct	292	293	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	292-293	326-327	20306	ccl7	GeneOrGeneProduct	292	293	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	292-293	328-329	20306	ccl7	GeneOrGeneProduct	292	293	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	292-293	330-331	20306	ccl7	GeneOrGeneProduct	292	293	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	292-293	333-334	20306	ccl7	GeneOrGeneProduct	292	293	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	292-293	393-395	20306	ccl7	GeneOrGeneProduct	292	293	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	292-293	406-407	20306	ccl7	GeneOrGeneProduct	292	293	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	292-293	408-409	20306	ccl7	GeneOrGeneProduct	292	293	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	292-293	454-456	20306	ccl7	GeneOrGeneProduct	292	293	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	294-295	296-297	17470	cd200	GeneOrGeneProduct	294	295	10	12512	cd63	GeneOrGeneProduct	296	297	10	1:NR:2	L2R	NON-CROSS	294-295	298-299	17470	cd200	GeneOrGeneProduct	294	295	10	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	NON-CROSS	294-295	300-301	17470	cd200	GeneOrGeneProduct	294	295	10	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	NON-CROSS	294-295	302-303	17470	cd200	GeneOrGeneProduct	294	295	10	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	NON-CROSS	294-295	304-305	17470	cd200	GeneOrGeneProduct	294	295	10	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	NON-CROSS	294-295	306-307	17470	cd200	GeneOrGeneProduct	294	295	10	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	NON-CROSS	294-295	308-309	17470	cd200	GeneOrGeneProduct	294	295	10	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	294-295	310-311	17470	cd200	GeneOrGeneProduct	294	295	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	294-295	312-313	17470	cd200	GeneOrGeneProduct	294	295	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	294-295	314-315	17470	cd200	GeneOrGeneProduct	294	295	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	294-295	316-317	17470	cd200	GeneOrGeneProduct	294	295	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	294-295	318-319	17470	cd200	GeneOrGeneProduct	294	295	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	294-295	320-321	17470	cd200	GeneOrGeneProduct	294	295	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	294-295	322-323	17470	cd200	GeneOrGeneProduct	294	295	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	294-295	324-325	17470	cd200	GeneOrGeneProduct	294	295	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	294-295	326-327	17470	cd200	GeneOrGeneProduct	294	295	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	294-295	328-329	17470	cd200	GeneOrGeneProduct	294	295	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	294-295	330-331	17470	cd200	GeneOrGeneProduct	294	295	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	294-295	333-334	17470	cd200	GeneOrGeneProduct	294	295	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	294-295	393-395	17470	cd200	GeneOrGeneProduct	294	295	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	294-295	406-407	17470	cd200	GeneOrGeneProduct	294	295	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	294-295	408-409	17470	cd200	GeneOrGeneProduct	294	295	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	294-295	454-456	17470	cd200	GeneOrGeneProduct	294	295	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	296-297	298-299	12512	cd63	GeneOrGeneProduct	296	297	10	-	cdbpd	GeneOrGeneProduct	298	299	10	1:NR:2	L2R	NON-CROSS	296-297	300-301	12512	cd63	GeneOrGeneProduct	296	297	10	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	NON-CROSS	296-297	302-303	12512	cd63	GeneOrGeneProduct	296	297	10	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	NON-CROSS	296-297	304-305	12512	cd63	GeneOrGeneProduct	296	297	10	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	NON-CROSS	296-297	306-307	12512	cd63	GeneOrGeneProduct	296	297	10	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	NON-CROSS	296-297	308-309	12512	cd63	GeneOrGeneProduct	296	297	10	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	296-297	310-311	12512	cd63	GeneOrGeneProduct	296	297	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	296-297	312-313	12512	cd63	GeneOrGeneProduct	296	297	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	296-297	314-315	12512	cd63	GeneOrGeneProduct	296	297	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	296-297	316-317	12512	cd63	GeneOrGeneProduct	296	297	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	296-297	318-319	12512	cd63	GeneOrGeneProduct	296	297	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	296-297	320-321	12512	cd63	GeneOrGeneProduct	296	297	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	296-297	322-323	12512	cd63	GeneOrGeneProduct	296	297	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	296-297	324-325	12512	cd63	GeneOrGeneProduct	296	297	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	296-297	326-327	12512	cd63	GeneOrGeneProduct	296	297	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	296-297	328-329	12512	cd63	GeneOrGeneProduct	296	297	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	296-297	330-331	12512	cd63	GeneOrGeneProduct	296	297	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	296-297	333-334	12512	cd63	GeneOrGeneProduct	296	297	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	296-297	393-395	12512	cd63	GeneOrGeneProduct	296	297	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	296-297	406-407	12512	cd63	GeneOrGeneProduct	296	297	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	296-297	408-409	12512	cd63	GeneOrGeneProduct	296	297	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	296-297	454-456	12512	cd63	GeneOrGeneProduct	296	297	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	298-299	300-301	-	cdbpd	GeneOrGeneProduct	298	299	10	12631	cfl1	GeneOrGeneProduct	300	301	10	1:NR:2	L2R	NON-CROSS	298-299	302-303	-	cdbpd	GeneOrGeneProduct	298	299	10	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	NON-CROSS	298-299	304-305	-	cdbpd	GeneOrGeneProduct	298	299	10	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	NON-CROSS	298-299	306-307	-	cdbpd	GeneOrGeneProduct	298	299	10	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	NON-CROSS	298-299	308-309	-	cdbpd	GeneOrGeneProduct	298	299	10	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	298-299	310-311	-	cdbpd	GeneOrGeneProduct	298	299	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	298-299	312-313	-	cdbpd	GeneOrGeneProduct	298	299	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	298-299	314-315	-	cdbpd	GeneOrGeneProduct	298	299	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	298-299	316-317	-	cdbpd	GeneOrGeneProduct	298	299	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	298-299	318-319	-	cdbpd	GeneOrGeneProduct	298	299	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	298-299	320-321	-	cdbpd	GeneOrGeneProduct	298	299	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	298-299	322-323	-	cdbpd	GeneOrGeneProduct	298	299	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	298-299	324-325	-	cdbpd	GeneOrGeneProduct	298	299	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	298-299	326-327	-	cdbpd	GeneOrGeneProduct	298	299	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	298-299	328-329	-	cdbpd	GeneOrGeneProduct	298	299	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	298-299	330-331	-	cdbpd	GeneOrGeneProduct	298	299	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	298-299	333-334	-	cdbpd	GeneOrGeneProduct	298	299	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	298-299	393-395	-	cdbpd	GeneOrGeneProduct	298	299	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	298-299	406-407	-	cdbpd	GeneOrGeneProduct	298	299	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	298-299	408-409	-	cdbpd	GeneOrGeneProduct	298	299	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	298-299	454-456	-	cdbpd	GeneOrGeneProduct	298	299	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	300-301	302-303	12631	cfl1	GeneOrGeneProduct	300	301	10	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	1:NR:2	L2R	NON-CROSS	300-301	304-305	12631	cfl1	GeneOrGeneProduct	300	301	10	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	NON-CROSS	300-301	306-307	12631	cfl1	GeneOrGeneProduct	300	301	10	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	NON-CROSS	300-301	308-309	12631	cfl1	GeneOrGeneProduct	300	301	10	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	300-301	310-311	12631	cfl1	GeneOrGeneProduct	300	301	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	300-301	312-313	12631	cfl1	GeneOrGeneProduct	300	301	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	300-301	314-315	12631	cfl1	GeneOrGeneProduct	300	301	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	300-301	316-317	12631	cfl1	GeneOrGeneProduct	300	301	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	300-301	318-319	12631	cfl1	GeneOrGeneProduct	300	301	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	300-301	320-321	12631	cfl1	GeneOrGeneProduct	300	301	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	300-301	322-323	12631	cfl1	GeneOrGeneProduct	300	301	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	300-301	324-325	12631	cfl1	GeneOrGeneProduct	300	301	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	300-301	326-327	12631	cfl1	GeneOrGeneProduct	300	301	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	300-301	328-329	12631	cfl1	GeneOrGeneProduct	300	301	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	300-301	330-331	12631	cfl1	GeneOrGeneProduct	300	301	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	300-301	333-334	12631	cfl1	GeneOrGeneProduct	300	301	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	300-301	393-395	12631	cfl1	GeneOrGeneProduct	300	301	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	300-301	406-407	12631	cfl1	GeneOrGeneProduct	300	301	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	300-301	408-409	12631	cfl1	GeneOrGeneProduct	300	301	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	300-301	454-456	12631	cfl1	GeneOrGeneProduct	300	301	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	302-303	304-305	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	14225	fkbp1a	GeneOrGeneProduct	304	305	10	1:NR:2	L2R	NON-CROSS	302-303	306-307	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	NON-CROSS	302-303	308-309	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	302-303	310-311	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	302-303	312-313	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	302-303	314-315	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	374-375	376-377	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	302-303	318-319	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	302-303	320-321	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	302-303	322-323	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	302-303	324-325	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	302-303	326-327	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	302-303	328-329	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	302-303	330-331	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	302-303	333-334	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:Association:2	L2R	NON-CROSS	374-375	393-395	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	374-375	406-407	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	374-375	408-409	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	374-375	454-456	19252	dusp1|dusp1	GeneOrGeneProduct	302:374	303:375	10:12	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	304-305	306-307	14225	fkbp1a	GeneOrGeneProduct	304	305	10	14319	fth1	GeneOrGeneProduct	306	307	10	1:NR:2	L2R	NON-CROSS	304-305	308-309	14225	fkbp1a	GeneOrGeneProduct	304	305	10	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	304-305	310-311	14225	fkbp1a	GeneOrGeneProduct	304	305	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	304-305	312-313	14225	fkbp1a	GeneOrGeneProduct	304	305	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	304-305	314-315	14225	fkbp1a	GeneOrGeneProduct	304	305	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	304-305	316-317	14225	fkbp1a	GeneOrGeneProduct	304	305	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	304-305	318-319	14225	fkbp1a	GeneOrGeneProduct	304	305	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	304-305	320-321	14225	fkbp1a	GeneOrGeneProduct	304	305	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	304-305	322-323	14225	fkbp1a	GeneOrGeneProduct	304	305	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	304-305	324-325	14225	fkbp1a	GeneOrGeneProduct	304	305	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	304-305	326-327	14225	fkbp1a	GeneOrGeneProduct	304	305	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	304-305	328-329	14225	fkbp1a	GeneOrGeneProduct	304	305	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	304-305	330-331	14225	fkbp1a	GeneOrGeneProduct	304	305	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	304-305	333-334	14225	fkbp1a	GeneOrGeneProduct	304	305	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	304-305	393-395	14225	fkbp1a	GeneOrGeneProduct	304	305	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	304-305	406-407	14225	fkbp1a	GeneOrGeneProduct	304	305	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	304-305	408-409	14225	fkbp1a	GeneOrGeneProduct	304	305	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	304-305	454-456	14225	fkbp1a	GeneOrGeneProduct	304	305	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	306-307	308-309	14319	fth1	GeneOrGeneProduct	306	307	10	15507	hspb1	GeneOrGeneProduct	308	309	10	1:NR:2	L2R	NON-CROSS	306-307	310-311	14319	fth1	GeneOrGeneProduct	306	307	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	306-307	312-313	14319	fth1	GeneOrGeneProduct	306	307	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	306-307	314-315	14319	fth1	GeneOrGeneProduct	306	307	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	306-307	316-317	14319	fth1	GeneOrGeneProduct	306	307	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	306-307	318-319	14319	fth1	GeneOrGeneProduct	306	307	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	306-307	320-321	14319	fth1	GeneOrGeneProduct	306	307	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	306-307	322-323	14319	fth1	GeneOrGeneProduct	306	307	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	306-307	324-325	14319	fth1	GeneOrGeneProduct	306	307	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	306-307	326-327	14319	fth1	GeneOrGeneProduct	306	307	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	306-307	328-329	14319	fth1	GeneOrGeneProduct	306	307	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	306-307	330-331	14319	fth1	GeneOrGeneProduct	306	307	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	306-307	333-334	14319	fth1	GeneOrGeneProduct	306	307	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	306-307	393-395	14319	fth1	GeneOrGeneProduct	306	307	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	306-307	406-407	14319	fth1	GeneOrGeneProduct	306	307	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	306-307	408-409	14319	fth1	GeneOrGeneProduct	306	307	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	306-307	454-456	14319	fth1	GeneOrGeneProduct	306	307	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	308-309	310-311	15507	hspb1	GeneOrGeneProduct	308	309	10	17357	marcksl1	GeneOrGeneProduct	310	311	10	1:NR:2	L2R	NON-CROSS	308-309	312-313	15507	hspb1	GeneOrGeneProduct	308	309	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	308-309	314-315	15507	hspb1	GeneOrGeneProduct	308	309	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	308-309	316-317	15507	hspb1	GeneOrGeneProduct	308	309	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	308-309	318-319	15507	hspb1	GeneOrGeneProduct	308	309	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	308-309	320-321	15507	hspb1	GeneOrGeneProduct	308	309	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	308-309	322-323	15507	hspb1	GeneOrGeneProduct	308	309	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	308-309	324-325	15507	hspb1	GeneOrGeneProduct	308	309	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	308-309	326-327	15507	hspb1	GeneOrGeneProduct	308	309	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	308-309	328-329	15507	hspb1	GeneOrGeneProduct	308	309	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	308-309	330-331	15507	hspb1	GeneOrGeneProduct	308	309	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	308-309	333-334	15507	hspb1	GeneOrGeneProduct	308	309	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	308-309	393-395	15507	hspb1	GeneOrGeneProduct	308	309	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	308-309	406-407	15507	hspb1	GeneOrGeneProduct	308	309	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	308-309	408-409	15507	hspb1	GeneOrGeneProduct	308	309	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	308-309	454-456	15507	hspb1	GeneOrGeneProduct	308	309	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	310-311	312-313	17357	marcksl1	GeneOrGeneProduct	310	311	10	17390	mmp2	GeneOrGeneProduct	312	313	10	1:NR:2	L2R	NON-CROSS	310-311	314-315	17357	marcksl1	GeneOrGeneProduct	310	311	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	310-311	316-317	17357	marcksl1	GeneOrGeneProduct	310	311	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	310-311	318-319	17357	marcksl1	GeneOrGeneProduct	310	311	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	310-311	320-321	17357	marcksl1	GeneOrGeneProduct	310	311	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	310-311	322-323	17357	marcksl1	GeneOrGeneProduct	310	311	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	310-311	324-325	17357	marcksl1	GeneOrGeneProduct	310	311	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	310-311	326-327	17357	marcksl1	GeneOrGeneProduct	310	311	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	310-311	328-329	17357	marcksl1	GeneOrGeneProduct	310	311	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	310-311	330-331	17357	marcksl1	GeneOrGeneProduct	310	311	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	310-311	333-334	17357	marcksl1	GeneOrGeneProduct	310	311	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	310-311	393-395	17357	marcksl1	GeneOrGeneProduct	310	311	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	310-311	406-407	17357	marcksl1	GeneOrGeneProduct	310	311	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	310-311	408-409	17357	marcksl1	GeneOrGeneProduct	310	311	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	310-311	454-456	17357	marcksl1	GeneOrGeneProduct	310	311	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	312-313	314-315	17390	mmp2	GeneOrGeneProduct	312	313	10	17918	myo5a	GeneOrGeneProduct	314	315	10	1:NR:2	L2R	NON-CROSS	312-313	316-317	17390	mmp2	GeneOrGeneProduct	312	313	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	312-313	318-319	17390	mmp2	GeneOrGeneProduct	312	313	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	312-313	320-321	17390	mmp2	GeneOrGeneProduct	312	313	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	312-313	322-323	17390	mmp2	GeneOrGeneProduct	312	313	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	312-313	324-325	17390	mmp2	GeneOrGeneProduct	312	313	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	312-313	326-327	17390	mmp2	GeneOrGeneProduct	312	313	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	312-313	328-329	17390	mmp2	GeneOrGeneProduct	312	313	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	312-313	330-331	17390	mmp2	GeneOrGeneProduct	312	313	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	312-313	333-334	17390	mmp2	GeneOrGeneProduct	312	313	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	312-313	393-395	17390	mmp2	GeneOrGeneProduct	312	313	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	312-313	406-407	17390	mmp2	GeneOrGeneProduct	312	313	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	312-313	408-409	17390	mmp2	GeneOrGeneProduct	312	313	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	312-313	454-456	17390	mmp2	GeneOrGeneProduct	312	313	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	314-315	316-317	17918	myo5a	GeneOrGeneProduct	314	315	10	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	1:NR:2	L2R	NON-CROSS	314-315	318-319	17918	myo5a	GeneOrGeneProduct	314	315	10	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	314-315	320-321	17918	myo5a	GeneOrGeneProduct	314	315	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	314-315	322-323	17918	myo5a	GeneOrGeneProduct	314	315	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	314-315	324-325	17918	myo5a	GeneOrGeneProduct	314	315	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	314-315	326-327	17918	myo5a	GeneOrGeneProduct	314	315	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	314-315	328-329	17918	myo5a	GeneOrGeneProduct	314	315	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	314-315	330-331	17918	myo5a	GeneOrGeneProduct	314	315	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	314-315	333-334	17918	myo5a	GeneOrGeneProduct	314	315	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	314-315	393-395	17918	myo5a	GeneOrGeneProduct	314	315	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	314-315	406-407	17918	myo5a	GeneOrGeneProduct	314	315	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	314-315	408-409	17918	myo5a	GeneOrGeneProduct	314	315	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	314-315	454-456	17918	myo5a	GeneOrGeneProduct	314	315	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	316-317	318-319	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	18503	pax1	GeneOrGeneProduct	318	319	10	1:NR:2	L2R	NON-CROSS	316-317	320-321	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	316-317	322-323	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	316-317	324-325	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	316-317	326-327	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	316-317	328-329	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	316-317	330-331	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	316-317	333-334	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:Association:2	L2R	NON-CROSS	376-377	393-395	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	376-377	406-407	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	376-377	408-409	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	376-377	454-456	18035	nfkbia|nfkbia	GeneOrGeneProduct	316:376	317:377	10:12	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	318-319	320-321	18503	pax1	GeneOrGeneProduct	318	319	10	18793	plaur	GeneOrGeneProduct	320	321	10	1:NR:2	L2R	NON-CROSS	318-319	322-323	18503	pax1	GeneOrGeneProduct	318	319	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	318-319	324-325	18503	pax1	GeneOrGeneProduct	318	319	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	318-319	326-327	18503	pax1	GeneOrGeneProduct	318	319	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	318-319	328-329	18503	pax1	GeneOrGeneProduct	318	319	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	318-319	330-331	18503	pax1	GeneOrGeneProduct	318	319	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	318-319	333-334	18503	pax1	GeneOrGeneProduct	318	319	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	318-319	393-395	18503	pax1	GeneOrGeneProduct	318	319	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	318-319	406-407	18503	pax1	GeneOrGeneProduct	318	319	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	318-319	408-409	18503	pax1	GeneOrGeneProduct	318	319	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	318-319	454-456	18503	pax1	GeneOrGeneProduct	318	319	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	320-321	322-323	18793	plaur	GeneOrGeneProduct	320	321	10	268373	ppia	GeneOrGeneProduct	322	323	10	1:NR:2	L2R	NON-CROSS	320-321	324-325	18793	plaur	GeneOrGeneProduct	320	321	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	320-321	326-327	18793	plaur	GeneOrGeneProduct	320	321	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	320-321	328-329	18793	plaur	GeneOrGeneProduct	320	321	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	320-321	330-331	18793	plaur	GeneOrGeneProduct	320	321	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	320-321	333-334	18793	plaur	GeneOrGeneProduct	320	321	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	320-321	393-395	18793	plaur	GeneOrGeneProduct	320	321	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	320-321	406-407	18793	plaur	GeneOrGeneProduct	320	321	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	320-321	408-409	18793	plaur	GeneOrGeneProduct	320	321	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	320-321	454-456	18793	plaur	GeneOrGeneProduct	320	321	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	322-323	324-325	268373	ppia	GeneOrGeneProduct	322	323	10	19246	ptpn1	GeneOrGeneProduct	324	325	10	1:NR:2	L2R	NON-CROSS	322-323	326-327	268373	ppia	GeneOrGeneProduct	322	323	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	322-323	328-329	268373	ppia	GeneOrGeneProduct	322	323	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	322-323	330-331	268373	ppia	GeneOrGeneProduct	322	323	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	322-323	333-334	268373	ppia	GeneOrGeneProduct	322	323	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	322-323	393-395	268373	ppia	GeneOrGeneProduct	322	323	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	322-323	406-407	268373	ppia	GeneOrGeneProduct	322	323	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	322-323	408-409	268373	ppia	GeneOrGeneProduct	322	323	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	322-323	454-456	268373	ppia	GeneOrGeneProduct	322	323	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	324-325	326-327	19246	ptpn1	GeneOrGeneProduct	324	325	10	19265	ptprcap	GeneOrGeneProduct	326	327	10	1:NR:2	L2R	NON-CROSS	324-325	328-329	19246	ptpn1	GeneOrGeneProduct	324	325	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	324-325	330-331	19246	ptpn1	GeneOrGeneProduct	324	325	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	324-325	333-334	19246	ptpn1	GeneOrGeneProduct	324	325	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	324-325	393-395	19246	ptpn1	GeneOrGeneProduct	324	325	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	324-325	406-407	19246	ptpn1	GeneOrGeneProduct	324	325	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	324-325	408-409	19246	ptpn1	GeneOrGeneProduct	324	325	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	324-325	454-456	19246	ptpn1	GeneOrGeneProduct	324	325	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	326-327	328-329	19265	ptprcap	GeneOrGeneProduct	326	327	10	20194	s100a10	GeneOrGeneProduct	328	329	10	1:NR:2	L2R	NON-CROSS	326-327	330-331	19265	ptprcap	GeneOrGeneProduct	326	327	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	326-327	333-334	19265	ptprcap	GeneOrGeneProduct	326	327	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	326-327	393-395	19265	ptprcap	GeneOrGeneProduct	326	327	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	326-327	406-407	19265	ptprcap	GeneOrGeneProduct	326	327	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	326-327	408-409	19265	ptprcap	GeneOrGeneProduct	326	327	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	326-327	454-456	19265	ptprcap	GeneOrGeneProduct	326	327	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	328-329	330-331	20194	s100a10	GeneOrGeneProduct	328	329	10	20465	sim2	GeneOrGeneProduct	330	331	10	1:NR:2	L2R	NON-CROSS	328-329	333-334	20194	s100a10	GeneOrGeneProduct	328	329	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	328-329	393-395	20194	s100a10	GeneOrGeneProduct	328	329	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	328-329	406-407	20194	s100a10	GeneOrGeneProduct	328	329	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	328-329	408-409	20194	s100a10	GeneOrGeneProduct	328	329	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	328-329	454-456	20194	s100a10	GeneOrGeneProduct	328	329	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	330-331	333-334	20465	sim2	GeneOrGeneProduct	330	331	10	21928	tnfaip2	GeneOrGeneProduct	333	334	10	1:NR:2	L2R	CROSS	330-331	393-395	20465	sim2	GeneOrGeneProduct	330	331	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	330-331	406-407	20465	sim2	GeneOrGeneProduct	330	331	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	330-331	408-409	20465	sim2	GeneOrGeneProduct	330	331	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	330-331	454-456	20465	sim2	GeneOrGeneProduct	330	331	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	CROSS	333-334	393-395	21928	tnfaip2	GeneOrGeneProduct	333	334	10	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	1:NR:2	L2R	CROSS	333-334	406-407	21928	tnfaip2	GeneOrGeneProduct	333	334	10	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	333-334	408-409	21928	tnfaip2	GeneOrGeneProduct	333	334	10	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	333-334	454-456	21928	tnfaip2	GeneOrGeneProduct	333	334	10	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	CROSS	393-395	406-407	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	11845	arf6	GeneOrGeneProduct	406	407	13	1:NR:2	L2R	CROSS	393-395	408-409	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	393-395	454-456	26416	p38 MAPK	GeneOrGeneProduct	393	395	12	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	NON-CROSS	406-407	408-409	11845	arf6	GeneOrGeneProduct	406	407	13	13426	dcnt1	GeneOrGeneProduct	408	409	13	1:NR:2	L2R	CROSS	406-407	454-456	11845	arf6	GeneOrGeneProduct	406	407	13	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15	1:NR:2	L2R	CROSS	408-409	454-456	13426	dcnt1	GeneOrGeneProduct	408	409	13	D003556	bladder inflammation|cystitis	DiseaseOrPhenotypicFeature	454:502	456:503	14:15
17445520	Caffeine challenge test in panic disorder and depression with panic attacks .|Our aim was to observe if patients with panic disorder ( PD ) and patients with major depression with panic attacks ( MDP ) ( Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition criteria ) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test .|We randomly selected 29 patients with PD , 27 with MDP , 25 with major depression without panic attacks ( MD ) , and 28 healthy volunteers .|The patients had no psychotropic drug for at least a 4 - week period .|In a randomized double - blind experiment performed in 2 occasions 7 days apart , 480 mg caffeine and a caffeine - free ( placebo ) solution were administered in a coffee form and anxiety scales were applied before and after each test .|A total of 58 . 6 % ( n = 17 ) of patients with PD , 44 . 4 % ( n = 12 ) of patients with MDP , 12 . 0 % ( n = 3 ) of patients with MD , and 7 . 1 % ( n = 2 ) of control subjects had a panic attack after the 480 - mg caffeine challenge test ( chi ( 2 ) ( 3 ) = 16 . 22 , P = . 001 ) .|The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers .|No panic attack was observed after the caffeine - free solution intake .|The patients with MD had a lower heart rate response to the test than all the other groups ( 2 - way analysis of variance , group by time interaction with Greenhouse - Geisser correction : F ( 3 , 762 ) = 2 . 85 , P = . 026 ) .|Our data suggest that there is an association between panic attacks , no matter if associated with PD or MDP , and hyperreactivity to an oral caffeine challenge test .	1:Association:2	R2L	NON-CROSS	4-6	0-1	D016584	panic disorder|panic attacks|panic disorder|PD|panic attacks|panic attacks|PD|panic attacks|PD|panic attack|PD|panic attack|panic attacks|PD	DiseaseOrPhenotypicFeature	4:9:20:23:31:58:73:84:169:214:246:264:338:346	6:11:22:24:33:60:74:86:170:216:247:266:340:347	0:0:1:1:1:1:2:2:5:5:6:7:9:9	D002110	Caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	0:63:127:130:221:253:270:355	1:64:128:131:222:254:271:356	0:1:4:4:5:6:7:9	1:NR:2	L2R	NON-CROSS	0-1	7-8	D002110	Caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	0:63:127:130:221:253:270:355	1:64:128:131:222:254:271:356	0:1:4:4:5:6:7:9	D003866	depression	DiseaseOrPhenotypicFeature	7	8	0	1:Association:2	R2L	NON-CROSS	258-259	253-254	D003865	major depression|major depression|MD|MD|MD|MD	DiseaseOrPhenotypicFeature	28:81:87:197:258:279	30:83:88:198:259:280	1:2:2:5:6:8	D002110	Caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	0:63:127:130:221:253:270:355	1:64:128:131:222:254:271:356	0:1:4:4:5:6:7:9	1:NR:2	L2R	NON-CROSS	248-249	253-254	D002110	Caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	0:63:127:130:221:253:270:355	1:64:128:131:222:254:271:356	0:1:4:4:5:6:7:9	D003865,D016584	MDP|MDP|MDP|MDP|MDP	DiseaseOrPhenotypicFeature	34:77:183:248:348	35:78:184:249:349	1:2:5:6:9	1:NR:2	L2R	NON-CROSS	42-44	63-64	D002110	Caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	0:63:127:130:221:253:270:355	1:64:128:131:222:254:271:356	0:1:4:4:5:6:7:9	D001523	Mental Disorders	DiseaseOrPhenotypicFeature	42	44	1	1:NR:2	L2R	NON-CROSS	130-131	144-145	D002110	Caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	0:63:127:130:221:253:270:355	1:64:128:131:222:254:271:356	0:1:4:4:5:6:7:9	D001008	anxiety	DiseaseOrPhenotypicFeature	144	145	4
23651211	Upregulation of T - cell factor - 4 isoform - responsive target genes in hepatocellular carcinoma .|BACKGROUND : The Wnt / beta - catenin signalling pathway regulates genes involved in cell proliferation , survival , migration and invasion through regulation by T - cell factor ( TCF ) - 4 transcription factor proteins .|However , the role of TCF - 4 isoforms generated by alternative splicing events in hepatocellular carcinoma ( HCC ) is unknown .|AIM : Here , we investigated TCF - 4 isoforms ( TCF - 4J and K ) - responsive target genes that are important in hepatic oncogenesis and tumour development .|METHODS : Gene expression microarray was performed on HCC cells overexpressing TCF - 4J and K isoforms .|Expression level of selected target genes was evaluated and correlations were made between their expression level and that of TCF - 4 isoform in 47 pairs of human HCC tumours .|RESULTS : Comparison by gene expression microarray revealed that 447 genes were upregulated and 343 downregulated more than 2 . 0 - fold in TCF - 4J compared with TCF - 4K expressing cells .|We validated expression of 18 selected target genes involved in Wnt / beta - catenin , insulin / IGF - 1 / IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues .|It was observed that 13 genes ( CLDN2 , STK17B , SPP1 , AXIN2 , WISP2 , MMP7 , IRS1 , ANXA1 , CAMK2N1 , ASPH , GPR56 , CD24 and JAG1 ) activated by TCF - 4J isoform in HCC cells , were also upregulated in HCC tumours compared with adjacent peritumour tissue ; more importantly , 10 genes exhibited a significant correlation with the TCF - 4J expression level in tumour .|CONCLUSION : TCF - 4 isoforms ( TCF - 4J and K ) activated different downstream target genes in HCC .|The biological consequence of TCF - 4J isoform expression was upregulation of genes associated with tripartite Wnt / beta - catenin , insulin / IGF - 1 / IRS1 and Notch signal transduction pathway activation , which contribute to the pathogenesis of HCC .	1:Association:2	L2R	NON-CROSS	267-270	272-273	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Positive_Correlation:2	L2R	NON-CROSS	331-334	343-344	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	1:Positive_Correlation:2	L2R	NON-CROSS	331-334	345-348	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	1:Association:2	L2R	NON-CROSS	298-301	304-305	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	1:Positive_Correlation:2	L2R	NON-CROSS	331-334	349-350	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	1:Positive_Correlation:2	L2R	NON-CROSS	331-334	351-354	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	1:Positive_Correlation:2	L2R	NON-CROSS	251-252	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	1:Positive_Correlation:2	L2R	NON-CROSS	331-334	357-358	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	1:Positive_Correlation:2	L2R	NON-CROSS	239-240	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	9075	CLDN2	GeneOrGeneProduct	239	240	8	1:Positive_Correlation:2	L2R	NON-CROSS	241-242	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	9262	STK17B	GeneOrGeneProduct	241	242	8	1:Positive_Correlation:2	L2R	NON-CROSS	243-244	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	6696	SPP1	GeneOrGeneProduct	243	244	8	1:Positive_Correlation:2	L2R	NON-CROSS	245-246	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:Positive_Correlation:2	L2R	NON-CROSS	247-248	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	8839	WISP2	GeneOrGeneProduct	247	248	8	1:Positive_Correlation:2	L2R	NON-CROSS	249-250	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	4316	MMP7	GeneOrGeneProduct	249	250	8	1:Positive_Correlation:2	L2R	NON-CROSS	253-254	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	301	ANXA1	GeneOrGeneProduct	253	254	8	1:Positive_Correlation:2	L2R	NON-CROSS	255-256	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:Positive_Correlation:2	L2R	NON-CROSS	257-258	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	444	ASPH	GeneOrGeneProduct	257	258	8	1:Positive_Correlation:2	L2R	NON-CROSS	259-260	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	9289	GPR56	GeneOrGeneProduct	259	260	8	1:Positive_Correlation:2	L2R	NON-CROSS	261-262	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	100133941	CD24	GeneOrGeneProduct	261	262	8	1:Positive_Correlation:2	L2R	NON-CROSS	263-264	267-270	6934	T - cell factor - 4|T - cell factor ( TCF ) - 4 transcription factor|TCF - 4|TCF - 4|TCF - 4J and K|TCF - 4J and K|TCF - 4|TCF - 4J|TCF - 4K|TCF - 4J|TCF - 4J|TCF - 4|TCF - 4J and K|TCF - 4J	GeneOrGeneProduct	2:42:60:84:89:120:146:182:187:267:298:308:313:331	8:53:63:87:94:125:149:185:190:270:301:311:318:334	0:1:2:3:3:4:5:6:6:8:8:9:9:10	182	JAG1	GeneOrGeneProduct	263	264	8	1:Association:2	R2L	NON-CROSS	20-21	14-16	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	22-25	14-16	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	225-226	209-210	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	225-226	211-214	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	225-226	215-216	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	225-226	217-218	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	239-240	225-226	9075	CLDN2	GeneOrGeneProduct	239	240	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	241-242	225-226	9262	STK17B	GeneOrGeneProduct	241	242	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	243-244	225-226	6696	SPP1	GeneOrGeneProduct	243	244	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	245-246	225-226	8313	AXIN2	GeneOrGeneProduct	245	246	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	247-248	225-226	8839	WISP2	GeneOrGeneProduct	247	248	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	272-273	249-250	4316	MMP7	GeneOrGeneProduct	249	250	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	272-273	253-254	301	ANXA1	GeneOrGeneProduct	253	254	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	272-273	255-256	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	272-273	257-258	444	ASPH	GeneOrGeneProduct	257	258	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	272-273	259-260	9289	GPR56	GeneOrGeneProduct	259	260	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	272-273	261-262	100133941	CD24	GeneOrGeneProduct	261	262	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	R2L	NON-CROSS	272-273	263-264	182	JAG1	GeneOrGeneProduct	263	264	8	D006528	hepatocellular carcinoma|hepatocellular carcinoma|HCC|hepatic oncogenesis|HCC|HCC tumours|HCCs|HCC|HCC tumours|HCC|HCC	DiseaseOrPhenotypicFeature	14:70:73:103:117:155:225:272:279:325:369	16:72:74:105:118:157:226:273:281:326:370	0:2:2:3:4:5:7:8:8:9:10	1:Association:2	L2R	NON-CROSS	20-21	22-25	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	1:NR:2	L2R	CROSS	304-305	343-344	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	1:NR:2	L2R	NON-CROSS	203-204	209-210	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	1:NR:2	L2R	NON-CROSS	203-204	211-214	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	1:NR:2	L2R	NON-CROSS	203-204	215-216	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	1:NR:2	L2R	NON-CROSS	203-204	217-218	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	1:NR:2	L2R	CROSS	203-204	239-240	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	9075	CLDN2	GeneOrGeneProduct	239	240	8	1:NR:2	L2R	CROSS	203-204	241-242	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	9262	STK17B	GeneOrGeneProduct	241	242	8	1:NR:2	L2R	CROSS	203-204	243-244	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	CROSS	203-204	245-246	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	CROSS	203-204	247-248	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	203-204	249-250	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	203-204	253-254	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	203-204	255-256	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	203-204	257-258	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	203-204	259-260	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	203-204	261-262	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	CROSS	203-204	263-264	7474	Wnt|Wnt|Wnt	GeneOrGeneProduct	20:203:343	21:204:344	1:7:10	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	CROSS	304-305	345-348	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	1:NR:2	L2R	NON-CROSS	205-208	209-210	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	1:NR:2	L2R	NON-CROSS	205-208	211-214	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	1:NR:2	L2R	NON-CROSS	205-208	215-216	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	1:NR:2	L2R	NON-CROSS	205-208	217-218	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	1:NR:2	L2R	CROSS	205-208	239-240	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	9075	CLDN2	GeneOrGeneProduct	239	240	8	1:NR:2	L2R	CROSS	205-208	241-242	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	9262	STK17B	GeneOrGeneProduct	241	242	8	1:NR:2	L2R	CROSS	205-208	243-244	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	CROSS	205-208	245-246	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	CROSS	205-208	247-248	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	205-208	249-250	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	205-208	253-254	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	205-208	255-256	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	205-208	257-258	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	205-208	259-260	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	205-208	261-262	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	CROSS	205-208	263-264	1499	beta - catenin|beta - catenin|beta - catenin	GeneOrGeneProduct	22:205:345	25:208:348	1:7:10	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	CROSS	304-305	349-350	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	1:NR:2	L2R	CROSS	304-305	351-354	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	1:NR:2	L2R	NON-CROSS	304-305	355-356	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	1:NR:2	L2R	CROSS	304-305	357-358	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	1:NR:2	L2R	NON-CROSS	239-240	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	9075	CLDN2	GeneOrGeneProduct	239	240	8	1:NR:2	L2R	NON-CROSS	241-242	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	9262	STK17B	GeneOrGeneProduct	241	242	8	1:NR:2	L2R	NON-CROSS	243-244	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	NON-CROSS	245-246	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	NON-CROSS	247-248	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	NON-CROSS	249-250	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	253-254	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	255-256	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	257-258	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	259-260	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	261-262	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	263-264	304-305	D009369	tumour|tumour	DiseaseOrPhenotypicFeature	106:304	107:305	3:8	182	JAG1	GeneOrGeneProduct	263	264	8	1:Association:2	L2R	NON-CROSS	209-210	211-214	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	1:Association:2	L2R	NON-CROSS	209-210	215-216	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	1:NR:2	L2R	NON-CROSS	209-210	217-218	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	1:NR:2	L2R	CROSS	209-210	239-240	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	9075	CLDN2	GeneOrGeneProduct	239	240	8	1:NR:2	L2R	CROSS	209-210	241-242	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	9262	STK17B	GeneOrGeneProduct	241	242	8	1:NR:2	L2R	CROSS	209-210	243-244	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	CROSS	209-210	245-246	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	CROSS	209-210	247-248	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	209-210	249-250	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	209-210	253-254	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	209-210	255-256	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	209-210	257-258	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	209-210	259-260	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	209-210	261-262	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	CROSS	209-210	263-264	3630	insulin|insulin	GeneOrGeneProduct	209:349	210:350	7:10	182	JAG1	GeneOrGeneProduct	263	264	8	1:Association:2	L2R	NON-CROSS	211-214	215-216	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	1:NR:2	L2R	NON-CROSS	211-214	217-218	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	1:NR:2	L2R	CROSS	211-214	239-240	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	9075	CLDN2	GeneOrGeneProduct	239	240	8	1:NR:2	L2R	CROSS	211-214	241-242	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	9262	STK17B	GeneOrGeneProduct	241	242	8	1:NR:2	L2R	CROSS	211-214	243-244	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	CROSS	211-214	245-246	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	CROSS	211-214	247-248	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	211-214	249-250	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	211-214	253-254	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	211-214	255-256	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	211-214	257-258	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	211-214	259-260	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	211-214	261-262	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	CROSS	211-214	263-264	3479	IGF - 1|IGF - 1	GeneOrGeneProduct	211:351	214:354	7:10	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	215-216	217-218	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	1:NR:2	L2R	NON-CROSS	239-240	251-252	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	9075	CLDN2	GeneOrGeneProduct	239	240	8	1:NR:2	L2R	NON-CROSS	241-242	251-252	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	9262	STK17B	GeneOrGeneProduct	241	242	8	1:NR:2	L2R	NON-CROSS	243-244	251-252	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	NON-CROSS	245-246	251-252	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	NON-CROSS	247-248	251-252	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	NON-CROSS	249-250	251-252	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	251-252	253-254	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	251-252	255-256	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	251-252	257-258	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	251-252	259-260	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	251-252	261-262	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	251-252	263-264	3667	IRS1|IRS1|IRS1	GeneOrGeneProduct	215:251:355	216:252:356	7:8:10	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	CROSS	217-218	239-240	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	9075	CLDN2	GeneOrGeneProduct	239	240	8	1:NR:2	L2R	CROSS	217-218	241-242	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	9262	STK17B	GeneOrGeneProduct	241	242	8	1:NR:2	L2R	CROSS	217-218	243-244	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	CROSS	217-218	245-246	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	CROSS	217-218	247-248	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	217-218	249-250	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	217-218	253-254	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	217-218	255-256	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	217-218	257-258	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	217-218	259-260	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	217-218	261-262	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	CROSS	217-218	263-264	4851	Notch|Notch	GeneOrGeneProduct	217:357	218:358	7:10	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	239-240	241-242	9075	CLDN2	GeneOrGeneProduct	239	240	8	9262	STK17B	GeneOrGeneProduct	241	242	8	1:NR:2	L2R	NON-CROSS	239-240	243-244	9075	CLDN2	GeneOrGeneProduct	239	240	8	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	NON-CROSS	239-240	245-246	9075	CLDN2	GeneOrGeneProduct	239	240	8	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	NON-CROSS	239-240	247-248	9075	CLDN2	GeneOrGeneProduct	239	240	8	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	NON-CROSS	239-240	249-250	9075	CLDN2	GeneOrGeneProduct	239	240	8	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	239-240	253-254	9075	CLDN2	GeneOrGeneProduct	239	240	8	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	239-240	255-256	9075	CLDN2	GeneOrGeneProduct	239	240	8	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	239-240	257-258	9075	CLDN2	GeneOrGeneProduct	239	240	8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	239-240	259-260	9075	CLDN2	GeneOrGeneProduct	239	240	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	239-240	261-262	9075	CLDN2	GeneOrGeneProduct	239	240	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	239-240	263-264	9075	CLDN2	GeneOrGeneProduct	239	240	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	241-242	243-244	9262	STK17B	GeneOrGeneProduct	241	242	8	6696	SPP1	GeneOrGeneProduct	243	244	8	1:NR:2	L2R	NON-CROSS	241-242	245-246	9262	STK17B	GeneOrGeneProduct	241	242	8	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	NON-CROSS	241-242	247-248	9262	STK17B	GeneOrGeneProduct	241	242	8	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	NON-CROSS	241-242	249-250	9262	STK17B	GeneOrGeneProduct	241	242	8	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	241-242	253-254	9262	STK17B	GeneOrGeneProduct	241	242	8	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	241-242	255-256	9262	STK17B	GeneOrGeneProduct	241	242	8	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	241-242	257-258	9262	STK17B	GeneOrGeneProduct	241	242	8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	241-242	259-260	9262	STK17B	GeneOrGeneProduct	241	242	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	241-242	261-262	9262	STK17B	GeneOrGeneProduct	241	242	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	241-242	263-264	9262	STK17B	GeneOrGeneProduct	241	242	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	243-244	245-246	6696	SPP1	GeneOrGeneProduct	243	244	8	8313	AXIN2	GeneOrGeneProduct	245	246	8	1:NR:2	L2R	NON-CROSS	243-244	247-248	6696	SPP1	GeneOrGeneProduct	243	244	8	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	NON-CROSS	243-244	249-250	6696	SPP1	GeneOrGeneProduct	243	244	8	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	243-244	253-254	6696	SPP1	GeneOrGeneProduct	243	244	8	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	243-244	255-256	6696	SPP1	GeneOrGeneProduct	243	244	8	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	243-244	257-258	6696	SPP1	GeneOrGeneProduct	243	244	8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	243-244	259-260	6696	SPP1	GeneOrGeneProduct	243	244	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	243-244	261-262	6696	SPP1	GeneOrGeneProduct	243	244	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	243-244	263-264	6696	SPP1	GeneOrGeneProduct	243	244	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	245-246	247-248	8313	AXIN2	GeneOrGeneProduct	245	246	8	8839	WISP2	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	NON-CROSS	245-246	249-250	8313	AXIN2	GeneOrGeneProduct	245	246	8	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	245-246	253-254	8313	AXIN2	GeneOrGeneProduct	245	246	8	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	245-246	255-256	8313	AXIN2	GeneOrGeneProduct	245	246	8	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	245-246	257-258	8313	AXIN2	GeneOrGeneProduct	245	246	8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	245-246	259-260	8313	AXIN2	GeneOrGeneProduct	245	246	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	245-246	261-262	8313	AXIN2	GeneOrGeneProduct	245	246	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	245-246	263-264	8313	AXIN2	GeneOrGeneProduct	245	246	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	247-248	249-250	8839	WISP2	GeneOrGeneProduct	247	248	8	4316	MMP7	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	247-248	253-254	8839	WISP2	GeneOrGeneProduct	247	248	8	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	247-248	255-256	8839	WISP2	GeneOrGeneProduct	247	248	8	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	247-248	257-258	8839	WISP2	GeneOrGeneProduct	247	248	8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	247-248	259-260	8839	WISP2	GeneOrGeneProduct	247	248	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	247-248	261-262	8839	WISP2	GeneOrGeneProduct	247	248	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	247-248	263-264	8839	WISP2	GeneOrGeneProduct	247	248	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	249-250	253-254	4316	MMP7	GeneOrGeneProduct	249	250	8	301	ANXA1	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	249-250	255-256	4316	MMP7	GeneOrGeneProduct	249	250	8	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	249-250	257-258	4316	MMP7	GeneOrGeneProduct	249	250	8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	249-250	259-260	4316	MMP7	GeneOrGeneProduct	249	250	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	249-250	261-262	4316	MMP7	GeneOrGeneProduct	249	250	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	249-250	263-264	4316	MMP7	GeneOrGeneProduct	249	250	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	253-254	255-256	301	ANXA1	GeneOrGeneProduct	253	254	8	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	253-254	257-258	301	ANXA1	GeneOrGeneProduct	253	254	8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	253-254	259-260	301	ANXA1	GeneOrGeneProduct	253	254	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	253-254	261-262	301	ANXA1	GeneOrGeneProduct	253	254	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	253-254	263-264	301	ANXA1	GeneOrGeneProduct	253	254	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	255-256	257-258	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	444	ASPH	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	255-256	259-260	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	255-256	261-262	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	255-256	263-264	55450	CAMK2N1	GeneOrGeneProduct	255	256	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	257-258	259-260	444	ASPH	GeneOrGeneProduct	257	258	8	9289	GPR56	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	257-258	261-262	444	ASPH	GeneOrGeneProduct	257	258	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	257-258	263-264	444	ASPH	GeneOrGeneProduct	257	258	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	259-260	261-262	9289	GPR56	GeneOrGeneProduct	259	260	8	100133941	CD24	GeneOrGeneProduct	261	262	8	1:NR:2	L2R	NON-CROSS	259-260	263-264	9289	GPR56	GeneOrGeneProduct	259	260	8	182	JAG1	GeneOrGeneProduct	263	264	8	1:NR:2	L2R	NON-CROSS	261-262	263-264	100133941	CD24	GeneOrGeneProduct	261	262	8	182	JAG1	GeneOrGeneProduct	263	264	8
15991002	Nicotine antagonizes caffeine - but not pentylenetetrazole - induced anxiogenic effect in mice .|RATIONALE : Nicotine and caffeine are widely consumed licit psychoactive drugs worldwide .|Epidemiological studies showed that they were generally used concurrently .|Although some studies in experimental animals indicate clear pharmacological interactions between them , no studies have shown a specific interaction on anxiety responses .|OBJECTIVES : The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug , pentylenetetrazole , in mice .|The elevated plus - maze ( EPM ) test was used to evaluate the effects of drugs on anxiety .|METHODS : Adult male Swiss Webster mice ( 25 - 32 g ) were given nicotine ( 0 . 05 - 0 . 25 mg / kg s . c . ) or saline 10 min before caffeine ( 70 mg / kg i . p . ) or pentylenetetrazole ( 15 and 30 mg / kg i . p . ) injections .|After 15 min , mice were evaluated for their open - and closed - arm time and entries on the EPM for a 10 - min session .|Locomotor activity was recorded for individual groups by using the same treatment protocol with the EPM test .|RESULTS : Nicotine ( 0 . 05 - 0 . 25 mg / kg ) itself did not produce any significant effect in the EPM test , whereas caffeine ( 70 mg / kg ) and pentylenetetrazole ( 30 mg / kg ) produced an anxiogenic effect , apparent with decreases in open - arm time and entry .|Nicotine ( 0 . 25 mg / kg ) pretreatment blocked the caffeine - but not pentylenetetrazole - induced anxiety .|Administration of each drug and their combinations did not produce any effect on locomotor activity .|CONCLUSIONS : Our results suggest that the antagonistic effect of nicotine on caffeine - induced anxiety is specific to caffeine , instead of a non - specific anxiolytic effect .|Thus , it may extend the current findings on the interaction between nicotine and caffeine .	1:Negative_Correlation:2	L2R	NON-CROSS	0-1	2-3	D009538	Nicotine|Nicotine|nicotine|nicotine|Nicotine|Nicotine|nicotine|nicotine	ChemicalEntity	0:16:70:121:218:275:322:354	1:17:71:122:219:276:323:355	0:1:4:6:9:10:12:13	D002110	caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	2:18:75:143:244:287:324:331:356	3:19:76:144:245:288:325:332:357	0:1:4:6:9:10:12:12:13	1:NR:2	L2R	NON-CROSS	0-1	6-7	D009538	Nicotine|Nicotine|nicotine|nicotine|Nicotine|Nicotine|nicotine|nicotine	ChemicalEntity	0:16:70:121:218:275:322:354	1:17:71:122:219:276:323:355	0:1:4:6:9:10:12:13	D010433	pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole	ChemicalEntity	6:81:155:252:291	7:82:156:253:292	0:4:6:9:10	1:Negative_Correlation:2	L2R	NON-CROSS	70-71	72-73	D009538	Nicotine|Nicotine|nicotine|nicotine|Nicotine|Nicotine|nicotine|nicotine	ChemicalEntity	0:16:70:121:218:275:322:354	1:17:71:122:219:276:323:355	0:1:4:6:9:10:12:13	D001008	anxiogenic effect|anxiety|anxiety|anxiety|anxiogenic effect|anxiety|anxiety	DiseaseOrPhenotypicFeature	9:58:72:104:261:294:327	11:59:73:105:263:295:328	0:3:4:5:9:10:12	1:NR:2	L2R	NON-CROSS	16-17	23-25	D009538	Nicotine|Nicotine|nicotine|nicotine|Nicotine|Nicotine|nicotine|nicotine	ChemicalEntity	0:16:70:121:218:275:322:354	1:17:71:122:219:276:323:355	0:1:4:6:9:10:12:13	D011619	psychoactive drugs	ChemicalEntity	23	25	1	1:NR:2	L2R	NON-CROSS	70-71	78-80	D009538	Nicotine|Nicotine|nicotine|nicotine|Nicotine|Nicotine|nicotine|nicotine	ChemicalEntity	0:16:70:121:218:275:322:354	1:17:71:122:219:276:323:355	0:1:4:6:9:10:12:13	D014151	anxiogenic drug	ChemicalEntity	78	80	4	1:NR:2	L2R	NON-CROSS	2-3	6-7	D002110	caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	2:18:75:143:244:287:324:331:356	3:19:76:144:245:288:325:332:357	0:1:4:6:9:10:12:12:13	D010433	pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole	ChemicalEntity	6:81:155:252:291	7:82:156:253:292	0:4:6:9:10	1:Positive_Correlation:2	L2R	NON-CROSS	72-73	75-76	D002110	caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	2:18:75:143:244:287:324:331:356	3:19:76:144:245:288:325:332:357	0:1:4:6:9:10:12:12:13	D001008	anxiogenic effect|anxiety|anxiety|anxiety|anxiogenic effect|anxiety|anxiety	DiseaseOrPhenotypicFeature	9:58:72:104:261:294:327	11:59:73:105:263:295:328	0:3:4:5:9:10:12	1:NR:2	L2R	NON-CROSS	18-19	23-25	D002110	caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	2:18:75:143:244:287:324:331:356	3:19:76:144:245:288:325:332:357	0:1:4:6:9:10:12:12:13	D011619	psychoactive drugs	ChemicalEntity	23	25	1	1:NR:2	L2R	NON-CROSS	75-76	78-80	D002110	caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine|caffeine	ChemicalEntity	2:18:75:143:244:287:324:331:356	3:19:76:144:245:288:325:332:357	0:1:4:6:9:10:12:12:13	D014151	anxiogenic drug	ChemicalEntity	78	80	4	1:Positive_Correlation:2	L2R	NON-CROSS	6-7	9-11	D010433	pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole	ChemicalEntity	6:81:155:252:291	7:82:156:253:292	0:4:6:9:10	D001008	anxiogenic effect|anxiety|anxiety|anxiety|anxiogenic effect|anxiety|anxiety	DiseaseOrPhenotypicFeature	9:58:72:104:261:294:327	11:59:73:105:263:295:328	0:3:4:5:9:10:12	1:NR:2	L2R	CROSS	6-7	23-25	D010433	pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole	ChemicalEntity	6:81:155:252:291	7:82:156:253:292	0:4:6:9:10	D011619	psychoactive drugs	ChemicalEntity	23	25	1	1:NR:2	L2R	NON-CROSS	78-80	81-82	D010433	pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole|pentylenetetrazole	ChemicalEntity	6:81:155:252:291	7:82:156:253:292	0:4:6:9:10	D014151	anxiogenic drug	ChemicalEntity	78	80	4	1:NR:2	L2R	CROSS	9-11	23-25	D001008	anxiogenic effect|anxiety|anxiety|anxiety|anxiogenic effect|anxiety|anxiety	DiseaseOrPhenotypicFeature	9:58:72:104:261:294:327	11:59:73:105:263:295:328	0:3:4:5:9:10:12	D011619	psychoactive drugs	ChemicalEntity	23	25	1	1:NR:2	L2R	NON-CROSS	72-73	78-80	D001008	anxiogenic effect|anxiety|anxiety|anxiety|anxiogenic effect|anxiety|anxiety	DiseaseOrPhenotypicFeature	9:58:72:104:261:294:327	11:59:73:105:263:295:328	0:3:4:5:9:10:12	D014151	anxiogenic drug	ChemicalEntity	78	80	4	1:NR:2	L2R	CROSS	23-25	78-80	D011619	psychoactive drugs	ChemicalEntity	23	25	1	D014151	anxiogenic drug	ChemicalEntity	78	80	4
16565833	The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin - induced cardiotoxicity in mice .|PURPOSE : Despite its well - known cardiotoxicity , the anthracyclin doxorubicin ( DOX ) continues to be an effective and widely used chemotherapeutic agent .|DOX - induced cardiac damage presumably results from the formation of free radicals by DOX .|Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system .|The semisynthetic flavonoid monohydroxyethylrutoside ( monoHER ) showed cardioprotection against DOX - induced cardiotoxicity through its radical scavenging and iron chelating properties .|Because of the relatively short final half - life of monoHER ( about 30 min ) , it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER .|Therefore , the aim of the present study was to investigate this possible effect .|METHODS : Six groups of 6 BALB / c mice were treated with saline , DOX alone or DOX ( 4 mg / kg i . v . ) preceded by monoHER ( 500 mg / kg i . p . ) with an interval of 10 , 30 , 60 or 120 min .|After a 6 - week treatment period and additional observation for 2 weeks , the mice were sacrificed .|Their cardiac tissues were processed for light microscopy , after which cardiomyocyte damage was evaluated according to Billingham ( in Cancer Treat Rep 62 ( 6 ) : 865 - 872 , 1978 ) .|Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group ( P < 0 . 001 ) .|RESULTS : The number of damaged cardiomyocytes was 9 . 6 - fold ( 95 % CI 4 . 4 - 21 . 0 ) higher in mice treated with DOX alone than that in animals of the control group .|The ratio of aberrant cardiomyocytes in mice treated with DOX preceded by monoHER and those in mice treated with saline ranged from 1 . 6 to 2 . 8 ( mean 2 . 2 , 95 % CI 1 . 2 - 4 . 1 , P = 0 . 019 ) .|The mean protective effect by adding monoHER before DOX led to a significant 4 . 4 - fold reduction ( P < 0 . 001 , 95 % CI 2 . 3 - 8 . 2 ) of abnormal cardiomyocytes .|This protective effect did not depend on the time interval between monoHER and DOX administration ( P = 0 . 345 ) .|CONCLUSION : The results indicate that in an outpatient clinical setting monoHER may be administered shortly before DOX .	1:Negative_Correlation:2	L2R	NON-CROSS	7-8	9-10	C522803	monoHER|monohydroxyethylrutoside|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER	ChemicalEntity	7:88:90:118:133:145:193:351:398:444:467	8:89:91:119:134:146:194:352:399:445:468	0:4:4:5:5:5:7:12:13:14:15	D004317	doxorubicin|doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	ChemicalEntity	9:15:33:35:48:62:95:135:177:180:277:328:348:400:446:473	10:16:34:36:49:63:96:136:178:181:278:329:349:401:447:474	0:0:1:1:2:2:4:5:7:7:10:11:12:13:14:15	1:Negative_Correlation:2	L2R	NON-CROSS	90-91	98-99	C522803	monoHER|monohydroxyethylrutoside|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER	ChemicalEntity	7:88:90:118:133:145:193:351:398:444:467	8:89:91:119:134:146:194:352:399:445:468	0:4:4:5:5:5:7:12:13:14:15	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	18:29:98	19:30:99	0:1:4	1:NR:2	L2R	CROSS	7-8	32-33	C522803	monoHER|monohydroxyethylrutoside|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER	ChemicalEntity	7:88:90:118:133:145:193:351:398:444:467	8:89:91:119:134:146:194:352:399:445:468	0:4:4:5:5:5:7:12:13:14:15	D018943	anthracyclin	ChemicalEntity	32	33	1	1:NR:2	L2R	CROSS	51-53	88-89	C522803	monoHER|monohydroxyethylrutoside|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER	ChemicalEntity	7:88:90:118:133:145:193:351:398:444:467	8:89:91:119:134:146:194:352:399:445:468	0:4:4:5:5:5:7:12:13:14:15	D006331	cardiac damage|cardiac damage	DiseaseOrPhenotypicFeature	51:281	53:283	2:10	1:NR:2	L2R	CROSS	65-66	88-89	C522803	monoHER|monohydroxyethylrutoside|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER	ChemicalEntity	7:88:90:118:133:145:193:351:398:444:467	8:89:91:119:134:146:194:352:399:445:468	0:4:4:5:5:5:7:12:13:14:15	D010100	oxygen	ChemicalEntity	65	66	3	1:NR:2	L2R	NON-CROSS	87-88	88-89	C522803	monoHER|monohydroxyethylrutoside|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER	ChemicalEntity	7:88:90:118:133:145:193:351:398:444:467	8:89:91:119:134:146:194:352:399:445:468	0:4:4:5:5:5:7:12:13:14:15	D005419	flavonoid	ChemicalEntity	87	88	4	1:Association:2	L2R	NON-CROSS	90-91	104-105	C522803	monoHER|monohydroxyethylrutoside|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER	ChemicalEntity	7:88:90:118:133:145:193:351:398:444:467	8:89:91:119:134:146:194:352:399:445:468	0:4:4:5:5:5:7:12:13:14:15	D007501	iron	ChemicalEntity	104	105	4	1:NR:2	L2R	CROSS	193-194	247-249	C522803	monoHER|monohydroxyethylrutoside|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER|monoHER	ChemicalEntity	7:88:90:118:133:145:193:351:398:444:467	8:89:91:119:134:146:194:352:399:445:468	0:4:4:5:5:5:7:12:13:14:15	D009202	cardiomyocyte damage	DiseaseOrPhenotypicFeature	247	249	9	1:Positive_Correlation:2	L2R	NON-CROSS	15-16	18-19	D004317	doxorubicin|doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	ChemicalEntity	9:15:33:35:48:62:95:135:177:180:277:328:348:400:446:473	10:16:34:36:49:63:96:136:178:181:278:329:349:401:447:474	0:0:1:1:2:2:4:5:7:7:10:11:12:13:14:15	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	18:29:98	19:30:99	0:1:4	1:NR:2	L2R	NON-CROSS	32-33	33-34	D004317	doxorubicin|doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	ChemicalEntity	9:15:33:35:48:62:95:135:177:180:277:328:348:400:446:473	10:16:34:36:49:63:96:136:178:181:278:329:349:401:447:474	0:0:1:1:2:2:4:5:7:7:10:11:12:13:14:15	D018943	anthracyclin	ChemicalEntity	32	33	1	1:Positive_Correlation:2	L2R	NON-CROSS	48-49	51-53	D004317	doxorubicin|doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	ChemicalEntity	9:15:33:35:48:62:95:135:177:180:277:328:348:400:446:473	10:16:34:36:49:63:96:136:178:181:278:329:349:401:447:474	0:0:1:1:2:2:4:5:7:7:10:11:12:13:14:15	D006331	cardiac damage|cardiac damage	DiseaseOrPhenotypicFeature	51:281	53:283	2:10	1:NR:2	L2R	CROSS	62-63	65-66	D004317	doxorubicin|doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	ChemicalEntity	9:15:33:35:48:62:95:135:177:180:277:328:348:400:446:473	10:16:34:36:49:63:96:136:178:181:278:329:349:401:447:474	0:0:1:1:2:2:4:5:7:7:10:11:12:13:14:15	D010100	oxygen	ChemicalEntity	65	66	3	1:Negative_Correlation:2	R2L	NON-CROSS	95-96	87-88	D005419	flavonoid	ChemicalEntity	87	88	4	D004317	doxorubicin|doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	ChemicalEntity	9:15:33:35:48:62:95:135:177:180:277:328:348:400:446:473	10:16:34:36:49:63:96:136:178:181:278:329:349:401:447:474	0:0:1:1:2:2:4:5:7:7:10:11:12:13:14:15	1:Association:2	R2L	NON-CROSS	104-105	95-96	D007501	iron	ChemicalEntity	104	105	4	D004317	doxorubicin|doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	ChemicalEntity	9:15:33:35:48:62:95:135:177:180:277:328:348:400:446:473	10:16:34:36:49:63:96:136:178:181:278:329:349:401:447:474	0:0:1:1:2:2:4:5:7:7:10:11:12:13:14:15	1:NR:2	L2R	CROSS	247-249	277-278	D004317	doxorubicin|doxorubicin|doxorubicin|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX|DOX	ChemicalEntity	9:15:33:35:48:62:95:135:177:180:277:328:348:400:446:473	10:16:34:36:49:63:96:136:178:181:278:329:349:401:447:474	0:0:1:1:2:2:4:5:7:7:10:11:12:13:14:15	D009202	cardiomyocyte damage	DiseaseOrPhenotypicFeature	247	249	9	1:NR:2	L2R	NON-CROSS	29-30	32-33	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	18:29:98	19:30:99	0:1:4	D018943	anthracyclin	ChemicalEntity	32	33	1	1:NR:2	L2R	CROSS	65-66	98-99	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	18:29:98	19:30:99	0:1:4	D010100	oxygen	ChemicalEntity	65	66	3	1:Negative_Correlation:2	R2L	NON-CROSS	98-99	87-88	D005419	flavonoid	ChemicalEntity	87	88	4	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	18:29:98	19:30:99	0:1:4	1:Association:2	R2L	NON-CROSS	104-105	98-99	D007501	iron	ChemicalEntity	104	105	4	D066126	cardiotoxicity|cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	18:29:98	19:30:99	0:1:4	1:NR:2	L2R	CROSS	32-33	51-53	D018943	anthracyclin	ChemicalEntity	32	33	1	D006331	cardiac damage|cardiac damage	DiseaseOrPhenotypicFeature	51:281	53:283	2:10	1:NR:2	L2R	CROSS	32-33	65-66	D018943	anthracyclin	ChemicalEntity	32	33	1	D010100	oxygen	ChemicalEntity	65	66	3	1:NR:2	L2R	CROSS	32-33	87-88	D018943	anthracyclin	ChemicalEntity	32	33	1	D005419	flavonoid	ChemicalEntity	87	88	4	1:NR:2	L2R	CROSS	32-33	104-105	D018943	anthracyclin	ChemicalEntity	32	33	1	D007501	iron	ChemicalEntity	104	105	4	1:NR:2	L2R	CROSS	32-33	247-249	D018943	anthracyclin	ChemicalEntity	32	33	1	D009202	cardiomyocyte damage	DiseaseOrPhenotypicFeature	247	249	9	1:NR:2	L2R	CROSS	51-53	65-66	D006331	cardiac damage|cardiac damage	DiseaseOrPhenotypicFeature	51:281	53:283	2:10	D010100	oxygen	ChemicalEntity	65	66	3	1:NR:2	L2R	CROSS	51-53	87-88	D006331	cardiac damage|cardiac damage	DiseaseOrPhenotypicFeature	51:281	53:283	2:10	D005419	flavonoid	ChemicalEntity	87	88	4	1:NR:2	L2R	CROSS	51-53	104-105	D006331	cardiac damage|cardiac damage	DiseaseOrPhenotypicFeature	51:281	53:283	2:10	D007501	iron	ChemicalEntity	104	105	4	1:NR:2	L2R	CROSS	65-66	87-88	D010100	oxygen	ChemicalEntity	65	66	3	D005419	flavonoid	ChemicalEntity	87	88	4	1:NR:2	L2R	CROSS	65-66	104-105	D010100	oxygen	ChemicalEntity	65	66	3	D007501	iron	ChemicalEntity	104	105	4	1:NR:2	L2R	CROSS	65-66	247-249	D010100	oxygen	ChemicalEntity	65	66	3	D009202	cardiomyocyte damage	DiseaseOrPhenotypicFeature	247	249	9	1:NR:2	L2R	NON-CROSS	87-88	104-105	D005419	flavonoid	ChemicalEntity	87	88	4	D007501	iron	ChemicalEntity	104	105	4	1:NR:2	L2R	CROSS	87-88	247-249	D005419	flavonoid	ChemicalEntity	87	88	4	D009202	cardiomyocyte damage	DiseaseOrPhenotypicFeature	247	249	9	1:NR:2	L2R	CROSS	104-105	247-249	D007501	iron	ChemicalEntity	104	105	4	D009202	cardiomyocyte damage	DiseaseOrPhenotypicFeature	247	249	9
16680561	Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl .|OBJECTIVE : In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme ( CYP ) 2D6 .|The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity , using desipramine as a probe substrate , in healthy subjects .|METHODS : Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized , open - label , crossover study to receive a single oral dose of desipramine ( 50 mg ) on two separate occasions , once alone and once after multiple doses of cinacalcet ( 90 mg for 7 days ) .|Blood samples were obtained predose and up to 72 h postdose .|RESULTS : Fourteen subjects completed both treatment arms .|Relative to desipramine alone , mean AUC and C ( max ) of desipramine increased 3 . 6 - and 1 . 8 - fold when coadministered with cinacalcet .|The t ( 1 / 2 , z ) of desipramine was longer when desipramine was coadministered with cinacalcet ( 21 . 0 versus 43 . 3 hs ) .|The t ( max ) was similar between the regimens .|Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and headache ) have been reported for patients treated with either desipramine or cinacalcet .|CONCLUSION : This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6 .|These data suggest that during concomitant treatment with cinacalcet , dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6 .	1:Cotreatment:2	L2R	NON-CROSS	221-222	223-224	D003891	desipramine HCl|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine	ChemicalEntity	2:49:89:139:150:177:181:216:221:249	4:50:90:140:151:178:182:217:222:250	0:2:3:6:6:7:7:9:9:9	C476217	cinacalcet HCl|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet	ChemicalEntity	7:18:43:107:165:185:223:251:259:275	9:19:44:108:166:186:224:252:260:276	0:1:2:3:6:7:9:9:10:11	1:NR:2	L2R	NON-CROSS	45-46	49-50	D003891	desipramine HCl|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine	ChemicalEntity	2:49:89:139:150:177:181:216:221:249	4:50:90:140:151:178:182:217:222:250	0:2:3:6:6:7:7:9:9:9	1565	cytochrome P450 isoenzyme ( CYP ) 2D6|CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	24:45:67:265:294	31:46:68:266:295	1:2:3:10:11	1:Positive_Correlation:2	L2R	NON-CROSS	237-238	249-250	D003891	desipramine HCl|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine	ChemicalEntity	2:49:89:139:150:177:181:216:221:249	4:50:90:140:151:178:182:217:222:250	0:2:3:6:6:7:7:9:9:9	D009325	nausea	DiseaseOrPhenotypicFeature	237	238	9	1:Positive_Correlation:2	L2R	NON-CROSS	239-240	249-250	D003891	desipramine HCl|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine|desipramine	ChemicalEntity	2:49:89:139:150:177:181:216:221:249	4:50:90:140:151:178:182:217:222:250	0:2:3:6:6:7:7:9:9:9	D006261	headache	DiseaseOrPhenotypicFeature	239	240	9	1:Negative_Correlation:2	L2R	NON-CROSS	43-44	45-46	C476217	cinacalcet HCl|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet	ChemicalEntity	7:18:43:107:165:185:223:251:259:275	9:19:44:108:166:186:224:252:260:276	0:1:2:3:6:7:9:9:10:11	1565	cytochrome P450 isoenzyme ( CYP ) 2D6|CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	24:45:67:265:294	31:46:68:266:295	1:2:3:10:11	1:Positive_Correlation:2	L2R	NON-CROSS	223-224	237-238	C476217	cinacalcet HCl|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet	ChemicalEntity	7:18:43:107:165:185:223:251:259:275	9:19:44:108:166:186:224:252:260:276	0:1:2:3:6:7:9:9:10:11	D009325	nausea	DiseaseOrPhenotypicFeature	237	238	9	1:Positive_Correlation:2	L2R	NON-CROSS	239-240	251-252	C476217	cinacalcet HCl|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet|cinacalcet	ChemicalEntity	7:18:43:107:165:185:223:251:259:275	9:19:44:108:166:186:224:252:260:276	0:1:2:3:6:7:9:9:10:11	D006261	headache	DiseaseOrPhenotypicFeature	239	240	9	1:NR:2	L2R	CROSS	237-238	265-266	1565	cytochrome P450 isoenzyme ( CYP ) 2D6|CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	24:45:67:265:294	31:46:68:266:295	1:2:3:10:11	D009325	nausea	DiseaseOrPhenotypicFeature	237	238	9	1:NR:2	L2R	CROSS	239-240	265-266	1565	cytochrome P450 isoenzyme ( CYP ) 2D6|CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	24:45:67:265:294	31:46:68:266:295	1:2:3:10:11	D006261	headache	DiseaseOrPhenotypicFeature	239	240	9
16867021	Antipsychotic - like profile of thioperamide , a selective H3 - receptor antagonist in mice .|Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia .|The present study was designed to study the effect of histamine H ( 3 ) - receptor ligands on neuroleptic - induced catalepsy , apomorphine - induced climbing behavior and amphetamine - induced locomotor activities in mice .|Catalepsy was induced by haloperidol ( 2 mg / kg p . o . ) , while apomorphine ( 1 . 5 mg / kg s . c . ) and amphetamine ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .|( R ) - alpha - methylhistamine ( RAMH ) ( 5 microg i . c . v . ) and thioperamide ( THP ) ( 15 mg / kg i . p . ) , per se did not cause catalepsy .|Administration of THP ( 3 . 75 , 7 . 5 and 15 mg / kg i . p . ) 1 h prior to haloperidol resulted in a dose - dependent increase in the catalepsy times ( P < 0 . 05 ) .|However , pretreatment with RAMH significantly reversed such an effect of THP ( 15 mg / kg i . p . ) .|RAMH per se showed significant reduction in locomotor time , distance traveled and average speed but THP ( 15 mg / kg i . p . ) per se had no effect on these parameters .|On amphetamine - induced hyperactivity , THP ( 3 . 75 and 7 . 5 mg / kg i . p . ) reduced locomotor time , distance traveled and average speed ( P < 0 . 05 ) .|Pretreatment with RAMH ( 5 microg i . c . v . ) could partially reverse such effects of THP ( 3 . 75 mg / kg i . p . ) .|Climbing behavior induced by apomorphine was reduced in animals treated with THP .|Such an effect was , however , reversed in presence of RAMH .|THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing amphetamine - induced hyperactivity and reducing apomorphine - induced climbing in mice .|Such effects of THP were reversed by RAMH indicating the involvement of histamine H ( 3 ) - receptors .|Findings suggest a potential for H ( 3 ) - receptor antagonists in improving the refractory cases of schizophrenia .	1:NR:2	L2R	NON-CROSS	372-373	375-376	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	1:NR:2	L2R	NON-CROSS	44-51	53-54	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	1:NR:2	L2R	CROSS	32-33	53-54	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	32:438	33:439	1:14	1:Positive_Correlation:2	L2R	NON-CROSS	53-54	56-57	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	D002375	catalepsy|Catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	56:72:167:204:384	57:73:168:205:385	2:3:4:5:12	1:NR:2	L2R	NON-CROSS	53-54	58-59	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	1:NR:2	L2R	NON-CROSS	53-54	64-65	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	1:NR:2	L2R	NON-CROSS	375-376	381-382	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	1:NR:2	L2R	CROSS	370-371	375-376	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	1:NR:2	L2R	NON-CROSS	375-376	390-391	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	D006948	hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	277:390	278:391	8:12	1:NR:2	L2R	CROSS	375-376	425-432	D014150	Antipsychotic|neuroleptic|antipsychotic	ChemicalEntity	0:53:375	1:54:376	0:2:12	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	1:Negative_Correlation:2	R2L	NON-CROSS	9-12	5-6	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	1:NR:2	L2R	CROSS	5-6	32-33	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	32:438	33:439	1:14	1:Positive_Correlation:2	L2R	NON-CROSS	167-168	171-172	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	D002375	catalepsy|Catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	56:72:167:204:384	57:73:168:205:385	2:3:4:5:12	1:Negative_Correlation:2	L2R	NON-CROSS	350-351	357-358	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	1:Negative_Correlation:2	L2R	NON-CROSS	274-275	279-280	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	1:Positive_Correlation:2	L2R	NON-CROSS	372-373	381-382	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	1:Negative_Correlation:2	R2L	NON-CROSS	372-373	370-371	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	1:Negative_Correlation:2	L2R	NON-CROSS	277-278	279-280	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	D006948	hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	277:390	278:391	8:12	1:NR:2	L2R	CROSS	403-404	425-432	C052075	thioperamide|thioperamide|THP|THP|THP|THP|THP|THP|THP|THP|THP	ChemicalEntity	5:147:149:171:225:253:279:332:357:372:403	6:148:150:172:226:254:280:333:358:373:404	0:4:4:5:6:7:8:9:10:12:13	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	1:NR:2	L2R	CROSS	32-33	44-51	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	32:438	33:439	1:14	1:NR:2	L2R	NON-CROSS	44-51	56-57	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	D002375	catalepsy|Catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	56:72:167:204:384	57:73:168:205:385	2:3:4:5:12	1:NR:2	L2R	NON-CROSS	44-51	58-59	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	1:NR:2	L2R	NON-CROSS	44-51	64-65	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	1:NR:2	L2R	CROSS	44-51	76-77	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	1:Association:2	R2L	NON-CROSS	412-419	407-408	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	1:NR:2	L2R	CROSS	390-391	412-419	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	D006948	hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	277:390	278:391	8:12	1:NR:2	L2R	CROSS	412-419	425-432	99296	H3 - receptor|histamine H ( 3 ) - receptor|histamine H ( 3 ) - receptors	GeneOrGeneProduct	9:44:412	12:51:419	0:2:13	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	1:NR:2	L2R	CROSS	32-33	58-59	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	32:438	33:439	1:14	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	1:NR:2	L2R	CROSS	32-33	64-65	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	32:438	33:439	1:14	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	1:NR:2	L2R	CROSS	32-33	76-77	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	32:438	33:439	1:14	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	1:NR:2	L2R	CROSS	407-408	438-439	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	32:438	33:439	1:14	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	1:Negative_Correlation:2	R2L	NON-CROSS	438-439	425-432	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	32:438	33:439	1:14	1:NR:2	L2R	NON-CROSS	56-57	58-59	D002375	catalepsy|Catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	56:72:167:204:384	57:73:168:205:385	2:3:4:5:12	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	1:NR:2	L2R	NON-CROSS	384-385	387-388	D002375	catalepsy|Catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	56:72:167:204:384	57:73:168:205:385	2:3:4:5:12	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	1:Positive_Correlation:2	R2L	NON-CROSS	384-385	381-382	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	D002375	catalepsy|Catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	56:72:167:204:384	57:73:168:205:385	2:3:4:5:12	1:NR:2	L2R	NON-CROSS	204-205	218-219	D002375	catalepsy|Catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	56:72:167:204:384	57:73:168:205:385	2:3:4:5:12	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	1:NR:2	L2R	CROSS	384-385	425-432	D002375	catalepsy|Catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	56:72:167:204:384	57:73:168:205:385	2:3:4:5:12	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	1:NR:2	L2R	NON-CROSS	58-59	64-65	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	1:NR:2	L2R	NON-CROSS	381-382	393-394	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	1:NR:2	L2R	CROSS	393-394	407-408	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	1:NR:2	L2R	NON-CROSS	390-391	393-394	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	D006948	hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	277:390	278:391	8:12	1:NR:2	L2R	CROSS	393-394	425-432	D001058	apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	58:89:350:393	59:90:351:394	2:3:10:12	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	1:NR:2	L2R	NON-CROSS	381-382	387-388	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	1:NR:2	L2R	CROSS	370-371	387-388	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	1:Positive_Correlation:2	L2R	NON-CROSS	274-275	277-278	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	D006948	hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	277:390	278:391	8:12	1:NR:2	L2R	CROSS	387-388	425-432	D000661	amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	64:103:274:387	65:104:275:388	2:3:8:12	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	1:NR:2	L2R	CROSS	370-371	381-382	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	1:NR:2	L2R	NON-CROSS	381-382	390-391	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	D006948	hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	277:390	278:391	8:12	1:NR:2	L2R	CROSS	381-382	425-432	D006220	haloperidol|haloperidol|haloperidol	ChemicalEntity	76:194:381	77:195:382	3:5:12	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	1:NR:2	L2R	CROSS	390-391	407-408	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	D006948	hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	277:390	278:391	8:12	1:NR:2	L2R	CROSS	407-408	425-432	C069357	( R ) - alpha - methylhistamine|RAMH|RAMH|RAMH|RAMH|RAMH|RAMH	ChemicalEntity	126:134:218:237:315:370:407	133:135:219:238:316:371:408	4:4:6:7:9:11:13	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14	1:NR:2	L2R	CROSS	390-391	425-432	D006948	hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	277:390	278:391	8:12	D054828	H ( 3 ) - receptor antagonists	ChemicalEntity	425	432	14
17042884	Placebo - level incidence of extrapyramidal symptoms ( EPS ) with quetiapine in controlled studies of patients with bipolar mania .|OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with quetiapine in patients with bipolar mania .|METHODS : Data were analyzed from four similarly designed , randomized , double - blind , 3 - to 12 - week studies .|Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .|Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .|Extrapyramidal symptoms were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .|RESULTS : The incidence of EPS - related adverse events , including akathisia , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .|Similarly , EPS - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .|Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .|The incidence of akathisia was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .|Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .|Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .|No significant differences were observed between quetiapine and placebo on SAS and BARS scores .|Anticholinergic use was low and similar with quetiapine or placebo .|CONCLUSIONS : In bipolar mania , the incidence of EPS , including akathisia , with quetiapine therapy is similar to that with placebo .	1:NR:2	L2R	NON-CROSS	8-9	11-12	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	DiseaseOrPhenotypicFeature	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	ChemicalEntity	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	1:Positive_Correlation:2	L2R	NON-CROSS	224-225	232-233	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	DiseaseOrPhenotypicFeature	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	ChemicalEntity	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	1:Positive_Correlation:2	L2R	NON-CROSS	262-263	273-274	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	DiseaseOrPhenotypicFeature	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	D006220	haloperidol|haloperidol|Haloperidol	ChemicalEntity	95:273:415	96:274:416	3:8:11	1:NR:2	L2R	NON-CROSS	147-148	155-157	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	DiseaseOrPhenotypicFeature	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	ChemicalEntity	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	1:NR:2	L2R	NON-CROSS	182-184	191-192	D001480	extrapyramidal symptoms|EPS|extrapyramidal symptoms|EPS|Extrapyramidal symptoms|EPS|EPS|EPS|EPS|extrapyramidal syndrome|EPS	DiseaseOrPhenotypicFeature	5:8:25:28:155:191:224:262:302:456:507	7:9:27:29:157:192:225:263:303:458:508	0:0:1:1:5:6:7:8:8:11:14	D018680	anticholinergic drug|Anticholinergic	ChemicalEntity	182:487	184:488	5:13	1:NR:2	L2R	NON-CROSS	35-36	39-41	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	ChemicalEntity	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D001714	bipolar mania|bipolar mania|bipolar mania	DiseaseOrPhenotypicFeature	18:39:501	20:41:503	0:1:14	1:NR:2	L2R	NON-CROSS	32-33	35-36	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	ChemicalEntity	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	DiseaseOrPhenotypicFeature	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	1:NR:2	L2R	NON-CROSS	125-126	127-128	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	ChemicalEntity	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	ChemicalEntity	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	1:NR:2	L2R	NON-CROSS	95-96	105-106	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	ChemicalEntity	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D006220	haloperidol|haloperidol|Haloperidol	ChemicalEntity	95:273:415	96:274:416	3:8:11	1:NR:2	L2R	NON-CROSS	123-124	125-126	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	ChemicalEntity	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	ChemicalEntity	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	1:NR:2	L2R	NON-CROSS	487-488	494-495	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	ChemicalEntity	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D018680	anticholinergic drug|Anticholinergic	ChemicalEntity	182:487	184:488	5:13	1:NR:2	L2R	NON-CROSS	372-373	380-381	C069541	quetiapine|quetiapine|quetiapine|quetiapine|QTP|quetiapine|QTP|quetiapine|QTP|quetiapine|quetiapine|quetiapine|quetiapine|quetiapine	ChemicalEntity	11:35:69:105:125:204:230:313:332:380:470:478:494:513	12:36:70:106:126:205:231:314:333:381:471:479:495:514	0:1:3:4:4:6:7:9:9:10:11:12:13:14	D014202	tremor|tremor|tremor|tremor	DiseaseOrPhenotypicFeature	372:389:408:442	373:390:409:443	10:10:10:11	1:NR:2	L2R	CROSS	39-41	93-94	D001714	bipolar mania|bipolar mania|bipolar mania	DiseaseOrPhenotypicFeature	18:39:501	20:41:503	0:1:14	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	ChemicalEntity	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	1:NR:2	L2R	CROSS	39-41	95-96	D001714	bipolar mania|bipolar mania|bipolar mania	DiseaseOrPhenotypicFeature	18:39:501	20:41:503	0:1:14	D006220	haloperidol|haloperidol|Haloperidol	ChemicalEntity	95:273:415	96:274:416	3:8:11	1:NR:2	L2R	CROSS	39-41	123-124	D001714	bipolar mania|bipolar mania|bipolar mania	DiseaseOrPhenotypicFeature	18:39:501	20:41:503	0:1:14	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	ChemicalEntity	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	1:NR:2	L2R	CROSS	487-488	501-503	D001714	bipolar mania|bipolar mania|bipolar mania	DiseaseOrPhenotypicFeature	18:39:501	20:41:503	0:1:14	D018680	anticholinergic drug|Anticholinergic	ChemicalEntity	182:487	184:488	5:13	1:NR:2	L2R	NON-CROSS	290-291	307-308	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	DiseaseOrPhenotypicFeature	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	ChemicalEntity	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	1:Positive_Correlation:2	R2L	NON-CROSS	429-430	415-416	D006220	haloperidol|haloperidol|Haloperidol	ChemicalEntity	95:273:415	96:274:416	3:8:11	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	DiseaseOrPhenotypicFeature	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	1:NR:2	L2R	NON-CROSS	307-308	336-337	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	DiseaseOrPhenotypicFeature	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	ChemicalEntity	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	1:NR:2	L2R	CROSS	182-184	198-199	D017109	akathisia|akathisia|akathisia|akathisia|akathisia	DiseaseOrPhenotypicFeature	32:198:307:429:510	33:199:308:430:511	1:6:9:11:14	D018680	anticholinergic drug|Anticholinergic	ChemicalEntity	182:487	184:488	5:13	1:NR:2	L2R	NON-CROSS	93-94	95-96	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	ChemicalEntity	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	D006220	haloperidol|haloperidol|Haloperidol	ChemicalEntity	95:273:415	96:274:416	3:8:11	1:NR:2	L2R	NON-CROSS	121-122	123-124	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	ChemicalEntity	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	ChemicalEntity	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	1:NR:2	L2R	CROSS	145-146	182-184	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	ChemicalEntity	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	D018680	anticholinergic drug|Anticholinergic	ChemicalEntity	182:487	184:488	5:13	1:Positive_Correlation:2	R2L	NON-CROSS	412-413	408-409	D014202	tremor|tremor|tremor|tremor	DiseaseOrPhenotypicFeature	372:389:408:442	373:390:409:443	10:10:10:11	D008094	lithium|lithium|Li|Li|Li|Li|lithium|Li|Li|Lithium|lithium|lithium	ChemicalEntity	93:121:127:145:232:248:290:334:346:356:398:412	94:122:128:146:233:249:291:335:347:357:399:413	3:4:4:4:7:7:8:9:9:10:10:10	1:NR:2	L2R	CROSS	250-251	273-274	D006220	haloperidol|haloperidol|Haloperidol	ChemicalEntity	95:273:415	96:274:416	3:8:11	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	ChemicalEntity	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	1:NR:2	L2R	CROSS	415-416	487-488	D006220	haloperidol|haloperidol|Haloperidol	ChemicalEntity	95:273:415	96:274:416	3:8:11	D018680	anticholinergic drug|Anticholinergic	ChemicalEntity	182:487	184:488	5:13	1:Positive_Correlation:2	L2R	NON-CROSS	408-409	415-416	D006220	haloperidol|haloperidol|Haloperidol	ChemicalEntity	95:273:415	96:274:416	3:8:11	D014202	tremor|tremor|tremor|tremor	DiseaseOrPhenotypicFeature	372:389:408:442	373:390:409:443	10:10:10:11	1:NR:2	L2R	CROSS	147-148	182-184	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	ChemicalEntity	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	D018680	anticholinergic drug|Anticholinergic	ChemicalEntity	182:487	184:488	5:13	1:NR:2	L2R	CROSS	348-349	372-373	D014635	divalproex|DVP|DVP|DVP|DVP|DVP|DVP	ChemicalEntity	123:129:147:234:250:336:348	124:130:148:235:251:337:349	4:4:4:7:7:9:9	D014202	tremor|tremor|tremor|tremor	DiseaseOrPhenotypicFeature	372:389:408:442	373:390:409:443	10:10:10:11	1:NR:2	L2R	CROSS	442-443	487-488	D018680	anticholinergic drug|Anticholinergic	ChemicalEntity	182:487	184:488	5:13	D014202	tremor|tremor|tremor|tremor	DiseaseOrPhenotypicFeature	372:389:408:442	373:390:409:443	10:10:10:11
17151160	Randomized comparison of olanzapine versus risperidone for the treatment of first - episode schizophrenia : 4 - month outcomes .|OBJECTIVE : The authors compared 4 - month treatment outcomes for olanzapine versus risperidone in patients with first - episode schizophrenia spectrum disorders .|METHOD : One hundred twelve subjects ( 70 % male ; mean age = 23 . 3 years [ SD = 5 . 1 ] ) with first - episode schizophrenia ( 75 % ) , schizophreniform disorder ( 17 % ) , or schizoaffective disorder ( 8 % ) were randomly assigned to treatment with olanzapine ( 2 . 5 - 20 mg / day ) or risperidone ( 1 - 6 mg / day ) .|RESULTS : Response rates did not significantly differ between olanzapine ( 43 . 7 % , 95 % CI = 28 . 8 % - 58 . 6 % ) and risperidone ( 54 . 3 % , 95 % CI = 39 . 9 % - 68 . 7 % ) .|Among those responding to treatment , more subjects in the olanzapine group ( 40 . 9 % , 95 % CI = 16 . 8 % - 65 . 0 % ) than in the risperidone group ( 18 . 9 % , 95 % CI = 0 % - 39 . 2 % ) had subsequent ratings not meeting response criteria .|Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications .|Extrapyramidal symptom severity scores were 1 . 4 ( 95 % CI = 1 . 2 - 1 . 6 ) with risperidone and 1 . 2 ( 95 % CI = 1 . 0 - 1 . 4 ) with olanzapine .|Significantly more weight gain occurred with olanzapine than with risperidone : the increase in weight at 4 months relative to baseline weight was 17 . 3 % ( 95 % CI = 14 . 2 % - 20 . 5 % ) with olanzapine and 11 . 3 % ( 95 % CI = 8 . 4 % - 14 . 3 % ) with risperidone .|Body mass index at baseline and at 4 months was 24 . 3 ( 95 % CI = 22 . 8 - 25 . 7 ) versus 28 . 2 ( 95 % CI = 26 . 7 - 29 . 7 ) with olanzapine and 23 . 9 ( 95 % CI = 22 . 5 - 25 . 3 ) versus 26 . 7 ( 95 % CI = 25 . 2 - 28 . 2 ) with risperidone .|CONCLUSIONS : Clinical outcomes with risperidone were equal to those with olanzapine , and response may be more stable .|Olanzapine may have an advantage for motor side effects .|Both medications caused substantial rapid weight gain , but weight gain was greater with olanzapine .	1:Comparison:2	L2R	NON-CROSS	3-4	5-6	C076029	olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|Olanzapine|olanzapine	ChemicalEntity	3:31:100:131:185:294:302:339:407:456:465:489	4:32:101:132:186:295:303:340:408:457:466:490	0:1:2:3:4:6:7:7:8:9:10:11	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	ChemicalEntity	5:33:112:153:210:275:305:361:443:450	6:34:113:154:211:276:306:362:444:451	0:1:2:3:4:6:7:7:8:9	1:Negative_Correlation:2	R2L	NON-CROSS	40-41	31-32	D012559	schizophrenia|schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	13:40:74	14:41:75	0:1:2	C076029	olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|Olanzapine|olanzapine	ChemicalEntity	3:31:100:131:185:294:302:339:407:456:465:489	4:32:101:132:186:295:303:340:408:457:466:490	0:1:2:3:4:6:7:7:8:9:10:11	1:Negative_Correlation:2	R2L	NON-CROSS	100-101	88-90	D011618	schizophreniform disorder|schizoaffective disorder	DiseaseOrPhenotypicFeature	80:88	82:90	2:2	C076029	olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|Olanzapine|olanzapine	ChemicalEntity	3:31:100:131:185:294:302:339:407:456:465:489	4:32:101:132:186:295:303:340:408:457:466:490	0:1:2:3:4:6:7:7:8:9:10:11	1:NR:2	L2R	CROSS	244-245	294-295	C076029	olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|Olanzapine|olanzapine	ChemicalEntity	3:31:100:131:185:294:302:339:407:456:465:489	4:32:101:132:186:295:303:340:408:457:466:490	0:1:2:3:4:6:7:7:8:9:10:11	D010302	parkinsonism	DiseaseOrPhenotypicFeature	244	245	5	1:NR:2	L2R	CROSS	246-247	294-295	C076029	olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|Olanzapine|olanzapine	ChemicalEntity	3:31:100:131:185:294:302:339:407:456:465:489	4:32:101:132:186:295:303:340:408:457:466:490	0:1:2:3:4:6:7:7:8:9:10:11	D017109	akathisia	DiseaseOrPhenotypicFeature	246	247	5	1:Association:2	R2L	NON-CROSS	294-295	253-255	D001480	Extrapyramidal symptom	DiseaseOrPhenotypicFeature	253	255	6	C076029	olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|Olanzapine|olanzapine	ChemicalEntity	3:31:100:131:185:294:302:339:407:456:465:489	4:32:101:132:186:295:303:340:408:457:466:490	0:1:2:3:4:6:7:7:8:9:10:11	1:Positive_Correlation:2	R2L	NON-CROSS	302-303	298-300	D015430	weight gain|weight gain|weight gain	DiseaseOrPhenotypicFeature	298:480:484	300:482:486	7:11:11	C076029	olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|olanzapine|Olanzapine|olanzapine	ChemicalEntity	3:31:100:131:185:294:302:339:407:456:465:489	4:32:101:132:186:295:303:340:408:457:466:490	0:1:2:3:4:6:7:7:8:9:10:11	1:Negative_Correlation:2	R2L	NON-CROSS	40-41	33-34	D012559	schizophrenia|schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	13:40:74	14:41:75	0:1:2	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	ChemicalEntity	5:33:112:153:210:275:305:361:443:450	6:34:113:154:211:276:306:362:444:451	0:1:2:3:4:6:7:7:8:9	1:Negative_Correlation:2	R2L	NON-CROSS	112-113	88-90	D011618	schizophreniform disorder|schizoaffective disorder	DiseaseOrPhenotypicFeature	80:88	82:90	2:2	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	ChemicalEntity	5:33:112:153:210:275:305:361:443:450	6:34:113:154:211:276:306:362:444:451	0:1:2:3:4:6:7:7:8:9	1:NR:2	L2R	CROSS	244-245	275-276	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	ChemicalEntity	5:33:112:153:210:275:305:361:443:450	6:34:113:154:211:276:306:362:444:451	0:1:2:3:4:6:7:7:8:9	D010302	parkinsonism	DiseaseOrPhenotypicFeature	244	245	5	1:NR:2	L2R	CROSS	246-247	275-276	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	ChemicalEntity	5:33:112:153:210:275:305:361:443:450	6:34:113:154:211:276:306:362:444:451	0:1:2:3:4:6:7:7:8:9	D017109	akathisia	DiseaseOrPhenotypicFeature	246	247	5	1:Association:2	R2L	NON-CROSS	275-276	253-255	D001480	Extrapyramidal symptom	DiseaseOrPhenotypicFeature	253	255	6	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	ChemicalEntity	5:33:112:153:210:275:305:361:443:450	6:34:113:154:211:276:306:362:444:451	0:1:2:3:4:6:7:7:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	298-300	305-306	D018967	risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone|risperidone	ChemicalEntity	5:33:112:153:210:275:305:361:443:450	6:34:113:154:211:276:306:362:444:451	0:1:2:3:4:6:7:7:8:9	D015430	weight gain|weight gain|weight gain	DiseaseOrPhenotypicFeature	298:480:484	300:482:486	7:11:11
17255138	Risks and benefits of COX - 2 inhibitors vs non - selective NSAIDs : does their cardiovascular risk exceed their gastrointestinal benefit ? A retrospective cohort study .|OBJECTIVES : The risk of acute myocardial infarction ( AMI ) with COX - 2 inhibitors may offset their gastrointestinal ( GI ) benefit compared with non - selective ( NS ) non - steroidal anti - inflammatory drugs ( NSAIDs ) .|We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX - 2 inhibitors , NS - NSAIDs and acetaminophen .|METHODS : We conducted a retrospective cohort study using administrative data of patients > or = 65 years of age who filled a prescription for NSAID or acetaminophen during 1999 - 2002 .|Outcomes were compared using Cox regression models with time - dependent exposures .|RESULTS : Person - years of exposure among non - users of aspirin were : 75 , 761 to acetaminophen , 42 , 671 to rofecoxib 65 , 860 to celecoxib , and 37 , 495 to NS - NSAIDs .|Among users of aspirin , they were : 14 , 671 to rofecoxib , 22 , 875 to celecoxib , 9 , 832 to NS - NSAIDs and 38 , 048 to acetaminophen .|Among non - users of aspirin , the adjusted hazard ratios ( 95 % confidence interval ) of hospitalization for AMI / GI vs the acetaminophen ( with no aspirin ) group were : rofecoxib 1 . 27 ( 1 . 13 , 1 . 42 ) , celecoxib 0 . 93 ( 0 . 83 , 1 . 03 ) , naproxen 1 . 59 ( 1 . 31 , 1 . 93 ) , diclofenac 1 . 17 ( 0 . 99 , 1 . 38 ) and ibuprofen 1 . 05 ( 0 . 74 , 1 . 51 ) .|Among users of aspirin , they were : rofecoxib 1 . 73 ( 1 . 52 , 1 . 98 ) , celecoxib 1 . 34 ( 1 . 19 , 1 . 52 ) , ibuprofen 1 . 51 ( 0 . 95 , 2 . 41 ) , diclofenac 1 . 69 ( 1 . 35 , 2 . 10 ) , naproxen 1 . 35 ( 0 . 97 , 1 . 88 ) and acetaminophen 1 . 29 ( 1 . 17 , 1 . 42 ) .|CONCLUSION : Among non - users of aspirin , naproxen seemed to carry the highest risk for AMI / GI bleeding .|The AMI / GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS - NSAIDs .|Among users of aspirin , both celecoxib and naproxen seemed to be the least toxic .	1:Comparison:2	L2R	NON-CROSS	88-92	95-96	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	1:Positive_Correlation:2	R2L	NON-CROSS	40-44	37-38	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	1:NR:2	L2R	NON-CROSS	82-84	88-92	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	1:Comparison:2	L2R	NON-CROSS	88-92	97-98	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	1:NR:2	L2R	CROSS	88-92	157-158	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	1:NR:2	L2R	CROSS	88-92	170-171	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	1:NR:2	L2R	CROSS	88-92	175-176	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	1:NR:2	L2R	CROSS	88-92	282-283	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	1:NR:2	L2R	CROSS	88-92	296-297	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	CROSS	88-92	310-311	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:NR:2	L2R	CROSS	88-92	441-443	D052246	COX - 2 inhibitors|COX - 2 inhibitors|COX - 2 inhibitors	ChemicalEntity	4:40:88	8:44:92	0:1:2	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10	1:Association:2	L2R	NON-CROSS	68-69	80-81	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	1:NR:2	L2R	NON-CROSS	82-84	95-96	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	1:Comparison:2	L2R	NON-CROSS	95-96	97-98	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	1:Negative_Correlation:2	R2L	NON-CROSS	189-190	184-185	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	1:NR:2	L2R	NON-CROSS	459-460	463-464	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	1:NR:2	L2R	NON-CROSS	204-205	212-213	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	1:NR:2	L2R	CROSS	463-464	473-474	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	1:NR:2	L2R	CROSS	212-213	296-297	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	CROSS	212-213	310-311	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:Association:2	R2L	NON-CROSS	463-464	441-443	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10	D000894	NSAIDs|non - steroidal anti - inflammatory drugs|NSAIDs|NSAIDs|NSAID|NSAIDs|NSAIDs|NSAIDs	ChemicalEntity	12:60:68:95:124:184:212:463	13:67:69:96:125:185:213:464	0:1:1:2:3:5:6:10	1:Association:2	R2L	NON-CROSS	245-246	240-241	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	1:NR:2	L2R	NON-CROSS	240-241	249-250	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	1:Association:2	R2L	NON-CROSS	254-255	240-241	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	1:Association:2	R2L	NON-CROSS	444-445	439-440	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	1:Positive_Correlation:2	R2L	NON-CROSS	433-434	425-426	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	1:NR:2	L2R	NON-CROSS	240-241	296-297	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	NON-CROSS	240-241	310-311	D009203	acute myocardial infarction|AMI|AMI|AMI|AMI|AMI	DiseaseOrPhenotypicFeature	33:37:80:240:433:439	36:38:81:241:434:440	1:1:2:7:9:10	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:Association:2	R2L	NON-CROSS	97-98	82-84	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	1:NR:2	L2R	NON-CROSS	423-424	435-437	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	1:Association:2	R2L	CROSS	459-460	435-437	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	1:Association:2	R2L	CROSS	444-445	435-437	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	1:Positive_Correlation:2	R2L	NON-CROSS	435-437	425-426	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	1:NR:2	L2R	CROSS	374-375	435-437	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	CROSS	360-361	435-437	D006471	GI bleeding|GI bleeding	DiseaseOrPhenotypicFeature	82:435	84:437	2:9	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:Negative_Correlation:2	R2L	NON-CROSS	249-250	245-246	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	1:NR:2	L2R	NON-CROSS	164-165	170-171	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	1:NR:2	L2R	NON-CROSS	444-445	450-451	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	1:NR:2	L2R	NON-CROSS	388-389	402-403	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	1:NR:2	L2R	NON-CROSS	374-375	402-403	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	NON-CROSS	360-361	402-403	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:Association:2	R2L	NON-CROSS	450-451	441-443	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10	D000082	acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	ChemicalEntity	97:126:164:218:245:402:450	98:127:165:219:246:403:451	2:3:5:6:7:8:10	1:Negative_Correlation:2	L2R	NON-CROSS	249-250	254-255	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	1:Negative_Correlation:2	L2R	NON-CROSS	468-469	471-472	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	1:NR:2	L2R	NON-CROSS	423-424	425-426	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	1:NR:2	L2R	NON-CROSS	296-297	327-328	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	NON-CROSS	310-311	327-328	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:NR:2	L2R	CROSS	423-424	441-443	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	ChemicalEntity	157:189:225:249:327:423:468	158:190:226:250:328:424:469	5:6:7:7:8:9:11	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10	1:NR:2	L2R	NON-CROSS	170-171	175-176	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	1:NR:2	L2R	NON-CROSS	459-460	473-474	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	1:NR:2	L2R	NON-CROSS	296-297	332-333	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	NON-CROSS	310-311	332-333	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:Association:2	R2L	NON-CROSS	459-460	441-443	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10	C116926	rofecoxib|rofecoxib|rofecoxib|rofecoxib|rofecoxib	ChemicalEntity	170:198:254:332:459	171:199:255:333:460	5:6:7:8:10	1:NR:2	L2R	NON-CROSS	471-472	473-474	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	1:NR:2	L2R	NON-CROSS	268-269	296-297	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	NON-CROSS	346-347	360-361	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:Association:2	R2L	NON-CROSS	444-445	441-443	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10	C105934	celecoxib|celecoxib|celecoxib|celecoxib|celecoxib|celecoxib	ChemicalEntity	175:204:268:346:444:471	176:205:269:347:445:472	5:6:7:8:10:11	1:NR:2	L2R	NON-CROSS	282-283	296-297	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	1:NR:2	L2R	NON-CROSS	282-283	310-311	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:NR:2	L2R	CROSS	425-426	441-443	D009288	naproxen|naproxen|naproxen|naproxen	ChemicalEntity	282:388:425:473	283:389:426:474	7:8:9:11	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10	1:NR:2	L2R	NON-CROSS	296-297	310-311	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	1:NR:2	L2R	CROSS	374-375	441-443	D004008	diclofenac|diclofenac	ChemicalEntity	296:374	297:375	7:8	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10	1:NR:2	L2R	CROSS	360-361	441-443	D007052	ibuprofen|ibuprofen	ChemicalEntity	310:360	311:361	7:8	D005767	GI toxicity	DiseaseOrPhenotypicFeature	441	443	10
17297207	Quinine - induced arrhythmia in a patient with severe malaria .|It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( premature ventricular contraction ) while getting quinine infusion was reported .|A man , 25 years old , was admitted to hospital with high fever , chill , vomiting , jaundice .|The patient was fully conscious , blood pressure 120 / 80 mmHg , pulse rate 100 x / minute , regular .|On admission , laboratory examination showed Plasmodium falciparum ( + + + + ) , total bilirubin 8 . 25 mg / dL , conjugated bilirubin 4 . 36 mg / dL , unconjugated bilirubin 3 . 89 mg / dL , potassium 3 . 52 meq / L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5 % 500 mg / 8 hour .|On the second day the patient had vomitus , diarrhea , tinnitus , loss of hearing .|After 30 hours of quinine infusion the patient felt palpitation and electrocardiography ( ECG ) recording showed premature ventricular contraction ( PVC ) > 5 x / minute , trigemini , constant type - - sinoatrial block , positive U wave .|He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5 % / 24 hour and potassium aspartate tablet .|Quinine infusion was discontinued and changed with sulfate quinine tablets .|Three hours later the patient felt better , the frequency of PVC reduced to 4 - 5 x / minute and on the third day ECG was normal , potassium level was 3 . 34 meq / L .|He was discharged on 7th day in good condition .|Quinine , like quinidine , is a chincona alkaloid that has anti - arrhythmic property , although it also pro - arrhythmic that can cause various arrhythmias , including severe arrhythmia such as multiple PVC .|Administration of parenteral quinine must be done carefully and with good observation because of its pro - arrhythmic effect , especially in older patients who have heart diseases or patients with electrolyte disorder ( hypokalemia ) which frequently occurs due to vomiting and or diarrhea in malaria cases .	1:Positive_Correlation:2	L2R	NON-CROSS	0-1	3-4	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D001145	arrhythmia|arrhythmia|arrhythmic|arrhythmic|arrhythmias|arrhythmia|arrhythmic	DiseaseOrPhenotypicFeature	3:28:312:320:325:329:352	4:29:313:321:326:330:353	0:1:11:11:11:11:12	1:Negative_Correlation:2	L2R	NON-CROSS	137-139	143-144	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D016778	severe malaria|severe malaria|severe malaria	DiseaseOrPhenotypicFeature	8:20:137	10:22:139	0:1:4	1:Negative_Correlation:2	R2L	NON-CROSS	143-144	140-141	D007565	jaundice|jaundice|jaundice	DiseaseOrPhenotypicFeature	24:60:140	25:61:141	1:2:4	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	1:Positive_Correlation:2	L2R	NON-CROSS	333-334	338-339	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D018879	premature ventricular contraction|premature ventricular contraction|PVC|PVC|PVC	DiseaseOrPhenotypicFeature	30:189:193:261:333	33:192:194:262:334	1:6:6:9:11	1:NR:2	L2R	CROSS	36-37	54-55	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D005334	fever	DiseaseOrPhenotypicFeature	54	55	2	1:NR:2	L2R	CROSS	36-37	56-57	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D023341	chill	DiseaseOrPhenotypicFeature	56	57	2	1:NR:2	L2R	NON-CROSS	162-163	176-177	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D014839	vomiting|vomitus|vomiting	DiseaseOrPhenotypicFeature	58:162:376	59:163:377	2:5:12	1:NR:2	L2R	NON-CROSS	118-119	143-144	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	1:NR:2	L2R	NON-CROSS	126-127	143-144	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	NON-CROSS	143-144	146-147	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	NON-CROSS	164-165	176-177	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D003967	diarrhea|diarrhea	DiseaseOrPhenotypicFeature	164:379	165:380	5:12	1:NR:2	L2R	CROSS	166-167	176-177	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D014012	tinnitus	DiseaseOrPhenotypicFeature	166	167	5	1:NR:2	L2R	CROSS	168-171	176-177	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D034381	loss of hearing	DiseaseOrPhenotypicFeature	168	171	5	1:Positive_Correlation:2	L2R	NON-CROSS	176-177	181-182	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D006331	palpitation|heart diseases	DiseaseOrPhenotypicFeature	181:361	182:363	6:12	1:Positive_Correlation:2	L2R	NON-CROSS	176-177	207-209	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D012848	sinoatrial block	DiseaseOrPhenotypicFeature	207	209	6	1:NR:2	L2R	CROSS	218-219	239-240	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	235-237	239-240	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	NON-CROSS	299-300	302-303	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	NON-CROSS	299-300	306-308	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	NON-CROSS	338-339	366-368	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D014883	electrolyte disorder	DiseaseOrPhenotypicFeature	366	368	12	1:NR:2	L2R	NON-CROSS	338-339	369-370	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D007008	hypokalemia	DiseaseOrPhenotypicFeature	369	370	12	1:NR:2	L2R	NON-CROSS	338-339	381-382	D011803	Quinine|quinine|quinine|quinine|Quinine|quinine|Quinine|quinine	ChemicalEntity	0:36:143:176:239:247:299:338	1:37:144:177:240:248:300:339	0:1:4:6:8:8:11:12	D008288	malaria	DiseaseOrPhenotypicFeature	381	382	12	1:NR:2	L2R	CROSS	28-29	100-101	D001145	arrhythmia|arrhythmia|arrhythmic|arrhythmic|arrhythmias|arrhythmia|arrhythmic	DiseaseOrPhenotypicFeature	3:28:312:320:325:329:352	4:29:313:321:326:330:353	0:1:11:11:11:11:12	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	1:NR:2	L2R	CROSS	279-280	312-313	D001145	arrhythmia|arrhythmia|arrhythmic|arrhythmic|arrhythmias|arrhythmia|arrhythmic	DiseaseOrPhenotypicFeature	3:28:312:320:325:329:352	4:29:313:321:326:330:353	0:1:11:11:11:11:12	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	CROSS	228-229	312-313	D001145	arrhythmia|arrhythmia|arrhythmic|arrhythmic|arrhythmias|arrhythmia|arrhythmic	DiseaseOrPhenotypicFeature	3:28:312:320:325:329:352	4:29:313:321:326:330:353	0:1:11:11:11:11:12	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	CROSS	218-219	312-313	D001145	arrhythmia|arrhythmia|arrhythmic|arrhythmic|arrhythmias|arrhythmia|arrhythmic	DiseaseOrPhenotypicFeature	3:28:312:320:325:329:352	4:29:313:321:326:330:353	0:1:11:11:11:11:12	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	235-237	312-313	D001145	arrhythmia|arrhythmia|arrhythmic|arrhythmic|arrhythmias|arrhythmia|arrhythmic	DiseaseOrPhenotypicFeature	3:28:312:320:325:329:352	4:29:313:321:326:330:353	0:1:11:11:11:11:12	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	NON-CROSS	302-303	312-313	D001145	arrhythmia|arrhythmia|arrhythmic|arrhythmic|arrhythmias|arrhythmia|arrhythmic	DiseaseOrPhenotypicFeature	3:28:312:320:325:329:352	4:29:313:321:326:330:353	0:1:11:11:11:11:12	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	NON-CROSS	306-308	312-313	D001145	arrhythmia|arrhythmia|arrhythmic|arrhythmic|arrhythmias|arrhythmia|arrhythmic	DiseaseOrPhenotypicFeature	3:28:312:320:325:329:352	4:29:313:321:326:330:353	0:1:11:11:11:11:12	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	NON-CROSS	118-119	137-139	D016778	severe malaria|severe malaria|severe malaria	DiseaseOrPhenotypicFeature	8:20:137	10:22:139	0:1:4	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	1:NR:2	L2R	NON-CROSS	126-127	137-139	D016778	severe malaria|severe malaria|severe malaria	DiseaseOrPhenotypicFeature	8:20:137	10:22:139	0:1:4	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	NON-CROSS	137-139	146-147	D016778	severe malaria|severe malaria|severe malaria	DiseaseOrPhenotypicFeature	8:20:137	10:22:139	0:1:4	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	CROSS	137-139	218-219	D016778	severe malaria|severe malaria|severe malaria	DiseaseOrPhenotypicFeature	8:20:137	10:22:139	0:1:4	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	137-139	235-237	D016778	severe malaria|severe malaria|severe malaria	DiseaseOrPhenotypicFeature	8:20:137	10:22:139	0:1:4	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	137-139	302-303	D016778	severe malaria|severe malaria|severe malaria	DiseaseOrPhenotypicFeature	8:20:137	10:22:139	0:1:4	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	137-139	306-308	D016778	severe malaria|severe malaria|severe malaria	DiseaseOrPhenotypicFeature	8:20:137	10:22:139	0:1:4	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	NON-CROSS	118-119	140-141	D007565	jaundice|jaundice|jaundice	DiseaseOrPhenotypicFeature	24:60:140	25:61:141	1:2:4	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	1:NR:2	L2R	NON-CROSS	126-127	140-141	D007565	jaundice|jaundice|jaundice	DiseaseOrPhenotypicFeature	24:60:140	25:61:141	1:2:4	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	NON-CROSS	140-141	146-147	D007565	jaundice|jaundice|jaundice	DiseaseOrPhenotypicFeature	24:60:140	25:61:141	1:2:4	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	CROSS	140-141	218-219	D007565	jaundice|jaundice|jaundice	DiseaseOrPhenotypicFeature	24:60:140	25:61:141	1:2:4	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	140-141	235-237	D007565	jaundice|jaundice|jaundice	DiseaseOrPhenotypicFeature	24:60:140	25:61:141	1:2:4	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	140-141	302-303	D007565	jaundice|jaundice|jaundice	DiseaseOrPhenotypicFeature	24:60:140	25:61:141	1:2:4	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	140-141	306-308	D007565	jaundice|jaundice|jaundice	DiseaseOrPhenotypicFeature	24:60:140	25:61:141	1:2:4	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	30-33	100-101	D018879	premature ventricular contraction|premature ventricular contraction|PVC|PVC|PVC	DiseaseOrPhenotypicFeature	30:189:193:261:333	33:192:194:262:334	1:6:6:9:11	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	1:NR:2	L2R	NON-CROSS	261-262	279-280	D018879	premature ventricular contraction|premature ventricular contraction|PVC|PVC|PVC	DiseaseOrPhenotypicFeature	30:189:193:261:333	33:192:194:262:334	1:6:6:9:11	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	CROSS	228-229	261-262	D018879	premature ventricular contraction|premature ventricular contraction|PVC|PVC|PVC	DiseaseOrPhenotypicFeature	30:189:193:261:333	33:192:194:262:334	1:6:6:9:11	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:Negative_Correlation:2	L2R	CROSS	193-194	218-219	D018879	premature ventricular contraction|premature ventricular contraction|PVC|PVC|PVC	DiseaseOrPhenotypicFeature	30:189:193:261:333	33:192:194:262:334	1:6:6:9:11	D008012	lidocaine	ChemicalEntity	218	219	7	1:Negative_Correlation:2	L2R	CROSS	235-237	261-262	D018879	premature ventricular contraction|premature ventricular contraction|PVC|PVC|PVC	DiseaseOrPhenotypicFeature	30:189:193:261:333	33:192:194:262:334	1:6:6:9:11	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	NON-CROSS	302-303	333-334	D018879	premature ventricular contraction|premature ventricular contraction|PVC|PVC|PVC	DiseaseOrPhenotypicFeature	30:189:193:261:333	33:192:194:262:334	1:6:6:9:11	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	NON-CROSS	306-308	333-334	D018879	premature ventricular contraction|premature ventricular contraction|PVC|PVC|PVC	DiseaseOrPhenotypicFeature	30:189:193:261:333	33:192:194:262:334	1:6:6:9:11	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	54-55	100-101	D005334	fever	DiseaseOrPhenotypicFeature	54	55	2	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	1:NR:2	L2R	CROSS	54-55	126-127	D005334	fever	DiseaseOrPhenotypicFeature	54	55	2	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	CROSS	54-55	146-147	D005334	fever	DiseaseOrPhenotypicFeature	54	55	2	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	CROSS	54-55	218-219	D005334	fever	DiseaseOrPhenotypicFeature	54	55	2	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	54-55	235-237	D005334	fever	DiseaseOrPhenotypicFeature	54	55	2	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	54-55	302-303	D005334	fever	DiseaseOrPhenotypicFeature	54	55	2	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	54-55	306-308	D005334	fever	DiseaseOrPhenotypicFeature	54	55	2	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	56-57	100-101	D023341	chill	DiseaseOrPhenotypicFeature	56	57	2	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	1:NR:2	L2R	CROSS	56-57	126-127	D023341	chill	DiseaseOrPhenotypicFeature	56	57	2	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	CROSS	56-57	146-147	D023341	chill	DiseaseOrPhenotypicFeature	56	57	2	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	CROSS	56-57	218-219	D023341	chill	DiseaseOrPhenotypicFeature	56	57	2	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	56-57	235-237	D023341	chill	DiseaseOrPhenotypicFeature	56	57	2	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	56-57	302-303	D023341	chill	DiseaseOrPhenotypicFeature	56	57	2	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	56-57	306-308	D023341	chill	DiseaseOrPhenotypicFeature	56	57	2	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	58-59	100-101	D014839	vomiting|vomitus|vomiting	DiseaseOrPhenotypicFeature	58:162:376	59:163:377	2:5:12	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	1:NR:2	L2R	CROSS	126-127	162-163	D014839	vomiting|vomitus|vomiting	DiseaseOrPhenotypicFeature	58:162:376	59:163:377	2:5:12	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	CROSS	146-147	162-163	D014839	vomiting|vomitus|vomiting	DiseaseOrPhenotypicFeature	58:162:376	59:163:377	2:5:12	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	CROSS	162-163	218-219	D014839	vomiting|vomitus|vomiting	DiseaseOrPhenotypicFeature	58:162:376	59:163:377	2:5:12	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	162-163	235-237	D014839	vomiting|vomitus|vomiting	DiseaseOrPhenotypicFeature	58:162:376	59:163:377	2:5:12	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	302-303	376-377	D014839	vomiting|vomitus|vomiting	DiseaseOrPhenotypicFeature	58:162:376	59:163:377	2:5:12	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	306-308	376-377	D014839	vomiting|vomitus|vomiting	DiseaseOrPhenotypicFeature	58:162:376	59:163:377	2:5:12	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	NON-CROSS	118-119	126-127	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	1:NR:2	L2R	NON-CROSS	118-119	146-147	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	CROSS	118-119	164-165	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D003967	diarrhea|diarrhea	DiseaseOrPhenotypicFeature	164:379	165:380	5:12	1:NR:2	L2R	CROSS	118-119	166-167	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D014012	tinnitus	DiseaseOrPhenotypicFeature	166	167	5	1:NR:2	L2R	CROSS	118-119	168-171	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D034381	loss of hearing	DiseaseOrPhenotypicFeature	168	171	5	1:NR:2	L2R	CROSS	118-119	181-182	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D006331	palpitation|heart diseases	DiseaseOrPhenotypicFeature	181:361	182:363	6:12	1:NR:2	L2R	CROSS	118-119	207-209	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D012848	sinoatrial block	DiseaseOrPhenotypicFeature	207	209	6	1:NR:2	L2R	CROSS	118-119	218-219	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	118-119	235-237	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	118-119	302-303	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	118-119	306-308	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	118-119	366-368	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D014883	electrolyte disorder	DiseaseOrPhenotypicFeature	366	368	12	1:NR:2	L2R	CROSS	118-119	369-370	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D007008	hypokalemia	DiseaseOrPhenotypicFeature	369	370	12	1:NR:2	L2R	CROSS	118-119	381-382	D001663	bilirubin|bilirubin|bilirubin	ChemicalEntity	100:109:118	101:110:119	4:4:4	D008288	malaria	DiseaseOrPhenotypicFeature	381	382	12	1:NR:2	L2R	NON-CROSS	126-127	146-147	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	1:NR:2	L2R	CROSS	126-127	164-165	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D003967	diarrhea|diarrhea	DiseaseOrPhenotypicFeature	164:379	165:380	5:12	1:NR:2	L2R	CROSS	126-127	166-167	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D014012	tinnitus	DiseaseOrPhenotypicFeature	166	167	5	1:NR:2	L2R	CROSS	126-127	168-171	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D034381	loss of hearing	DiseaseOrPhenotypicFeature	168	171	5	1:NR:2	L2R	CROSS	126-127	181-182	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D006331	palpitation|heart diseases	DiseaseOrPhenotypicFeature	181:361	182:363	6:12	1:NR:2	L2R	CROSS	207-209	279-280	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D012848	sinoatrial block	DiseaseOrPhenotypicFeature	207	209	6	1:NR:2	L2R	CROSS	218-219	279-280	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	235-237	279-280	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	279-280	302-303	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	279-280	306-308	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	279-280	366-368	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D014883	electrolyte disorder	DiseaseOrPhenotypicFeature	366	368	12	1:NR:2	L2R	CROSS	279-280	369-370	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D007008	hypokalemia	DiseaseOrPhenotypicFeature	369	370	12	1:NR:2	L2R	CROSS	279-280	381-382	D011188	potassium|potassium	ChemicalEntity	126:279	127:280	4:9	D008288	malaria	DiseaseOrPhenotypicFeature	381	382	12	1:NR:2	L2R	CROSS	146-147	164-165	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D003967	diarrhea|diarrhea	DiseaseOrPhenotypicFeature	164:379	165:380	5:12	1:NR:2	L2R	CROSS	146-147	166-167	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D014012	tinnitus	DiseaseOrPhenotypicFeature	166	167	5	1:NR:2	L2R	CROSS	146-147	168-171	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D034381	loss of hearing	DiseaseOrPhenotypicFeature	168	171	5	1:NR:2	L2R	CROSS	146-147	181-182	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D006331	palpitation|heart diseases	DiseaseOrPhenotypicFeature	181:361	182:363	6:12	1:NR:2	L2R	CROSS	207-209	228-229	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D012848	sinoatrial block	DiseaseOrPhenotypicFeature	207	209	6	1:NR:2	L2R	NON-CROSS	218-219	228-229	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	NON-CROSS	228-229	235-237	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	228-229	302-303	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	228-229	306-308	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	228-229	366-368	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D014883	electrolyte disorder	DiseaseOrPhenotypicFeature	366	368	12	1:NR:2	L2R	CROSS	228-229	369-370	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D007008	hypokalemia	DiseaseOrPhenotypicFeature	369	370	12	1:NR:2	L2R	CROSS	228-229	381-382	D005947	dextrose|dextrose	ChemicalEntity	146:228	147:229	4:7	D008288	malaria	DiseaseOrPhenotypicFeature	381	382	12	1:NR:2	L2R	CROSS	164-165	218-219	D003967	diarrhea|diarrhea	DiseaseOrPhenotypicFeature	164:379	165:380	5:12	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	164-165	235-237	D003967	diarrhea|diarrhea	DiseaseOrPhenotypicFeature	164:379	165:380	5:12	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	302-303	379-380	D003967	diarrhea|diarrhea	DiseaseOrPhenotypicFeature	164:379	165:380	5:12	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	306-308	379-380	D003967	diarrhea|diarrhea	DiseaseOrPhenotypicFeature	164:379	165:380	5:12	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	166-167	218-219	D014012	tinnitus	DiseaseOrPhenotypicFeature	166	167	5	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	166-167	235-237	D014012	tinnitus	DiseaseOrPhenotypicFeature	166	167	5	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	166-167	302-303	D014012	tinnitus	DiseaseOrPhenotypicFeature	166	167	5	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	166-167	306-308	D014012	tinnitus	DiseaseOrPhenotypicFeature	166	167	5	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	168-171	218-219	D034381	loss of hearing	DiseaseOrPhenotypicFeature	168	171	5	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	168-171	235-237	D034381	loss of hearing	DiseaseOrPhenotypicFeature	168	171	5	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	168-171	302-303	D034381	loss of hearing	DiseaseOrPhenotypicFeature	168	171	5	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	168-171	306-308	D034381	loss of hearing	DiseaseOrPhenotypicFeature	168	171	5	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	181-182	218-219	D006331	palpitation|heart diseases	DiseaseOrPhenotypicFeature	181:361	182:363	6:12	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	181-182	235-237	D006331	palpitation|heart diseases	DiseaseOrPhenotypicFeature	181:361	182:363	6:12	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	302-303	361-363	D006331	palpitation|heart diseases	DiseaseOrPhenotypicFeature	181:361	182:363	6:12	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	306-308	361-363	D006331	palpitation|heart diseases	DiseaseOrPhenotypicFeature	181:361	182:363	6:12	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	207-209	218-219	D012848	sinoatrial block	DiseaseOrPhenotypicFeature	207	209	6	D008012	lidocaine	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	207-209	235-237	D012848	sinoatrial block	DiseaseOrPhenotypicFeature	207	209	6	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	207-209	302-303	D012848	sinoatrial block	DiseaseOrPhenotypicFeature	207	209	6	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	207-209	306-308	D012848	sinoatrial block	DiseaseOrPhenotypicFeature	207	209	6	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	NON-CROSS	218-219	235-237	D008012	lidocaine	ChemicalEntity	218	219	7	D001224	potassium aspartate	ChemicalEntity	235	237	7	1:NR:2	L2R	CROSS	218-219	302-303	D008012	lidocaine	ChemicalEntity	218	219	7	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	218-219	306-308	D008012	lidocaine	ChemicalEntity	218	219	7	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	218-219	366-368	D008012	lidocaine	ChemicalEntity	218	219	7	D014883	electrolyte disorder	DiseaseOrPhenotypicFeature	366	368	12	1:NR:2	L2R	CROSS	218-219	369-370	D008012	lidocaine	ChemicalEntity	218	219	7	D007008	hypokalemia	DiseaseOrPhenotypicFeature	369	370	12	1:NR:2	L2R	CROSS	218-219	381-382	D008012	lidocaine	ChemicalEntity	218	219	7	D008288	malaria	DiseaseOrPhenotypicFeature	381	382	12	1:NR:2	L2R	CROSS	235-237	302-303	D001224	potassium aspartate	ChemicalEntity	235	237	7	D011802	quinidine	ChemicalEntity	302	303	11	1:NR:2	L2R	CROSS	235-237	306-308	D001224	potassium aspartate	ChemicalEntity	235	237	7	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	235-237	366-368	D001224	potassium aspartate	ChemicalEntity	235	237	7	D014883	electrolyte disorder	DiseaseOrPhenotypicFeature	366	368	12	1:NR:2	L2R	CROSS	235-237	369-370	D001224	potassium aspartate	ChemicalEntity	235	237	7	D007008	hypokalemia	DiseaseOrPhenotypicFeature	369	370	12	1:NR:2	L2R	CROSS	235-237	381-382	D001224	potassium aspartate	ChemicalEntity	235	237	7	D008288	malaria	DiseaseOrPhenotypicFeature	381	382	12	1:NR:2	L2R	NON-CROSS	302-303	306-308	D011802	quinidine	ChemicalEntity	302	303	11	-	chincona alkaloid	ChemicalEntity	306	308	11	1:NR:2	L2R	CROSS	302-303	366-368	D011802	quinidine	ChemicalEntity	302	303	11	D014883	electrolyte disorder	DiseaseOrPhenotypicFeature	366	368	12	1:NR:2	L2R	CROSS	302-303	369-370	D011802	quinidine	ChemicalEntity	302	303	11	D007008	hypokalemia	DiseaseOrPhenotypicFeature	369	370	12	1:NR:2	L2R	CROSS	302-303	381-382	D011802	quinidine	ChemicalEntity	302	303	11	D008288	malaria	DiseaseOrPhenotypicFeature	381	382	12	1:NR:2	L2R	CROSS	306-308	366-368	-	chincona alkaloid	ChemicalEntity	306	308	11	D014883	electrolyte disorder	DiseaseOrPhenotypicFeature	366	368	12	1:NR:2	L2R	CROSS	306-308	369-370	-	chincona alkaloid	ChemicalEntity	306	308	11	D007008	hypokalemia	DiseaseOrPhenotypicFeature	369	370	12	1:NR:2	L2R	CROSS	306-308	381-382	-	chincona alkaloid	ChemicalEntity	306	308	11	D008288	malaria	DiseaseOrPhenotypicFeature	381	382	12
17384765	Succimer chelation improves learning , attention , and arousal regulation in lead - exposed rats but produces lasting cognitive impairment in the absence of lead exposure .|BACKGROUND : There is growing pressure for clinicians to prescribe chelation therapy at only slightly elevated blood lead levels .|However , very few studies have evaluated whether chelation improves cognitive outcomes in Pb - exposed children , or whether these agents have adverse effects that may affect brain development in the absence of Pb exposure .|OBJECTIVES : The present study was designed to answer these questions , using a rodent model of early childhood Pb exposure and treatment with succimer , a widely used chelating agent for the treatment of Pb poisoning .|RESULTS : Pb exposure produced lasting impairments in learning , attention , inhibitory control , and arousal regulation , paralleling the areas of dysfunction seen in Pb - exposed children .|Succimer treatment of the Pb - exposed rats significantly improved learning , attention , and arousal regulation , although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit .|In contrast , succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen .|CONCLUSIONS : These are the first data , to our knowledge , to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure .|These findings suggest that it may be possible to identify a succimer treatment protocol that improves cognitive outcomes in Pb - exposed children .|However , they also suggest that succimer treatment should be strongly discouraged for children who do not have elevated tissue levels of Pb or other heavy metals .	1:Negative_Correlation:2	L2R	NON-CROSS	153-154	157-158	D004113	Succimer|succimer|Succimer|succimer|succimer|succimer	ChemicalEntity	0:108:153:195:265:284	1:109:154:196:266:285	0:3:5:6:8:9	D007854	lead|lead|lead|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb	ChemicalEntity	11:24:44:60:81:103:124:148:157:183:203:221:251:273:300	12:25:45:61:82:104:125:149:158:184:204:222:252:274:301	0:0:1:2:2:3:4:4:5:5:6:6:7:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	247-249	265-266	D004113	Succimer|succimer|Succimer|succimer|succimer|succimer	ChemicalEntity	0:108:153:195:265:284	1:109:154:196:266:285	0:3:5:6:8:9	D003072	cognitive impairment|cognitive deficits	DiseaseOrPhenotypicFeature	18:247	20:249	0:7	1:Negative_Correlation:2	L2R	NON-CROSS	108-109	119-121	D004113	Succimer|succimer|Succimer|succimer|succimer|succimer	ChemicalEntity	0:108:153:195:265:284	1:109:154:196:266:285	0:3:5:6:8:9	D007855	Pb poisoning	DiseaseOrPhenotypicFeature	119	121	3	1:NR:2	L2R	CROSS	128-140	153-154	D004113	Succimer|succimer|Succimer|succimer|succimer|succimer	ChemicalEntity	0:108:153:195:265:284	1:109:154:196:266:285	0:3:5:6:8:9	D007859,D019958	impairments in learning , attention , inhibitory control , and arousal regulation	DiseaseOrPhenotypicFeature	128	140	4	1:NR:2	L2R	NON-CROSS	195-196	208-212	D004113	Succimer|succimer|Succimer|succimer|succimer|succimer	ChemicalEntity	0:108:153:195:265:284	1:109:154:196:266:285	0:3:5:6:8:9	D003072,D019964	cognitive and affective dysfunction	DiseaseOrPhenotypicFeature	208	212	6	1:Positive_Correlation:2	L2R	NON-CROSS	247-249	251-252	D007854	lead|lead|lead|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb	ChemicalEntity	11:24:44:60:81:103:124:148:157:183:203:221:251:273:300	12:25:45:61:82:104:125:149:158:184:204:222:252:274:301	0:0:1:2:2:3:4:4:5:5:6:6:7:8:9	D003072	cognitive impairment|cognitive deficits	DiseaseOrPhenotypicFeature	18:247	20:249	0:7	1:Positive_Correlation:2	L2R	NON-CROSS	119-121	124-125	D007854	lead|lead|lead|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb	ChemicalEntity	11:24:44:60:81:103:124:148:157:183:203:221:251:273:300	12:25:45:61:82:104:125:149:158:184:204:222:252:274:301	0:0:1:2:2:3:4:4:5:5:6:6:7:8:9	D007855	Pb poisoning	DiseaseOrPhenotypicFeature	119	121	3	1:NR:2	L2R	NON-CROSS	124-125	128-140	D007854	lead|lead|lead|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb	ChemicalEntity	11:24:44:60:81:103:124:148:157:183:203:221:251:273:300	12:25:45:61:82:104:125:149:158:184:204:222:252:274:301	0:0:1:2:2:3:4:4:5:5:6:6:7:8:9	D007859,D019958	impairments in learning , attention , inhibitory control , and arousal regulation	DiseaseOrPhenotypicFeature	128	140	4	1:NR:2	L2R	NON-CROSS	203-204	208-212	D007854	lead|lead|lead|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb|Pb	ChemicalEntity	11:24:44:60:81:103:124:148:157:183:203:221:251:273:300	12:25:45:61:82:104:125:149:158:184:204:222:252:274:301	0:0:1:2:2:3:4:4:5:5:6:6:7:8:9	D003072,D019964	cognitive and affective dysfunction	DiseaseOrPhenotypicFeature	208	212	6
17608141	Attenuation of methamphetamine - induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment .|Immunological activation has been proposed to play a role in methamphetamine - induced dopaminergic terminal damage .|In this study , we examined the roles of lipopolysaccharide , a pro - inflammatory and inflammatory factor , treatment in modulating the methamphetamine - induced nigrostriatal dopamine neurotoxicity .|Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine - elicited hyperthermia three days later .|Such systemic lipopolysaccharide treatment mitigated methamphetamine - induced striatal dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions in a dose - dependent manner .|As the most potent dose ( 1 mg / kg ) of lipopolysaccharide was administered two weeks , one day before or after the methamphetamine dosing regimen , methamphetamine - induced striatal dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions remained unaltered .|Moreover , systemic lipopolysaccharide pretreatment ( 1 mg / kg ) attenuated local methamphetamine infusion - produced dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions in the striatum , indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine .|We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine - induced nigrostriatal dopamine neurotoxicity .	1:Association:2	L2R	NON-CROSS	2-3	6-7	D008694	methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine	ChemicalEntity	2:24:54:71:84:128:132:161:196:213	3:25:55:72:85:129:133:162:197:214	0:1:2:3:4:5:5:6:6:7	D004298	dopaminergic|dopamine|dopamine|dopamine|dopamine|dopamine	ChemicalEntity	6:58:88:136:165:217	7:59:89:137:166:218	0:2:4:5:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	2-3	7-8	D008694	methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine	ChemicalEntity	2:24:54:71:84:128:132:161:196:213	3:25:55:72:85:129:133:162:197:214	0:1:2:3:4:5:5:6:6:7	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	7:59:218	8:60:219	0:2:7	1:Negative_Correlation:2	R2L	NON-CROSS	84-85	81-82	D008070	lipopolysaccharide|lipopolysaccharide|Lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide	ChemicalEntity	11:40:61:81:116:151:184:206	12:41:62:82:117:152:185:207	0:2:3:4:5:6:6:7	D008694	methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine	ChemicalEntity	2:24:54:71:84:128:132:161:196:213	3:25:55:72:85:129:133:162:197:214	0:1:2:3:4:5:5:6:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	24-25	27-30	D008694	methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine	ChemicalEntity	2:24:54:71:84:128:132:161:196:213	3:25:55:72:85:129:133:162:197:214	0:1:2:3:4:5:5:6:6:7	D009422	dopaminergic terminal damage	DiseaseOrPhenotypicFeature	27	30	1	1:NR:2	L2R	NON-CROSS	47-48	54-55	D008694	methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine	ChemicalEntity	2:24:54:71:84:128:132:161:196:213	3:25:55:72:85:129:133:162:197:214	0:1:2:3:4:5:5:6:6:7	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	45:47	46:48	2:2	1:Positive_Correlation:2	L2R	NON-CROSS	71-72	74-75	D008694	methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine	ChemicalEntity	2:24:54:71:84:128:132:161:196:213	3:25:55:72:85:129:133:162:197:214	0:1:2:3:4:5:5:6:6:7	D005334	hyperthermia	DiseaseOrPhenotypicFeature	74	75	3	1:Association:2	L2R	NON-CROSS	84-85	90-96	D008694	methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine|methamphetamine	ChemicalEntity	2:24:54:71:84:128:132:161:196:213	3:25:55:72:85:129:133:162:197:214	0:1:2:3:4:5:5:6:6:7	D015102	3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid	ChemicalEntity	90:138:167	96:144:173	4:5:6	1:Positive_Correlation:2	L2R	NON-CROSS	6-7	7-8	D004298	dopaminergic|dopamine|dopamine|dopamine|dopamine|dopamine	ChemicalEntity	6:58:88:136:165:217	7:59:89:137:166:218	0:2:4:5:6:7	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	7:59:218	8:60:219	0:2:7	1:Association:2	R2L	NON-CROSS	61-62	58-59	D008070	lipopolysaccharide|lipopolysaccharide|Lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide	ChemicalEntity	11:40:61:81:116:151:184:206	12:41:62:82:117:152:185:207	0:2:3:4:5:6:6:7	D004298	dopaminergic|dopamine|dopamine|dopamine|dopamine|dopamine	ChemicalEntity	6:58:88:136:165:217	7:59:89:137:166:218	0:2:4:5:6:7	1:NR:2	L2R	CROSS	6-7	27-30	D004298	dopaminergic|dopamine|dopamine|dopamine|dopamine|dopamine	ChemicalEntity	6:58:88:136:165:217	7:59:89:137:166:218	0:2:4:5:6:7	D009422	dopaminergic terminal damage	DiseaseOrPhenotypicFeature	27	30	1	1:NR:2	L2R	NON-CROSS	47-48	58-59	D004298	dopaminergic|dopamine|dopamine|dopamine|dopamine|dopamine	ChemicalEntity	6:58:88:136:165:217	7:59:89:137:166:218	0:2:4:5:6:7	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	45:47	46:48	2:2	1:NR:2	L2R	CROSS	74-75	88-89	D004298	dopaminergic|dopamine|dopamine|dopamine|dopamine|dopamine	ChemicalEntity	6:58:88:136:165:217	7:59:89:137:166:218	0:2:4:5:6:7	D005334	hyperthermia	DiseaseOrPhenotypicFeature	74	75	3	1:NR:2	L2R	NON-CROSS	88-89	90-96	D004298	dopaminergic|dopamine|dopamine|dopamine|dopamine|dopamine	ChemicalEntity	6:58:88:136:165:217	7:59:89:137:166:218	0:2:4:5:6:7	D015102	3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid	ChemicalEntity	90:138:167	96:144:173	4:5:6	1:Negative_Correlation:2	R2L	NON-CROSS	61-62	59-60	D008070	lipopolysaccharide|lipopolysaccharide|Lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide	ChemicalEntity	11:40:61:81:116:151:184:206	12:41:62:82:117:152:185:207	0:2:3:4:5:6:6:7	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	7:59:218	8:60:219	0:2:7	1:NR:2	L2R	CROSS	59-60	90-96	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	7:59:218	8:60:219	0:2:7	D015102	3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid	ChemicalEntity	90:138:167	96:144:173	4:5:6	1:NR:2	L2R	CROSS	27-30	40-41	D008070	lipopolysaccharide|lipopolysaccharide|Lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide	ChemicalEntity	11:40:61:81:116:151:184:206	12:41:62:82:117:152:185:207	0:2:3:4:5:6:6:7	D009422	dopaminergic terminal damage	DiseaseOrPhenotypicFeature	27	30	1	1:Association:2	L2R	NON-CROSS	40-41	45-46	D008070	lipopolysaccharide|lipopolysaccharide|Lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide	ChemicalEntity	11:40:61:81:116:151:184:206	12:41:62:82:117:152:185:207	0:2:3:4:5:6:6:7	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	45:47	46:48	2:2	1:NR:2	L2R	NON-CROSS	74-75	81-82	D008070	lipopolysaccharide|lipopolysaccharide|Lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide	ChemicalEntity	11:40:61:81:116:151:184:206	12:41:62:82:117:152:185:207	0:2:3:4:5:6:6:7	D005334	hyperthermia	DiseaseOrPhenotypicFeature	74	75	3	1:Association:2	L2R	NON-CROSS	167-173	184-185	D008070	lipopolysaccharide|lipopolysaccharide|Lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide|lipopolysaccharide	ChemicalEntity	11:40:61:81:116:151:184:206	12:41:62:82:117:152:185:207	0:2:3:4:5:6:6:7	D015102	3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid	ChemicalEntity	90:138:167	96:144:173	4:5:6	1:NR:2	L2R	CROSS	27-30	90-96	D009422	dopaminergic terminal damage	DiseaseOrPhenotypicFeature	27	30	1	D015102	3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid	ChemicalEntity	90:138:167	96:144:173	4:5:6	1:NR:2	L2R	CROSS	47-48	90-96	D007249	inflammatory|inflammatory	DiseaseOrPhenotypicFeature	45:47	46:48	2:2	D015102	3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid	ChemicalEntity	90:138:167	96:144:173	4:5:6	1:NR:2	L2R	CROSS	74-75	90-96	D005334	hyperthermia	DiseaseOrPhenotypicFeature	74	75	3	D015102	3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid|3 , 4 - dihydroxyphenylacetic acid	ChemicalEntity	90:138:167	96:144:173	4:5:6
18162529	Hypothalamic prolactin receptor messenger ribonucleic acid levels , prolactin signaling , and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol .|Hyperprolactinemia can reduce fertility and libido .|Although central prolactin actions are thought to contribute to this , the mechanisms are poorly understood .|We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility : pulsatile LH secretion and the estrogen - induced LH surge .|Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .|Sulpiride did not affect the magnitude of a steroid - induced LH surge or the percentage of GnRH neurons activated during the surge .|Estradiol is known to influence expression of the long form of prolactin receptors ( PRL - R ) and components of prolactin 's signaling pathway .|To test the hypothesis that estrogen increases PRL - R expression and sensitivity to prolactin , we next demonstrated that estradiol greatly augments prolactin - induced STAT5 activation .|Lastly , we measured PRL - R and suppressor of cytokine signaling ( SOCS - 1 and - 3 and CIS , which reflect the level of prolactin signaling ) mRNAs in response to sulpiride and estradiol .|Sulpiride induced only SOCS - 1 in the medial preoptic area , where GnRH neurons are regulated , but in the arcuate nucleus and choroid plexus , PRL - R , SOCS - 3 , and CIS mRNA levels were also induced .|Estradiol enhanced these effects on SOCS - 3 and CIS .|Interestingly , estradiol also induced PRL - R , SOCS - 3 , and CIS mRNA levels independently .|These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid - dependent manner .|They also provide evidence for estradiol - dependent and brain region - specific regulation of PRL - R expression and signaling responses by prolactin .	1:NR:2	L2R	NON-CROSS	1-3	4-6	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	D012313	ribonucleic acid	ChemicalEntity	4	6	0	1:NR:2	L2R	NON-CROSS	144-147	151-152	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	1:NR:2	L2R	NON-CROSS	1-3	12-13	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	1:NR:2	L2R	NON-CROSS	1-3	16-18	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	1:Positive_Correlation:2	R2L	NON-CROSS	282-285	279-280	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	1:Positive_Correlation:2	R2L	NON-CROSS	163-166	161-162	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	1:NR:2	L2R	CROSS	79-80	141-143	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	D004298	dopamine	ChemicalEntity	79	80	4	1:Positive_Correlation:2	R2L	NON-CROSS	250-253	223-224	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	1:NR:2	L2R	CROSS	310-311	330-333	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	1:NR:2	L2R	NON-CROSS	182-183	189-192	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	NON-CROSS	189-192	193-197	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	NON-CROSS	189-192	198-204	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	NON-CROSS	250-253	259-260	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	NON-CROSS	226-229	250-253	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	NON-CROSS	250-253	254-257	24684	prolactin receptor|prolactin receptors|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R|PRL - R	GeneOrGeneProduct	1:141:144:163:189:250:282:330	3:143:147:166:192:253:285:333	0:6:6:7:8:9:11:13	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	4-6	8-9	D012313	ribonucleic acid	ChemicalEntity	4	6	0	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	1:NR:2	L2R	NON-CROSS	4-6	12-13	D012313	ribonucleic acid	ChemicalEntity	4	6	0	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	1:NR:2	L2R	NON-CROSS	4-6	16-18	D012313	ribonucleic acid	ChemicalEntity	4	6	0	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	1:NR:2	L2R	NON-CROSS	4-6	22-23	D012313	ribonucleic acid	ChemicalEntity	4	6	0	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	1:NR:2	L2R	CROSS	4-6	68-69	D012313	ribonucleic acid	ChemicalEntity	4	6	0	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	1:NR:2	L2R	CROSS	4-6	79-80	D012313	ribonucleic acid	ChemicalEntity	4	6	0	D004298	dopamine	ChemicalEntity	79	80	4	1:NR:2	L2R	CROSS	4-6	81-82	D012313	ribonucleic acid	ChemicalEntity	4	6	0	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	1:NR:2	L2R	CROSS	4-6	114-115	D012313	ribonucleic acid	ChemicalEntity	4	6	0	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	1:NR:2	L2R	CROSS	4-6	182-183	D012313	ribonucleic acid	ChemicalEntity	4	6	0	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	CROSS	4-6	193-197	D012313	ribonucleic acid	ChemicalEntity	4	6	0	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	CROSS	4-6	198-204	D012313	ribonucleic acid	ChemicalEntity	4	6	0	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	CROSS	4-6	205-206	D012313	ribonucleic acid	ChemicalEntity	4	6	0	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	4-6	226-229	D012313	ribonucleic acid	ChemicalEntity	4	6	0	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	4-6	254-257	D012313	ribonucleic acid	ChemicalEntity	4	6	0	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	8-9	12-13	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	1:NR:2	L2R	NON-CROSS	8-9	16-18	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	1:Positive_Correlation:2	R2L	NON-CROSS	179-180	176-177	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	1:Association:2	R2L	NON-CROSS	170-171	161-162	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	1:NR:2	L2R	CROSS	33-34	79-80	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	D004298	dopamine	ChemicalEntity	79	80	4	1:NR:2	L2R	NON-CROSS	212-213	219-220	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	1:NR:2	L2R	CROSS	310-311	338-339	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	1:Positive_Correlation:2	L2R	NON-CROSS	179-180	182-183	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	NON-CROSS	179-180	193-197	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	NON-CROSS	198-204	212-213	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:Association:2	R2L	NON-CROSS	212-213	205-206	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	1:Association:2	R2L	CROSS	226-229	212-213	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	1:Association:2	R2L	CROSS	254-257	212-213	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	24683	prolactin|prolactin|prolactin|prolactin|prolactin|prolactin|prolactin	GeneOrGeneProduct	8:33:151:170:179:212:338	9:34:152:171:180:213:339	0:2:6:7:7:8:13	1:NR:2	L2R	NON-CROSS	12-13	16-18	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	1:NR:2	L2R	NON-CROSS	22-23	24-25	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	1:NR:2	L2R	NON-CROSS	68-69	75-76	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	1:NR:2	L2R	NON-CROSS	75-76	79-80	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	D004298	dopamine	ChemicalEntity	79	80	4	1:Positive_Correlation:2	L2R	NON-CROSS	75-76	81-82	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	1:Association:2	L2R	NON-CROSS	307-308	310-311	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	1:NR:2	L2R	CROSS	75-76	182-183	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	CROSS	193-197	307-308	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	CROSS	198-204	307-308	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	CROSS	291-292	307-308	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	226-229	307-308	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	286-289	307-308	D006966	hyperprolactinemic|Hyperprolactinemia|hyperprolactinemia|hyperprolactinemia|hyperprolactinemia	DiseaseOrPhenotypicFeature	12:24:53:75:307	13:25:54:76:308	0:1:3:4:12	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	16-18	22-23	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	1:Association:2	R2L	NON-CROSS	71-72	68-69	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	1:NR:2	L2R	NON-CROSS	71-72	79-80	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	D004298	dopamine	ChemicalEntity	79	80	4	1:Negative_Correlation:2	R2L	NON-CROSS	87-88	81-82	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	1:Association:2	R2L	NON-CROSS	117-118	114-115	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	1:NR:2	L2R	CROSS	117-118	182-183	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	CROSS	117-118	193-197	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	CROSS	117-118	198-204	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	CROSS	117-118	205-206	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	117-118	226-229	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	117-118	254-257	D007986	luteinizing hormone|LH|LH|LH|LH	ChemicalEntity	16:64:71:87:117	18:65:72:88:118	0:3:3:4:5	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	161-162	176-177	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	1:NR:2	L2R	NON-CROSS	79-80	104-105	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	D004298	dopamine	ChemicalEntity	79	80	4	1:NR:2	L2R	NON-CROSS	104-105	106-107	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	1:NR:2	L2R	CROSS	104-105	114-115	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	1:Positive_Correlation:2	L2R	NON-CROSS	176-177	182-183	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	NON-CROSS	176-177	193-197	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	NON-CROSS	198-204	221-222	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:Positive_Correlation:2	L2R	NON-CROSS	275-276	279-280	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	221-222	226-229	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:Positive_Correlation:2	L2R	NON-CROSS	266-267	271-274	D004958	estradiol|estradiol|Estradiol|estradiol|estradiol|Estradiol|estradiol|estradiol	ChemicalEntity	22:104:130:176:221:266:279:320	23:105:131:177:222:267:280:321	0:4:6:7:8:10:11:13	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	CROSS	68-69	79-80	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	D004298	dopamine	ChemicalEntity	79	80	4	1:NR:2	L2R	CROSS	68-69	81-82	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	1:NR:2	L2R	CROSS	68-69	114-115	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	1:NR:2	L2R	NON-CROSS	161-162	182-183	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	CROSS	161-162	193-197	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	CROSS	161-162	198-204	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	CROSS	161-162	205-206	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	161-162	226-229	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	161-162	254-257	D004967	estrogen|estrogen	ChemicalEntity	68:161	69:162	3:7	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:Negative_Correlation:2	L2R	NON-CROSS	79-80	81-82	D004298	dopamine	ChemicalEntity	79	80	4	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	1:NR:2	L2R	CROSS	79-80	114-115	D004298	dopamine	ChemicalEntity	79	80	4	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	1:NR:2	L2R	CROSS	79-80	182-183	D004298	dopamine	ChemicalEntity	79	80	4	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	CROSS	79-80	193-197	D004298	dopamine	ChemicalEntity	79	80	4	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	CROSS	79-80	198-204	D004298	dopamine	ChemicalEntity	79	80	4	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	CROSS	79-80	205-206	D004298	dopamine	ChemicalEntity	79	80	4	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	79-80	226-229	D004298	dopamine	ChemicalEntity	79	80	4	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	79-80	254-257	D004298	dopamine	ChemicalEntity	79	80	4	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	106-107	114-115	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	1:NR:2	L2R	CROSS	182-183	219-220	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	NON-CROSS	193-197	219-220	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	NON-CROSS	198-204	223-224	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:Positive_Correlation:2	L2R	NON-CROSS	205-206	219-220	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:Positive_Correlation:2	L2R	NON-CROSS	223-224	226-229	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:Positive_Correlation:2	L2R	NON-CROSS	223-224	254-257	D013469	sulpiride|Sulpiride|sulpiride|Sulpiride	ChemicalEntity	81:106:219:223	82:107:220:224	4:5:8:9	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	CROSS	114-115	182-183	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	24918	STAT5	GeneOrGeneProduct	182	183	7	1:NR:2	L2R	CROSS	114-115	193-197	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	CROSS	114-115	198-204	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	CROSS	291-292	310-311	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	226-229	310-311	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	286-289	310-311	D013256	steroid|steroid	ChemicalEntity	114:310	115:311	5:12	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	CROSS	182-183	193-197	24918	STAT5	GeneOrGeneProduct	182	183	7	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	1:NR:2	L2R	CROSS	182-183	198-204	24918	STAT5	GeneOrGeneProduct	182	183	7	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	CROSS	182-183	205-206	24918	STAT5	GeneOrGeneProduct	182	183	7	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	182-183	226-229	24918	STAT5	GeneOrGeneProduct	182	183	7	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	182-183	254-257	24918	STAT5	GeneOrGeneProduct	182	183	7	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	193-197	198-204	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	1:NR:2	L2R	NON-CROSS	193-197	205-206	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	193-197	226-229	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	193-197	254-257	252971,83681,89829	suppressor of cytokine signaling	GeneOrGeneProduct	193	197	8	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	198-204	205-206	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	1:NR:2	L2R	CROSS	198-204	226-229	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	CROSS	198-204	254-257	252971,89829	SOCS - 1 and - 3	GeneOrGeneProduct	198	204	8	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	205-206	226-229	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	1:NR:2	L2R	NON-CROSS	286-289	291-292	83681	CIS|CIS|CIS|CIS	GeneOrGeneProduct	205:259:275:291	206:260:276:292	8:9:10:11	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11	1:NR:2	L2R	NON-CROSS	226-229	254-257	252971	SOCS - 1	GeneOrGeneProduct	226	229	9	89829	SOCS - 3|SOCS - 3|SOCS - 3	GeneOrGeneProduct	254:271:286	257:274:289	9:10:11
18308784	Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats .|Rg1 , as a ginsenoside extracted from Panax ginseng , could ameliorate spatial learning impairment .|Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine .|The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect .|Male rats were subcutaneously injected with morphine ( 10 mg / kg ) twice a day at 12 hour intervals for 10 days , and Rg1 ( 30 mg / kg ) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days .|Spatial learning capacity was assessed in the Morris water maze .|The results showed that rats treated with Morphine / Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency .|By implantation of electrodes and electrophysiological recording in vivo , the results showed that Rg1 restored the long - term potentiation ( LTP ) impaired by morphine in both freely moving and anaesthetised rats .|The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine , but not changed LTP in the slices from normal saline - or morphine / Rg1 - treated rats ; this restoration could be inhibited by N - methyl - D - aspartate ( NMDA ) receptor antagonist MK801 .|We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine - inhibited LTP .|This effect is NMDA receptor dependent .	1:Negative_Correlation:2	L2R	NON-CROSS	65-66	67-69	C035054	Ginsenoside Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1	ChemicalEntity	0:15:36:65:106:151:181:209:236:264	2:16:37:66:107:152:182:210:237:265	0:1:2:3:4:6:7:8:8:9	D007859	impairment of learning|learning impairment|learning impairment	DiseaseOrPhenotypicFeature	4:28:67	7:30:69	0:1:3	1:Negative_Correlation:2	L2R	NON-CROSS	149-150	151-152	C035054	Ginsenoside Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1	ChemicalEntity	0:15:36:65:106:151:181:209:236:264	2:16:37:66:107:152:182:210:237:265	0:1:2:3:4:6:7:8:8:9	D009020	morphine|morphine|morphine|morphine|morphine|Morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	10:52:71:87:123:149:193:220:234:275:280	11:53:72:88:124:150:194:221:235:276:281	0:2:3:4:4:6:7:8:8:9:9	1:NR:2	L2R	NON-CROSS	15-16	19-20	C035054	Ginsenoside Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1	ChemicalEntity	0:15:36:65:106:151:181:209:236:264	2:16:37:66:107:152:182:210:237:265	0:1:2:3:4:6:7:8:8:9	D036145	ginsenoside	ChemicalEntity	19	20	1	1:Association:2	L2R	NON-CROSS	247-258	264-265	C035054	Ginsenoside Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1	ChemicalEntity	0:15:36:65:106:151:181:209:236:264	2:16:37:66:107:152:182:210:237:265	0:1:2:3:4:6:7:8:8:9	24408	N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor	GeneOrGeneProduct	247:288	258:290	8:10	1:Negative_Correlation:2	R2L	NON-CROSS	264-265	259-260	D016291	MK801	ChemicalEntity	259	260	8	C035054	Ginsenoside Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1|Rg1	ChemicalEntity	0:15:36:65:106:151:181:209:236:264	2:16:37:66:107:152:182:210:237:265	0:1:2:3:4:6:7:8:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	67-69	71-72	D007859	impairment of learning|learning impairment|learning impairment	DiseaseOrPhenotypicFeature	4:28:67	7:30:69	0:1:3	D009020	morphine|morphine|morphine|morphine|morphine|Morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	10:52:71:87:123:149:193:220:234:275:280	11:53:72:88:124:150:194:221:235:276:281	0:2:3:4:4:6:7:8:8:9:9	1:NR:2	L2R	NON-CROSS	19-20	28-30	D007859	impairment of learning|learning impairment|learning impairment	DiseaseOrPhenotypicFeature	4:28:67	7:30:69	0:1:3	D036145	ginsenoside	ChemicalEntity	19	20	1	1:NR:2	L2R	CROSS	67-69	247-258	D007859	impairment of learning|learning impairment|learning impairment	DiseaseOrPhenotypicFeature	4:28:67	7:30:69	0:1:3	24408	N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor	GeneOrGeneProduct	247:288	258:290	8:10	1:NR:2	L2R	CROSS	67-69	259-260	D007859	impairment of learning|learning impairment|learning impairment	DiseaseOrPhenotypicFeature	4:28:67	7:30:69	0:1:3	D016291	MK801	ChemicalEntity	259	260	8	1:NR:2	L2R	CROSS	10-11	19-20	D009020	morphine|morphine|morphine|morphine|morphine|Morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	10:52:71:87:123:149:193:220:234:275:280	11:53:72:88:124:150:194:221:235:276:281	0:2:3:4:4:6:7:8:8:9:9	D036145	ginsenoside	ChemicalEntity	19	20	1	1:NR:2	L2R	NON-CROSS	280-281	288-290	D009020	morphine|morphine|morphine|morphine|morphine|Morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	10:52:71:87:123:149:193:220:234:275:280	11:53:72:88:124:150:194:221:235:276:281	0:2:3:4:4:6:7:8:8:9:9	24408	N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor	GeneOrGeneProduct	247:288	258:290	8:10	1:NR:2	L2R	NON-CROSS	259-260	275-276	D009020	morphine|morphine|morphine|morphine|morphine|Morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	10:52:71:87:123:149:193:220:234:275:280	11:53:72:88:124:150:194:221:235:276:281	0:2:3:4:4:6:7:8:8:9:9	D016291	MK801	ChemicalEntity	259	260	8	1:NR:2	L2R	CROSS	19-20	247-258	D036145	ginsenoside	ChemicalEntity	19	20	1	24408	N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor	GeneOrGeneProduct	247:288	258:290	8:10	1:NR:2	L2R	CROSS	19-20	259-260	D036145	ginsenoside	ChemicalEntity	19	20	1	D016291	MK801	ChemicalEntity	259	260	8	1:Negative_Correlation:2	L2R	NON-CROSS	247-258	259-260	24408	N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor	GeneOrGeneProduct	247:288	258:290	8:10	D016291	MK801	ChemicalEntity	259	260	8
18951540	Repetitive transcranial magnetic stimulation for levodopa - induced dyskinesias in Parkinson 's disease .|In a placebo - controlled , single - blinded , crossover study , we assessed the effect of " real " repetitive transcranial magnetic stimulation ( rTMS ) versus " sham " rTMS ( placebo ) on peak dose dyskinesias in patients with Parkinson 's disease ( PD ) .|Ten patients with PD and prominent dyskinesias had rTMS ( 1 , 800 pulses ; 1 Hz rate ) delivered over the motor cortex for 4 consecutive days twice , once real stimuli and once sham stimulation were used ; evaluations were done at the baseline and 1 day after the end of each of the treatment series .|Direct comparison between sham and real rTMS effects showed no significant difference in clinician - assessed dyskinesia severity .|However , comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo .|The major effect was on dystonia subscore .|Similarly , in patient diaries , although both treatments caused reduction in subjective dyskinesia scores during the days of intervention , the effect was sustained for 3 days after the intervention for the real rTMS only .|Following rTMS , no side effects and no adverse effects on motor function and PD symptoms were noted .|The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low - frequency rTMS on dyskinesias in PD .|The effects may be further exploited for potential therapeutic uses .	1:Positive_Correlation:2	L2R	NON-CROSS	5-6	8-9	D007980	levodopa	ChemicalEntity	5	6	0	D004409	dyskinesias|dyskinesias|dyskinesias|dyskinesia|dyskinesia|dyskinesia|dyskinesias	DiseaseOrPhenotypicFeature	8:53:70:139:154:184:247	9:54:71:140:155:185:248	0:1:2:3:4:6:8	1:NR:2	L2R	NON-CROSS	5-6	10-13	D007980	levodopa	ChemicalEntity	5	6	0	D010300	Parkinson 's disease|Parkinson 's disease|PD|PD|PD|PD	DiseaseOrPhenotypicFeature	10:57:61:67:222:249	13:60:62:68:223:250	0:1:1:2:7:8	1:NR:2	L2R	CROSS	5-6	168-169	D007980	levodopa	ChemicalEntity	5	6	0	D004421	dystonia	DiseaseOrPhenotypicFeature	168	169	5
19759529	The glycine transporter - 1 inhibitor SSR103800 displays a selective and specific antipsychotic - like profile in normal and transgenic mice .|Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission .|However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( NMDA ) receptor produce schizophrenic - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .|As a result , there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor .|Among them are glycine transporter - 1 ( GlyT1 ) inhibitors such as SSR103800 , which indirectly enhance NMDA receptor function by increasing the glycine ( a co - agonist for the NMDA receptor ) levels in the synapse .|This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of hyperactivity , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .|Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .|In contrast , SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg p . o . ) .|Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of hyperactivity .|However , unlike these latter , SSR103800 did not produce catalepsy ( retention on the bar test ) up to 30 mg / kg p . o .|Together these findings show that the GlyT1 inhibitor , SSR103800 , produces antipsychotic - like effects , which differ from those observed with compounds primarily targeting the dopaminergic system , and has a reduced side - effect potential as compared with these latter drugs .	1:NR:2	L2R	NON-CROSS	1-5	6-7	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	1:NR:2	L2R	CROSS	1-5	22-23	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	1:NR:2	L2R	NON-CROSS	358-359	379-380	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	1:NR:2	L2R	NON-CROSS	109-111	115-119	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	1:NR:2	L2R	NON-CROSS	120-121	136-137	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D005998	glycine	ChemicalEntity	136	137	4	1:NR:2	L2R	CROSS	322-323	358-359	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	CROSS	120-121	182-183	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	1:NR:2	L2R	CROSS	120-121	184-187	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	1:NR:2	L2R	CROSS	276-277	358-359	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:NR:2	L2R	CROSS	303-304	358-359	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	308-309	358-359	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	310-311	358-359	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	312-313	358-359	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	CROSS	334-335	358-359	14664	glycine transporter - 1|glycine transporter - 1|GlyT1|GlyT1	GeneOrGeneProduct	1:115:120:358	5:119:121:359	0:4:4:10	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:NR:2	L2R	CROSS	6-7	22-23	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	1:NR:2	L2R	NON-CROSS	361-362	379-380	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	1:NR:2	L2R	NON-CROSS	125-126	130-132	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	1:NR:2	L2R	NON-CROSS	125-126	136-137	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D005998	glycine	ChemicalEntity	136	137	4	1:NR:2	L2R	NON-CROSS	261-262	265-266	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	NON-CROSS	261-262	268-269	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	1:NR:2	L2R	NON-CROSS	164-165	184-187	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	1:NR:2	L2R	NON-CROSS	203-204	214-215	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:NR:2	L2R	CROSS	303-304	330-331	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	308-309	330-331	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	310-311	330-331	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	312-313	330-331	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	NON-CROSS	330-331	334-335	-	SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800|SSR103800	ChemicalEntity	6:125:164:214:261:330:361	7:126:165:215:262:331:362	0:4:5:6:7:9:10	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:Association:2	L2R	NON-CROSS	22-23	30-31	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	1:Association:2	R2L	NON-CROSS	54-55	41-53	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	1:NR:2	L2R	CROSS	54-55	136-137	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	D005998	glycine	ChemicalEntity	136	137	4	1:NR:2	L2R	CROSS	54-55	182-183	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	1:NR:2	L2R	CROSS	54-55	184-187	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	1:NR:2	L2R	CROSS	54-55	203-204	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:NR:2	L2R	CROSS	54-55	303-304	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	54-55	308-309	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	54-55	310-311	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	54-55	312-313	D012559	Schizophrenia|schizophrenic	DiseaseOrPhenotypicFeature	22:54	23:55	1:2	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	CROSS	30-31	41-53	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	1:NR:2	L2R	CROSS	30-31	136-137	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	D005998	glycine	ChemicalEntity	136	137	4	1:NR:2	L2R	CROSS	322-323	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	CROSS	268-269	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	1:NR:2	L2R	CROSS	239-242	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	1:NR:2	L2R	CROSS	276-277	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:NR:2	L2R	CROSS	303-304	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	308-309	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	310-311	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	312-313	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	CROSS	334-335	379-380	D004298	dopamine|dopaminergic	ChemicalEntity	30:379	31:380	1:10	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:Positive_Correlation:2	R2L	NON-CROSS	136-137	130-132	D005998	glycine	ChemicalEntity	136	137	4	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	1:Association:2	R2L	NON-CROSS	248-250	246-247	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	1:NR:2	L2R	NON-CROSS	182-183	194-196	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	1:Negative_Correlation:2	L2R	NON-CROSS	235-237	239-242	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	1:NR:2	L2R	NON-CROSS	194-196	203-204	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:NR:2	L2R	CROSS	248-250	303-304	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	248-250	308-309	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	248-250	310-311	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	248-250	312-313	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	CROSS	248-250	334-335	14810	glutamate N - methyl - D - aspartate ( NMDA ) receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA receptor|NMDA Nr1|NMDA receptor|NMDA Nr1	GeneOrGeneProduct	41:74:109:130:144:194:235:248	53:76:111:132:146:196:237:250	2:2:3:4:4:5:6:6	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:NR:2	L2R	CROSS	136-137	173-174	D005998	glycine	ChemicalEntity	136	137	4	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	CROSS	136-137	182-183	D005998	glycine	ChemicalEntity	136	137	4	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	1:NR:2	L2R	CROSS	136-137	184-187	D005998	glycine	ChemicalEntity	136	137	4	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	1:NR:2	L2R	CROSS	136-137	203-204	D005998	glycine	ChemicalEntity	136	137	4	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:NR:2	L2R	CROSS	136-137	303-304	D005998	glycine	ChemicalEntity	136	137	4	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	136-137	308-309	D005998	glycine	ChemicalEntity	136	137	4	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	136-137	310-311	D005998	glycine	ChemicalEntity	136	137	4	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	136-137	312-313	D005998	glycine	ChemicalEntity	136	137	4	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	CROSS	136-137	334-335	D005998	glycine	ChemicalEntity	136	137	4	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:Positive_Correlation:2	L2R	NON-CROSS	265-266	268-269	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	1:Positive_Correlation:2	L2R	NON-CROSS	239-242	246-247	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	1:NR:2	L2R	NON-CROSS	265-266	273-275	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:Negative_Correlation:2	R2L	NON-CROSS	322-323	303-304	D006220	haloperidol	ChemicalEntity	303	304	8	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:Negative_Correlation:2	R2L	NON-CROSS	322-323	308-309	C076029	olanzapine	ChemicalEntity	308	309	8	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:Negative_Correlation:2	R2L	NON-CROSS	322-323	310-311	D003024	clozapine	ChemicalEntity	310	311	8	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:Negative_Correlation:2	R2L	NON-CROSS	322-323	312-313	C094645	aripiprazole	ChemicalEntity	312	313	8	D006948	hyperactivity|hyperactivity|hyperactivity|hyperactivity|hyperactivity	DiseaseOrPhenotypicFeature	173:228:246:265:322	174:229:247:266:323	5:6:6:7:8	1:NR:2	L2R	NON-CROSS	182-183	184-187	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	1:NR:2	L2R	NON-CROSS	268-269	273-275	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:NR:2	L2R	CROSS	268-269	303-304	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	268-269	308-309	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	268-269	310-311	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	268-269	312-313	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	CROSS	268-269	334-335	D000661	amphetamine|amphetamine	ChemicalEntity	182:268	183:269	5:7	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:NR:2	L2R	NON-CROSS	184-187	203-204	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	1:NR:2	L2R	CROSS	239-242	303-304	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	239-242	308-309	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	239-242	310-311	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	239-242	312-313	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	CROSS	239-242	334-335	D016291	MK - 801|MK - 801	ChemicalEntity	184:239	187:242	5:6	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:NR:2	L2R	CROSS	276-277	303-304	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	D006220	haloperidol	ChemicalEntity	303	304	8	1:NR:2	L2R	CROSS	276-277	308-309	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	CROSS	276-277	310-311	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	CROSS	276-277	312-313	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	C094645	aripiprazole	ChemicalEntity	312	313	8	1:NR:2	L2R	CROSS	276-277	334-335	13162	DAT|dopamine transporter|DAT	GeneOrGeneProduct	203:273:276	204:275:277	5:7:7	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:NR:2	L2R	NON-CROSS	303-304	308-309	D006220	haloperidol	ChemicalEntity	303	304	8	C076029	olanzapine	ChemicalEntity	308	309	8	1:NR:2	L2R	NON-CROSS	303-304	310-311	D006220	haloperidol	ChemicalEntity	303	304	8	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	NON-CROSS	303-304	312-313	D006220	haloperidol	ChemicalEntity	303	304	8	C094645	aripiprazole	ChemicalEntity	312	313	8	1:Positive_Correlation:2	L2R	CROSS	303-304	334-335	D006220	haloperidol	ChemicalEntity	303	304	8	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:NR:2	L2R	NON-CROSS	308-309	310-311	C076029	olanzapine	ChemicalEntity	308	309	8	D003024	clozapine	ChemicalEntity	310	311	8	1:NR:2	L2R	NON-CROSS	308-309	312-313	C076029	olanzapine	ChemicalEntity	308	309	8	C094645	aripiprazole	ChemicalEntity	312	313	8	1:Positive_Correlation:2	L2R	CROSS	308-309	334-335	C076029	olanzapine	ChemicalEntity	308	309	8	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:NR:2	L2R	NON-CROSS	310-311	312-313	D003024	clozapine	ChemicalEntity	310	311	8	C094645	aripiprazole	ChemicalEntity	312	313	8	1:Positive_Correlation:2	L2R	CROSS	310-311	334-335	D003024	clozapine	ChemicalEntity	310	311	8	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9	1:Positive_Correlation:2	L2R	CROSS	312-313	334-335	C094645	aripiprazole	ChemicalEntity	312	313	8	D002375	catalepsy	DiseaseOrPhenotypicFeature	334	335	9
19914299	Fluoxetine improves the memory deficits caused by the chemotherapy agent 5 - fluorouracil .|Cancer patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition .|A widely used chemotherapeutic agent , 5 - fluorouracil ( 5 - FU ) , readily crosses the blood - brain barrier and so could have a direct effect on brain function .|In particular this anti mitotic drug could reduce cell proliferation in the neurogenic regions of the adult brain .|In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the SSRI antidepressant Fluoxetine .|In this investigation the behavioural effects of chronic ( two week ) treatment with 5 - FU and ( three weeks ) with Fluoxetine either separately or in combination with 5 - FU were tested on adult Lister hooded rats .|Behavioural effects were tested using a context dependent conditioned emotional response test ( CER ) which showed that animals treated with 5 - FU had a significant reduction in freezing time compared to controls .|A separate group of animals was tested using a hippocampal dependent spatial working memory test , the object location recognition test ( OLR ) .|Animals treated only with 5 - FU showed significant deficits in their ability to carry out the OLR task but co administration of Fluoxetine improved their performance .|5 - FU chemotherapy caused a significant reduction in the number of proliferating cells in the sub granular zone of the dentate gyrus compared to controls .|This reduction was eliminated when Fluoxetine was co administered with 5 - FU .|Fluoxetine on its own had no effect on proliferating cell number or behaviour .|These findings suggest that 5 - FU can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant Fluoxetine .	1:Negative_Correlation:2	L2R	NON-CROSS	0-1	3-5	D005473	Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine	ChemicalEntity	0:99:124:225:262:271:317	1:100:125:226:263:272:318	0:4:5:8:10:11:12	D008569	memory deficits	DiseaseOrPhenotypicFeature	3	5	0	1:Negative_Correlation:2	L2R	NON-CROSS	267-270	271-272	D005473	Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine	ChemicalEntity	0:99:124:225:262:271:317	1:100:125:226:263:272:318	0:4:5:8:10:11:12	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	10:37:41:115:131:163:206:230:267:289	13:40:44:118:134:166:209:233:270:292	0:2:2:5:5:6:8:9:10:12	1:NR:2	L2R	CROSS	0-1	14-15	D005473	Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine	ChemicalEntity	0:99:124:225:262:271:317	1:100:125:226:263:272:318	0:4:5:8:10:11:12	D009369	Cancer	DiseaseOrPhenotypicFeature	14	15	1	1:NR:2	L2R	NON-CROSS	97-98	99-100	D005473	Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine|Fluoxetine	ChemicalEntity	0:99:124:225:262:271:317	1:100:125:226:263:272:318	0:4:5:8:10:11:12	D017367	SSRI	ChemicalEntity	97	98	4	1:Positive_Correlation:2	L2R	NON-CROSS	3-5	10-13	D008569	memory deficits	DiseaseOrPhenotypicFeature	3	5	0	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	10:37:41:115:131:163:206:230:267:289	13:40:44:118:134:166:209:233:270:292	0:2:2:5:5:6:8:9:10:12	1:NR:2	L2R	CROSS	3-5	97-98	D008569	memory deficits	DiseaseOrPhenotypicFeature	3	5	0	D017367	SSRI	ChemicalEntity	97	98	4	1:Negative_Correlation:2	L2R	CROSS	10-13	14-15	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	10:37:41:115:131:163:206:230:267:289	13:40:44:118:134:166:209:233:270:292	0:2:2:5:5:6:8:9:10:12	D009369	Cancer	DiseaseOrPhenotypicFeature	14	15	1	1:NR:2	L2R	CROSS	97-98	115-118	D005472	5 - fluorouracil|5 - fluorouracil|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU|5 - FU	ChemicalEntity	10:37:41:115:131:163:206:230:267:289	13:40:44:118:134:166:209:233:270:292	0:2:2:5:5:6:8:9:10:12	D017367	SSRI	ChemicalEntity	97	98	4	1:NR:2	L2R	CROSS	14-15	97-98	D009369	Cancer	DiseaseOrPhenotypicFeature	14	15	1	D017367	SSRI	ChemicalEntity	97	98	4
20195852	Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .|Despite increasing reports on nonionic contrast media - induced nephropathy ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .|This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .|The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .|Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .|Urine samples for Na and Cr also were checked at the same intervals .|Risk of renal failure , Injury to the kidney , Failure of kidney function , Loss of kidney function , and End - stage renal damage ( RIFLE criteria ) were used to define CIN and its incidence in the study population .|Accordingly , among the 15 CIN patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had renal injury , whereas 5 % of group B had increased risk and 2 . 5 % had renal injury .|Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of CM ( p = 0 . 014 ) .|Among the 15 patients with CIN , 6 had cyanotic congenital heart diseases , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .|Although clinically silent , CIN is not rare in pediatrics .|The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of cyanosis , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .	1:Positive_Correlation:2	R2L	NON-CROSS	28-29	24-26	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	DiseaseOrPhenotypicFeature	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	1:Positive_Correlation:2	L2R	NON-CROSS	71-72	81-82	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	DiseaseOrPhenotypicFeature	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	1:Positive_Correlation:2	L2R	NON-CROSS	71-72	83-84	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	DiseaseOrPhenotypicFeature	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	1:NR:2	L2R	CROSS	191-192	226-228	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	DiseaseOrPhenotypicFeature	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	151-152	226-228	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	DiseaseOrPhenotypicFeature	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	1:NR:2	L2R	CROSS	193-194	226-228	D007674	nephropathy|nephropathy|CIN|CIN|renal damage|CIN|CIN|CIN|CIN|CIN|CIN|CIN	DiseaseOrPhenotypicFeature	2:28:30:71:226:236:250:308:343:364:398:429	3:29:31:72:228:237:251:309:344:365:399:430	0:1:1:2:6:6:7:8:8:9:10:11	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	1:NR:2	L2R	NON-CROSS	78-79	81-82	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	1:NR:2	L2R	NON-CROSS	78-79	83-84	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	1:Association:2	L2R	NON-CROSS	107-108	112-113	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D003490	cyanosis|cyanosis	DiseaseOrPhenotypicFeature	112:425	113:426	2:11	1:NR:2	L2R	NON-CROSS	185-186	191-192	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	1:NR:2	L2R	NON-CROSS	151-152	185-186	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	1:NR:2	L2R	NON-CROSS	185-186	193-194	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	1:NR:2	L2R	CROSS	185-186	204-206	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D051437	renal failure|Failure of kidney function|Loss of kidney function	DiseaseOrPhenotypicFeature	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	296-298	318-319	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D058186	Injury to the kidney|renal injury|renal injury	DiseaseOrPhenotypicFeature	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	350-351	369-372	D003287	contrast media|contrast media|contrast media|CM|CM|CM|CM|CM|CM	ChemicalEntity	7:24:75:78:107:185:318:350:418	9:26:77:79:108:186:319:351:419	0:1:2:2:2:4:8:8:11	D006331	congenital heart diseases	DiseaseOrPhenotypicFeature	369	372	9	1:NR:2	L2R	NON-CROSS	81-82	83-84	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	1:NR:2	L2R	NON-CROSS	112-113	123-124	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	D003490	cyanosis|cyanosis	DiseaseOrPhenotypicFeature	112:425	113:426	2:11	1:NR:2	L2R	CROSS	123-124	144-145	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	123-124	149-150	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	1:NR:2	L2R	CROSS	123-124	155-156	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	1:NR:2	L2R	CROSS	123-124	204-206	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	D051437	renal failure|Failure of kidney function|Loss of kidney function	DiseaseOrPhenotypicFeature	204:212:217	206:216:221	6:6:6	1:Positive_Correlation:2	L2R	CROSS	123-124	207-211	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	D058186	Injury to the kidney|renal injury|renal injury	DiseaseOrPhenotypicFeature	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	123-124	369-372	C038192	iopromide|iopromide	ChemicalEntity	81:123	82:124	2:3	D006331	congenital heart diseases	DiseaseOrPhenotypicFeature	369	372	9	1:NR:2	L2R	NON-CROSS	112-113	133-134	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	D003490	cyanosis|cyanosis	DiseaseOrPhenotypicFeature	112:425	113:426	2:11	1:NR:2	L2R	CROSS	133-134	144-145	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	133-134	149-150	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	1:NR:2	L2R	CROSS	133-134	155-156	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	1:NR:2	L2R	CROSS	133-134	204-206	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	D051437	renal failure|Failure of kidney function|Loss of kidney function	DiseaseOrPhenotypicFeature	204:212:217	206:216:221	6:6:6	1:Positive_Correlation:2	L2R	CROSS	133-134	207-211	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	D058186	Injury to the kidney|renal injury|renal injury	DiseaseOrPhenotypicFeature	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	133-134	369-372	D007472	iohexol|iohexol	ChemicalEntity	83:133	84:134	2:3	D006331	congenital heart diseases	DiseaseOrPhenotypicFeature	369	372	9	1:NR:2	L2R	CROSS	112-113	144-145	D003490	cyanosis|cyanosis	DiseaseOrPhenotypicFeature	112:425	113:426	2:11	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	112-113	149-150	D003490	cyanosis|cyanosis	DiseaseOrPhenotypicFeature	112:425	113:426	2:11	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	1:NR:2	L2R	CROSS	112-113	155-156	D003490	cyanosis|cyanosis	DiseaseOrPhenotypicFeature	112:425	113:426	2:11	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	1:NR:2	L2R	NON-CROSS	146-147	149-150	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	1:NR:2	L2R	NON-CROSS	191-192	193-194	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	1:NR:2	L2R	CROSS	191-192	204-206	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	D051437	renal failure|Failure of kidney function|Loss of kidney function	DiseaseOrPhenotypicFeature	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	191-192	207-211	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	D058186	Injury to the kidney|renal injury|renal injury	DiseaseOrPhenotypicFeature	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	191-192	369-372	D012964	sodium|Na|Na	ChemicalEntity	144:146:191	145:147:192	4:4:5	D006331	congenital heart diseases	DiseaseOrPhenotypicFeature	369	372	9	1:NR:2	L2R	NON-CROSS	151-152	155-156	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	1:NR:2	L2R	CROSS	151-152	204-206	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	D051437	renal failure|Failure of kidney function|Loss of kidney function	DiseaseOrPhenotypicFeature	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	151-152	207-211	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	D058186	Injury to the kidney|renal injury|renal injury	DiseaseOrPhenotypicFeature	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	151-152	369-372	D011188	potassium|K	ChemicalEntity	149:151	150:152	4:4	D006331	congenital heart diseases	DiseaseOrPhenotypicFeature	369	372	9	1:NR:2	L2R	CROSS	193-194	204-206	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	D051437	renal failure|Failure of kidney function|Loss of kidney function	DiseaseOrPhenotypicFeature	204:212:217	206:216:221	6:6:6	1:NR:2	L2R	CROSS	193-194	207-211	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	D058186	Injury to the kidney|renal injury|renal injury	DiseaseOrPhenotypicFeature	207:278:296	211:280:298	6:7:7	1:NR:2	L2R	CROSS	193-194	369-372	D003404	creatinine|Cr|Cr	ChemicalEntity	155:157:193	156:158:194	4:4:5	D006331	congenital heart diseases	DiseaseOrPhenotypicFeature	369	372	9
20621845	Elevation of ADAM10 , ADAM17 , MMP - 2 and MMP - 9 expression with media degeneration features CaCl2 - induced thoracic aortic aneurysm in a rat model .|PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .|METHODS : Thoracic aorta of male Sprague - Dawley rats was exposed to 0 . 5M CaCl ( 2 ) or normal saline ( NaCl ) .|After 12weeks , animals were euthanized , and CaCl ( 2 ) - treated , CaCl ( 2 ) - untreated ( n = 12 ) and NaCl - treated aortic segments ( n = 12 ) were collected for histological and molecular assessments .|MMP - TIMP and ADAM mRNAs were semi - quantitatively analyzed and protein expressions were determined by immunohistochemistry .|RESULTS : Despite similar external diameters among CaCl ( 2 ) - treated , non - CaCl ( 2 ) - treated and NaCl - treated segments , aneurymal alteration ( n = 6 , 50 % ) , media degeneration with regional disruption , fragmentation of elastic fiber , and increased collagen deposition ( n = 12 , 100 % ) were demonstrated in CaCl ( 2 ) - treated segments .|MMP - 2 , MMP - 9 , ADAM - 10 and ADAM - 17 mRNA levels were increased in CaCl ( 2 ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in CaCl ( 2 ) - untreated segments , as compared with NaCl - treated segments .|Immunohistochemistry displayed significantly increased expressions of MMP - 2 , MMP - 9 , ADAM - 10 and ADAM - 17 ( all p < 0 . 01 ) in intima and media for CaCl ( 2 ) - treated segments .|TIMP mRNA and tissue levels did not differ obviously among the three aortic segments .|CONCLUSION : This study establishes a TAA model by periarterial CaCl ( 2 ) exposure in rats , and demonstrates a significant elevation of expression of MMP - 2 , MMP - 9 , ADAM10 and ADAM17 in the pathogenesis of vascular remodeling .	1:NR:2	L2R	NON-CROSS	2-3	4-5	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	1:NR:2	L2R	NON-CROSS	2-3	6-9	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	1:NR:2	L2R	NON-CROSS	399-402	403-404	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	1:Positive_Correlation:2	L2R	NON-CROSS	263-266	275-279	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	1:Association:2	L2R	NON-CROSS	2-3	21-24	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	1:NR:2	L2R	CROSS	2-3	58-60	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	1:NR:2	L2R	CROSS	2-3	67-71	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	1:NR:2	L2R	CROSS	2-3	75-77	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	1:NR:2	L2R	NON-CROSS	307-308	326-329	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	CROSS	326-329	354-355	29650	ADAM10|ADAM - 10|ADAM - 10|ADAM10	GeneOrGeneProduct	2:263:326:403	3:266:329:404	0:6:7:9	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:NR:2	L2R	NON-CROSS	4-5	6-9	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	1:NR:2	L2R	NON-CROSS	399-402	405-406	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	1:Positive_Correlation:2	L2R	NON-CROSS	267-270	275-279	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	1:Association:2	L2R	NON-CROSS	4-5	21-24	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	1:NR:2	L2R	CROSS	4-5	58-60	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	1:NR:2	L2R	CROSS	4-5	67-71	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	1:NR:2	L2R	CROSS	4-5	75-77	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	1:NR:2	L2R	NON-CROSS	307-308	330-333	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	CROSS	330-333	354-355	57027	ADAM17|ADAM - 17|ADAM - 17|ADAM17	GeneOrGeneProduct	4:267:330:405	5:270:333:406	0:6:7:9	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:NR:2	L2R	NON-CROSS	6-9	10-13	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	1:Positive_Correlation:2	L2R	NON-CROSS	247-251	255-258	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	1:Association:2	L2R	NON-CROSS	6-9	21-24	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	1:NR:2	L2R	CROSS	6-9	58-60	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	1:NR:2	L2R	CROSS	6-9	67-71	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	1:NR:2	L2R	CROSS	6-9	75-77	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	1:NR:2	L2R	NON-CROSS	307-308	318-321	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	CROSS	318-321	354-355	81686	MMP - 2|MMP - 2|MMP - 2|MMP - 2	GeneOrGeneProduct	6:255:318:395	9:258:321:398	0:6:7:9	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:Positive_Correlation:2	L2R	NON-CROSS	10-13	18-19	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	1:Association:2	L2R	NON-CROSS	10-13	21-24	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	1:NR:2	L2R	CROSS	10-13	58-60	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	1:NR:2	L2R	CROSS	10-13	67-71	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	1:NR:2	L2R	CROSS	10-13	75-77	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	1:NR:2	L2R	NON-CROSS	307-308	322-325	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	CROSS	322-325	354-355	81687	MMP - 9|MMP - 9|MMP - 9|MMP - 9	GeneOrGeneProduct	10:259:322:399	13:262:325:402	0:6:7:9	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:Positive_Correlation:2	L2R	NON-CROSS	18-19	21-24	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	1:Positive_Correlation:2	L2R	NON-CROSS	51-55	58-60	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	1:NR:2	L2R	NON-CROSS	51-55	67-71	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	1:NR:2	L2R	NON-CROSS	51-55	75-77	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	1:NR:2	L2R	NON-CROSS	198-202	205-206	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	CROSS	346-350	354-355	D002122	CaCl2|calcium chloride|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )|CaCl ( 2 )	ChemicalEntity	18:48:51:107:126:133:189:198:247:275:296:346:379	19:50:55:111:130:137:193:202:251:279:300:350:383	0:1:1:2:3:3:5:5:5:6:6:7:9	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:NR:2	L2R	NON-CROSS	72-73	88-89	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	1:NR:2	L2R	NON-CROSS	78-79	88-89	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	1:NR:2	L2R	CROSS	88-89	115-116	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	CROSS	354-355	375-376	D017545	thoracic aortic aneurysm|thoracic aortic aneurysm|TAA|TAA|TAA	DiseaseOrPhenotypicFeature	21:41:45:88:375	24:44:46:89:376	0:1:1:1:9	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:NR:2	L2R	NON-CROSS	58-60	67-71	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	1:NR:2	L2R	NON-CROSS	58-60	75-77	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	1:NR:2	L2R	CROSS	58-60	115-116	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	CROSS	58-60	165-166	D014652	arterial injury	DiseaseOrPhenotypicFeature	58	60	1	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:NR:2	L2R	NON-CROSS	72-73	75-77	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	1:NR:2	L2R	CROSS	145-146	167-168	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	NON-CROSS	165-166	167-168	29650,57027	a disintegrin and metalloproteinase|ADAM|ADAM	GeneOrGeneProduct	67:72:167	71:73:168	1:1:4	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:NR:2	L2R	CROSS	145-146	163-164	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	1:NR:2	L2R	NON-CROSS	163-164	165-166	81686,81687	matrix metalloproteinases|MMPs|MMP	GeneOrGeneProduct	75:78:163	77:79:164	1:1:4	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8	1:NR:2	L2R	CROSS	145-146	165-166	D012965	NaCl|NaCl|NaCl|NaCl	ChemicalEntity	115:145:205:307	116:146:206:308	2:3:5:6	116510	TIMP|TIMP	GeneOrGeneProduct	165:354	166:355	4:8
23872883	Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity .|Cardiovascular diseases ( CVDs ) are the major health problem of advanced as well as developing countries of the world .|The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol - induced cardiotoxicity in rats .|The subcutaneous injection of isoproterenol ( 30 mg / kg ) into rats twice at an interval of 24 h , for two consecutive days , led to a significant increase in serum lactate dehydrogenase , creatine phosphokinase , alanine transaminase , aspartate transaminase , and angiotensin - converting enzyme activities , total cholesterol , triglycerides , free serum fatty acid , cardiac tissue malondialdehyde ( MDA ) , and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group ( P < 0 . 05 ) .|Pretreatment with S . virgaurea extract for 5 weeks at a dose of 250 mg / kg followed by isoproterenol injection significantly prevented the observed alterations .|Captopril ( 50 mg / kg / day , given orally ) , an inhibitor of angiotensin - converting enzyme used as a standard cardioprotective drug , was used as a positive control in this study .|The data of the present study suggest that S . virgaurea extract exerts its protective effect by decreasing MDA level and increasing the antioxidant status in isoproterenol - treated rats .|The study emphasizes the beneficial action of S . virgaurea extract as a cardioprotective agent .	1:Negative_Correlation:2	L2R	NON-CROSS	3-6	8-9	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	1:NR:2	L2R	CROSS	3-6	10-12	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	1:Negative_Correlation:2	L2R	NON-CROSS	45-48	49-50	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	1:NR:2	L2R	CROSS	45-48	89-91	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	1:NR:2	L2R	CROSS	45-48	92-94	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	1:NR:2	L2R	CROSS	45-48	95-97	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	1:NR:2	L2R	CROSS	45-48	98-100	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	1:NR:2	L2R	CROSS	201-205	230-234	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:NR:2	L2R	CROSS	109-110	160-164	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D002784	cholesterol	ChemicalEntity	109	110	3	1:NR:2	L2R	CROSS	111-112	160-164	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	CROSS	115-117	160-164	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D005227	fatty acid	ChemicalEntity	115	117	3	1:Negative_Correlation:2	L2R	NON-CROSS	230-234	240-241	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	CROSS	126-128	160-164	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	CROSS	136-137	160-164	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	CROSS	138-140	160-164	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	160-164	185-186	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	NON-CROSS	260-264	266-268	D010936	Solidago virgaurea extract|Solidago virgaurea extract|S . virgaurea extract|S . virgaurea extract|S . virgaurea extract	ChemicalEntity	3:45:160:230:260	6:48:164:234:264	0:2:4:6:7	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:Positive_Correlation:2	R2L	NON-CROSS	52-53	49-50	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	1:NR:2	L2R	CROSS	52-53	89-91	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	1:NR:2	L2R	CROSS	52-53	92-94	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	1:NR:2	L2R	CROSS	52-53	95-97	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	1:NR:2	L2R	CROSS	52-53	98-100	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	1:NR:2	L2R	CROSS	52-53	102-106	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:NR:2	L2R	CROSS	52-53	109-110	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	D002784	cholesterol	ChemicalEntity	109	110	3	1:NR:2	L2R	CROSS	52-53	111-112	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	CROSS	52-53	115-117	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	CROSS	52-53	120-121	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	CROSS	52-53	126-128	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	CROSS	52-53	136-137	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	CROSS	52-53	138-140	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	52-53	185-186	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	52-53	209-211	D066126	cardiotoxicity|cardiotoxicity	DiseaseOrPhenotypicFeature	8:52	9:53	0:2	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	CROSS	13-14	49-50	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	1:NR:2	L2R	CROSS	13-14	89-91	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	1:NR:2	L2R	CROSS	13-14	92-94	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	1:NR:2	L2R	CROSS	13-14	95-97	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	1:NR:2	L2R	CROSS	13-14	98-100	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	1:NR:2	L2R	CROSS	13-14	102-106	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:NR:2	L2R	CROSS	13-14	109-110	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D002784	cholesterol	ChemicalEntity	109	110	3	1:NR:2	L2R	CROSS	13-14	111-112	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	CROSS	13-14	115-117	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	CROSS	13-14	120-121	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	CROSS	13-14	126-128	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	CROSS	13-14	136-137	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	CROSS	13-14	138-140	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	13-14	185-186	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	13-14	209-211	D002318	Cardiovascular diseases|CVDs	DiseaseOrPhenotypicFeature	10:13	12:14	1:1	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:Positive_Correlation:2	L2R	NON-CROSS	60-61	89-91	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	1:Positive_Correlation:2	L2R	NON-CROSS	60-61	92-94	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	1:Positive_Correlation:2	L2R	NON-CROSS	60-61	95-97	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	1:Positive_Correlation:2	L2R	NON-CROSS	60-61	98-100	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	1:Positive_Correlation:2	L2R	NON-CROSS	177-178	201-205	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:Positive_Correlation:2	L2R	NON-CROSS	60-61	109-110	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D002784	cholesterol	ChemicalEntity	109	110	3	1:Positive_Correlation:2	L2R	NON-CROSS	60-61	111-112	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D014280	triglycerides	ChemicalEntity	111	112	3	1:Positive_Correlation:2	L2R	NON-CROSS	60-61	115-117	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D005227	fatty acid	ChemicalEntity	115	117	3	1:Positive_Correlation:2	L2R	NON-CROSS	240-241	248-249	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:Positive_Correlation:2	L2R	NON-CROSS	126-128	177-178	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D009569	nitric oxide	ChemicalEntity	126	128	3	1:Negative_Correlation:2	L2R	NON-CROSS	136-137	177-178	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D005978	glutathione	ChemicalEntity	136	137	3	1:Negative_Correlation:2	L2R	NON-CROSS	138-140	177-178	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	177-178	185-186	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	248-249	266-268	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	49:60:177:248	50:61:178:249	2:3:4:6	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	89-91	92-94	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	1:NR:2	L2R	NON-CROSS	89-91	95-97	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	1:NR:2	L2R	NON-CROSS	89-91	98-100	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	1:NR:2	L2R	NON-CROSS	89-91	102-106	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:NR:2	L2R	NON-CROSS	89-91	109-110	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	D002784	cholesterol	ChemicalEntity	109	110	3	1:NR:2	L2R	NON-CROSS	89-91	111-112	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	NON-CROSS	89-91	115-117	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	NON-CROSS	89-91	120-121	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	NON-CROSS	89-91	126-128	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	89-91	136-137	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	89-91	138-140	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	89-91	185-186	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	89-91	209-211	24533	lactate dehydrogenase	GeneOrGeneProduct	89	91	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	92-94	95-97	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	1:NR:2	L2R	NON-CROSS	92-94	98-100	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	1:NR:2	L2R	NON-CROSS	92-94	102-106	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:NR:2	L2R	NON-CROSS	92-94	109-110	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	D002784	cholesterol	ChemicalEntity	109	110	3	1:NR:2	L2R	NON-CROSS	92-94	111-112	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	NON-CROSS	92-94	115-117	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	NON-CROSS	92-94	120-121	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	NON-CROSS	92-94	126-128	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	92-94	136-137	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	92-94	138-140	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	92-94	185-186	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	92-94	209-211	24264	creatine phosphokinase	GeneOrGeneProduct	92	94	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	95-97	98-100	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	1:NR:2	L2R	NON-CROSS	95-97	102-106	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:NR:2	L2R	NON-CROSS	95-97	109-110	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	D002784	cholesterol	ChemicalEntity	109	110	3	1:NR:2	L2R	NON-CROSS	95-97	111-112	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	NON-CROSS	95-97	115-117	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	NON-CROSS	95-97	120-121	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	NON-CROSS	95-97	126-128	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	95-97	136-137	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	95-97	138-140	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	95-97	185-186	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	95-97	209-211	81670	alanine transaminase	GeneOrGeneProduct	95	97	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	98-100	102-106	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:NR:2	L2R	NON-CROSS	98-100	109-110	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	D002784	cholesterol	ChemicalEntity	109	110	3	1:NR:2	L2R	NON-CROSS	98-100	111-112	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	NON-CROSS	98-100	115-117	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	NON-CROSS	98-100	120-121	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	NON-CROSS	98-100	126-128	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	98-100	136-137	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	98-100	138-140	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	98-100	185-186	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	98-100	209-211	25721	aspartate transaminase	GeneOrGeneProduct	98	100	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	102-106	109-110	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	D002784	cholesterol	ChemicalEntity	109	110	3	1:NR:2	L2R	NON-CROSS	102-106	111-112	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	NON-CROSS	102-106	115-117	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	NON-CROSS	102-106	120-121	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	NON-CROSS	102-106	126-128	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	102-106	136-137	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	102-106	138-140	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:Negative_Correlation:2	R2L	NON-CROSS	201-205	185-186	D002216	Captopril	ChemicalEntity	185	186	5	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	1:NR:2	L2R	NON-CROSS	201-205	209-211	24310	angiotensin - converting enzyme|angiotensin - converting enzyme	GeneOrGeneProduct	102:201	106:205	3:5	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	109-110	111-112	D002784	cholesterol	ChemicalEntity	109	110	3	D014280	triglycerides	ChemicalEntity	111	112	3	1:NR:2	L2R	NON-CROSS	109-110	115-117	D002784	cholesterol	ChemicalEntity	109	110	3	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	NON-CROSS	109-110	120-121	D002784	cholesterol	ChemicalEntity	109	110	3	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	NON-CROSS	109-110	126-128	D002784	cholesterol	ChemicalEntity	109	110	3	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	109-110	136-137	D002784	cholesterol	ChemicalEntity	109	110	3	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	109-110	138-140	D002784	cholesterol	ChemicalEntity	109	110	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	109-110	185-186	D002784	cholesterol	ChemicalEntity	109	110	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	109-110	209-211	D002784	cholesterol	ChemicalEntity	109	110	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	111-112	115-117	D014280	triglycerides	ChemicalEntity	111	112	3	D005227	fatty acid	ChemicalEntity	115	117	3	1:NR:2	L2R	NON-CROSS	111-112	120-121	D014280	triglycerides	ChemicalEntity	111	112	3	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	NON-CROSS	111-112	126-128	D014280	triglycerides	ChemicalEntity	111	112	3	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	111-112	136-137	D014280	triglycerides	ChemicalEntity	111	112	3	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	111-112	138-140	D014280	triglycerides	ChemicalEntity	111	112	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	111-112	185-186	D014280	triglycerides	ChemicalEntity	111	112	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	111-112	209-211	D014280	triglycerides	ChemicalEntity	111	112	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	115-117	120-121	D005227	fatty acid	ChemicalEntity	115	117	3	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	1:NR:2	L2R	NON-CROSS	115-117	126-128	D005227	fatty acid	ChemicalEntity	115	117	3	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	115-117	136-137	D005227	fatty acid	ChemicalEntity	115	117	3	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	115-117	138-140	D005227	fatty acid	ChemicalEntity	115	117	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	115-117	185-186	D005227	fatty acid	ChemicalEntity	115	117	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	115-117	209-211	D005227	fatty acid	ChemicalEntity	115	117	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	122-123	126-128	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	D009569	nitric oxide	ChemicalEntity	126	128	3	1:NR:2	L2R	NON-CROSS	122-123	136-137	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	122-123	138-140	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	185-186	240-241	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	240-241	266-268	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	120:122:240	121:123:241	3:3:6	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	126-128	136-137	D009569	nitric oxide	ChemicalEntity	126	128	3	D005978	glutathione	ChemicalEntity	136	137	3	1:NR:2	L2R	NON-CROSS	126-128	138-140	D009569	nitric oxide	ChemicalEntity	126	128	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	126-128	185-186	D009569	nitric oxide	ChemicalEntity	126	128	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	126-128	209-211	D009569	nitric oxide	ChemicalEntity	126	128	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	136-137	138-140	D005978	glutathione	ChemicalEntity	136	137	3	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	1:NR:2	L2R	CROSS	136-137	185-186	D005978	glutathione	ChemicalEntity	136	137	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	136-137	209-211	D005978	glutathione	ChemicalEntity	136	137	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	CROSS	138-140	185-186	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	D002216	Captopril	ChemicalEntity	185	186	5	1:NR:2	L2R	CROSS	138-140	209-211	24786	superoxide dismutase	GeneOrGeneProduct	138	140	3	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7	1:NR:2	L2R	NON-CROSS	185-186	209-211	D002216	Captopril	ChemicalEntity	185	186	5	D002316	cardioprotective drug|cardioprotective agent	ChemicalEntity	209:266	211:268	5:7
24333387	Glial activation and post - synaptic neurotoxicity : the key events in Streptozotocin ( ICV ) induced memory impairment in rats .|In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin ( STZ ) induced memory impaired rats was explored .|In experiment set up 1 : Memory deficit was found in Morris water maze test on 14 - 16 days after STZ ( ICV ; 3mg / Kg ) administration .|STZ causes increased expression of GFAP , CD11b and TNF - a indicating glial activation and neuroinflammation .|STZ also significantly increased the level of ROS , nitrite , Ca ( 2 + ) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity .|Increased expression and activity of Caspase - 3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex .|STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD - 95 , while , expression of pre synaptic markers ( synaptophysin and SNAP - 25 ) remains unaltered indicating selective post synaptic neurotoxicity .|Oral treatment with Memantine ( 10mg / kg ) and Ibuprofen ( 50 mg / kg ) daily for 13 days attenuated STZ induced glial activation , apoptotic cell death and post synaptic neurotoxicity in rat brain .|Further , in experiment set up 2 : where memory function was not affected i . e .|7 - 9 days after STZ treatment .|The level of GFAP , CD11b , TNF - a , ROS and nitrite levels were increased .|On the other hand , apoptotic marker , synaptic markers , mitochondrial activity and Ca ( 2 + ) levels remained unaffected .|Collective data indicates that neuroinflammatory process and oxidative stress occurs earlier to apoptosis and does not affect memory function .|Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death .	1:Positive_Correlation:2	R2L	NON-CROSS	12-13	6-7	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	1:NR:2	L2R	CROSS	223-224	257-258	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	1:NR:2	L2R	CROSS	223-224	259-260	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	1:NR:2	L2R	CROSS	223-224	261-264	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	1:NR:2	L2R	CROSS	223-224	265-266	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	1:NR:2	L2R	CROSS	223-224	267-268	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:NR:2	L2R	CROSS	286-291	325-326	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	133-136	188-189	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	NON-CROSS	162-163	188-189	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	NON-CROSS	164-167	188-189	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	NON-CROSS	176-177	188-189	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	NON-CROSS	178-181	188-189	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:Negative_Correlation:2	R2L	NON-CROSS	193-194	188-189	D008559	Memantine	ChemicalEntity	193	194	7	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	1:Negative_Correlation:2	R2L	NON-CROSS	200-201	188-189	D007052	Ibuprofen	ChemicalEntity	200	201	7	D020258	neurotoxicity|neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	6:188:223:325	7:189:224:326	0:6:7:13	1:Positive_Correlation:2	L2R	NON-CROSS	331-332	333-335	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	1:NR:2	L2R	NON-CROSS	34-35	37-38	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	1:Positive_Correlation:2	L2R	NON-CROSS	79-80	84-85	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	1:Positive_Correlation:2	L2R	NON-CROSS	79-80	86-87	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	1:Positive_Correlation:2	L2R	NON-CROSS	88-91	97-98	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	1:Positive_Correlation:2	L2R	NON-CROSS	95-96	97-98	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	1:Positive_Correlation:2	L2R	NON-CROSS	97-98	104-105	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	1:Positive_Correlation:2	L2R	NON-CROSS	97-98	106-107	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:Positive_Correlation:2	L2R	NON-CROSS	97-98	108-113	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:Positive_Correlation:2	L2R	NON-CROSS	133-136	140-141	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:Negative_Correlation:2	L2R	NON-CROSS	153-154	162-163	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:Negative_Correlation:2	L2R	NON-CROSS	153-154	164-167	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	NON-CROSS	153-154	176-177	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	NON-CROSS	153-154	178-181	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:Negative_Correlation:2	L2R	NON-CROSS	193-194	212-213	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D008559	Memantine	ChemicalEntity	193	194	7	1:Negative_Correlation:2	L2R	NON-CROSS	200-201	212-213	D013311	Streptozotocin|Streptozotocin|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ|STZ	ChemicalEntity	12:37:39:69:79:97:140:153:212:251:331	13:38:40:70:80:98:141:154:213:252:332	0:1:1:2:3:4:5:6:7:9:13	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	CROSS	54-56	84-85	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	1:NR:2	L2R	CROSS	54-56	86-87	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	1:NR:2	L2R	CROSS	54-56	88-91	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	1:NR:2	L2R	CROSS	54-56	104-105	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	1:NR:2	L2R	CROSS	54-56	106-107	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:NR:2	L2R	CROSS	286-291	333-335	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	54-56	133-136	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	54-56	162-163	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	54-56	164-167	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	54-56	176-177	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	54-56	178-181	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	54-56	193-194	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	200-201	333-335	D008569	memory impairment|memory impaired|Memory deficit|memory impairment	DiseaseOrPhenotypicFeature	17:42:54:333	19:44:56:335	0:1:2:13	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	CROSS	84-85	126-127	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	1:NR:2	L2R	CROSS	86-87	126-127	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	1:NR:2	L2R	CROSS	88-91	126-127	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	1:NR:2	L2R	NON-CROSS	104-105	126-127	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	1:NR:2	L2R	NON-CROSS	106-107	126-127	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:NR:2	L2R	NON-CROSS	108-113	126-127	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	126-127	133-136	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	126-127	162-163	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	126-127	164-167	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	126-127	176-177	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	126-127	178-181	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	126-127	193-194	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	126-127	200-201	D064420	toxicity|excitotoxicity	DiseaseOrPhenotypicFeature	34:126	35:127	1:4	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	84-85	86-87	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	1:NR:2	L2R	NON-CROSS	84-85	88-91	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	1:NR:2	L2R	NON-CROSS	84-85	95-96	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	1:NR:2	L2R	NON-CROSS	257-258	265-266	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	1:NR:2	L2R	NON-CROSS	257-258	267-268	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:NR:2	L2R	CROSS	84-85	108-113	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	84-85	133-136	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	84-85	162-163	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	84-85	164-167	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	176-177	257-258	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	178-181	257-258	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	193-194	257-258	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	200-201	257-258	24387	GFAP|GFAP	GeneOrGeneProduct	84:257	85:258	3:10	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	86-87	88-91	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	1:NR:2	L2R	NON-CROSS	86-87	95-96	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	1:NR:2	L2R	NON-CROSS	259-260	265-266	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	1:NR:2	L2R	NON-CROSS	259-260	267-268	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:NR:2	L2R	CROSS	86-87	108-113	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	86-87	133-136	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	86-87	162-163	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	86-87	164-167	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	176-177	259-260	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	178-181	259-260	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	193-194	259-260	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	200-201	259-260	25021	CD11b|CD11b	GeneOrGeneProduct	86:259	87:260	3:10	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	88-91	95-96	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	1:NR:2	L2R	NON-CROSS	261-264	265-266	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	1:NR:2	L2R	NON-CROSS	261-264	267-268	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:NR:2	L2R	CROSS	88-91	108-113	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	88-91	133-136	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	88-91	162-163	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	88-91	164-167	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	176-177	261-264	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	178-181	261-264	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	193-194	261-264	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	200-201	261-264	24835	TNF - a|TNF - a	GeneOrGeneProduct	88:261	91:264	3:10	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	CROSS	95-96	104-105	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	1:NR:2	L2R	CROSS	95-96	106-107	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:NR:2	L2R	CROSS	286-291	299-300	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	95-96	133-136	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	95-96	162-163	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	95-96	164-167	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	95-96	176-177	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	95-96	178-181	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	95-96	193-194	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	200-201	299-300	D007249	neuroinflammation|neuroinflammatory	DiseaseOrPhenotypicFeature	95:299	96:300	3:12	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	104-105	106-107	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	1:NR:2	L2R	NON-CROSS	104-105	108-113	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	104-105	133-136	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	104-105	162-163	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	104-105	164-167	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	104-105	176-177	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	104-105	178-181	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	193-194	265-266	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	200-201	265-266	D017382	ROS|ROS	ChemicalEntity	104:265	105:266	4:10	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	106-107	108-113	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	1:NR:2	L2R	CROSS	106-107	133-136	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	106-107	162-163	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	106-107	164-167	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	106-107	176-177	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	106-107	178-181	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	193-194	267-268	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	200-201	267-268	D009573	nitrite|nitrite	ChemicalEntity	106:267	107:268	4:10	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	CROSS	108-113	133-136	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	1:NR:2	L2R	CROSS	108-113	162-163	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	108-113	164-167	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	108-113	176-177	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	108-113	178-181	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	108-113	193-194	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	200-201	286-291	D002118	Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	108:286	113:291	4:11	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	CROSS	133-136	162-163	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	1:NR:2	L2R	CROSS	133-136	164-167	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	CROSS	133-136	176-177	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	CROSS	133-136	178-181	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	133-136	193-194	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	133-136	200-201	25402	Caspase - 3	GeneOrGeneProduct	133	136	5	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	162-163	164-167	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	29495	PSD - 95	GeneOrGeneProduct	164	167	6	1:NR:2	L2R	NON-CROSS	162-163	176-177	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	NON-CROSS	162-163	178-181	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	162-163	193-194	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	162-163	200-201	25400	CaMKIIa	GeneOrGeneProduct	162	163	6	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	164-167	176-177	29495	PSD - 95	GeneOrGeneProduct	164	167	6	24804	synaptophysin	GeneOrGeneProduct	176	177	6	1:NR:2	L2R	NON-CROSS	164-167	178-181	29495	PSD - 95	GeneOrGeneProduct	164	167	6	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	164-167	193-194	29495	PSD - 95	GeneOrGeneProduct	164	167	6	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	164-167	200-201	29495	PSD - 95	GeneOrGeneProduct	164	167	6	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	176-177	178-181	24804	synaptophysin	GeneOrGeneProduct	176	177	6	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	1:NR:2	L2R	CROSS	176-177	193-194	24804	synaptophysin	GeneOrGeneProduct	176	177	6	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	176-177	200-201	24804	synaptophysin	GeneOrGeneProduct	176	177	6	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	CROSS	178-181	193-194	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	D008559	Memantine	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	178-181	200-201	25012	SNAP - 25	GeneOrGeneProduct	178	181	6	D007052	Ibuprofen	ChemicalEntity	200	201	7	1:NR:2	L2R	NON-CROSS	193-194	200-201	D008559	Memantine	ChemicalEntity	193	194	7	D007052	Ibuprofen	ChemicalEntity	200	201	7
24438483	Pre - treatment of bupivacaine - induced cardiovascular depression using different lipid formulations of propofol .|BACKGROUND : Pre - treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine , and the lipid content of propofol may alleviate bupivacaine - induced cardiotoxicity .|The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine - induced cardiotoxicity .|METHODS : Rats were anaesthetised with ketamine and were given 0 . 5 mg / kg / min propofol in intralipid ( Group P ) , propofol in medialipid ( Group L ) , or saline ( Group C ) over 20 min .|Thereafter , 2 mg / kg / min bupivacaine 0 . 5 % was infused .|We recorded time to first dysrhythmia occurrence , respective times to 25 % and 50 % reduction of the heart rate ( HR ) and mean arterial pressure , and time to asystole and total amount of bupivacaine consumption .|Blood and tissue samples were collected following asystole .|RESULTS : The time to first dysrhythmia occurrence , time to 25 % and 50 % reductions in HR , and time to asystole were longer in Group P than the other groups .|The cumulative bupivacaine dose given at those time points was higher in Group P . Plasma bupivacaine levels were significantly lower in Group P than in Group C .|Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C .|CONCLUSION : We conclude that pre - treatment with propofol in intralipid , compared with propofol in medialipid or saline , delayed the onset of bupivacaine - induced cardiotoxic effects as well as reduced plasma bupivacaine levels .|Further studies are needed to explore tissue bupivacaine levels of propofol in medialipid and adapt these results to clinical practice .	1:Positive_Correlation:2	L2R	NON-CROSS	4-5	7-9	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	D002318	cardiovascular depression	DiseaseOrPhenotypicFeature	7	9	0	1:Negative_Correlation:2	R2L	NON-CROSS	65-66	62-63	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	1:Negative_Correlation:2	R2L	NON-CROSS	42-43	39-40	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	1:Association:2	R2L	NON-CROSS	32-33	22-24	D005217	lipid emulsions	ChemicalEntity	22	24	1	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	1:Positive_Correlation:2	L2R	NON-CROSS	42-43	45-46	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	D066126	cardiotoxicity|cardiotoxicity|cardiotoxic	DiseaseOrPhenotypicFeature	45:68:291	46:69:292	1:2:10	1:Negative_Correlation:2	R2L	NON-CROSS	65-66	60-61	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	1:NR:2	L2R	CROSS	65-66	76-77	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	D007649	ketamine	ChemicalEntity	76	77	3	1:NR:2	L2R	NON-CROSS	122-123	135-136	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	D001145	dysrhythmia|dysrhythmia	DiseaseOrPhenotypicFeature	135:185	136:186	5:7	1:NR:2	L2R	NON-CROSS	162-163	167-168	D002045	bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|bupivacaine|Bupivacaine|bupivacaine|bupivacaine|bupivacaine	ChemicalEntity	4:32:42:65:122:167:215:229:242:288:298:308	5:33:43:66:123:168:216:230:243:289:299:309	0:1:1:2:4:5:8:8:9:10:10:11	D006323	asystole|asystole|asystole	DiseaseOrPhenotypicFeature	162:177:202	163:178:203	5:6:7	1:NR:2	L2R	NON-CROSS	7-9	11-12	D002318	cardiovascular depression	DiseaseOrPhenotypicFeature	7	9	0	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	1:Negative_Correlation:2	R2L	NON-CROSS	14-15	7-9	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	D002318	cardiovascular depression	DiseaseOrPhenotypicFeature	7	9	0	1:NR:2	L2R	CROSS	7-9	22-24	D002318	cardiovascular depression	DiseaseOrPhenotypicFeature	7	9	0	D005217	lipid emulsions	ChemicalEntity	22	24	1	1:NR:2	L2R	CROSS	7-9	60-61	D002318	cardiovascular depression	DiseaseOrPhenotypicFeature	7	9	0	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	1:NR:2	L2R	CROSS	7-9	76-77	D002318	cardiovascular depression	DiseaseOrPhenotypicFeature	7	9	0	D007649	ketamine	ChemicalEntity	76	77	3	1:Association:2	R2L	NON-CROSS	98-99	96-97	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	1:NR:2	L2R	NON-CROSS	11-12	22-24	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	D005217	lipid emulsions	ChemicalEntity	22	24	1	1:Negative_Correlation:2	L2R	NON-CROSS	62-63	68-69	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	D066126	cardiotoxicity|cardiotoxicity|cardiotoxic	DiseaseOrPhenotypicFeature	45:68:291	46:69:292	1:2:10	1:Comparison:2	R2L	NON-CROSS	62-63	60-61	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	1:NR:2	L2R	NON-CROSS	62-63	76-77	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	D007649	ketamine	ChemicalEntity	76	77	3	1:NR:2	L2R	CROSS	98-99	135-136	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	D001145	dysrhythmia|dysrhythmia	DiseaseOrPhenotypicFeature	135:185	136:186	5:7	1:NR:2	L2R	CROSS	98-99	162-163	D008055	lipid|lipid|medialipid|medialipid|medialipid|medialipid	ChemicalEntity	11:36:62:98:280:313	12:37:63:99:281:314	0:1:2:3:10:11	D006323	asystole|asystole|asystole	DiseaseOrPhenotypicFeature	162:177:202	163:178:203	5:6:7	1:NR:2	L2R	NON-CROSS	14-15	22-24	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	D005217	lipid emulsions	ChemicalEntity	22	24	1	1:Negative_Correlation:2	L2R	NON-CROSS	39-40	45-46	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	D066126	cardiotoxicity|cardiotoxicity|cardiotoxic	DiseaseOrPhenotypicFeature	45:68:291	46:69:292	1:2:10	1:Association:2	L2R	NON-CROSS	58-59	60-61	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	1:NR:2	L2R	NON-CROSS	76-77	88-89	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	D007649	ketamine	ChemicalEntity	76	77	3	1:NR:2	L2R	CROSS	96-97	135-136	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	D001145	dysrhythmia|dysrhythmia	DiseaseOrPhenotypicFeature	135:185	136:186	5:7	1:NR:2	L2R	CROSS	96-97	162-163	D015742	propofol|propofol|propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	14:39:58:88:96:272:278:311	15:40:59:89:97:273:279:312	0:1:2:3:3:10:10:11	D006323	asystole|asystole|asystole	DiseaseOrPhenotypicFeature	162:177:202	163:178:203	5:6:7	1:NR:2	L2R	NON-CROSS	22-24	45-46	D005217	lipid emulsions	ChemicalEntity	22	24	1	D066126	cardiotoxicity|cardiotoxicity|cardiotoxic	DiseaseOrPhenotypicFeature	45:68:291	46:69:292	1:2:10	1:NR:2	L2R	CROSS	22-24	60-61	D005217	lipid emulsions	ChemicalEntity	22	24	1	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	1:NR:2	L2R	CROSS	22-24	76-77	D005217	lipid emulsions	ChemicalEntity	22	24	1	D007649	ketamine	ChemicalEntity	76	77	3	1:NR:2	L2R	CROSS	22-24	135-136	D005217	lipid emulsions	ChemicalEntity	22	24	1	D001145	dysrhythmia|dysrhythmia	DiseaseOrPhenotypicFeature	135:185	136:186	5:7	1:NR:2	L2R	CROSS	22-24	162-163	D005217	lipid emulsions	ChemicalEntity	22	24	1	D006323	asystole|asystole|asystole	DiseaseOrPhenotypicFeature	162:177:202	163:178:203	5:6:7	1:Negative_Correlation:2	R2L	NON-CROSS	68-69	60-61	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	D066126	cardiotoxicity|cardiotoxicity|cardiotoxic	DiseaseOrPhenotypicFeature	45:68:291	46:69:292	1:2:10	1:NR:2	L2R	CROSS	68-69	76-77	D066126	cardiotoxicity|cardiotoxicity|cardiotoxic	DiseaseOrPhenotypicFeature	45:68:291	46:69:292	1:2:10	D007649	ketamine	ChemicalEntity	76	77	3	1:NR:2	L2R	NON-CROSS	76-77	90-91	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	D007649	ketamine	ChemicalEntity	76	77	3	1:NR:2	L2R	CROSS	90-91	135-136	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	D001145	dysrhythmia|dysrhythmia	DiseaseOrPhenotypicFeature	135:185	136:186	5:7	1:NR:2	L2R	CROSS	90-91	162-163	C545823	intralipid|intralipid|intralipid	ChemicalEntity	60:90:274	61:91:275	2:3:10	D006323	asystole|asystole|asystole	DiseaseOrPhenotypicFeature	162:177:202	163:178:203	5:6:7	1:NR:2	L2R	CROSS	76-77	135-136	D007649	ketamine	ChemicalEntity	76	77	3	D001145	dysrhythmia|dysrhythmia	DiseaseOrPhenotypicFeature	135:185	136:186	5:7	1:NR:2	L2R	CROSS	76-77	162-163	D007649	ketamine	ChemicalEntity	76	77	3	D006323	asystole|asystole|asystole	DiseaseOrPhenotypicFeature	162:177:202	163:178:203	5:6:7
25119790	Curcumin prevents maleate - induced nephrotoxicity : relation to hemodynamic alterations , oxidative stress , mitochondrial oxygen consumption and activity of respiratory complex I .|The potential protective effect of the dietary antioxidant curcumin ( 120 mg / Kg / day for 6 days ) against the renal injury induced by maleate was evaluated .|Tubular proteinuria and oxidative stress were induced by a single injection of maleate ( 400 mg / kg ) in rats .|Maleate - induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein , glucose , sodium , neutrophil gelatinase - associated lipocalin ( NGAL ) and N - acetyl b - D - glucosaminidase ( NAG ) , upregulation of kidney injury molecule ( KIM ) - 1 , decrease in renal blood flow and claudin - 2 expression besides of necrosis and apoptosis of tubular cells on 24 h .|Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels .|Studies were also conducted in renal epithelial LLC - PK1 cells and in mitochondria isolated from kidneys of all the experimental groups .|Maleate induced cell damage and reactive oxygen species ( ROS ) production in LLC - PK1 cells in culture .|In addition , maleate treatment reduced oxygen consumption in ADP - stimulated mitochondria and diminished respiratory control index when using malate / glutamate as substrate .|The activities of both complex I and aconitase were also diminished .|All the above - described alterations were prevented by curcumin .|It is concluded that curcumin is able to attenuate in vivo maleate - induced nephropathy and in vitro cell damage .|The in vivo protection was associated to the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I , and the in vitro protection was associated to the prevention of ROS production .	1:Negative_Correlation:2	L2R	NON-CROSS	0-1	2-3	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	1:Negative_Correlation:2	L2R	NON-CROSS	0-1	5-6	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	1:NR:2	L2R	NON-CROSS	0-1	16-17	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	1:NR:2	L2R	NON-CROSS	21-24	33-34	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	1:NR:2	L2R	CROSS	33-34	56-57	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	1:NR:2	L2R	CROSS	33-34	97-98	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D005947	glucose	ChemicalEntity	97	98	3	1:NR:2	L2R	CROSS	33-34	99-100	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D012964	sodium	ChemicalEntity	99	100	3	1:NR:2	L2R	CROSS	33-34	101-106	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	1:NR:2	L2R	CROSS	33-34	110-118	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:NR:2	L2R	CROSS	33-34	124-132	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:NR:2	L2R	CROSS	33-34	139-142	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	CROSS	33-34	145-151	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	164-165	264-265	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	171-172	264-265	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	270-271	323-324	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	226-227	264-265	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	237-238	264-265	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	239-240	264-265	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	250-251	264-265	D003474	Curcumin|curcumin|curcumin|curcumin	ChemicalEntity	0:33:264:270	1:34:265:271	0:1:9:10	50655	aconitase	GeneOrGeneProduct	250	251	8	1:Positive_Correlation:2	L2R	NON-CROSS	2-3	5-6	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	1:Association:2	L2R	NON-CROSS	220-221	223-224	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	1:NR:2	L2R	NON-CROSS	2-3	21-24	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	1:Positive_Correlation:2	R2L	NON-CROSS	56-57	51-52	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	1:Association:2	L2R	NON-CROSS	77-78	97-98	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D005947	glucose	ChemicalEntity	97	98	3	1:Association:2	L2R	NON-CROSS	77-78	99-100	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D012964	sodium	ChemicalEntity	99	100	3	1:Association:2	L2R	NON-CROSS	77-78	101-106	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	1:NR:2	L2R	NON-CROSS	77-78	110-118	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:Positive_Correlation:2	L2R	NON-CROSS	77-78	124-132	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:Negative_Correlation:2	L2R	NON-CROSS	139-142	197-198	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	NON-CROSS	145-151	197-198	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	164-165	197-198	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	171-172	197-198	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:Positive_Correlation:2	L2R	NON-CROSS	197-198	202-205	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	NON-CROSS	220-221	226-227	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	NON-CROSS	220-221	237-238	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	NON-CROSS	220-221	239-240	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	D018698	glutamate	ChemicalEntity	239	240	7	1:Negative_Correlation:2	L2R	CROSS	250-251	277-278	C030272	maleate|maleate|maleate|Maleate|Maleate|maleate|maleate	ChemicalEntity	2:51:67:77:197:220:277	3:52:68:78:198:221:278	0:1:2:3:6:7:10	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	5-6	16-17	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	1:NR:2	L2R	NON-CROSS	5-6	21-24	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	1:Association:2	L2R	NON-CROSS	80-82	97-98	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	D005947	glucose	ChemicalEntity	97	98	3	1:Association:2	L2R	NON-CROSS	80-82	99-100	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	D012964	sodium	ChemicalEntity	99	100	3	1:Association:2	L2R	NON-CROSS	80-82	101-106	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	1:NR:2	L2R	NON-CROSS	80-82	110-118	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:Positive_Correlation:2	L2R	NON-CROSS	80-82	124-132	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:Negative_Correlation:2	L2R	NON-CROSS	80-82	139-142	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	CROSS	80-82	164-165	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	80-82	171-172	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	280-281	323-324	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	226-227	280-281	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	237-238	280-281	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	239-240	280-281	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	250-251	280-281	D007674	nephrotoxicity|renal injury|renal injury|nephropathy	DiseaseOrPhenotypicFeature	5:47:80:280	6:49:82:281	0:1:3:10	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	16-17	21-24	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	1:NR:2	L2R	CROSS	16-17	56-57	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	1:NR:2	L2R	CROSS	16-17	97-98	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D005947	glucose	ChemicalEntity	97	98	3	1:NR:2	L2R	CROSS	16-17	99-100	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D012964	sodium	ChemicalEntity	99	100	3	1:NR:2	L2R	CROSS	16-17	101-106	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	1:NR:2	L2R	CROSS	16-17	110-118	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:NR:2	L2R	CROSS	124-132	223-224	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:NR:2	L2R	CROSS	139-142	223-224	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	CROSS	145-151	223-224	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	164-165	223-224	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	171-172	223-224	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	NON-CROSS	206-207	223-224	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	NON-CROSS	223-224	226-227	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	NON-CROSS	223-224	237-238	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	NON-CROSS	223-224	239-240	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	223-224	250-251	D010100	oxygen|oxygen|oxygen	ChemicalEntity	16:223:303	17:224:304	0:7:11	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	CROSS	21-24	56-57	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	1:NR:2	L2R	CROSS	21-24	97-98	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	D005947	glucose	ChemicalEntity	97	98	3	1:NR:2	L2R	CROSS	21-24	99-100	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	D012964	sodium	ChemicalEntity	99	100	3	1:NR:2	L2R	CROSS	21-24	101-106	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	1:NR:2	L2R	CROSS	21-24	110-118	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:NR:2	L2R	CROSS	21-24	124-132	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:NR:2	L2R	CROSS	21-24	139-142	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	CROSS	21-24	145-151	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	21-24	164-165	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	171-172	308-311	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	NON-CROSS	308-311	323-324	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	226-227	308-311	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	237-238	308-311	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	239-240	308-311	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	250-251	308-311	D042967	respiratory complex I|respiratory complex I	ChemicalEntity	21:308	24:311	0:11	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	CROSS	56-57	97-98	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	D005947	glucose	ChemicalEntity	97	98	3	1:NR:2	L2R	CROSS	56-57	99-100	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	D012964	sodium	ChemicalEntity	99	100	3	1:NR:2	L2R	CROSS	56-57	101-106	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	1:NR:2	L2R	CROSS	56-57	110-118	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:NR:2	L2R	CROSS	56-57	124-132	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:NR:2	L2R	CROSS	56-57	139-142	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	CROSS	56-57	164-165	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	56-57	171-172	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	56-57	202-205	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	56-57	226-227	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	56-57	237-238	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	56-57	239-240	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	56-57	250-251	D011507	proteinuria	DiseaseOrPhenotypicFeature	56	57	2	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	97-98	99-100	D005947	glucose	ChemicalEntity	97	98	3	D012964	sodium	ChemicalEntity	99	100	3	1:NR:2	L2R	NON-CROSS	97-98	101-106	D005947	glucose	ChemicalEntity	97	98	3	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	1:NR:2	L2R	NON-CROSS	97-98	110-118	D005947	glucose	ChemicalEntity	97	98	3	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:NR:2	L2R	NON-CROSS	97-98	124-132	D005947	glucose	ChemicalEntity	97	98	3	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:NR:2	L2R	NON-CROSS	97-98	139-142	D005947	glucose	ChemicalEntity	97	98	3	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	NON-CROSS	97-98	145-151	D005947	glucose	ChemicalEntity	97	98	3	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	97-98	164-165	D005947	glucose	ChemicalEntity	97	98	3	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	97-98	171-172	D005947	glucose	ChemicalEntity	97	98	3	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	97-98	202-205	D005947	glucose	ChemicalEntity	97	98	3	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	97-98	226-227	D005947	glucose	ChemicalEntity	97	98	3	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	97-98	237-238	D005947	glucose	ChemicalEntity	97	98	3	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	97-98	239-240	D005947	glucose	ChemicalEntity	97	98	3	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	97-98	250-251	D005947	glucose	ChemicalEntity	97	98	3	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	99-100	101-106	D012964	sodium	ChemicalEntity	99	100	3	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	1:NR:2	L2R	NON-CROSS	99-100	110-118	D012964	sodium	ChemicalEntity	99	100	3	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:NR:2	L2R	NON-CROSS	99-100	124-132	D012964	sodium	ChemicalEntity	99	100	3	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:NR:2	L2R	NON-CROSS	99-100	139-142	D012964	sodium	ChemicalEntity	99	100	3	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	NON-CROSS	99-100	145-151	D012964	sodium	ChemicalEntity	99	100	3	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	99-100	164-165	D012964	sodium	ChemicalEntity	99	100	3	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	99-100	171-172	D012964	sodium	ChemicalEntity	99	100	3	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	99-100	202-205	D012964	sodium	ChemicalEntity	99	100	3	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	99-100	226-227	D012964	sodium	ChemicalEntity	99	100	3	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	99-100	237-238	D012964	sodium	ChemicalEntity	99	100	3	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	99-100	239-240	D012964	sodium	ChemicalEntity	99	100	3	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	99-100	250-251	D012964	sodium	ChemicalEntity	99	100	3	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	107-108	110-118	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	1:NR:2	L2R	NON-CROSS	107-108	124-132	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:NR:2	L2R	NON-CROSS	107-108	139-142	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	NON-CROSS	107-108	145-151	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	107-108	164-165	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	107-108	171-172	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	107-108	202-205	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	107-108	226-227	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	107-108	237-238	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	107-108	239-240	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	107-108	250-251	170496	neutrophil gelatinase - associated lipocalin|NGAL	GeneOrGeneProduct	101:107	106:108	3:3	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	119-120	124-132	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	1:NR:2	L2R	NON-CROSS	119-120	139-142	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	NON-CROSS	119-120	145-151	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	119-120	164-165	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	119-120	171-172	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	119-120	202-205	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	119-120	226-227	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	119-120	237-238	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	119-120	239-240	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	119-120	250-251	-	N - acetyl b - D - glucosaminidase|NAG	GeneOrGeneProduct	110:119	118:120	3:3	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	124-132	139-142	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	733684	claudin - 2	GeneOrGeneProduct	139	142	3	1:NR:2	L2R	NON-CROSS	124-132	145-151	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	124-132	164-165	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	124-132	171-172	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	124-132	202-205	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	124-132	226-227	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	124-132	237-238	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	124-132	239-240	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	124-132	250-251	286934	kidney injury molecule ( KIM ) - 1	GeneOrGeneProduct	124	132	3	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	139-142	145-151	733684	claudin - 2	GeneOrGeneProduct	139	142	3	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	1:NR:2	L2R	CROSS	139-142	164-165	733684	claudin - 2	GeneOrGeneProduct	139	142	3	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	139-142	171-172	733684	claudin - 2	GeneOrGeneProduct	139	142	3	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	139-142	202-205	733684	claudin - 2	GeneOrGeneProduct	139	142	3	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	139-142	226-227	733684	claudin - 2	GeneOrGeneProduct	139	142	3	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	139-142	237-238	733684	claudin - 2	GeneOrGeneProduct	139	142	3	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	139-142	239-240	733684	claudin - 2	GeneOrGeneProduct	139	142	3	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	139-142	250-251	733684	claudin - 2	GeneOrGeneProduct	139	142	3	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	CROSS	145-151	164-165	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	D008055	lipids	ChemicalEntity	164	165	4	1:NR:2	L2R	CROSS	145-151	171-172	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	145-151	202-205	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	145-151	226-227	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	145-151	237-238	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	145-151	239-240	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	145-151	250-251	D007673	necrosis and apoptosis of tubular cells	DiseaseOrPhenotypicFeature	145	151	3	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	164-165	171-172	D008055	lipids	ChemicalEntity	164	165	4	83619	Nrf2	GeneOrGeneProduct	171	172	4	1:NR:2	L2R	CROSS	164-165	202-205	D008055	lipids	ChemicalEntity	164	165	4	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	164-165	226-227	D008055	lipids	ChemicalEntity	164	165	4	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	164-165	237-238	D008055	lipids	ChemicalEntity	164	165	4	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	164-165	239-240	D008055	lipids	ChemicalEntity	164	165	4	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	164-165	250-251	D008055	lipids	ChemicalEntity	164	165	4	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	CROSS	171-172	202-205	83619	Nrf2	GeneOrGeneProduct	171	172	4	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	1:NR:2	L2R	CROSS	171-172	226-227	83619	Nrf2	GeneOrGeneProduct	171	172	4	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	171-172	237-238	83619	Nrf2	GeneOrGeneProduct	171	172	4	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	171-172	239-240	83619	Nrf2	GeneOrGeneProduct	171	172	4	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	171-172	250-251	83619	Nrf2	GeneOrGeneProduct	171	172	4	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	CROSS	206-207	226-227	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	D000244	ADP	ChemicalEntity	226	227	7	1:NR:2	L2R	CROSS	206-207	237-238	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	CROSS	206-207	239-240	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	206-207	250-251	D017382	reactive oxygen species|ROS|ROS	ChemicalEntity	202:206:323	205:207:324	6:6:11	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	226-227	237-238	D000244	ADP	ChemicalEntity	226	227	7	C030298	malate	ChemicalEntity	237	238	7	1:NR:2	L2R	NON-CROSS	226-227	239-240	D000244	ADP	ChemicalEntity	226	227	7	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	226-227	250-251	D000244	ADP	ChemicalEntity	226	227	7	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	NON-CROSS	237-238	239-240	C030298	malate	ChemicalEntity	237	238	7	D018698	glutamate	ChemicalEntity	239	240	7	1:NR:2	L2R	CROSS	237-238	250-251	C030298	malate	ChemicalEntity	237	238	7	50655	aconitase	GeneOrGeneProduct	250	251	8	1:NR:2	L2R	CROSS	239-240	250-251	D018698	glutamate	ChemicalEntity	239	240	7	50655	aconitase	GeneOrGeneProduct	250	251	8
